




CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Proposed Grant Awards

August 18, 2021




Attachment #1

***Academic Research Program Priorities Addressed by Recommended Awards**

(*Some grant awards address more than one program priority and are double counted.)

Scale	Recruitment of outstanding cancer researchers to Texas	Investment in Core Facilities	A broad range of innovative, investigator-initiated research projects	Computational biology and analytic methods	Childhood cancers	Hepatocellular cancer	Expand Access to innovative clinical trials	Stimulating commercialization of technologies developed at Texas institutions
-------	--	-------------------------------	---	--	-------------------	-----------------------	---	---





CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: OVERSIGHT COMMITTEE
FROM: JAMES WILLSON, M.D., CPRIT CHIEF SCIENTIFIC OFFICER
SUBJECT: ACADEMIC RESEARCH FY2021 REVIEW CYCLE 2, AND
RECRUITMENT AWARD RECOMMENDATIONS FY2021, CYCLES
21.10, 21.11 AND 21.12
DATE: AUGUST 11, 2021

The Program Integration Committee (PIC) has completed its review of the recommendations forwarded by the Scientific Review Council (SRC) recommendations for FY2021 review cycle 2 and recruitment cycles 21.10, 21.11 and 21.12 include 62 awards from eight grant mechanisms totaling **\$103,416,042** as displayed in Table 1.

The following tables summarize the FY21.2 recommended applications and funding totals by Mechanism (Table 1); Institution (Table 2); and CPRIT Priority (Table 3).

Table 1: FY21.2 Recommended Applications by Mechanism

Grant Mechanism	SRC Recommendations	
	Awards	Funding
Early Clinical Investigator Award	5	\$7,442,391
Core Facility Support Awards	12	\$43,099,721
Clinical Trials Network Award	1	\$3,000,000
High-Impact/High Risk Awards	28	\$6,995,235
Texas Clinical Trials Participation Award	2	\$2,999,327
Texas Regional Excellence in Cancer Award	2	\$11,881,670
Recruitment of Rising Stars	2	\$7,998,389
Recruitment of First-Time, Tenure Track Faculty Members	10	\$19,999,309
Total	62	\$103,416,042

Table 2. FY21.2 Recommended Applications by Institution

Institution	SRC Recommendations	
	Awards	Funding
Baylor College of Medicine	8	\$15,977,680
Baylor University	1	\$248,938
Rice University	2	\$4,250,000
Southern Methodist University	1	\$249,272
Texas A&M University	2	\$2,250,000
Texas A&M University System Health Science Center	3	\$4,473,083
Texas Tech University Health Sciences Center	2	\$8,965,162
The Methodist Hospital Research Institute	3	\$4,496,417
The University of Texas at Arlington	1	\$249,999
The University of Texas at Austin	5	\$6,182,808
The University of Texas at Dallas	1	\$250,000
The University of Texas at El Paso	2	\$6,131,733
The University of Texas at San Antonio	1	\$3,087,131
The University of Texas Health Science Center at Houston	4	\$4,749,998
The University of Texas Health Science Center at San Antonio	4	\$5,645,481
The University of Texas M. D. Anderson Cancer Center	9	\$12,749,033
The University of Texas Medical Branch at Galveston	2	\$3,186,731
The University of Texas Rio Grande Valley	1	\$2,525,000
The University of Texas Southwestern Medical Center	9	\$17,498,267
University of Houston	1	\$250,000
Total	62	\$103,416,042

Table 3: Program Priorities Addressed

Program Priorities Addressed by Grant Recommendations		
# Awards*	Program Priorities	Funding*
12	Recruitment of outstanding cancer researchers to Texas	\$27,997,698
35	A broad range of innovative, investigator-initiated research projects	\$14,437,626
12	Investment in Core Facilities	\$43,099,721
4	Childhood Cancers	\$8,249,999
1	Population Disparities	\$5,881,734
2	Hepatocellular Cancer	\$5,998,389
10	Expand Access to Innovative Clinical Trials	\$20,406,944
3	Computational biology and analytic methods	\$5,999,309
3	Stimulating commercialization of technologies developed at Texas institutions	\$11,076,571

*Some grant awards address more than one program priority and are double counted.

1. The Texas Regional Excellence in Cancer Awards (RFA R-21.2 TREC) Slate

Purpose of The Texas Regional Excellence in Cancer Awards:

The Texas Regional Excellence in Cancer (TREC) award is a multicomponent award designed to strengthen cancer research at institutions located in regions of Texas that have historically received low levels of peer-reviewed cancer research funding. Applicants may request up to \$6.0 million in CPRIT funds over 5 years to support program leadership, investigator-initiated research projects, recruitment of new junior faculty, and research infrastructure. Academic research institutions located greater than 100 miles from an NCI designated Cancer Center were eligible to apply.

Peer Review Recommendations:

Reviewers were instructed to evaluate the applications based on the following criteria: (1) Will the TREC enhance the institution's cancer research capabilities and ability of research faculty to compete successfully for peer reviewed cancer research awards?; (2) Do the individual research projects proposed have clearly defined cancer relevant goals?; (3) Will research project leaders have formal mentoring to help them acquire preliminary data and successfully compete for independent research grant support?; (4) Does the Principal Investigator have the required experience and accomplishments to provide the necessary leadership of the TREC and to oversee mentorship of junior faculty?; (5) Is there strong institutional commitment?. Of the eight institutions eligible, seven applied. The SRC has recommended TREC applications from Texas Tech University Health Sciences Center and The University of Texas at El Paso.

RP210154

PI: Charles Reynolds, M.D., Ph.D.

Title: Texas Regional Excellence in Cancer Developmental Therapeutics Center at TTUHSC

Applicant Organization: Texas Tech University Health Sciences Center

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.0

Recommended Total Budget Award and Duration: \$5,999,936

CPRIT Priorities Addressed: A broad range of innovative, investigator-initiated research projects

Description:

Texas Regional Excellence in Cancer Developmental Therapeutics Center at Texas Tech University Health Sciences Center (TTUHSC) will build on an existing program in cancer drug development at TTUHSC leveraging existing CPRIT grants and institutional cores to support research of junior faculty on the Lubbock, Amarillo, and Abilene campuses of TTUHSC. The TREC leader, Dr. Patrick Reynolds, is an accomplished leader in drug development in pediatric oncology and well positioned at the institution to lead the center. The TREC research projects cover a range of topics from small-molecule discovery to the development of biologics and are expected to reach independent funding. The system to evaluate the TREC on an annual basis is detailed and compelling and a strong external advisory committee will provide added expertise.

While institutional leadership provide letters in support of the TREC and existing shared resources will support the TREC mission, the lack of additional institutional commitment to provide support for the recruitment of new investigators with the necessary start-up funding will limit the impact of this otherwise promising initiative.

RP210153

PI: Marc Cox, Ph.D.

Title: UTEP/UTMDACC Partnership for Hispanic Cancer Disparities Research

Applicant Organization: The University of Texas at El Paso

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 3.1

Recommended Total Budget Award and Duration: \$5,881,734

CPRIT Priorities Addressed: A broad range of innovative, investigator-initiated research projects; Population Disparities

Description:

The TREC from the University of Texas at El Paso (UTEP) led by Dr. Marc Cox will support infrastructure and a mentoring plan to development early-stage investigators with enhanced skills around cancer disparities research. UTEP has made considerable investments into strengthening its science infrastructure and the TREC will build upon these. A recently constructed Biosciences Research Building, which includes core research facilities, will provide significant research space for new investigators. The UTEP Border Biomedical Research Center, supported by the NIH Research Centers in Minority Institutions program, will provide TREC research projects access to biospecimens and other infrastructure to study the molecular and genetic mechanisms underlying cancer progression among underserved populations in southwest Texas. A strong mentoring plan has paired scientific leaders from MD Anderson Cancer Center with each of the TREC research projects who will work with UTEP faculty to provide the scientific depth needed to take full advantage of the environment and opportunity that UTEP has created. UTEP/UTMDACC Partnership for Hispanic Cancer Disparities Research represents a strong model for how an emerging research university in Texas can use the TREC program to build a focus in cancer research that takes advantage of the institution's unique resources and opportunities. Reviewers commented that the goals of the UTEP TREC would be greatly enhanced by recruitment of senior level investigators to UTEP who focus on Hispanic health disparities.

***2. Core Facility Support Awards
(RFA R-21.2 CFSA) Slate***

Scientific Review Council Recommendations:

Out of 25 Core Facility Support (CFSA) grant applications submitted, the SRC recommended twelve, totaling \$43,099,721.

Purpose of Core Facility Support Awards:

Solicits applications from institutions to establish or enhance core facilities (laboratory, clinical, population-based, or computer-based) that will directly support cancer research programs to advance knowledge of the causes, prevention, and/or treatment of cancer or improve quality of life for patients with and survivors of cancer.

Core Facility Support Award Funding Levels:

Award: Up to \$4M (total costs); Maximum duration: 5 years.

Recommended CFSA Institutions:

Baylor College of Medicine (2 awards), Rice University, Texas A&M University Health Science Center in Houston Campus, Texas Tech University Health Sciences Center Lubbock Campus, Texas Tech University Health Sciences Center Dallas Campus, The University of Texas Austin, The University of Texas Health Science Center San Antonio, UT Medical Branch at Galveston, The University of Texas San Antonio, The University of Texas Southwestern Medical Center, and The University of Texas Rio Grande Valley.

Note that the awards are listed in order of the evaluation score.

RP210227

PI: Dean Edwards, Ph.D.

Title: Proteomics and Metabolomics Core Facility

Applicant Organization: Baylor College of Medicine

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.0

Recommended Total Budget Award and Duration: \$3,977,681

CPRIT Priorities Addressed: Investment in core facilities.

Description:

This is the second renewal award to support the Proteomics and Metabolomics Core Facility at Baylor College of Medicine (BCM). The core provides BCM cancer researchers and a limited number of researchers in the Texas Medical Center with access to cutting-edge proteomics and metabolomics technologies and computational expertise necessary for multiomic studies in preclinical models and clinical tumor specimens. Projects supported by this core pinpoint avenues for development of new treatment regimens to overcome drug resistance and to substitute generic chemotherapies with specific low toxicity targeted treatments. Outstanding institutional commitments along with continued CPRIT support has allowed the core to diversify its technological platforms and develop new assays that push the limits of protein and metabolite detection. The productivity of the core is demonstrated by 96 publications from users during the past support period and 54 new cancer-related research grants bringing \$74 M to user laboratories.

RP210208**PI:** Stanton McHardy, Ph.D.**Title:** Center for Innovative Drug Discovery: Expansion of a Highly Productive Shared Cancer Drug Discovery Resource for Texas**Applicant Organization:** The University of Texas at San Antonio**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.1**Recommended Total Budget Award and Duration:** \$3,087,131**CPRIT Priorities Addressed:** Investment in core facilities; Stimulating commercialization of technologies developed at Texas institutions**Description:**

This is a renewal award to continue support of two integrated drug discovery facilities, a medicinal chemistry resource based at the UT San Antonio campus and a high throughput screening resource at the UT San Antonio Health Science Center. These facilities provide researchers in San Antonio and southwest Texas access to pharmaceutical industry level resources and expertise for drug discovery and development. The core supported 86 grant applications bringing \$34M in research funding to Texas and identified 20 advanced lead candidates. With this renewal, the core will establish a PROTAC (Proteolysis-targeting chimeras) chemistry platform and high-throughput screening technologies to provide users with a resource for protein degradation approaches in cancers, which is a new, innovative, small molecule therapeutic approach. The outreach of the core is notable, including cancer programs at UT Rio Grande Valley, UT Austin, Texas Tech HSC, MD Anderson Cancer Center, University of Houston, Texas Southern University, UTMB Galveston, as well as collaborations with pharmaceutical industry partners based in Houston, Austin and Dallas.

RP210088**PI:** Kevin Dalby, Ph.D.**Title:** Targeted Therapeutic Drug Discovery and Development Program**Applicant Organization:** The University of Texas at Austin**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.9**Recommended Total Budget Award and Duration:** \$3,989,441**CPRIT Priorities Addressed:** Investment in core facilities; Stimulating commercialization of technologies developed at Texas institutions**Description:**

This is a renewal award to support specialized resources at UT Austin that provide access to technical help and expertise required to conduct pre-clinical drug development research, including high-throughput screens, lead progression, and target validation. The core is a founding member of the Gulf Coast Consortium's CFSA-funded core facilities supporting cancer-related drug discovery research. The core has supported research projects from twenty investigators from five Texas institutions and contributed to the award of 18 new research grants bringing \$51M in new research grants to Texas. Core supported studies led to a patent for a highly potent MELK-selective inhibitor, which shows promising activity in pre-clinical models of inflammatory breast cancer. Going forward, the core will establish new platforms for the

production of cancer-related recombinant proteins and a new cancer-related drug discovery program based on the application of targeted protein degradation via Proteolysis Targeting Chimeras (PROTACs).

RP210108

PI: Clifford Stephan, Ph.D.

Title: The GCC Microphysiological Lead Optimization and Toxicity Screening Facility

Applicant Organization: Texas A&M University System Health Science Center

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.0

Recommended Total Budget Award and Duration: \$3,973,083

CPRIT Priorities Addressed: Investment in core facilities.

Description:

The Gulf Coast Consortium (GCC) Microphysiological Lead Optimization and Toxicity Screening facility is a new drug discovery core facility based at Texas A&M Health Science Center Houston campus that will provide cancer researchers access to platforms designed to serve as a ‘bridge’ between academic lead discovery and pre-clinical testing by evaluating the efficacy of novel candidate cancer therapeutics and identifying toxicity liabilities that may limit future clinical applications. This core will be a new component in the network of CPRIT-funded core facilities organized by the Gulf Coast Consortium that are supporting cancer therapeutics research in Texas.

RP210116

PI: Gang Bao, Ph.D.

Title: The Genetic Design and Engineering Center (GDEC): A CPRIT Core Facility

Applicant Organization: Rice University

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.3

Recommended Total Budget Award and Duration: \$4,000,000

CPRIT Priorities Addressed: Investment in core facilities.

Description:

The Genetic Design & Engineering Center is a new resource to accelerate discovery of biological cancer therapies created through molecular cloning of recombinant DNA constructs for cancer vaccine development, viral gene therapy, adoptive cell therapy, as well as cancer genetics and cell biology. Efficiently generating new and diverse constructs and validating them can be challenging and time consuming, especially for translational researchers and physician scientists. The resource draws on the synthetic engineering expertise at Rice University to design workflows to support the assembling DNA molecules and to introduce them into living cells. This time-consuming process can be greatly accelerated by a DNA assembly infrastructure based on industrial-style robotic liquid handling. The core is led by Dr. Gang Bao, who is Chair of Department of Bioengineering at Rice and a CPRIT Scholar brought to Texas in 2015 through the *Recruitment of Established Investigators Award Program*.

RP210180**PI:** Subhash Chauhan, Ph.D.**Title:** Integrated Cancer Research Core (ICRC)**Applicant Organization:** The University of Texas Rio Grande Valley**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.5**Recommended Total Budget Award and Duration:** \$2,525,000**CPRIT Priorities Addressed:** Investment in core facilities.**Description:**

This is a new core facility support award that will provide a new cohort of cancer investigators at the UT Rio Grande Valley access to basic cancer research tools. Cancer research is a new initiative of the UT RGV School of Medicine established with the recent hiring of Dr. Subhash Chauhan, a well-funded cancer investigator, and several junior faculty who are beginning to obtain peer reviewed research support. The UT RGV, the UT System, and the local community, have provided substantial support to inaugurate this cancer research initiative and the program occupies outstanding new research space. CPRIT reviewers recognized the importance of building a cancer research program committed study of cancers prominent in the Rio Grande Valley region and were confident in Dr. Chauhan's leadership. Reviewers recommended funding the support of the core facility leadership, operation, and the purchase of 2 of the 5 major pieces of equipment requested, a PET/CT imager and a ImageStream Imaging Flow Cytometer.

RP210126**PI:** Michael Berton, Ph.D.**Title:** High-Parameter Analysis, Sorting, and Imaging Flow Cytometry Shared Resource**Applicant Organization:** The University of Texas Health Science Center at San Antonio**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.5**Recommended Total Budget Award and Duration:** \$3,645,500**CPRIT Priorities Addressed:** Investment in core facilities.**Description:**

This is a new award to up-grade the flow cytometry instruments available to cancer investigators at the Mays Cancer Center and the University of Texas Health Science Center at San Antonio. The award will add cutting-edge flow cytometry instruments and the research capabilities needed to assure the expanding cancer research programs in San Antonio have access to cutting-edge cancer research capabilities.

RP210099**PI:** Anke Henning, Ph.D.**Title:** North Texas Multimodal Small-Animal Imaging Core Facility**Applicant Organization:** The University of Texas Southwestern Medical Center**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.8**Recommended Total Budget Award and Duration:** \$3,999,929**CPRIT Priorities Addressed:** Investment in core facilities.

Description:

This facility will leverage an existing pre-clinical multimodal imaging core facility at UT Southwestern to support cancer research of nearly 100 different investigators from UT Southwestern and other research institutions across North Texas including UT Dallas, UT Arlington, Baylor University Medical Center, Southern Methodist University and Texas Christian University. Extensive investments in new imaging capabilities by UT Southwestern and the NIH have established a facility with an exceptional array of small animal imaging capabilities. This award will support acquisition of additional equipment that complement the existing equipment and will provide technical assistance and education to North Texas cancer investigators. The PI, Dr Henning, a CPRIT Established Investigator, is a renowned imaging scientist who is well qualified to direct the facility.

RP210209**PI:** William Putnam, Ph.D.**Title:** North Texas Clinical Pharmacology Cancer Core**Applicant Organization:** Texas Tech University Health Sciences Center**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.9**Recommended Total Budget Award and Duration:** \$2,965,226**CPRIT Priorities Addressed:** Investment in core facilities; Expand access to innovative clinical trials**Description:**

This is the second renewal for a facility that provides pharmacology support for preclinical and investigator initiated clinical trials of cancer therapeutics and diagnostics. The core is located at the Texas Tech Health Science Center facility in Dallas and is adjacent to the UT Southwestern campus. It provides essential support for preclinical drug development and clinical trials by investigators at UT Southwestern. This renewal will provide funds to upgrade equipment and to support continuation of collaborations with North Texas researchers predominantly at UT Southwestern.

RP210119**PI:** Qingyun Liu, Ph.D.**Title:** A Preclinical Development Core for Large-Molecule Therapeutics**Applicant Organization:** The University of Texas Health Science Center at Houston**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 3.1**Recommended Total Budget Award and Duration:** \$3,999,999**CPRIT Priorities Addressed:** Investment in core facilities; Stimulating commercialization of technologies developed at Texas institutions.**Description:**

This facility will establish a preclinical development core facility that will provide scale-up production, pharmacokinetics, toxicology, and in vivo imaging of novel antibodies and antibody drug conjugates. Seven projects (with funding from CPRIT, NIH, Department of Defense) across 3 Texas state institutions have already been identified, and all 7 have lead molecules that

are ready for core services upon approval. The core would dovetail with an existing CPRIT funded core, the advanced cancer antibody drug modalities core facility, which is generating a pipeline of antibody and antibody drug conjugates leads that will require both PK and toxicology support for further development.

RP210064

PI: Michael Scheurer, Ph.D.

Title: The Adolescent and Childhood Cancer Epidemiology and Susceptibility Service (ACCESS) for Texas

Applicant Organization: Baylor College of Medicine

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 3.1

Recommended Total Budget Award and Duration: *\$4,000,000

CPRIT Priorities Addressed: Investment in core facilities; Childhood Cancers

Description:

This is a renewal award that will continue support of a biorepository and data bank for childhood cancers in Texas with multiple recruitment/data collection centers that utilize the same protocols and data harmonization. The resource is designed to support the conduct of research to identify novel genetic and environmental risk factors and gene-environment interactions important in understanding cancer susceptibility among children and adolescents, particularly among the diverse pediatric population in Texas. While the impact of the resource has yet to be fully realized, continued support is justified because this type of resource requires time to establish and the potential for supporting research to better understand childhood cancer in Texas. *The application request for support that exceeds the RFA maximum limit was not justified by the volume of samples and the number of storage biobank sites proposed and the recommended funding was reduced accordingly.

RP210130

PI: Yong-Fang Kuo, Ph.D.

Title: Data Management and Analysis Core for Comparative Effectiveness Research on Cancer in Texas

Applicant Organization: The University of Texas Medical Branch at Galveston

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 3.1

Recommended Total Budget Award and Duration: \$2,936,731

CPRIT Priorities Addressed: Investment in core facilities

Description:

This new core will support comparative effectiveness research on cancer by providing investigators access to large administrative databases—including Texas Cancer Registry, Texas Medicare/Medicaid linkages, and other national data sets. With these large databases, investigators can examine patterns of care and outcomes in patient subgroups to determine which treatment(s) work best for which patients in specific clinical contexts and assess the effectiveness and safety of interventions in real-world settings, and address, the limitations of randomized controlled clinical trials, such as generalizability, small sample size, and short follow-up. The

core leadership includes two senior investigators and four biostatisticians from UTMB and MD Anderson Cancer Center, who have collaborated for more than 10 years in cancer research using CER databases. They will provide expertise in study design, data management, and statistics analysis to users.

3. Early Clinical Investigator Award (RFA R-21.2 ECI) Slate

Scientific Review Council Recommendations:

Out of eleven Early Clinical Investigator (ECI) grant applications submitted, the SRC recommended five totaling \$7,442,391.

Purpose of Early Clinical Investigator Award:

Solicits applications from institutions to provide cancer physicians early in their academic career the opportunity to develop clinical research skills and to gain experience in advanced methods and experimental approaches needed to become clinical investigators. The award is designed to protect time from clinical responsibilities to allow the early clinical investigator to develop and conduct an investigator initiated clinical trial and to establish a partnership with a laboratory-based collaborator in order to conduct the correlative studies needed to interpret the outcome of the trial. The overall goal of this mechanism is to increase the pool of clinical investigators at Texas academic institutions who are conducting patient-oriented studies, capitalizing on basic discoveries and translating them through conduct of innovative clinical trials involving cancer patients or individuals at risk for cancer.

Early Clinical Investigator Award Funding Levels:

Award: Up to \$1,500,000 (total costs); Maximum duration: 5 years

Recommended ECI Institutions: The University of Texas Southwestern Medical Center, The University of Texas M.D. Anderson Cancer Center, The University of Texas Health Science Center at San Antonio and The University of Texas at Austin.

RP210176

PI: Moran Amit, M.D., Ph.D.

Title: CPRIT Early Clinical Investigator Award: Moran Amit

Applicant Organization: The University of Texas M. D. Anderson Cancer Center

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.0

Recommended Total Budget Award and Duration: \$1,499,042

CPRIT Priorities Addressed: A broad range of innovative, investigator-initiated research projects; Expand access to innovative clinical trials.

Description:

Moran Amit, MD, PhD, is an assistant professor in the Department of Thoracic/Head & Neck Surgery, The University of Texas MD Anderson Cancer Center, where he trained. He received his M.D. from Tel Aviv University and completed surgical training at MD Anderson. He has a

R37 MERIT award for early-stage investigators from the NCI to develop a laboratory research program that is dedicated to studying the head and neck cancer microenvironment. The Early Clinical Investigator award will support development of a clinical trial platform for the local delivery of immunotherapy using intralesional immune checkpoint inhibitor therapy for premalignant lesions of the head and neck. Dr. Padmanee Sharma, co-director of MD Anderson's Moon Shots Program Immunotherapy platform will serve as primary mentor.

RP210159

PI: Carl Gay, M.D., Ph.D.

Title: CPRIT Early Clinical Investigator Award: Carl Gay

Applicant Organization: The University of Texas M. D. Anderson Cancer Center

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.8

Recommended Total Budget Award and Duration: \$1,499,997

CPRIT Priorities Addressed: A broad range of innovative, investigator-initiated research projects; Expand access to innovative clinical trials.

Description:

Carl M Gay, M.D., Ph.D., is an Assistant Professor in the Department of Thoracic/Head & Neck Medical Oncology. He received his M.D./Ph.D. at New York University School of Medicine where his thesis work on angiogenesis was published in *Developmental Cell* and did his medical oncology training at MD Anderson Cancer Center. His Early Clinical Investigator plan is focused on integrating his preclinical work on small cell lung cancer, recently published in both *Nature Cancer* and *Cancer Cell*, into a clinical trial testing the impact of a personalized, biomarker-selected treatment. Lauren Byers, M.D., an expert in small cell lung cancer will serve as Dr. Gay's primary mentor and John Heymach, M.D., Ph.D., Chairman of Thoracic/Head & Neck Medical Oncology and a CPRIT grantee, will serve as co-mentor.

RP210164

PI: William Kelly, M.D.

Title: Early Clinical Investigator Award: William Kelly

Applicant Organization: The University of Texas Health Science Center at San Antonio

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.5

Recommended Total Budget Award and Duration: \$1,499,985

CPRIT Priorities Addressed: A broad range of innovative, investigator-initiated research projects; Expand access to innovative clinical trials.

Description:

William Kelly, M. D., is Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at UT Health Science Center San Antonio. He received his M.D. from the Georgetown University School of Medicine, residency training at University of Texas Medical Branch at Galveston, and oncology and neuro-oncology training at Georgetown and the NIH. His Early Clinical Investigator award will focus on the clinical development of a novel antibody drug conjugate targeting the epithelial glycoprotein Trop2, in the treatment of recurrent glioblastoma.

Drs. Andrew Brenner, a senior neuro-oncologist, and Tyler Curiel, a leading cancer researcher in the field of immunology, will serve as co-mentors.

RP210140

PI: Kalil Abdullah, M.D., MSc

Title: Targeting Altered Metabolism in IDH-Mutant Glioma

Applicant Organization: The University of Texas Southwestern Medical Center

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.6

Recommended Total Budget Award and Duration: \$1,500,000

CPRIT Priorities Addressed: A broad range of innovative, investigator-initiated research projects; Expand access to innovative clinical trials.

Description:

Kalil Abdullah, M. D., MSc, is a neurosurgical oncologist and Assistant Professor in the Department of Neurosurgery, UT Southwestern Medical Center. He received an M.D., from the Cleveland Clinic and neurosurgical training at the University of Pennsylvania. Following his medical training he completed a Howard Hughes Medical Institute Research Scholars Program followed by a post-doctoral research fellowship in the Departments of Bioengineering and Radiation Oncology at Penn where he developed a self-assembling, injectable hydrogel for intracranial drug delivery in gliomas. His Early Clinical Investigator award will support clinical trials testing novel drugs administered preoperatively for a few days to weeks before surgical resection to determine cellular and pharmacodynamic markers of drug target engagement and tumor response in surgically resected glioma tissue prior to adjuvant treatment. Ralph DeBerardinis, MD, PhD a Howard Hughes Medical Institute Investigator and David Gerber, MD Associate Director Clinical Research at the Simmons Comprehensive Cancer Center, will serve as co-mentors.

RP210234

PI: Kyaw Aung, M.D., Ph.D.

Title: Targeting Src Homology-2 Domain-Containing Phosphatase to Overcome Resistance to Immune Checkpoint Blockade in Pancreatic Ductal Adenocarcinoma

Applicant Organization: The University of Texas at Austin

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.7

Recommended Total Budget Award and Duration: \$1,443,367

CPRIT Priorities Addressed: A broad range of innovative, investigator-initiated research projects; Expand access to innovative clinical trials.

Description:

Kyaw Aung, M.D., Ph.D., is an Assistant Professor of Oncology at the University of Texas at Austin. He did medical oncology training in the UK and received a Ph.D. from the University of Manchester where he investigated the utility of mutation testing from circulating tumor DNA as potential predictive biomarkers for mechanism-based cancer therapeutics. He then pursued

fellowship training in phase 1 drug development and GI oncology at the Princess Margaret Cancer Center at the University of Toronto, Canada with Dr. Lillian Siu where he developed a research interest in pancreatic cancer. His Early Clinical Investigator award will provide the opportunity to develop strategies to overcome resistance to immunotherapy in pancreatic cancer. Gail Eckhardt, M.D., Director, Livestrong Cancer Institutes, will serve as the primary mentor.

4. Clinical Trials Network Award (RFA R-21.2 CTNA) Slate

Scientific Review Council Recommendations:

Out of five Clinical Trials Network Award (CTNA) grant applications submitted, the SRC recommended one totaling \$3,000,000.

Purpose of Clinical Trials Network Award:

The Clinical Trials Network Award is designed to provide support to Texas cancer centers with established clinical trials infrastructure and clinical trials portfolio to develop and oversee a network of cancer care facilities that currently have limited access to clinical trials. The award is designed to support 2 network affiliates (stage 1) and once an initial network is satisfactorily demonstrated, the Lead Institution will be eligible to expand its network to two additional facilities located outside its current catchment area (stage 2).

Clinical Trials Network Award Funding Levels:

Award: Up to \$600,000 annually for stage 1 and up to \$900,000, annually for stage 2; Maximum duration: 5 years

Recommended CTNA Institution: The University of Texas M.D. Anderson Cancer Center

RP210122

PI: Michael Overman, M.D.

Title: Building a Clinical Trial Network for Texas Community Affiliates

Applicant Organization: The University of Texas M. D. Anderson Cancer Center

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.5

Recommended Total Budget Award and Duration: \$3,000,000

CPRIT Priorities Addressed: Expand access to innovative clinical trials.

Description:

The Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center will serve as the lead institution for the establishment of a clinical trials network to provide access to therapeutic clinical cancer trials to patients at the Lyndon B. Johnson Hospital of Harris County and the University of Texas Medical Branch in Galveston County, Texas. The program will support evidence-based interventions to increase minority enrollment via use of patient navigators, reimbursement for non-medical clinical-trial participation expenses, and relevant training for research staff and providers. Clinical-trial awareness in underserved communities

will be promoted by harnessing previously established relationships formed by MD Anderson's Center for Community-Engaged Translational Research. Stage-2 site selection will focus upon sites external to the regional Houston area with access to underserved minority populations and tentatively will be The University of Texas at Tyler and the Dell Seton Medical Center at The University of Texas at Austin.

5. Texas Clinical Trials Participation Program Award (RFA R-21.2 TCTPA) Slate

Scientific Review Council Recommendations:

Out of four Texas Clinical Trials Participation Program (TCTPA) grant applications submitted, the SRC recommended two totaling \$2,999,327.

Purpose of the Texas Clinical Trials Participation Program Award:

The Texas Clinical Trials Participation Award is designed to increase the number and diversity of subjects participating in therapeutic cancer clinical trials in Texas by removing the out-of-pocket expenses related to travel to and from clinics, lodging, meals and any extra childcare, as a barrier to participation for financially burdened subjects.

Texas Clinical Trials Participating Program Award Funding Levels:

Award: Up to \$1,500,00 in total costs; Maximum duration: 3 years. A minimum of two-thirds of the award expenditures must be used to reimburse subjects for nonclinical expenses such as travel costs, lodging, parking, tolls, and childcare costs associated with their participation in a therapeutic cancer clinical trial.

Recommended TCTPA Institutions: Baylor College of Medicine and The University of Texas Southwestern Medical Center.

RP210143

PI: Martha Mims, M.D., Ph.D.

Title: Dan L. Duncan Comprehensive Cancer Center Harris Health Clinical Trials Financial Support Project

Applicant Organization: Baylor College of Medicine

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.5

Recommended Total Budget Award and Duration: \$1,500,000

CPRIT Priorities Addressed: Expand access to innovative clinical trials.

Description:

The Duncan Comprehensive Cancer Center at Baylor College of Medicine has more than 40 therapeutic studies open at the Ben Taub Hospital, the Harris County safety-net hospital. But only 34 patients participated in 2019. A needs assessment suggests that more patients would enroll if they could obtain transportation, meals and childcare during study visits and support for an accompanying caregiver. This award will attempt to remove these barriers and improve

participation in therapeutic cancer trials by supporting a patient navigator and providing financial assistance for non-clinical expenses associated with trial participation. They expect this project to reach 258 individual patients over the course of three years.

RP210115

PI: David Gerber, M.D.

Title: Enhancing Access to and Diversity in Cancer Clinical Trials Through a Financial Reimbursement and Outreach Program

Applicant Organization: The University of Texas Southwestern Medical Center

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.7

Recommended Total Budget Award and Duration: \$1,499,327

CPRIT Priorities Addressed: Expand access to innovative clinical trials.

Description:

This award will implement a financial reimbursement and outreach program at clinical sites within the Harold C. Simmons Comprehensive Cancer Center, including UT Southwestern, Parkland Health and Hospital System, and Children’s Health. Project staff will work with clinic personnel and clinical research teams to identify patients considering participation in therapeutic cancer clinical trials. Project staff will provide verbal and written information on and navigate patients through eligibility (up to 700% Federal poverty rate), enrollment, and reimbursement processes. The reimbursement process will be overseen by the Lazarex Cancer Foundation.

**6. HIGH IMPACT/HIGH RISK RESEARCH AWARDS
(RFA R-21.2 HIHR) SLATE**

Scientific Review Council Recommendations:

Out of 105 High Impact/High Risk research award grant applications submitted, the SRC recommended 28, totaling \$6,995,235. Note the SRC recommended application #RP210167, which was subsequently withdrawn by the organization and is not counted in the tally.

Purpose of High Impact/High Risk Research Awards:

Provides short-term funding to explore the feasibility of high-risk projects that, if successful, would contribute major new insights into the etiology, diagnosis, treatment, or prevention of cancers.

High Impact/High Risk Research Award Funding Levels:

Up to \$250,000 (total costs); Maximum duration: 2 years.

Recommended HIHR Institutions (17): The University of Texas at El Paso, Rice University, The University of Texas M. D. Anderson Cancer Center, The Methodist Hospital Research Institute, The University of Texas Medical Branch at Galveston, The University of Texas Health Science Center at Houston, The University of Texas Southwestern Medical Center,

Baylor College of Medicine, The University of Texas at Arlington, The University of Texas at Austin, The University of Texas at Dallas, The University of Texas Health Science Center at San Antonio, Southern Methodist University, Texas A&M University, University of Houston, Texas A&M University System Health Science Center and Baylor University.

Table 4: *High Impact/High Risk Research Awards Recommended for Funding. Note that awards are listed in order of the evaluation score.

ID	Score	Application Title	PI	PI Organization	Budget
RP210165	1.6	Rapid Point-of-Care Detection of Ovarian Cancer Biomarkers Using a Common Thermometer for Low-Resource Settings	Li, Xiujun (James)	The University of Texas at El Paso	\$249,999
RP210205	1.9	Cytokine Factories for the Treatment of Mesothelioma	Veiseh, Omid	Rice University	\$250,000
RP210173	1.9	Multiplex CRISPR Genetic Modeling of Polypharmacology for Precision Medicine	Hart, Traver	The University of Texas M. D. Anderson Cancer Center	\$250,000
RP210144	2.0	Leveraging Glioma Stem Cell Electrophysiology for Therapy	Rostomily, Robert	The Methodist Hospital Research Institute	\$248,028
RP210168	2.0	Overcoming Myeloma Resistance to Proteasome Inhibitors	Yi, Qing	The Methodist Hospital Research Institute	\$250,000
RP210062	2.0	Protein Degradation of CDK9 for Treatment of Drug-Resistant Mantle Cell Lymphoma	Zhou, Jia	The University of Texas Medical Branch at Galveston	\$250,000
RP210073	2.1	Identification of Collateral Lethal and Synthetic Lethal Targets in Pancreatic and Colorectal Cancers	DePinho, Ronald	The University of Texas M. D. Anderson Cancer Center	\$249,994
RP210111	2.1	Single-Cell Proteomics to Dissect Intratumor Heterogeneity	Pan, Sheng	The University of Texas Health Science Center at Houston	\$250,000
RP210134	2.2	High-Throughput Discovery of Anticancer Protein Degradors	Tambar, Uttam	The University of Texas Southwestern Medical Center	\$250,000
RP210158	2.3	Improving CAR T-Cell Therapy of T-ALL by Cotargeting Additional Antigens	Mamonkin, Maksim	Baylor College of Medicine	\$250,000

RP210206	2.4	Novel Tumor-Specific Bioactive Nanoparticles for Cancer Therapy	Nguyen, Kytai	The University of Texas at Arlington	\$249,999
RP210089	2.6	Dissecting Therapeutic Immunomodulation of Gut Microbiome on Colorectal Cancer	Kim, Hyun Jung	The University of Texas at Austin	\$250,000
RP210079	2.7	Targeting Mitochondrial NAD ⁺ in Leukemias	Cambronne, Xiaolu	The University of Texas at Austin	\$250,000
RP210236	2.7	Magnetomechanical Modulation of Blood-Brain Barrier Permeability	Qin, Zhenpeng	The University of Texas at Dallas	\$250,000
RP210105	2.8	Targeting Lymphotoxin Beta Receptor in Sensory Neurons for Control of Chemotherapy-Induced Neuropathic Pain	Tumanov, Alexei	The University of Texas Health Science Center at San Antonio	\$249,996
RP210068	2.8	Role of Aberrant Translational Quality Control in Tumorigenesis of Glioblastoma	Wu, Zhihao	Southern Methodist University	\$249,272
RP210102	2.8	Deciphering BRCA1-BARD1 E3 Ligase Activity in Genome Maintenance and Tumor Suppression	ZHAO, WEIXING	The University of Texas Health Science Center at San Antonio	\$250,000
RP210137	2.8	Development of TCR-Based Immunotherapies Targeting Hotspot EGFR Mutations for the Treatment of Non-Small Cell Lung Cancer	Reuben, Alexandre	The University of Texas M. D. Anderson Cancer Center	\$250,000
RP210092	3.0	Antibody-Drug Conjugate Combination Treatment for Targeting Colorectal Cancer Cell Plasticity	Carmon, Kendra	The University of Texas Health Science Center at Houston	\$250,000
RP210131	3.0	Antibodylike Therapeutics That Target Polyclonal T Cells to CMV-Positive Glioblastomas	Maynard, Jennifer	The University of Texas at Austin	\$250,000
RP210075	3.0	Exploring the Biological Basis of Ethnic and Social Disparities in Pediatric Acute Lymphoblastic Leukemia Outcomes	Schraw, Jeremy	Baylor College of Medicine	\$249,999
RP210199	3.0	Treating Metastatic Cancer Using Microbubble-Assisted Ultrasound-	Lux, Jacques	The University of Texas Southwestern Medical Center	\$249,011

		Guided Immunotherapy of Cancer of Cancer (MUSIC)			
RP210127	3.0	Engineered Enteric Nerve-Perineural Invasion Models to Improve Predictive Preclinical Screens in Early-Stage Colorectal Adenocarcinoma	Raghavan, Shreya	Texas A&M University	\$250,000
RP210148	3.0	Novel Pharmacodynamic Assay to Predict Response to CDK4/6 Inhibitor Therapy	Trivedi, Meghana	University of Houston	\$250,000
RP210070	3.1	Tunable Epigenetic Remodeling to Modulate CAR T-Cell-Based Immunotherapy	Zhou, Yubin	Texas A&M University System Health Science Center	\$250,000
RP210132	3.1	Synergy Between Epigenetic Reprogramming and Wnt Inhibition to Enhance Neuroendocrine Tumor Radionuclide Therapy	Frost, Jeffrey	The University of Texas Health Science Center at Houston	\$249,999
RP210183	3.3	Virulence Modulation of Helicobacter pylori, the Strongest Risk Factor for Gastric Cancer	Kearney, Christopher	Baylor University	\$248,938
RP210213	3.3	Therapeutic Inhibition of Cholangiocarcinoma Progression by Targeting Tumor-Lymphatic Cross Talk	Chakraborty, Sanjukta	Texas A&M University System Health Science Center	\$250,000

*All High-Impact/High Risk Awards meet the following priority: A broad range of innovative, investigator-initiated research projects

7. RECRUITMENT OF RISING STARS SLATE FY21.10, FY21.11 and FY21.12

Peer Review Recommendations

The applications were evaluated and scored by the Scientific Review Council (SRC) to determine the candidates' potential to make a significant contribution to the cancer research program of the nominating institution. Review criteria focused on the overall impression of the candidate and his/her potential for continued superb performance as a cancer researcher, scientific merit of the proposed research program, his/her long-term contribution to and impact on the field of cancer research, and strength of the institutional commitment to the candidate.

Purpose of Recruitment of Rising Stars Awards:

The aim is to recruit outstanding early-stage investigators to Texas, who have demonstrated the promise for continued and enhanced contributions to the field of cancer research.

Funding levels for Recruitment of Rising Stars Awards:

Up to \$4 million over a period of 5 years.

Recommended Awards:

Three Recruitment of Rising Stars grant applications were submitted and two were recommended by the Scientific Review Council for an award.

Recommended Recruitment of Rising Stars Awards Institutions: The Methodist Hospital Research Institute and The University of Texas Southwestern Medical Center.

Below is a listing of the candidates with their associated expertise.

RR210067

Candidate: Yong Lu, Ph.D.

Funding Mechanism: Recruitment of Rising Stars

Applicant Organization: The Methodist Hospital Research Institute

Original Organization of Nominee: Wake Forest School of Medicine

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.7

Recommended Total Budget Award and Duration: \$3,998,389

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas; Hepatocellular Cancer.

Description:

Yong Lu, Ph.D., is recommended for a Rising Star award to support his recruitment to The Methodist Hospital Research Institute from Wake Forest. He is a cancer immunologist with a well-funded program to overcome solid tumor resistance to immune cell therapy. His research is currently funded by 3 R01s including an R37 Merit award that provides longer term grant support to Early-Stage Investigators from the NCI. At Houston Methodist Cancer Center, he plans to work with clinical colleagues at Methodist and the Texas Medical Center to bring novel strategies to overcome resistance of hepatocellular cancers to adoptive immune cell therapy. The clinical translation of his program will be facilitated by the cellular therapy facility at the Houston Methodist Cancer Center.

RR210079

Candidate: Tian Zhang, M.D

Funding Mechanism: Recruitment of Rising Stars

Applicant Organization: The University of Texas Southwestern Medical Center

Original Organization of Nominee: Duke University Medical Center

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.0

Recommended Total Budget Award and Duration: \$4,000,000

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas; Expand access to innovative clinical trials.

Description:

Tian Zhang, M.D., is a cancer clinical trialist who is recommended for a Rising Star award to support her recruitment to The University of Texas Southwestern Medical Center from Duke University. Dr. Zhang graduated *magna cum laude* from Columbia University with a B.A. in Biochemistry and then earned an M.D. from the combined Harvard Medical School/MIT program in Health Sciences and Technology. She completed an internal medicine residency, a fellowship in Medical Oncology, and a Master of Health Science at Duke. Dr. Zhang is a recognized expert in the management of renal cell cancer and a leader in research designed to answer biological and clinical questions through translational methods.

**8. RECRUITMENT FIRST-TIME TENURE TRACK FACULTY MEMBERS
SLATE FY21.10, FY21.11 and FY21.12****Peer Review Recommendations**

The applications were evaluated and scored by the Scientific Review Council to determine the candidates' potential to make a significant contribution to the cancer research program of the nominating institution. Review criteria focused on the overall impression of the candidate and his/her potential for continued superb performance as a cancer researcher, his/her scientific merit of the proposed research program, his/her long-term contribution to and impact on the field of cancer research, and strength of the institutional commitment to the candidate.

Purpose of First Time Tenure Track Faculty Recruitment

The aim is to recruit and support very promising emerging investigators, pursuing their first faculty appointment in Texas, who can make outstanding contributions to the field of cancer research.

Funding levels for First Time Tenure Track Faculty Members Recruitment

Up to \$2 million over a period of up to 5 years.

Recommended Projects:

Twenty-one Recruitment of First-Time Tenure Track Faculty Members grant applications were submitted and eleven were recommended by the Scientific Review Council for an award. Note grant application #RR210055 recommended by the SRC was withdrawn by the organization prior to PIC.

Recommended Recruitment of First-Time Tenure Track Faculty Members: Baylor College of Medicine, The University of Texas Southwestern Medical Center, The University of Texas M.D. Anderson Cancer Center and Texas A&M University.

Below is a listing of the ten candidates with their associated expertise.

RR210056

Candidate: Xia Gao, Ph.D.

Funding Mechanism: Recruitment of First Time Tenure Track Faculty Member

Applicant Organization: Baylor College of Medicine

Original Organization of Nominee: Duke University School of Medicine

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.0

Recommended Total Budget Award and Duration: \$2,000,000.

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas

Description:

Xia Gao, Ph.D., is recommended for a First Time Tenure Track Faculty Member award to support her recruitment to Baylor College of Medicine from Duke where she currently has a K99/R00 pathway to independence award from the NCI. Dr. Gao's career goals focus on the investigation of nutritional interventions as cancer prevention and cancer treatment.

RR210059

Candidate: Javier Garcia-Bermudez, Ph.D.

Funding Mechanism: Recruitment of First Time Tenure Track Faculty Member

Applicant Organization: The University of Texas Southwestern Medical Center

Original Organization of Nominee: The Rockefeller University

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.0

Recommended Total Budget Award and Duration: \$2,000,000.

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas

Description:

Javier Garcia-Bermudez, Ph.D., is recommended for a First Time Tenure Track Faculty Member award to support his recruitment to Children's Research Institute at UT Southwestern from Rockefeller University where he has a K99/R00 award. He plans to investigate the mechanisms by which squalene and other endogenous antioxidants support cancer progression and to use genomic screens to identify new metabolic pathways that protect cancer cells against oxidative stress.

RR210066

Candidate: Chad W. Johnston, DrPH

Funding Mechanism: Recruitment of First Time Tenure Track Faculty Member

Applicant Organization: Baylor College of Medicine

Original Organization of Nominee: Massachusetts Institute of Technology

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.0

Recommended Total Budget Award and Duration: \$2,000,000.

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas;
Hepatocellular Cancer

Description:

Chad Johnston, Ph.D., is recommended for a First Time Tenure Track Faculty Member award to support his recruitment to Baylor College of Medicine from MIT. He is a natural products chemist who intends to discover new antibiotics with a focus on re-programming the microbiome to fight cancer.

RR210082

Candidate: Kyle Eagen, Ph.D.

Funding Mechanism: Recruitment of First Time Tenure Track Faculty Member

Applicant Organization: Baylor College of Medicine

Original Organization of Nominee: Northwestern University Feinberg School of Medicine

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.0

Recommended Total Budget Award and Duration: \$2,000,000.

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas; Computational Biology

Description:

Kyle Eagen, Ph.D. is recommended for a First Time Tenure Track Faculty award to support his recruitment to Baylor College of Medicine from Northwestern. As a Feinberg Fellow at Northwestern University, he obtained an NIH Directors Early Independence Award and has established his own research group using genomic and computational methods to investigate chromosome structure. At Baylor College of Medicine, his research will focus on the link between oncogenic mutations and aberrant chromosome structure.

RR210077

Candidate: Edward J. Grow, Ph.D.

Funding Mechanism: Recruitment of First Time Tenure Track Faculty Member

Applicant Organization: The University of Texas Southwestern Medical Center

Original Organization of Nominee: University of Utah

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.9

Recommended Total Budget Award and Duration: \$2,000,000.

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas; Childhood cancer (Sarcomas).

Description:

Edward Grow, Ph.D., is recommended for a First Time Tenure Track Faculty Member award to support his recruitment to The University of Texas Southwestern Medical Center from the Huntsman Institute at the University of Utah. As a post-doc he discovered a novel DNA damage response involving p53 activation of a transposable element network and he will test the idea that this network can be activated to promote anti-tumor immunity in rhabdomyosarcoma.

RR210085

Candidate: Yuan Pan, Ph.D.

Funding Mechanism: Recruitment of First Time Tenure Track Faculty Member

Applicant Organization: The University of Texas M.D. Anderson Cancer Center

Original Organization of Nominee: Stanford University

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.9

Recommended Total Budget Award and Duration: \$2,000,000.

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas

Description:

Yuan Pan, Ph.D., is recommended for a First Time Tenure Track Faculty award to support her recruitment to MD Anderson from Stanford University. As a postdoctoral fellow she published high impact work on brain tumor microenvironment. At MD Anderson she plans to follow-up her finding of a link between neural activity and carcinogenesis both in the central nervous system and the peripheral nervous system.

RR210083

Candidate: David Braun, M.D., Ph.D.

Funding Mechanism: Recruitment of First Time Tenure Track Faculty Member

Applicant Organization: The University of Texas M. D. Anderson Cancer Center

Original Organization of Nominee: Dana-Farber Cancer Institute

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.0

Recommended Total Budget Award and Duration: \$2,000,000.

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas;
Computational Biology

Description:

David Braun, M.D., Ph.D., is a physician scientist recommended for a First Time Tenure Track Faculty award to support his recruitment to MD Anderson from the Dana Farber/Harvard Cancer Center. He received his Ph.D. in computational biology from NYU in 2012 and his M.D. in 2013 from Mount Sinai. He was a resident in internal medicine at Brigham and Women's followed by a fellowship in hematology and oncology at Dana Farber. His research proposal is focused on renal cell carcinoma where he will use his skills in computational biology to discover neoantigens and T cell populations with greater activity against renal cell cancers.

RR210086

Candidate: Seungwon "Sebastian" Choi, Ph.D.

Funding Mechanism: Recruitment of First Time Tenure Track Faculty Member

Applicant Organization: The University of Texas Southwestern Medical Center

Original Organization of Nominee: Harvard Medical School

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.0

Recommended Total Budget Award and Duration: \$2,000,000.

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas

Description:

Seungwon "Sebastian" Choi, Ph.D., is recommended for a First Time Tenure Track Faculty award to support his recruitment as an Assistant Professor in the Department of Psychiatry at UT Southwestern from Harvard. As a postdoctoral fellow he identified two genetically defined populations of spinal projection neurons that mediate pain. At UT Southwestern he plans to apply the tools developed during his postdoctoral work to the study of cancer pain using melanoma metastases models developed by CPRIT Established Investigator Sean Morrison.

RR210080

Candidate: Jason George, M.D., Ph.D.

Funding Mechanism: Recruitment of First Time Tenure Track Faculty Member

Applicant Organization: Texas A&M Engineering Experiment Station

Original Organization of Nominee: The University of Texas M.D. Anderson Cancer Center

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.0

Recommended Total Budget Award and Duration: \$1,999,309

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas; Computational Biology

Description:

Jason George, M.D., Ph.D., is recommended for a First Time Tenure Track Faculty Member award to support his recruitment to Texas A&M from Rice University and MD Anderson. He is a physician-engineer with an M.D. from Baylor and a Ph.D. from Rice. He plans to leverage his dual expertise in mathematics and medicine to develop a mathematical model to quantify the degree to which cancer populations employ adaptive, immune-specific evasion strategies, and to propose model-predicted hematopoietic stem cell transplant strategies in the setting of acute myeloid leukemia. His research program will be in the Texas Medical Center where he will collaborate with clinical oncologists at MD Anderson.

RR210070

Candidate: Shih-Han Lee, Ph.D.

Funding Mechanism: Recruitment of First Time Tenure Track Faculty Member

Applicant Organization: The University of Texas M. D. Anderson Cancer Center

Original Organization of Nominee: Memorial Sloan Kettering Cancer Center

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.3

Recommended Total Budget Award and Duration: \$2,000,000.

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas; Childhood cancer (Leukemias)

Description:

Shih-Han Lee, Ph.D., is recommended for a First Time Tenure Track Faculty Member award to support her recruitment to The University of Texas M. D. Anderson Cancer Center from Memorial Sloan Kettering. Dr. Lee's research goals are to understand the mechanisms by which RNA processing is altered in leukemias, including CLL and childhood acute lymphoblastic leukemia.

Ludwig Institute for
Cancer Research Ltd

Richard D. Kolodner
Ph.D.

Head, Laboratory of
Cancer Genetics
San Diego Branch

Distinguished Professor of
Cellular & Molecular
Medicine, University of
California San Diego School
of Medicine

rkolodner@health.ucsd.edu

San Diego Branch

UC San Diego School of
Medicine
CMM-East / Rm 3058
9500 Gilman Dr - MC 0660
La Jolla, CA 92093-0660

T 858 534 7804
F 858 534 7750

July 21, 2021

Mr. Dee Margo
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dee@deemargo.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Mr. Margo and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for Core Facility Support Awards (CFSA), Clinical Trials Network Awards (CTNA), Early Clinical Investigator Awards (ECI), High-Impact/High Risk Awards (HIHR), Texas Clinical Trials Participation Awards (TCTPA) and Texas Regional Excellence in Cancer Award (TREC).

The SRC met on July 8, 2021 to consider the applications recommended by the peer review panels following their meetings held May 20, 2021 – May 27, 2021.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the applications recommended is \$75,418,344. *Please note that the peer review panels and SRC recommended reduced budgets for applications # RP210180 and #RP210064, the reductions are reflected in the table.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Rank	ID	Mechanism	Score	Application Title	PI	Organization	Rec. Budget
1	RP210227	CFSA	1.0	Proteomics and Metabolomics Core Facility	Edwards, Dean	Baylor College of Medicine	\$3,977,681
2	RP210176	ECI	1.0	CPRIT Early Clinical Investigator Award: Moran Amit	Draetta, Gulio	The University of Texas M. D. Anderson Cancer Center	\$1,499,042
3	RP210208	CFSA	1.1	Center for Innovative Drug Discovery: Expansion of a Highly Productive Shared Cancer Drug Discovery Resource for Texas	McHardy, Stanton	The University of Texas at San Antonio	\$3,087,131
4	RP210143	TCTPA	1.5	Dan L. Duncan Comprehensive Cancer Center (DLDCCC) Harris Health Clinical Trials Financial Support Project	Mims, Martha	Baylor College of Medicine	\$1,500,000
5	RP210165	HIHRRRA	1.6	Rapid Point-of-Care Detection of Ovarian Cancer Biomarkers Using a Common Thermometer for Low-Resource Settings	Li, Xiujun (James)	The University of Texas at El Paso	\$249,999
6	RP210115	TCTPA	1.7	Enhancing Access to and Diversity in Cancer Clinical Trials Through a Financial Reimbursement and Outreach Program	Gerber, David	The University of Texas Southwestern Medical Center	\$1,499,327
7	RP210159	ECI	1.8	CPRIT Early Clinical Investigator Award: Carl Gay	Draetta, Gulio	The University of Texas M. D. Anderson Cancer Center	\$1,499,997

8	RP210088	CFSA	1.9	Targeted Therapeutic Drug Discovery and Development Program	Dalby, Kevin	The University of Texas at Austin	\$3,989,441
9	RP210205	HIHRRA	1.9	Cytokine Factories for the Treatment of Mesothelioma	Veiseh, Omid	Rice University	\$250,000
10	RP210173	HIHRRA	1.9	Multiplex CRISPR Genetic Modeling of Polypharmacology for Precision Medicine	Hart, Traver	The University of Texas M. D. Anderson Cancer Center	\$250,000
11	RP210108	CFSA	2.0	The GCC Microphysiological Lead Optimization and Toxicity Screening Facility	Stephan, Clifford	Texas A&M University System Health Science Center	\$3,973,083
12	RP210144	HIHRRA	2.0	Leveraging Glioma Stem Cell Electrophysiology for Therapy	Rostomily, Robert	The Methodist Hospital Research Institute	\$248,028
13	RP210168	HIHRRA	2.0	Overcoming Myeloma Resistance to Proteasome Inhibitors	Yi, Qing	The Methodist Hospital Research Institute	\$250,000
14	RP210062	HIHRRA	2.0	Protein Degradation of CDK9 for Treatment of Drug-Resistant Mantle Cell Lymphoma	Zhou, Jia	The University of Texas Medical Branch at Galveston	\$250,000
15	RP210154	TREC	2.0	Texas Regional Excellence in Cancer Developmental Therapeutics Center at TTUHSC	Reynolds, Charles	Texas Tech University Health Sciences Center	\$5,999,936
16	RP210073	HIHRRA	2.1	Identification of Collateral Lethal and Synthetic Lethal Targets in	DePinho, Ronald	The University of Texas M. D. Anderson Cancer Center	\$249,994

				Pancreatic and Colorectal Cancers			
17	RP210111	HIHRRRA	2.1	Single-Cell Proteomics to Dissect Intratumor Heterogeneity	Pan, Sheng	The University of Texas Health Science Center at Houston	\$250,000
18	RP210134	HIHRRRA	2.2	High-Throughput Discovery of Anticancer Protein Degradors	Tambar, Uttam	The University of Texas Southwestern Medical Center	\$250,000
19	RP210116	CFSA	2.3	The Genetic Design and Engineering Center (GDEC): A CPRIT Core Facility	Bao, Gang	Rice University	\$4,000,000
20	RP210158	HIHRRRA	2.3	Improving CAR T-Cell Therapy of T-ALL by Cotargeting Additional Antigens	Mamonkin, Maksim	Baylor College of Medicine	\$250,000
21	RP210206	HIHRRRA	2.4	Novel Tumor-Specific Bioactive Nanoparticles for Cancer Therapy	Nguyen, Kytai	The University of Texas at Arlington	\$249,999
22	RP210180	CFSA	2.5	Integrated Cancer Research Core (ICRC)	CHAUHAN, SUBHASH	The University of Texas Rio Grande Valley	*\$2,525,000
23	RP210126	CFSA	2.5	High-Parameter Analysis, Sorting, and Imaging Flow Cytometry Shared Resource	Berton, Michael	The University of Texas Health Science Center at San Antonio	\$3,645,500
24	RP210122	CTNA	2.5	Building a Clinical Trial Network for Texas Community Affiliates	Overman, Michael	The University of Texas M. D. Anderson Cancer Center	\$3,000,000
25	RP210164	ECI	2.5	Early Clinical Investigator Award: William Kelly	Hromas, Robert	The University of Texas Health Science Center at San Antonio	\$1,499,985
26	RP210140	ECI	2.6	Targeting Altered Metabolism in IDH-Mutant Glioma	Arteaga, Carlos	The University of Texas Southwestern Medical Center	\$1,500,000

27	RP210089	HIHRRA	2.6	Dissecting Therapeutic Immunomodulation of Gut Microbiome on Colorectal Cancer	Kim, Hyun Jung	The University of Texas at Austin	\$250,000
28	RP210079	HIHRRA	2.7	Targeting Mitochondrial NAD+ in Leukemias	Cambronne, Xiaolu	The University of Texas at Austin	\$250,000
29	RP210236	HIHRRA	2.7	Magnetomechanical Modulation of Blood-Brain Barrier Permeability	Qin, Zhenpeng	The University of Texas at Dallas	\$250,000
30	RP210234	ECI	2.7	Targeting Src Homology-2 Domain-Containing Phosphatase to Overcome Resistance to Immune Checkpoint Blockade in Pancreatic Ductal Adenocarcinoma	Johnston, Sterling	The University of Texas at Austin	\$1,443,367
31	RP210105	HIHRRA	2.8	Targeting Lymphotoxin Beta Receptor in Sensory Neurons for Control of Chemotherapy-Induced Neuropathic Pain	Tumanov, Alexei	The University of Texas Health Science Center at San Antonio	\$249,996
32	RP210068	HIHRRA	2.8	Role of Aberrant Translational Quality Control in Tumorigenesis of Glioblastoma	Wu, Zhihao	Southern Methodist University	\$249,272
33	RP210102	HIHRRA	2.8	Deciphering BRCA1-BARD1 E3 Ligase Activity in Genome Maintenance and Tumor Suppression	ZHAO, WEIXING	The University of Texas Health Science Center at San Antonio	\$250,000

34	RP210099	CFSA	2.8	North Texas Multimodal Small-Animal Imaging Core Facility	Henning, Anke	The University of Texas Southwestern Medical Center	\$3,999,929
35	RP210137	HIHRRA	2.8	Development of TCR-Based Immunotherapies Targeting Hotspot EGFR Mutations for the Treatment of Non-Small Cell Lung Cancer	Reuben, Alexandre	The University of Texas M. D. Anderson Cancer Center	\$250,000
36	RP210209	CFSA	2.9	North Texas Clinical Pharmacology Cancer Core	Putnam, William	Texas Tech University Health Sciences Center	\$2,965,226
37	RP210092	HIHRRA	3.0	Antibody-Drug Conjugate Combination Treatment for Targeting Colorectal Cancer Cell Plasticity	Carmon, Kendra	The University of Texas Health Science Center at Houston	\$250,000
38	RP210131	HIHRRA	3.0	Antibodylike Therapeutics That Target Polyclonal T Cells to CMV-Positive Glioblastomas	Maynard, Jennifer	The University of Texas at Austin	\$250,000
39	RP210075	HIHRRA	3.0	Exploring the Biological Basis of Ethnic and Social Disparities in Pediatric Acute Lymphoblastic Leukemia Outcomes	Schraw, Jeremy	Baylor College of Medicine	\$249,999
40	RP210199	HIHRRA	3.0	Treating Metastatic Cancer Using Microbubble-Assisted Ultrasound-Guided Immunotherapy of	Lux, Jacques	The University of Texas Southwestern Medical Center	\$249,011

				Cancer of Cancer (MUSIC)			
41	RP210127	HIHRRA	3.0	Engineered Enteric Nerve-Perineural Invasion Models to Improve Predictive Preclinical Screens in Early-Stage Colorectal Adenocarcinoma	Raghavan, Shreya	Texas A&M University	\$250,000
42	RP210148	HIHRRA	3.0	Novel Pharmacodynamic Assay to Predict Response to CDK4/6 Inhibitor Therapy	Trivedi, Meghana	University of Houston	\$250,000
43	RP210119	CFSA	3.1	A Preclinical Development Core for Large-Molecule Therapeutics	Liu, Qingyun	The University of Texas Health Science Center at Houston	\$3,999,999
44	RP210064	CFSA	3.1	The Adolescent and Childhood Cancer Epidemiology and Susceptibility Service (ACCESS) for Texas	Scheurer, Michael	Baylor College of Medicine	*\$4,000,000
45	RP210130	CFSA	3.1	Data Management and Analysis Core for Comparative Effectiveness Research on Cancer in Texas	Kuo, Yong-Fang	The University of Texas Medical Branch at Galveston	\$2,936,731
46	RP210070	HIHRRA	3.1	Tunable Epigenetic Remodeling to Modulate CAR T-Cell-Based Immunotherapy	Zhou, Yubin	Texas A&M University System Health Science Center	\$250,000
47	RP210132	HIHRRA	3.1	Synergy Between Epigenetic Reprogramming and Wnt Inhibition to Enhance	Frost, Jeffrey	The University of Texas Health Science Center at Houston	\$249,999

				Neuroendocrine Tumor Radionuclide Therapy			
48	RP210153	TREC	3.1	UTEP/UTMDACC Partnership for Hispanic Cancer Disparities Research	Cox, Marc	The University of Texas at El Paso	\$5,881,734
49	RP210183	HIHRRA	3.3	Virulence Modulation of Helicobacter pylori, the Strongest Risk Factor for Gastric Cancer	Kearney, Christopher	Baylor University	\$248,938
50	RP210213	HIHRRA	3.3	Therapeutic Inhibition of Cholangiocarcinoma Progression by Targeting Tumor-Lymphatic Cross Talk	Chakraborty, Sanjukta	Texas A&M University System Health Science Center	\$250,000

CFSA = Core Facility Support Awards

CTNA = Clinical Trials Network Award

ECI = Early Clinical Investigator Awards

HIHR = High-Impact/High Risk Awards

TCTPA = Texas Clinical Trials Participation Award

TREC = Texas Regional Excellence in Cancer Award

San Diego

**Ludwig Institute for
Cancer Research Ltd**

**Richard D. Kolodner
Ph.D.**

Head, Laboratory of
Cancer Genetics
San Diego Branch

Distinguished Professor of
Cellular & Molecular
Medicine, University of
California San Diego School
of Medicine

rkolodner@health.ucsd.edu

San Diego Branch

UC San Diego School of
Medicine
CMM-East / Rm 3058
9500 Gilman Dr - MC 0660
La Jolla, CA 92093-0660

T 858 534 7804
F 858 534 7750

July 21, 2021

Mr. Dee Margo
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dee@deemargo.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Mr. Margo and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of recruitment grant recommendations. The SRC met on May 13, 2021 (REC Cycle 21.10), on June 10, 2021 (REC Cycle 21.11) and on July 8, 2021 (REC Cycle 21.12) to review the applications submitted to CPRIT under the Recruitment of Established Investigators, Recruitment of Rising Stars and Recruitment of First-Time, Tenure Track Faculty Members.

The projects on the attached list are numerically ranked in the order the SRC recommends the applications be funded. Recommended funding amounts and the overall evaluation scores are stated for each grant application. There were no recommended changes to funding amounts, goals, timelines, or project objectives requested. The total amount for the applications recommended is \$27,997,698.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting candidates at all career levels that have demonstrated academic excellence, innovation, excellent training, a commitment to cancer research and exceptional potential for achieving future impact in basic, translational, population based or clinical research.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Rank	ID	Award Mechanism	Candidate	Organization	Budget	Final Overall Score
1	RR210082	RFTFM	Dr. Kyle Eagen	Baylor College of Medicine	\$2,000,000	1.0
2	RR210066	RFTFM	Dr. Chad W. Johnston	Baylor College of Medicine	\$2,000,000	1.0
3	RR210056	RFTFM	Dr. Xia Gao	Baylor College of Medicine	\$2,000,000	1.0
4	RR210059	RFTFM	Dr. Javier Garcia-Bermudez	The University of Texas Southwestern Medical Center	\$2,000,000	1.0
5	RR210067	RRS	Dr. Yong Lu	The Methodist Hospital Research Institute	\$3,998,389	1.7
6	RR210085	RFTFM	Dr. Yuan Pan	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.9
7	RR210077	RFTFM	Dr. Edward J. Grow	The University of Texas Southwestern Medical Center	\$2,000,000	1.9
8	RR210083	RFTFM	Dr. David Braun	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	2.0
9	RR210086	RFTFM	Dr. Seungwon "Sebastian" Choi	The University of Texas Southwestern Medical Center	\$2,000,000	2.0
10	RR210079	RRS	Dr. Tian Zhang	The University of Texas Southwestern Medical Center	\$4,000,000	2.0
11	RR210080	RFTFM	Dr. Jason George	Texas A&M Engineering Experiment Station	\$1,999,309	2.0
12	RR210070	RFTFM	Dr. Shih-Han Lee	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	2.3

*RRS = Recruitment of Rising Stars

RFTFM = Recruitmen of First-Time, Tenure Track Faculty Members

Prevention Program Priorities Addressed by Recommended Awards August 18, 2021

Prioritize populations disproportionately affected by cancer incidence, mortality or cancer risk prevalence	Prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality or cancer risk prevalence	Prioritize underserved populations
--	--	---

**\$11,396,581
9 projects**

- PP210007
- PP210020
- PP210026
- PP210027
- PP210031
- PP210042
- PP210044
- PP210045
- PP210049

**\$11,096,603
8 projects**

- PP210007
- PP210020
- PP210027
- PP210031
- PP210042
- PP210044
- PP210045
- PP210049

**\$11,386,581
9 projects**

- PP210007
- PP210020
- PP210026
- PP210027
- PP210031
- PP210042
- PP210044
- PP210045
- PP210049

Note: Some grant awards address more than one program priority and will be double counted.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: CPRIT OVERSIGHT COMMITTEE MEMBERS
FROM: RAMONA MAGID, CHIEF PREVENTION OFFICER
SUBJECT: PREVENTION GRANT RECOMMENDATIONS – FY 2021 CYCLE 1
DATE: AUGUST 10, 2021

Summary and Recommendation:

The Program Integration Committee (PIC) has completed its review of the recommendations forwarded by the Prevention Review Council (PRC). The PIC recommends awarding 9 projects for FY 2021 Cycle 2 totaling \$11,396,581. One of the recommended projects, PP210007, was deferred from Cycle 21.1. The grant recommendations are presented in four slates.

Grant Mechanism	Number	Amount
<i>Evidence-Based Cancer Prevention Services</i>	1	\$ 1,000,000
<i>Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations</i>	2	\$ 4,497,017
<i>Tobacco Control and Lung Cancer Screening</i>	3	\$ 4,999,604
<i>Dissemination of CPRIT-Funded Cancer Control Interventions</i>	3	\$ 899,960
TOTAL	9	\$11,396,581

Background:

FY 2021 Cycle 1 (21.2)

CPRIT released four (4) RFAs in August 2021 for the second review cycle of FY 2021. Twenty-two (22) applications were submitted and fourteen (14) prevention applications requesting \$17,801,576 underwent peer review and discussion by teleconference on April 26 and 27, 2021. Four (4) Dissemination applications requesting \$1,198,638 were reviewed by the PRC on May 27. Programmatic review by the PRC was conducted March 4, 2021.

Program Priorities Addressed

All the recommended applications address one or more of the Prevention Program priorities. Some applications address more than one priority. See the attached chart for additional detail.

Number of Applications Addressing Priorities		
9	Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence	\$11,396,581
8	Prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence	\$11,096,603
9	Prioritize underserved populations	\$11,396,581

Prevention Program Slates

Evidence-Based Cancer Prevention Services

Mechanism: This award mechanism seeks to fund projects that will deliver evidence-based cancer prevention and control clinical services. Priority will be given to projects that propose to address CPRIT areas of emphasis and serve areas of the state not well addressed by current CPRIT funded projects.

Award: Maximum of \$1.0M; Maximum duration of 36 months.

Recommended projects (1): \$1,000,000

Ten (10) applications were submitted in this mechanism. One (1) Evidence-Based Cancer Prevention Services project is recommended.

Project Description

PP210049	Texas Southern University Breast Cancer Screening and Prevention Center	Ajewole, Veronica	Texas Southern University	1.8	\$1,000,000
CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize underserved populations					

Texas Southern University proposes to expand the Breast Cancer Screening and Prevention Center to provide 1) breast cancer screening and diagnostic services to eligible AA and other ethnic minority women who are first time or rarely screened 2) patient navigation/barrier reduction services, and 3) evidence-based culturally appropriate breast cancer awareness and education services for women living in Harris, Grimes, Matagorda, Walker, and Wharton counties. Partnerships with community churches, centers, and libraries, and Federally Qualified Health Centers will be instrumental to recruitment and outreach efforts. Mobile mammography will be provided by The Rose and Assured Imaging and clinic mammograms will be available at the Houston Methodist Breast Cancer Centers. Barrier reduction services, such as scheduling services, appointment reminders, and transportation assistance, will be provided.

Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations

Mechanism:

This award mechanism seeks to support the coordination and expansion of evidence-based services to prevent cancer in underserved populations who do not have adequate access to cancer

prevention interventions and health care, bringing together networks of public health and community partners to carry out programs tailored for their communities. Projects should identify cancers that cause the most burden in the community and use evidence-based models shown to work in similar communities to prevent and control these cancers. Currently funded CPRIT projects should propose to expand their programs to include additional types of prevention clinical services and/or an expansion of current clinical services into additional counties. In either case, the expansion must include delivery of services to nonmetropolitan and medically underserved counties in the state.

Award: Maximum of \$2M for initial expansions and \$2.5M for maintenance expansions; Maximum duration of 60 months.

Recommended projects (2): \$4,497,017

Three (3) applications were submitted in this mechanism. Two (2) Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations projects are recommended. One of these, PP210007, was deferred from Cycle 21.1.

Project Descriptions

PP210020	Vaccinating Medically Underserved Women Against HPV: Expansion of Clinical Services to Increase Access	Berenson, Abbey	The University of Texas Medical Branch at Galveston	2.0	\$1,999,988
CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize underserved populations					

This project proposes to expand on the successful program that offers the HPV vaccine at no cost to women attending UTMB’s Regional Maternal Child Health Program clinics in Hidalgo and Galveston counties and to add a 3rd clinical site to increase access for women from 3 additional medically underserved counties (Cameron, Matagorda, and Wharton). To increase provider recommendation of the vaccine during and after the project has been completed, UTMB medical, nursing and nurse practitioner students will also be trained on how to counsel patients and offer the vaccine at every opportunity. Information about the importance of getting vaccinated will be widely disseminated throughout the targeted communities through partnerships with 5 colleges serving low-income students as well as 2 community health clinics and 5 WIC offices.

PP210007	Strengthening Safety Net Health Systems to Improve Cervical and Colorectal Cancer Screening and Follow-up among the Medically Underserved	Montealegre, Jane R	Baylor College of Medicine	3.3	\$2,497,029
CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize underserved populations					

This project proposes to build on the colorectal and cervical cancer screening services, education, and navigation delivered by the Community Network for Cancer Prevention, an academic-community partnership to empower medically underserved Harris County residents to seek and obtain cancer prevention, screening, and follow-up services. The network includes Harris Health System and other safety net providers. The proposed program will address critical gaps and challenges of sustaining comprehensive cancer control programs in safety net health systems with low resources. Proposed strategies include implementation of health system changes to increase capacity and expand access to screening, eliminate missed opportunities, and ensure follow-up through the cancer continuum of care; and adaptation and implementation of community-based strategies to promote screening among medically underserved residents. Specific new components include implementing a mailed home-based fecal immunochemical test (FIT) program for CRC screening, using patient education videos to increase access to telehealth, and expanding outreach to the Vietnamese community, among others.

Tobacco Control and Lung Cancer Screening

Mechanism: This award mechanism seeks to fund programs on tobacco prevention and cessation, as well as screening for early detection of lung cancer. Through release of this RFA, CPRIT’s goal is to stimulate more programs across the state, thereby providing greater access for underserved populations and reducing the incidence and mortality rates of tobacco-related cancers. This RFA seeks to promote and deliver evidence-based programming designed to significantly increase tobacco cessation among adults and/or prevent tobacco use by youth.

Award: Maximum of \$2M for expansion projects and \$1M for new projects; Maximum duration of 36 months.

Recommended projects (3): \$4,999,604

Five (5) applications were submitted in this mechanism. Three (3) tobacco control and lung cancer screening projects are recommended.

Project Descriptions

PP210042	A Regional Expansion of Lung Cancer Screening and Patient Navigation (E-LSPAN)	Argenbright, Keith	The University of Texas Southwestern Medical Center	2.1	\$1,999,993
CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize underserved populations					

The Lung Cancer Screening and Patient Navigation (E-LSPAN) program proposes to leverage existing framework including community outreach and health promotion, comprehensive lung cancer screening with nurse-driven clinical navigation through follow-up and treatment where appropriate, supported by tobacco cessation education and counseling, and centralized reimbursement for local providers. The evidence-based program will bring lung cancer screening into real-world settings across 26 rural and underserved North Texas, including

eight additional counties. Providers identified through targeted community outreach will refer screen-eligible patients to the program once shared-decision making has occurred. These patients will then receive lung cancer screening supported by telephone-based navigation, with tobacco cessation education counseling being offered to patients who are active smokers. Linkage to care will be navigated by the program team and delivered by clinical partners within the region. E-LSPAN will provide multilevel support to facilitate completion of the screening episode as defined for lung cancer, up to and including the start of treatment. A patient-centered approach to quality metrics will standardize the evaluation approach, allowing for comparisons between organ sites and identify potential intervention points within the screening process to support optimization of delivery and improve screening process outcomes.

PP210027	Increasing Accessibility to Smoking Cessation and Lung Cancer Screening Services for Low-Income/Uninsured Texans	McKnight, Jason	Texas A&M University System Health Science Center	3.1	\$999,947
----------	--	-----------------	---	-----	-----------

CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize underserved populations

This project proposes to provide lung cancer prevention education, support smoking cessation activities, perform low dose CT screenings (LDCT), and provide patient navigation across the continuum of care to qualifying persons. This project will operate in sync with the lung cancer screening/early detection program at St. Joseph Regional Health Center, leverage existing well-established clinical and community partnerships to obtain referrals from safety-net providers, and incorporate community health workers for patient education and intake, barriers reduction, and navigation to services. The project coordinates LDCT screening and relevant diagnostics, with a robust program of smoking cessation intervention.

PP210044	Expansion of the Lung Cancer Screening and Tobacco Control (LCTC) Network to Rural and Medically Underserved Populations	Zoorob, Roger	Baylor College of Medicine	3.6	\$1,999,664
----------	--	---------------	----------------------------	-----	-------------

CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize underserved populations

In partnership with Harris Health System and Baylor-St. Luke’s Medical Group, the LUNG CANCER SCREENING AND TOBACCO CONTROL (LCTC) NETWORK proposes to reduce disparities in access and outcomes in 29 clinics in Metropolitan Houston and rural, high-risk/high poverty populations in two counties in Southeast TX. Outreach and education about lung cancer prevention, including tobacco cessation and screening guidelines and services, will reach age-eligible community residents served by the LCTC network through a community engagement collaborative. The multi-level strategy will operationalize and coordinate services

according to a detailed Lung Cancer Screening (LCS) program implementation guide which includes process flow maps, Electronic Medical Records enhancement, clinic-specific plans for integration, and expansion of integrative pharmacotherapy and behavioral therapy services onsite. The project aims to address gaps in lung cancer screening and provider training through an expanded network of high-priority venues. Primary care providers will be trained to use evidence-based shared decision making and screening tools that promote increased identification, screening, and management of high-risk patients for lung cancer and be trained on smoking cessation practices, local services, and referral protocols. Smoking cessation treatment will be provided to all patients before and after lung cancer screening.

Dissemination of CPRIT-Funded Cancer Control Interventions

Mechanism: This award mechanism seeks to fund projects that will facilitate the dissemination and implementation of successful CPRIT-funded, evidence-based cancer prevention and control interventions across Texas. The proposed project should be able to develop one or more “products” based on the results of the CPRIT-funded intervention. The proposed project should also identify and assist others to prepare to implement the intervention and/or prepare for grant funding. Award: Maximum of \$300,000; Maximum duration of 24 months

Recommended projects (3): \$899,960

Four (4) applications were submitted in this mechanism. Three (3) Dissemination of CPRIT-Funded Cancer Control Interventions projects are recommended.

Project Descriptions

PP210045	Dissemination of a Mailed Stool Testing Program for Colorectal Cancer Prevention in Underserved Communities in Texas	Pignone, Michael	The University of Texas at Austin	1.0	\$300,000
CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize underserved populations					

This project seeks to develop an evidence-informed blueprint, implementation guide, and consultation service for expanding mailed FIT programs to underserved areas of Texas, in cooperation with other Texas institutions and a statewide organization of Federally Qualified Health Centers. The proposed project will form an expert team to 1) identify areas of Texas in high need of screening improvement (low screening rates, high incidence and mortality) not currently served by existing programs; 2) reach out to local community health centers and gastroenterologists in these areas to identify local support for development of mailed screening programs through the use of active dissemination strategies, including technical assistance and site-specific consultation; and 3) understand the cost and potential benefits of implementing mailed FIT in communities at highest need, based on different levels of investment in program development and expansion.

PP210026	Taking Texas Tobacco Free: Dissemination to and Implementation Within Agencies Serving Texans Experiencing Homelessness	Reitzel, Lorraine	University of Houston	2.7	\$299,978
CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize underserved populations					

The project proposes to disseminate and implement Taking Texas Tobacco Free (TTTF), a successful, evidence-based tobacco control intervention for cancer prevention within agencies serving individuals who are homeless and/or vulnerably housed. TTTF implementation in 2 homeless-serving agencies will include: 1) the initiation of tobacco-free workplace policies; 2) education to all employees about the benefits of living tobacco-free; 3) specialized training for providers on treating tobacco use, including embedding Certified Tobacco Treatment Specialist expertise within agencies; 4) the integration of tobacco use assessments/screenings into routine practice; 5) the provision of evidence-based practices for cessation to agency consumers and staff (including Nicotine Replacement Therapies); and 6) local community outreach/education.

PP210031	Application of mHealth Technologies to Improve Latino Childhood Cancer Survivor Engagement and Use of Evidence for Personalized Follow-Up Care and Screening	Poplack, David	Baylor College of Medicine	3.3	\$299,982
CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize underserved populations					

This project proposes to expand Passport for Care, a web-based clinical decision support tool that employs long-term follow-up survivorship guidelines to generate for survivors a personalized survivorship care plan based upon their cancer treatment summary, to engage medically underserved Latino adolescent, young adult cancer survivors and childhood cancer survivors (via parents) through their smart phones. The project proposes to share healthcare information on the importance of screening for late effects of previous cancer treatments accompanied by personalized steps to take with clinicians to protect the health of these survivors. Goals of this project include: (1) Partnering with Latino survivors to convert the website to a mobile health app to meet the healthcare information access and communications needs of this population; (2) Developing an implementation plan for deployment and utilization of the mHealth app through clinics and via app stores; and (3) Disseminating the mHealth app to clinics serving Latino survivors living in medically underserved areas or rural areas and evaluating survivor uptake, use, and engagement.

Dee Margo
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dee@deemargo.com

Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Mr. Roberts and Mr. Margo,

On behalf of the Prevention Review Council (PRC), I am pleased to provide the PRC's recommendations for the cycle 21.2 Evidence-Based Cancer Prevention Services (EBP), Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations (EPS), and Tobacco Control and Lung Cancer Screening (TCL) awards.

The PRC met on May 27, 2021 to review the applications submitted to CPRIT under the Dissemination of CPRIT-Funded Cancer Control Interventions (DI) mechanism. The PRC met again on June 17, 2021 to consider these applications and those recommended by the peer review panel following their April 26 meeting. The PRC recommends 9 projects totaling \$11,396,581.

The projects are numerically ranked in the order the PRC recommends the applications be funded. Recommended funding amounts and the overall evaluation score are stated for each grant application. The PRC made no changes to the goals, project objectives, or timelines of the applications.

Our recommendations meet the PRC's standards for grant award funding of projects that are evidence-based, deliver programs or services to underserved populations, and focus on primary, secondary, or tertiary prevention. In making these recommendations the PRC continued to consider the available funding, the composition of the current portfolio, and the programmatic priorities in the RFA which include potential for impact and return on investment, geographic distribution, cancer type and type of program. All the recommended grants address one or more of the Prevention Program priorities.

Sincerely,
Stephen W. Wyatt, DMD, MPH
Chair, CPRIT Prevention Review Council

Attachment



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Cycle 21.2 Recommended Prevention Program Awards

App. ID	Mech	Application Title	PD	Organization	Score	Rank Order	Budget
PP210045	DI	Dissemination of a Mailed Stool Testing Program for Colorectal Cancer Prevention in Underserved Communities in Texas	Pignone, Michael	The University of Texas at Austin	1.00	1	\$300,000
PP210049	EBP	Texas Southern University Breast Cancer Screening and Prevention Center	Ajewole, Veronica	Texas Southern University	1.80	2	\$1,000,000
PP210020	EPS	Vaccinating Medically Underserved Women Against HPV: Expansion of Clinical Services to Increase Access	Berenson, Abbey	The University of Texas Medical Branch at Galveston	2.00	3	\$1,999,988
PP210042	TCL	A Regional Expansion of Lung Cancer Screening and Patient Navigation (E-LSPAN)	Argenbright, Keith	The University of Texas Southwestern Medical Center	2.10	4	\$1,999,993
PP210026	DI	Taking Texas Tobacco Free: Dissemination to and Implementation Within Agencies Serving Texans Experiencing	Reitzel, Lorraine	University of Houston	2.70	5	\$299,978
PP210027	TCL	Increasing Accessibility to Smoking Cessation and Lung Cancer Screening Services for Low-Income/Uninsured Texans	McKnight, Jason	Texas A&M University System Health Science Center	3.10	6	\$999,947
PP210031	DI	Application of mHealth Technologies to Improve Latino Childhood Cancer Survivor Engagement and Use of Evidence for Personalized Follow-Up Care	Poplack, David	Baylor College of Medicine	3.30	7	\$299,982
PP210007	EPS	Strengthening Safety Net Health Systems to Improve Cervical and Colorectal Cancer Screening and Follow-up among the Medically Underserved	Montealegre, Jane R	Baylor College of Medicine	3.30	8	\$2,497,029
PP210044	TCL	Expansion of the Lung Cancer Screening and Tobacco Control (LCTC) Network to Rural and Medically Underserved Populations	Zoorob, Roger	Baylor College of Medicine	3.60	9	\$1,999,664

DI: Dissemination of CPRIT-Funded Cancer Control Interventions

EBP: Evidence-Based Cancer Prevention Services

EPS: Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations

TCL: Tobacco Control and Lung Cancer Screening



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS
FROM: WAYNE R. ROBERTS, CHIEF EXECUTIVE OFFICER
SUBJECT: T.A.C. § 702.19 STANDING WAIVER FOR FY 2021
DATE: AUGUST 28, 2020

Summary

This is to notify the Oversight Committee that pursuant to the authority provided to the Chief Executive Officer in T.A.C. § 702.19(e), I grant CPRIT's Chief Prevention Officer Ramona Magid a waiver from the general prohibition against communicating with grant applicants. The waiver is applicable for FY 2021. Unlike the two communication waivers I granted Ms. Magid for each FY 2020 review cycle, this standing FY 2021 waiver will be effective for both review cycles planned for FY 2021. No Oversight Committee action related to this waiver is necessary.

Background and Discussion

The Chief Prevention Officer is a statutorily mandated member of the Program Integration Committee (PIC). Texas Administrative Code § 702.19 prohibits substantive communication between the grant applicant and a member of the peer review panel, the PIC, or the Oversight Committee while the application is pending a final decision. The restriction on communication prevents even the appearance of unequal treatment during the grant review process.

Traditionally, a chief program officer leads each CPRIT program with the assistance of a program manager. The program manager fields inquiries from and provides technical help to applicants completing their CPRIT grant applications. I promoted Ms. Magid to the Chief Prevention Officer position upon Dr. Becky Garcia's retirement in June 2019. However, the prevention program manager position has remained vacant since Ms. Magid's promotion. Until CPRIT fills the program manager position, she is the sole point of contact for the prevention program. The communication waiver is necessary so that Ms. Magid can assist grant applicants who have questions during the application process.

I previously granted Ms. Magid separate waivers for the two review cycles of FY 2020. It is unlikely that CPRIT will fill the prevention program manager position in FY 2021. Accordingly, I am granting a standing waiver for Ms. Magid for FY 2021 as long as she remains the sole point of contact for the prevention program. Approving this standing waiver does not favor any grant applicant over another. Ms. Magid will provide technical assistance only and will not comment on the substance of a grant application. CPRIT will include this waiver in the grant record for the FY 2021 prevention grant applications.

Product Development Research Priorities Addressed by the Recommended 21.1 Cycle Awards					
Funding novel projects that offer therapeutics or diagnostics not currently available, i.e., disruptive technologies	Funding projects addressing large or challenging unmet medical needs	Investing in early stage projects when private capital is least available	Stimulating commercialization of technologies developed at Texas institutions	Supporting new company formation in Texas or attracting promising companies to Texas that will recruit staff with life sciences expertise, especially C-level staff to lead seed clusters of life science expertise at various Texas locations	Providing appropriate return on Texas taxpayer investment
\$27,565,207 2 projects	\$27,565,207 2 projects	\$14,449,638 1 project	\$13,115,569 1 project	\$27,565,207 2 projects	\$27,565,207 2 projects
<ul style="list-style-type: none"> • DP210005 • DP210042 	<ul style="list-style-type: none"> • DP210005 • DP210042 	<ul style="list-style-type: none"> • DP210005 	<ul style="list-style-type: none"> • DP210042 	<ul style="list-style-type: none"> • DP210005 • DP210042 	<ul style="list-style-type: none"> • DP210005 • DP210042

Note: Some grant awards address more than one program priority and will be double counted.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

To: OVERSIGHT COMMITTEE MEMBERS
From: CINDY WALKERPEACH, PHD
 CHIEF PRODUCT DEVELOPMENT OFFICER
Subject: FY 21.1 PRODUCT DEVELOPMENT RESEARCH AWARD
 RECOMMENDATIONS
Date: AUGUST 4, 2021

Summary of Recommendation:

The Product Development Review Council (PDRC) and the Program Integration Committee (PIC) recommend that the Oversight Committee approve product development research awards to the following applicants: Dialectic Therapeutics, Inc. and Marker Therapeutics, Inc. Table 1 reflects the ranked award recommendations, including the maximum recommended funding amounts and the evaluation scores for the two applications recommended for awards.

The PDRC did not make any changes to the proposed goals and objectives, timelines or budgets for the two projects recommended for funding. In addition, the PDRC did not identify any contingencies associated with either of the two award recommendations.

Table 1: 21.1 Review Cycle PDRC and PIC Award Recommendations

Rank	Application ID	Mechanism (Cycle)	Company Name	Project	Score*	Maximum Budget
1	DP210005	TXCO (21.1)	Dialectic Therapeutics, Inc.	Clinical Development of DT2216, a First-in-Class APTaD™ for Cancer Therapy	3.0	\$14,449,638
2	DP210042	TXCO (21.1)	Marker Therapeutics, Inc.	Efficacy of a Multi Tumor Associated Antigen Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant	2.2	\$13,115,569
					Total	\$27,565,207

* average reviewer score from videoconference “in-person” peer review. Note that the PDRC’s ranking of the two award recommendations is different from score order due to the outcome of the due diligence discussion.

Background - FY 2021 Review Cycle 1

CPRIT released the TXCO, RELCO and SEED Product Development Research RFAs on November 9, 2020, and accepted applications through January 27, 2021. Applicants submitted thirty-six (36) responses to the RFAs. Upon administrative review, one (1) application was withdrawn, resulting in a total of thirty-five (35) applications for peer review. See Table 1. The peer review screen held on March 22-23, 2021, resulted in a total of eight (8) applications invited to in-person presentations (via Zoom) from April 19-22, 2021. As a result of the Zoom Peer Review Meeting, the peer review panels recommended five (5) applications for diligence evaluation.

The PDRC convened on July 8th for the Due Diligence Evaluation meeting. After thoughtful consideration of the diligence materials, the PDRC recommended two (2) of the 21.1 applications for awards. Dr. Jack Geltosky, Chair PDRC, noted in his letter to the PIC and the Oversight Committee, the PDRC's recommendation to fund these two (2) awards reflected 50+ hours of individual review and panel discussion of each application as well as the PDRC's review of the diligence materials for each company.

Product Development Research Priorities Addressed by the 21.1 Cycle Proposed Awards

The chart below reflects that all recommended applications address one or more of the Product Development Research priorities.

Applications Addressing Priorities*	Product Development Research Priorities	Award Amount per Priority*
2	Funding novel projects that offer therapeutic or diagnostic benefits not currently available, i.e. disruptive technologies	\$27,565,207
2	Funding projects addressing large or challenging unmet medical needs	\$27,565,207
1	Investing in early-stage projects where private capital is least available	\$14,449,638
1	Stimulating commercialization of technologies developed at Texas institutions	\$13,115,569
2	Supporting new company formation in Texas or attracting promising companies to Texas that will recruit staff with life science expertise, especially experienced C-level staff to lead to seed clusters of life science expertise at various Texas locations	\$27,565,207
2	Providing appropriate return on taxpayer investment	\$27,565,207

*Some proposed awards address more than one priority.

Mechanisms of Support and Product Development Research Objectives

Applications submitted in the 21.1 review cycle responded to one of three product development research RFAs.

- *Texas Company Product Development Research Award (TXCO)*
This award mechanism seeks to support early stage “startup” and established companies in the development of innovative products and services with significant potential impact on cancer patient care. The proposed project must further the development of new products or services for the diagnosis, treatment, or prevention of cancer; must foster a robust biotechnology industry ecosystem; or must fulfill a critical unmet need in cancer patient care. Companies must be headquartered in Texas.

Strong candidates for the TXCO award have developed a sufficiently robust data package, value proposition, regulatory strategy, manufacturing plan, and experienced business/management team to warrant the amount of funding requested.

Award: Maximum amount \$20 million over 36 months

- *Relocation Company Product Development Research Award (RELCO)*
This award mechanism seeks to support early stage “startup” and established companies in the development of innovative products and services with significant potential impact on cancer patient care. The proposed project must further the development of new products or services for the diagnosis, treatment, or prevention of cancer; must foster a robust biotechnology industry ecosystem; or must fulfill a critical unmet need in cancer patient care. Companies must relocate to Texas upon receipt of award.

Strong candidates for the RELCO award have developed a sufficiently robust data package, value proposition, regulatory strategy, manufacturing plan, and experienced business/management team to warrant the amount of funding requested.

Award: Maximum amount \$20 million over 36 months

- *Seed Award for Product Development Research (SEED)*
This award mechanism seeks to support early stage “startup” companies in the development of innovative products and services with significant potential impact on cancer patient care.

The proposed project must further the development of new products or services for the diagnosis, treatment, or prevention of cancer; must foster a robust biotechnology industry ecosystem; or must fulfill a critical unmet need in cancer patient care. Company applicants must be headquartered in Texas or be willing to relocate to Texas upon receipt of award

Strong candidates for the SEED award have developed compelling discovery stage data and/or developed a working prototype (if applicable) around a novel compound, diagnostic, device, computational tool, etc. that warrants further development efforts to establish proof of concept (POC) on the early pathway to commercial product. In addition, strong candidates have at a minimum developed a strong value proposition, preliminary regulatory strategy, preliminary manufacturing plan, and early business/management team to warrant the amount of funding requested.

Award: Maximum amount of \$3 million over 36 months.

CPRIT Award Contract and Risk Mitigation

Investing in early-stage translational cancer research is inherently risky. Products in development at CPRIT Product Development Research awardees that show promise in the laboratory and in animal studies may not make a measurable difference in humans or the treatment's side effects may be so severe as to not justify the benefits. Along with the increased risk of technical failure, human studies are more complex and expensive than laboratory and animal studies.

CPRIT addresses the risk associated with product development research awards by tying disbursement of funds to the grantee achieving specific project goals and objectives. The award contract requires the company to report at least annually on its progress. To receive the next tranche of project funding, the grantee must show that it has accomplished all the goals and objectives for the previous project year. The company will only receive the entire approved award amount if it successfully achieves all project goals and objectives. Because contractual goals are usually associated with project milestones, such as receiving FDA approval for an Investigational New Drug filing or completing a clinical trial, achieving all agreed-upon goals also means that the project is making meaningful progress to becoming a treatment option.

Product Development Research Awards
Recommended by the PDRC and PIC for FY 2021 Review Cycle 1

Dialectic Therapeutics, Inc.
Proposed Texas Company Product Development Research Award

Summary of Recommendation

The PDRC and the PIC recommend that the Oversight Committee approve a Texas Company Product Development Research Award to Dialectic Therapeutics, Inc. for \$14,449,638.

Dialectic Therapeutics, Inc. is a biotech startup company based in Dallas and founded by three cancer scientists and two biotech investors, with research facilities/partners at the University of Texas Health Science Center San Antonio (UTHSA) and the University of Florida. Dialectic's lead candidate, DT2216, is a unique programmed protein degradation compound that selectively induces cancer cells to degrade BCL-XL, stimulating the cells to commit suicide on their own, or become more susceptible to chemotherapy. The work supported by the recommended CPRIT TXCO award will enable Dialectic Therapeutics to perform critical manufacturing development and phase 1 and 2 clinical trials for DT2216 in the treatment of T-cell lymphoma and small cell lung cancer.

Dialectic Therapeutics, Inc. was the recipient of a CPRIT Seed Award for Product Development Research in February 2020 for \$3,000,000. The PDRC's recommendation represents the first time that a Seed awardee has been recommended to receive a subsequent TXCO award. This represents an important milestone for CPRIT Product Development Research, as the Seed award was designed to provide a mechanism to support critical early-stage development work to sufficiently de-risk technologies and position the awardee for additional downstream development and funding.

CPRIT Product Development Research Priorities Addressed

Dialectic Therapeutics, Inc.'s proposed project addresses five of the six Product Development Research Priorities:

- Funding novel projects that offer therapeutic or diagnostic benefits not currently available, i.e. disruptive technologies;
- Funding projects addressing large or challenging unmet medical needs;
- Investing in early-stage projects where private capital is least available;
- Supporting new company formation in Texas or attracting promising companies to Texas that will recruit staff with life science expertise, especially experienced C-level staff to lead to seed clusters of life science expertise at various Texas locations; and
- Providing appropriate return on taxpayer investment.

Project Summary and Scientific Rationale

DT2216, is a novel Antiapoptotic Protein Targeted Degradation (APTaD™) compound that selectively induces cancer cells to degrade B-cell lymphoma extra-large, or BCL-XL, stimulating the cells to commit suicide or become more susceptible to chemotherapy. Preliminary studies show that DT2216 destroys T-cell lymphoma / T-cell leukemia as a single agent. In addition, the technology has been demonstrated to be effective against small cell lung cancer and breast cancer when combined with traditional chemotherapy. The toxicity profile is favorable showing only a dose dependent decrease in platelets. This novel approach to cancer therapy will fill a significant need in current cancer treatment regimens.

The work supported by the CPRIT TXCO award will enable Dialectic Therapeutics to perform phase 1 and 2 clinical trials for DT2216 in the treatment of T-cell lymphoma and small cell lung cancer, two areas of high unmet medical need.

Select Reviewer Comments

- *A well-validated target that has been the focus of many drug development efforts over the years.*
- *Company is advancing a novel approach to attack the target, a key driver of many different kinds of cancer, that bypasses the most common side effect of many of these drug candidates, thrombocytopenia.*
- *The management and operational leaders are experienced and have clearly laid out a practical and achievable set of goals and objectives that anticipates development through the design of their adequate and well-controlled registration study.*

Marker Therapeutics, Inc.
Proposed Texas Company Product Development Research Award

Summary of Recommendation

The PDRC and the PIC recommend that the Oversight Committee approve a Texas Company Product Development Research Award to Market Therapeutics, Inc. for \$13,115,569.

Marker Therapeutics, a publicly traded company based in Houston, focuses on novel cell-based therapies for a variety of cancer indications. Marker proposes the development of MT-401 an innovative allogeneic T cell product for the treatment of patients with acute myeloid leukemia (AML). AML is a deadly cancer, treated with chemotherapy, often followed by stem cell transplant (SCT). However, relapse after SCT remains a major cause of death, with poor 1-year survival. Limited treatments are available for patients who fail chemotherapy and SCT.

Although immune T cell-based interventions such as chimeric antigen receptor (CAR) T cell therapies have been explored in AML, their therapeutic impact has been limited due to: 1) lack of one antigen with sufficient tumor specificity, 2) negative antigen selection leading to tumor immune escape, 3) requirement for lymphodepletion, preventing engagement of the endogenous immune system (epitope spreading) and leading to adverse events, and 4) risk of graft-versus-host disease (GVHD). Marker proposes MT-401 as a novel T cell-based therapy that targets multiple tumor-associated antigens (mTAAs) simultaneously, thereby minimizing tumor escape.

Marker proposes to use CPRIT funds to advance a phase 2 clinical study to support registration and clinical implementation of MT-401 in AML patients post-SCT. The underlying technology was developed at Baylor College of Medicine.

CPRIT Product Development Research Priorities Addressed

Marker Therapeutics, Inc.'s proposed project addresses five of the six Product Development Research Priorities:

- Funding novel projects that offer therapeutic or diagnostic benefits not currently available, i.e. disruptive technologies;
- Funding projects addressing large or challenging unmet medical needs;
- Stimulating commercialization of technologies developed at Texas institutions;
- Supporting new company formation in Texas or attracting promising companies to Texas that will recruit staff with life science expertise, especially experienced C-level staff to lead to seed clusters of life science expertise at various Texas locations; and
- Providing appropriate return on taxpayer investment.

Project Summary and Scientific Rationale

According to the American Cancer Society, in 2020 there will be an estimated 60,530 new cases of leukemia in the US and 22,100 deaths from leukemia (all types), of which 19,940 new cases will be AML. The 5-year survival rate for AML patients is only 28%. Standard treatment is chemotherapy, often followed by SCT. Relapse after SCT is high at over 60% of patients, leading to 1-year overall survival (OS) of ~20% and complete remission (CR) rates of 10-30%. For AML patients who fail chemotherapy and SCT, there are limited treatment options on the market; this is Marker's target population for MT-401.

MT-401 is a novel T cell-based therapy that targets multiple tumor-associated antigens (mTAAs) highly expressed in AML cancer cells (with absent / low expression in healthy tissue), minimizing the chance of tumor cells escaping treatment. MT-401 has been demonstrated to recognize and kill target cancer cells and leads to activation of other immune cells and recognition of additional cancer cells. mTAA T cells have shown safety and efficacy in preclinical and early phase clinical testing in a multiple cancer types, including AML. In this CPRIT proposal, Marker will conduct a Phase 2 clinical trial of MT-401 in AML patients post-SCT in the adjuvant setting (in remission, at risk of relapse). Completion of this trial aims to advance MT-401 towards market approval and provide a safe, effective treatment option where none currently exists on the market

Select Reviewer Comments

- *This is a strong application that addresses a key unmet need: How to prevent relapsed AML in high-risk patients after allogeneic hematopoietic stem cell transplantation.*
- *The product has been successfully manufactured in an academic setting. There is good biological proof of principle, and multiple antigens are being targeted by T cells stimulated with an overlapping peptide pool.*
- *The team has been successful in raising investments. The company is led by investigators who have a proven track record in the field of cellular immunotherapy and is supported by a well-qualified scientific advisory board.*

July 23, 2021

Donald "Dee" Margo
Oversight Committee Chair
Cancer Prevention and Research Institute of Texas
Via email to dee@deemargo.com
Via email to Dee Margo's assistant, Olivia Zepeda: ozepeda@deemargo.com

Wayne R. Roberts
Program Integration Committee Chair
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Dee and Wayne,

On behalf of the Product Development Review Council (PDRC), I am pleased to provide the PDRC's recommendation for CPRIT's Product Development Research 21.1 award cycle. The PDRC convened on July 8, 2021 and recommends that the Program Integration Committee and the Oversight Committee approve the following Product Development Research awards:


- A Texas Company Product Development Research Award (TXCO) for Dialectic Therapeutics, Inc.
- A Texas Company Product Development Research Award (TXCO) for Marker Therapeutics, Inc.

The attached table reflects the PDRC's ranked award recommendations for the two applications. Note that the PDRC's ranking of the two award recommendations is different from score order due to the outcome of the due diligence discussion.

The PDRC did not make any changes to the proposed goals and objectives, timelines or budget for the two projects recommended for funding. In addition, there were no contractual contingencies associated with either of these award recommendations.

Each of the companies included in the PDRC's recommendation reflects 50+ hours of individual review and panel discussion of the applicants' proposals as well as the PDRC's review of the due diligence reports. Our recommendations are consistent with one or more of the priorities of the Oversight Committee for product development award funding. These standards include the potential of these companies to (1) bring important products to market; (2) promote the translation of research at Texas institutions into new companies able to compete in the marketplace; and (3) develop tools and technologies of special relevance to cancer research, treatment and prevention.

Sincerely,



/JG/
Jack Geltosky, PhD
Chair, CPRIT Product Development Review Council

Attachment

Product Development Review Council Award Recommendations

FY 2021 Cycle 1

Rank	Application ID	Mechanism (Cycle)	Company Name	Project	Maximum Recommended Budget	Overall Score*
1	DP210005	TXCO (21.1)	Dialectic Therapeutics, Inc.	Clinical Development of DT2216, a First-in-Class APTaD™ for Cancer Therapy	\$14,449,638	3.0
2	DP210042	TXCO (21.1)	Marker Therapeutics, Inc.	Efficacy of a Multi Tumor Associated Antigen Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant	\$13,115,569	2.2
				Total	\$27,565,207	

* average reviewer score from videoconference "in-person" peer review



August 11, 2021

Oversight Committee Members,

Pursuant to 25 T.A.C. § 703.7(j), I request that the Oversight Committee approve authority for CPRIT to advance grant funds upon execution of grant contracts for the two companies that the Oversight Committee will consider for product development grant awards at its August 18, 2021, meeting. The Program Integration Committee has recommended these companies for grant awards.

Although CPRIT disburses most grant funds pursuant to requests for reimbursement, CPRIT may disburse grant funds in advance payments consistent with the General Appropriations Act, Article IX, § 4.02(a). Typically, the grant amount to be paid in advance is based upon the project year budget or tranche amount. All grant recipients, including those that receive advance payment of grant funds, are required to submit quarterly financial status reports that are reviewed and approved by CPRIT's financial staff. The product development grant recipients must also certify that they have matching funds available to invest in the project prior to any disbursement of funds. Failure to submit the financial status reports on a timely basis or to certify matching funds will result in forfeiture of reimbursement for expenses for the quarter and may result in grant termination and repayment of grant funds.

Advance payment of grant funds is necessary because the projects proposed for grant awards involve preclinical work and/or clinical trials. The cost structure for this type of work is highly front loaded and service providers require substantial upfront payments. Advancing grant funds allows these projects to begin work as quickly as possible.

Sincerely,

A handwritten signature in black ink, appearing to read "Wayne Roberts", is written in a cursive style.

Wayne Roberts
CPRIT Chief Executive Officer



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

August 5, 2021

Dear Oversight Committee Members:

I am pleased to present the Program Integration Committee's (PIC) unanimous recommendations for funding 73 grant applications totaling \$142,377,830. The PIC recommendations for 62 academic research, 9 prevention, and 2 product development research grant awards are attached.

Dr. Jim Willson, CPRIT's Chief Scientific Officer, Ramona Magid, CPRIT's Chief Prevention Officer, and Dr. Cindy WalkerPeach, CPRIT's Chief Product Development Officer, have prepared overviews of the academic research, prevention, and product development research slates to assist your evaluation of the recommended awards. The overviews are intended to provide a comprehensive summary with enough detail to understand the substance of the proposal and the reasons endorsing grant funding. In addition to the full overviews, all the information considered by each Review Council is available by clicking on the appropriate link in the portal. This information includes the application, peer reviewer critiques, and the CEO affidavit for each proposal.

The approval of these grant recommendations is governed by a statutory process that requires two-thirds of the members present and voting to approve each recommendation. Vince Burgess, CPRIT's Chief Compliance Officer, will certify that the review process for the recommended grants followed CPRIT's award process prior to any Oversight Committee action.

The award recommendations will not be considered final until the Oversight Committee meeting on August 18, 2021. Consistent with the non-disclosure agreement that all Oversight Committee members have signed, the recommendations should be kept confidential and not be disclosed to anyone until the award list is publicly announced at the Oversight Committee meeting. I request that Oversight Committee members not print, email or save to your computer's hard drive any material on the portal. I appreciate your assistance in taking all necessary precautions to protect this information.

If you have any questions or would like more information on the review process or any of the projects recommended for an award, CPRIT's staff, including myself and Dr. Willson, Dr. WalkerPeach, and Ms. Magid are always available. Please feel free to contact us directly should you have any questions. The programs that will be supported by the CPRIT awards are an important step in our efforts to mitigate the effects of cancer in Texas.

Thank you for being part of this endeavor.

Sincerely,
Wayne R. Roberts,
Chief Executive Officer

Academic Research Award Recommendations

The PIC unanimously recommends approval of 62 academic research grant proposals totaling \$103,416,042. The recommended grant proposals were submitted in response to the *Early Clinical Investigator Award (ECI)*; *Core Facility Support Awards (CFSA)*; *Clinical Trials Network Award (CTNA)*; *High-Impact/High Risk Awards (HIHRA)*; *Texas Clinical Trials Participation Award (TCTPA)*; *Texas Regional Excellence in Cancer Award (TREC)*; *Recruitment of First-Time, Tenure Track Faculty Members (RFTFM)*; and *Recruitment of Rising Stars (RRS)* grant mechanisms. The Scientific Review Council provided the prioritized list of recommendations for the awards to the presiding officers on July 22, 2021. The PIC approved the award recommendations as presented by the SRC.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these academic research proposals met the following CPRIT funding priorities:

- could lead to immediate or long-term medical and scientific breakthroughs in the area of cancer prevention or cures for cancer;
 - met by TREC; CFSA; CTNA; ECI; HIHRA; RRS; and RFTFM
- strengthen and enhance fundamental science in cancer research;
 - met by TREC; CFSA; CTNA; ECI; TCTPA; HIHRA; RRS; and RFTFM
- ensure a comprehensive coordinated approach to cancer research and cancer prevention;
 - met by TREC; CFSA; CTNA; ECI; TCTPA; HIHRA; RRS; and RFTFM
- are interdisciplinary or interinstitutional;
 - met by TREC; CFSA; CTNA; ECI; HIHRA; RRS; and RFTFM
- Address federal or other major research sponsors' priorities in emerging scientific or institutions of higher education;
 - met by TREC; CFSA; CTNA; ECI; TCTPA; HIHRA; RRS; and RFTFM
- Are matched with funds available by a private or nonprofit entity and institution or institutions of higher education;
 - met by TREC; CFSA; CTNA; ECI; HIHRA; RRS; and RFTFM
- are collaborative between any combination of private and nonprofit entities, public or private agencies or institutions in this state, and public or private institutions outside this state;
 - met by TREC; CFSA; CTNA; ECI; TCTPA; HIHRA; RRS; and RFTFM
- have a demonstrable economic development benefit to this state;
 - met by TREC; CFSA; CTNA; ECI; TCTPA; HIHRA; RRS; and RFTFM
- enhance research superiority at institutions of higher education in this state by creating new research superiority, attracting existing research superiority from institutions not

located in this state and other research entities, or enhancing existing research superiority by attracting from outside this state additional researchers and resources;

- met by TREC; CFSA; ECI; RRS; and RFTFM
- expedite innovations and commercialization, attract, create, or expand private sector entities that will drive a substantial increase in high-quality jobs, and increase higher education applied science or Technology research capabilities; and
 - met by TREC; CFSA
- address the goals of the Texas Cancer Plan.
 - met by TREC; CFSA; CTNA; ECI; TCTPA; HIHRRA; RRS; and RFTFM

Academic Research Grant Award Recommendations

Rank	Application ID	Mechanism	PI	Application Title	Organization	Budget	Final Overall Score
1	RP210227	CFSA	Edwards, Dean	Proteomics and Metabolomics Core Facility	Baylor College of Medicine	\$3,977,681	1.0
2	RP210176	ECI	Draetta, Gulio	CPRIT Early Clinical Investigator Award: Moran Amit	The University of Texas M. D. Anderson Cancer Center	\$1,499,042	1.0
3	RP210208	CFSA	McHardy, Stanton	Center for Innovative Drug Discovery: Expansion of a Highly Productive Shared Cancer Drug Discovery Resource for Texas	The University of Texas at San Antonio	\$3,087,131	1.1
4	RP210143	TCTPA	Mims, Martha	Dan L. Duncan Comprehensive Cancer Center (DLDCCC) Harris Health Clinical Trials Financial Support Project	Baylor College of Medicine	\$1,500,000	1.5
5	RP210165	HIHRA	Li, Xiujun (James)	Rapid Point-of-Care Detection of Ovarian Cancer Biomarkers Using a Common Thermometer for Low-Resource Settings	The University of Texas at El Paso	\$249,999	1.6
6	RP210115	TCTPA	Gerber, David	Enhancing Access to and Diversity in Cancer Clinical Trials Through a Financial Reimbursement and Outreach Program	The University of Texas Southwestern Medical Center	\$1,499,327	1.7
7	RP210159	ECI	Draetta, Gulio	CPRIT Early Clinical Investigator Award: Carl Gay	The University of Texas M. D. Anderson Cancer Center	\$1,499,997	1.8

PIC Recommendation
 FY2021 (August)

Rank	Application ID	Mechanism	PI	Application Title	Organization	Budget	Final Overall Score
8	RP210088	CFSA	Dalby, Kevin	Targeted Therapeutic Drug Discovery and Development Program	The University of Texas at Austin	\$3,989,441	1.9
9	RP210205	HIHRA	Veisoh, Omid	Cytokine Factories for the Treatment of Mesothelioma	Rice University	\$250,000	1.9
10	RP210173	HIHRA	Hart, Traver	Multiplex CRISPR Genetic Modeling of Polypharmacology for Precision Medicine	The University of Texas M. D. Anderson Cancer Center	\$250,000	1.9
11	RP210108	CFSA	Stephan, Clifford	The GCC Microphysiological Lead Optimization and Toxicity Screening Facility	Texas A&M University System Health Science Center	\$3,973,083	2.0
12	RP210144	HIHRA	Rostomily, Robert	Leveraging Glioma Stem Cell Electrophysiology for Therapy	The Methodist Hospital Research Institute	\$248,028	2.0
13	RP210168	HIHRA	Yi, Qing	Overcoming Myeloma Resistance to Proteasome Inhibitors	The Methodist Hospital Research Institute	\$250,000	2.0
14	RP210062	HIHRA	Zhou, Jia	Protein Degradation of CDK9 for Treatment of Drug-Resistant Mantle Cell Lymphoma	The University of Texas Medical Branch at Galveston	\$250,000	2.0
15	RP210154	TREC	Reynolds, Charles	Texas Regional Excellence in Cancer Developmental Therapeutics Center at TTUHSC	Texas Tech University Health Sciences Center	\$5,999,936	2.0

PIC Recommendation
 FY2021 (August)

Rank	Application ID	Mechanism	PI	Application Title	Organization	Budget	Final Overall Score
16	RP210073	HIHRA	DePinho, Ronald	Identification of Collateral Lethal and Synthetic Lethal Targets in Pancreatic and Colorectal Cancers	The University of Texas M. D. Anderson Cancer Center	\$249,994	2.1
17	RP210111	HIHRA	Pan, Sheng	Single-Cell Proteomics to Dissect Intratumor Heterogeneity	The University of Texas Health Science Center at Houston	\$250,000	2.1
18	RP210134	HIHRA	Tambar, Uttam	High-Throughput Discovery of Anticancer Protein Degradors	The University of Texas Southwestern Medical Center	\$250,000	2.2
19	RP210116	CFSA	Bao, Gang	The Genetic Design and Engineering Center (GDEC): A CPRIT Core Facility	Rice University	\$4,000,000	2.3
20	RP210158	HIHRA	Mamonkin, Maksim	Improving CAR TCell Therapy of TALL by Cotargeting Additional Antigens	Baylor College of Medicine	\$250,000	2.3
21	RP210206	HIHRA	Nguyen, Kytai	Novel Tumor-Specific Bioactive Nanoparticles for Cancer Therapy	The University of Texas at Arlington	\$249,999	2.4
22	RP210180	CFSA	CHAUHAN, SUBHASH	Integrated Cancer Research Core (ICRC)	The University of Texas Rio Grande Valley	\$2,525,000	2.5
23	RP210126	CFSA	Berton, Michael	High-Parameter Analysis, Sorting, and Imaging Flow Cytometry Shared Resource	The University of Texas Health Science Center at San Antonio	\$3,645,500	2.5
24	RP210122	CTNA	Overman, Michael	Building a Clinical Trial Network for Texas Community Affiliates	The University of Texas M. D. Anderson Cancer Center	\$3,000,000	2.5

PIC Recommendation
 FY2021 (August)

Rank	Application ID	Mechanism	PI	Application Title	Organization	Budget	Final Overall Score
25	RP210164	ECI	Hromas, Robert	Early Clinical Investigator Award: William Kelly	The University of Texas Health Science Center at San Antonio	\$1,499,985	2.5
26	RP210140	ECI	Arteaga, Carlos	Targeting Altered Metabolism in IDH Mutant Glioma	The University of Texas Southwestern Medical Center	\$1,500,000	2.6
27	RP210089	HIHRRRA	Kim, Hyun Jung	Dissecting Therapeutic Immunomodulation of Gut Microbiome on Colorectal Cancer	The University of Texas at Austin	\$250,000	2.6
28	RP210079	HIHRRRA	Cambronne, Xiaolu	Targeting Mitochondrial NAD+ in Leukemias	The University of Texas at Austin	\$250,000	2.7
29	RP210236	HIHRRRA	Qin, Zhenpeng	Magnetomechanical Modulation of Blood-Brain Barrier Permeability	The University of Texas at Dallas	\$250,000	2.7
30	RP210234	ECI	Johnston, Sterling	Targeting Src Homology-2 Domain-Containing Phosphatase to Overcome Resistance to Immune Checkpoint Blockade in Pancreatic Ductal Adenocarcinoma	The University of Texas at Austin	\$1,443,367	2.7
31	RP210105	HIHRRRA	Tumanov, Alexei	Targeting Lymphotoxin Beta Receptor in Sensory Neurons for Control of Chemotherapy-Induced Neuropathic Pain	The University of Texas Health Science Center at San Antonio	\$249,996	2.8

PIC Recommendation
 FY2021 (August)

Rank	Application ID	Mechanism	PI	Application Title	Organization	Budget	Final Overall Score
32	RP210068	HIHRRRA	Wu, Zhihao	Role of Aberrant Translational Quality Control in Tumorigenesis of Glioblastoma	Southern Methodist University	\$249,272	2.8
33	RP210102	HIHRRRA	ZHAO, WEIXING	Deciphering BRCA1-BARD1 E3 Ligase Activity in Genome Maintenance and Tumor Suppression	The University of Texas Health Science Center at San Antonio	\$250,000	2.8
34	RP210099	CFSA	Henning, Anke	North Texas Multimodal Small-Animal Imaging Core Facility	The University of Texas Southwestern Medical Center	\$3,999,929	2.8
35	RP210137	HIHRRRA	Reuben, Alexandre	Development of TCR-Based Immunotherapies Targeting Hotspot EGFR Mutations for the Treatment of Non-Small Cell Lung Cancer	The University of Texas M. D. Anderson Cancer Center	\$250,000	2.8
36	RP210209	CFSA	Putnam, William	North Texas Clinical Pharmacology Cancer Core	Texas Tech University Health Sciences Center	\$2,965,226	2.9
37	RP210092	HIHRRRA	Carmon, Kendra	Antibody-Drug Conjugate Combination Treatment for Targeting Colorectal Cancer Cell Plasticity	The University of Texas Health Science Center at Houston	\$250,000	3.0
38	RP210131	HIHRRRA	Maynard, Jennifer	Antibodylike Therapeutics That Target Polyclonal T Cells to CMVPositive Glioblastomas	The University of Texas at Austin	\$250,000	3.0

PIC Recommendation
 FY2021 (August)

Rank	Application ID	Mechanism	PI	Application Title	Organization	Budget	Final Overall Score
39	RP210075	HIHRA	Schraw, Jeremy	Exploring the Biological Basis of Ethnic and Social Disparities in Pediatric Acute Lymphoblastic Leukemia Outcomes	Baylor College of Medicine	\$249,999	3.0
40	RP210199	HIHRA	Lux, Jacques	Treating Metastatic Cancer Using Microbubble-Assisted Ultrasound-Guided Immunotherapy of Cancer of Cancer (MUSIC)	The University of Texas Southwestern Medical Center	\$249,011	3.0
41	RP210127	HIHRA	Raghavan, Shreya	Engineered Enteric Nerve-Perineural Invasion Models to Improve Predictive Preclinical Screens in Early-Stage Colorectal Adenocarcinoma	Texas A&M University	\$250,000	3.0
42	RP210148	HIHRA	Trivedi, Meghana	Novel Pharmacodynamic Assay to Predict Response to CDK4/6 Inhibitor Therapy	University of Houston	\$250,000	3.0
43	RP210119	CFSA	Liu, Qingyun	A Preclinical Development Core for Large-Molecule Therapeutics	The University of Texas Health Science Center at Houston	\$3,999,999	3.1
44	RP210064	CFSA	Scheurer, Michael	The Adolescent and Childhood Cancer Epidemiology and Susceptibility Service (ACCESS) for Texas	Baylor College of Medicine	\$4,000,000	3.1

PIC Recommendation
 FY2021 (August)

Rank	Application ID	Mechanism	PI	Application Title	Organization	Budget	Final Overall Score
45	RP210130	CFSA	Kuo, Yong-Fang	Data Management and Analysis Core for Comparative Effectiveness Research on Cancer in Texas	The University of Texas Medical Branch at Galveston	\$2,936,731	3.1
46	RP210070	HIHRRRA	Zhou, Yubin	Tunable Epigenetic Remodeling to Modulate CAR TCell-Based Immunotherapy	Texas A&M University System Health Science Center	\$250,000	3.1
47	RP210132	HIHRRRA	Frost, Jeffrey	Synergy Between Epigenetic Reprogramming and Wnt Inhibition to Enhance Neuroendocrine Tumor Radionuclide Therapy	The University of Texas Health Science Center at Houston	\$249,999	3.1
48	RP210153	TREC	Cox, Marc	UTEP/UTMDACC Partnership for Hispanic Cancer Disparities Research	The University of Texas at El Paso	\$5,881,734	3.1
49	RP210183	HIHRRRA	Kearney, Christopher	Virulence Modulation of Helicobacter pylori, the Strongest Risk Factor for Gastric Cancer	Baylor University	\$248,938	3.3
50	RP210213	HIHRRRA	Chakraborty, Sanjukta	Therapeutic Inhibition of Cholangiocarcinoma Progression by Targeting Tumor-Lymphatic Cross Talk	Texas A&M University System Health Science Center	\$250,000	3.3

CFSA: Core Facility Support Awards
 CTNA: Clinical Trials Network Award
 ECI: Early Clinical Investigator Awards
 HIHRRRA: High-Impact/High Risk Awards
 TCTPA: Texas Clinical Trials Participation Award
 TREC: Texas Regional Excellence in Cancer Award

Academic Research Recruitment Grant Award Recommendations

Rank	Application ID	Mechanism	Candidate	Organization	Budget	Final Overall Score
1	RR210082	RFTFM	Dr. Kyle Eagen	Baylor College of Medicine	\$2,000,000	1.0
2	RR210066	RFTFM	Dr. Chad W. Johnston	Baylor College of Medicine	\$2,000,000	1.0
3	RR210056	RFTFM	Dr. Xia Gao	Baylor College of Medicine	\$2,000,000	1.0
4	RR210059	RFTFM	Dr. Javier Garcia-Bermudez	The University of Texas Southwestern Medical Center	\$2,000,000	1.0
5	RR210067	RRS	Dr. Yong Lu	The Methodist Hospital Research Institute	\$3,998,389	1.7
6	RR210085	RFTFM	Dr. Yuan Pan	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.9
7	RR210077	RFTFM	Dr. Edward J. Grow	The University of Texas Southwestern Medical Center	\$2,000,000	1.9
8	RR210083	RFTFM	Dr. David Braun	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	2.0
9	RR210086	RFTFM	Dr. Seungwon "Sebastian" Choi	The University of Texas Southwestern Medical Center	\$2,000,000	2.0
10	RR210079	RRS	Dr. Tian Zhang	The University of Texas Southwestern Medical Center	\$4,000,000	2.0
11	RR210080	RFTFM	Dr. Jason George	Texas A&M Engineering Experiment Station	\$1,999,309	2.0

PIC Recommendation
FY2021 (August)

Rank	Application ID	Mechanism	Candidate	Organization	Budget	Final Overall Score
12	RR210070	RFTFM	Dr. Shih-Han Lee	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	2.3

RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members

RRS: Recruitment of Rising Stars

Prevention Award Recommendations

The PIC unanimously recommends approval of nine prevention grant proposals totaling \$11,396,581. The recommended grant proposals were submitted in response to the *Evidence-Based Cancer Prevention Services; Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations; Tobacco Control and Lung Cancer Screening; and Dissemination of CPRIT-Funded Cancer Control Interventions* grant mechanism. The Prevention Review Council (PRC) provided the prioritized list of recommendations for the awards to the presiding officers on June 21, 2021. The PIC approved the recommendations made by the PRC.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these prevention proposals met the following CPRIT funding priorities:

- ensure a comprehensive coordinated approach to cancer research and cancer prevention;
- are interdisciplinary or interinstitutional;
- are collaborative between any combination of private and nonprofit entities, public or private agencies or institutions in this state, and public or private institutions outside this state
- have a demonstrable economic development benefit to this state; and
- address the goals of the Texas Cancer Plan.

Prevention Grant Award Recommendations

Rank	Application ID	Mechanism	PD	Title	Organization	Budget	Final Overall Score
1	PP210045	DI	Pignone, Michael	Dissemination of a Mailed Stool Testing Program for Colorectal Cancer Prevention in Underserved Communities in Texas	The University of Texas at Austin	\$300,000	1.0
2	PP210049	EBP	Ajewole, Veronica	Texas Southern University Breast Cancer Screening and Prevention Center	Texas Southern University	\$1,000,000	1.8
3	PP210020	EPS	Berenson, Abbey	Vaccinating Medically Underserved Women Against HPV: Expansion of Clinical Services to Increase Access	The University of Texas Medical Branch at Galveston	\$1,999,988	2.0
4	PP210042	TCL	Argenbright, Keith	A Regional Expansion of Lung Cancer Screening and Patient Navigation (E-LSPAN)	The University of Texas Southwestern Medical Center	\$1,999,993	2.1
5	PP210026	DI	Reitzel, Lorraine	Taking Texas Tobacco Free: Dissemination to and Implementation Within Agencies Serving Texans Experiencing	University of Houston	\$299,978	2.7
6	PP210027	TCL	McKnight, Jason	Increasing Accessibility to Smoking Cessation and Lung Cancer	Texas A&M University System Health	\$999,947	3.1

PIC Recommendation
 FY2021 (August)

Rank	Application ID	Mechanism	PD	Title	Organization	Budget	Final Overall Score
				Screening Services for Low-Income/Uninsured Texans	Science Center		
7	PP210031	DI	Poplack, David	Application of mHealth Technologies to Improve Latino Childhood Cancer Survivor Engagement and Use of Evidence for Personalized Follow-Up Care	Baylor College of Medicine	\$299,982	3.3
8	PP210007	EPS	Montealegre, Jane R	Strengthening Safety Net Health Systems to Improve Cervical and Colorectal Cancer Screening and Follow-up among the Medically Underserved	Baylor College of Medicine	\$2,497,029	3.3
9	PP210044	TCL	Zoorob, Roger	Expansion of the Lung Cancer Screening and Tobacco Control (LCTC) Network to Rural and Medically Underserved Populations	Baylor College of Medicine	\$1,999,664	3.6

DI: Dissemination of CPRIT-Funded Cancer Control Interventions

EBP: Evidence-Based Cancer Prevention Services

EPS: Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations

TCL: Tobacco Control and Lung Cancer Screening

Product Development Research Award Recommendations

The PIC unanimously recommends approval of two product development research grant proposals totaling \$27,565,207. The recommended grant proposals were submitted in response to the *Texas Company Product Development Awards* grant mechanism. The Product Development Review Council (PDRC) provided the prioritized list of recommendations for the awards to the presiding officers on July 24, 2021. The PDRC recommended applications from this grant mechanism out of score order, which is allowed by Texas Administrative Code § 703.6(d)(1). The PIC approved the recommendations in the rank order presented by the PDRC.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these product development research proposals met the following CPRIT funding priorities:

- could lead to immediate or long-term medical and scientific breakthroughs in the area of cancer prevention or cures for cancer;
- strengthen and enhance fundamental science in cancer research;
- ensure a comprehensive coordinated approach to cancer research and cancer prevention;
- are interdisciplinary or interinstitutional;
- Address federal or other major research sponsors' priorities in emerging scientific or institutions of higher education;
- Are matched with funds available by a private or nonprofit entity and institution or institutions of higher education;
- are collaborative between any combination of private and nonprofit entities, public or private agencies or institutions in this state, and public or private institutions outside this state;
- have a demonstrable economic development benefit to this state;
- expedite innovations and commercialization, attract, create, or expand private sector entities that will drive a substantial increase in high-quality jobs, and increase higher education applied science or Technology research capabilities; and
- address the goals of the Texas Cancer Plan.

Product Development Research Grant Award Recommendations
Texas Company Product Development Awards

Rank	Application ID	PI	Application Title	Company	Budget	Final Overall Score
1	DP210005	Joshua Sills	Clinical Development of DT2216, a First-in-Class APTaD™ for Cancer Therapy	Dialectic Therapeutics, Inc.	\$14,449,638	3.0
2	DP210042	Juan F. Vera	Efficacy of a Multi Tumor Associated Antigen Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant	Marker Therapeutics, Inc.	\$13,115,569	2.2



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS
FROM: VINCE BURGESS, CHIEF COMPLIANCE OFFICER
SUBJECT: COMPLIANCE CERTIFICATION – AUGUST 2021 AWARDS
DATE: AUGUST 4, 2021

Summary and Recommendation:

As CPRIT's Chief Compliance Officer, I am responsible for reporting to the Oversight Committee regarding the agency's compliance with applicable statutory and administrative rule requirements during the grant review process. I have reviewed the compliance pedigrees for the grant applications submitted to CPRIT for the:

- Recruitment of Rising Stars
- Recruitment of First-Time, Tenure-Track Faculty Members
- Core Facility Support Awards
- Clinical Trials Network Awards
- Early Clinical Investigator Awards
- High-Impact/High-Risk Research Awards
- Texas Clinical Trials Participation Awards
- Texas Regional Excellence in Cancer Award
- Texas Company Product Development Research Awards
- Evidence-Based Cancer Prevention Services
- Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations
- Tobacco Control and Lung Cancer Screening
- Dissemination of CPRIT-Funded Cancer Control Interventions

The following mechanisms also received applications during this award cycle; however, did not result in recommendations to the Oversight Committee for its August 18, 2021, meeting: Recruitment of Established Investigators, Company Relocation Product Development Awards; and Seed Awards for Product Development Research. I have conferred with staff at CPRIT and General Dynamics Information Technology (GDIT), CPRIT's contracted third-party grants administrator, regarding the academic research, product development research, and prevention awards and studied the supporting

grant review documentation, including third-party observer reports for the peer review meetings. I am satisfied that the application review process that resulted in the above mechanisms recommended by the Program Integration Committee (PIC) followed applicable laws and agency administrative rules. I certify the academic research, product development research, and prevention award recommendations for the Oversight Committee's consideration.

At its August 3, 2021, meeting, the PIC voted to recommend an application from cycle 1 that the Prevention Review Council previously took no action on at its March 4, 2021, meeting. I certified the Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations mechanism for the May 19, 2021, Oversight Committee meeting; therefore, I will not repeat the certification here but instead will make available copies of those previous certifications.

Background:

CPRIT's Chief Compliance Officer must report to the Oversight Committee regarding compliance with the statute and the agency's administrative rules. Among the Chief Compliance Officer's responsibilities is the obligation "to ensure that all grant proposals comply with this chapter and rules adopted under this chapter before the proposals are submitted to the oversight committee for approval." Texas Health & Safety Code § 102.051(c) and (d).

CPRIT uses a compliance pedigree process to formally document compliance for the grant award process. The compliance pedigree tracks the grant application as it moves through the review process and documents compliance with applicable laws and administrative rules. A compliance pedigree is created for each application; the information related to the procedural steps listed on the pedigree is entered and attested to by GDIT employees and CPRIT employees. CPRIT relies on GDIT to accurately record a majority of the information on the pedigree from the pre-receipt stage to final Review Council recommendation. To the greatest extent possible, information reported in the compliance pedigree is imported directly from data contained in CPRIT's Application Receipt System (CARS), the grant application database managed by GDIT. This is done to minimize the opportunity for error caused by manual data entry.

No Prohibited Donations:

Although CPRIT is statutorily authorized to accept gifts and grants pursuant to Texas Health & Safety Code § 102.054, the statute prohibits CPRIT from awarding a grant to an applicant who has made a gift or grant to CPRIT, or a nonprofit organization established to provide support to CPRIT. I note that Texas Health & Safety Code § 102.251(a)(3) specifically addresses "donors from any nonprofit organization established to provide support to the institute compiled from information made available under § 102.262(c)." To the best of my knowledge, there are no nonprofit organizations that have been established to provide support to CPRIT on or after June

14, 2013, the effective date of this statutory change. The only nonprofit organization established to provide support to the Institute was the CPRIT Foundation; however, the CPRIT Foundation ceased operations and changed its name and its purpose prior to June 14, 2013. The institute has received no donations from the CPRIT Foundation made on or after June 14, 2013.

I have reviewed the list of donors to CPRIT maintained by CPRIT (and listed on CPRIT's website) and compared the donors to the list of applicants. No donors to CPRIT have submitted applications for grant awards during the award cycles that are the subject of this report.

Pre-Receipt Compliance:

The activities listed on a compliance pedigree in the pre-receipt stage cover the period beginning with CPRIT's approval and issuance of the Request for Applications (RFA) through the submission of grant applications. The RFA specifies a deadline and mandates that only those applications submitted electronically through CPRIT's Application Receipt System (CARS) are eligible for consideration. CARS blocks an application from being submitted once the deadline passes. Occasionally, an applicant may have technical difficulties that prevent the applicant from completing the application submission. When this occurs, the applicant may appeal to CPRIT (through the CPRIT Helpdesk that is managed by GDIT) to allow for a submission after the deadline. The program officer considers any requests for extension and may approve an extension for good cause. When a late filing request is approved, the applicant is notified, and CARS is reopened for a brief period – usually two to three hours – the next business day.

Academic Research:

For Recruitment Cycles 21.10, 21.11 and 21.12, three applications were received for the Recruitment of Established Investigators RFA, three applications were received in response to the Recruitment of Rising Stars RFA, and 21 applications were received in response to the Recruitment of First-Time, Tenure Track Faculty members RFA. Three academic research recruitment applications were voluntarily withdrawn by the applicants before the SRC meetings.

In response to the academic, non-recruitment RFAs for Cycle 21.2, CPRIT received 159 applications. Two applications were administratively withdrawn prior to peer review and one application was voluntarily withdrawn by the applicant after peer review but prior to the Scientific Review Council (SRC) meeting.

All applications were submitted through CARS. One applicant requested an extension to submit an application after the deadline. The program officer determined that there was good cause for the request and the deadline was extended.

Product Development Research:

For product development cycle 21.1, CPRIT uploaded the RFAs on the Texas.gov eGrants website; however, a technical/system error prevented publication. CPRIT is currently working with the eGrants staff to resolve the issue. For Cycle 21.1, eight applications were received for the Texas Company Product Development Awards RFA, six applications were received for the Company Relocation Product Development Research Awards RFA, and 22 applications were received for the Seed Awards for Product Development Research RFA.

One application was administratively withdrawn prior to peer review. All applications were submitted through CARS. Two applicants requested an extension to submit an application after the deadline. The program officer determined that there was good cause for the two requests and the deadline was extended.

Prevention:

For prevention cycle 21.2, CPRIT uploaded the RFAs on the Texas.gov eGrants website; however, a technical/system error prevented publication. CPRIT is currently working with the eGrants staff to resolve the issue. For Cycle 21.2, 10 applications were received for the Evidence-Based Cancer Prevention Services RFA, five applications were received for the Tobacco Control and Lung Cancer Screening RFA, three applications were received for the Expansion of Cancer Prevention Services to Rural, Medically Underserved Populations RFA, and four applications were received for the Dissemination of CPRIT-Funded Cancer Control Interventions RFA.

All applications were submitted through CARS.

Receipt, Referral, and Assignment Compliance:

Once applications have been submitted through CARS, GDIT staff reviews the applications for compliance with RFA directions. If an applicant does not comply with the directions, GDIT notifies the program officer, and the program officer makes the final decision whether to administratively withdraw the application. Recruitment grant applications are assigned to the Scientific Review Council members for peer review. All other academic research, product development research, and prevention applications are assigned by the peer review panel chair to their respective peer review panels. Prior to distribution of the applications, reviewers are given summary information about the applicant, including the Project Director and collaborators. Reviewers must sign a conflict of interest agreement and confirm that they do not have a conflict of interest with the application before they are provided with the full application.

The pedigrees attest that a conflict of interest statement was signed by each primary reviewer for each Grant Application.

Academic Research:

Three academic research recruitment applications were voluntarily withdrawn by the applicants before the SRC meetings.

Two academic research non-recruitment applications were administratively withdrawn prior to peer review and one application was voluntarily withdrawn by the applicant after peer review but prior to the Scientific Review Council (SRC) meeting.

Product Development Research:

One Product Development Research application was administratively withdrawn prior to peer review.

Prevention:

No applications were withdrawn during this cycle.

Peer Review:

Primary reviewers (typically three) must submit written critiques for each of their assigned applications prior to the peer review meeting. Sign out sheets are used to document when a reviewer with a conflict of interest associated with a particular application leaves the room (or disengages from the conference call) during the discussion and scoring of the application.

Following the peer review meeting, each participating peer reviewer must sign a post-review peer review statement certifying that the reviewer knew of and understood CPRIT's conflict of interest policy and followed the policy for this review process. After the peer review meetings, a final score report from the review committee is delivered to the Review Council for additional review.

Academic Research:

For the Recruitment Awards, the applications are reviewed by the Scientific Review Council (SRC), which assigns two members of the SRC to be primary reviewers. I reviewed the supporting documentation, such as the sign-out sheets, third-party observer reports, and post-review peer reviewer statements. Sign out sheets are used to document when a reviewer with a conflict of interest associated with a particular application leaves the room (or disengages from the conference call) during the discussion and scoring of the application. One conflict of interest was declared by the SRC for Recruitment Cycle 21.10, four conflicts of interest were declared for Recruitment Cycle 21.11, and one conflict of interest was declared for Recruitment Cycle 21.12.

I reviewed and confirmed that the post review conflict of interest statements were signed by the seven SRC members that attended the 21.10 Recruitment Review Panel meeting on May 13, 2021, the eight SRC members that attended the 21.11 Recruitment Review Panel on June 10, 2021, the nine SRC members that attended the 21.12 Recruitment Review Panel on July 8, 2021.

Academic research applications (non-recruitment) are reviewed by peer review panels and recommended to the SRC. As documented by GDIT, reviewers with conflicts of interest did not participate in review of those applications. I reviewed supporting documentation, such as conflict of interest statements (COIs), third-party observer reports, and sign out sheets. All declared COIs left the room or disengaged from the conference call and did not participate in the discussion of relevant applications.

I also reviewed and confirmed that the post review conflict of interest statements were signed by peer review members for each review panel as well as the eight SRC members that attended the Review Council meeting on July 8, 2021.

Product Development Research:

Product Development Research awards go through a peer review teleconference screening call to determine which applications will be invited to in-person (or video teleconference) review. Those applicants that attend in-person review are once again evaluated by peer reviewers. Applicants recommended after in-person review must then go through operations and management due diligence review, which is conducted by outside contractors and outside intellectual property counsel. The Product Development Review Council (PDRC) recommends awards after due diligence to the PIC. I have verified from GDIT documentation and the third-party observer reports that those reviewers with conflicts did not participate in review of applications for which they indicated a conflict of interest. All declared COIs left the room or disengaged from the conference call and did not participate in the discussion of relevant applications.

I also reviewed and confirmed that the post review conflict of interest statements were signed by peer review members for each panel as well as the eight PDRC members and four expert reviewers that attended the Due Diligence meeting on July 8, 2021.

Prevention:

For the Dissemination of CPRIT-Funded Cancer Control Interventions RFA, the applications are reviewed by the Prevention Review Council (PRC), which assigns two members of the PRC to be primary reviewers. All other Prevention applications are reviewed by peer review panels and then sent to the PRC.

I reviewed the supporting documentation, such as the sign-out sheets, third-party observer reports, and post-review peer reviewer statements. As documented by GDIT and verified by third-party observer reports, reviewers with conflicts of interest did not participate in review of those applications. All declared COIs left the room or disengaged from the conference call and did not participate in the discussion of relevant applications.

I reviewed and confirmed that the post review conflict of interest statements were signed by 13 peer review members for Prevention Panel 1 on April 26-27, 2021, and the three PRC members that attended the Dissemination of CPRIT-Funded Cancer Control Interventions Panel on May 27, 2021, and the PRC meeting on June 17, 2021.

Programmatic Review:

Programmatic review is conducted by the Scientific Review Council, Prevention Review Council, and Product Development Review Council for their respective awards. Each review council creates a final list of grant applications it will recommend to the PIC for grant award slates.

To the extent that any Review Council member identified a conflict of interest, I reviewed documentation confirming that the review council member did not participate in the discussion or vote on the application(s).

I also reviewed the third-party observer reports for each Review Council meeting. The third-party observer reports document that the Review Council discussions were limited to the merits of the applications and established evaluation criteria and that conflicted reviewers, if applicable, exited the room or the conference call when the application was discussed.

For the Academic Research, Product Development Research and Prevention awards, I reviewed and confirmed that the Review Council recommendations corresponded to RFAs that had been released. I also confirmed that the pedigrees reflect the date of the Review Council meeting and that the applications were recommended by the Review Council.

Academic Research:

The SRC met on July 8, 2021, to consider 51 applications recommended by the peer review panels following their meetings held on May 20-May 27, 2021. After review of these applications, the SRC recommended 50 applications to the Program Integration Committee (PIC) for consideration. I note that the CFSA application not recommended by the SRC had a score equal to other CFSA applications that were recommended. As allowed by 25 T.A.C. § 703.6 (d)(1), a review council's numerical rank order is substantially based on the final overall evaluation score assigned by the peer review panels, but it may also consider how well a grant application achieves program priorities set by the Oversight Committee, the overall program portfolio balance, and any other criteria described in the RFA.

I note that on October 28, 2020, Mr. Roberts granted the Chief Scientific Officer, Dr. Jim Willson, a waiver from the general prohibition against communicating with a grant applicant, pursuant to Texas Administrative Code § 702.19(e). The waiver was applicable to communication regarding questions about a potential Core Facility Support Award (CFSA) application. A copy of the waiver is included in the "CEO Affidavit-Supporting Information" packet for the 2021 CFSA mechanism.

Product Development Research:

For Cycle 21.1, five applications went through due diligence. The PDRC met on July 8, 2021, and after review and discussion recommended two applications to the PIC for consideration. Both applications were submitted in response to the Texas Company Product Development Awards RFA.

I note that the PDRC recommended applications from this grant mechanism out of score order. Additionally, the PDRC did not recommend an application responsive to this RFA that has a score equal to another application that was recommended. As allowed in 25 T.A.C. § 703.6(d)(1), the PDRC's numerical rank order is substantially based on the final overall evaluation score, but also takes into consideration how well the grant application achieves program priorities and the overall program portfolio.

Prevention:

Six applications were recommended by the peer review panel to the PRC. After review and discussion of these applications, the PRC recommended all six applications to the PIC for consideration. The PRC's recommendation from its June 17 meeting included a cycle 1 application that the review council previously took no action on at its March 4, 2021, meeting.

I note that on August 28, 2020, Mr. Roberts granted the Chief Prevention Officer, Ramona Magid, a waiver from the general prohibition against communicating with grant applicants, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the "CEO Affidavit-Supporting Information" packet for each of the prevention mechanisms recommended by the PIC.

Program Integration Committee (PIC) Review:

Texas Health & Safety Code § 102.051(d) requires the Chief Compliance Officer to attend and observe the PIC meetings to ensure compliance with CPRIT's statute and administrative rules. CPRIT's statute requires that, at the time the PIC's final Grant Award recommendations are formally submitted to the Oversight Committee, the Chief Executive Officer shall prepare a written affidavit for each Grant Application recommended by the PIC containing relevant information related to the Grant Application recommendations.

I attended the August 3, 2021, PIC meeting as an observer and confirm that the PIC review process complied with CPRIT's statute and administrative rules. All five PIC members were present for the meeting.

The PIC considered 73 applications that were recommended by the three review councils. The PIC voted to recommend all 73 applications to move forward to the Oversight Committee. Dr. Willson declared a conflict of interest for RP210236, a High-Impact/High-Risk Research Award (HIHRA) from the University of Texas at Dallas. Pursuant to a Texas Health and Safety Code §102.1062

waiver, Dr. Willson generally presented the HIHRRRA recommendations to the PIC that included RP210236, which he did not advocate for at the expense of other applications. Dr. Willson abstained from voting on all applications under the HIHRRRA mechanism.

A review of the CEO affidavits confirms that such affidavits were executed and provided for each grant application recommendation.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS
FROM: VINCE BURGESS, CHIEF COMPLIANCE OFFICER
SUBJECT: COMPLIANCE CERTIFICATION – MAY 2021 AWARDS
DATE: MAY 5, 2021

Summary and Recommendation:

As CPRIT’s Chief Compliance Officer, I am responsible for reporting to the Oversight Committee regarding the agency’s compliance with applicable statutory and administrative rule requirements during the grant review process. I have reviewed the compliance pedigrees for the grant applications submitted to CPRIT for the:

- Recruitment of Rising Stars
- Recruitment of First-Time, Tenure-Track Faculty Members
- Research Training Awards
- Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations

I have conferred with staff at CPRIT and General Dynamics Information Technology (GDIT), CPRIT’s contracted third-party grants administrator, regarding the academic research and prevention awards and studied the supporting grant review documentation, including third-party observer reports for the peer review meetings. CPRIT received applications for the Recruitment of Established Investigators; however, the recommended application was withdrawn prior to the PIC meeting. I am satisfied that the application review process that resulted in the above mechanisms recommended by the Program Integration Committee (PIC) followed applicable laws and agency administrative rules. I certify the academic research and prevention award recommendations for the Oversight Committee’s consideration.

Background:

CPRIT’s Chief Compliance Officer must report to the Oversight Committee regarding compliance with the statute and the agency’s administrative rules. Among the Chief Compliance Officer’s responsibilities is the obligation “to ensure that all grant proposals comply with this chapter and rules

adopted under this chapter before the proposals are submitted to the oversight committee for approval.” Texas Health & Safety Code § 102.051(c) and (d).

CPRIT uses a compliance pedigree process to formally document compliance for the grant award process. The compliance pedigree tracks the grant application as it moves through the review process and documents compliance with applicable laws and administrative rules. A compliance pedigree is created for each application; the information related to the procedural steps listed on the pedigree is entered and attested to by GDIT employees and CPRIT employees. CPRIT relies on GDIT to accurately record a majority of the information on the pedigree from the pre-receipt stage to final Review Council recommendation. To the greatest extent possible, information reported in the compliance pedigree is imported directly from data contained in CPRIT’s Application Receipt System (CARS), the grant application database managed by GDIT. This is done to minimize the opportunity for error caused by manual data entry.

No Prohibited Donations:

Although CPRIT is statutorily authorized to accept gifts and grants pursuant to Texas Health & Safety Code § 102.054, the statute prohibits CPRIT from awarding a grant to an applicant who has made a gift or grant to CPRIT or a nonprofit organization established to provide support to CPRIT. I note that Texas Health & Safety Code § 102.251(a)(3) specifically addresses “donors from any nonprofit organization established to provide support to the institute compiled from information made available under § 102.262(c).” To the best of my knowledge, there are no nonprofit organizations that have been established to provide support to CPRIT on or after June 14, 2013, the effective date of this statutory change. The only nonprofit organization established to provide support to the Institute was the CPRIT Foundation; however, the CPRIT Foundation ceased operations and changed its name and its purpose prior to June 14, 2013. The institute has received no donations from the CPRIT Foundation made on or after June 14, 2013.

I have reviewed the list of donors to CPRIT maintained by CPRIT (and listed on CPRIT’s website) and compared the donors to the list of applicants. No donors to CPRIT have submitted applications for grant awards during the award cycles that are the subject of this report.

Pre-Receipt Compliance:

The activities listed on a compliance pedigree in the pre-receipt stage cover the period beginning with CPRIT’s approval and issuance of the Request for Applications (RFA) through the submission of grant applications. For the period covering these RFAs, CPRIT published the RFAs on the Texas.gov eGrants website. The RFA specifies a deadline and mandates that only those applications submitted electronically through CPRIT’s Application Receipt System (CARS) are eligible for consideration. CARS blocks an application from being submitted once the deadline passes. Occasionally, an applicant may have technical difficulties that prevent the applicant from completing the application submission. When this occurs, the applicant may

appeal to CPRIT (through the CPRIT Helpdesk that is managed by GDIT) to allow for a submission after the deadline. The program officer considers any requests for extension and may approve an extension for good cause. When a late filing request is approved, the applicant is notified, and CARS is reopened for a brief period – usually two to three hours – the next business day.

Academic Research:

For recruitment cycles 21.6, 21.7, 21.8 and 21.9, two applications were received for the Recruitment of Established Investigators RFA, five applications were received in response to the Recruitment of Rising Stars RFA, and 17 applications were received in response to the Recruitment of First-Time, Tenure Track Faculty members RFA.

In response to the academic, non-recruitment RFAs for cycle 21.1, CPRIT received 15 applications pursuant to the Research Training Awards (RTA) RFA.

All academic research RFAs were posted on the Texas.gov eGrants website and all applications were submitted through CARS. Three applicants requested an extension to submit an application after the deadline. The program officer determined that there was good cause for the three requests and the deadline was extended.

Prevention:

For prevention cycle 21.1, 12 applications were received for the Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations RFA.

The prevention RFA was posted on the Texas.gov eGrants website and all applications were submitted through CARS.

Receipt, Referral, and Assignment Compliance:

Once applications have been submitted through CARS, GDIT staff reviews the applications for compliance with RFA directions. If an applicant does not comply with the directions, GDIT notifies the program officer and the program officer makes the final decision whether to administratively withdraw the application. Recruitment grant applications are assigned to the Scientific Review Council members for peer review. All other academic research, product development research, and prevention applications are assigned by the peer review panel chair to their respective peer review panels. Prior to distribution of the applications, reviewers are given summary information about the applicant, including the Project Director and collaborators. Reviewers must sign a conflict of interest agreement and confirm that they do not have a conflict of interest with the application before they are provided with the full application.

The pedigrees attest that a conflict of interest statement was signed by each primary reviewer for each Grant Application.

Academic Research:

In total, two recruitment applications during cycle 21.7-8 were withdrawn after initial receipt. One recruitment application was administratively rejected and therefore, not assigned to the SRC for review. A second application was withdrawn by the applicant after it was recommended by the SRC but prior to the PIC meeting.

Prevention:

No applications were withdrawn during this cycle.

Peer Review:

Primary reviewers (typically three) must submit written critiques for each of their assigned applications prior to the peer review meeting. Sign out sheets are used to document when a reviewer with a conflict of interest associated with a particular application leaves the room (or disengages from the conference call) during the discussion and scoring of the application.

Following the peer review meeting, each participating peer reviewer must sign a post-review peer review statement certifying that the reviewer knew of and understood CPRIT's conflict of interest policy and followed the policy for this review process. After the peer review meetings, a final score report from the review committee is delivered to the Review Council for additional review.

Academic Research:

For the Recruitment Awards, the applications are reviewed by the Scientific Review Council (SRC), which assigns two members of the SRC to be primary reviewers. I reviewed the supporting documentation, such as the sign-out sheets, third-party observer reports, and post-review peer reviewer statements. Sign out sheets are used to document when a reviewer with a conflict of interest associated with a particular application leaves the room (or disengages from the conference call) during the discussion and scoring of the application. Two conflicts of interest were declared by the SRC for recruitment cycle 21.7-8 and two conflicts of interest were declared by the SRC for recruitment cycle 21.9. For recruitment cycle 21.6, no conflicts of interest were declared.

I reviewed and confirmed that the post review conflict of interest statements were signed by the eight SRC members that attended the 21.6 Recruitment Review Panel meeting on January 21, 2021, the six SRC members that attended the 21.7-8 Recruitment Review Panel on March 11, 2021, and the eight SRC members that attended the 21.9 Recruitment Review Panel on April 15, 2021.

Academic research applications (non-recruitment) are reviewed by peer review panels and recommended to the SRC. As documented by GDIT, reviewers with conflicts of interest did not participate in review of those applications. I reviewed supporting documentation, such as conflict of interest statements (COIs), third-party observer reports, and sign out sheets. All declared COIs left the room or disengaged from the conference call and did not participate in the discussion of relevant applications.

I also reviewed and confirmed that the post review conflict of interest statements were signed by the 16 peer review members for the 21.1 RTA review panel on February 18, 2021, as well as the five SRC members that attended the Review Council meeting on March 25, 2021.

Prevention:

Prevention applications are reviewed by peer review panels and then sent to the Prevention Review Council (PRC).

I reviewed the supporting documentation, such as the sign-out sheets, third-party observer reports, and post-review peer reviewer statements. As documented by GDIT and verified by third-party observer reports, reviewers with conflicts of interest did not participate in review of those applications. All declared COIs left the room or disengaged from the conference call and did not participate in the discussion of relevant applications.

I reviewed and confirmed that the post review conflict of interest statements were signed by nine peer review members for Prevention Panel 1 on January 19, 2021 and the three PRC members that attended the PRC meeting on March 4, 2021.

Programmatic Review:

Programmatic review is conducted by the Scientific Review Council, Prevention Review Council, and Product Development Review Council for their respective awards. Each review council creates a final list of grant applications it will recommend to the PIC for grant award slates.

To the extent that any Review Council member identified a conflict of interest, I reviewed documentation confirming that the review council member did not participate in the discussion or vote on the application(s).

I also reviewed the third-party observer reports for each Review Council meeting. The third-party observer reports document that the Review Council discussions were limited to the merits of the applications and established evaluation criteria and that conflicted reviewers, if applicable, exited the room or the conference call when the application was discussed.

For the Academic Research and Prevention awards, I reviewed and confirmed that the Review Council recommendations corresponded to RFAs that had been released. I also confirmed that the

pedigrees reflect the date of the Review Council meeting and that the applications were recommended by the Review Council.

Academic Research:

The SRC met on March 25, 2021 to consider eight applications recommended by the RTA peer review panel following their meeting held on February 18, 2021. After review of these applications, the SRC recommended all eight applications to the Program Integration Committee (PIC) for consideration. Of the eight RTA applications, the SRC recommended a budget reduction for one RTA grant application.

In their review of recruitment applications, the SRC did not recommend applications from recruitment cycle 21.6 to the PIC. After the SRC recommended RR210032 to the PIC, the applicant withdrew the application from consideration prior to the PIC meeting. This application was the only recommended Established Investigator award from cycles 21.6-9.

I note that on February 1, 2021, Wayne Robert's, CPRIT's Chief Executive Officer, granted Dr. Jim Willson, CPRIT's Chief Scientific Officer, a waiver from the general prohibition against communicating with grant applicants, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is available in the CEO Affidavit Supporting information for the recruitment cycles 21.6-9.

Prevention:

Out of 11 applications considered by the PRC following the peer review panel meeting on January 19, 2021, five were recommended to the PIC. The PRC took no action on one application with the same score as an application on which the PRC took no action. As allowed in 25 T.A.C. § 703.6(d)(1), the PRC's numerical rank order is substantially based on the final overall evaluation score, but also takes into consideration how well the grant application achieves program priorities, programmatic review criteria, and the overall program portfolio.

I note that on August 28, 2020, Mr. Roberts granted the Chief Prevention Officer, Ramona Magid, a waiver from the general prohibition against communicating with grant applicants, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the "CEO Affidavit-Supporting Information" packet for each of the prevention mechanisms recommended by the PIC.

Program Integration Committee (PIC) Review:

Texas Health & Safety Code § 102.051(d) requires the Chief Compliance Officer to attend and observe the PIC meetings to ensure compliance with CPRIT's statute and administrative rules. CPRIT's statute requires that, at the time the PIC's final Grant Award recommendations are formally submitted to the Oversight Committee, the Chief Executive Officer shall prepare a written affidavit

for each Grant Application recommended by the PIC containing relevant information related to the Grant Application recommendations.

I attended the May 4, 2021, PIC meeting as an observer and confirm that the PIC review process complied with CPRIT's statute and administrative rules.

The PIC considered 26 applications that were recommended by the Academic Research and Prevention Review Councils; The PIC voted to recommend all 26 applications to move forward to the Oversight Committee. The PIC recommended RP210037 to the Oversight Committee with the recommended budget reduction by the SRC.

A review of the CEO affidavits confirms that such affidavits were executed and provided for each Grant Application recommendation.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Product Development Research
FY 2021—Cycle 1
*Texas Company Product Development
Awards***

Request for Applications



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS RFA C-21.1-TXCO

Texas Company Product Development Research Awards

**Please also refer to the Instructions for Applicants document,
which will be posted on December 2, 2020**

Application Receipt Opening Date: December 2, 2020

Application Receipt Closing Date: January 27, 2021

FY 2021

Fiscal Year Award Period

September 1, 2020-August 31, 2021

TABLE OF CONTENTS

1. KEY POINTS	4
2. ABOUT CPRIT	5
2.1. PRODUCT DEVELOPMENT RESEARCH PROGRAM PRIORITIES	6
3. EXECUTIVE SUMMARY	7
4. MECHANISM OF SUPPORT	7
5. OBJECTIVES	7
6. FUNDING INFORMATION	8
7. KEY DATES	9
8. ELIGIBILITY	9
8.1. APPLICANTS	9
8.2. RESUBMISSION POLICY	12
9. APPLICATION REVIEW	13
9.1. OVERVIEW	13
9.2. REVIEW PROCESS.....	13
9.2.1. Confidentiality of Review	14
9.3. REVIEW CRITERIA.....	15
9.3.1. Primary Criteria.....	15
9.3.2. Secondary Criteria.....	16
10. SUBMISSION GUIDELINES	17
10.1. ONLINE APPLICATION RECEIPT SYSTEM AND APPLICATION SUBMISSION DEADLINE	17
10.2. SUBMISSION DEADLINE EXTENSION	17
10.3. PRODUCT DEVELOPMENT REVIEW FEE	18
10.4. APPLICATION COMPONENTS	19
10.4.1. Layperson’s Summary (1,500-character maximum).....	19
10.4.2. Abstract and Significance (5,000-character maximum).....	19
10.4.3. Goals and Objectives (maximum of 1,200 characters each).....	20
10.4.4. Timeline (1-page maximum).....	20
10.4.5. Slide Presentation (10-page maximum).....	20
10.4.6. Resubmission Summary (1-page maximum).....	20
10.4.7. Development Plan (12-page maximum).....	21
10.4.8. Business Plan	24
10.4.9. Biographical Sketches of Key Scientific Personnel (8-page maximum)	26
10.4.10. Budget	26
11. AWARD ADMINISTRATION	28
12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS	29
13. CONTACT INFORMATION	30
13.1. HELPDESK.....	30
13.2. PROGRAMMATIC QUESTIONS	30
14. APPENDIX	31
14.1. REVIEWER EVALUATION GUIDELINES FOR THERAPEUTICS	31
14.2. REVIEWER EVALUATION GUIDELINES FOR MEDICAL DEVICES AND DIAGNOSTICS.....	37

RFA VERSION HISTORY

Rev 11/9/2020 RFA release

1. KEY POINTS

This Texas Company Product Development Research Award mechanism is governed by the following guidelines:

- All cancer-related sectors are eligible: therapeutics, diagnostics, devices, and tools. Products must diagnose cancer, treat cancer, or treat sequelae specific to cancer.
- For therapeutics, Product Development Research Award funding supports preclinical research and early clinical research necessary to demonstrate initial clinical safety and efficacy (typically phase 1, phase 2A).
- Recipient companies must currently be Texas based (see [section 8.1](#)) and must have a chief executive officer (CEO) as part of the applicant's management team prior to submitting an application. The Cancer Prevention and Research Institute of Texas (CPRIT) requires the use of Texas-based subcontractors and suppliers unless adequate justification is provided for the use of out-of-state entities.
- CPRIT requires recipient companies to raise a portion of the total project budget from external sources. For a company receiving an initial CPRIT award, CPRIT will contribute \$2.00 for every \$1.00 contributed in matching funds by the recipient company. CPRIT reserves the right to seek a higher matching funds contribution (ie, CPRIT will contribute \$1.00 for every \$1.00 contributed in matching funds by the company) from a company that has already received a CPRIT award and is approved for a second award. The demonstration of available matching funds must be made prior to the distribution of CPRIT grant funds, not at the time the application is submitted. CPRIT funds should, whenever possible, be spent in Texas. A company's matching funds must be dedicated to the CPRIT-funded project but may be spent outside of Texas.
- Applicants may request up to \$20 million in CPRIT funds. CPRIT receives many more applications each year than available funds can support. While all requests for funding must be well justified, a funding request at or near the maximum amount will be heavily scrutinized. Such a request must be exceptionally well justified to warrant dedicating a large percentage of CPRIT's product development research budget to the applicant's project.

- Funding will be tranching and tied to the achievement of contract-specified milestones. The contract-specific milestones are the Goals & Objectives submitted by the applicant within the proposal. The progress-based release of funds will be dependent on the completion of the applicant's proposed Goals & Objectives for each project year.
- All award contracts include a revenue-sharing agreement. **A copy of the revenue-sharing agreement can be found at www.cprit.texas.gov in the Product Development Research Program section.** Other contract provisions are specified in CPRIT's Administrative Rules, which are also available at www.cprit.texas.gov.
- An application last submitted but not funded (including resubmission) before December 5, 2018, may be submitted as a new application, even if it was previously resubmitted (see [section 8.2](#)).
- Applicant companies are limited to 1 submission per cycle across all CPRIT Product Development award mechanisms.

2. ABOUT CPRIT

The State of Texas established CPRIT, which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and product or service development, thereby enhancing the potential for a medical or scientific breakthrough in the prevention, treatment, and possible cures for cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Continue to develop and implement the Texas Cancer Plan by promoting the development and coordination of effective and efficient statewide public and private policies, programs, and services related to cancer and by encouraging cooperative, comprehensive, and complementary planning among the public, private, and volunteer sectors involved in cancer prevention, detection, treatment, and research.

CPRIT furthers cancer research in Texas by providing financial support for a wide variety of projects relevant to cancer research.

2.1. Product Development Research Program Priorities

Legislation from the 83rd Texas Legislature requires that CPRIT's Oversight Committee establish program priorities on an annual basis. The priorities are intended to provide transparency in how the Oversight Committee directs the orientation of the agency's funding portfolio. The Product Development Research Program's principles and priorities will also guide CPRIT staff and the Product Development Review Council on the development and issuance of program-specific Requests for Applications (RFAs) and the evaluation of applications submitted in response to those RFAs.

Established Principles:

- Moving forward the development of commercial products to diagnose and treat cancer and improve the lives of patients with cancer
- Creation of good, high-paying jobs for Texans
- Sound financial return on the monies invested
- Development of the Texas high-tech life sciences business environment

Product Development Research Program Priorities

- Funding novel projects that offer therapeutic or diagnostic benefits not currently available; ie, disruptive technologies
- Funding projects addressing large or challenging unmet medical needs
- Investing in early-stage projects when private capital is least available
- Stimulating commercialization of technologies developed at Texas institutions
- Supporting new company formation in Texas or attracting promising companies to Texas that will recruit staff with life science expertise, especially experienced C-level staff, to lead to seed clusters of life science expertise at various Texas locations
- Providing appropriate return on Texas taxpayer investment

A full description of CPRIT's program priorities may be found at

<http://priorities.cprit.texas.gov/>.

3. EXECUTIVE SUMMARY

CPRIT will foster cancer research as well as product and service development in Texas by providing financial support for a wide variety of projects relevant to cancer. This RFA solicits applications for the research and development of innovative products addressing critically important needs related to diagnosis, prevention, and/or treatment of cancer and the product development infrastructure needed to support these efforts. CPRIT encourages applicants who seek to apply or develop state-of-the-art products, services (eg, contract research organization services), technologies, tools, and/or resources for cancer research, prevention, or treatment. CPRIT expects outcomes of supported activities to directly and indirectly benefit subsequent cancer research efforts, cancer public health policy, or the continuum of cancer care—from prevention to treatment and cure. To fulfill this vision, applications may address any topic or issue related to cancer biology, causation, prevention, detection or screening, treatment, or cure. The overall goal of this award program is to improve outcomes of patients with cancer by accelerating the development of groundbreaking therapeutics, diagnostics, and tools with a primary focus on Texas-centric programs.

4. MECHANISM OF SUPPORT

The goal of the Texas Company Product Development Research Award is to finance the research and development of innovative products, services, and infrastructure with significant potential impact on patient care. These investments will provide companies or limited partnerships located and headquartered in Texas with the opportunity to further the research and development of new products for the diagnosis, treatment, supportive care, or prevention of cancer; to establish infrastructure that is critical to the development of a robust industry; or to fill a treatment, industry, or research gap. This award is intended to support companies that will be staffed with a majority of Texas-based employees, including C-level executives.

5. OBJECTIVES

The long-term objective of this award is to support commercially oriented therapeutic and medical technology products, diagnostic- or treatment-oriented information technology products, diagnostics, tools, services, and infrastructure projects. Common to all applications under this RFA should be the intent to further the research and development of products that would eventually be approved and marketed for the diagnosis, prevention, and/or treatment of cancer.

Eligible products or services include—but are not limited to—therapeutics (eg, small molecules and biologics), diagnostics, devices, and potential breakthrough technologies, including software and research discovery techniques.

CPRIT seeks to maximize the clinical impact of our funding. Hence, we focus investment in translational research and development activities, including the following eligible stages:

- Studies that establish preclinical proof of concept
- GLP studies to support INDs
- Phase 1 to establish safety and a maximally tolerated dose
- Phase 2 studies to determine safety and efficacy in initial targeted patient populations (up to 100 patients)

CPRIT typically does not fund efforts outside of these parameters. We do not consider studies larger than what are described as “translational,” and hence, such studies are outside the scope of our interest. Companies that have clinically demonstrated safety and efficacy should be able to acquire necessary capital via other sources. By exception, later clinical trials or later-stage product development projects may be considered where exceptional circumstances warrant CPRIT investment.

CPRIT’s objectives and program priorities are established by its Oversight Committee.

Consistent with the above, these priorities include “funding projects at Texas companies and relocating companies that are most likely to bring important products to the market.” A full description of CPRIT’s program priorities may be found at <http://priorities.cprit.texas.gov/>.

6. FUNDING INFORMATION

This is a 3-year funding program. Financial support will be awarded based upon the breadth and nature of the research and development project proposed. Requested funds must be well justified. Funding will be milestone driven.

Funds may be used for salary and fringe benefits, research supplies, equipment, clinical trial expenses, intellectual property (IP) acquisition and protection, external consultants and service providers, travel in support of the project, and other appropriate research and development costs, subject to certain limitations set forth by Texas law. If a company is working on multiple projects, care should be taken to ensure that CPRIT funds are used to support activities directly

related to the specific project being funded. Requests for funds to support construction and/or renovation may be considered under compelling circumstances for projects that require facilities that do not already exist in the state. Texas law limits the amount of awarded funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs).

For companies receiving an initial CPRIT award, CPRIT will award \$2.00 for every \$1.00 contributed in matching funds by the company. CPRIT reserves the right to seek a higher matching funds contribution, ie, CPRIT will contribute \$1.00 for every \$1.00 contributed in matching funds by the company, from a company that has already received a CPRIT award and is approved for a second award. The demonstration of available matching funds must be made prior to the distribution of CPRIT funds, not at the time the application is submitted. The matching funds commitment may be fulfilled on a year-by-year basis.

7. KEY DATES

RFA release	November 9, 2020
Online application opens	December 2, 2020, 7 AM central time
Applications due	January 27, 2021, 4 PM central time
Invitations to present sent	March 2021
Notifications sent if not invited	March 2021
Presentations to CPRIT*	April 2021
Award Notification	August 2021
Anticipated Start Date	September 2021

* Applicants will be notified of their peer review panel assignments prior to the peer review meeting dates. Information on the timing of subsequent steps will be provided to applicants later in the process.

8. ELIGIBILITY

8.1. Applicants

- Either for-profit or nonprofit companies may apply. However, nonprofit companies must intend to bring a product to market. Applications may be submitted prior to company formation, but company formation must be completed before award receipt. Applicants

will be required to provide a data universal numbering system (DUNS) number before award receipt.

- Award recipients must be Texas-based. A company is considered to be Texas based if it currently fulfills or commits to fulfilling a majority of the following criteria:
 1. The US headquarters are physically located in Texas.
 2. The chief executive officer resides in Texas.
 3. A majority of the company's personnel, including at least 2 other C-level employees (or equivalent) reside in Texas.
 4. Manufacturing activities take place in Texas.
 5. At least 90% of grant award funds are paid to individuals and entities in Texas, including salaries and personnel costs for employees and contractors.
 6. At least 1 clinical trial site is in Texas.
 7. The company collaborates with a medical research organization in Texas, including a public or private institution of higher education.

In exceptional circumstances, the applicant may propose 1 or more alternative location requirements, which the Oversight Committee may approve by a majority vote in an open meeting.

- Unless otherwise specified by the award contract, the company must fulfill all location requirements identified in the application within 1 year of receiving the initial disbursement of funds. Failure to maintain compliance with the location criteria will result in consequences ranging from suspension of grant funding to early termination of the grant contract and repayment of grant funds.
- All cancer-related sectors are eligible: therapeutics, diagnostics, devices, and tools. Project must diagnose cancer, treat cancer, or treat sequelae specific to cancer.
- An application last submitted before December 5, 2018, may be submitted as a new application, even if it was previously resubmitted.
- CPRIT is releasing 3 Product Development RFAs in this funding cycle. Please note that in any given application round, applicants are allowed to apply for only 1 Product Development Award (TXCO, RELCO, or SEED). Applicants are advised to review each RFA and select the program that best fits their development status.

- Only 1 coapplicant may be included on the application. For the Product Development Research Program, a coapplicant is an individual(s) designated by the applicant organization to have the appropriate level of authority and responsibility to direct the project or program to be supported by the award. If so designated by the applicant organization, coapplicants share the authority and responsibility for leading and directing the project, intellectually and logistically. When multiple applicants are named, each is responsible and accountable for the proper conduct of the project, program, or activity, including the submission of all required reports. The presence of more than 1 applicant on an application or award diminishes neither the responsibility nor the accountability of any individual applicant.
- An applicant is eligible to receive a grant award only if the applicant certifies that the company, including the company representative, any senior member or key personnel listed on the application, or any company officer or director (or any person related to 1 or more of these individual within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive CPRIT funding if the company representative, any senior member or key personnel listed on the application, or any company officer or director is related to a CPRIT Oversight Committee member.
- The applicant must report whether the company, company representative, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, whether or not those individuals are slated to receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application. If the applicant or other individuals are ineligible to receive federal grant funds or have had a grant terminated for cause, the applicant may be contacted to provide more information.
- CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although the applicant need not demonstrate the ability to comply with these contractual requirements

at the time the application is submitted, applicants should familiarize themselves with these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 11](#) and [section 12](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

8.2. Resubmission Policy

- An application previously submitted to CPRIT within the last 2 years (after December 5, 2018) but not funded may be resubmitted once and must follow all resubmission guidelines. **An application that was last submitted before December 5, 2018, may be submitted as a new application, even if the most recent submittal (prior to December 5, 2018), was a resubmission.** For additional clarity regarding the 21.1 application cycle, this means that an application that was last submitted during or before the 19.1 cycle is considered a new application. In contrast, an application that was last submitted during or after the 19.2 cycle is considered a resubmission. It is expected that significant progress will have been made on the project; a simple revision of the prior application with editorial or technical changes is not sufficient, and applicants are advised not to submit an application with such modest changes.
- An application is considered a resubmission if the proposed project is the same project as presented in the original submission. A change in the identity of the applicant or company representative for a project or a change of title of the project that was previously submitted to CPRIT does not constitute a new application; the application would be considered a resubmission. An application that was administratively withdrawn by the applicant or by CPRIT prior to review by the review panel is not considered a submission for purposes of CPRIT's resubmission policy.
- Applicants who choose to resubmit should carefully consider the reasons for lack of prior success. Applications that received an overall numerical score of 5 or higher are likely to need considerable attention. All resubmitted applications should be carefully reconstructed; a simple revision of the prior application with editorial or technical changes is not sufficient, and applicants are advised not to direct reviewers to such modest changes. A 1-page summary of the approach to the resubmission should be included. Resubmitted applications may be assigned to reviewers who did not review the

original submission. Reviewers of resubmissions are asked to assess whether the resubmission adequately addresses critiques from the previous review. **Applicants should note that addressing previous critiques is advisable; however, it does not guarantee the success of the resubmission.** All resubmitted applications must conform to the structure and guidelines outlined in this RFA.

9. APPLICATION REVIEW

9.1. Overview

Applications will be assessed based on evaluation of the quality of the company and the potential for continued product development. CPRIT requires the submission of a comprehensive development plan (see [section 10.4.7](#)) and a detailed business plan (see [section 10.4.8](#)). The review will address the commercial viability, product feasibility, scientific merit, and therapeutic impact as detailed in the company's business and development plans. The plans will be reviewed by an integrated panel of individuals with biotechnology expertise and experience in translational and clinical research as well as in the business development/regulatory approval processes for therapeutics, devices, and diagnostics. In addition, advocate reviewers will participate in the review process.

Funding decisions are made via the review process described below.

9.2. Review Process

- **Product Development and Scientific Review:** Applications that pass initial administrative review are assigned to independent CPRIT Product Development Peer Review Panel members for evaluation using the criteria listed below. Based on the initial evaluation and discussion by the Product Development Review Panel, a subset of applicants may be invited to deliver in-person presentations to the review panel.
- **Due Diligence Review:** Following the in-person presentations, a subset of applications judged to be most meritorious by the Product Development Review Panels will be referred for additional in-depth due diligence, including—but not limited to—IP, management, regulatory, manufacturing, and market assessments. Please note that CPRIT may request to review any correspondence that an applicant has conducted with regulatory agencies (eg, the FDA) as part of the diligence process. Following the due

diligence review, applications may be recommended for funding by the CPRIT Product Development Review Council based on the information set forth in the due diligence and IP reviews, comparisons with applications from the Product Development Review Panels, and programmatic priorities.

- **Program Integration Committee Review:** Applications recommended by the Product Development Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding.
- **Oversight Committee Approval:** The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote.

The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

9.2.1. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Product Development Peer Review Panel members, Product Development Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website. Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Product Development Peer Review Panel members and Product Development Review Council members are non-Texas residents.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed conflict of interest as set forth in CPRIT's Administrative Rules, [chapter 703, section 703.9](#).

Any form of communication regarding any aspect of a pending application is prohibited between the applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, a Product Development Review Panel member, or a Product Development Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant applicant from further consideration for a grant award.

9.3. Review Criteria

Full peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Review committees will evaluate and score each primary criterion and subsequently assign a global score that reflects an overall assessment of the application. **The overall assessment will not be an average of the scores of the individual criteria; rather, it will reflect the reviewers' overall impression of the application. Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

Attached to this RFA is a list of more detailed questions considered by CPRIT reviewers when assessing therapeutic applications ([Appendix 1](#), "Reviewer Evaluation Guidelines for Therapeutics") and when assessing medical devices, diagnostics, and/or tools ([Appendix 2](#), "Reviewer Evaluations Guidelines for Medical Devices and Diagnostics"). Applicants are encouraged to review these documents and, to the extent possible, address the questions within their application.

9.3.1. Primary Criteria

Primary review criteria will evaluate the scientific merit and potential impact of the proposed work contained in the application. Concerns with any of these criteria potentially indicate a major flaw in the significance and/or design of the proposed program.

The criteria provided below are designed to provide an **overview** of topics that may be pertinent to the assessment of applications during peer review. Specific criteria applied to evaluate a given

application will depend on the type of product described by the applicant (eg, therapeutic versus medical device). **Detailed descriptions of the specific criteria employed for different product classes are provided in the appendices to this RFA.**

Primary review criteria are heavily weighted in determining the quality of an application. Reviewers provide numerical scores for these topic areas when evaluating applications. Primary criteria are intended to address the following topics:

- Significance and Impact
- Unmet Medical Need
- Product Validation/Proof of Concept
- Safety
- Preclinical Strength/Development to Date
- Development Plan
- Competitive Landscape
- Intellectual Property
- Business/Commercial Aspects
- Management and Staffing
- Production/Manufacturing Plan
- Overview of Clinical/Regulatory Plan

More details regarding these topics can be found in the appendices to this document.

9.3.2. Secondary Criteria

Secondary review criteria contribute to the global score assigned to the application and are not assigned individual numerical scores. Concerns with these criteria potentially question the feasibility of the proposed research and development activities.

Secondary criteria include the following:

- Budget and Duration of Support

Please see appendices for more details.

10. SUBMISSION GUIDELINES

Applicants are advised to review carefully all instructions in this section to ensure the accurate and complete submission of all components of the application. Please refer to the *Instructions for Applicants* document for details that will be available on December 2, 2020. Applications that are missing 1 or more components, exceed the specified page or word limits, or that do not meet the eligibility requirements listed above will be administratively withdrawn without review.

10.1. Online Application Receipt System and Application Submission Deadline

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The applicant must create a user account in the system to start and submit an application. The coapplicant, if applicable, must also create a user account to participate in the application. Furthermore, the Application Signing Official (ASO) (an individual authorized to sign and submit an application on behalf of the applicant) must also create a user account in CARS. An application may not be submitted without ASO approval. Only the ASO is authorized to officially submit the application to CPRIT. It is acceptable (and not uncommon) for the applicant to also serve as the designated ASO. However, if the applicant intends to also serve as the ASO, the system requires that the applicant and the ASO have 2 different accounts and user names. Applications will be accepted beginning at 7 AM central time on December 2, 2020, and must be submitted by 4 PM central time on January 27, 2021. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

10.2. Submission Deadline Extension

The submission deadline may be extended upon a showing of good cause. Late submissions are permitted only in exceptional instances, usually for technology failures in the CARS. It is imperative that applicants allow sufficient time to familiarize themselves with the application format and instructions to avoid unexpected issues. The applicant's failure to adequately plan is not sufficient grounds to justify approval of a late submission.

Peer review schedules are set far in advance and do not accommodate receipt of an application days after the deadline. Therefore, potential applicants that are unable to meet the deadline due to

issues such as travel, sabbaticals, conferences, prolonged illness or other leave, etc, should not request additional time to submit an application but should instead consider submitting the application in the next review cycle.

A request to extend the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records.

10.3. Product Development Review Fee

All applicants must submit a nonrefundable fee of \$1,000 for review of Product Development Research applications. Payment should be made by check or money order payable to Cancer Prevention and Research Institute of Texas; electronic and credit card payments are not acceptable. The application ID and the name of the submitter must be indicated on the payment. Unless a request to submit a late fee has been approved by CPRIT, all payments must be postmarked by the application submission deadline and mailed as described below.

Checks may be mailed via the US Postal Service to the following address:

Cancer Prevention and Research Institute of Texas
PO Box 12097
Austin, Texas 78711

Contact name: Michelle Huddleston
Phone 1-512-305-8420

Mail sent via a delivery services (ie, FedEx, UPS, etc) will need to use this address:

Cancer Prevention and Research Institute of Texas
Wm B Travis State Office Building
1701 N Congress Ave Ste 6-127
Austin, Texas 78701

Contact name: Michelle Huddleston
Phone 1-512-305-8420

10.4. Application Components

Applicants are advised to minimize repetition among application components to the extent possible. In addition, applicants should use discretion in cross-referencing sections to maximize the amount of information presented within the page limits.

Please note that letters of commitment and/or memoranda of understanding from community organizations, key faculty, etc, are **not** required or requested. Please do not submit letters of support as part of your application package. **Any such information will be removed from your application before review.**

10.4.1. Layperson’s Summary (1,500-character maximum)

Provide a summary of the proposed project using clear, nontechnical terms. Describe specifically how the proposed project would support CPRIT’s mission (see [section 2](#)). Describe the overall goals of the project, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the fields of diagnosis, treatment, or prevention of cancer. Clearly address how the company’s work, if successful, will have a major impact on the care of patients with cancer. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. The layperson’s summary will also be used by advocate reviewers in evaluating the significance and impact of the proposed work. Do not include any proprietary information in this section.

10.4.2. Abstract and Significance (5,000-character maximum)

Coherently explain the question or problem to be addressed and the approach to its answer or solution. The specific aims of the application must be obvious from the abstract although they need not be restated verbatim from the research plan. Address how the proposed project, if successful, will have a major impact on the care of patients with cancer. Describe how this application provides a path for acquiring proof-of-principle data necessary for next-stage commercial development. Clearly explain the product, service, technology, or infrastructure proposed; competition; market need and size; development or implementation plans; regulatory path; reimbursement strategy; and funding needs. Applicants must clearly describe the existing or proposed company infrastructure and personnel located in Texas for this endeavor.

10.4.3. Goals and Objectives (maximum of 1,200 characters each)

List specific goals and objectives for each year of the project. These goals and objectives will also be used during the submission and evaluation of progress reports and assessment of project success if the award is made. Identify time-specific references as follows: Year 1, Quarter 1 (Y1Q1), Y1Q2, etc. Do not specify actual calendar dates as this can be confusing when dates change.

10.4.4. Timeline (1-page maximum)

Provide a visual depiction of anticipated major milestones to be tracked in the form of a Gantt chart. Identify time-specific references as follows: Y1Q1, Y1Q2, etc, as opposed to naming specific months and years. Timelines will be reviewed for reasonableness, and adherence to timelines will be a criterion for continued support of successful applications. If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

10.4.5. Slide Presentation (10-page maximum)

Provide a slide presentation summarizing the application. The presentation should be submitted in PDF format, with 1 slide filling each landscape-orientated page. The slides should succinctly capture all essential elements of the application and should stand alone.

10.4.6. Resubmission Summary (1-page maximum)

If this is a resubmission, upload a summary of the approach, including a summary of the applicant's response to previous feedback. Clearly indicate to reviewers how the application has been improved in response to the critiques. Refer the reviewers to specific sections of other documents in the application where further detail on the points in question may be found. When a resubmission is evaluated, responsiveness to previous critiques is assessed. If this is not a resubmission, then no summary is required.

Note: An application submitted or resubmitted before December 5, 2018, may be submitted as a new application, even if it was previously resubmitted. For the “new” applications, no summary is required.

10.4.7. Development Plan (12-page maximum)

Present the rationale behind the proposed product or service, emphasizing the pressing problem in cancer care that will be addressed. Summarize the evidence gathered to date in support of the company's ideas. **Describe the label claims that the company ultimately hopes to make, and describe the plan to gather evidence to support these claims.** Outline the steps to be taken during the proposed period of the award, including the design of the translational and/or clinical research, methods, and anticipated results. Describe potential problems or pitfalls and alternative approaches to these risks. If clinical research is proposed, present a realistic plan to accrue a sufficient number of human subjects meeting the inclusion criteria within the proposed time period.

The development plan should include a defined **target product profile (TPP)** or analogous document for a medical device, in vitro diagnostic, or service that projects a clear path to full commercialization (see <https://www.fda.gov/drugs/guidance-compliance-regulatory-information/drug-compliance-programs>). The TPP provides a statement of the *overall intent* of the product development program and gives information about the product *at a particular time* in development. Usually, the TPP is organized according to the key sections in the product package insert for a drug or biologic or medical device labeling and links development activities to specific concepts intended for inclusion in the product labeling. CPRIT recognizes that many applications are early in the development process and that not all elements of the TPP will be known at the time of application. Consequently, not only does the TPP serve as a snapshot in time of the development status of the program, but it additionally serves as an aspirational target upon eventual commercialization. The TPP should include the parameters below; the questions are intended to guide the thinking process and may include, but are not limited to, the examples provided.

- Identification of a target that is applicable to human cancer treatment. Is intervention with this target likely to lead to a therapeutic, medical device, diagnostic, or service that could be useful in the treatment of cancer?
- Selection of a lead compound, assay, or device technology based on the target. Is the identification of potential developmental candidates based on a set of in vitro tests followed by selection of a lead candidate based on considerations (as appropriate for the

candidate) of pharmacodynamic parameters and the results of preclinical, in vivo, proof-of-principle studies in relevant animal models of disease?

- Description of a high-level clinical development plan detailing each of the clinical studies supporting marketing approval (phase 1, 2, and 3) the preclinical work is meant to support. Designing the preclinical program requires an understanding of the duration of the clinical studies required by regulatory authorities. Consequently, a brief outline of each of the phase 1, phase 2, and phase 3 studies necessary to obtain regulatory approval and reimbursement funding must be sketched out prior to deciding which toxicology studies would be required.

Applicants developing cancer therapeutics are encouraged to become familiar with FDA guidance documents for submission of applications related to new product development. These documents provide a standard framework for new drug submissions and biologic license applications to the FDA. Utilizing this framework helps ensure that the submission to CPRIT contains all relevant elements and is optimally organized.

Additionally, for therapeutics, the following apply:

Intended route of administration and dosing regimen. Is the intended route of administration and dosing regimen consistent with accepted convention and medical need for the therapeutic, or will the use of this new agent require a paradigm shift (more frequent or less frequent dosing, new route or method of administration), and if so, what impact will it have on current standard of care?

Optimization of the lead to ensure desired characteristics, including, but not limited to, the following studies:

- Indication of the threshold of both the safety and efficacy necessary to be a competitive product when the product is introduced
- Absorption, distribution, metabolism, excretion, including, but not limited to, relevant studies based on route of administration
- Safety (studies as mandated by ICH guidelines)
- Biomarkers (assays) that potentially target specific patient populations for clinical trials
- Biomarkers (assays) that can serve as potential pharmacodynamic markers of clinical activity during early clinical trials designed to demonstrate proof of concept

- Proposed current good manufacturing practice (including estimated costs) that can be scalable from phase 1 through phase 2. Include information on whether there are plans for possible formulation.

The FDA’s website provides “Common Technical Documents” (CTDs, see <https://www.ich.org/page/ctd>) for guidance documents. There are 3 CTDs covering safety, efficacy, and quality. This guidance presents a standard format for the preparation of a well-structured application. Applicants may condense or summarize the CTD format as they deem appropriate to meet page limitations.

While originally intended for regulatory authorities, these formats are also applicable for a CPRIT application. Many of our reviewers have extensive pharmaceutical development expertise and are familiar with these standard formats. Hence, utilizing the CTD format will simplify the review and ensure that the application contains all the relevant elements.

CPRIT recognizes that many applications are early in the product development process. Hence, not all elements of the CTD will be known at time of CPRIT application. We encourage applicants to complete as much of the Safety and Efficacy CTD sections as possible and to follow the submission format prescribed.

References for the Development Plan section should be provided as a stand-alone document that will be separately uploaded into CARS. In the interests of brevity include only the most pertinent and current literature. While references will not count toward the Development Plan section page limit, it is essential to be concise and to select only those references relevant to the development plan. **Do not use the references to circumvent Development Plan section page limits by including data analysis or other nonbibliographic material.**

The development plan submitted must be of sufficient depth and quality to pass rigorous scrutiny by a highly qualified panel of reviewers. To the extent possible, the development plan should be driven by data. In the past, applications that have been scored poorly have been criticized for assuming that assertions could be taken on faith. Convincing data are much preferred. Please avoid redundancy!

10.4.8. Business Plan

CPRIT can only provide a portion of the funds required to successfully develop a novel product or service. Companies typically need to raise substantial funds from private sources to fully fund development. Hence, we require companies to provide a business plan that summarizes the rationale for investing in this project. Private investors will seek a financial return on their investment. They will need to be convinced that this project has high investment return potential based on its risk profile. They typically focus on market opportunity size, development path, and key risk issues.

Successful applicants will provide a thoughtful, careful, and succinct rationale explaining why this program is an appropriate investment of CPRIT and private funds. Note that if the company is selected to undergo due diligence, additional information (such as the company's interactions with regulatory agencies like the FDA, etc.) to support the application may be requested at that time. Award applicants will be evaluated based not only on the current status of the components of the business plan but also on whether current weaknesses and gaps are acknowledged and whether plans to address them are outlined.

Please provide an overview of the business rationale for investing in this project. The business rationale overview will be 2 pages maximum. In addition, please provide summaries of the following key development issues with a maximum of 1 page each.

1. **Product and Market:** Provide an overview of the envisioned product and how the product will be administered to patients. Describe the initial market that will be targeted and how the envisioned product will fit within the standard of care, ie, primary therapy, second-line therapy, adjunctive to current therapies, etc. Information on patient populations and market segments is helpful.
2. **Competition and Value Proposition:** Provide an overview of the competitive environment (current and future) and how the envisioned product will compete in the marketplace. Provide information on how the clinical utility (efficacy, safety, cost, etc) of this therapy compares with current and potential future therapies. A clear delineation of competitive advantages and data demonstrating these advantages are helpful.
3. **Clinical and Regulatory Plans:** Provide a detailed regulatory plan, including preclinical and clinical activities and the regulatory pathway for major markets. Please describe how

this is driven by interactions with the FDA, if possible. The regulatory plan should include regulatory communications (including all interactions to date with the FDA) and strategy, with clarity provided on regulatory matters and current regulatory strategies.

4. **Pricing and Reimbursement:** Provide an overview of the product cost and anticipated revenue. Cost, price, and reimbursement references from similar products are helpful. An overview of how the company plans to obtain CMS and private insurance reimbursement approval is also helpful.
5. **Commercial Strategy:** Provide an overview of your financial projections and how you will generate a return on this investment. Describe how the company plans to bring the product to market. Information on physicians to be targeted, sales channels, etc, is helpful. Alternatively, many drugs are acquired by large pharma firms in the late development stages. If the company plans to seek acquisition, please provide an overview of similar transactions.
6. **Risk Analysis:** Describe the specific risks inherent to the product plan and how they would be mitigated. Key risk issues typically include efficacy versus competitors, toxicity, clinical trials, FDA approval, dosage and delivery, CMC synthesis, changing competitive environment, etc.
7. **Funding to Date:** Provide an overview of the funding received, including a list of funding sources and a comprehensive capitalization table that should comprise all parties who have investments, stock, or rights in the company. A template exemplifying an appropriate capitalization table is provided among the application materials and **MUST** be used when completing your application. The identities of all parties must be listed. It is not appropriate to list any funding source as anonymous.
8. **Intellectual Property:** Provide a concise discussion of the IP issues related to the project. List any relevant issued patents and patent applications. Please include the titles and dates the patents were issued/filed/published. List any licensing agreements that the company has signed that are relevant to this application.
9. **Key Personnel Located in Texas and Any Key Management Located Outside of Texas:** For each member of the senior management and scientific team, provide a paragraph briefly summarizing his or her present title and position, prior industry

experience, education, and any other information considered essential for evaluation of qualifications. Key personnel are the Principal Investigator/Project Director as well as other individuals who contribute to the development or the execution of the project in a substantive, measurable way. *Substantive* means they have a critical role in the overall success of the project and that their absence from the project would have a significant impact on executing the approved scope of the project. *Measurable* means that they devote a specified percentage of time to the project. The indicated time is an obligatory commitment, regardless of whether or not they request salaries or compensation. “Zero percent” effort or “TBD” or “as needed” are not acceptable levels of involvement for those designated as key personnel. While all participants that meet these criteria should be identified as “key,” it is expected that the number of key personnel will be kept to a minimum.

The entire Business Plan section shall typically comprise a maximum of 11 pages: a 2-page overview and nine, 1-page key issue summaries. Please avoid redundancy. Note that the section “Funding to Date” above may exceed this 1-page limit if necessary.

10.4.9. Biographical Sketches of Key Scientific Personnel (8-page maximum)

Provide a biographical sketch for up to 4 key scientific personnel that describes their education and training, professional experience, awards and honors, and publications relevant to cancer research. Each biographical sketch must not exceed 2 pages. You may use either the provided “Product Development Research Programs: Biographical Sketch” template or the NIH biographical sketch format. (In addition, information on the members of the senior management and scientific team should be included in the “Key Personnel” section of the Business Plan [see [section 10.4.8](#)]).

10.4.10. Budget

In preparing the requested budget, applicants should be aware of the following:

- Each award mechanism allows for up to a 3-year funding program with an opportunity for extension after the term expires. **The budget must be aligned with the proposed milestones.** Financial support will be awarded based upon the breadth and nature of the project proposed. Requested funds must be well justified. Funding will be trached and milestone driven.

- CPRIT considers equipment to be items having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit. If awarded, management of your grant will be facilitated if specific equipment is clearly identified in the application using plain language. **Equipment not listed in the applicant’s budget must be specifically approved by CPRIT subsequent to the award contract.**
- Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in CPRIT’s Administrative Rules, which are available at www.cprit.texas.gov.
- The total amount of CPRIT funds allowed for an annual salary of an individual for FY 2021 is \$200,000. In other words, an individual may request salary proportional to the percent effort up to a maximum of \$200,000. Salary amounts in excess of this limit must be paid from matching funds. Salary does not include fringe benefits. CPRIT FY 2021 is from September 1, 2020, through August 31, 2021. Additionally, adjustments of up to a 3% increase in annual salary are permitted for Years 2 and 3 up to the cap of \$200,000. The salary cap may be revised at CPRIT’s discretion.

The Budget section is composed of 4 subtabs that must be completed:

- A. Budget for All Project Personnel:** Provide the name, role, appointment type, percent effort, salary requested, and fringe benefits for all personnel participating on this project. If funding is requested for a role that is not currently occupied, applicant should note “new hire” as name.
- B. Detailed Budget for Year 1:** This section should only include the amount requested from CPRIT; do NOT include the amount of the matching funds or the budget for the total project. Provide the amount requested from CPRIT for direct costs in the first year of the project. Direct cost categories include Travel, Equipment, Supplies, Contractual (Subaward/Services Contracts), or Other. Applicants will be required to itemize costs.
- C. Budget for Entire Proposed Period of Performance:** This section should only include the amount requested from CPRIT; do NOT include the amount of the matching funds or the budget for the total project. Provide the amount requested from CPRIT for direct costs for all subsequent years. Amounts for *Budget Year 1* will be automatically populated based on the information provided on the previous subtabs; namely, *Budget for All Project Personnel* and *Detailed Budget for Year 1*.

D. Budget Justification: Please specify your CPRIT-requested funds and other amounts that will comprise the total budget for the project, including the use of matching funds. Use of the provided Budget Justification template is mandatory. Please specify each line item from your CPRIT budget as well as other funds (including matching funds). Provide a compelling justification for the budget for each line item of the entire proposed period of support, including salaries and benefits, supplies, equipment, patient care costs, animal care costs, and other expenses. **If travel costs will include out-of-state or international travel, make that clear here.** The budget must be aligned with the proposed milestones.

11. AWARD ADMINISTRATION

Texas law requires that CPRIT awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to entities, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and IP rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov.

Applicants are advised to review CPRIT's Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10 to 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT utilizes 2 methods of disbursement of grant funds, (1) reimbursement and (2) advancement. Under the reimbursement method, the grantee is expected to finance its operations with its own working capital. Under the advancement method, CPRIT disburses grant funds in advance of the grantee incurring expenses. Grantees must be approved by the Oversight

Committee to receive advancement of funds. Please see Chapter 8 of the [CPRIT Grant Policies & Procedures Guide](#) for additional details regarding the disbursement of grant funds.

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

Project Revenue Sharing: Recipients should also be aware that the funding award contract will include a revenue-sharing agreement, which can be found at www.cprit.texas.gov and will require CPRIT to have input on any future patents, agreements, or other financial arrangements related to the products, services, or infrastructure supported by the CPRIT investment. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov.

12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient demonstrate that it has appropriate matching funds. For companies receiving an initial CPRIT award, the company must contribute \$1.00 in matching funds for every \$2.00 awarded by CPRIT. CPRIT reserves the right to seek a higher matching funds contribution, ie, the company will contribute \$1.00 in matching funds for every \$1.00 awarded by CPRIT, from a company that has already received a CPRIT award and is approved for a second award. Matching funds need not be in hand when the application is submitted, nor does the entire amount of matching funds for the full 3 years of the project need to be available at the start of the grant. However, the appropriate amount of matching funds for each specific tranche must be obtained before each tranche of CPRIT funds will be released for use. CPRIT funds must, whenever possible, be spent in Texas. A company's matching funds must be targeted for the CPRIT-funded project but may be spent outside of Texas. Grant applicants are advised to consult CPRIT's Administrative Rules, [chapter 703, section 703.11](#), for specific requirements associated with the requirement to demonstrate available funds.

13. CONTACT INFORMATION

13.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding scientific and product development aspects of applications. **Before contacting the helpdesk, please refer to the *Instructions for Applicants* document, which provides a step-by-step guide on using CARS. In addition, for Frequently Asked Programmatic Questions, please go [here](#), and for Frequently Asked Technical Questions, please go [here](#).**

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146 (toll free in the United States only—international applicants should use the email address below)

Email: Help@CPRITGrants.org

13.2. Programmatic Questions

Questions regarding the CPRIT Program, including questions regarding this or other funding opportunities, should be directed to the CPRIT Product Development Research Program Senior Manager.

Tel: 512-305-7676

Email: Help@CPRITGrants.org

Website: www.cprit.texas.gov

14. APPENDIX

14.1. Reviewer Evaluation Guidelines for Therapeutics

Primary Review Criteria (Scored)

Unmet Medical Need: Target Product Profile (TPP)

- Assuming successful accomplishment of development objectives, as reflected in the target product profile, will the intended product significantly address an unmet medical need in the diagnosis, treatment (including supportive care), prognosis, or prevention of cancer?
- In terms of incidence/prevalence of the patient populations or subpopulations intended to be targeted by the development of this product, what is the extent of the unmet need?

Target Validation

- If this is a “targeted” agent, to what extent has the target been validated, eg, through knockdown studies and/or pharmacological intervention?
- Has engagement of the target with the agent been demonstrated by biochemical assay? What is the potency of the agent?
- Are there validated downstream pharmacodynamic (PD) markers of target modulation? How extensive is the in vitro evidence for expected PD effects? Has the agent shown biologically significant modulation of the target in vivo, especially in tumor tissue?
- Is the target uniquely or substantially overexpressed by tumor versus normal cells?
- Does the target represent an activating mutation? If so, has binding of the agent to the target and other activating mutations been characterized?
- Has the company’s demonstration of target validation been externally/independently confirmed?
- Are there known mechanisms of resistance to the modulation of this target? If so, has the company proposed possible mitigation/preemptive approaches, such as combination chemotherapy?

Preclinical Characterization: Pharmacodynamic Proof of Concept

- Considering in vivo preclinical pharmacodynamic characterization and the patient populations or subpopulation(s) representing the initial clinical indication(s) for the drug, what is the clinical relevance of the preclinical models? To elaborate, were in vivo/xenograft studies carried out in cell line–based models or PDX-derived models? In how many such models have studies been carried out? To what extent do these models reflect standard of care (SOC) for refractory versus drug-naive tumors? At the time of treatment initiation, were tumors established and measurable, or was treatment initiated shortly after tumor inoculation?
- Was antitumor activity predominantly growth inhibition or tumor regression? Were sustained complete remissions or “cures” achieved in the majority of animals and models? Were comparisons with optimally dosed SOC agents made? Where the agent is intended to be added to the SOC, is there compelling evidence of in vitro/in vivo synergy with SOC agents?
- Have results of preclinical efficacy studies carried out by the company been externally/independently confirmed?
- Overall, considering clinical relevance and study results, how strong is the preclinical efficacy profile of the agent?
- How strongly does the preclinical pharmacodynamic profile support the clinical efficacy expectations reflected in the TPP?

Preclinical Characterization: Safety

- How extensive is the in vitro and in vivo preclinical safety characterization carried out so far?
- Has the agent undergone CEREP-type screening for interactions with targets with known safety liabilities, eg, CYP 450, hERG?
- Considering potency and target selectivity, what is the potential both for off-target and pharmacologically on-target deleterious effects?
- Can exposures associated with substantial antitumor efficacy/PD effects be achieved safely in vivo?

- Do preclinical pharmacokinetics (PK) studies indicate potential for clinical safety issues, eg, accumulation, variability, lack of dose proportionality?
- Have PK/PD issues been investigated with alternate dosing schedules in order to optimize the therapeutic index of the agent?
- Are there any issues with the distribution or metabolism of the agent?
- Overall, are results of safety characterization carried out so far such that the agent can be considered reasonably derisked from a safety perspective, or are there red flags?
Alternatively, is the extent of preclinical safety characterization carried out so far insufficient to address this question?

Pharmaceutical Properties/Chemistry and Pharmacy

- In the case of agents intended for oral absorption, are there any issues with water solubility? Do formulation studies indicate the feasibility of oral administration?
- Were Lipinski-type criteria applied during the lead optimization process such that the lead compound has demonstrated properties that make it likely to be an orally active drug in humans?
- Are there any issues with the stability of the drug substance or the drug product?
- Is there scope for further lead optimization through structure-activity studies?
- In the case of biologicals, has a high-quality cell line been developed yet? Are yields acceptable? Does the purification process appear reasonable and scalable?
- Have analytical methods been adequately developed?
- Has the (lead) protein been adequately characterized biochemically, immunogenetically, and biophysically? Has absence of aggregate formation been demonstrated in stability studies?

Development Plan/Regulatory Aspects

- Are development proposals scientifically rational and sufficiently comprehensive considering development efforts and results to date?
- Does the applicant demonstrate adequate familiarity with pertaining regulatory guidelines in major jurisdictions (United States/European Union)? Do development proposals reflect specific regulatory authority input; eg, from pre-IND interactions? Alternatively, has regulatory authority interaction been insufficient so far?

- In the case of clinical studies, are patient populations adequately described and consistent with those representing the initial target indication(s)?
- Are efficacy end points appropriate for study designs? Is the sample size statistically adequately justified in terms of the target effect size?
- In the case of potentially pivotal clinical trials, moreover, are the proposed primary efficacy end points and target effect sizes consistent with regulatory precedence?
- Considering target indication prevalence, will the agent qualify for orphan drug designation? If so, does the applicant intend to apply for this?
- Has the applicant demonstrated reasonable diligence in researching patient availability, competitive clinical trial activity, and recruitment issues such that patient enrollment projections can be considered realistic?
- Will the proposed programs advance development of the agent to commercially significant milestone(s), such as might attract either partner interest or the raising of further development funding?
- Are development milestones clear and adequately described? Is the overall project timeline realistic?

Competitive Analysis

- Has the applicant carried out a comprehensive and realistic analysis of the likely strengths and weaknesses of the agent compared to clinically relevant competitive products, including potentially competitive agents in development?
- Are the applicant's assumptions regarding the strengths and weaknesses of the agent relative to likely competitors reasonable, considering the preclinical efficacy and safety data on the agent generated so far?

Intellectual Property/Freedom to Operate

- Have IP and freedom-to-operate aspects been addressed in the application?
- Considering patent type (Composition of Matter/Formulation/Manufacturing Process/Use) and duration of patent life, how strong is the IP?
- Are there opportunities for meaningful patent life extension?
- Has the applicant secured appropriate licenses conferring freedom to operate?

Chemistry, Manufacturing, and Controls (CMC)

- How advanced is CMC and manufacturing development?
- Are there any sourcing issues?
- Has the applicant demonstrated the likelihood that the product can be manufactured at commercial scale and with a reasonable cost of goods?
- Are there significant technical difficulties within CMC/manufacturing scale up still to be addressed?

Business/Commercial Aspects

- Does the applicant need to raise further funds for the CPRIT matching requirement? In this case, how realistic are the applicant's assumptions about a successful fundraising campaign? Does the applicant have a track record of success in raising development funding?
- Does the applicant indicate intentions for attracting a development partner or for outright acquisition? Do the development milestones and assumed results of the research program of studies reasonably support such expectations?
- Considering the initial clinical indications for the product, its competitive strengths and weaknesses, and pricing/reimbursement objectives, are market/segment penetration and sales and profitability projections reasonable?
- Has the applicant articulated a coherent plan for using results on clinical end points in pivotal trials as a basis for cost-effectiveness analyses to support pricing and reimbursement?

Management Team

- Does the management team have the appropriate level of experience and track record of relevant accomplishments to execute the development and commercialization strategy?
- Does the company have experienced and appropriately accomplished in-house personnel in such key areas as translational research, clinical development, regulatory affairs, and CMC/manufacturing? If not, are there plans to address such deficiencies?

- Has the applicant demonstrated appropriate engagement of outside development expertise through, for example, a scientific advisory board, individual consultantships, and regulatory authority interactions?

Secondary Review Criteria (Unscored)

Budget and Duration of Support

- Are the budget and duration of support appropriate for the program of studies described in the application?
- Is there sufficient clarity in the budget proposal as to how funds will be expended?
- Is there sufficient clarity in the budget proposal as to the spending of funds in Texas?
- Do plans reflect a substantial commitment to Texas? Is it clear that no CPRIT funds will be sent out of Texas to a corporate headquarters?

14.2. Reviewer Evaluation Guidelines for Medical Devices and Diagnostics

Primary Review Criteria (Scored)

Unmet Medical Need

- Assuming successful accomplishment of development objectives, will the intended product significantly address an unmet medical need in the diagnosis, treatment (including supportive care), prognosis, or prevention of cancer?
- In terms of incidence/prevalence of the patient populations or subpopulations intended to be targeted by the development of this product, what is the extent of the unmet need?

Product Validation

- Technical Validation: Has the product or technology been successfully validated, ie, prototyped, built and tested in ex vivo, animal, or clinical setting?
- Have biological proof of principle and product mechanism of action been demonstrated?
- Have efficacy and safety in an accepted in vitro or animal model been demonstrated?
- Clinical Validation: Are clinical trials required to demonstrate product performance? If so, have they been planned or conducted?
- Biological Risk: What are the risks to the patients, eg, toxicology, biological, interactions with other therapies?

Production/Manufacturing

- Has the applicant demonstrated the likelihood that the product can be manufactured at commercial scale and with a reasonable cost of goods?
- How advanced is manufacturing development?
- Are there any sourcing issues?

Intellectual Property/Freedom to Operate

- Have barriers to entry been identified? Has a route to patentability been mapped out, eg, independent patent, first-mover advantage, unique knowhow, etc?
- Does the company have issued patents? If not, have they conducted freedom to operate and patentability analysis?

- Considering patent type (Composition of Matter/ Formulation/Manufacturing Process/Use), and duration of patent life, how strong is the IP?
- Are there opportunities for meaningful patent life extension?
- Has the applicant secured appropriate licenses conferring freedom to operate, if required?

Market Opportunity

- Does the product address a clearly defined unmet need; lack of available therapy, poor efficacy, side effects, lack of available diagnostic, safety problems, cost reduction, enhanced convenience?
- Are target indication and market clearly defined?
- Is channel to market available? Does the company understand the entire value chain and all constituencies involved in procuring and utilizing the product?
- Does the company understand the clinical pathway that leads to utilizing the product?
- Is market opportunity of significant size and lucrative enough to justify investment?
- Has the applicant demonstrated time or cost savings?
- How does product fit with existing “ecosystem”; ie, are the benefits provided worth the time and cost of implementing the new approach?

Competition

- Is this a “Whole Product,” ie, a complete product or service sold to a defined customer that provides a defined value proposition?
- Is value proposition clearly delineated, ie, improve efficacy, improve safety, reduce cost, or improve convenience)?
- Has the company demonstrated its value proposition versus competition?
- Has the company conducted a competitive analysis? Does it provide a comprehensive, realistic assessment of strengths and weakness versus competition based on the data generated to date?

Development Plan/Regulatory Aspects

- Have a comprehensive development plan and market entry strategy been developed? How realistic are these plans?
- Has determination of FDA-defined device classification been completed? Is the clinical and regulatory pathway well understood and feasible?

Management Team

- Does the management team have the appropriate level of experience and track record of relevant accomplishments to execute the development and commercialization strategy?
- Does the company have experienced and appropriately accomplished in house personnel in such key areas as product engineering, clinical development, regulatory affairs, manufacturing, etc? If not, are there plans to address such deficiencies?
- Has the applicant demonstrated appropriate engagement of outside development expertise through, eg, a scientific advisory board, individual consultantships, and regulatory authority interactions?

Business/Commercial Aspects

- Considering the initial clinical indications for the product, its competitive strengths and weaknesses, and pricing/reimbursement objectives, are market/segment penetration and sales and profitability projections reasonable?
- Has the applicant articulated a coherent plan for using results on clinical end points in pivotal trials as a basis for cost-effectiveness analyses to support pricing and reimbursement?
- Has the company clearly anticipated pricing strategy and reimbursement environment?
- Is the projected return on investment congruent with investment opportunity and risks?

Funding

- Is investor interest in this sector sufficient to fund the company through profitability?
- Does the applicant already have available funds to meet the CPRIT matching requirement, or do they need to raise additional funds? In this case, how realistic are assumptions about a successful fundraising campaign? Does the applicant have a track record of success in raising development funding?
- Have likely acquirers been identified by the applicant?
- Does the company have the resources to support required activities while fundraising?
- Does the applicant indicate intentions for attracting a development partner or for outright acquisition? Do the development milestones and assumed results of the research program reasonably support such expectations?

Secondary Review Criteria (Unscored)

Budget and Duration of Support

- Are the budget and duration of support appropriate for the program of studies described in the application?
- Is there sufficient clarity in the budget proposal as to how funds will be expended?
- Is there sufficient clarity in the budget proposal as to the spending of funds in Texas?
- Do plans reflect a substantial commitment to Texas? Does the applicant demonstrate an understanding of the Texas spending requirement for CPRIT funds?

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)

21.1 Product Development Research Panel-1

(21.1 PDR PDP P1)

Observation Report

Report No. 2021-03-22 21.1_PDR_PDP_P1
Program Name: Product Development Research
Panel Name: 21.1 Product Development Research Panel-1 (21.1_PDR_PDP_P1)
Panel Date: March 22, 2021
Report Date: April 5, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.1 Product Development Research Panel-1 (21.1_PDR_PDP_P1) meeting. The meeting was chaired by David Shoemaker, and conducted via teleconference on March 22, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: ten (10) applications were discussed and eight (8) applications were not discussed
- Panelists: One (1) panel chair, thirteen (13) expert reviewers and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: three (3)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were four (4) Conflict of Interest (COIs) identified prior to and/or during the meeting. The COIs was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive name that appears to be 'Mara Ash'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

21.1 Product Development Research Panel-2

(21.1 PDR PDP P2)

Observation Report

Report No. 2021-03-23 21.1_PDR_PDP_P2
Program Name: Product Development Research
Panel Name: 21.1 Product Development Research Panel-2 (21.1_PDR_PDP_P2)
Panel Date: March 23, 2021
Report Date: April 5, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.1 Product Development Research Panel-2 (21.1_PDR_PDP_P2) meeting. The meeting was chaired by Jack Geltosky and conducted via teleconference on March 23, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: fourteen (14) applications were discussed and three (3) applications were not discussed
- Panelists: One (1) panel chair, thirteen (13) expert reviewers and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Three (3)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were eleven (11) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive 'M' followed by a horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.1 Product Development Research Panel-1 (21.1 PDR-P1)
Observation Report

Report No. 2021-04-19-20 21.1_PDR-P1
Program Name: Product Development Research
Panel Name: 21.1 Product Development Research Panel-1 (21.1_PDR-P1)
Panel Date: April 19, 2021 and April 20, 2021
Report Date: April 30, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.1 Product Development Research Panel-1 (21.1_PDR-P1) meeting. The meeting was chaired by David Shoemaker and conducted via videoconference on April 19, 2021 and April 20, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Three (3) applications were discussed on April 19, 2021; two (2) applications were discussed, and thirteen (13) applications were not discussed on April 20, 2021
- Panelists: One (1) panel chair, thirteen (13) expert reviewers and two (2) advocate reviewers were present on both days
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4) were present on both days
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4) on April 19, 2021 and three (3) April 20, 2021
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were four (4) Conflicts of Interest (COIs) identified prior to and/or during the meeting. Three (3) COIs were on applications discussed and one (1) COI was on an application not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of review and staff attendees, a sign-in log of reviewers and staff, as well as some informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet of reviewers and staff as well as a sign-in log of reviewers and staff was provided following the meeting to confirm review and staff attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and

scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to read 'Mara Ash', with a long horizontal flourish extending to the right.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.1 Product Development Research Panel-2 (21.1 PDR-P2)
Observation Report

Report No. 2021-04-21 21.1_PDR-P2
Program Name: Product Development Research
Panel Name: 21.1 Product Development Research Panel-2 (21.1_PDR-P2)
Panel Date: April 21, 2021
Report Date: April 30, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.1 Product Development Research Panel-2 (21.1_PDR-P2) meeting. The meeting was chaired by Jack Geltosky and conducted via video conference on April 21, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Three (3) applications were discussed, and fourteen (14) applications were not discussed
- Panelists: One (1) panel chair, twelve (12) expert reviewers and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were twelve (12) Conflicts of Interest (COI) identified prior to and/or during the meeting. The COIs was excluded from discussions concerning applications for which there was a conflict.

A list of review and staff attendees, a sign-in log of reviewers and staff, as well as some informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet of reviewers and staff as well as a sign-in log of reviewers and staff was provided following the meeting to confirm review and staff attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.1 Product Development Research Council Due Diligence
(21.1 PDRC-DD)
Observation Report

Report No. 2021-07-08 21.1_PDRC-DD
Program Name: Product Development Research
Panel Name: 21.1 Product Development Research Council Due Diligence
(21.1_PDRC-DD)
Panel Date: July 8, 2021
Report Date: July 16, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.1 Product Development Research Council Due Diligence (21.1_PDRC-DD) meeting. The meeting was chaired by Jack Geltosky and conducted via videoconference on July 8, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Five (5) applications were discussed
- Panelists: One (1) panel chair, and eleven (11) reviewers
- Panelists' discussions were limited to the application evaluation criteria
- ICON employees: Five (5)
- IP Attorneys: One (1)
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and limited informational materials (No scores received prior to meeting) were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet, sign-in log and final scores sheet was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to read 'Mara Ash', with a long horizontal flourish extending to the right.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Product Development Research Cycle 21.1

Awards Announced at the August 18, 2021, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Product Development Research Cycle 21.1 include *Company Relocation Product Development Awards*; *Seed Awards for Product Development Research*; and *Texas Company Product Development Awards*

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant/Principal Investigator	Principal Investigator Organization	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
DP210005	Joshua Sills	Dialectic Therapeutics, Inc.	L. Greenberger
DP210042	Juan Vera	Marker Therapeutics, Inc.	R. Humphrey
Applications not considered by the PIC or Oversight Committee:			
DP210007	Stuart Marcus	SonALAsense, Inc.	M. Moasser
DP210010	Jonathan Northrup	Stingray Therapeutics, Inc.	N. Vasan; V. Lee
DP210052	Arthur Sands	Nurix Therapeutics	M. Moasser
DP210006	Gregory Stein	PLUS Therapeutics, Inc.	J. McKew
DP210009	David Arthur	Salarius Pharmaceuticals, Inc.	C. Turtle; J. Britz; K. Swiderek
DP210022	Annemarie Moseley	Sandhill Therapeutics, Inc.	L. Alland

Application ID	Applicant/Principal Investigator	Principal Investigator Organization	Conflict Noted by Reviewer
DP210040	Frank Perabo	Tachyon Therapeutics, Inc.	J. Britz; L. Alland
DP210049	Roy de Souza	BreakBio Corp	E. Jones
DP210050	Manijeh Goldberg	Privo Technologies, Inc.	M. Cheng
DP210057	Atul Varahachary	Fannin Partners, LLC	E. Jones

High Level Summary of Due Diligence

TXCO

High Level Summary of CPRIT Product Development Diligence and Recommendation

The Product Development Review Council (PDRC) recommended that the Program Integration Committee and the Oversight Committee approve the following Texas Company Product Development Research award:

- Dialectic Therapeutics, Inc. for \$14,449,638. The PDRC did not recommend any contract contingencies for this award.

Dialectic Therapeutics, Inc.

The Product Development Review Council (PDRC), upon its review of the independent business and intellectual property due diligence performed on this application, has recommended to the Program Integration Committee that this application is suitable for CPRIT funding.

Dialectic Therapeutics, Inc. is a biotech startup company based in Dallas and founded by three cancer scientists and two biotech investors, with research facilities/partners at the University of Texas Health Science Center San Antonio (UTHSA) and the University of Florida. Dialectic's lead candidate, DT2216, is a unique programmed protein degradation compound that selectively induces cancer cells to degrade BCL-XL, stimulating the cells to commit suicide on their own, or become more susceptible to chemotherapy. The work supported by the recommended CPRIT TXCO award will enable Dialectic Therapeutics to perform critical manufacturing development and phase 1 and 2 clinical trials for DT2216 in the treatment of T-cell lymphoma and small cell lung cancer.

DT2216, is a novel Antiapoptotic Protein Targeted Degradation (APTaD™) compound that selectively induces cancer cells to degrade B-cell lymphoma extra-large, or BCL-XL, stimulating the cells to commit suicide or become more susceptible to chemotherapy. Preliminary studies show that DT2216 destroys T-cell lymphoma / T-cell leukemia as a single agent. In addition, the technology has been demonstrated to be effective against small cell lung cancer and breast cancer when combined with traditional chemotherapy. The toxicity profile is favorable showing only a dose dependent decrease in platelets. This novel approach to cancer therapy will fill a significant need in current cancer treatment regimens.

The work supported by the CPRIT TXCO award will enable Dialectic Therapeutics to perform phase 1 and 2 clinical trials for DT2216 in the treatment of T-cell lymphoma and small cell lung cancer, two areas of high unmet medical need.

Select reviewer comments summarize the significance and impact as follows:

- *A well-validated target that has been the focus of many drug development efforts over the years.*

- *Company is advancing a novel approach to attack the target, a key driver of many different kinds of cancer, that bypasses the most common side effect of many of these drug candidates, thrombocytopenia.*
- *The management and operational leaders are experienced and have clearly laid out a practical and achievable set of goals and objectives that anticipates development through the design of their adequate and well-controlled registration study.*

TXCO

High Level Summary of CPRIT Product Development Diligence and Recommendation

The Product Development Review Council (PDRC) recommended that the Program Integration Committee and the Oversight Committee approve the following Texas Company Product Development Research award:

- Marker Therapeutics, Inc. for \$13,115,569. The PDRC did not recommend any contract contingencies for this award.

Marker Therapeutics, Inc.

The Product Development Review Council (PDRC), upon its review of the independent business and intellectual property due diligence performed on this application, has recommended to the Program Integration Committee that this application is suitable for CPRIT funding.

Marker Therapeutics, a publicly traded company based in Houston, focuses on novel cell-based therapies for a variety of cancer indications. Marker proposes the development of MT-401 an innovative allogeneic T cell product for the treatment of patients with acute myeloid leukemia (AML). AML is a deadly cancer, treated with chemotherapy, often followed by stem cell transplant (SCT). However, relapse after SCT remains a major cause of death, with poor 1-year survival. Limited treatments are available for patients who fail chemotherapy and SCT.

Although immune T cell-based interventions such as chimeric antigen receptor (CAR) T cell therapies have been explored in AML, their therapeutic impact has been limited due to: 1) lack of one antigen with sufficient tumor specificity, 2) negative antigen selection leading to tumor immune escape, 3) requirement for lymphodepletion, preventing engagement of the endogenous immune system (epitope spreading) and leading to adverse events, and 4) risk of graft-versus-host disease (GVHD). Marker proposes MT-401 as a novel T cell-based therapy that targets multiple tumor-associated antigens (mTAAs) simultaneously, thereby minimizing tumor escape.

Marker proposes to use CPRIT funds to advance a phase 2 clinical study to support registration and clinical implementation of MT-401 in AML patients post-SCT. The underlying technology was developed at Baylor College of Medicine.

Select reviewer comments summarize the significance and impact as follows:

- *This is a strong application that addresses a key unmet need: How to prevent relapsed AML in high-risk patients after allogeneic hematopoietic stem cell transplantation.*
- *The product has been successfully manufactured in an academic setting. There is good biological proof of principle, and multiple antigens are being targeted by T cells stimulated with an overlapping peptide pool.*

- *The team has been successful in raising investments. The company is led by investigators who have a proven track record in the field of cellular immunotherapy and is supported by a well-qualified scientific advisory board.*

De-Identified Overall Evaluation Scores

Texas Company Product Development Awards

Product Development Research Cycle 21.1

The Product Development Review Council (PDRC) did not recommend an application responsive to this RFA that has a score equal to another application that was recommended. As allowed in 25 T.A.C. § 703.6(d)(1), the PDRC's numerical rank order is substantially based on the final overall evaluation score, but also takes into consideration how well the grant application achieves program priorities and the overall program portfolio.

Application ID	Final Overall Evaluation Score
DP210042*	2.2
DP210005*	3.0
a	3.0
b	3.5
c	3.5
d	3.5
e	4.5
f	5.0

* Recommended for funding

Final Overall Evaluation Scores and Rank Order Scores

July 23, 2021

Donald "Dee" Margo
Oversight Committee Chair
Cancer Prevention and Research Institute of Texas
Via email to dee@deemargo.com
Via email to Dee Margo's assistant, Olivia Zepeda: ozepeda@deemargo.com

Wayne R. Roberts
Program Integration Committee Chair
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Dee and Wayne,

On behalf of the Product Development Review Council (PDRC), I am pleased to provide the PDRC's recommendation for CPRIT's Product Development Research 21.1 award cycle. The PDRC convened on July 8, 2021 and recommends that the Program Integration Committee and the Oversight Committee approve the following Product Development Research awards:

- A Texas Company Product Development Research Award (TXCO) for Dialectic Therapeutics, Inc.
- A Texas Company Product Development Research Award (TXCO) for Marker Therapeutics, Inc.

The attached table reflects the PDRC's ranked award recommendations for the two applications. Note that the PDRC's ranking of the two award recommendations is different from score order due to the outcome of the due diligence discussion.

The PDRC did not make any changes to the proposed goals and objectives, timelines or budget for the two projects recommended for funding. In addition, there were no contractual contingencies associated with either of these award recommendations.

Each of the companies included in the PDRC's recommendation reflects 50+ hours of individual review and panel discussion of the applicants' proposals as well as the PDRC's review of the due diligence reports. Our recommendations are consistent with one or more of the priorities of the Oversight Committee for product development award funding. These standards include the potential of these companies to (1) bring important products to market; (2) promote the translation of research at Texas institutions into new companies able to compete in the marketplace; and (3) develop tools and technologies of special relevance to cancer research, treatment and prevention.

Sincerely,



/JG/
Jack Geltosky, PhD
Chair, CPRIT Product Development Review Council

Attachment

Product Development Review Council Award Recommendations

FY 2021 Cycle 1

Rank	Application ID	Mechanism (Cycle)	Company Name	Project	Maximum Recommended Budget	Overall Score*
1	DP210005	TXCO (21.1)	Dialectic Therapeutics, Inc.	Clinical Development of DT2216, a First-in-Class APTaD™ for Cancer Therapy	\$14,449,638	3.0
2	DP210042	TXCO (21.1)	Marker Therapeutics, Inc.	Efficacy of a Multi Tumor Associated Antigen Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant	\$13,115,569	2.2
				Total	\$27,565,207	

* average reviewer score from videoconference "in-person" peer review



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

Prevention

FY 2021 – Cycle 1

*Expansion of Cancer Prevention Services to Rural
and Medically Underserved Populations*

Updated August 2021

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA P-21.1-EPS

**Expansion of Cancer Prevention Services to
Rural and Medically Underserved Populations**

**Please also refer to the Instructions for Applicants document,
which will be posted on August 17, 2020**

Application Receipt Opening Date: August 17, 2020

Application Receipt Closing Date: October 5, 2020

FY 2021

Fiscal Year Award Period

September 1, 2020-August 31, 2021

TABLE OF CONTENTS

1. ABOUT CPRIT	5
1.1 PREVENTION PROGRAM PRIORITIES	5
2. FUNDING OPPORTUNITY DESCRIPTION	6
2.1 SUMMARY	6
2.2 PROJECT OBJECTIVES	8
2.3 AWARD DESCRIPTION	9
2.4 PRIORITIES	12
2.5 SPECIFIC AREAS OF EMPHASIS	13
2.6 OUTCOME METRICS	15
2.7 ELIGIBILITY	16
2.8 RESUBMISSION POLICY	17
2.9 FUNDING INFORMATION	18
3. KEY DATES.....	19
4. APPLICATION SUBMISSION GUIDELINES.....	19
4.1 <i>INSTRUCTIONS FOR APPLICANTS</i> DOCUMENT	19
4.2 ONLINE APPLICATION RECEIPT SYSTEM	19
4.3 SUBMISSION DEADLINE EXTENSION	20
4.4 APPLICATION COMPONENTS	20
4.4.1 <i>Abstract and Significance (5,000 characters)</i>	20
4.4.2 <i>Goals and Objectives (700 characters each)</i>	21
4.4.3 <i>Project Timeline (2 pages)</i>	21
4.4.4 <i>Project Plan (12 pages; fewer pages permissible)</i>	21
4.4.5 <i>People Reached (Indirect Contact)</i>	24
4.4.6 <i>Number of Services Delivered (Direct Contact)</i>	24
4.4.7 <i>Number of Clinical Services Delivered</i>	25
4.4.8 <i>Number of Unique People Served (Direct Contact)</i>	25
4.4.9 <i>References</i>	25
4.4.10 <i>Resubmission Summary</i>	25
4.4.11 <i>Most Recently Funded Relevant Project Summary (3 pages)</i>	25
4.4.12 <i>CPRIT Grants Summary</i>	26
4.4.13 <i>Budget and Justification</i>	26
4.4.14 <i>Current and Pending Support and Sources of Funding</i>	28
4.4.15 <i>Biographical Sketches</i>	28
4.4.16 <i>Collaborating Organizations</i>	29
4.4.17 <i>Letters of Commitment (10 pages)</i>	29

5. APPLICATION REVIEW	29
5.1 REVIEW PROCESS OVERVIEW	29
5.2 REVIEW CRITERIA.....	31
5.2.1 <i>Primary Evaluation Criteria</i>	31
5.2.2 <i>Secondary Evaluation Criteria</i>	33
6. AWARD ADMINISTRATION.....	33
7. CONTACT INFORMATION.....	35
7.1 HELPDESK.....	35
7.2 PROGRAM QUESTIONS	35
8. RESOURCES.....	36
9. REFERENCES.....	37
APPENDIX A: KEY TERMS.....	38
APPENDIX B: WRITING GOALS AND OBJECTIVES.....	41

RFA VERSION HISTORY

Rev 8/3/2020 RFA release

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$3 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of or cures for cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

1.1 Prevention Program Priorities

Legislation from the 83rd Texas Legislature requires that CPRIT's Oversight Committee establish program priorities on an annual basis. The priorities are intended to provide transparency in how the Oversight Committee directs the orientation of the agency's funding portfolio. The Prevention Program's principles and priorities will also guide CPRIT staff and the Prevention Review Council on the development and issuance of program-specific Requests for Applications (RFAs) and the evaluation of applications submitted in response to those RFAs.

Established Principles

- Fund evidence-based interventions and their dissemination
- Support the prevention continuum of primary, secondary, and tertiary (includes survivorship) prevention interventions

Prevention Program Priorities

- Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
- Prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
- Prioritize underserved populations

2. FUNDING OPPORTUNITY DESCRIPTION

2.1 Summary

The ultimate goals of the CPRIT Prevention Program are to reduce overall cancer incidence and mortality and to improve the lives of individuals who have survived or are living with cancer.


The ability to reduce cancer death rates depends in part on the application of currently available evidence-based technologies and strategies. CPRIT fosters the prevention of cancer in Texas by providing financial support for a wide variety of evidence-based prevention interventions.

This award mechanism seeks to support the coordination and expansion of evidence-based services to prevent or screen for cancer in underserved populations who do not have adequate access to cancer prevention interventions and health care, bringing together networks of public health and community partners to carry out programs tailored for their communities. The proposed project should be designed to reach and serve as many people as possible. Projects should identify cancers that cause the most burden in the community and use evidence-based models to prevent and control these cancers.


Eligible applicants include only those with currently or previously funded CPRIT Prevention projects.

Initial Expansion: For the first expansion application, eligible applicants should propose to expand their programs to include additional types of prevention clinical services or to expand current clinical services into additional counties. In either case, the expansion must include the delivery of services to nonmetropolitan (rural) and/or medically underserved counties in the state. These may be identified via Web-based tools from the [Texas Department of State Health Services](#) and [US Department of Health and Human Services](#).

Maintenance Expansion: For a subsequent expansion, additional clinical services and/or expansion to additional counties is optional; however, the counties and the services offered in the first expansion should not be decreased. The number of clinical services delivered during the maintenance expansion must be increased substantially if no further geographic or clinical service expansion is proposed.



Texas Medically Underserved Areas (MUA) and Populations (MUP)



Data source: US Health Resources and Services Administration Data Warehouse, October 2017

2.2 Project Objectives

CPRIT seeks to fund initial expansion evidence-based prevention projects that will do the following:

- Expand an eligible CPRIT project by adding and integrating the delivery of 1 or more of the following to an existing project:
 - Screenings, rescreenings, and diagnostics for breast, cervical, colorectal cancers; hepatitis C virus; genetic risk factors
 - Vaccinations against HPV and hepatitis B virus
 - Evidence-based interventions focused on tobacco prevention (prevent tobacco use or sustained abstinence) and tobacco cessation among youth and/or adults
- Expand an eligible CPRIT project by adding and integrating the delivery of services to additional nonmetropolitan and/or medically underserved counties.

CPRIT seeks to fund maintenance expansion evidence-based prevention projects that will do the following:

- Maintain, at a minimum, clinical service delivery and geographic area expansion as proposed in the previously funded expansion project. Further expansion of clinical services and geographic area are optional.
- Substantially increase the number of clinical services delivered if no further expansion is proposed.

Both initial and maintenance expansion evidence-based prevention projects funded by CPRIT will do the following:

- Coordinate the resources (clinical service providers, community organizations, etc) in nonmetropolitan and medically underserved areas (MUAs) to increase the availability of services and, where providers are available, help connect people with their local health care providers.
- Leverage the infrastructure, networks, and resources that have been put in place by CPRIT supported projects while minimizing startup time.
- Deliver comprehensive projects comprising all of the following: public and/or professional education, outreach, delivery of clinical services, follow-up navigation, and system and/or policy improvements.

- Offer effective and efficient systems of delivery of prevention services based on the existing body of knowledge about, and evidence for, cancer prevention in ways that far exceed current performance in a given service area.
- Implement policy changes and/or system improvements that are sustainable over time (eg, decrease wait times between positive screen and diagnostic tests and treatment through improved navigation, reminder systems, etc).

2.3 Award Description

CPRIT’s **Expansion of Cancer Prevention Services** grants are intended to fund the expansion of eligible projects that have demonstrated exemplary success, as evidenced by progress reports and project evaluations, and desire to further enhance their impact on priority populations. Detailed descriptions of **established infrastructure, results, barriers, outcomes, and impact of the most recently funded relevant project are required** (see outline of Project Plan, [section 4.4.4](#)).

Projects in the last year of a current grant or previously funded projects may apply for this expansion. Programs must have at least 1 full year of data to report before applying (see [section 2.7](#) eligibility criteria).

Applicants should not request funds for any of the above components if these components are already being funded from other sources. If clinical services are being provided and paid by others, the applicant must explain and report on the outcomes and services that are delivered to the people navigated by the program.

The following are required components of the project:

- **Initial Expansion:** Expansion to nonmetropolitan/MUA counties and/or offering additional clinical services are required for an initial expansion. To qualify for this Expansion RFA, CPRIT requires applicants to either add the delivery of 1 or more of the following clinical services to their project or to expand to additional nonmetropolitan and/or MUA counties.
 - Screenings and rescreenings for breast, cervical, colorectal cancers; hepatitis C virus; genetic risk factors
 - Vaccinations against HPV; hepatitis B virus
 - Evidence-based interventions focused on tobacco prevention (prevent tobacco use or sustained abstinence) and tobacco cessation among youth and/or adults

Expansion of eligible projects into nonmetropolitan/medically underserved geographic areas not well served by the CPRIT portfolio (see maps at <https://www.cprit.texas.gov/our-programs/prevention/portfolio-maps>), will receive priority consideration.

- **Maintenance Expansion:** The clinical service and/or geographic expansion from the previously funded CPRIT expansion project must be maintained, at a minimum. Further expansion is optional. If no further expansion of clinical services and/or geography is proposed, the number of clinical services delivered must be substantially increased from the initial expansion.
- **Comprehensive Projects:** Comprehensive projects include a continuum of services and systems and policy changes and comprise all of the following: Public and/or professional education and training, outreach, delivery of screening and diagnostic services, follow-up navigation, data collection and tracking, and systems improvement.

This mechanism will fund case management/patient navigation to screening, to diagnostic testing, and to treatment. Applicants must ensure that there is access to treatment services for patients with cancers or precancers that are detected as a result of the project and must describe the process for ensuring access to treatment services in their application.

- **Evidence Based:** CPRIT's service grants are intended to fund effective and efficient systems of delivery of prevention services based on the existing body of knowledge about and evidence for cancer prevention in ways that far exceed current performance in a given service area. The provision of clinical services, including rescreening at the appropriate interval, must comply with established and current national guidelines (eg, US Preventive Services Task Force [USPSTF], American Cancer Society, etc).

If evidence-based strategies have not been implemented or tested for the specific population or service setting proposed, provide evidence that the proposed service is appropriate for the population and has a high likelihood of success. Baseline data (eg, availability of resources and screening coverage) for the target population and target service region are required. If no baseline data exist, the applicant must present clear plans and describe method(s) of measurement used to collect the data necessary to establish a baseline.

Clinical Service and Community Partner Networks. Applicants are strongly encouraged to coordinate and describe a collaboration of clinical service providers and community partners that can deliver outreach, education, clinical, and navigation services to the most counties and the most people possible in a selected service region. Partnerships with other organizations that can support and leverage resources (ie, community-based organizations, local and voluntary agencies, nonprofit agencies, groups that represent priority populations, etc) are encouraged. Letters of commitment or memoranda of understanding describing their specific role in the partnership will greatly strengthen the application. Leveraging of the infrastructure, existing networks, and other resources that were established for the eligible CPRIT-funded project are expected and should be well described.

Project Coordination and Technical Assistance. The overall program should be directed and overseen by the Program Director (PD) who is responsible for establishing and managing the network. Responsibilities of the PD include the following:

- Establishing any necessary subcontracts or memoranda of understanding with project partners and clinical service providers;
- Regularly communicating with partners to discuss progress and barriers, resolve potential problems, and provide technical assistance as needed throughout the duration of the project;
- Meeting all reporting requirements. CPRIT expects measurable outcomes of supported activities, such as a significant increase over baseline (for the proposed service area) in the provision of evidence-based services, changes in provider practice, systems changes, and cost-effectiveness.

If applicable, in cases where the project proposes to work with multiple clinical providers, the PD should facilitate the establishment of standard protocols for all clinical service providers in the network as well as standard systems, policies, and procedures for the participating clinical service providers and organizations. These may include, but are not limited to, patient tracking and timely follow-up of all abnormal screening results and/or diagnoses of cancer.

Under this RFA, CPRIT **will not** consider the following:

- **Continuation of currently funded projects.** Projects must include the required expansion criteria detailed in the RFA for an initial expansion, and a substantial increase in the number of clinical services provided is required for any subsequent expansion.

- **Projects focusing on computerized tomography screening for lung cancer for ages 55 to 77.** Applicants with projects including lung cancer CT screening should apply under CPRIT’s Tobacco Control and Lung Cancer Screening RFA.
- **New evidence-based cancer prevention services projects.** These applicants should apply under CPRIT’s Evidence-Based Cancer Prevention Services RFA.
- **Projects focused solely on systems and/or policy change or solely on education and/or outreach that do not include the delivery of cancer preventive clinical services.**
- **Projects focusing solely on case management/patient navigation services through the treatment phase of cancer.** Case management/patient navigation services must be paired with the delivery of a clinical cancer prevention service and reported to CPRIT.
- **Projects focused solely on counseling services with no additional evidence-based clinical services.**
- **Resources for the treatment of cancer or viral treatment for hepatitis.**
- **Prevention/intervention research** (Applicants interested in prevention research should review CPRIT’s Academic Research RFAs (available at <http://www.cprit.texas.gov>).

2.4 Priorities

Types of Cancer: Applications addressing the services listed in [section 2.2](#) Project Objectives and that are responsive to this RFA will be considered for funding.

The Prevention Program’s priorities for funding include the following:

1) **Populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence.**

CPRIT programs must address underserved populations. Underserved populations are subgroups that are disproportionately affected by cancer. CPRIT-funded efforts must address 1 or more of these priority populations:

- Underinsured and uninsured individuals
- Medically unserved or underserved populations
- Racial, ethnic, and cultural minority populations
- Populations with low screening rates, high incidence rates, and high mortality rates, focusing on individuals never before screened or who are significantly out of compliance

with nationally recommended screening guidelines (more than 5 years for breast/cervical cancers).

The age of the priority population and frequency of screening for provision of clinical services described in the application must comply with established and current national guidelines (eg, USPSTF, American Cancer Society).

2) Geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence.

While disparities and needs exist across the state, CPRIT will also prioritize applications proposing to serve geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence. For this RFA, projects must propose to serve nonmetropolitan and/or MUAs of the state. In addition, projects addressing areas of emphasis (see [section 2.5](#)) will receive priority consideration.

Geographic and Population Balance in Current CPRIT portfolio

At the programmatic level of review conducted by the Prevention Review Council (see [section 5.1](#)), priority will be given to projects that target geographic regions of the state and population subgroups that are not adequately covered by the current CPRIT Prevention project portfolio (see <https://www.cprit.texas.gov/our-programs/prevention/portfolio-maps> and <https://www.cprit.texas.gov/grants-funded?search=prevention>).

2.5 Specific Areas of Emphasis

Applications addressing any of the services listed in [section 2.2](#) and that are responsive to this RFA will be considered. For those services, CPRIT has identified the following areas of emphasis for this cycle of awards.

<u>Primary Prevention</u>
HPV Vaccination
<ul style="list-style-type: none"> Increasing access to, delivery of, and completion of the HPV vaccine regimen to males and females through evidence-based intervention efforts in all areas of the state.¹
Tobacco Prevention and Control
<ul style="list-style-type: none"> Vulnerable and high-risk populations, including people with mental illness, history of substance abuse, youth, and pregnant women, that have higher tobacco usage rates than the general population. Areas that have higher smoking rates per capita than other areas of the state. Public Health Regions (PHR) 4, 5, and 9 have significantly higher tobacco use among adults than in other regions of the state.
Liver Cancer
<ul style="list-style-type: none"> Screening for HBV infection and HCV infection in populations at high risk of infection and 1-time screening for HCV infection in adults born between 1945 and 1965. Increasing screening rates in Public Health Region (PHR) 8, 9, 10, and 11, where the highest rates of cancer incidence and mortality are found.²
<u>Secondary Prevention - Screening and Early Detection Services</u>
Colorectal Cancer
<ul style="list-style-type: none"> Decreasing disparities in incidence and mortality rates of colorectal cancer in racial/ethnic populations. Blacks have the highest incidence and mortality rates, followed by non-Hispanic whites and Hispanics.² Increasing screening/detection rates in PHR 1, 2, 4, 5, and 9, where the highest rates of cancer incidence and mortality are found. Decreasing incidence and mortality rates in nonmetropolitan counties. Incidence and mortality rates are higher in nonmetropolitan counties compared with metropolitan counties.²
Breast Cancer
<ul style="list-style-type: none"> Decreasing disparities in mortality rates of breast cancer in racial/ethnic populations. The mortality rate is significantly higher in blacks than in other populations.² Increasing screening/detection rates in medically underserved areas of the state.
Cervical Cancer
<ul style="list-style-type: none"> Decreasing disparities in incidence and mortality rates of cervical cancer in racial/ethnic populations. Hispanics have the highest incidence rates while blacks have the highest mortality rates.² Increasing screening/detection rates for women in PHR 2, 4, 5, and 11. Incidence is highest in Texas-Mexico border counties (PHR 5 and 11). The mortality rate is highest in PHR 2, 4, 5, and 11.²

2.6 Outcome Metrics

Applicants are required to clearly describe their assessment and evaluation methodology. The applicant is required to describe final outcome measures for the project. Output measures that are associated with the final outcome measures should be identified in the project plan and will serve as a measure of program effectiveness. Planned policy or system changes/improvements should be identified and the plan for qualitative analysis described. **Baseline data for each measure proposed are required.** In addition, applicants should describe how funds from the CPRIT grant will improve outcomes over baseline. If the applicant is not providing baseline data for a measure, the applicant must provide a well-justified explanation and describe clear plans and method(s) of measurement to collect the data necessary to establish a baseline.

Reporting Requirements

Funded projects are required to report quantitative output and outcome metrics (as appropriate for each project) through the submission of quarterly progress reports, annual reports, and a final report. If clinical services are being paid for and provided by others, the applicant is required to report on the number of clinical services and patient outcomes (eg, screenings/diagnostics, vaccinations, cancer precursors, cancers detected) that are delivered to the people navigated by the program.

- Quarterly progress report sections include, but are not limited to, the following:
 - Summary page, including narrative on project progress (required)
 - Services, other than clinical services, provided to the public/professionals
 - Actions taken by people/professionals as a result of education or training
 - Clinical services provided (county of residence of client is required)
 - Precursors and cancers detected
- Annual and final progress report sections include, but are not limited to, the following:
 - Key accomplishments, **including qualitative analysis of policy change and/or lasting systems change**
 - Progress toward goals and outcome objectives, including percentage increase over baseline in provision of age- and risk-appropriate comprehensive preventive services to eligible individuals in a defined service area
 - Materials produced and publications
 - Economic impact of the project

2.7 Eligibility

- Eligible applicants include only those with currently or previously funded CPRIT Prevention projects.
- To justify the expansion, applicants must leverage the infrastructure and networks of the most recently funded CPRIT project.
- Applicants may submit an expansion application before the end of the currently funded project but should time their submission during the last year of the current project to ensure minimal overlap of funding. Unexpended funds from the original project will not carry forward to the expansion project. To apply for an expansion of a current project, projects must have at least 1 full year of results and data.
- The applicant must be a Texas-based entity that previously received CPRIT funding through Prevention Program RFAs.
- The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application is submitted.
- The designated Program Director (PD) will be responsible for the overall performance of the funded project. The PD must have relevant education and management experience and must reside in Texas during the project performance time.
- The evaluation of the project must be headed by a professional who has demonstrated expertise in the field and who resides in Texas during the time that the project is conducted.
- If the applicant or a partner is an existing Department of State Health Services (DSHS) contractor, CPRIT funds may not be used as a match, and the application must explain how this grant complements or leverages existing state and federal funds. DSHS contractors who also receive CPRIT funds must be in compliance with and fulfill all contractual obligations within CPRIT. CPRIT and DSHS reserve the right to discuss the contractual standing of any contractor receiving funds from both entities.
- Collaborations are permitted and encouraged, and collaborators may or may not reside in Texas. However, collaborators who do not reside in Texas are not eligible to receive CPRIT funds. Subcontracting and collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.

- An applicant is not eligible to receive a CPRIT grant award if the applicant PD, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member.
- An applicant organization is eligible to receive a grant award only if the applicant certifies that the applicant organization, including the PD, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization, (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation created to benefit CPRIT.
- The applicant must report whether the applicant organization, the PD, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way (whether slated to receive salary or compensation under the grant award or not), are currently ineligible to receive federal grant funds because of scientific misconduct or fraud or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. CPRIT grants are funded on a reimbursement-only basis. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 6](#). All statutory provisions and relevant administrative rules can be found [on the CPRIT website](#).

2.8 Resubmission Policy

- **One resubmission** is permitted. An application is considered a resubmission if the proposed project is the same project as presented in the original submission. A change in the identity of the PD for a project or a change of title for a project that was previously submitted to CPRIT does not constitute a new application; the application would still be considered a resubmission.

- Applicants who choose to resubmit should carefully consider the reasons for lack of prior success. Applications that received overall numerical scores of 5 or higher are likely to need considerable attention. All resubmitted applications should be carefully reconstructed; a simple revision of the prior application with editorial or technical changes is not sufficient, and applicants are advised not to direct reviewers to such modest changes. A 1-page summary of the approach to the resubmission should be included. Resubmitted applications may be assigned to reviewers who did not review the original submission. Reviewers of resubmissions are asked to assess whether the resubmission adequately addresses critiques from the previous review. **Applicants should note that addressing previous critiques is advisable; however, it does not guarantee the success of the resubmission.** All resubmitted applications must conform to the structure and guidelines outlined in this RFA.

2.9 Funding Information

Applicants may request any amount of funding up to a maximum of \$2 million in total funding over a maximum of 36 months for an initial expansion. For any subsequent expansion, applicants may request up to a maximum of \$2.5 million in total funding over a maximum of 5 years (60 months). A **significant expansion** in the geographic area and/or clinical services provided for the initial expansion, or number of clinical services delivered for any subsequent expansion, as described in [section 2.3](#), is required. Grant funds may be used to pay for clinical services, navigation services, salary and benefits, project supplies, equipment, costs for outreach and education of populations, and travel of project personnel to project site(s). Applicants must ensure that there is access to treatment services for patients with precancers or cancers that are detected as a result of the program and must describe access to treatment services in their application.

Requests for funds to support construction or renovation or requests to support lobbying will not be approved under this mechanism. Cost sharing for equipment purchases is encouraged. Grantees may request funds for travel for 2 project staff to attend CPRIT's conference.

The budget should be proportional to the number of individuals receiving programs and services, and a significant proportion of funds is expected to be used for program delivery as opposed to program development. In addition, CPRIT funding should not be used to replace existing funding,

supplant funds that would normally be expended by the applicant's organization, or make up for funding reductions from other sources.

State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the **total** award amount.

3. KEY DATES

RFA release	August 3, 2020
Online application opens	August 17, 2020, 7 AM central time
Application due	October 5, 2020, 4 PM central time
Application review	November-April 2021
Award notification	May 2021
Anticipated start date	June 1, 2021

Applicants will be notified of peer review panel assignment prior to the peer review meeting dates.

4. APPLICATION SUBMISSION GUIDELINES

4.1 *Instructions for Applicants* document

It is imperative that applicants read the accompanying instructions document for this RFA that will be available August 17, 2020 (<https://CPRITGrants.org>). Requirements may have changed from previous versions.

4.2 Online Application Receipt System

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The PD must create a user account in the system to start and submit an application. The Co-PD, if applicable, must also create a user account to participate in the application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (an individual who will help manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on August 17, 2020, and must be submitted by 4 PM central time on October 5, 2020. Detailed instructions for submitting an application are in the *Instructions for Applicants* document, posted on CARS.

Submission of an application is considered an acceptance of the terms and conditions of the RFA.

4.3 Submission Deadline Extension

The submission deadline may be extended for 1 or more grant applications upon a showing of good cause. All requests for extension of the submission deadline must be submitted via email to the CPRIT Helpdesk within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records.

4.4 Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Refer to the *Instructions for Applicants* document for details.

Submissions that are missing 1 or more components or do not meet the eligibility requirements may be administratively withdrawn without review.

4.4.1 Abstract and Significance (5,000 characters)

Clearly explain the problem(s) to be addressed, the approach(es) to the solution, and how the application is responsive to this RFA. In the event that the project is funded, the abstract will be made public; therefore, no proprietary information should be included in this statement. Initial compliance decisions are based in part upon review of this statement.

The abstract format is as follows (use headings as outlined below):

- **Need:** Include a description of need in the specific service area. Include rates of incidence, mortality, and screening in the service area compared to overall Texas rates. Describe barriers, plans to overcome these barriers, and the priority population to be served.
- **Overall Project Strategy:** Describe the project and how it will address the identified need. Clearly explain what the project is and what it will specifically do, including the services to be provided and the process/system for delivery of services and outreach to the priority population.
- **Specific Goals:** State specifically the overall goals of the proposed project; include the estimated overall numbers of people (public and/or professionals) reached and people (public and/or professionals) served.

- **Significance and Impact:** Explain how the proposed project, if successful, will have a major impact on cancer prevention and control for the population proposed to be served and for the State of Texas.

4.4.2 Goals and Objectives (700 characters each)

List only major **outcome goals** and **measurable objectives** for each year of the project. **Do not include process objectives**; these should be described in the project plan only. Include the proposed metric within both the stated objective **and** the measure (eg, Measure: 2,000 individuals, age 9-12, will initiate HPV vaccination during the grant period). Refer to the *Instructions for Applicants* document for details. The **maximum** number is 3 goals with 3 objectives each. Projects will be evaluated annually on progress toward outcome goals and objectives. See [Appendix B](#) for instructions on writing outcome goals and objectives.

A baseline and method(s) of measurement are required for each objective. Provide both raw numbers and percent changes for the baseline and target. If a baseline has not been defined, applicants are required to explain plans to establish baseline and describe method(s) of measurement.

4.4.3 Project Timeline (2 pages)

Provide a project timeline for project activities that includes deliverables and dates. Use Years 1, 2, 3, and Months 1, 2, 3, etc, as applicable (eg, Year 1, Months 3-5) **instead of specific months or years**. Month 1 is the first full month of the grant award.

4.4.4 Project Plan (12 pages; fewer pages permissible)

The required project plan format follows. Applicants must use the headings outlined below.

Background: Briefly present the rationale behind the proposed service, emphasizing the critical barriers to current service delivery that will be addressed. Identify the evidence-based service to be implemented for the priority population. Describe the race, ethnicity, age, and other defining characteristics of the population to be served.

If evidence-based strategies have not been implemented or tested for the specific population or service setting proposed, provide evidence that the proposed service is appropriate for the

population and has a high likelihood of success. Baseline data for the priority population and target service area are required where applicable.

Reviewers will be aware of national and state statistics, and these should be used only to compare rates for the proposed service area. Describe the geographic region of the state that the project will serve; maps are encouraged.

Goals and Objectives: Process objectives should be included in the project plan. Outcome goals and objectives will be entered in separate fields in CARS. However, if desired, outcome goals and objectives may be fully repeated or briefly summarized here. See [Appendix B](#) for instructions on writing goals and objectives.

Components of the Project: Clearly describe the need, delivery method, and evidence base (provide references) for the services as well as anticipated results. Be explicit about the base of evidence and any necessary adaptations for the proposed project. Describe why this project is nonduplicative. Describe how the proposed project leverages the infrastructure, networks, and resources that have been put in place by the most recently funded CPRIT project while minimizing startup time.

It is important to distinguish between Texas counties where the project proposes to deliver services and counties of residence of population served (see [Appendix A](#) for definitions and *Instructions for Applicants*). Only counties with service delivery should be listed in the Geographic Area to be Served section of the application. Projecting counties of residence of population served is not required but may be described in the project plan.

Clearly demonstrate the ability to provide the proposed service and describe how results will be improved over baseline and the ability to reach the priority population. Describe the method(s) that will be used to recall for appropriate rescreening those individuals who have been screened through this project. Describe any planned policy changes or system improvements. If clinical services are being paid for and provided by others, the applicant must explain and report on the number of clinical services and patient outcomes (eg, screenings/diagnostics, vaccinations, cancer precursors, cancers detected) that are delivered to the people navigated by the program. Applicants must also clearly and thoroughly describe plans to **ensure access to treatment** services should precancer or cancer be detected.

Evaluation Strategy: A strong commitment to evaluation of the project is required. Describe the plan for outcome and output measurements, including qualitative analysis of policy and system changes. Describe data collection and management methods, data analyses, and anticipated results. Evaluation and reporting of results should be headed by a professional who has demonstrated expertise in the field. If needed, applicants may want to consider seeking expertise at Texas-based academic cancer centers, schools/programs of public health, or the like. Applicants should budget accordingly for the evaluation activity and should involve that professional during grant application preparation to ensure, among other things, that the evaluation plan is linked to the proposed goals and objectives.

Organizational Qualifications and Capabilities: Describe the organization and its track record and success in providing health programs and services. Describe the role and qualifications of the key collaborators/partners in the project. Include information on the organization's financial stability and viability. The applicant should demonstrate how the organizational environment will contribute to a successful project. If equipment or physical resources are required to carry out the project, the applicant should describe the availability of these resources and the organizational capacity to use the equipment. To ensure access to preventive services and reporting of services outcomes, applicants should demonstrate that they have provider partnerships and agreements (via memoranda of understanding) or commitments (via letters of commitment) in place.

CPRIT acknowledges that full maintenance and sustainability of projects when CPRIT funding ends may not be feasible, especially in cases involving the delivery of clinical services. However, it is important to consider sustainability early in the life cycle of a project, particularly regarding organizational characteristics and processes that are modifiable.

Washington University in St Louis has developed a useful tool ([Program Sustainability Assessment Tool](#)) to assess program capacity for sustainability. The tool assesses several factors that contribute to program sustainability. These factors include environmental support, funding stability, partnerships, organizational capacity, program evaluation, program adaptation, communication, and strategic planning. Applicants are not required to use this tool; however, it provides practical guidance on factors that should be considered and should be included in the application to describe a program's organizational capacity for sustainability.

It is expected that steps toward building sustainability capacity for the program will be taken and plans for such be briefly described in the application. The applicant should assess and describe the factors that will contribute to the organization's capacity to facilitate sustainability.

Dissemination and Replication: Dissemination of project results and outcomes, including barriers encountered and successes achieved, is critical to building the evidence base for cancer prevention and control efforts in the state. Dissemination efforts should consider the message, source, audience, and channel (Brownson, R.C., et al. [J Pub Health Manag Pract. 24\(2\):102-111](#), March/April 2018). Dissemination methods may include, but are not limited to, presentations at workshops and seminars, one-on-one meetings, publications, news media, social media, etc.

While passive dissemination methods are common (eg, publications, presentations at professional meetings), plans should include some active dissemination methods (eg, meetings with stakeholders, blogs, social media). Applicants should describe their dissemination plans. The plans should include the kinds of audiences to be targeted and methods for reaching the targeted audiences.

Replication by others is an additional way to disseminate the project. For applicable components, describe how the project or components of the project lend themselves to application by other communities and/or organizations in the state or expansion in the same communities. Describe what components of this project can be adapted to a larger or lower resource setting. Note that some programs may have unique resources and may not lend themselves to replication by others.

4.4.5 People Reached (Indirect Contact)

Provide the estimated overall number of people (members of the public and professionals) to be reached by the funded project. The applicant is required to itemize separately the types of indirect noninteractive education and outreach activities, with estimates, that led to the calculation of the overall estimates provided. Refer to [Appendix A](#) for definitions.

4.4.6 Number of Services Delivered (Direct Contact)

Provide the estimated overall number of services directly delivered to members of the public and to professionals by the funded project. Each individual service should be counted, regardless of the number of services one person receives. The applicant is required to itemize separately the

education, navigation, and clinical activities/services, with estimates, that led to the calculation of the overall estimate provided. Refer to [Appendix A](#) for definitions.

4.4.7 Number of Clinical Services Delivered

Provide the estimated overall number of clinical services directly delivered to members of the public by the funded project. Each individual clinical service should be counted, regardless of the number of services one person receives. Separately itemize the clinical services, with estimates, that led to the calculation of the overall estimate provided. Refer to [Appendix A](#) for definitions.

4.4.8 Number of Unique People Served (Direct Contact)

Provide the estimated overall number of unique members of the public and professionals served by the funded project. One person may receive multiple services but should only be counted once here. Refer to [Appendix A](#) for definitions.

4.4.9 References

Provide a concise and relevant list of references cited for the application. The successful applicant will provide referenced evidence and literature support for the proposed services.

4.4.10 Resubmission Summary

Use the template provided on the CARS (<https://CPRITGrants.org>). Describe the approach to the resubmission and how reviewers' comments were addressed. Clearly indicate to reviewers how the application has been improved in response to the critiques. Refer the reviewers to specific sections of other documents in the application where further detail on the points in question may be found. When a resubmission is evaluated, responsiveness to previous critiques is assessed.

The summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission; the applicant is not responsible for providing this document.

4.4.11 Most Recently Funded Relevant Project Summary (3 pages)

Upload a summary that outlines the progress made with the most recently funded CPRIT award upon which this expansion is based. Applicants must describe results and outcomes of the most recently funded relevant award and demonstrate why further funding is warranted.

Please note that a different set of reviewers from those assigned to the previously funded application may evaluate this application. Applicants should make it easy for reviewers to compare the most recently funded relevant project with the proposed expansion project.

In the description include the following:

- Describe the evidence-based intervention, its purpose, and how it was implemented in the priority population. Describe any adaptations made for the population served.
- List approved goals and objectives of the most recently funded grant.
- For each objective, provide the following information:
 - Milestones/target dates and target metrics
 - Actual completion dates and metrics
- For the most recently funded project, describe major activities; significant results, including major findings, developments or conclusions (both positive and negative); and key outcomes. If the project has not yet ended, provide projections for completion dates and final metrics. Include a discussion of objectives not fully met. Explain any barriers encountered and strategies used to overcome these.
- Describe steps taken toward sustainability for components of the project. Fully describe systems or policy improvements and enhancements.
- Describe how project results were disseminated or plans for future dissemination of results.

4.4.12 CPRIT Grants Summary

Use the template provided on the CARS (<https://CPRITGrants.org>). Provide a listing of **all** projects funded by the CPRIT Prevention program for the PD and the Co-PD, regardless of their connection to this application.

4.4.13 Budget and Justification

Provide a brief outline and detailed justification of the budget for the entire proposed period of support, including salaries and benefits, travel, equipment, supplies, contractual expenses, services delivery, and other expenses. CPRIT funds will be distributed on a reimbursement basis.

Applications requesting more than the maximum allowed cost (total costs) as specified in [section 2.9](#) will be administratively withdrawn.

- **Average Cost per Service:** The average cost per service will be automatically calculated from the total cost of the project divided by the total number of services delivered (refer to [Appendix A](#)). A significant proportion of funds is expected to be used for program delivery as opposed to program development and organizational infrastructure.
- **Average Cost per Person:** The average cost per person will be automatically calculated from the total cost of the project divided by the total number of unique people served (refer to [Appendix A](#)).
- **Average Cost per Clinical Service:** The average cost per clinical service will be automatically calculated from the total cost of the project divided by the total number of clinical services delivered (refer to [Appendix A](#)).
- **Personnel:** The individual salary cap for CPRIT awards is \$200,000 per year. Describe the source of funding for all project personnel where CPRIT funds are not requested.
- **Travel:** PDs and related project staff are expected to attend CPRIT's conference. CPRIT funds may be used to send up to 2 people to the conference.
- **Equipment:** Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application. Justification must be provided for why funding for this equipment cannot be found elsewhere; CPRIT funding should not supplant existing funds. Cost sharing of equipment purchases is strongly encouraged.
- **Services Costs:**
 - CPRIT reimburses for services using Medicare reimbursement rates. Describe the source of funding for all services where CPRIT funds are not requested. If clinical services are being paid for and provided by others, the applicant is required to explain and report on the number of clinical services and patient outcomes (eg, screenings/diagnostics, vaccinations, cancer precursors, cancers detected) that are delivered to the people navigated by the program.
 - CPRIT does not allow recovery of costs related to tests that have not been recommended by the USPSTF. In several cases (eg, breast self-exams, clinical breast exams, PSA tests), the Task Force has concluded there is not enough evidence available to draw reliable conclusions about the additional benefits and harms of these tests. (See <https://www.uspreventiveservicestaskforce.org/>)

- **Other Expenses:**
 - **Incentives:** Use of incentives or positive rewards to change or elicit behavior is allowed; however, incentives may only be used based on strong evidence of their effectiveness for the purpose and in the priority population identified by the applicant. CPRIT will not fund cash incentives. The maximum dollar value allowed for an incentive per person, per activity or session, is \$25.
 - **Costs Not Related to Cancer Prevention and Control:** CPRIT does not allow recovery of any costs for services not related to cancer (eg, health physicals, HIV testing).
- **Indirect/Shared Costs:** Texas law limits the amount of grant funds that may be spent on indirect/shared expenses to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in [CPRIT's Administrative Rules](#).

4.4.14 Current and Pending Support and Sources of Funding

Use the template provided on the CARS (<https://CPRITGrants.org>). Describe the funding source and duration of **all** current and pending support for the proposed project, including a capitalization table that reflects private investors, if any.

4.4.15 Biographical Sketches

The designated PD will be responsible for the overall performance of the funded project and must have relevant education and management experience. The PD/Co-PD(s) must provide a biographical sketch that describes his or her education and training, professional experience, awards and honors, and publications and/or involvement in programs relevant to cancer prevention and/or service delivery.

- Use the Co-PD Biographical Sketch section **ONLY** if a Co-PD has been identified.
- The evaluation professional must provide a biographical sketch in the Evaluation Professional Biographical sketch section.
- Up to 3 additional biographical sketches for key personnel may be provided in the Key Personnel Biographical Sketch section.

Each biographical sketch must not exceed 2 pages and should use either the “Prevention Programs: Biographical Sketch” template provided on the CARS (<https://CPRITGrants.org>) or the NIH Biographical Sketch format. Only biographical sketches will be accepted; do not submit resumes and/or CVs. If a position is not yet filled, please upload a job description.

4.4.16 Collaborating Organizations

List all key participating organizations that will partner with the applicant organization to provide 1 or more components essential to the success of the program (eg, evaluation, clinical services, recruitment to screening). Please be sure to also include anyone listed as key personnel and/or listed under the Current & Pending Support section.

4.4.17 Letters of Commitment (10 pages)

Applicants should provide letters of commitment and/or memoranda of understanding from community organizations, key faculty, or any other component essential to the success of the program. Letters should be specific to the contribution of each organization.

5. APPLICATION REVIEW

5.1 Review Process Overview

All eligible applications will be reviewed using a 2-stage peer review process: (1) evaluation of applications by peer review panels and (2) prioritization of grant applications by the Prevention Review Council. In the first stage, applications will be evaluated by an independent review panel using the criteria listed below. In the second stage, applications judged to be meritorious by review panels will be evaluated by the Prevention Review Council and recommended for funding based on comparisons with applications from all of the review panels and programmatic priorities.

Programmatic considerations may include, but are not limited to, geographic distribution, cancer type, population served, and type of program or service. The scores are only 1 factor considered during programmatic review. At the programmatic level of review, priority will be given to proposed projects that target geographic regions of the state or population subgroups that are not well represented in the current CPRIT Prevention project portfolio.

Applications approved by Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the

Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

Each stage of application review is conducted confidentially, and all CPRIT Peer Review Panel members, Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Peer Review Panel members and Review Council members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer Review Panel members are listed by panel on CPRIT's website. **By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules, [chapter 703, section 703.9](#).**

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, a Review Panel member, or a Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period when preapplications or letters of

interest are accepted. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

5.2 Review Criteria

Peer review of applications will be based on primary scored criteria and secondary unscored criteria, identified below. Review panels consisting of experts in the field and advocates will evaluate and score each primary criterion and subsequently assign an overall score that reflects an overall assessment of the application. The overall evaluation score will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application and responsiveness to the RFA priorities.

5.2.1 Primary Evaluation Criteria

Impact

- Do the proposed services address an important problem or need in cancer prevention and control? Do the proposed project strategies support desired outcomes in cancer incidence, morbidity, and/or mortality? Do the proposed project strategies reach a priority population (eg, low income, minority, rural) at high risk of cancer?
- For the proposed expansion, does the project build on its initial results (baseline)? Does it go beyond the initial project to address what the applicant has learned or explore new partnerships, new audiences, or improvements to systems?
- Will the project reach and serve/impact an appropriate number of people based on the budget allocated to providing services and the cost of providing services?
- If applicable, have partners demonstrated that the collaborative effort will provide a greater impact on cancer prevention and control than the applicant organization's effort separately?
- Does the program address adaptation, if applicable, of the evidence-based intervention to the priority population? Is the base of evidence clearly explained and referenced?

Project Strategy and Feasibility

- Does the proposed project provide services specified in the RFA?
- Are the overall program approach, strategy, and design clearly described and supported by established theory and practice? Are the proposed objectives and activities feasible within

the duration of the award? Has the applicant convincingly demonstrated the short- and long-term impacts of the project?

- Has the applicant proposed policy changes and/or system improvements?
- Are possible barriers addressed and approaches for overcoming them proposed?
- Are the priority population and culturally appropriate methods to reach the priority population clearly described?
- If applicable, does the application demonstrate the availability of resources and expertise to provide case management, including follow-up for abnormal results and access to treatment?
- Does the program leverage partners and resources to maximize the reach of the services proposed? Does the program leverage and complement other state, federal, and nonprofit grants?

Outcomes Evaluation

- Are specific goals and measurable **outcome** objectives for each year of the project provided?
- Are the proposed **outcome** measures appropriate for the services provided?
- Are the proposed outcome objectives realistic, based upon the project timeline and resources being invested?
- Does the application provide a detailed plan for data collection, data management, and data analyses?
- Do the proposed evaluation professionals demonstrate adequate and appropriate evaluation expertise and time commitment?

Organizational Qualifications and Capabilities

- Do the organization and its collaborators/partners demonstrate the ability to provide the proposed preventive services?
- Does the described role of each collaborating organization make it clear that each organization adds value to the project and is committed to working together to implement the project?

- Have the appropriate personnel been recruited to design, implement, evaluate, and complete the project?
- Is the organization structurally and financially stable and viable?
- Does the applicant describe their current activities and the program's organizational capacity for sustainability?
- Does the applicant describe steps that will be taken toward building internal capacity and partnerships?
- Does the applicant describe a plan for systems changes that are sustainable over time; eg, improve results, provider practice, efficiency, cost-effectiveness?

5.2.2 Secondary Evaluation Criteria

Budget

- Is the budget appropriate and reasonable for the scope and services of the proposed work?
- Is the cost per person served appropriate and reasonable?
- Is the proportion of the funds allocated for direct services reasonable?
- Is the project a good investment of Texas public funds?

Dissemination and Replication

- Are plans for dissemination of the project's results and outcomes, including target audiences and methods clearly described?
- Are active dissemination strategies included and described in the plan?
- Does the applicant describe whether and/or how the project lends itself to replication of all or some components of the project by others in the state?

6. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use

shall be in accordance with CPRIT's electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in [CPRIT's Administrative Rules](#). Applicants are advised to review CPRIT's administrative rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires the PD of the award to submit quarterly, annual, and final progress reports. These reports summarize the progress made toward project goals and address plans for the upcoming year and performance during the previous year(s). In addition, quarterly fiscal reporting and reporting on selected metrics will be required per the instructions to award recipients. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract.

7. CONTACT INFORMATION

7.1 Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding the scope and focus of applications. Before contacting the Helpdesk, please refer to the *Instructions for Applicants* document (posted on August 17, 2020), which provides a step-by-step guide to using CARS.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

7.2 Program Questions

Questions regarding the CPRIT Prevention program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Prevention Program Office.

Tel: 512-305-8417

Email: Help@CPRITGrants.org

Website: www.cprit.texas.gov

8. RESOURCES

- The Texas Cancer Registry. <https://www.dshs.texas.gov/tcr> or contact the Texas Cancer Registry at the Department of State Health Services.
- The Community Guide. <https://www.thecommunityguide.org/>
- Cancer Control P.L.A.N.E.T. <http://cancercontrolplanet.cancer.gov>
- Guide to Clinical Preventive Services: Recommendations of the U.S. Preventive Services Task Force. <http://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/guide/>
- Brownson, R.C., Colditz G.A., and Proctor, E.K. (Editors). *Dissemination and Implementation Research in Health: Translating Science to Practice*. Oxford University Press, March 2012
- Program Sustainability Assessment Tool, copyright 2012, Washington University, St Louis, MO, <https://www.sustaintool.org/about-us/>
- Getting the Word Out: New Approaches for Disseminating Public Health Science Ross C. Brownson, PhD; Amy A. Eyler, PhD; Jenine K. Harris, PhD; Justin B. Moore, PhD, MS; Rachel G. Tabak, PhD, RD, **Journal of Public Health Management & Practice**. 24(2):102-111, March/April 2018. https://journals.lww.com/jphmp/Fulltext/2018/03000/Getting_the_Word_Out__New_Approaches_for.4.aspx
- Centers for Disease Control and Prevention: The Program Sustainability Assessment Tool: A New Instrument for Public Health Programs. http://www.cdc.gov/pcd/issues/2014/13_0184.htm
- Centers for Disease Control and Prevention: Using the Program Sustainability Tool to Assess and Plan for Sustainability. http://www.cdc.gov/pcd/issues/2014/13_0185.htm
- Cancer Prevention and Control Research Network: Putting Public Health Evidence in Action Training Workshop. <http://cpcrn.org/pub/evidence-in-action/>
- Centers for Disease Control and Prevention. Distinguishing Public Health Research and Public Health Nonresearch. <https://www.cdc.gov/os/integrity/docs/cdc-policy-distinguishing-public-health-research-nonresearch.pdf>

9. REFERENCES

1. <http://www.cdc.gov/hpv/parents/questions-answers.html>
2. Texas Cancer Registry, Cancer Epidemiology and Surveillance Branch, Texas Department of State Health Services. <https://www.cancer-rates.info/tx/>

APPENDIX A: KEY TERMS

- **Activities:** A listing of the “who, what, when, where, and how” for each objective that will be accomplished.
- **Capacity Building:** Any activity (eg, training, identification of alternative resources, building internal assets) that builds durable resources and enables the grantee’s setting or community to continue the delivery of some or all components of the evidence-based intervention.
- **Clinical Services:** Number of clinical services such as screenings, diagnostic tests, vaccinations, counseling sessions, or other evidence-based preventive services delivered by a health care practitioner in an office, clinic, or health care system. Other examples include genetic testing or assessments, physical rehabilitation, tobacco cessation counseling or nicotine replacement therapy, case management, primary prevention clinical assessments, and family history screening.
- **Counties of Residence of Population Served:** Counties where the project does not plan to have a physical presence but people who live in these counties have received services. This includes counties of residence of people or places of business of professionals who participate in or receive education, navigation or clinical services. Examples include people traveling to receive services as a result of marketing and programs accessible via the website or social media. These counties may be described in the project plan and must be reported in the quarterly progress report.
- **Counties with Service Delivery:** Counties where an activity or service will occur and the project has a physical presence for the services provided. Examples include onsite outreach and educational activities and delivery of clinical services through clinics, mobile vans, or telemedicine consults. These counties must be entered in the Geographic Area to be Served section of the application.
- **Education Services:** Number of evidence-based, culturally appropriate cancer prevention and control education and outreach services delivered to the public and to health care professionals. Examples include education or training sessions (group or individual), focus groups, and knowledge assessments. One individual may receive multiple education services.

- **Evidence-Based Program:** A program that is validated by some form of documented research or applied evidence. CPRIT’s website provides links to resources for evidence-based strategies, programs, and clinical recommendations for cancer prevention and control. To access this information, visit <https://www.cprit.state.tx.us/our-programs/prevention>.
- **Goals:** Broad statements of general purpose to guide planning. Outcome goals should be few in number and focus on aspects of highest importance to the project. ([Appendix B](#))
- **Integration:** The extent the evidence-based intervention is integrated within the culture of the grantee’s setting or community through policies and practice.
- **Navigation Services:** Number of unique activities/services that offer assistance to help overcome health care system barriers in a timely and informative manner and facilitate cancer screening and diagnosis to improve health care access and outcomes (Examples include patient reminders, transportation assistance, and appointment scheduling assistance). One individual may receive multiple navigation services.
- **Number of Clinical Services:** Number of [clinical services](#) delivered directly to members of the public by the funded project. One individual may receive multiple clinical services.
- **Number of Services (Direct Contact):** Number of services delivered directly to members of the public and/or professionals—direct, interactive public or professional education, outreach, training, navigation service, or clinical service, such as live educational and/or training sessions, vaccine administration, screening, diagnostics, case management/navigation services, and physician consults. One individual may receive multiple services.
- **Objectives:** Specific, measurable, actionable, realistic, and timely projections for outcomes; example: “Increase screening service provision in X population from Y% to Z% by 20xx.” Baseline data for the priority population must be included as part of each objective. ([Appendix B](#)). The proposed metric should be included in **both** the objective and the measure (eg, Measure: 2,000 individuals, age 9-12, will initiate HPV vaccination during the grant period).
- **People Reached (Indirect Contact):** Number of members of the public and/or professionals reached via indirect noninteractive public or professional education and

outreach activities, such as mass media efforts, brochure distribution, public service announcements, newsletters, and journals. (This category includes individuals who would be reached through activities that are directly funded by CPRIT as well as individuals who would be reached through activities that occur as a direct consequence of the CPRIT-funded project's leveraging of other resources/funding to implement the CPRIT-funded project).

- **Unique People Served (Direct Contact):** Number of unique members of the public and/or professionals served via direct, interactive public or professional education, outreach, training, navigation service, or clinical service. This category includes individuals who would be served through activities that are directly funded by CPRIT as well as individuals who would be served through activities that occur as a direct consequence of the CPRIT-funded project's leveraging of other resources/funding to implement the CPRIT-funded project.

APPENDIX B: WRITING GOALS AND OBJECTIVES

List only major **outcome goals** and **measurable objectives** for each year of the project. **Do not include process objectives**; these should be described in the project plan only. Include the proposed metric within **both** the stated objective and the measure (eg, Measure: 2,000 individuals, age 9-12, will initiate HPV vaccination during the grant period).

The maximum number is 3 goals with 3 objectives each. Projects will be evaluated annually on progress toward **outcome** goals and objectives.

The following guide has been adapted with permission from Appalachia Community Cancer Network, NIH Grant U54 CA 153604:

Develop well-defined goals and objectives.

Goals provide a roadmap or plan for where a group wants to go. Goals can be long term (over several years) or short term (over several months). Goals should be based on needs of the community and evidence-based data.

Goals should be:

- Believable – situations or conditions that the group believes can be achieved
- Attainable – possible within a designated time
- Tangible – capable of being understood or realized
- On a timetable – with a completion date
- Win-Win – beneficial to individual members and the coalition

Objectives are measurable steps toward achieving the goal. They are clear statements of specific activities required to achieve the goal. The best objectives have several characteristics in common – S.M.A.R.T. + C:

- Specific – they tell how much (number or percent), who (participants), what (action or activity), and by when (date)
 - Example: 115 uninsured individuals age 50 and older will complete colorectal cancer screening by March 31, 2018.
- Measurable – specific measures that can be collected, detected, or obtained to determine successful attainment of the objective.

- Example: How many screened at an event? How many completed pre/post assessment?
- Achievable – not only are the objectives themselves possible, it is likely that your organization will be able to accomplish them
- Relevant to the mission – your organization has a clear understanding of how these objectives fit in with the overall vision and mission of the group
- Timed – developing a timeline is important for when your task will be achieved
- Challenging – objectives should stretch the group to aim on significant improvements that are important to members of the community

Evaluate and refine your objectives

Review your developed objectives and determine the type and level of each using the following information:

There are 2 types of objectives:

- Outcome objectives – measure the “what” of a program; should be in the Goals and Objectives form (see [section 4.4.2](#))
- Process objectives – measure the “how” of a program; should be in the project plan only (see [section 4.4.4](#))

There are 3 levels of objectives:

- Community-level – objectives measure the planned community change
- Program impact – objectives measure the impact the program will have on a specific group of people
- Individual – objectives measures participant changes resulting from a specific program, using these factors:
 - Knowledge – understanding (know screening guidelines; recall the number to call for screening)
 - Attitudes – feeling about something (will consider secondhand smoke dangerous; believe eating 5 or more fruits and vegetable is important)
 - Skills – the ability to do something (complete fecal occult blood test)
 - Intentions – regarding plan for future behavior (will agree to talk to the doctor, will plan to schedule a Pap test)

- Behaviors (past or current) – to act in a particular way (will exercise 30+ minutes a day, will have a mammogram)

Well-defined outcome goals and objectives can be used to track, measure, and report progress toward achievement.

Summary Table

	Outcome – Use in Goals and Objectives	Process – Use in Project Plan only
Community-level	<p>WHAT will change in a community</p> <p><i>Example: As a result of CPRIT funding, FIT (fecal immunochemical tests) will be available to 1,500 uninsured individuals age 50 and over through 10 participating local clinics and doctors.</i></p>	<p>HOW the community change will come about</p> <p><i>Example: Contracts will be signed with participating local providers to enable uninsured individuals over age 50 have access to free colorectal cancer screening in their communities.</i></p>
Program impact	<p>WHAT will change in the target group as a result of a particular program</p> <p><i>Example: As a result of this project, 200 uninsured women between 40 and 49 will receive free breast and cervical cancer screening.</i></p>	<p>HOW the program will be implemented to affect change in a group/population</p> <p><i>Example: 2,000 female clients, between 40 and 49, will receive a letter inviting them to participate in breast and cervical cancer screening.</i></p>
Individual	<p>WHAT an individual will learn as a result of a particular program, or WHAT change an individual will make as a result of a particular program</p> <p><i>Example: As a result of one-to-one education of 500 individuals, at least 20% of participants will participate in a smoking cessation program to quit smoking.</i></p>	<p>HOW the program will be implemented to affect change in an individual's knowledge or actions</p> <p><i>Example: As a result of one-to-one counseling, all participants will identify at least 1 smoking cessation service and 1 smoking cessation aid.</i></p>

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)

21.1 Prevention Review Panel - 1 (21.1 PRV-P1)

Observation Report

Report No. 2021-01-21 21.1_PRV-P1
Program Name: Prevention
Panel Name: 21.1 Prevention Review Panel - 1 (21.1_PRV-P1)
Panel Date: January 19, 2021
Report Date: January 25, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.1 Prevention Review Panel - 1 (21.1_PRV-P1) meeting. The meeting was chaired by R. Brownson and conducted via video conference on January 19, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number of applications: Eleven (11) applications were discussed, and one (1) application was not discussed
- Panelists: One (1) panel chair, six (6) expert reviewers and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were zero (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive name that appears to be 'Mara Ash'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

21.1 Prevention Review Council (21.1_PRC-M1)

Observation Report

Report No. 2021-03-04 21.1_PRC-M1
Program Name: Prevention
Panel Name: 21.1 Prevention Review Council (21.1_PRC-M1)
Panel Date: March 4, 2021
Report Date: March 16, 2020

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.1 Prevention Review Council (21.1_PRC-M1) meeting. The meeting was chaired by Stephen Wyatt and conducted via teleconference on March 4, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: eleven (11) applications were discussed
- Panelists: One (1) panel chair, and two (2) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were zero (0) Conflict of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line extending to the right.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

21.2 Prevention Review Council (21.2_PRC-M2)

Observation Report

Report No. 2021-06-17 21.2_PRC-M2
Program Name: Prevention
Panel Name: 21.2 Prevention Review Council (21.2_PRC-M2)
Panel Date: June 17, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Prevention Review Council (21.2_PRC-M2) meeting. The meeting was chaired by Stephen Wyatt and conducted via teleconference on June 17, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Nine (9) applications were discussed
- Panelists: One (1) panel chair, and two (2) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: One (1)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was zero (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the closing text.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Prevention Cycle 21.1

Prevention Cycle 21.1 Awards Announced at the May 19, and August 18, 2021, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Prevention Cycle 21.1 include *Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations*. All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC. COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant/PD	Institution	Conflict Noted
Applications considered by the PIC and Oversight Committee:			
No conflicts reported.			
Applications not considered by the PIC or Oversight Committee:			
No conflicts reported.			

T.A.C. Section 702.19 Waiver



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS
FROM: WAYNE R. ROBERTS, CHIEF EXECUTIVE OFFICER
SUBJECT: T.A.C. § 702.19 STANDING WAIVER FOR FY 2021
DATE: AUGUST 28, 2020

Summary

This is to notify the Oversight Committee that pursuant to the authority provided to the Chief Executive Officer in T.A.C. § 702.19(e), I grant CPRIT's Chief Prevention Officer Ramona Magid a waiver from the general prohibition against communicating with grant applicants. The waiver is applicable for FY 2021. Unlike the two communication waivers I granted Ms. Magid for each FY 2020 review cycle, this standing FY 2021 waiver will be effective for both review cycles planned for FY 2021. No Oversight Committee action related to this waiver is necessary.

Background and Discussion

The Chief Prevention Officer is a statutorily mandated member of the Program Integration Committee (PIC). Texas Administrative Code § 702.19 prohibits substantive communication between the grant applicant and a member of the peer review panel, the PIC, or the Oversight Committee while the application is pending a final decision. The restriction on communication prevents even the appearance of unequal treatment during the grant review process.

Traditionally, a chief program officer leads each CPRIT program with the assistance of a program manager. The program manager fields inquiries from and provides technical help to applicants completing their CPRIT grant applications. I promoted Ms. Magid to the Chief Prevention Officer position upon Dr. Becky Garcia's retirement in June 2019. However, the prevention program manager position has remained vacant since Ms. Magid's promotion. Until CPRIT fills the program manager position, she is the sole point of contact for the prevention program. The communication waiver is necessary so that Ms. Magid can assist grant applicants who have questions during the application process.

I previously granted Ms. Magid separate waivers for the two review cycles of FY 2020. It is unlikely that CPRIT will fill the prevention program manager position in FY 2021. Accordingly, I am granting a standing waiver for Ms. Magid for FY 2021 as long as she remains the sole point of contact for the prevention program. Approving this standing waiver does not favor any grant applicant over another. Ms. Magid will provide technical assistance only and will not comment on the substance of a grant application. CPRIT will include this waiver in the grant record for the FY 2021 prevention grant applications.

De-Identified Overall Evaluation Scores

Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations

Prevention Cycle 21.1

The Prevention Review Council (PRC) recommended two applications to the PIC with the same score as an application on which the PRC took no action. As allowed in 25 T.A.C. § 703.6(d)(1), the PRC's numerical rank order is substantially based on the final overall evaluation score, but also takes into consideration how well the grant application achieves program priorities, programmatic review criteria, and the overall program portfolio.

Application ID	Final Overall Evaluation Score
PP210003*	1.4
PP210004*	2.3
PP210005*	2.9
PP210016*	3.3
PP210017*	3.3
a ¹	3.3
b	3.5
c	3.6
d	3.8
e	3.8
f	3.9
g	4.8

* Recommended for funding

¹ The PRC took no action on this application.

Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations

Prevention Cycle 21.2

Application ID	Final Overall Evaluation Score
PP210020*	2.0
PP210007* ¹	3.3
ca	5.0
cb	5.3

¹ The Prevention Review Council (PRC) took no action on this application at its March 4, 2021, meeting and recommended it to the PIC at its June 17, 2021, meeting

* Recommended for funding

Final Overall Evaluation Scores and Rank Order Scores

Dee Margo
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dee@deemargo.com

Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Mr. Roberts and Mr. Margo,

On behalf of the Prevention Review Council (PRC), I am pleased to provide the PRC's recommendations for the cycle 21.1 Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations (EPS) awards.

The PRC met on March 4, 2021 to consider the applications recommended by the peer review panel following their January 19 meeting. The PRC recommends 5 projects totaling \$11,202,949.

The projects are numerically ranked in the order the PRC recommends the applications be funded. Recommended funding amounts and the overall evaluation score are stated for each grant application. The PRC made no changes to the goals, project objectives, or timelines of the applications.

Our recommendations meet the PRC's standards for grant award funding of projects that are evidence-based, deliver programs or services to underserved populations, and focus on primary, secondary or tertiary prevention. In making these recommendations the PRC continued to consider the available funding, the composition of the current portfolio, and the programmatic priorities in the RFA which include potential for impact and return on investment, geographic distribution, cancer type and type of program. All the recommended grants address one or more of the Prevention Program priorities.

Sincerely,
Stephen W. Wyatt, DMD, MPH
Chair, CPRIT Prevention Review Council

Attachment



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Cycle 21.1 Recommended Prevention Program Awards

App. ID	Mech	Application Title	PD	Organization	Score	Rank Order	Budget
PP210003	EPS	Taking Texas Tobacco Free among Substance Users within Community-based Healthcare Settings in Rural and Medically Underserved Areas Across Texas	Reitzel, Lorraine R	University of Houston	1.4	1	\$1,998,572
PP210004	EPS	BEST 3: The Breast Cancer Education Screening and Navigation Program in West and South Texas.	Shokar, Navkiran K	Texas Tech University Health Sciences Center at El Paso	2.3	2	\$2,500,000
PP210005	EPS	Southwest Coalition for Colorectal Cancer Screening (SuCCCeS) 2	Shokar, Navkiran K	Texas Tech University Health Sciences Center at El Paso	2.9	3	\$2,500,000
PP210016	EPS	Hep C - C.A.R.E (Colonias Advancing & Restoring Esperanza)	Villarreal, Roberto	University Health System	3.3	4	\$1,712,190
PP210017	EPS	Get F.I.T. to Stay Fit, Stepping up to Fight Colorectal Cancer in the Panhandle	Obokhare , Izi D	Texas Tech University Health Sciences Center	3.3	5	\$2,492,187

EPS: Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations

Dee Margo
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dee@deemargo.com

Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Mr. Roberts and Mr. Margo,

On behalf of the Prevention Review Council (PRC), I am pleased to provide the PRC's recommendations for the cycle 21.2 Evidence-Based Cancer Prevention Services (EBP), Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations (EPS), and Tobacco Control and Lung Cancer Screening (TCL) awards.

The PRC met on May 27, 2021 to review the applications submitted to CPRIT under the Dissemination of CPRIT-Funded Cancer Control Interventions (DI) mechanism. The PRC met again on June 17, 2021 to consider these applications and those recommended by the peer review panel following their April 26 meeting. The PRC recommends 9 projects totaling \$11,396,581.

The projects are numerically ranked in the order the PRC recommends the applications be funded. Recommended funding amounts and the overall evaluation score are stated for each grant application. The PRC made no changes to the goals, project objectives, or timelines of the applications.

Our recommendations meet the PRC's standards for grant award funding of projects that are evidence-based, deliver programs or services to underserved populations, and focus on primary, secondary, or tertiary prevention. In making these recommendations the PRC continued to consider the available funding, the composition of the current portfolio, and the programmatic priorities in the RFA which include potential for impact and return on investment, geographic distribution, cancer type and type of program. All the recommended grants address one or more of the Prevention Program priorities.

Sincerely,
Stephen W. Wyatt, DMD, MPH
Chair, CPRIT Prevention Review Council

Attachment



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Cycle 21.2 Recommended Prevention Program Awards

App. ID	Mech	Application Title	PD	Organization	Score	Rank Order	Budget
PP210045	DI	Dissemination of a Mailed Stool Testing Program for Colorectal Cancer Prevention in Underserved Communities in Texas	Pignone, Michael	The University of Texas at Austin	1.00	1	\$300,000
PP210049	EBP	Texas Southern University Breast Cancer Screening and Prevention Center	Ajewole, Veronica	Texas Southern University	1.80	2	\$1,000,000
PP210020	EPS	Vaccinating Medically Underserved Women Against HPV: Expansion of Clinical Services to Increase Access	Berenson, Abbey	The University of Texas Medical Branch at Galveston	2.00	3	\$1,999,988
PP210042	TCL	A Regional Expansion of Lung Cancer Screening and Patient Navigation (E-LSPAN)	Argenbright, Keith	The University of Texas Southwestern Medical Center	2.10	4	\$1,999,993
PP210026	DI	Taking Texas Tobacco Free: Dissemination to and Implementation Within Agencies Serving Texans Experiencing	Reitzel, Lorraine	University of Houston	2.70	5	\$299,978
PP210027	TCL	Increasing Accessibility to Smoking Cessation and Lung Cancer Screening Services for Low-Income/Uninsured Texans	McKnight, Jason	Texas A&M University System Health Science Center	3.10	6	\$999,947
PP210031	DI	Application of mHealth Technologies to Improve Latino Childhood Cancer Survivor Engagement and Use of Evidence for Personalized Follow-Up Care	Poplack, David	Baylor College of Medicine	3.30	7	\$299,982
PP210007	EPS	Strengthening Safety Net Health Systems to Improve Cervical and Colorectal Cancer Screening and Follow-up among the Medically Underserved	Montealegre, Jane R	Baylor College of Medicine	3.30	8	\$2,497,029
PP210044	TCL	Expansion of the Lung Cancer Screening and Tobacco Control (LCTC) Network to Rural and Medically Underserved Populations	Zoorob, Roger	Baylor College of Medicine	3.60	9	\$1,999,664

DI: Dissemination of CPRIT-Funded Cancer Control Interventions

EBP: Evidence-Based Cancer Prevention Services

EPS: Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations

TCL: Tobacco Control and Lung Cancer Screening



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Prevention
FY 2021—Cycle 2
*Dissemination of CPRIT-Funded Cancer
Control Interventions***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA P-21.2-DI

**Dissemination of CPRIT-Funded Cancer
Control Interventions**

**Please also refer to the Instructions for Applicants document,
which will be posted on November 16, 2020**

Application Receipt Opening Date: November 16, 2020

Application Receipt Closing Date: February 10, 2021

FY 2021

Fiscal Year Award Period

September 1, 2020-August 31, 2021

TABLE OF CONTENTS

1. ABOUT CPRIT	4
1.1 PREVENTION PROGRAM PRIORITIES.....	4
2. FUNDING OPPORTUNITY DESCRIPTION	5
2.1 SUMMARY.....	5
2.2 PROJECT OBJECTIVES.....	5
2.3 AWARD DESCRIPTION	6
2.4 PRIORITIES	8
2.5 SPECIFIC AREAS OF EMPHASIS.....	9
2.6 OUTCOME METRICS.....	10
2.7 ELIGIBILITY	10
2.8 RESUBMISSION POLICY	12
2.9 FUNDING INFORMATION.....	12
3. KEY DATES	13
4. APPLICATION SUBMISSION GUIDELINES	13
4.1 <i>INSTRUCTIONS FOR APPLICANTS</i> DOCUMENT	13
4.2 ONLINE APPLICATION RECEIPT SYSTEM	13
4.3 SUBMISSION DEADLINE EXTENSION	14
4.4 APPLICATION COMPONENTS	14
4.4.1 <i>Abstract and Significance (5,000 characters)</i>	14
4.4.2 <i>Goals and Objectives (700 characters each)</i>	14
4.4.3 <i>Project Timeline (2 pages)</i>	15
4.4.4 <i>Project Plan (12 pages; fewer pages permissible)</i>	15
4.4.5 <i>References</i>	16
4.4.6 <i>Resubmission Summary</i>	16
4.4.7 <i>CPRIT Grants Summary</i>	17
4.4.8 <i>Budget and Justification</i>	17
4.4.9 <i>Current and Pending Support and Sources of Funding</i>	17
4.4.10 <i>Biographical Sketches</i>	18
4.4.11 <i>Collaborating Organizations</i>	18
4.4.12 <i>Letters of Commitment (10 pages)</i>	18
5. APPLICATION REVIEW	18
5.1 REVIEW PROCESS OVERVIEW	18
5.2 REVIEW CRITERIA.....	20
5.2.1 <i>Primary Evaluation Criteria</i>	20
5.2.2 <i>Secondary Evaluation Criteria</i>	21
6. AWARD ADMINISTRATION	21
7. CONTACT INFORMATION	22
7.1 HELPDESK.....	22
7.2 PROGRAM QUESTIONS	22
8. RESOURCES	23
9. REFERENCES	23
APPENDIX: WRITING GOALS AND OBJECTIVES.....	24

RFA VERSION HISTORY

Rev 10/16/2020 RFA release

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and enhance the potential for a medical or scientific breakthrough in the prevention of or cures for cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

1.1. Prevention Program Priorities

Legislation from the 83rd Texas Legislature requires that CPRIT's Oversight Committee establish program priorities on an annual basis. The priorities are intended to provide transparency in how the Oversight Committee directs the orientation of the agency's funding portfolio. The Prevention Program's principles and priorities will also guide CPRIT staff and the Prevention Review Council on the development and issuance of program-specific Requests for Applications (RFAs) and the evaluation of applications submitted in response to those RFAs.

Established Principles

- Fund evidence-based interventions and their dissemination
- Support the prevention continuum of primary, secondary, and tertiary (includes survivorship) prevention interventions

Prevention Program Priorities

- Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
- Prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
- Prioritize underserved populations

2. FUNDING OPPORTUNITY DESCRIPTION

2.1. Summary

The ultimate goals of the CPRIT Prevention Program are to reduce overall cancer incidence and mortality and to improve the lives of individuals who have survived or are living with cancer. The ability to reduce cancer death rates depends in part on the application of currently available evidence-based technologies and strategies. CPRIT will foster the primary, secondary, and tertiary prevention of cancer in Texas by providing financial support for a wide variety of evidence-based risk reduction, early detection, and survivorship interventions.

The **Dissemination of CPRIT-Funded Cancer Control Interventions (DI)** award mechanism seeks to fund programs that facilitate the continuation of CPRIT projects through their dissemination and implementation across Texas. **This award mechanism is open only to previously or currently funded CPRIT projects.** Applicants may request any amount of funding up to a maximum of \$300,000 in total funding over a maximum of 24 months.

The proposed program should describe and package strategies or approaches to introduce, modify, and implement previously funded CPRIT evidence-based cancer prevention and control interventions for dissemination to other settings and populations in the state. To be eligible, the applicant should be in a position to develop 1 or more “products” based on the results of the CPRIT-funded intervention. Of particular interest is the dissemination of “products” that address the unique challenges to program implementation in resource-limited settings, particularly in nonmetropolitan and medically underserved areas of the state.

The proposed projects should also identify and assist others in preparing to implement the intervention and/or preparing to apply for grant funding.

2.2. Project Objectives

CPRIT seeks to fund projects that will provide 1 or more of the following:

- Dissemination of tools or models to public health professionals, health care practitioners, health planners, policymakers, and advocacy groups
- Dissemination of materials or information about an intervention to broader settings/systems
- Dissemination or scaling up of best practices (infrastructure and tools) and evidence-based interventions for implementation (ie, implementation guides)

2.3. Award Description

The **Dissemination of CPRIT-Funded Cancer Control Interventions** RFA solicits applications from currently or previously funded CPRIT projects that have demonstrated exemplary success and have materials, policies, and other resources that have been successfully implemented and evaluated and could be scaled up and/or applied to other systems and settings. The ultimate goal is to continue and expand successful models for the delivery of prevention interventions all across the state through adaptation or replication.

The Center for Research in Implementation Science and Prevention website

(<https://dissemination-implementation.org/content/measures.aspx>) defines active and passive dissemination strategies as follows: “Dissemination strategies describe mechanisms and approaches that are used to communicate and spread information about interventions to targeted users. Dissemination strategies are concerned with the packaging of the information about the intervention and the communication channels that are used to reach potential adopters and target audience. Passive dissemination strategies include mass mailings, publication of information including practice guidelines, and untargeted presentations to heterogeneous groups. Active dissemination strategies include hands on technical assistance, replication guides, point-of-decision prompts for use, and mass media campaigns. It is consistently stated in the literature that dissemination strategies are necessary but not sufficient to ensure wide-spread use of an intervention.”

Adopters will need to employ implementation strategies to replicate or adapt projects to their settings or populations. Implementation strategies are described as the systematic processes, activities, and resources that are used to integrate interventions into usual settings. Core implementation components or implementation drivers can be staff selection, preservice and in-service training, ongoing consultation and coaching, staff and program evaluation, facilitative administrative support, and systems interventions. (See <https://dissemination-implementation.org/content/measures.aspx>)

This award will support both passive and active dissemination strategies but must include 2 or more active dissemination strategies. This award will also support implementation strategies in the form of technical assistance, coaching, and consultation within the time period of the grant. CPRIT recognizes that there are limits to the amount of technical assistance or coaching that can be

accomplished within the grant period; however, priority will be given to those projects that identify and assist potential adopters in preparing to implement the intervention and/or preparing to apply for grant funding. Examples of active dissemination strategies and implementation strategies follow.

Tools/models

- Toolkits with materials, sample policies, and procedures for implementation of CPRIT-funded programs
- Interactive websites that provide future adopters with key information on how to implement CPRIT-related interventions
- Approaches for dissemination of findings via nontraditional channels (eg, social media)
- User-friendly summaries—short issue or policy briefs that tell a story for decision makers based on CPRIT findings
- Brief, user-friendly case studies from program developers and recipients to illustrate key issues

Implementation guides

- Targeted communication materials emphasizing how to apply them to different populations, systems, and settings
- Step-by-step implementation guides on how to translate an evidence-based intervention/program to broader settings, including guidelines for retaining core elements of the interventions or programs while offering suggested adaptations for the elements that would enhance the adoption and sustainability of the programs in different populations, settings, or circumstances (See Partnership for Prevention examples: <https://innovations.ahrq.gov/qualitytools/community-health-promotion-handbook-action-guides-improve-community-health>)

Training/Technical assistance

- Provision of training and technical assistance to guide adopters in developing their plans to adapt, refine, and implement their projects

In addition, proposed dissemination materials should include a discussion of barriers to dissemination; a description of personnel and necessary resources to overcome barriers to implementation of the project; a description of expected outcomes, evaluation strategies with a sample evaluation plan, and tools (if applicable); and suggestions or plan for project sustainability.

By the end of Year 1, the project timeline should include, but is not limited to, the following:

- A step-by-step implementation guide that includes how to translate an evidence-based intervention/program to broader settings, including guidelines for retaining core elements of the interventions or programs while offering suggested adaptations for the elements that would enhance the adoption and sustainability of the programs in different populations, settings, or circumstances.

Under this RFA, CPRIT **will not** consider the following:

- Applications to disseminate projects not previously or currently funded by CPRIT
- Projects involving prevention/intervention research

Applicants interested in prevention research should review CPRIT's Academic Research RFAs (available at <http://www.cprit.texas.gov>).

2.4. Priorities

Types of Cancer:

Applications addressing any cancer type(s) that are responsive to this RFA will be considered for funding. See [section 2.5](#) for specific areas of emphasis. Priority will be given to applications to disseminate and replicate projects that when implemented can address the following program priorities set by the CPRIT Oversight Committee:

- Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
- Prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
- Prioritize underserved populations

Priority Populations

The age of the priority population described in the application must comply with established and current national guidelines (eg, US Preventive Services Task Force [USPSTF], American Cancer Society, American College of Physicians).

Priority populations are subgroups that are underserved and disproportionately affected by cancer. Insured populations are not the priority of CPRIT's programs; however, some health promotion and education activities may include insured individuals as well as those who are underinsured or uninsured.

CPRIT-funded efforts must address 1 or more of these priority populations:

- Underinsured and uninsured individuals
- Geographically or culturally isolated populations
- Medically unserved or underserved populations
- Populations with low health literacy skills
- Racial, ethnic, and cultural minority populations, or
- Other populations with low screening rates, high incidence rates, and high mortality rates, focusing on individuals never before screened or who are significantly out of compliance with nationally recommended screening guidelines

2.5. Specific Areas of Emphasis

Applications that propose dissemination of any previously funded CPRIT project delivering an evidence-based preventive service or education and outreach program that includes navigation to services that is responsive to this RFA will be considered. However, CPRIT has identified the following area of emphasis for this cycle of awards:

- Dissemination of the programs that address the unique challenges to program implementation in resource-limited settings, in particular, nonmetropolitan and medically underserved areas of the state.

2.6. Outcome Metrics

The applicant is required to describe how the goals and objectives for each year of the project as well as the final outcomes will be measured. The applicant should provide a clear and appropriate plan for data collection and interpretation of results to report against goals and objectives.

Reporting Requirements

Funded projects are required to report quantitative output and outcome metrics (as appropriate for each project) through the submission of quarterly progress reports, annual reports, and a final report.

- Quarterly progress report sections include, but are not limited to, the following:
 - Narrative on project progress, including the number and description of all active and passive dissemination and implementation activities undertaken
- Annual and final progress report sections include, but are not limited to, the following:
 - Key accomplishments, including discussion of barriers to dissemination
 - Progress toward goals and objectives
 - Materials produced, presentations, publications, etc
 - Economic impact of the project

2.7. Eligibility

- The applicant must be a Texas-based entity, such as a community-based organization, health institution, government organization, public or private company, college or university, or academic health institution.
- The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted.
- The designated Program Director (PD) will be responsible for the overall performance of the funded project. The PD must have relevant education and management experience and must reside in Texas during the project performance time.
- The applicant may submit more than 1 application, but each application must be for distinctly different projects without overlap in the projects. Applicants who do not meet this criterion will have all applications administratively withdrawn without peer review.

- Collaborations are permitted and encouraged, and collaborators may or may not reside in Texas. However, collaborators who do not reside in Texas are not eligible to receive CPRIT funds. Subcontracting and collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.
- An applicant organization is eligible to receive a grant award only if the applicant certifies that the applicant organization, including the PD, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant PD, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant organization, the PD, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way (whether slated to receive salary or compensation under the grant award or not) are currently ineligible to receive federal grant funds because of scientific misconduct or fraud or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. CPRIT grants are funded on a reimbursement-only basis. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 6](#). All statutory provisions and relevant administrative rules can be found [on the CPRIT website](#).

2.8. Resubmission Policy

- **One resubmission** is permitted. An application is considered a resubmission if the proposed project is the same project as presented in the original submission. A change in the identity of the PD for a project or a change of title for a project that was previously submitted to CPRIT does not constitute a new application; the application would be considered a resubmission.
- Applicants who choose to resubmit should carefully consider the reasons for lack of prior success. Applications that received overall numerical scores of 4 or higher are likely to need considerable attention. All resubmitted applications should be carefully reconstructed; a simple revision of the prior application with editorial or technical changes is not sufficient, and applicants are advised not to direct reviewers to such modest changes. A 1-page summary of the approach to the resubmission should be included. Resubmitted applications may be assigned to reviewers who did not review the original submission. Reviewers of resubmissions are asked to assess whether the resubmission adequately addresses critiques from the previous review. **Applicants should note that addressing previous critiques is advisable; however, it does not guarantee the success of the resubmission.** All resubmitted applications must conform to the structure and guidelines outlined in this RFA.

2.9. Funding Information

Applicants may request any amount of funding up to a maximum of \$300,000 in total funding over a maximum of 24 months. Grant funds may be used to pay for salary and benefits, project supplies, equipment, costs for outreach and education, and travel of project personnel to project site(s). Requests for funds to support construction, renovation, or any other infrastructure needs or requests to support lobbying will not be approved under this mechanism. Grantees may request funds for travel for 2 project staff to attend CPRIT's conference.

The budget should be well justified. In addition, CPRIT seeks to fill gaps in funding rather than replace existing funding, supplant funds that would normally be expended by the applicant's organization, or make up for funding reductions from other sources.

State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the **total** award amount.

3. KEY DATES

RFA release	October 16, 2020
Online application opens	November 16, 2020, 7 AM central time
Application due	February 10, 2021, 4 PM central time
Application review	March-July 2021
Award notification	August 2021
Anticipated start date	August 31, 2021

4. APPLICATION SUBMISSION GUIDELINES

4.1. *Instructions for Applicants* document

It is imperative that applicants read the accompanying instructions document for this RFA that will be available November 16, 2020 (<https://CPRITGrants.org>). Requirements may have changed from previous versions.

4.2. Online Application Receipt System

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The PD must create a user account in the system to start and submit an application. The Co-PD, if applicable, must also create a user account to participate in the application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (an individual who will help manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on November 16, 2020, and must be submitted by 4 PM central time on February 10, 2021. Detailed instructions for submitting an application are in the *Instructions for Applicants* document, posted on CARS.

Submission of an application is considered an acceptance of the terms and conditions of the RFA.

4.3. Submission Deadline Extension

The submission deadline may be extended for 1 or more grant applications upon a showing of good cause. All requests for extension of the submission deadline must be submitted via email to the [CPRIT Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records.

4.4. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Refer to the *Instructions for Applicants* document for details.

Submissions that are missing 1 or more components or do not meet the eligibility requirements may be administratively withdrawn without review.

4.4.1. Abstract and Significance (5,000 characters)

Clearly explain the problem(s) to be addressed, the approach(es) to the solution, and how the application is responsive to this RFA. In the event that the project is funded, the abstract will be made public; therefore, no proprietary information should be included in this statement. Initial compliance decisions are based in part upon review of this statement.

The abstract format is as follows (use headings as outlined below):

- **Need:** Include a description of need for the proposed project.
- **Overall Project Strategy:** Describe the project and how it will address the identified need.
- **Specific Goals:** State specifically the overall goals of the proposed project.
- **Significance and Impact:** Explain how the proposed project, if successful, will have a unique and major impact on cancer prevention and control and for the State of Texas.

4.4.2. Goals and Objectives (700 characters each)

List only major **outcome** goals and **measurable** objectives for each year of the project. **Do not include process objectives**; these should be described in the project plan only. Include the proposed metric within both the stated Objective **and** the Measure sections (eg, Measure: Number of lesson plans, handout and other materials posted online or delivered in-person). Applications

may be returned for revision if the proposed metric is not included within the Measure section. Refer to the *Instructions for Applicants* document for details.

The maximum number is 3 outcome goals with 3 objectives each. Projects will be evaluated annually on progress toward **outcome** goals and objectives. See [Appendix](#) for instructions on writing **outcome** goals and objectives.

A baseline and method(s) of measurement are required for each objective. Provide both raw numbers and percent changes for the baseline and target. If a baseline has not yet been defined, applicants are required to explain plans to establish baseline and describe method(s) of measurement.

4.4.3. Project Timeline (2 pages)

Provide a project timeline for project activities that includes deliverables and dates. Use Years 1 and 2 and Months 1, 2, 3, etc, as applicable (eg, Year 1, Months 3-5) instead of specific months or years. Month 1 is the first full month of the grant award.

4.4.4. Project Plan (12 pages; fewer pages permissible)

The required project plan format follows. Applicants must use the headings outlined below.

Background: Describe the project to be disseminated and how and why it lends itself to replication and scalability. Describe the effectiveness of the intervention that is being proposed for replication/dissemination and the expected short- and long-term impacts of the project.

Goals and Objectives: Process objectives should be included in the project plan. Outcome goals and objectives will be entered in separate fields in CARS. However, if desired, outcome goals and objectives may be fully repeated or briefly summarized here. See [Appendix](#) for instructions on writing goals and objectives.

Components of the Project: Clearly describe the data demonstrating success of the CPRIT-funded project that justifies dissemination. Describe components of the proposed dissemination project and the dissemination approach, strategy (eg, passive and active dissemination and implementation strategies), and the products being designed or packaged. The dissemination approach and strategy should also consider the message, source, audience, and channel (Brownson, R.C., et al. [*J Pub Health Manag Pract.* 24\(2\):102-111](#), March/April 2018). Clearly describe the established theory

and practice that support the proposed approach or strategy. Describe parameters of the CPRIT-funded project that may affect its dissemination and replication, such as target audience for which it was designed, specialized resources that may be needed, or geographic considerations.

Evaluation Strategy: Describe the evaluation plan and methodology to assess dissemination effectiveness (eg, include short-term and intermediate impact of dissemination activities, knowledge and behavior change among the audience likely to adopt the project). Describe a clear and appropriate plan for data collection and interpretation of results to report against goals and objectives. If needed, applicants may want to consider seeking expertise at Texas-based academic cancer centers, schools/programs of public health, prevention research centers, or the like. Applicants should budget accordingly for the evaluation activity and should ensure, among other things, that the evaluation plan is linked to the proposed goals and objectives.

Organizational Qualifications and Capabilities: Describe the organization and its qualifications and capabilities to deliver the proposed project. Describe the role and qualifications of key collaborating organizations/partners (if applicable) and how they add value to the project and demonstrate commitment to working together to implement the project. Describe the key personnel who are in place or will be recruited to implement, evaluate, and complete the project.

4.4.5. References

Provide a concise and relevant list of references cited for the application. The successful applicant will provide referenced evidence and literature support for the proposed project.

4.4.6. Resubmission Summary

Use the template provided on the CARS (<https://CPRITGrants.org>). Describe the approach to the resubmission and how reviewers' comments were addressed. Clearly indicate to reviewers how the application has been improved in response to the critiques. Refer the reviewers to specific sections of other documents in the application where further detail on the points in question may be found. When a resubmission is evaluated, responsiveness to previous critiques is assessed.

The overall summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission; the applicant is not responsible for providing this document.

4.4.7. CPRIT Grants Summary

Use the template provided on the CARS (<https://CPRITGrants.org>). Provide a listing of **all** projects funded by the CPRIT Prevention program for the PD and the Co-PD, regardless of their connection to this application.

4.4.8. Budget and Justification

Provide a brief outline and detailed justification of the budget for the entire proposed period of support, including salaries and benefits, travel, equipment, supplies, contractual expenses, and other expenses. CPRIT funds will be distributed on a reimbursement basis. Applications requesting more than the maximum allowed cost (total costs) as specified in [section 2.9](#) will be administratively withdrawn.

- **Personnel:** The individual salary cap for CPRIT awards is \$200,000 per year. Describe the source of funding for all project personnel where CPRIT funds are not requested.
- **Travel:** PDs and related project staff are expected to attend CPRIT's conference. CPRIT funds may be used to send up to 2 people to the conference.
- **Equipment:** Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application. Justification must be provided for why funding for this equipment cannot be found elsewhere; CPRIT funding should not supplant existing funds. Cost sharing of equipment purchases is strongly encouraged.
- **Indirect/Shared Costs:** Texas law limits the amount of grant funds that may be spent on indirect/shared expenses to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in [CPRIT's Administrative Rules](#).

4.4.9. Current and Pending Support and Sources of Funding

Use the template provided on the CARS (<https://CPRITGrants.org>). Describe the funding source and duration of **all** current and pending support for the proposed project, including a capitalization table that reflects private investors, if any. Information for the initial funded project need not be included.

4.4.10. Biographical Sketches

The designated PD will be responsible for the overall performance of the funded project and must have relevant education and management experience. The PD must provide a biographical sketch that describes his or her education and training, professional experience, awards and honors, and publications and/or involvement in programs relevant to cancer prevention and/or service delivery.

Up to 3 additional biographical sketches for key personnel may be provided. The evaluation professional biographical sketch is optional and will count as 1 of the 3 additional biosketches.

Each biographical sketch must not exceed 2 pages and must use the “Prevention Programs: Biographical Sketch” template provided on the CARS (<https://CPRITGrants.org>) or the NIH Biographical Sketch format. Only biographical sketches will be accepted; do not submit resumes and/or CVs. If a position is not yet filled, please upload a job description.

4.4.11. Collaborating Organizations

List all key participating organizations that will partner with the applicant organization to provide 1 or more components essential to the success of the program (eg, evaluation). Please be sure to also include anyone listed as key personnel and/or listed under the Current & Pending Support section.

4.4.12. Letters of Commitment (10 pages)

Applicants may provide optional letters of commitment and/or memoranda of understanding from community organizations, key faculty, or any other component essential to the success of the program.

5. APPLICATION REVIEW

5.1. Review Process Overview

All eligible applications will be reviewed and scored by the [CPRIT Prevention Review Council](#) based on the criteria in [section 5.2](#) below. Review Council members are listed on CPRIT’s website.

The Prevention Review Council will review applications and provide an overall evaluation score reflecting their overall impression of the application and responsiveness to the RFA priorities.

Additional considerations may include, but are not limited to, geographic distribution, cancer type, population served, and type of program or service.

Applications approved by the Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 through 703.8](#).

Each stage of application review is conducted confidentially, and all CPRIT Prevention Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Peer Review Panel members and Review Council members are non-Texas residents.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules, [chapter 703, section 703.9](#).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, a Review Panel member, or a Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention and Communications Officer, the Chief Product Development Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period when preapplications or letters of interest are accepted. Intentional, serious, or frequent

violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

5.2. Review Criteria

The Prevention Review Council will review the applications based on the criteria below and will provide an overall evaluation score reflecting their overall impression of the application and responsiveness to the RFA priorities. Additional considerations may include, but are not limited to, geographic distribution, cancer type, population served, and type of program or service.

5.2.1. Primary Evaluation Criteria

Impact

- Does the applicant describe the project to be disseminated and how and why it lends itself to replication and scalability?
- Does the applicant outline the target metrics established for the CPRIT-funded project and describe the effectiveness of the intervention that is being proposed for replication/dissemination?
- Do the data (results) demonstrate success of the CPRIT-funded project and justify dissemination?
- Has the applicant convincingly demonstrated the short- and long-term impacts of the project?

Project Strategy and Feasibility

- Does the proposed project address the requirements of the RFA? Does it include a step-by-step implementation guide in Year 1?
- Are the overall project dissemination approach, strategy, and design clearly described and supported by established theory and practice and likely to result in successful dissemination and adoption? Are 2 or more active dissemination strategies described?
- Are the proposed objectives and activities feasible within the duration of the award?
- If the CPRIT-funded project is to be adapted for different populations and settings, are specific adaptations and evaluation strategies clearly outlined as a part of the project?
- Does the project identify and assist potential adopters in preparing to implement the intervention and/or preparing to apply for grant funding?

Evaluation

- Are specific goals and measurable objectives for each year of the project provided?
- Are the proposed measures appropriate for the project?
- Does the application provide a clear and appropriate plan for data collection and interpretation of results to report against goals and objectives?

Organizational Qualifications and Capabilities

- Do the organization and its collaborators/partners (if applicable) demonstrate the ability to deliver the proposed project?
- Are the appropriate personnel in place or have they been recruited to develop, evaluate, and complete the project?

5.2.2. Secondary Evaluation Criteria

Budget

- Is the budget appropriate and reasonable for the scope of the proposed work?
- Are all costs well justified?
- Is the project a good investment of Texas public funds?

6. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's [Administrative Rules](#). Applicants are advised to review CPRIT's administrative rules related to contractual requirements associated with CPRIT grant

awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires the PD of the award to submit quarterly, annual, and final progress reports. These reports summarize the progress made toward project goals and address plans for the upcoming year and performance during the previous year(s). In addition, quarterly fiscal reporting and reporting on selected metrics will be required per the instructions to award recipients. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract.

7. CONTACT INFORMATION

7.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding the scope and focus of applications. Before contacting the helpdesk, please refer to the *Instructions for Applicants* document (posted on November 16, 2020), which provides a step-by-step guide to using CARS.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

7.2. Program Questions

Questions regarding the CPRIT Prevention program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Prevention Program Office.

Tel: 512-305-8417

Email: Help@CPRITGrants.org

Website: www.cprit.texas.gov

8. RESOURCES

- The Texas Cancer Registry. <http://www.dshs.texas.gov/tcr> or contact the Texas Cancer Registry at the Department of State Health Services.
- The Community Guide. <http://www.thecommunityguide.org/>
- Cancer Control P.L.A.N.E.T. <http://cancercontrolplanet.cancer.gov>
- Guide to Clinical Preventive Services: Recommendations of the U.S. Preventive Services Task Force. <http://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/guide/>
- Brownson, R.C., Colditz G.A., and Proctor, E.K. (Editors). *Dissemination and Implementation Research in Health: Translating Science to Practice*. Oxford University Press, March 2012
- Centers for Disease Control and Prevention: The Program Sustainability Assessment Tool: A New Instrument for Public Health Programs
http://www.cdc.gov/pcd/issues/2014/13_0184.htm
- Centers for Disease Control and Prevention: Using the Program Sustainability Tool to Assess and Plan for Sustainability. http://www.cdc.gov/pcd/issues/2014/13_0185.htm
- Cancer Prevention and Control Research Network: Putting Public Health Evidence in Action Training Workshop. <http://cpcrn.org/pub/evidence-in-action/>
- Getting the Word Out: New Approaches for Disseminating Public Health Science; Brownson, R.C., et al, *Journal of Public Health Management & Practice*. 24(2):102-111, March/April 2018.
https://journals.lww.com/jphmp/Fulltext/2018/03000/Getting_the_Word_Out__New_Approaches_for.4.aspx

9. REFERENCES

1. <http://www.cdc.gov/hpv/parents/questions-answers.html>
2. Texas Cancer Registry, Cancer Epidemiology and Surveillance Branch, Texas Department of State Health Services. <https://www.cancer-rates.info/tx/>

APPENDIX: WRITING GOALS AND OBJECTIVES

List only major **outcome goals** and **measurable objectives** for each year of the project. **Do not include process objectives**; these should be described in the project plan only. Include the proposed metric within **both** the stated Objective and the Measure sections (eg, Measure: Number of lesson plans, handout and other materials posted online or delivered in-person). The maximum number is 3 goals with 3 objectives each. Projects will be evaluated annually on progress toward **outcome** goals and objectives.

The following has been adapted with permission from Appalachia Community Cancer Network, NIH Grant U54 CA 153604:

Develop well-defined goals and objectives

Goals provide a roadmap or plan for where a group wants to go. Goals can be long term (over several years) or short term (over several months). Goals should be based on needs of the community and evidence-based data.

Goals should be

- Believable – situations or conditions that the group believes can be achieved
- Attainable – possible within a designated time
- Tangible – capable of being understood or realized
- On a timetable – with a completion date
- Win-Win – beneficial to individual members and the coalition

Objectives are measurable steps toward achieving the goal. They are clear statements of specific activities required to achieve the goal. The best objectives have several characteristics in common—S.M.A.R.T. + C:

- Specific – they tell how much (number or percent), who (participants), what (action or activity), and by when (date)
 - Example: 115 uninsured individuals age 50 and older will complete colorectal cancer screening by March 31, 2019.
- Measurable – specific measures that can be collected, detected, or obtained to determine successful attainment of the objective
 - Example: How many screened at an event? How many completed pre/post assessment?

- Achievable – not only are the objectives themselves possible, it is likely that your organization will be able to accomplish them
- Relevant to the mission – your organization has a clear understanding of how these objectives fit in with the overall vision and mission of the group
- Timed – developing a timeline is important for when your task will be achieved
- Challenging – objectives should stretch the group to aim on significant improvements that are important to members of the community

Evaluate and refine your objectives

Review your developed objectives and determine the type and level of each using the following information:

There are 2 types of objectives:

- Outcome objectives – measure the “what” of a program; should be in the Goals and Objectives form (see [section 4.4.2](#))
- Process objectives – measure the “how” of a program; should be in the project plan (see [section 4.4.4](#))

There are 3 levels of objectives:

- Community-level – objectives measure the planned community change
- Program impact – objectives measure the impact the program will have on a specific group of people
- Individual – objectives measure participant changes resulting from a specific program, using these factors:
 - Knowledge – understanding (know screening guidelines; recall the number to call for screening)
 - Attitudes – feelings about something (will consider secondhand smoke dangerous; believe eating 5 or more fruits and vegetables is important)
 - Skills – the ability to do something (complete fecal occult blood test)
 - Intentions – regarding plan for future behavior (will agree to talk to the doctor, will plan to schedule a Pap test)
 - Behaviors (past or current) – to act in a particular way (will exercise 30+ minutes a day, will have a mammogram)

Well-defined goals and objectives can be used to track, measure, and report progress toward achievement.

Summary Table

	Outcome – Use in Goals and Objectives	Process – Use in Project Plan only
Community-level	<p>WHAT will change in a community</p> <p><i>Example: As a result of CPRIT funding, FIT (fecal immunochemical tests) will be available to 1,500 uninsured individuals age 50 and over through 10 participating local clinics and doctors.</i></p>	<p>HOW the community change will come about</p> <p><i>Example: Contracts will be signed with participating local providers to enable uninsured individuals over age 50 to have access to free colorectal cancer screening in their communities.</i></p>
Program Impact	<p>WHAT will change in the target group as a result of a particular program</p> <p><i>Example: As a result of this project, 200 uninsured women between 40 and 49 will receive free breast and cervical cancer screening.</i></p>	<p>HOW the program will be implemented to affect change in a group/population</p> <p><i>Example: 2,000 female clients, between 40 and 49, will receive a letter inviting them to participate in breast and cervical cancer screening.</i></p>
Individual	<p>WHAT an individual will learn as a result of a particular program, or WHAT change an individual will make as a result of a particular program</p> <p><i>Example: As a result of one-to-one education of 500 individuals, at least 20% of participants will participate in a smoking cessation program to quit smoking.</i></p>	<p>HOW the program will be implemented to affect change in an individual's knowledge or actions</p> <p><i>Example: As a result of one-to-one counseling, all participants will identify at least 1 smoking cessation service and 1 smoking cessation aid.</i></p>

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)

21.2 Prevention Review Panel - 1 (21.2 PRV-DI2)

Observation Report

Report No. 2021-05-27 21.2_PRV-DI2
Program Name: Prevention
Panel Name: 21.2 Prevention Review Panel - 1 (21.2_PRV-DI2)
Panel Date: May 27, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Prevention Review Panel - 1 (21.2_PRV-DI2) meeting. The meeting was chaired by Stephen Wyatt and conducted via teleconference on May 27, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Four (4) applications were discussed
- Panelists: One (1) panel chair, and two (2) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: One (1)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the closing text.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

21.2 Prevention Review Council (21.2_PRC-M2)

Observation Report

Report No. 2021-06-17 21.2_PRC-M2
Program Name: Prevention
Panel Name: 21.2 Prevention Review Council (21.2_PRC-M2)
Panel Date: June 17, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Prevention Review Council (21.2_PRC-M2) meeting. The meeting was chaired by Stephen Wyatt and conducted via teleconference on June 17, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Nine (9) applications were discussed
- Panelists: One (1) panel chair, and two (2) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: One (1)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was zero (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line extending to the right.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Prevention Cycle 21.2

Awards Announced at the August 18, 2021, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Prevention Cycle 21.2 include *Evidence-Based Cancer Prevention Services*; *Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations*; *Tobacco Control and Lung Cancer Screening*; and *Dissemination of CPRIT-Funded Cancer Control Interventions*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant/Principal Investigator	Principal Investigator Institution	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
No conflicts reported.			
Applications not considered by the PIC or Oversight Committee:			
PP210023	Gail Tomlinson	The University of Texas Health Science Center at San Antonio	R. Riter

T.A.C. Section 702.19 Waiver



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS
FROM: WAYNE R. ROBERTS, CHIEF EXECUTIVE OFFICER
SUBJECT: T.A.C. § 702.19 STANDING WAIVER FOR FY 2021
DATE: AUGUST 28, 2020

Summary

This is to notify the Oversight Committee that pursuant to the authority provided to the Chief Executive Officer in T.A.C. § 702.19(e), I grant CPRIT's Chief Prevention Officer Ramona Magid a waiver from the general prohibition against communicating with grant applicants. The waiver is applicable for FY 2021. Unlike the two communication waivers I granted Ms. Magid for each FY 2020 review cycle, this standing FY 2021 waiver will be effective for both review cycles planned for FY 2021. No Oversight Committee action related to this waiver is necessary.

Background and Discussion

The Chief Prevention Officer is a statutorily mandated member of the Program Integration Committee (PIC). Texas Administrative Code § 702.19 prohibits substantive communication between the grant applicant and a member of the peer review panel, the PIC, or the Oversight Committee while the application is pending a final decision. The restriction on communication prevents even the appearance of unequal treatment during the grant review process.

Traditionally, a chief program officer leads each CPRIT program with the assistance of a program manager. The program manager fields inquiries from and provides technical help to applicants completing their CPRIT grant applications. I promoted Ms. Magid to the Chief Prevention Officer position upon Dr. Becky Garcia's retirement in June 2019. However, the prevention program manager position has remained vacant since Ms. Magid's promotion. Until CPRIT fills the program manager position, she is the sole point of contact for the prevention program. The communication waiver is necessary so that Ms. Magid can assist grant applicants who have questions during the application process.

I previously granted Ms. Magid separate waivers for the two review cycles of FY 2020. It is unlikely that CPRIT will fill the prevention program manager position in FY 2021. Accordingly, I am granting a standing waiver for Ms. Magid for FY 2021 as long as she remains the sole point of contact for the prevention program. Approving this standing waiver does not favor any grant applicant over another. Ms. Magid will provide technical assistance only and will not comment on the substance of a grant application. CPRIT will include this waiver in the grant record for the FY 2021 prevention grant applications.

De-Identified Overall Evaluation Scores

Dissemination of CPRIT-Funded Cancer Control Interventions

Prevention Cycle 21.2

Application ID	Final Overall Evaluation Score
PP210045*	1.0
PP210026*	2.7
PP200031*	3.3
aa	4.3

* Recommended for funding

Final Overall Evaluation Scores and Rank Order Scores

Dee Margo
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dee@deemargo.com

Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Mr. Roberts and Mr. Margo,

On behalf of the Prevention Review Council (PRC), I am pleased to provide the PRC's recommendations for the cycle 21.2 Evidence-Based Cancer Prevention Services (EBP), Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations (EPS), and Tobacco Control and Lung Cancer Screening (TCL) awards.

The PRC met on May 27, 2021 to review the applications submitted to CPRIT under the Dissemination of CPRIT-Funded Cancer Control Interventions (DI) mechanism. The PRC met again on June 17, 2021 to consider these applications and those recommended by the peer review panel following their April 26 meeting. The PRC recommends 9 projects totaling \$11,396,581.

The projects are numerically ranked in the order the PRC recommends the applications be funded. Recommended funding amounts and the overall evaluation score are stated for each grant application. The PRC made no changes to the goals, project objectives, or timelines of the applications.

Our recommendations meet the PRC's standards for grant award funding of projects that are evidence-based, deliver programs or services to underserved populations, and focus on primary, secondary, or tertiary prevention. In making these recommendations the PRC continued to consider the available funding, the composition of the current portfolio, and the programmatic priorities in the RFA which include potential for impact and return on investment, geographic distribution, cancer type and type of program. All the recommended grants address one or more of the Prevention Program priorities.

Sincerely,
Stephen W. Wyatt, DMD, MPH
Chair, CPRIT Prevention Review Council

Attachment



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Cycle 21.2 Recommended Prevention Program Awards

App. ID	Mech	Application Title	PD	Organization	Score	Rank Order	Budget
PP210045	DI	Dissemination of a Mailed Stool Testing Program for Colorectal Cancer Prevention in Underserved Communities in Texas	Pignone, Michael	The University of Texas at Austin	1.00	1	\$300,000
PP210049	EBP	Texas Southern University Breast Cancer Screening and Prevention Center	Ajewole, Veronica	Texas Southern University	1.80	2	\$1,000,000
PP210020	EPS	Vaccinating Medically Underserved Women Against HPV: Expansion of Clinical Services to Increase Access	Berenson, Abbey	The University of Texas Medical Branch at Galveston	2.00	3	\$1,999,988
PP210042	TCL	A Regional Expansion of Lung Cancer Screening and Patient Navigation (E-LSPAN)	Argenbright, Keith	The University of Texas Southwestern Medical Center	2.10	4	\$1,999,993
PP210026	DI	Taking Texas Tobacco Free: Dissemination to and Implementation Within Agencies Serving Texans Experiencing	Reitzel, Lorraine	University of Houston	2.70	5	\$299,978
PP210027	TCL	Increasing Accessibility to Smoking Cessation and Lung Cancer Screening Services for Low-Income/Uninsured Texans	McKnight, Jason	Texas A&M University System Health Science Center	3.10	6	\$999,947
PP210031	DI	Application of mHealth Technologies to Improve Latino Childhood Cancer Survivor Engagement and Use of Evidence for Personalized Follow-Up Care	Poplack, David	Baylor College of Medicine	3.30	7	\$299,982
PP210007	EPS	Strengthening Safety Net Health Systems to Improve Cervical and Colorectal Cancer Screening and Follow-up among the Medically Underserved	Montealegre, Jane R	Baylor College of Medicine	3.30	8	\$2,497,029
PP210044	TCL	Expansion of the Lung Cancer Screening and Tobacco Control (LCTC) Network to Rural and Medically Underserved Populations	Zoorob, Roger	Baylor College of Medicine	3.60	9	\$1,999,664

DI: Dissemination of CPRIT-Funded Cancer Control Interventions

EBP: Evidence-Based Cancer Prevention Services

EPS: Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations

TCL: Tobacco Control and Lung Cancer Screening



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Prevention
FY 2021—Cycle 2
*Evidence-Based Cancer Prevention
Services***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA P-21.2-EBP

Evidence-Based Cancer Prevention Services

**Please also refer to the Instructions for Applicants document,
which will be posted on November 16, 2020**

Application Receipt Opening Date: November 16, 2020

Application Receipt Closing Date: February 10, 2021

FY 2021

Fiscal Year Award Period

September 1, 2020–August 31, 2021

TABLE OF CONTENTS

1. ABOUT CPRIT.....	5
1.1 PREVENTION PROGRAM PRIORITIES.....	5
2. FUNDING OPPORTUNITY DESCRIPTION	6
2.1 SUMMARY	6
2.2 PROJECT OBJECTIVES	7
2.3 AWARD DESCRIPTION.....	8
2.4 PRIORITIES.....	11
2.5 SPECIFIC AREAS OF EMPHASIS.....	12
2.6 OUTCOME METRICS.....	13
2.7 ELIGIBILITY	14
2.8 RESUBMISSION POLICY	16
2.9 EXPANSION POLICY (IF APPLICABLE).....	16
2.10 FUNDING INFORMATION	17
3. KEY DATES	18
4. APPLICATION SUBMISSION GUIDELINES	18
4.1 <i>INSTRUCTIONS FOR APPLICANTS</i> DOCUMENT	18
4.2 ONLINE APPLICATION RECEIPT SYSTEM.....	19
4.3 SUBMISSION DEADLINE EXTENSION	19
4.4 APPLICATION COMPONENTS	19
4.4.1 <i>Abstract and Significance (5,000 characters)</i>	19
4.4.2 <i>Goals and Objectives (700 characters each)</i>	20
4.4.3 <i>Project Timeline (2 pages)</i>	21
4.4.4 <i>Project Plan (12 pages; fewer pages permissible)</i>	21
4.4.5 <i>People Reached (Indirect Contact)</i>	24
4.4.6 <i>Number of Services Delivered (Direct Contact)</i>	24
4.4.7 <i>Number of Clinical Services Delivered</i>	24
4.4.8 <i>Number of Unique People Served (Direct Contact)</i>	24
4.4.9 <i>References</i>	24
4.4.10 <i>Resubmission Summary</i>	25
4.4.11 <i>Most Recently Funded Relevant Project Summary (if applicable) (3 pages)</i>	25
4.4.12 <i>CPRIT Grants Summary</i>	26
4.4.13 <i>Budget and Justification</i>	26
4.4.14 <i>Current and Pending Support and Sources of Funding</i>	28
4.4.15 <i>Biographical Sketches</i>	28
4.4.16 <i>Collaborating Organizations</i>	28
4.4.17 <i>Letters of Commitment (10 pages)</i>	29
5. APPLICATION REVIEW.....	29
5.1 REVIEW PROCESS OVERVIEW	29
5.2 REVIEW CRITERIA	30
5.2.1 <i>Primary Evaluation Criteria</i>	31
5.2.2 <i>Secondary Evaluation Criteria</i>	32
6. AWARD ADMINISTRATION	33

7. CONTACT INFORMATION34
7.1 HELPDESK 34
7.2 PROGRAM QUESTIONS 34
8. RESOURCES.....35
9. REFERENCES36
APPENDIX A: KEY TERMS..... 37
APPENDIX B: WRITING GOALS AND OBJECTIVES..... 40

RFA VERSION HISTORY

Rev 10/16/2020 RFA release

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and enhance the potential for a medical or scientific breakthrough in the prevention of or cures for cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

1.1 Prevention Program Priorities

Legislation from the 83rd Texas Legislature requires that CPRIT's Oversight Committee establish program priorities on an annual basis. The priorities are intended to provide transparency in how the Oversight Committee directs the orientation of the agency's funding portfolio. The Prevention Program's principles and priorities will also guide CPRIT staff and the Prevention Review Council on the development and issuance of program-specific Requests for Applications (RFAs) and the evaluation of applications submitted in response to those RFAs.

Established Principles:

- Fund evidence-based interventions and their dissemination
- Support the prevention continuum of primary, secondary, and tertiary (includes survivorship) prevention interventions

Prevention Program Priorities

- Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
- Prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
- Prioritize underserved populations


2. FUNDING OPPORTUNITY DESCRIPTION

2.1 Summary


The ultimate goals of the CPRIT Prevention Program are to reduce overall cancer incidence and mortality and to improve the lives of individuals who have survived or are living with cancer. The ability to reduce cancer death rates depends in part on the application of currently available evidence-based technologies and strategies. CPRIT fosters the primary, secondary, and tertiary prevention of cancer in Texas by providing financial support for a wide variety of evidence-based risk reduction, early detection, and survivorship interventions.

The **Evidence-Based Cancer Prevention Services (EBP)** award mechanism seeks to fund programs that greatly challenge the status quo in cancer prevention and control services. The proposed program should be designed to reach and serve as many people as possible.

Only proposals for new projects or expansion of currently/previously funded projects focused on obesity control/healthy living or survivor care are eligible under this mechanism. Eligible applications must include the delivery of services to nonmetropolitan (rural) and medically underserved counties in the state. These may be identified via Web-based tools from the [Texas Department of State Health Services](#) and [US Department of Health and Human Services](#) respectively.



Texas Medically Underserved Areas (MUA) and Populations (MUP)



Data source: US Health Resources and Services Administration Data Warehouse, October 2019

Partnerships with other organizations that can support and leverage resources are strongly encouraged. A coordinated submission of a collaborative partnership program in which all partners have a substantial role in the proposed project is preferred.

2.2 Project Objectives

CPRIT seeks to fund projects that will do the following:

- Deliver comprehensive projects comprising all of the following: public and/or professional education, outreach, delivery of clinical services, follow-up navigation, and system and/or policy improvements.

- Offer effective and efficient systems of delivery of prevention services based on the existing body of knowledge about and evidence for cancer prevention in ways that far exceed current performance in a given service area.
- Implement policy changes and/or system improvements that are sustainable over time (eg, decrease wait times between positive screen and diagnostic tests and treatment through improved navigation, reminder systems, etc) and treatment.
- Provide tailored, culturally appropriate outreach and accurate information on early detection and prevention to the public and health care professionals that results in a health impact that can be measured.
- Deliver evidence-based survivorship services aimed at reducing the morbidity associated with cancer diagnosis and treatment.

2.3 Award Description

The Evidence-Based Cancer Prevention Services RFA solicits applications for eligible projects up to 36 months in duration that will deliver evidence-based services in cancer prevention and control to nonmetropolitan (rural) and medically underserved counties in Texas.

In addition to other primary prevention and screening/early detection services, CPRIT considers evidence-based clinical counseling services (eg, tobacco cessation, survivorship) when done on a one-on-one basis or in small groups and delivered by qualified providers as clinical services. This mechanism will fund case management/patient navigation to screening, to diagnostic testing, and to treatment. Applicants must ensure that there is access to treatment services for patients with precancer or cancers that are detected as a result of the project and must describe the process for ensuring access to treatment services in their application.

Applicants should not request funds for any of the above components if these components are already being funded from other sources. If clinical services are being provided and paid by others, the applicant must demonstrate and report on the outcomes and services that are delivered to the people navigated by the program.

The following are required components of the project:

- **Geographic Area to be Served:** Clinical service delivery to nonmetropolitan/medically underserved area (MUA) counties is required. Service to urban/nonmedically underserved

counties is allowable as long as the project proposes to also serve nonmetropolitan/medically underserved counties. Eligible projects in nonmetropolitan/medically underserved geographic areas not well served by the CPRIT portfolio (see maps at <https://www.cprit.state.tx.us/our-programs/prevention/portfolio-maps>) will receive priority consideration.

- **Comprehensive Projects:** Comprehensive projects include a continuum of services and systems and policy changes and comprise all of the following: Public and professional education and training, outreach, delivery of screening and diagnostic services, follow-up navigation, data collection and tracking, and systems improvement.
- **Evidence Based:** CPRIT's prevention grants are intended to fund effective and efficient systems of delivery of prevention services based on the existing body of knowledge about and evidence for cancer prevention in ways that far exceed current performance in a given service area. The provision of clinical services, including rescreening at the appropriate interval, must comply with established and current national guidelines (eg, US Preventive Services Task Force [USPSTF], American Cancer Society, etc).

If evidence-based strategies have not been implemented or tested for the specific population or service setting proposed, provide evidence that the proposed service is appropriate for the population and has a high likelihood of success. Baseline data (eg, availability of resources and screening coverage) for the target population and target service region are required. If no baseline data exist, the applicant must present clear plans and describe method(s) of measurement used to collect the data necessary to establish a baseline.

Clinical Service and Community Partner Networks. If applicable to the proposed project, applicants are encouraged to coordinate and describe a collaboration of clinical service providers and community partners that can deliver outreach, education, clinical, and navigation services to the most counties and the most people possible in a selected service region. Partnerships with other organizations that can support and leverage resources (ie, community-based organizations, local and voluntary agencies, nonprofit agencies, groups that represent priority populations, etc) are encouraged. Letters of commitment or memoranda of understanding describing their specific role in the partnership will strengthen the application.

In cases where the project proposes to work with multiple clinical providers, the Program Director (PD) should facilitate the establishment of standard protocols for all clinical service providers in the network as well as standard systems, policies, and procedures for the participating clinical service providers and organizations. These may include, but are not limited to, patient tracking and timely follow-up of all abnormal screening results and/or diagnoses of cancer.

CPRIT expects measurable outcomes of supported activities, such as a significant increase over baseline (for the proposed service area) in the provision of evidence-based services, changes in provider practice, systems changes, and cost-effectiveness. Applicants must demonstrate how these outcomes will ultimately impact incidence, mortality, morbidity, or quality of life.

Under this RFA, CPRIT **will not** consider the following:

- **Projects focused solely on metropolitan/non–medically underserved counties.**
- **Currently or previously funded CPRIT Prevention projects other than those focused on obesity control/healthy living and/or survivor care.** These applicants should apply under the Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations (EPS) RFA.
- **Projects focusing solely on systems and/or policy change or solely on education and/or outreach** that do not include the delivery of cancer preventive clinical services.
- **Projects focused solely on counseling services** with no additional evidence-based clinical services.
- **Projects focusing solely on case management/patient navigation services.** Case management/patient navigation services must be paired with the delivery of a clinical cancer prevention service and reported to CPRIT. Furthermore, while navigation to the point of treatment of cancer is required when cancer is discovered through a CPRIT-funded project, applications seeking funds to provide coordination of care while an individual is in treatment are not allowed under this RFA.
- **Projects focusing on tobacco prevention and/or cessation for any age or computerized tomography screening for lung cancer for ages 55 to 77** should apply under CPRIT’s Tobacco Control and Lung Cancer Screening RFA.

- **Projects involving prevention/intervention research.** Applicants interested in prevention research should review CPRIT’s Academic Research RFAs (available at <http://www.cprit.texas.gov>).
- **Resources for the treatment of cancer or viral treatment for hepatitis.**

2.4 Priorities

Types of Cancer: Applications addressing any cancer type(s) that are responsive to this RFA will be considered for funding. See [section 2.5](#) for specific areas of emphasis.

The Prevention Program’s priorities for funding include the following:

1) **Populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence.**

CPRIT programs must address underserved populations. Underserved populations are subgroups that are disproportionately affected by cancer. CPRIT-funded efforts must address 1 or more of these priority populations:

- Underinsured and uninsured individuals;
- Medically unserved or underserved populations;
- Racial, ethnic, and cultural minority populations;
- Populations with low screening rates, high incidence rates, and high mortality rates, focusing on individuals never before screened or who are significantly out of compliance with nationally recommended screening guidelines (more than 5 years for breast/cervical cancers).

The age of the priority population and frequency of screening/rescreening for provision of clinical services described in the application must comply with established and current national guidelines (eg, USPSTF, American Cancer Society).

2) **Geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence.**

While disparities and needs exist across the state, CPRIT will also prioritize applications proposing to serve geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence. For this RFA, projects must propose to serve nonmetropolitan and/or

MUAs of the state. In addition, projects addressing areas of emphasis (see [section 2.5](#)) will receive priority consideration.

Geographic and Population Balance in Current CPRIT portfolio

At the programmatic level of review conducted by the Prevention Review Council (see [section 5.1](#)), priority will be given to projects that target geographic regions of the state and population subgroups that are not adequately covered by the current CPRIT Prevention project portfolio (see <https://www.cprit.state.tx.us/our-programs/prevention/portfolio-maps> and <https://www.cprit.state.tx.us/grants-funded?search=prevention>).

2.5 Specific Areas of Emphasis

CPRIT has identified the following areas of emphasis for this cycle of awards.

<u>Primary Prevention</u>
HPV Vaccination
<ul style="list-style-type: none"> Increasing access to, delivery of, and completion of the HPV vaccine regimen to males and females through evidence-based intervention efforts in all areas of the state.¹
Liver Cancer
<ul style="list-style-type: none"> Screening for HBV infection and HCV infection in populations at high risk of infection Increasing screening rates in Public Health Region (PHR) 8, 10, and 11. Incidence and mortality rates are highest in PHR 10 and 11.²
<u>Secondary Prevention - Screening and Early Detection Services</u>
Colorectal Cancer
<ul style="list-style-type: none"> Decreasing disparities in incidence and mortality rates of colorectal cancer in racial/ethnic populations. Blacks have the highest incidence and mortality rates, followed by non-Hispanic whites and Hispanics.² Increasing screening/detection rates in PHR 2, 4, and 5, where the highest rates of cancer incidence and mortality are found. Decreasing incidence and mortality rates in nonmetropolitan counties. Incidence and mortality rates are higher in nonmetropolitan counties compared with metropolitan counties.²
Breast Cancer
<ul style="list-style-type: none"> Decreasing disparities in mortality rates of breast cancer in racial/ethnic populations. The mortality rate is significantly higher in blacks than in other populations.² Increasing screening/detection rates in medically underserved areas of the state.

Cervical Cancer
<ul style="list-style-type: none"> Decreasing disparities in incidence and mortality rates of cervical cancer in racial/ethnic populations. Hispanics have the highest incidence rates while blacks have the highest mortality rates.² Increasing screening/detection rates in medically underserved areas of the state.²
<u>Tertiary Prevention – Survivorship Services</u>
<ul style="list-style-type: none"> Preventing secondary cancers and recurrence of cancer through evidence-based interventions. Improving quality of life of cancer survivors by managing the aftereffects of cancer, including the use of survivorship care plans.

2.6 Outcome Metrics

Applicants are required to clearly describe their assessment and evaluation methodology. The applicant is required to describe final outcome measures for the project. Output measures that are associated with the final outcome measures should be identified in the project plan and will serve as a measure of program effectiveness. Planned policy or system changes/improvements should be identified and the plan for qualitative analysis described. **Baseline data for each measure proposed are required.** In addition, applicants should describe how funds from the CPRIT grant will improve outcomes over baseline. If the applicant is not providing baseline data for a measure, the applicant must provide a well-justified explanation and describe clear plans and method(s) of measurement to collect the data necessary to establish a baseline.

Reporting Requirements

Funded projects are required to report quantitative output and outcome metrics (as appropriate for each project) through the submission of quarterly progress reports, annual reports, and a final report.

If clinical services are being paid for and provided by others, the applicant is required to report on the number of clinical services and patient outcomes (eg, cancers detected) that are delivered to the people navigated by the program.

- Quarterly progress report sections include, but are not limited to, the following:
 - Summary page, including narrative on project progress (required)
 - Services, other than clinical services, provided to the public/professionals
 - Actions taken by people/professionals as a result of education or training

- Clinical services provided (county of residence of client is required)
- Precursors and cancers detected
- Annual and final progress report sections include, but are not limited to, the following:
 - Key accomplishments, **including qualitative analysis of policy change and/or lasting systems change**
 - Progress toward goals and outcome objectives, including percentage increase over baseline in provision of age- and risk-appropriate comprehensive preventive services to eligible individuals in a defined service area
 - Materials produced and publications
 - Economic impact of the project

2.7 Eligibility

- Eligible applications include only new cancer prevention projects or expansion of previously funded obesity control/healthy living and survivor care projects.
- The applicant must be a Texas-based entity, such as a community-based organization, health institution, government organization, public or private company, college or university, or academic health institution.
- The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted.
- The designated PD will be responsible for the overall performance of the funded project. The PD must have relevant education and management experience and must reside in Texas during the project performance time.
- The evaluation of the project must be headed by a professional who has demonstrated expertise in the field and who resides in Texas during the time that the project is conducted.
- The applicant may submit more than 1 application, but each application must be for distinctly different services without overlap in the services provided. Applicants who do not meet this criterion will have all applications administratively withdrawn without peer review.
- If an organization has a current CPRIT grant that is the same or similar to the prevention intervention being proposed, the applicant must explain how the projects are nonduplicative or complementary.

- If the applicant or a partner is an existing Department of State Health Services (DSHS) contractor, CPRIT funds may not be used as a match, and the application must explain how this grant complements or leverages existing state and federal funds. DSHS contractors who also receive CPRIT funds must be in compliance with and fulfill all contractual obligations within CPRIT. CPRIT and DSHS reserve the right to discuss the contractual standing of any contractor receiving funds from both entities.
- Collaborations are permitted and encouraged, and collaborators may or may not reside in Texas. However, collaborators who do not reside in Texas are not eligible to receive CPRIT funds. Subcontracting and collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.
- An applicant is not eligible to receive a CPRIT grant award if the applicant PD, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member.
- An applicant organization is eligible to receive a grant award only if the applicant certifies that the applicant organization, including the PD, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation created to benefit CPRIT.
- The applicant must report whether the applicant organization, the PD, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, (whether slated to receive salary or compensation under the grant award or not), are currently ineligible to receive federal grant funds because of scientific misconduct or fraud or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. CPRIT grants are funded on a reimbursement-only basis. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted,

applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 6](#). All statutory provisions and relevant administrative rules can be found [on the CPRIT website](#).

2.8 Resubmission Policy

- **One resubmission** is permitted. An application is considered a resubmission if the proposed project is the same project as presented in the original submission. A change in the identity of the PD for a project or a change of title for a project that was previously submitted to CPRIT does not constitute a new application; the application would be considered a resubmission.
- Applicants who choose to resubmit should carefully consider the reasons for lack of prior success. Applications that received overall numerical scores of 5 or higher are likely to need considerable attention. All resubmitted applications should be carefully reconstructed; a simple revision of the prior application with editorial or technical changes is not sufficient, and applicants are advised not to direct reviewers to such modest changes. A 1-page summary of the approach to the resubmission should be included. Resubmitted applications may be assigned to reviewers who did not review the original submission. Reviewers of resubmissions are asked to assess whether the resubmission adequately addresses critiques from the previous review. **Applicants should note that addressing previous critiques is advisable; however, it does not guarantee the success of the resubmission.** All resubmitted applications must conform to the structure and guidelines outlined in this RFA.

2.9 Expansion Policy (if applicable)

- A grant recipient that has previously been awarded grant funding from CPRIT for an obesity control/healthy living or survivor care project may submit an application under this mechanism to be considered for an expansion grant if expansion of current services into additional counties and/or additional types of prevention clinical services has been included. The eligibility criteria described in [section 2.7](#) also apply to expansion applications.

- Expansion grants are intended to fund expansion of currently or previously funded projects that have demonstrated exemplary success, as evidenced by progress reports and project evaluations, and desire to further enhance their impact on priority populations. Detailed descriptions of **results, barriers, outcomes, and impact of the currently or previously funded project are required** (see outline of Most Recently Funded Project Summary, [section 4.4.12](#)).
- Proposed expansion projects should NOT be new projects but should closely follow the intent and core elements of the currently or previously funded project. Established infrastructure/processes and fully described prior project results are required. Expansion of current projects into geographic areas not well served by the CPRIT Prevention portfolio (see maps at <http://www.cprit.state.tx.us/our-programs/prevention/portfolio-maps>) will receive priority consideration.
- CPRIT expects measurable outcomes of supported activities, such as a significant increase over baseline (for the proposed service area). It is expected that baselines will have already been established and that continued improvement over baseline is demonstrated in the current application. However, in the case of a proposed expansion where no baseline data exist for the priority population, the applicant must present clear plans and describe method(s) of measurement used to collect the data necessary to establish a baseline. Applicants must demonstrate how these outcomes will ultimately impact cancer incidence, mortality, morbidity, or quality of life.
- CPRIT also expects that applications for continuation **will not** require startup time, that applicants can demonstrate that they have overcome barriers encountered, and that applicants have identified **lasting systems changes** that improve results, efficiency, and sustainability. Leveraging of resources and plans for dissemination are expected and should be well described.

2.10 Funding Information

Applicants may request any amount of funding up to a maximum of \$1 million in total funding over a maximum of 36 months. Grant funds may be used to pay for clinical services, navigation services, project staff salary and benefits, project supplies, equipment, costs for outreach and education of populations, and travel of project personnel to project site(s). Applicants must ensure

that there is access to treatment services for patients with precancer or cancers detected as a result of the program and must describe access to treatment.

Requests for funds to support construction, renovation, or any other infrastructure needs or requests to support lobbying will not be approved under this mechanism. Grantees may request funds for travel for 2 project staff to attend CPRIT's conference.

The budget should be proportional to the number of individuals receiving programs and services, and a significant proportion of funds is expected to be used for program delivery as opposed to program development. In addition, CPRIT seeks to fill gaps in funding rather than replace existing funding, supplant funds that would normally be expended by the applicant's organization, or make up for funding reductions from other sources.

State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the **total** award amount.

3. KEY DATES

RFA release	October 16, 2020
Online application opens	November 16, 2020, 7 AM central time
Application due	February 10, 2021, 4 PM central time
Application review	March-July 2021
Award notification	August 2021
Anticipated start date	August 31, 2021

Applicants will be notified of peer review panel assignment prior to the peer review meeting dates.

4. APPLICATION SUBMISSION GUIDELINES

4.1 *Instructions for Applicants* document

It is **imperative** that applicants read the accompanying instructions document for this RFA that will be available November 16, 2020 (<https://CPRITGrants.org>). Requirements may have changed from previous versions.

4.2 Online Application Receipt System

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The PD must create a user account in the system to start and submit an application. The Co-PD, if applicable, must also create a user account to participate in the application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (an individual who will help manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on November 16, 2020, and must be submitted by 4 PM central time on February 10, 2021. Detailed instructions for submitting an application are in the *Instructions for Applicants* document, posted on CARS. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

4.3 Submission Deadline Extension

The submission deadline may be extended for 1 or more grant applications upon a showing of good cause. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records.

4.4 Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Refer to the *Instructions for Applicants* document for details.

Submissions that are missing 1 or more components or do not meet the eligibility requirements may be administratively withdrawn without review.

4.4.1 Abstract and Significance (5,000 characters)

Clearly explain the problem(s) to be addressed, the approach(es) to the solution, and how the application is responsive to this RFA. In the event that the project is funded, the abstract will be made public; therefore, no proprietary information should be included in this statement. Initial compliance decisions are based in part upon review of this statement.

The abstract format is as follows (use headings as outlined below):

- **Need:** Include a description of need in the specific service area. Include rates of incidence, mortality, and screening in the service area compared to overall Texas rates. Describe barriers, plans to overcome these barriers, and the priority population to be served.
- **Overall Project Strategy:** Describe the project and how it will address the identified need. Clearly explain what the project is and what it will specifically do, including the services to be provided and the process/system for delivery of services and outreach to the priority population.
- **Specific Goals:** State specifically the overall goals of the proposed project; include the estimated overall numbers of people (public and/or professionals) reached and people (public and/or professionals) served.
- **Significance and Impact:** Explain how the proposed project, if successful, will have a major impact on cancer prevention and control for the population proposed to be served and for the State of Texas.

4.4.2 Goals and Objectives (700 characters each)

List only major **outcome goals** and **measurable objectives** for each year of the project. **Do not include process objectives**; these should be described in the project plan only. Include the proposed metric within both the stated Objective **and** the Measure sections (eg, Measure: 2,000 individuals, ages 9-12, will initiate HPV vaccination during the grant period). Applications may be returned for revision if the proposed metric is not included within the Measure section. Refer to the *Instructions for Applicants* document for details.

The maximum number is 3 goals with 3 objectives each. Projects will be evaluated annually on progress toward outcome goals and objectives. See [Appendix B](#) for instructions on writing outcome goals and objectives.

A baseline and method(s) of measurement are required for each objective. Provide both raw numbers and percent changes for the baseline and target. If a baseline has not been defined, applicants are required to explain plans to establish baseline and describe method(s) of measurement.

4.4.3 Project Timeline (2 pages)

Provide a project timeline for project activities that includes deliverables and dates. Use Years 1, 2, 3, and Months 1, 2, 3, etc, as applicable (eg, Year 1, Months 3-5) instead of specific months or years. Month 1 is the first full month of the grant award.

4.4.4 Project Plan (12 pages; fewer pages permissible)

The required project plan format follows. Applicants must use the headings outlined below.

Background: Briefly present the rationale behind the proposed services, emphasizing the critical barriers to current service delivery that will be addressed. Identify the evidence-based service to be implemented for the priority population. Describe the race, ethnicity, age, and other defining characteristics of the population to be served.

If evidence-based strategies have not been implemented or tested for the specific population or service setting proposed, provide evidence that the proposed service is appropriate for the population and has a high likelihood of success. Baseline data for the priority population and target service area are required where applicable.

Reviewers will be aware of national and state statistics, and these should be used only to compare rates for the proposed service area. Describe the geographic region of the state that the project will serve; maps are encouraged.

Goals and Objectives: Process objectives should be included in the project plan. Outcome goals and objectives will be entered in separate fields in CARS. However, if desired, outcome goals and objectives may be fully repeated or briefly summarized here. See [Appendix B](#) for instructions on writing goals and objectives.

Components of the Project: Clearly describe the need, delivery method, and evidence base (provide references) for the services, as well as anticipated results. Be explicit about the base of evidence and any necessary adaptations for the proposed project. Describe why this project is nonduplicative. If an organization has a current CPRIT grant that is the same or similar to the prevention intervention being proposed, the applicant must explain how the projects are nonduplicative or complementary.

It is important to distinguish between Texas counties where the project proposes to deliver services and counties of residence of population served (see [Appendix A](#) for definitions and *Instructions for Applicants*). Only counties with service delivery should be listed in the Geographic Area to be Served section of the application. Projecting counties of residence of population served is not required but may be described in the project plan.

Clearly demonstrate the ability to provide the proposed service and describe how results will be improved over baseline and the ability to reach the priority population. Describe the method(s) that will be used to recall for appropriate rescreening those individuals who have been screened through this project.

If clinical services are being paid for and provided by others, the applicant must explain and report on the number of clinical services and patient outcomes (eg, screenings/diagnostics, vaccinations, cancer precursors, cancers detected) that are delivered to the people navigated by the program. Applicants must also clearly describe plans to **ensure access to treatment services** should precancer or cancer be detected.

Evaluation Strategy: A strong commitment to evaluation of the project is required. Describe the plan for outcome and output measurements, including qualitative analysis of policy and system changes. Describe data collection and management methods, data analyses, and anticipated results. Evaluation and reporting of results should be headed by a professional who has demonstrated expertise in the field. If needed, applicants may want to consider seeking expertise at Texas-based academic cancer centers, schools/programs of public health, or the like. Applicants should budget accordingly for the evaluation activity and should involve that professional during grant application preparation to ensure, among other things, that the evaluation plan is linked to the proposed goals and objectives.

Organizational Qualifications and Capabilities: Describe the organization and its track record and success in providing health programs and services. Describe the role and qualifications of the key collaborators/partners in the project. Include information on the organization's financial stability and viability. The applicant should demonstrate how the organizational environment will contribute to a successful project. If equipment or physical resources are required to carry out the project, the applicant should describe the availability of these resources and the organizational capacity to use equipment. To ensure access to preventive services and reporting of services

outcomes, applicants should demonstrate that they have provider partnerships and agreements (via memoranda of understanding) or commitments (via letters of commitment) in place.

CPRIT acknowledges that full maintenance and sustainability of projects when CPRIT funding ends may not be feasible, especially in cases involving the delivery of clinical services. However, it is important to consider sustainability early in the life cycle of a project, particularly regarding organizational characteristics and processes that are modifiable.

Washington University in St Louis has developed a useful tool ([Program Sustainability Assessment Tool](#)) to assess program capacity for sustainability. The tool assesses several factors that contribute to program sustainability. These factors include environmental support, funding stability, partnerships, organizational capacity, program evaluation, program adaptation, communication and strategic planning. Applicants are not required to use this tool; however, it provides practical guidance on factors that should be considered and should be included in the application to describe a program's organizational capacity for sustainability.

It is expected that steps toward building capacity for the program will be taken and plans for such be briefly described in the application. The applicant should describe the factors that will contribute to the organization's capacity to facilitate sustainability.

Dissemination and Replication: Dissemination of project results and outcomes, including barriers encountered and successes achieved, is critical to building the evidence base for cancer prevention and control efforts in the state. Dissemination efforts should consider the message, source, audience, and channel (Brownson, R.C., et al. [J Pub Health Manag Pract. 24\(2\):102-111](#), March/April 2018). Dissemination methods may include, but are not limited to, presentations at workshops and seminars, one-on-one meetings, publications, news media, social media, etc.

While passive dissemination methods are common (eg, publications, presentations at professional meetings), plans should include some active dissemination methods (eg, meetings with stakeholders, blogs, social media). Applicants should describe their dissemination plans. The plans should include the kinds of audiences to be targeted and methods for reaching the targeted audiences.

Replication by others is an additional way to disseminate the project. For applicable components, describe how the project or components of the project lend themselves to application by other

communities and/or organizations in the state or expansion in the same communities. Describe what components of this project can be adapted to a larger or lower resource setting. Note that some programs may have unique resources and may not lend themselves to replication by others.

4.4.5 People Reached (Indirect Contact)

Provide the estimated overall number of people (members of the public and professionals) to be reached by the funded project. The applicant is required to itemize separately the types of indirect noninteractive education and outreach activities, with estimates, that led to the calculation of the overall estimates provided. Refer to [Appendix A](#) for definitions.

4.4.6 Number of Services Delivered (Direct Contact)

Provide the estimated overall number of services directly delivered to members of the public and to professionals by the funded project. Each individual service should be counted, regardless of the number of services one person receives. The applicant is required to itemize separately the education, navigation, and clinical activities/services, with estimates, that led to the calculation of the overall estimate provided. Refer to [Appendix A](#) for definitions.

4.4.7 Number of Clinical Services Delivered

Provide the estimated overall number of clinical services directly delivered to members of the public by the funded project. Each individual clinical service should be counted, regardless of the number of services one person receives. Separately itemize the clinical services, with estimates, that led to the calculation of the overall estimate provided. Refer to [Appendix A](#) for definitions.

4.4.8 Number of Unique People Served (Direct Contact)

Provide the estimated overall number of unique members of the public and professionals served by the funded project. One person may receive multiple services but should only be counted once here. Refer to [Appendix A](#) for definitions.

4.4.9 References

Provide a concise and relevant list of references cited for the application. The successful applicant will provide referenced evidence and literature support for the proposed services.

4.4.10 Resubmission Summary

Use the template provided on the CARS (<https://CPRITGrants.org>). Describe the approach to the resubmission and how reviewers' comments were addressed. Clearly indicate to reviewers how the application has been improved in response to the critiques. Refer the reviewers to specific sections of other documents in the application where further detail on the points in question may be found. When a resubmission is evaluated, responsiveness to previous critiques is assessed.

The summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission; the applicant is not responsible for providing this document.

4.4.11 Most Recently Funded Relevant Project Summary (if applicable) (3 pages)

Upload a summary that outlines the progress made with the most recently funded relevant CPRIT award. Applicants must describe results and outcomes of the most recently funded award and demonstrate why further funding is warranted.

Please note that a different set of reviewers from those assigned to the previously funded application may evaluate this application. Applicants should make it easy for reviewers to compare the most recently funded project with the proposed project.

In the description, include the following:

- Describe the evidence-based intervention, its purpose, and how it was implemented in the priority population. Describe any adaptations made for the population served.
- List approved goals and objectives of the most recently funded grant.
- For each objective, provide the following information:
 - Milestones/target dates and target metrics
 - Actual completion dates and metrics
- For the most recently funded project, describe major activities; significant results, including major findings, developments or conclusions (both positive and negative); and key outcomes. Include a discussion of objectives not fully met. Explain any barriers encountered and strategies used to overcome these.
- Describe steps taken toward sustainability for components of the project. Fully describe systems or policy improvements and enhancements.

- Describe how project results were disseminated or plans for future dissemination of results.

4.4.12 CPRIT Grants Summary

Use the template provided on CARS (<https://CPRITGrants.org>). Provide a listing of **all** projects funded by the CPRIT Prevention program for the PD and the Co-PD, regardless of their connection to this application.

4.4.13 Budget and Justification

Provide a brief outline and detailed justification of the budget for the entire proposed period of support, including salaries and benefits, travel, equipment, supplies, contractual expenses, services delivery, and other expenses. CPRIT funds will be distributed on a reimbursement basis.

Applications requesting more than the maximum allowed cost (total costs) as specified in [section 2.10](#) will be administratively withdrawn.

- **Average Cost per Person:** The average cost per person will be automatically calculated from the total cost of the project divided by the total number of unique people served (refer to [Appendix A](#)).
- **Average Cost per Service:** The average cost per service will be automatically calculated from the total cost of the project divided by the total number of services delivered (refer to [Appendix A](#)). A significant proportion of funds is expected to be used for program delivery as opposed to program development and organizational infrastructure.
- **Average Cost per Clinical Service:** The average cost per clinical service will be automatically calculated from the total cost of the project divided by the total number of clinical services delivered (refer to [Appendix A](#)).
- **Personnel:** The individual salary cap for CPRIT awards is \$200,000 per year. Describe the source of funding for all project personnel where CPRIT funds are not requested.
- **Travel:** PDs and related project staff are expected to attend CPRIT's conference. CPRIT funds may be used to send up to 2 people to the conference.
- **Equipment:** Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application. Justification must be provided

for why funding for this equipment cannot be found elsewhere; CPRIT funding should not supplant existing funds. Cost sharing of equipment purchases is strongly encouraged.

- **Services Costs:**

- CPRIT reimburses for services using Medicare reimbursement rates. Describe the source of funding for all services where CPRIT funds are not requested. If clinical services are being paid for and provided by others, the applicant is required to explain and report on the number of clinical services and patient outcomes (eg, screenings/diagnostics, vaccinations, cancer precursors, cancers detected) that are delivered to the people navigated by the program.
- CPRIT does not allow recovery of costs related to tests that have not been recommended by the USPSTF. In several cases (eg, breast self-exams, clinical breast exams, PSA tests), the Task Force has concluded there is not enough evidence available to draw reliable conclusions about the additional benefits and harms of these tests. (See <https://www.uspreventiveservicestaskforce.org/>)

- **Other Expenses:**

- **Incentives:** Use of incentives or positive rewards to change or elicit behavior is allowed; however, incentives may only be used based on strong evidence of their effectiveness for the purpose and in the priority population identified by the applicant. CPRIT will not fund cash incentives. The maximum dollar value allowed for an incentive per person, per activity or session, is \$25.
- **Costs Not Related to Cancer Prevention and Control:** CPRIT does not allow recovery of any costs for services not related to cancer (eg, health physicals, HIV testing).

- **Indirect/Shared Costs:** Texas law limits the amount of grant funds that may be spent on indirect/shared expenses to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in [CPRIT's Administrative Rules](#).

4.4.14 Current and Pending Support and Sources of Funding

Use the template provided on the CARS (<https://CPRITGrants.org>). Describe the funding source and duration of **all** current and pending support for the proposed project, including a capitalization table that reflects private investors, if any.

4.4.15 Biographical Sketches

The designated PD will be responsible for the overall performance of the funded project and must have relevant education and management experience. The PD/Co-PD(s) must provide a biographical sketch that describes his or her education and training, professional experience, awards and honors, and publications and/or involvement in programs relevant to cancer prevention and/or service delivery.

- Use the Co-PD Biographical Sketch section **ONLY** if a Co-PD has been identified.
- The evaluation professional must provide a biographical sketch in the Evaluation Professional Biographical Sketch section.
- Up to 3 additional biographical sketches for key personnel may be provided in the Key Personnel Biographical sketch section.

Each biographical sketch must not exceed 2 pages and should use either the “Prevention Programs: Biographical Sketch” template provided on the CARS (<https://CPRITGrants.org>) or the NIH Biographical Sketch format. Only biographical sketches will be accepted; do not submit resumes and/or CVs. If a position is not yet filled, please upload a job description.

4.4.16 Collaborating Organizations

List all key participating organizations that will partner with the applicant organization to provide 1 or more components essential to the success of the program (eg, evaluation, clinical services, recruitment to screening). Please be sure to also include anyone listed as key personnel and/or listed under the Current & Pending Support section.

4.4.17 Letters of Commitment (10 pages)

Applicants should provide letters of commitment and/or memoranda of understanding from community organizations, key faculty, or any other component essential to the success of the program. Letters should be specific to the contribution of each organization.

5. APPLICATION REVIEW

5.1 Review Process Overview

All eligible applications will be reviewed using a 2-stage peer review process: (1) evaluation of applications by peer review panels and (2) prioritization of grant applications by the Prevention Review Council. In the first stage, applications will be evaluated by an independent review panel using the criteria listed below. In the second stage, applications judged to be meritorious by review panels will be evaluated by the Prevention Review Council and recommended for funding based on comparisons with applications from all of the review panels and programmatic priorities.

Programmatic considerations may include, but are not limited to, geographic distribution, cancer type, population served, and type of program or service. The scores are only 1 factor considered during programmatic review. At the programmatic level of review, priority will be given to proposed projects that target geographic regions of the state or population subgroups that are not well represented in the current CPRIT Prevention project portfolio.

Applications approved by Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

Each stage of application review is conducted confidentially, and all CPRIT Peer Review Panel members, Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in

the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Peer Review Panel members and Review Council members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer Review Panel members are listed by panel on CPRIT's website. **By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules, [chapter 703, section 703.9](#).**

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, a Review Panel member, or a Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention and Communications Officer, the Chief Product Development Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period when preapplications or letters of interest are accepted. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

5.2 Review Criteria

Peer review of applications will be based on primary scored criteria and secondary unscored criteria, identified below. Review panels consisting of experts in the field and advocates will evaluate and score each primary criterion and subsequently assign an overall score that reflects an overall assessment of the application. The overall evaluation score will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application and responsiveness to the RFA priorities.

5.2.1 Primary Evaluation Criteria

Impact

- Do the proposed services address an important problem or need in cancer prevention and control? Do the proposed project strategies support desired outcomes in cancer incidence, morbidity, and/or mortality? Do the proposed project strategies reach a priority population (eg, low income, minority, rural) at high risk of cancer?
- Will the project reach and serve/impact an appropriate number of people based on the budget allocated to providing services and the cost of providing services?
- If applicable, have partners demonstrated that the collaborative effort will provide a greater impact on cancer prevention and control than the applicant organization's effort separately?
- Does the program address adaptation, if applicable, of the evidence-based intervention to the priority population? Is the base of evidence clearly explained and referenced?

Project Strategy and Feasibility

- Does the proposed project provide services specified in the RFA?
- Are the overall program approach, strategy, and design clearly described and supported by established theory and practice? Are the proposed objectives and activities feasible within the duration of the award? Has the applicant convincingly demonstrated the short- and long-term impacts of the project?
- Has the applicant proposed policy changes and/or system improvements?
- Are possible barriers addressed and approaches for overcoming them proposed?
- Are the priority population and culturally appropriate methods to reach the priority population clearly described?
- If applicable, does the application demonstrate the availability of resources and expertise to provide case management, including followup for abnormal results and access to treatment?
- Does the program leverage partners and resources to maximize the reach of the services proposed? Does the program leverage and complement other state, federal, and nonprofit grants?

Outcomes Evaluation

- Are specific goals and measurable objectives for each year of the project provided?

- Are the proposed outcome measures appropriate for the services provided, and are the expected changes clinically significant?
- If clinical services are being paid for and provided by others, does the applicant explain the methods used to collect data and report on these clinical services and outcomes?
- Does the application provide a clear and appropriate plan for data collection and management and data analyses?
- Are clear baseline data provided for the priority population, or are clear plans included to collect baseline data?
- If an evidence-based intervention is being adapted in a population where it has not been implemented or tested, are plans for evaluation of barriers, effectiveness, and fidelity to the model described?
- Is the qualitative analysis of planned policy or system changes described?

Organizational Qualifications and Capabilities

- Do the organization and its collaborators/partners demonstrate the ability to provide the proposed preventive services?
- Does the described role of each collaborating organization make it clear that each organization adds value to the project and is committed to working together to implement the project?
- Have the appropriate personnel been recruited to design, implement, evaluate, and complete the project?
- Is the organization structurally and financially stable and viable?
- Does the applicant describe the program's organizational capacity for sustainability?
- Does the applicant describe steps that will be taken toward building internal capacity and partnerships?
- Does the applicant describe a plan for systems changes that are sustainable over time (eg, improve results, provider practice, efficiency, cost-effectiveness)?

5.2.2 Secondary Evaluation Criteria

Budget

- Is the budget appropriate and reasonable for the scope and services of the proposed work?

- Is the cost per person served appropriate and reasonable?
- Is the proportion of the funds allocated for direct services reasonable?
- Is the project a good investment of Texas public funds?

Dissemination and Replication

- Are plans for dissemination of the project’s results and outcomes, including target audiences and methods, clearly described?
- Are active dissemination strategies included and described in the plan?
- Does the applicant describe whether and/or how the project lends itself to replication of all or some components of the project by others in the state?

6. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT’s electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT’s electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in [CPRIT’s Administrative Rules](#). Applicants are advised to review CPRIT’s administrative rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT’s Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires the PD of the award to submit quarterly, annual, and final progress reports. These reports summarize the progress made toward project goals and address plans for the upcoming year and performance during the previous year(s). In addition, quarterly fiscal reporting and reporting on selected metrics will be required per the instructions to award recipients. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract.

7. CONTACT INFORMATION

7.1 Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding the scope and focus of applications. Before contacting the helpdesk, please refer to the *Instructions for Applicants* document (posted on November 16, 2020), which provides a step-by-step guide to using CARS.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

7.2 Program Questions

Questions regarding the CPRIT Prevention program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Prevention Program Office.

Tel: 512-305-8417

Email: Help@CPRITGrants.org

Website: www.cprit.texas.gov

8. RESOURCES

- The Texas Cancer Registry. <https://www.dshs.texas.gov/tcr> or contact the Texas Cancer Registry at the Department of State Health Services.
- The Community Guide. <https://www.thecommunityguide.org/>
- Cancer Control P.L.A.N.E.T. <http://cancercontrolplanet.cancer.gov>
- Guide to Clinical Preventive Services: Recommendations of the U.S. Preventive Services Task Force. <http://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/guide/>
- Brownson, R.C., Colditz G.A., and Proctor, E.K. (Editors). *Dissemination and Implementation Research in Health: Translating Science to Practice*. Oxford University Press, March 2012
- Program Sustainability Assessment Tool, copyright 2012, Washington University, St Louis, MO, <https://www.sustaintool.org/about-us/>
- Getting the Word Out: New Approaches for Disseminating Public Health Science Ross C. Brownson, PhD; Amy A. Eyler, PhD; Jenine K. Harris, PhD; Justin B. Moore, PhD, MS; Rachel G. Tabak, PhD, RD, **Journal of Public Health Management & Practice**. 24(2):102-111, March/April 2018.
(https://journals.lww.com/jphmp/Fulltext/2018/03000/Getting_the_Word_Out__New_Approaches_for.4.aspx)
- Centers for Disease Control and Prevention: The Program Sustainability Assessment Tool: A New Instrument for Public Health Programs.
http://www.cdc.gov/pcd/issues/2014/13_0184.htm
- Centers for Disease Control and Prevention: Using the Program Sustainability Tool to Assess and Plan for Sustainability. http://www.cdc.gov/pcd/issues/2014/13_0185.htm
- Cancer Prevention and Control Research Network: Putting Public Health Evidence in Action Training Workshop. <http://cpcrn.org/pub/evidence-in-action/>
- Centers for Disease Control and Prevention. Distinguishing Public Health Research and Public Health Nonresearch. <https://www.cdc.gov/os/integrity/docs/cdc-policy-distinguishing-public-health-research-nonresearch.pdf>

9. REFERENCES

1. <http://www.cdc.gov/hpv/parents/questions-answers.html>
2. Texas Cancer Registry, Cancer Epidemiology and Surveillance Branch, Texas Department of State Health Services. <https://www.cancer-rates.info/tx/>

APPENDIX A: KEY TERMS

- **Activities:** A listing of the “who, what, when, where, and how” for each objective that will be accomplished
- **Capacity Building:** Any activity (eg, training, identification of alternative resources, building internal assets) that builds durable resources and enables the grantee’s setting or community to continue the delivery of some or all components of the evidence-based intervention
- **Clinical Services:** Number of clinical services such as screenings, diagnostic tests, vaccinations, counseling sessions, or other evidence-based preventive services delivered by a health care practitioner in an office, clinic, or health care system. Other examples include genetic testing or assessments, physical rehabilitation, tobacco cessation counseling or nicotine replacement therapy, case management, primary prevention clinical assessments, and family history screening.
- **Counties of Residence of Population Served:** Counties where the project does not plan to have a physical presence but people who live in these counties have received services. This includes counties of residence of people or places of business of professionals who participate in or receive education, navigation or clinical services. Examples include people traveling to receive services as a result of marketing and programs accessible via the website or social media. These counties may be described in the project plan and must be reported in the quarterly progress report.
- **Counties with Service Delivery:** Counties where an activity or service will occur and the project has a physical presence for the services provided. Examples include onsite outreach and educational activities and delivery of clinical services through clinics, mobile vans, or telemedicine consults. These counties must be entered in the Geographic Area to be Served section of the application.
- **Education Services:** Number of evidence-based, culturally appropriate cancer prevention and control education and outreach services delivered to the public and to health care professionals. Examples include education or training sessions (group or individual), focus groups, and knowledge assessments. One individual may receive multiple education services.

- **Evidence-Based Program:** A program that is validated by some form of documented research or applied evidence. CPRIT’s website provides links to resources for evidence-based strategies, programs, and clinical recommendations for cancer prevention and control. To access this information, visit <https://www.cprit.state.tx.us/our-programs/prevention>.
- **Goals:** Broad statements of general purpose to guide planning. Outcome goals should be few in number and focus on aspects of highest importance to the project ([Appendix B](#)).
- **Integration:** The extent the evidence-based intervention is integrated within the culture of the grantee’s setting or community through policies and practice.
- **Navigation Services:** Number of activities/services that offer assistance to help overcome health care system barriers in a timely and informative manner and facilitate cancer screening and diagnosis to improve health care access and outcomes. Examples include patient reminders, transportation assistance, and appointment scheduling assistance. One individual may receive multiple navigation services.
- **Number of Clinical Services:** Number of [clinical services](#) delivered directly to members of the public by the funded project. One individual may receive multiple clinical services.
- **Number of Services (Direct Contact):** Number of services delivered directly to members of the public and/or professionals—direct, interactive public or professional education, outreach, training, navigation service, or clinical service, such as live educational and/or training sessions, vaccine administration, screening, diagnostics, case management/navigation services, and physician consults. One individual may receive multiple services.
- **Objectives:** Specific, **measurable**, actionable, realistic, and timely projections for outcomes; example: “Increase screening service provision in X population from Y% to Z% by 20xx.” Baseline data for the priority population must be included as part of each objective ([Appendix B](#)). The proposed metric should be included in **both** the objective and the measure.
- **People Reached (Indirect Contact):** Number of members of the public and/or professionals reached via indirect noninteractive public or professional education and outreach activities, such as mass media efforts, brochure distribution, public service announcements, newsletters, and journals. (This category includes individuals who would

be reached through activities that are directly funded by CPRIT as well as individuals who would be reached through activities that occur as a direct consequence of the CPRIT-funded project's leveraging of other resources/funding to implement the CPRIT-funded project).

- **Unique People Served (Direct Contact):** Number of unique members of the public and/or professionals served via direct, interactive public or professional education, outreach, training, navigation service, or clinical service. This category includes individuals who would be served through activities that are directly funded by CPRIT as well as individuals who would be served through activities that occur as a direct consequence of the CPRIT-funded project's leveraging of other resources/funding to implement the CPRIT-funded project.

APPENDIX B: WRITING GOALS AND OBJECTIVES

List only major **outcome goals** and **measurable objectives** for each year of the project. **Do not include process objectives**; these should be described in the project plan only. Include the proposed metric within **both** the stated Objective and the Measure sections (eg, Measure: 2,000 individuals, ages 9-12, will initiate HPV vaccination during the grant period).

The maximum number is 3 goals with 3 objectives each. Projects will be evaluated annually on progress toward **outcome** goals and objectives.

The following has been adapted with permission from Appalachia Community Cancer Network, NIH Grant U54 CA 153604:

Develop well-defined goals and objectives.

Goals provide a roadmap or plan for where a group wants to go. Goals can be long term (over several years) or short term (over several months). Goals should be based on needs of the community and evidence-based data.

Goals should be:

- Believable – situations or conditions that the group believes can be achieved
- Attainable – possible within a designated time
- Tangible – capable of being understood or realized
- On a timetable – with a completion date
- Win-Win – beneficial to individual members and the coalition

Objectives are measurable steps toward achieving the goal. They are clear statements of specific activities required to achieve the goal. The best objectives have several characteristics in common – S.M.A.R.T. + C:

- Specific – they tell how much (number or percent), who (participants), what (action or activity), and by when (date)
 - Example: 115 uninsured individuals age 50 and older will complete colorectal cancer screening by March 31, 2018.
- Measurable – specific measures that can be collected, detected, or obtained to determine successful attainment of the objective

- Example: How many screened at an event? How many completed pre/post assessment?
- Achievable – not only are the objectives themselves possible, it is likely that your organization will be able to accomplish them
- Relevant to the mission – your organization has a clear understanding of how these objectives fit in with the overall vision and mission of the group
- Timed – developing a timeline is important for when your task will be achieved
- Challenging – objectives should stretch the group to aim on significant improvements that are important to members of the community

Evaluate and refine your objectives

Review your developed objectives and determine the type and level of each using the following information:

There are 2 types of objectives:

- Outcome objectives – measure the “what” of a program; should be in the Goals and Objectives form (see [section 4.4.2](#))
- Process objectives – measure the “how” of a program; should be in the project plan only (see [section 4.4.4](#))

There are 3 levels of objectives:

- Community-level – objectives measure the planned community change
- Program impact – objectives measure the impact the program will have on a specific group of people
- Individual – objectives measures participant changes resulting from a specific program, using these factors:
 - Knowledge – understanding (know screening guidelines; recall the number to call for screening)
 - Attitudes – feeling about something (will consider secondhand smoke dangerous; believe eating 5 or more fruits and vegetable is important)
 - Skills – the ability to do something (complete fecal occult blood test)
 - Intentions – regarding plan for future behavior (will agree to talk to the doctor, will plan to schedule a Pap test)

- Behaviors (past or current) – to act in a particular way (will exercise 30+ minutes a day, will have a mammogram)

Well-defined outcome goals and objectives can be used to track, measure, and report progress toward achievement.

Summary Table

	Outcome – Use in Goals and Objectives	Process – Use in Project Plan only
Community-level	<p>WHAT will change in a community</p> <p><i>Example: As a result of CPRIT funding, FIT (fecal immunochemical tests) will be available to 1,500 uninsured individuals age 50 and over through 10 participating local clinics and doctors.</i></p>	<p>HOW the community change will come about</p> <p><i>Example: Contracts will be signed with participating local providers to enable uninsured individuals over age 50 have access to free colorectal cancer screening in their communities.</i></p>
Program impact	<p>WHAT will change in the target group as a result of a particular program</p> <p><i>Example: As a result of this project, 200 uninsured women between 40 and 49 will receive free breast and cervical cancer screening.</i></p>	<p>HOW the program will be implemented to affect change in a group/population</p> <p><i>Example: 2,000 female clients, between 40 and 49, will receive a letter inviting them to participate in breast and cervical cancer screening.</i></p>
Individual	<p>WHAT an individual will learn as a result of a particular program, or WHAT change an individual will make as a result of a particular program</p> <p><i>Example: As a result of one-to-one education of 500 individuals, at least 20% of participants will participate in a smoking cessation program to quit smoking.</i></p>	<p>HOW the program will be implemented to affect change in an individual's knowledge or actions</p> <p><i>Example: As a result of one-to-one counseling, all participants will identify at least 1 smoking cessation service and 1 smoking cessation aid.</i></p>

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)

21.2 Prevention Review Panel - 1 (21.2 PRV-P1)

Observation Report

Report No. 2021-04- 21.2_PRV-P1
Program Name: Prevention
Panel Name: 21.2 Prevention Review Panel - 1 (21.2_PRV-P1)
Panel Date: April 26, 2021 and April 27, 2021
Report Date: May 6, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Prevention Review Panel - 1 (21.2_PRV-P1) meeting. The meeting was chaired by Nancy Lee and conducted via videoconference on April 26, 2021 and April 27, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Eleven (11) applications were discussed on April 26, 2021; three (3) applications were discussed, and four (4) applications were not discussed on April 27, 2021
- Panelists: One (1) panel chair, nine (9) expert reviewers and three (3) advocate reviewers were present on April 26, 2021 and one (1) panel chair, eight (8) expert reviewers and three (3) advocate reviewers on April 27, 2021
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4) were present on April 26, 2021 and three (3) on April 27, 2021
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: One (1) on both days
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. There were zero (0) COIs on applications discussed and one (1) COI on an application not discussed.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the closing text.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

21.2 Prevention Review Council (21.2_PRC-M2)

Observation Report

Report No. 2021-06-17 21.2_PRC-M2
Program Name: Prevention
Panel Name: 21.2 Prevention Review Council (21.2_PRC-M2)
Panel Date: June 17, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Prevention Review Council (21.2_PRC-M2) meeting. The meeting was chaired by Stephen Wyatt and conducted via teleconference on June 17, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Nine (9) applications were discussed
- Panelists: One (1) panel chair, and two (2) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: One (1)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was zero (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line extending to the right.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Prevention Cycle 21.2

Awards Announced at the August 18, 2021, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Prevention Cycle 21.2 include *Evidence-Based Cancer Prevention Services*; *Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations*; *Tobacco Control and Lung Cancer Screening*; and *Dissemination of CPRIT-Funded Cancer Control Interventions*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant/Principal Investigator	Principal Investigator Institution	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
No conflicts reported.			
Applications not considered by the PIC or Oversight Committee:			
PP210023	Gail Tomlinson	The University of Texas Health Science Center at San Antonio	R. Riter

T.A.C. Section 702.19 Waiver



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS
FROM: WAYNE R. ROBERTS, CHIEF EXECUTIVE OFFICER
SUBJECT: T.A.C. § 702.19 STANDING WAIVER FOR FY 2021
DATE: AUGUST 28, 2020

Summary

This is to notify the Oversight Committee that pursuant to the authority provided to the Chief Executive Officer in T.A.C. § 702.19(e), I grant CPRIT's Chief Prevention Officer Ramona Magid a waiver from the general prohibition against communicating with grant applicants. The waiver is applicable for FY 2021. Unlike the two communication waivers I granted Ms. Magid for each FY 2020 review cycle, this standing FY 2021 waiver will be effective for both review cycles planned for FY 2021. No Oversight Committee action related to this waiver is necessary.

Background and Discussion

The Chief Prevention Officer is a statutorily mandated member of the Program Integration Committee (PIC). Texas Administrative Code § 702.19 prohibits substantive communication between the grant applicant and a member of the peer review panel, the PIC, or the Oversight Committee while the application is pending a final decision. The restriction on communication prevents even the appearance of unequal treatment during the grant review process.

Traditionally, a chief program officer leads each CPRIT program with the assistance of a program manager. The program manager fields inquiries from and provides technical help to applicants completing their CPRIT grant applications. I promoted Ms. Magid to the Chief Prevention Officer position upon Dr. Becky Garcia's retirement in June 2019. However, the prevention program manager position has remained vacant since Ms. Magid's promotion. Until CPRIT fills the program manager position, she is the sole point of contact for the prevention program. The communication waiver is necessary so that Ms. Magid can assist grant applicants who have questions during the application process.

I previously granted Ms. Magid separate waivers for the two review cycles of FY 2020. It is unlikely that CPRIT will fill the prevention program manager position in FY 2021. Accordingly, I am granting a standing waiver for Ms. Magid for FY 2021 as long as she remains the sole point of contact for the prevention program. Approving this standing waiver does not favor any grant applicant over another. Ms. Magid will provide technical assistance only and will not comment on the substance of a grant application. CPRIT will include this waiver in the grant record for the FY 2021 prevention grant applications.

De-Identified Overall Evaluation Scores

Evidence-Based Cancer Prevention Services Prevention Cycle 21.2

Application ID	Final Overall Evaluation Score
PP210049*	1.8
ba	4.3
bb	4.5
bc	4.7
bd	4.8
be	5.2
bf	5.5
bg	5.8
bh	6.3
bi	6.8

* Recommended for funding

Final Overall Evaluation Scores and Rank Order Scores

Dee Margo
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dee@deemargo.com

Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Mr. Roberts and Mr. Margo,

On behalf of the Prevention Review Council (PRC), I am pleased to provide the PRC's recommendations for the cycle 21.2 Evidence-Based Cancer Prevention Services (EBP), Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations (EPS), and Tobacco Control and Lung Cancer Screening (TCL) awards.

The PRC met on May 27, 2021 to review the applications submitted to CPRIT under the Dissemination of CPRIT-Funded Cancer Control Interventions (DI) mechanism. The PRC met again on June 17, 2021 to consider these applications and those recommended by the peer review panel following their April 26 meeting. The PRC recommends 9 projects totaling \$11,396,581.

The projects are numerically ranked in the order the PRC recommends the applications be funded. Recommended funding amounts and the overall evaluation score are stated for each grant application. The PRC made no changes to the goals, project objectives, or timelines of the applications.

Our recommendations meet the PRC's standards for grant award funding of projects that are evidence-based, deliver programs or services to underserved populations, and focus on primary, secondary, or tertiary prevention. In making these recommendations the PRC continued to consider the available funding, the composition of the current portfolio, and the programmatic priorities in the RFA which include potential for impact and return on investment, geographic distribution, cancer type and type of program. All the recommended grants address one or more of the Prevention Program priorities.

Sincerely,
Stephen W. Wyatt, DMD, MPH
Chair, CPRIT Prevention Review Council

Attachment



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Cycle 21.2 Recommended Prevention Program Awards

App. ID	Mech	Application Title	PD	Organization	Score	Rank Order	Budget
PP210045	DI	Dissemination of a Mailed Stool Testing Program for Colorectal Cancer Prevention in Underserved Communities in Texas	Pignone, Michael	The University of Texas at Austin	1.00	1	\$300,000
PP210049	EBP	Texas Southern University Breast Cancer Screening and Prevention Center	Ajewole, Veronica	Texas Southern University	1.80	2	\$1,000,000
PP210020	EPS	Vaccinating Medically Underserved Women Against HPV: Expansion of Clinical Services to Increase Access	Berenson, Abbey	The University of Texas Medical Branch at Galveston	2.00	3	\$1,999,988
PP210042	TCL	A Regional Expansion of Lung Cancer Screening and Patient Navigation (E-LSPAN)	Argenbright, Keith	The University of Texas Southwestern Medical Center	2.10	4	\$1,999,993
PP210026	DI	Taking Texas Tobacco Free: Dissemination to and Implementation Within Agencies Serving Texans Experiencing	Reitzel, Lorraine	University of Houston	2.70	5	\$299,978
PP210027	TCL	Increasing Accessibility to Smoking Cessation and Lung Cancer Screening Services for Low-Income/Uninsured Texans	McKnight, Jason	Texas A&M University System Health Science Center	3.10	6	\$999,947
PP210031	DI	Application of mHealth Technologies to Improve Latino Childhood Cancer Survivor Engagement and Use of Evidence for Personalized Follow-Up Care	Poplack, David	Baylor College of Medicine	3.30	7	\$299,982
PP210007	EPS	Strengthening Safety Net Health Systems to Improve Cervical and Colorectal Cancer Screening and Follow-up among the Medically Underserved	Montealegre, Jane R	Baylor College of Medicine	3.30	8	\$2,497,029
PP210044	TCL	Expansion of the Lung Cancer Screening and Tobacco Control (LCTC) Network to Rural and Medically Underserved Populations	Zoorob, Roger	Baylor College of Medicine	3.60	9	\$1,999,664

DI: Dissemination of CPRIT-Funded Cancer Control Interventions

EBP: Evidence-Based Cancer Prevention Services

EPS: Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations

TCL: Tobacco Control and Lung Cancer Screening



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

Prevention

FY 2021—Cycle 2

***Expansion of Cancer Prevention Services to Rural
and Medically Underserved Populations***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA P-21.2-EPS

**Expansion of Cancer Prevention Services to
Rural and Medically Underserved Populations**

**Please also refer to the Instructions for Applicants document,
which will be posted on November 16, 2020**

Application Receipt Opening Date: November 16, 2020

Application Receipt Closing Date: February 10, 2021

FY 2021

Fiscal Year Award Period

September 1, 2020–August 31, 2021

TABLE OF CONTENTS

1. ABOUT CPRIT	5
1.1 PREVENTION PROGRAM PRIORITIES.....	5
2. FUNDING OPPORTUNITY DESCRIPTION	6
2.1 SUMMARY	6
2.2 PROJECT OBJECTIVES	8
2.3 AWARD DESCRIPTION.....	9
2.4 PRIORITIES.....	12
2.5 SPECIFIC AREAS OF EMPHASIS.....	13
2.6 OUTCOME METRICS.....	15
2.7 ELIGIBILITY	16
2.8 RESUBMISSION POLICY	17
2.9 FUNDING INFORMATION	18
3. KEY DATES.....	19
4. APPLICATION SUBMISSION GUIDELINES	19
4.1 <i>INSTRUCTIONS FOR APPLICANTS</i> DOCUMENT	19
4.2 ONLINE APPLICATION RECEIPT SYSTEM.....	19
4.3 SUBMISSION DEADLINE EXTENSION	20
4.4 APPLICATION COMPONENTS	20
4.4.1 <i>Abstract and Significance (5,000 characters)</i>	20
4.4.2 <i>Goals and Objectives (700 characters each)</i>	21
4.4.3 <i>Project Timeline (2 pages)</i>	21
4.4.4 <i>Project Plan (12 pages; fewer pages permissible)</i>	21
4.4.5 <i>People Reached (Indirect Contact)</i>	24
4.4.6 <i>Number of Services Delivered (Direct Contact)</i>	24
4.4.7 <i>Number of Clinical Services Delivered</i>	25
4.4.8 <i>Number of Unique People Served (Direct Contact)</i>	25
4.4.9 <i>References</i>	25
4.4.10 <i>Resubmission Summary</i>	25
4.4.11 <i>Most Recently Funded Project Summary (3 pages)</i>	25
4.4.12 <i>CPRIT Grants Summary</i>	26
4.4.13 <i>Budget and Justification</i>	26
4.4.14 <i>Current and Pending Support and Sources of Funding</i>	28
4.4.15 <i>Biographical Sketches</i>	28
4.4.16 <i>Collaborating Organizations</i>	29
4.4.17 <i>Letters of Commitment (10 pages)</i>	29
5. APPLICATION REVIEW	29
5.1 REVIEW PROCESS OVERVIEW	29
5.2 REVIEW CRITERIA	31
5.2.1 <i>Primary Evaluation Criteria</i>	31
5.2.2 <i>Secondary Evaluation Criteria</i>	33
6. AWARD ADMINISTRATION.....	33

7. CONTACT INFORMATION 35
7.1 HELPDESK 35
7.2 PROGRAM QUESTIONS 35
8. RESOURCES 36
9. REFERENCES 37
APPENDIX A: KEY TERMS 38
APPENDIX B: WRITING GOALS AND OBJECTIVES 41

RFA VERSION HISTORY

Rev 10/16/2020 RFA release

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of or cures for cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

1.1 Prevention Program Priorities

Legislation from the 83rd Texas Legislature requires that CPRIT's Oversight Committee establish program priorities on an annual basis. The priorities are intended to provide transparency in how the Oversight Committee directs the orientation of the agency's funding portfolio. The Prevention Program's principles and priorities will also guide CPRIT staff and the Prevention Review Council on the development and issuance of program-specific Requests for Applications (RFAs) and the evaluation of applications submitted in response to those RFAs.

Established Principles

- Fund evidence-based interventions and their dissemination
- Support the prevention continuum of primary, secondary, and tertiary (includes survivorship) prevention interventions

Prevention Program Priorities

- Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
- Prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
- Prioritize underserved populations

2. FUNDING OPPORTUNITY DESCRIPTION

2.1 Summary


The ultimate goals of the CPRIT Prevention Program are to reduce overall cancer incidence and mortality and to improve the lives of individuals who have survived or are living with cancer. The ability to reduce cancer death rates depends in part on the application of currently available evidence-based technologies and strategies. CPRIT fosters the primary, secondary, and tertiary prevention of cancer in Texas by providing financial support for a wide variety of evidence-based risk reduction, early detection, and survivorship interventions.

This award mechanism seeks to support the coordination and expansion of evidence-based services to prevent or screen for cancer in underserved populations who do not have adequate access to cancer prevention interventions and health care, bringing together networks of public health and community partners to carry out programs tailored for their communities. Projects should identify cancers that cause the most burden in the community and use evidence-based models to prevent and control these cancers.


Eligible applicants include only those with currently or previously funded CPRIT Prevention projects.

Initial Expansion: For the first expansion application, eligible applicants should propose to expand their programs to include additional types of prevention clinical services or to expand current clinical services into additional counties. In either case, the expansion must include the delivery of services to nonmetropolitan (rural) and/or medically underserved counties in the state. These may be identified via Web-based tools from the [Texas Department of State Health Services](#) and [US Department of Health and Human Services](#).

Maintenance Expansion: For a subsequent expansion, additional clinical services and/or expansion to additional counties is optional; however, the counties and the services offered in the first expansion should not be decreased. The number of clinical services delivered during the maintenance expansion must be increased substantially if no further geographic or clinical service expansion is proposed.



Texas Medically Underserved Areas (MUA) and Populations (MUP)



Data source: US Health Resources and Services Administration Data Warehouse, October 2019

2.2 Project Objectives

CPRIT seeks to fund initial expansion evidence-based prevention projects that will do the following:

- Expand an eligible CPRIT project by adding and integrating the delivery of 1 or more of the following to an existing project:
 - Screenings, rescreenings, and diagnostics for breast, cervical, colorectal cancers; hepatitis C virus; genetic risk factors
 - Vaccinations against HPV and hepatitis B virus
 - Evidence-based interventions focused on tobacco prevention (prevent tobacco use or sustained abstinence) and tobacco cessation among youth and/or adults
- Expand an eligible CPRIT project by adding and integrating the delivery of services to additional nonmetropolitan and/or medically underserved counties.

CPRIT seeks to fund maintenance expansion evidence-based prevention projects that will do the following:

- Maintain, at a minimum, clinical service delivery and geographic area expansion as proposed in the previously funded expansion project. Further expansion of clinical services and geographic area is optional.
- Substantially increase the number of clinical services delivered if no further expansion is proposed.

Both initial and maintenance expansion evidence-based prevention projects funded by CPRIT will do the following:

- Coordinate the resources (clinical service providers, community organizations, etc) in nonmetropolitan and medically underserved areas (MUAs) to increase the availability of services and, where providers are available, help connect people with their local health care providers.
- Leverage the infrastructure, networks, and resources that have been put in place by CPRIT-supported projects while minimizing start-up time.
- Deliver comprehensive projects comprising all of the following: public and/or professional education, outreach, delivery of clinical services, follow-up navigation, and system and/or policy improvements.

- Offer effective and efficient systems of delivery of prevention services based on the existing body of knowledge about, and evidence for, cancer prevention in ways that far exceed current performance in a given service area.
- Implement policy changes and/or system improvements that are sustainable over time (eg, decrease wait times between positive screen and diagnostic tests and treatment through improved navigation, reminder systems, etc).

2.3 Award Description

CPRIT’s **Expansion of Cancer Prevention Services** grants are intended to fund the expansion of eligible projects that have demonstrated exemplary success, as evidenced by progress reports and project evaluations, and desire to further enhance their impact on priority populations. Detailed descriptions of **established infrastructure, results, barriers, outcomes, and impact of the most recently funded project are required** (see outline of Project Plan, [section 4.4.4](#)).

Projects in the last year of a current grant or previously funded projects may apply for this expansion. Programs must have at least 1 full year of data to report before applying (see [section 2.7](#) eligibility criteria).

This mechanism will fund case management/patient navigation to screening, to diagnostic testing, and to treatment. Applicants must ensure that there is access to treatment services for patients with precancer or cancers that are detected as a result of the project and must describe in detail the process for ensuring access to treatment services in their application.

Applicants should not request funds for any of the above components if these components are already being funded from other sources. If clinical services are being provided and paid by others, the applicant must explain and report on the outcomes and services that are delivered to the people navigated by the program.

The following are required components of the project:

- **Initial Expansion:** Expansion to nonmetropolitan/MUA counties and/or offering additional clinical services are required for an initial expansion. To qualify for this Expansion RFA, CPRIT requires applicants to either add the delivery of 1 or more of the following clinical services to their project or to expand to additional nonmetropolitan and/or MUA counties.

- Screenings and rescreenings for breast, cervical, colorectal cancers; hepatitis C virus; genetic risk factors
- Vaccinations against HPV; hepatitis B virus
- Evidence-based interventions focused on tobacco prevention (prevent tobacco use or sustained abstinence) and tobacco cessation among youth and/or adults

Expansion of eligible projects into nonmetropolitan/medically underserved geographic areas not well served by the CPRIT portfolio (see maps at <https://www.cprit.texas.gov/our-programs/prevention/portfolio-maps>) will receive priority consideration.

- **Maintenance Expansion:** The clinical service and/or geographic expansion from the previously funded CPRIT expansion project must be maintained, at a minimum. Further expansion is optional. If no further expansion of clinical services and/or geography is proposed, the number of clinical services delivered must be substantially increased from the initial expansion.
- **Comprehensive Projects:** Comprehensive projects include a continuum of services and systems and policy changes and comprise all of the following: Public and/or professional education and training, outreach, delivery of screening and diagnostic services, follow-up navigation, data collection and tracking, and systems improvement.
- **Evidence Based:** CPRIT’s service grants are intended to fund effective and efficient systems of delivery of prevention services based on the existing body of knowledge about and evidence for cancer prevention in ways that far exceed current performance in a given service area. The provision of clinical services, including rescreening at the appropriate interval, must comply with established and current national guidelines (eg, US Preventive Services Task Force [USPSTF], American Cancer Society, etc).

If evidence-based strategies have not been implemented or tested for the specific population or service setting proposed, provide evidence that the proposed service is appropriate for the population and has a high likelihood of success. Baseline data (eg, availability of resources and screening coverage) for the target population and target service region are required. If no baseline data exist, the applicant must present clear plans and describe method(s) of measurement used to collect the data necessary to establish a baseline.

Clinical Service and Community Partner Networks. Applicants are encouraged to coordinate and describe a coalition of clinical service providers and community partners that can deliver outreach, education, clinical, and navigation services to the most counties and the most people possible in a selected service region. Partnerships with other organizations that can support and leverage resources (ie, community-based organizations, local and voluntary agencies, nonprofit agencies, groups that represent priority populations, etc) are encouraged. Letters of commitment or memoranda of understanding describing their specific role in the partnership will strengthen the application. Leveraging of the infrastructure, existing networks, and other resources that were established for the eligible CPRIT-funded project are expected and should be well described.

Project Coordination and Technical Assistance. The overall program should be directed and overseen by the Program Director (PD) who is responsible for establishing and managing the network. Responsibilities of the PD include the following:

- Establishing any necessary subcontracts or memoranda of understanding with project partners and clinical service providers;
- Regularly communicating with partners to discuss progress and barriers, resolve potential problems, and provide technical assistance as needed throughout the duration of the project;
- Meeting all reporting requirements. CPRIT expects measurable outcomes of supported activities, such as a significant increase over baseline (for the proposed service area) in the provision of evidence-based services, changes in provider practice, systems changes, and cost-effectiveness.

If applicable, in cases where the project proposes to work with multiple clinical providers, the PD should facilitate the establishment of standard protocols for all clinical service providers in the network as well as standard systems, policies, and procedures for the participating clinical service providers and organizations. These may include, but are not limited to, patient tracking and timely follow-up of all abnormal screening results and/or diagnoses of cancer.

Under this RFA, CPRIT **will not** consider the following:

- **Continuation of currently funded projects.** Projects must include the required expansion criteria detailed in the RFA.
- **New or expansion projects focusing solely on tobacco prevention and/or cessation for any age** should apply under CPRIT's Tobacco Control and Lung Cancer Screening RFA.

- **Projects focusing on computerized tomography screening for lung cancer for ages 55 to 77.** Applicants with projects including lung cancer CT screening should apply under CPRIT’s Tobacco Control and Lung Cancer Screening RFA.
- **New evidence-based cancer prevention services projects;** these applicants should apply under CPRIT’s Evidence-Based Cancer Prevention Services RFA.
- **Expansion of currently funded primary prevention projects focused on obesity control/healthy living or tertiary prevention projects;** these applicants should apply under CPRIT’s Evidence-Based Cancer Prevention Services RFA.
- **Projects focused solely on systems and/or policy change or solely on education and/or outreach that do not include the delivery of cancer preventive clinical services.**
- **Projects focusing solely on case management/patient navigation services through the treatment phase of cancer.** Case management/patient navigation services must be paired with the delivery of a clinical cancer prevention service and reported to CPRIT.
- **Projects focused solely on counseling services with no additional evidence-based clinical services.**
- **Resources for the treatment of cancer or viral treatment for hepatitis.**
- **Prevention/intervention research.** Applicants interested in prevention research should review CPRIT’s Academic Research RFAs (available at <http://www.cprit.texas.gov>).

2.4 Priorities

Types of Cancer: Applications addressing the services listed in [section 2.2](#) Project Objectives and that are responsive to this RFA will be considered for funding. See [section 2.5](#) for specific areas of emphasis.

The Prevention Program’s priorities for funding include the following:

1) **Populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence.**

CPRIT programs must address underserved populations. Underserved populations are subgroups that are disproportionately affected by cancer. CPRIT-funded efforts must address 1 or more of these priority populations:

- Underinsured and uninsured individuals

- Medically unserved or underserved populations
- Racial, ethnic, and cultural minority populations
- Populations with low screening rates, high incidence rates, and high mortality rates, focusing on individuals never before screened or who are significantly out of compliance with nationally recommended screening guidelines (more than 5 years for breast/cervical cancers).

The age of the priority population and frequency of screening for provision of clinical services described in the application must comply with established and current national guidelines (eg, USPSTF, American Cancer Society).

2) Geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence.

While disparities and needs exist across the state, CPRIT will also prioritize applications proposing to serve geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence. For this RFA, projects must propose to serve nonmetropolitan and/or MUAs of the state. In addition, projects addressing areas of emphasis (see [section 2.5](#)) will receive priority consideration.

Geographic and Population Balance in Current CPRIT portfolio

At the programmatic level of review conducted by the Prevention Review Council (see [section 5.1](#)), priority will be given to projects that target geographic regions of the state and population subgroups that are not adequately covered by the current CPRIT Prevention project portfolio (see <https://www.cprit.texas.gov/our-programs/prevention/portfolio-maps> and <https://www.cprit.texas.gov/grants-funded?search=prevention>).

2.5 Specific Areas of Emphasis

Applications addressing any of the services listed in [section 2.2](#) and that are responsive to this RFA will be considered. For those services, CPRIT has identified the following areas of emphasis for this cycle of awards.

<u>Primary Prevention</u>
HPV Vaccination
<ul style="list-style-type: none"> Increasing access to, delivery of, and completion of the HPV vaccine regimen to males and females through evidence-based intervention efforts in all areas of the state.¹
Tobacco Prevention and Control
<ul style="list-style-type: none"> Vulnerable and high-risk populations, including people with mental illness, history of substance abuse, youth, and pregnant women, that have higher tobacco usage rates than the general population. Areas that have higher smoking rates per capita than other areas of the state. Public Health Regions (PHR) 2, 4, 5, 8, and 9 have significantly higher tobacco use among adults than in other regions of the state.
Liver Cancer
<ul style="list-style-type: none"> Screening for HBV infection and HCV infection in populations at high risk of infection. Increasing screening rates in PHR 8, 10, and 11. Incidence and mortality rates are highest in PHR 10 and 11.²
<u>Secondary Prevention - Screening and Early Detection Services</u>
Colorectal Cancer
<ul style="list-style-type: none"> Decreasing disparities in incidence and mortality rates of colorectal cancer in racial/ethnic populations. Blacks have the highest incidence and mortality rates, followed by non-Hispanic whites and Hispanics.² Increasing screening/detection rates in PHR 2, 4, and 5, where the highest rates of cancer incidence and mortality are found. Decreasing incidence and mortality rates in nonmetropolitan counties. Incidence and mortality rates are higher in nonmetropolitan counties compared with metropolitan counties.²
Breast Cancer
<ul style="list-style-type: none"> Decreasing disparities in mortality rates of breast cancer in racial/ethnic populations. The mortality rate is significantly higher in blacks than in other populations.² Increasing screening/detection rates in medically underserved areas of the state.
Cervical Cancer
<ul style="list-style-type: none"> Decreasing disparities in incidence and mortality rates of cervical cancer in racial/ethnic populations. Hispanics have the highest incidence rates while blacks have the highest mortality rates.² Increasing screening/detection rates in medically underserved areas of the state.

2.6 Outcome Metrics

Applicants are required to clearly describe their assessment and evaluation methodology. The applicant is required to describe final outcome measures for the project. Output measures that are associated with the final outcome measures should be identified in the project plan and will serve as a measure of program effectiveness. Planned policy or system changes/improvements should be identified and the plan for qualitative analysis described. **Baseline data for each measure proposed are required.** In addition, applicants should describe how funds from the CPRIT grant will improve outcomes over baseline. If the applicant is not providing baseline data for a measure, the applicant must provide a well-justified explanation and describe clear plans and method(s) of measurement to collect the data necessary to establish a baseline.

Reporting Requirements

Funded projects are required to report quantitative output and outcome metrics (as appropriate for each project) through the submission of quarterly progress reports, annual reports, and a final report.

If clinical services are being paid for and provided by others, the applicant is required to report on the number of clinical services and patient outcomes (eg, screenings/diagnostics, vaccinations, cancer precursors, cancers detected) that are delivered to the people navigated by the program.

- Quarterly progress report sections include, but are not limited to, the following:
 - Summary page, including narrative on project progress (required);
 - Services, other than clinical services, provided to the public/professionals;
 - Actions taken by people/professionals as a result of education or training;
 - Clinical services provided (county of residence of client is required); and
 - Precursors and cancers detected.
- Annual and final progress report sections include, but are not limited to, the following:
 - Key accomplishments, **including qualitative analysis of policy change and/or lasting systems change**;
 - Progress toward goals and outcome objectives, including percentage increase over baseline in provision of age- and risk-appropriate comprehensive preventive services to eligible individuals in a defined service area;
 - Materials produced and publications; and
 - Economic impact of the project.

2.7 Eligibility

- Eligible applicants include only those with currently or previously funded CPRIT Prevention projects.
- To justify the expansion, applicants must leverage the infrastructure and networks of the most recently funded CPRIT project.
- Applicants may submit an expansion application before the end of the currently funded project but should time their submission during the last year of the current project to ensure minimal overlap of funding. Unexpended funds from the original project will not carry forward to the expansion project. To apply for an expansion of a current project, projects must have at least 1 full year of results and data.
- The applicant must be a Texas-based entity that previously received CPRIT funding through Prevention Program RFAs.
- The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application is submitted.
- The designated Program Director (PD) will be responsible for the overall performance of the funded project. The PD must have relevant education and management experience and must reside in Texas during the project performance time.
- The evaluation of the project must be headed by a professional who has demonstrated expertise in the field and who resides in Texas during the time that the project is conducted.
- If the applicant or a partner is an existing Department of State Health Services (DSHS) contractor, CPRIT funds may not be used as a match, and the application must explain how this grant complements or leverages existing state and federal funds. DSHS contractors who also receive CPRIT funds must be in compliance with and fulfill all contractual obligations within CPRIT. CPRIT and DSHS reserve the right to discuss the contractual standing of any contractor receiving funds from both entities.
- Collaborations are permitted and encouraged, and collaborators may or may not reside in Texas. However, collaborators who do not reside in Texas are not eligible to receive CPRIT funds. Subcontracting and collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.

- An applicant is not eligible to receive a CPRIT grant award if the applicant PD, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member.
- An applicant organization is eligible to receive a grant award only if the applicant certifies that the applicant organization, including the PD, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization, (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation created to benefit CPRIT.
- The applicant must report whether the applicant organization, the PD, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way (whether slated to receive salary or compensation under the grant award or not) are currently ineligible to receive federal grant funds because of scientific misconduct or fraud or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. CPRIT grants are funded on a reimbursement-only basis. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 6](#). All statutory provisions and relevant administrative rules can be found [on the CPRIT website](#).

2.8 Resubmission Policy

- **One resubmission** is permitted. An application is considered a resubmission if the proposed project is the same project as presented in the original submission. A change in the identity of the PD for a project or a change of title for a project that was previously submitted to CPRIT does not constitute a new application; the application would be considered a resubmission.

- Applicants who choose to resubmit should carefully consider the reasons for lack of prior success. Applications that received overall numerical scores of 5 or higher are likely to need considerable attention. All resubmitted applications should be carefully reconstructed; a simple revision of the prior application with editorial or technical changes is not sufficient, and applicants are advised not to direct reviewers to such modest changes. A 1-page summary of the approach to the resubmission should be included. Resubmitted applications may be assigned to reviewers who did not review the original submission. Reviewers of resubmissions are asked to assess whether the resubmission adequately addresses critiques from the previous review. **Applicants should note that addressing previous critiques is advisable; however, it does not guarantee the success of the resubmission.** All resubmitted applications must conform to the structure and guidelines outlined in this RFA.

2.9 Funding Information

Applicants may request any amount of funding up to a maximum of \$2 million in total funding over a maximum of 36 months for an initial expansion. For any subsequent expansion, applicants may request up to a maximum of \$2.5 million in total funding over a maximum of 5 years (60 months). A **significant expansion** in the geographic area and/or clinical services provided for the initial expansion, or number of clinical services delivered for any subsequent expansion, as described in [section 2.3](#), is required. Grant funds may be used to pay for clinical services, navigation services, salary and benefits, project supplies, equipment, costs for outreach and education of populations, and travel of project personnel to project site(s). Applicants must ensure that there is access to treatment services for patients with precancers or cancers that are detected as a result of the program and must describe access to treatment services in their application.

Requests for funds to support construction or renovation or requests to support lobbying will not be approved under this mechanism. Cost sharing for equipment purchases is encouraged. Grantees may request funds for travel for 2 project staff to attend CPRIT's conference.

The budget should be proportional to the number of individuals receiving programs and services, and a significant proportion of funds is expected to be used for program delivery as opposed to program development. In addition, CPRIT funding should not be used to replace existing funding,

supplant funds that would normally be expended by the applicant's organization, or make up for funding reductions from other sources.

State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the **total** award amount.

3. KEY DATES

RFA release	October 16, 2020
Online application opens	November 16, 2020, 7 AM central time
Application due	February 10, 2021, 4 PM central time
Application review	March-July 2021
Award notification	August 2021
Anticipated start date	August 31, 2021

Applicants will be notified of peer review panel assignment prior to the peer review meeting dates.

4. APPLICATION SUBMISSION GUIDELINES

4.1 *Instructions for Applicants* document

It is imperative that applicants read the accompanying instructions document for this RFA that will be available November 16, 2020 (<https://CPRITGrants.org>). Requirements may have changed from previous versions.

4.2 **Online Application Receipt System**

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The PD must create a user account in the system to start and submit an application. The Co-PD, if applicable, must also create a user account to participate in the application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (an individual who will help manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on November 16, 2020, and must be submitted by 4 PM central time on February 10, 2021. Detailed instructions for submitting an application are in the *Instructions for Applicants* document, posted on CARS.

Submission of an application is considered an acceptance of the terms and conditions of the RFA.

4.3 Submission Deadline Extension

The submission deadline may be extended for 1 or more grant applications upon a showing of good cause. All requests for extension of the submission deadline must be submitted via email to the [CPRIT Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records.

4.4 Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Refer to the *Instructions for Applicants* document for details.

Submissions that are missing 1 or more components or do not meet the eligibility requirements may be administratively withdrawn without review.

4.4.1 Abstract and Significance (5,000 characters)

Clearly explain the problem(s) to be addressed, the approach(es) to the solution, and how the application is responsive to this RFA. In the event that the project is funded, the abstract will be made public; therefore, no proprietary information should be included in this statement. Initial compliance decisions are based in part upon review of this statement.

The abstract format is as follows (use headings as outlined below):

- **Need:** Include a description of need in the specific service area. Include rates of incidence, mortality, and screening in the service area compared to overall Texas rates. Describe barriers, plans to overcome these barriers, and the priority population to be served.
- **Overall Project Strategy:** Describe the project and how it will address the identified need. Clearly explain what the project is and what it will specifically do, including the services to be provided and the process/system for delivery of services and outreach to the priority population.
- **Specific Goals:** State specifically the overall goals of the proposed project; include the estimated overall numbers of people (public and/or professionals) reached and people (public and/or professionals) served.

- **Significance and Impact:** Explain how the proposed project, if successful, will have a major impact on cancer prevention and control for the population proposed to be served and for the State of Texas.

4.4.2 Goals and Objectives (700 characters each)

List only major **outcome goals** and **measurable objectives** for each year of the project. **Do not include process objectives**; these should be described in the project plan only. Include the proposed metric within both the stated Objective **and** the Measure sections (eg, Measure: 2,000 individuals, age 9-12, will initiate HPV vaccination during the grant period). Applications may be returned for revision if the proposed metric is not included within the Measure section. Refer to the *Instructions for Applicants* document for details.

The maximum number is 3 goals with 3 objectives each. Projects will be evaluated annually on progress toward outcome goals and objectives. See [Appendix B](#) for instructions on writing outcome goals and objectives.

A baseline and method(s) of measurement are required for each objective. Provide both raw numbers and percent changes for the baseline and target. If a baseline has not been defined, applicants are required to explain plans to establish baseline and describe method(s) of measurement.

4.4.3 Project Timeline (2 pages)

Provide a project timeline for project activities that includes deliverables and dates. Use Years 1, 2, 3 and Months 1, 2, 3, etc, as applicable (eg, Year 1, Months 3-5), instead of specific months or years. Month 1 is the first full month of the grant award.

4.4.4 Project Plan (12 pages; fewer pages permissible)

The required project plan format follows. Applicants must use the headings outlined below.

Background: Briefly present the rationale behind the proposed service, emphasizing the critical barriers to current service delivery that will be addressed. Identify the evidence-based service to be implemented for the priority population. Describe the race, ethnicity, age, and other defining characteristics of the population to be served.

If evidence-based strategies have not been implemented or tested for the specific population or service setting proposed, provide evidence that the proposed service is appropriate for the population and has a high likelihood of success. Baseline data for the priority population and target service area are required where applicable.

Reviewers will be aware of national and state statistics, and these should be used only to compare rates for the proposed service area. Describe the geographic region of the state that the project will serve; maps are encouraged.

Goals and Objectives: Process objectives should be included in the project plan. Outcome goals and objectives will be entered in separate fields in CARS. However, if desired, outcome goals and objectives may be fully repeated or briefly summarized here. See [Appendix B](#) for instructions on writing goals and objectives.

Components of the Project: Clearly describe the need, delivery method, and evidence base (provide references) for the services as well as anticipated results. Be explicit about the base of evidence and any necessary adaptations for the proposed project. Describe why this project is nonduplicative. Describe how the proposed project leverages the infrastructure, networks, and resources that have been put in place by the most recently funded CPRIT project while minimizing start-up time.

It is important to distinguish between Texas counties where the project proposes to deliver services and counties of residence of population served (see [Appendix A](#) for definitions and *Instructions for Applicants*). Only counties with service delivery should be listed in the Geographic Area to be Served section of the application. Projecting counties of residence of population served is not required but may be described in the project plan.

Clearly demonstrate the ability to provide the proposed service and describe how results will be improved over baseline and the ability to reach the priority population. Describe the method(s) that will be used to recall for appropriate rescreening those individuals who have been screened through this project. Describe any planned policy changes or system improvements.

If clinical services are being paid for and provided by others, the applicant must explain and report on the number of clinical services and patient outcomes (eg, screenings/diagnostics, vaccinations, cancer precursors, cancers detected) that are delivered to the people navigated by the program.

Applicants must also clearly and thoroughly describe plans to **ensure access to treatment** services should precancer or cancer be detected.

Evaluation Strategy: A strong commitment to evaluation of the project is required. Describe the plan for outcome and output measurements, including qualitative analysis of policy and system changes. Describe data collection and management methods, data analyses, and anticipated results. Evaluation and reporting of results should be headed by a professional who has demonstrated expertise in the field. If needed, applicants may want to consider seeking expertise at Texas-based academic cancer centers, schools/programs of public health, or the like. Applicants should budget accordingly for the evaluation activity and should involve that professional during grant application preparation to ensure, among other things, that the evaluation plan is linked to the proposed goals and objectives.

Organizational Qualifications and Capabilities: Describe the organization and its track record and success in providing health programs and services. Describe the role and qualifications of the key collaborators/partners in the project. Include information on the organization's financial stability and viability. The applicant should demonstrate how the organizational environment will contribute to a successful project. If equipment or physical resources are required to carry out the project, the applicant should describe the availability of these resources and the organizational capacity to use the equipment. To ensure access to preventive services and reporting of services outcomes, applicants should demonstrate that they have provider partnerships and agreements (via memoranda of understanding) or commitments (via letters of commitment) in place.

CPRIT acknowledges that full maintenance and sustainability of projects when CPRIT funding ends may not be feasible, especially in cases involving the delivery of clinical services. However, it is important to consider sustainability early in the life cycle of a project, particularly regarding organizational characteristics and processes that are modifiable.

Washington University in St Louis has developed a useful tool ([Program Sustainability Assessment Tool](#)) to assess program capacity for sustainability. The tool assesses several factors that contribute to program sustainability. These factors include environmental support, funding stability, partnerships, organizational capacity, program evaluation, program adaptation, communication, and strategic planning. Applicants are not required to use this tool; however, it provides practical

guidance on factors that should be considered and should be included in the application to describe a program's organizational capacity for sustainability.

It is expected that steps toward building sustainability capacity for the program will be taken and plans for such be briefly described in the application. The applicant should assess and describe the factors that will contribute to the organization's capacity to facilitate sustainability.

Dissemination and Replication: Dissemination of project results and outcomes, including barriers encountered and successes achieved, is critical to building the evidence base for cancer prevention and control efforts in the state. Dissemination efforts should consider the message, source, audience, and channel (Brownson, R.C., et al. [*J Pub Health Manag Pract.* 24\(2\):102-111](#), March/April 2018). Dissemination methods may include, but are not limited to, presentations at workshops and seminars, one-on-one meetings, publications, news media, social media, etc.

While passive dissemination methods are common (eg, publications, presentations at professional meetings), plans should include some active dissemination methods (eg, meetings with stakeholders, blogs, social media). Applicants should describe their dissemination plans. The plans should include the kinds of audiences to be targeted and methods for reaching the targeted audiences.

Replication by others is an additional way to disseminate the project. For applicable components, describe how the project or components of the project lend themselves to application by other communities and/or organizations in the state or expansion in the same communities. Describe what components of this project can be adapted to a larger or lower-resource setting. Note that some programs may have unique resources and may not lend themselves to replication by others.

4.4.5 People Reached (Indirect Contact)

Provide the estimated overall number of people (members of the public and professionals) to be reached by the funded project. The applicant is required to itemize separately the types of indirect noninteractive education and outreach activities, with estimates, that led to the calculation of the overall estimates provided. Refer to [Appendix A](#) for definitions.

4.4.6 Number of Services Delivered (Direct Contact)

Provide the estimated overall number of services directly delivered to members of the public and to professionals by the funded project. Each individual service should be counted, regardless of the

number of services one person receives. The applicant is required to itemize separately the education, navigation, and clinical activities/services, with estimates, that led to the calculation of the overall estimate provided. Refer to [Appendix A](#) for definitions.

4.4.7 Number of Clinical Services Delivered

Provide the estimated overall number of clinical services directly delivered to members of the public by the funded project. Each individual clinical service should be counted, regardless of the number of services one person receives. Separately itemize the clinical services, with estimates, that led to the calculation of the overall estimate provided. Refer to [Appendix A](#) for definitions.

4.4.8 Number of Unique People Served (Direct Contact)

Provide the estimated overall number of unique members of the public and professionals served by the funded project. One person may receive multiple services but should only be counted once here. Refer to [Appendix A](#) for definitions.

4.4.9 References

Provide a concise and relevant list of references cited for the application. The successful applicant will provide referenced evidence and literature support for the proposed services.

4.4.10 Resubmission Summary

Use the template provided on the CARS (<https://CPRITGrants.org>). Describe the approach to the resubmission and how reviewers' comments were addressed. Clearly indicate to reviewers how the application has been improved in response to the critiques. Refer the reviewers to specific sections of other documents in the application where further detail on the points in question may be found.

When a resubmission is evaluated, responsiveness to previous critiques is assessed.

The summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission; the applicant is not responsible for providing this document.

4.4.11 Most Recently Funded Relevant Project Summary (3 pages)

Upload a summary that outlines the progress made with the most recently funded relevant CPRIT award. Applicants must describe results and outcomes of the most recently funded relevant award and demonstrate why further funding is warranted.

Please note that a different set of reviewers from those assigned to the previously funded application may evaluate this application. Applicants should make it easy for reviewers to compare the most recently funded relevant project with the proposed expansion project.

In the description include the following:

- Describe the evidence-based intervention, its purpose, and how it was implemented in the priority population. Describe any adaptations made for the population served.
- List approved goals and objectives of the most recently funded grant.
- For each objective, provide the following information:
 - Milestones/target dates and target metrics
 - Actual completion dates and metrics
- For the most recently funded relevant project, describe major activities; significant results, including major findings, developments, or conclusions (both positive and negative); and key outcomes. If the project has not yet ended, provide projections for completion dates and final metrics. Include a discussion of objectives not fully met. Explain any barriers encountered and strategies used to overcome these.
- Describe steps taken toward sustainability for components of the project. Fully describe systems or policy improvements and enhancements.
- Describe how project results were disseminated or plans for future dissemination of results.

4.4.12 CPRIT Grants Summary

Use the template provided on the CARS (<https://CPRITGrants.org>). Provide a listing of **all** projects funded by the CPRIT Prevention program for the PD and the Co-PD, regardless of their connection to this application.

4.4.13 Budget and Justification

Provide a brief outline and detailed justification of the budget for the entire proposed period of support, including salaries and benefits, travel, equipment, supplies, contractual expenses, services delivery, and other expenses. CPRIT funds will be distributed on a reimbursement basis.

Applications requesting more than the maximum allowed cost (total costs) as specified in [section 2.9](#) will be administratively withdrawn.

- **Average Cost per Service:** The average cost per service will be automatically calculated from the total cost of the project divided by the total number of services delivered (refer to [Appendix A](#)). A significant proportion of funds is expected to be used for program delivery as opposed to program development and organizational infrastructure.
- **Average Cost per Person:** The average cost per person will be automatically calculated from the total cost of the project divided by the total number of unique people served (refer to [Appendix A](#)).
- **Average Cost per Clinical Service:** The average cost per clinical service will be automatically calculated from the total cost of the project divided by the total number of clinical services delivered (refer to [Appendix A](#)).
- **Personnel:** The individual salary cap for CPRIT awards is \$200,000 per year. Describe the source of funding for all project personnel where CPRIT funds are not requested.
- **Travel:** PDs and related project staff are expected to attend CPRIT's conference. CPRIT funds may be used to send up to 2 people to the conference.
- **Equipment:** Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application. Justification must be provided for why funding for this equipment cannot be found elsewhere; CPRIT funding should not supplant existing funds. Cost sharing of equipment purchases is strongly encouraged.
- **Services Costs:**
 - CPRIT reimburses for services using Medicare reimbursement rates. Describe the source of funding for all services where CPRIT funds are not requested. If clinical services are being paid for and provided by others, the applicant is required to explain and report on the number of clinical services and patient outcomes (eg, screenings/diagnostics, vaccinations, cancer precursors, cancers detected) that are delivered to the people navigated by the program.
 - CPRIT does not allow recovery of costs related to tests that have not been recommended by the USPSTF. In several cases (eg, breast self-exams, clinical breast exams, PSA tests), the Task Force has concluded there is not enough evidence available to draw reliable conclusions about the additional benefits and harms of these tests. (See <https://www.uspreventiveservicestaskforce.org/>)

- **Other Expenses:**
 - **Incentives:** Use of incentives or positive rewards to change or elicit behavior is allowed; however, incentives may only be used based on strong evidence of their effectiveness for the purpose and in the priority population identified by the applicant. CPRIT will not fund cash incentives. The maximum dollar value allowed for an incentive per person, per activity or session, is \$25.
 - **Costs Not Related to Cancer Prevention and Control:** CPRIT does not allow recovery of any costs for services not related to cancer (eg, health physicals, HIV testing).
- **Indirect/Shared Costs:** Texas law limits the amount of grant funds that may be spent on indirect/shared expenses to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in [CPRIT's Administrative Rules](#).

4.4.14 Current and Pending Support and Sources of Funding

Use the template provided on the CARS (<https://CPRITGrants.org>). Describe the funding source and duration of **all** current and pending support for the proposed project, including a capitalization table that reflects private investors, if any.

4.4.15 Biographical Sketches

The designated PD will be responsible for the overall performance of the funded project and must have relevant education and management experience. The PD/Co-PD(s) must provide a biographical sketch that describes his or her education and training, professional experience, awards and honors, and publications and/or involvement in programs relevant to cancer prevention and/or service delivery.

- Use the Co-PD Biographical Sketch section **ONLY** if a Co-PD has been identified.
- The evaluation professional must provide a biographical sketch in the Evaluation Professional Biographical sketch section.
- Up to 3 additional biographical sketches for key personnel may be provided in the Key Personnel Biographical Sketch section.

Each biographical sketch must not exceed 2 pages and should use either the “Prevention Programs: Biographical Sketch” template provided on the CARS (<https://CPRITGrants.org>) or the NIH Biographical Sketch format. Only biographical sketches will be accepted; do not submit resumes and/or CVs. If a position is not yet filled, please upload a job description.

4.4.16 Collaborating Organizations

List all key participating organizations that will partner with the applicant organization to provide 1 or more components essential to the success of the program (eg, evaluation, clinical services, recruitment to screening). Please be sure to also include anyone listed as key personnel and/or listed under the Current & Pending Support section.

4.4.17 Letters of Commitment (10 pages)

Applicants should provide letters of commitment and/or memoranda of understanding from community organizations, key faculty, or any other component essential to the success of the program. Letters should be specific to the contribution of each organization.

5. APPLICATION REVIEW

5.1 Review Process Overview

All eligible applications will be reviewed using a 2-stage peer review process: (1) evaluation of applications by peer review panels and (2) prioritization of grant applications by the Prevention Review Council. In the first stage, applications will be evaluated by an independent review panel using the criteria listed below. In the second stage, applications judged to be meritorious by review panels will be evaluated by the Prevention Review Council and recommended for funding based on comparisons with applications from all of the review panels and programmatic priorities.

Programmatic considerations may include, but are not limited to, geographic distribution, cancer type, population served, and type of program or service. The scores are only 1 factor considered during programmatic review. At the programmatic level of review, priority will be given to proposed projects that target geographic regions of the state or population subgroups that are not well represented in the current CPRIT Prevention project portfolio.

Applications approved by Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the

Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

Each stage of application review is conducted confidentially, and all CPRIT Peer Review Panel members, Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Peer Review Panel members and Review Council members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer Review Panel members are listed by panel on CPRIT's website. **By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed conflict of interest as set forth in CPRIT's Administrative Rules, [chapter 703, section 703.9](#).**

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, a Review Panel member, or a Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention and Communications Officer, the Chief Product Development Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period when preapplications or letters of interest are accepted. Intentional, serious, or frequent

violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

5.2 Review Criteria

Peer review of applications will be based on primary scored criteria and secondary unscored criteria, identified below. Review panels consisting of experts in the field and advocates will evaluate and score each primary criterion and subsequently assign an overall score that reflects an overall assessment of the application. The overall evaluation score will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application and responsiveness to the RFA priorities.

5.2.1 Primary Evaluation Criteria

Impact

- Do the proposed services address an important problem or need in cancer prevention and control? Do the proposed project strategies support desired outcomes in cancer incidence, morbidity, and/or mortality? Do the proposed project strategies reach a priority population (eg, low income, minority, rural) at high risk of cancer?
- For the proposed expansion, does the project build on its initial results (baseline)? Does it go beyond the initial project to address what the applicant has learned or explore new partnerships, new audiences, or improvements to systems?
- Will the project reach and serve/impact an appropriate number of people based on the budget allocated to providing services and the cost of providing services?
- If applicable, have partners demonstrated that the collaborative effort will provide a greater impact on cancer prevention and control than the applicant organization's effort separately?
- Does the program address adaptation, if applicable, of the evidence-based intervention to the priority population? Is the base of evidence clearly explained and referenced?

Project Strategy and Feasibility

- Does the proposed project provide services specified in the RFA?
- Are the overall program approach, strategy, and design clearly described and supported by established theory and practice? Are the proposed objectives and activities feasible within

the duration of the award? Has the applicant convincingly demonstrated the short- and long-term impacts of the project?

- Has the applicant proposed policy changes and/or system improvements?
- Are possible barriers addressed and approaches for overcoming them proposed?
- Are the priority population and culturally appropriate methods to reach the priority population clearly described?
- If applicable, does the application demonstrate the availability of resources and expertise to provide case management, including follow-up for abnormal results and access to treatment?
- Does the program leverage partners and resources to maximize the reach of the services proposed? Does the program leverage and complement other state, federal, and nonprofit grants?

Outcomes Evaluation

- Are specific goals and measurable objectives for each year of the project provided?
- Are the proposed outcome measures appropriate for the services provided, and are the expected changes clinically significant?
- If clinical services are being paid for and provided by others, does the applicant explain the methods used to collect data and report on these clinical services and outcomes?
- Does the application provide a clear and appropriate plan for data collection and management and data analyses?
- Are clear baseline data provided for the priority population, or are clear plans included to collect baseline data?
- If an evidence-based intervention is being adapted in a population where it has not been implemented or tested, are plans for evaluation of barriers, effectiveness, and fidelity to the model described?
- Is the qualitative analysis of planned policy or system changes described?

Organizational Qualifications and Capabilities

- Do the organization and its collaborators/partners demonstrate the ability to provide the proposed preventive services?

- Does the described role of each collaborating organization make it clear that each organization adds value to the project and is committed to working together to implement the project?
- Have the appropriate personnel been recruited to design, implement, evaluate, and complete the project?
- Is the organization structurally and financially stable and viable?
- Does the applicant describe their current activities and the program's organizational capacity for sustainability?
- Does the applicant describe steps that will be taken toward building internal capacity and partnerships?
- Does the applicant describe a plan for systems changes that are sustainable over time; eg, improve results, provider practice, efficiency, cost-effectiveness?

5.2.2 Secondary Evaluation Criteria

Budget

- Is the budget appropriate and reasonable for the scope and services of the proposed work?
- Is the cost per person served appropriate and reasonable?
- Is the proportion of the funds allocated for direct services reasonable?
- Is the project a good investment of Texas public funds?

Dissemination and Replication

- Are plans for dissemination of the project's results and outcomes, including target audiences and methods, clearly described?
- Are active dissemination strategies included and described in the plan?
- Does the applicant describe whether and/or how the project lends itself to replication of all or some components of the project by others in the state?

6. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has

approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in [CPRIT's Administrative Rules](#). Applicants are advised to review CPRIT's administrative rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires the PD of the award to submit quarterly, annual, and final progress reports. These reports summarize the progress made toward project goals and address plans for the upcoming year and performance during the previous year(s). In addition, quarterly fiscal reporting and reporting on selected metrics will be required per the instructions to award recipients. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract.

7. CONTACT INFORMATION

7.1 Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding the scope and focus of applications. Before contacting the helpdesk, please refer to the *Instructions for Applicants* document (posted on November 16, 2020), which provides a step-by-step guide to using CARS.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

7.2 Program Questions

Questions regarding the CPRIT Prevention program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Prevention Program Office.

Tel: 512-305-8417

Email: Help@CPRITGrants.org

Website: www.cprit.texas.gov

8. RESOURCES

- The Texas Cancer Registry. <https://www.dshs.texas.gov/tcr> or contact the Texas Cancer Registry at the Department of State Health Services.
- The Community Guide. <https://www.thecommunityguide.org/>
- Cancer Control P.L.A.N.E.T. <http://cancercontrolplanet.cancer.gov>
- Guide to Clinical Preventive Services: Recommendations of the U.S. Preventive Services Task Force. <http://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/guide/>
- Brownson, R.C., Colditz G.A., and Proctor, E.K. (Editors). *Dissemination and Implementation Research in Health: Translating Science to Practice*. Oxford University Press, March 2012
- Program Sustainability Assessment Tool, copyright 2012, Washington University, St Louis, MO, <https://www.sustaintool.org/about-us/>
- Getting the Word Out: New Approaches for Disseminating Public Health Science. Ross C. Brownson, PhD; Amy A. Eyler, PhD; Jenine K. Harris, PhD; Justin B. Moore, PhD, MS; Rachel G. Tabak, PhD, RD, *Journal of Public Health Management & Practice*. 24(2):102-111, March/April 2018.
https://journals.lww.com/jphmp/Fulltext/2018/03000/Getting_the_Word_Out__New_Approaches_for.4.aspx
- Centers for Disease Control and Prevention: The Program Sustainability Assessment Tool: A New Instrument for Public Health Programs.
http://www.cdc.gov/pcd/issues/2014/13_0184.htm
- Centers for Disease Control and Prevention: Using the Program Sustainability Tool to Assess and Plan for Sustainability. http://www.cdc.gov/pcd/issues/2014/13_0185.htm
- Cancer Prevention and Control Research Network: Putting Public Health Evidence in Action Training Workshop. <http://cpcrn.org/pub/evidence-in-action/>
- Centers for Disease Control and Prevention. Distinguishing Public Health Research and Public Health Nonresearch. <https://www.cdc.gov/os/integrity/docs/cdc-policy-distinguishing-public-health-research-nonresearch.pdf>

9. REFERENCES

1. <http://www.cdc.gov/hpv/parents/questions-answers.html>
2. Texas Cancer Registry, Cancer Epidemiology and Surveillance Branch, Texas Department of State Health Services. <https://www.cancer-rates.info/tx/>

APPENDIX A: KEY TERMS

- **Activities:** A listing of the “who, what, when, where, and how” for each objective that will be accomplished.
- **Capacity Building:** Any activity (eg, training, identification of alternative resources, building internal assets) that builds durable resources and enables the grantee’s setting or community to continue the delivery of some or all components of the evidence-based intervention.
- **Clinical Services:** Number of clinical services such as screenings, diagnostic tests, vaccinations, counseling sessions, or other evidence-based preventive services delivered by a health care practitioner in an office, clinic, or health care system. Other examples include genetic testing or assessments, physical rehabilitation, tobacco cessation counseling or nicotine replacement therapy, case management, primary prevention clinical assessments, and family history screening.
- **Counties of Residence of Population Served:** Counties where the project does not plan to have a physical presence but people who live in these counties have received services. This includes counties of residence of people or places of business of professionals who participate in or receive education, navigation, or clinical services. Examples include people traveling to receive services as a result of marketing and programs accessible via the website or social media. These counties may be described in the project plan and must be reported in the quarterly progress report.
- **Counties with Service Delivery:** Counties where an activity or service will occur and the project has a physical presence for the services provided. Examples include onsite outreach and educational activities and delivery of clinical services through clinics, mobile vans, or telemedicine consults. These counties must be entered in the Geographic Area to be Served section of the application.
- **Education Services:** Number of evidence-based, culturally appropriate cancer prevention and control education and outreach services delivered to the public and to health care professionals. Examples include education or training sessions (group or individual), focus groups, and knowledge assessments. One individual may receive multiple education services.

- **Evidence-Based Program:** A program that is validated by some form of documented research or applied evidence. CPRIT’s website provides links to resources for evidence-based strategies, programs, and clinical recommendations for cancer prevention and control. To access this information, visit <https://www.cprit.state.tx.us/our-programs/prevention>.
- **Goals:** Broad statements of general purpose to guide planning. Outcome goals should be few in number and focus on aspects of highest importance to the project. ([Appendix B](#))
- **Integration:** The extent the evidence-based intervention is integrated within the culture of the grantee’s setting or community through policies and practice.
- **Navigation Services:** Number of unique activities/services that offer assistance to help overcome health care system barriers in a timely and informative manner and facilitate cancer screening and diagnosis to improve health care access and outcomes (Examples include patient reminders, transportation assistance, and appointment scheduling assistance). One individual may receive multiple navigation services.
- **Number of Clinical Services:** Number of [clinical services](#) delivered directly to members of the public by the funded project. One individual may receive multiple clinical services.
- **Number of Services (Direct Contact):** Number of services delivered directly to members of the public and/or professionals—direct, interactive public or professional education, outreach, training, navigation service, or clinical service, such as live educational and/or training sessions, vaccine administration, screening, diagnostics, case management/navigation services, and physician consults. One individual may receive multiple services.
- **Objectives:** Specific, measurable, actionable, realistic, and timely projections for outcomes; example: “Increase screening service provision in X population from Y% to Z% by 20xx.” Baseline data for the priority population must be included as part of each objective. ([Appendix B](#)). The proposed metric should be included in **both** the objective and the measure (eg, Measure: 2,000 individuals, age 9-12, will initiate HPV vaccination during the grant period).
- **People Reached (Indirect Contact):** Number of members of the public and/or professionals reached via indirect noninteractive public or professional education and

outreach activities, such as mass media efforts, brochure distribution, public service announcements, newsletters, and journals. (This category includes individuals who would be reached through activities that are directly funded by CPRIT as well as individuals who would be reached through activities that occur as a direct consequence of the CPRIT-funded project's leveraging of other resources/funding to implement the CPRIT-funded project).

- **Unique People Served (Direct Contact):** Number of unique members of the public and/or professionals served via direct, interactive public or professional education, outreach, training, navigation service, or clinical service. This category includes individuals who would be served through activities that are directly funded by CPRIT as well as individuals who would be served through activities that occur as a direct consequence of the CPRIT-funded project's leveraging of other resources/funding to implement the CPRIT-funded project.

APPENDIX B: WRITING GOALS AND OBJECTIVES

List only major **outcome goals** and **measurable objectives** for each year of the project. **Do not include process objectives**; these should be described in the project plan only. Include the proposed metric within **both** the stated objective and the measure (eg, Measure: 2,000 individuals, age 9-12, will initiate HPV vaccination during the grant period).

The maximum number is 3 goals with 3 objectives each. Projects will be evaluated annually on progress toward **outcome** goals and objectives.

The following guide has been adapted with permission from Appalachia Community Cancer Network, NIH Grant U54 CA 153604:

Develop well-defined goals and objectives.

Goals provide a roadmap or plan for where a group wants to go. Goals can be long term (over several years) or short term (over several months). Goals should be based on needs of the community and evidence-based data.

Goals should be:

- Believable – situations or conditions that the group believes can be achieved
- Attainable – possible within a designated time
- Tangible – capable of being understood or realized
- On a timetable – with a completion date
- Win-Win – beneficial to individual members and the coalition

Objectives are measurable steps toward achieving the goal. They are clear statements of specific activities required to achieve the goal. The best objectives have several characteristics in common – S.M.A.R.T. + C:

- Specific – they tell how much (number or percent), who (participants), what (action or activity), and by when (date)
 - Example: 115 uninsured individuals age 50 and older will complete colorectal cancer screening by March 31, 2018.
- Measurable – specific measures that can be collected, detected, or obtained to determine successful attainment of the objective

- Example: How many screened at an event? How many completed pre/post assessment?
- Achievable – not only are the objectives themselves possible, it is likely that your organization will be able to accomplish them
- Relevant to the mission – your organization has a clear understanding of how these objectives fit in with the overall vision and mission of the group
- Timed – developing a timeline is important for when your task will be achieved
- Challenging – objectives should stretch the group to aim on significant improvements that are important to members of the community

Evaluate and refine your objectives

Review your developed objectives and determine the type and level of each using the following information:

There are 2 types of objectives:

- Outcome objectives – measure the “what” of a program; should be in the Goals and Objectives form (see [section 4.4.2](#))
- Process objectives – measure the “how” of a program; should be in the project plan only (see [section 4.4.4](#))

There are 3 levels of objectives:

- Community-level – objectives measure the planned community change
- Program impact – objectives measure the impact the program will have on a specific group of people
- Individual – objectives measures participant changes resulting from a specific program, using these factors:
 - Knowledge – understanding (know screening guidelines; recall the number to call for screening)
 - Attitudes – feeling about something (will consider secondhand smoke dangerous; believe eating 5 or more fruits and vegetable is important)
 - Skills – the ability to do something (complete fecal occult blood test)
 - Intentions – regarding plan for future behavior (will agree to talk to the doctor, will plan to schedule a Pap test)

- Behaviors (past or current) – to act in a particular way (will exercise 30+ minutes a day, will have a mammogram)

Well-defined outcome goals and objectives can be used to track, measure, and report progress toward achievement.

Summary Table

	Outcome – Use in Goals and Objectives	Process – Use in Project Plan only
Community-level	<p>WHAT will change in a community</p> <p><i>Example: As a result of CPRIT funding, FIT (fecal immunochemical tests) will be available to 1,500 uninsured individuals age 50 and over through 10 participating local clinics and doctors.</i></p>	<p>HOW the community change will come about</p> <p><i>Example: Contracts will be signed with participating local providers to enable uninsured individuals over age 50 have access to free colorectal cancer screening in their communities.</i></p>
Program impact	<p>WHAT will change in the target group as a result of a particular program</p> <p><i>Example: As a result of this project, 200 uninsured women between 40 and 49 will receive free breast and cervical cancer screening.</i></p>	<p>HOW the program will be implemented to affect change in a group/population</p> <p><i>Example: 2,000 female clients, between 40 and 49, will receive a letter inviting them to participate in breast and cervical cancer screening.</i></p>
Individual	<p>WHAT an individual will learn as a result of a particular program, or WHAT change an individual will make as a result of a particular program</p> <p><i>Example: As a result of one-to-one education of 500 individuals, at least 20% of participants will participate in a smoking cessation program to quit smoking.</i></p>	<p>HOW the program will be implemented to affect change in an individual’s knowledge or actions</p> <p><i>Example: As a result of one-to-one counseling, all participants will identify at least 1 smoking cessation service and 1 smoking cessation aid.</i></p>

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)

21.2 Prevention Review Panel - 1 (21.2 PRV-P1)

Observation Report

Report No. 2021-04- 21.2_PRV-P1
Program Name: Prevention
Panel Name: 21.2 Prevention Review Panel - 1 (21.2_PRV-P1)
Panel Date: April 26, 2021 and April 27, 2021
Report Date: May 6, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Prevention Review Panel - 1 (21.2_PRV-P1) meeting. The meeting was chaired by Nancy Lee and conducted via videoconference on April 26, 2021 and April 27, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Eleven (11) applications were discussed on April 26, 2021; three (3) applications were discussed, and four (4) applications were not discussed on April 27, 2021
- Panelists: One (1) panel chair, nine (9) expert reviewers and three (3) advocate reviewers were present on April 26, 2021 and one (1) panel chair, eight (8) expert reviewers and three (3) advocate reviewers on April 27, 2021
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4) were present on April 26, 2021 and three (3) on April 27, 2021
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: One (1) on both days
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. There were zero (0) COIs on applications discussed and one (1) COI on an application not discussed.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to read 'Mara Ash', with a long horizontal flourish extending to the right.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

21.2 Prevention Review Council (21.2_PRC-M2)

Observation Report

Report No. 2021-06-17 21.2_PRC-M2
Program Name: Prevention
Panel Name: 21.2 Prevention Review Council (21.2_PRC-M2)
Panel Date: June 17, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Prevention Review Council (21.2_PRC-M2) meeting. The meeting was chaired by Stephen Wyatt and conducted via teleconference on June 17, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Nine (9) applications were discussed
- Panelists: One (1) panel chair, and two (2) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: One (1)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was zero (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the closing text.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Prevention Cycle 21.2

Awards Announced at the August 18, 2021, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Prevention Cycle 21.2 include *Evidence-Based Cancer Prevention Services*; *Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations*; *Tobacco Control and Lung Cancer Screening*; and *Dissemination of CPRIT-Funded Cancer Control Interventions*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant/Principal Investigator	Principal Investigator Institution	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
No conflicts reported.			
Applications not considered by the PIC or Oversight Committee:			
PP210023	Gail Tomlinson	The University of Texas Health Science Center at San Antonio	R. Riter

T.A.C. Section 702.19 Waiver



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS
FROM: WAYNE R. ROBERTS, CHIEF EXECUTIVE OFFICER
SUBJECT: T.A.C. § 702.19 STANDING WAIVER FOR FY 2021
DATE: AUGUST 28, 2020

Summary

This is to notify the Oversight Committee that pursuant to the authority provided to the Chief Executive Officer in T.A.C. § 702.19(e), I grant CPRIT's Chief Prevention Officer Ramona Magid a waiver from the general prohibition against communicating with grant applicants. The waiver is applicable for FY 2021. Unlike the two communication waivers I granted Ms. Magid for each FY 2020 review cycle, this standing FY 2021 waiver will be effective for both review cycles planned for FY 2021. No Oversight Committee action related to this waiver is necessary.

Background and Discussion

The Chief Prevention Officer is a statutorily mandated member of the Program Integration Committee (PIC). Texas Administrative Code § 702.19 prohibits substantive communication between the grant applicant and a member of the peer review panel, the PIC, or the Oversight Committee while the application is pending a final decision. The restriction on communication prevents even the appearance of unequal treatment during the grant review process.

Traditionally, a chief program officer leads each CPRIT program with the assistance of a program manager. The program manager fields inquiries from and provides technical help to applicants completing their CPRIT grant applications. I promoted Ms. Magid to the Chief Prevention Officer position upon Dr. Becky Garcia's retirement in June 2019. However, the prevention program manager position has remained vacant since Ms. Magid's promotion. Until CPRIT fills the program manager position, she is the sole point of contact for the prevention program. The communication waiver is necessary so that Ms. Magid can assist grant applicants who have questions during the application process.

I previously granted Ms. Magid separate waivers for the two review cycles of FY 2020. It is unlikely that CPRIT will fill the prevention program manager position in FY 2021. Accordingly, I am granting a standing waiver for Ms. Magid for FY 2021 as long as she remains the sole point of contact for the prevention program. Approving this standing waiver does not favor any grant applicant over another. Ms. Magid will provide technical assistance only and will not comment on the substance of a grant application. CPRIT will include this waiver in the grant record for the FY 2021 prevention grant applications.

De-Identified Overall Evaluation Scores

Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations

Prevention Cycle 21.2

Application ID	Final Overall Evaluation Score
PP210020*	2.0
PP210007* ¹	3.3
ca	5.0
cb	5.3

¹ The Prevention Review Council (PRC) took no action on this application at its March 4, 2021, meeting and recommended it to the PIC at its June 17, 2021, meeting

* Recommended for funding

Final Overall Evaluation Scores and Rank Order Scores

Dee Margo
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dee@deemargo.com

Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Mr. Roberts and Mr. Margo,

On behalf of the Prevention Review Council (PRC), I am pleased to provide the PRC's recommendations for the cycle 21.2 Evidence-Based Cancer Prevention Services (EBP), Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations (EPS), and Tobacco Control and Lung Cancer Screening (TCL) awards.

The PRC met on May 27, 2021 to review the applications submitted to CPRIT under the Dissemination of CPRIT-Funded Cancer Control Interventions (DI) mechanism. The PRC met again on June 17, 2021 to consider these applications and those recommended by the peer review panel following their April 26 meeting. The PRC recommends 9 projects totaling \$11,396,581.

The projects are numerically ranked in the order the PRC recommends the applications be funded. Recommended funding amounts and the overall evaluation score are stated for each grant application. The PRC made no changes to the goals, project objectives, or timelines of the applications.

Our recommendations meet the PRC's standards for grant award funding of projects that are evidence-based, deliver programs or services to underserved populations, and focus on primary, secondary, or tertiary prevention. In making these recommendations the PRC continued to consider the available funding, the composition of the current portfolio, and the programmatic priorities in the RFA which include potential for impact and return on investment, geographic distribution, cancer type and type of program. All the recommended grants address one or more of the Prevention Program priorities.

Sincerely,
Stephen W. Wyatt, DMD, MPH
Chair, CPRIT Prevention Review Council

Attachment



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Cycle 21.2 Recommended Prevention Program Awards

App. ID	Mech	Application Title	PD	Organization	Score	Rank Order	Budget
PP210045	DI	Dissemination of a Mailed Stool Testing Program for Colorectal Cancer Prevention in Underserved Communities in Texas	Pignone, Michael	The University of Texas at Austin	1.00	1	\$300,000
PP210049	EBP	Texas Southern University Breast Cancer Screening and Prevention Center	Ajewole, Veronica	Texas Southern University	1.80	2	\$1,000,000
PP210020	EPS	Vaccinating Medically Underserved Women Against HPV: Expansion of Clinical Services to Increase Access	Berenson, Abbey	The University of Texas Medical Branch at Galveston	2.00	3	\$1,999,988
PP210042	TCL	A Regional Expansion of Lung Cancer Screening and Patient Navigation (E-LSPAN)	Argenbright, Keith	The University of Texas Southwestern Medical Center	2.10	4	\$1,999,993
PP210026	DI	Taking Texas Tobacco Free: Dissemination to and Implementation Within Agencies Serving Texans Experiencing	Reitzel, Lorraine	University of Houston	2.70	5	\$299,978
PP210027	TCL	Increasing Accessibility to Smoking Cessation and Lung Cancer Screening Services for Low-Income/Uninsured Texans	McKnight, Jason	Texas A&M University System Health Science Center	3.10	6	\$999,947
PP210031	DI	Application of mHealth Technologies to Improve Latino Childhood Cancer Survivor Engagement and Use of Evidence for Personalized Follow-Up Care	Poplack, David	Baylor College of Medicine	3.30	7	\$299,982
PP210007	EPS	Strengthening Safety Net Health Systems to Improve Cervical and Colorectal Cancer Screening and Follow-up among the Medically Underserved	Montealegre, Jane R	Baylor College of Medicine	3.30	8	\$2,497,029
PP210044	TCL	Expansion of the Lung Cancer Screening and Tobacco Control (LCTC) Network to Rural and Medically Underserved Populations	Zoorob, Roger	Baylor College of Medicine	3.60	9	\$1,999,664

DI: Dissemination of CPRIT-Funded Cancer Control Interventions

EBP: Evidence-Based Cancer Prevention Services

EPS: Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations

TCL: Tobacco Control and Lung Cancer Screening



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Prevention
FY 2021—Cycle 2
*Tobacco Control and Lung Cancer
Screening***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA P-21.2-TCL

Tobacco Control and Lung Cancer Screening

**Please also refer to the Instructions for Applicants document,
which will be posted on November 16, 2020**

Application Receipt Opening Date: November 16, 2020

Application Receipt Closing Date: February 10, 2021

FY 2021

Fiscal Year Award Period

September 1, 2020-August 31, 2021

TABLE OF CONTENTS

1. ABOUT CPRIT	5
1.1 PREVENTION PROGRAM PRIORITIES	5
2. FUNDING OPPORTUNITY DESCRIPTION.....	6
2.1 SUMMARY	6
2.2 PROJECT OBJECTIVES	9
2.3 AWARD DESCRIPTION	10
2.4 PRIORITIES	15
2.5 SPECIFIC AREAS OF EMPHASIS	16
2.6 OUTCOME METRICS	16
2.7 ELIGIBILITY	18
2.8 RESUBMISSION POLICY	19
2.9 EXPANSION POLICY	20
2.10 FUNDING INFORMATION	21
2.11 OPPORTUNITY FOR APPLIED RESEARCH	22
3. KEY DATES.....	23
4. APPLICATION SUBMISSION GUIDELINES	23
4.1 <i>INSTRUCTIONS FOR APPLICANTS</i> DOCUMENT	23
4.2 ONLINE APPLICATION RECEIPT SYSTEM.....	23
4.3 SUBMISSION DEADLINE EXTENSION	24
4.4 APPLICATION COMPONENTS	24
4.4.1 <i>Abstract and Significance (5,000 characters)</i>	24
4.4.2 <i>Goals and Objectives (700 characters each)</i>	25
4.4.3 <i>Project Timeline (2 pages)</i>	25
4.4.4 <i>Project Plan (12 pages, fewer pages permissible)</i>	25
4.4.5 <i>People Reached (Indirect Contact)</i>	28
4.4.6 <i>Number of Services Delivered (Direct Contact)</i>	29
4.4.7 <i>Number of Clinical Services Delivered</i>	29
4.4.8 <i>Number of Unique People Served (Direct Contact)</i>	29
4.4.9 <i>References</i>	29
4.4.10 <i>Resubmission Summary</i>	29
4.4.11 <i>Expansion Application Documents</i>	30
4.4.12 <i>Most Recently Funded Project Summary, if Applicable (3 pages)</i>	30
4.4.13 <i>CPRIT Grants Summary</i>	31
4.4.14 <i>Budget and Justification</i>	31
4.4.15 <i>Current and Pending Support and Sources of Funding</i>	32
4.4.16 <i>Biographical Sketches</i>	32
4.4.17 <i>Collaborating Organizations</i>	33
4.4.18 <i>Letters of Commitment (10 pages)</i>	33
5. APPLICATION REVIEW	33
5.1 REVIEW PROCESS OVERVIEW	33
5.2 REVIEW CRITERIA.....	35
5.2.1 <i>Primary Evaluation Criteria</i>	35
5.2.2 <i>Secondary Evaluation Criteria</i>	37

6. AWARD ADMINISTRATION..... 38
7. CONTACT INFORMATION..... 39
 7.1 HELPDESK 39
 7.2 PROGRAM QUESTIONS 39
8. RESOURCES 40
9. REFERENCES..... 41
APPENDIX A: KEY TERMS 42
APPENDIX B: WRITING GOALS AND OBJECTIVES 45

RFA VERSION HISTORY

Rev 10/16/2020 RFA release

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and enhance the potential for a medical or scientific breakthrough in the prevention of or cures for cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

1.1. Prevention Program Priorities

Legislation from the 83rd Texas Legislature requires that CPRIT's Oversight Committee establish program priorities on an annual basis. The priorities are intended to provide transparency in how the Oversight Committee directs the orientation of the agency's funding portfolio. The Prevention Program's principles and priorities will also guide CPRIT staff and the Prevention Review Council on the development and issuance of program-specific Requests for Applications (RFAs) and the evaluation of applications submitted in response to those RFAs.

Established Principles:

- Fund evidence-based interventions and their dissemination
- Support the prevention continuum of primary, secondary, and tertiary (includes survivorship) prevention interventions

Prevention Program Priorities

- Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
- Prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
- Prioritize underserved populations

2. FUNDING OPPORTUNITY DESCRIPTION

2.1. Summary

The ultimate goals of the CPRIT Prevention Program are to reduce overall cancer incidence and mortality and to improve the lives of individuals who have survived or are living with cancer. The ability to reduce cancer death rates depends in part on the application of currently available evidence-based technologies and strategies. CPRIT will foster the primary, secondary, and tertiary prevention of cancer in Texas by providing financial support for a wide variety of evidence-based risk reduction, early detection, and survivorship interventions.

People who use tobacco products or who are regularly around [environmental tobacco smoke](#) have an increased risk of cancer because tobacco products and secondhand smoke contain many chemicals that damage DNA. Tobacco use causes many types of cancer, and there is no safe level of tobacco use. People who quit smoking, regardless of their age, have substantial gains in life expectancy compared with those who continue to smoke. Also, quitting smoking at the time of a cancer diagnosis reduces the risk of death.¹

Tobacco use accounts for at least 30% of all cancer deaths, causing 83% of lung cancer deaths in men and 76% of lung cancer deaths in women.² Lung cancer is the leading cause of cancer-related mortality in Texas; in 2016 there were an estimated 9,438 deaths.³

The **Tobacco Control and Lung Cancer Screening (TCL)** award mechanism seeks to fund programs on tobacco prevention and cessation, as well as screening for early detection of lung cancer. Through release of this RFA, CPRIT's goal is to stimulate more programs across the state, thereby providing greater access for underserved populations and reducing the incidence and mortality rates of tobacco-related cancers.



This RFA seeks to promote and deliver evidence-based programming designed to significantly increase tobacco cessation among adults and/or prevent tobacco use by youth. In addition to evidence-based interventions for tobacco prevention and cessation, screening to detect cancer early, before it has spread, can reduce lung cancer mortality. For the early detection of lung cancer, the US Preventive Services Task Force (USPSTF) recommends annual lung cancer screening with low-dose computerized tomography (LDCT) for persons between the ages of 55 and 80 years old who have a history of heavy smoking (30 pack years or more) and who currently

smoke or have quit within the past 15 years. The Centers for Medicare and Medicaid Services (CMS) has approved coverage and reimbursement for lung cancer screening for individuals 55 to 77 years of age that meet their criteria. CMS also has eligibility criteria for radiologists and facilities delivering the screening services (<https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=274>).

CPRIT will support programs screening individuals aged 55 to 77 that follow the CMS criteria for screening, radiologists, and facilities. CMS also requires delivery of smoking cessation counseling if LCDT screening is offered; however, for funding through this mechanism, CPRIT requires that robust evidence-based cessation interventions that go beyond offering only a referral or provision of information about smoking cessation interventions be delivered (see [section 2.3](#) for details).

Programs proposed under this mechanism should be designed to reach and serve as many people as possible. Partnerships with other organizations that can support and leverage resources are strongly encouraged. A coordinated submission of a collaborative partnership program in which all partners have a substantial role in the proposed project is preferred.

Applicants with currently or previously funded CPRIT Tobacco Control and Lung Cancer Screening projects are required to expand current services into additional counties or to include additional types of prevention clinical services. In either case, the expansion must include the delivery of services to nonmetropolitan (rural) and/or medically underserved counties in the state. These may be identified via Web-based tools from the [Texas Department of State Health Services](#) and [US Department of Health and Human Services](#) respectively.



Data source: US Health Resources and Services Administration Data Warehouse, October 2019

Currently funded projects must be in their final year, and programs must have at least 1 full year of data to report before applying for an expansion.

2.2. Project Objectives

CPRIT seeks to fund **new** projects that will address objectives listed under Option A **or** Option B. **Expansion** projects **may** address objectives under **both** Options A **and** B.

A. Tobacco Prevention and Cessation for any age group

- Promote and deliver evidence-based programming designed to significantly increase tobacco cessation among adults and/or prevent tobacco use by youth including combustible cigarettes, oral tobacco products, and/or electronic devices that deliver nicotine.
- Increase the adoption and sustained implementation of evidence-based strategies by state and local public health agencies designed to reduce tobacco use.
- Increase the adoption and implementation of evidence-based strategies designed to mobilize communities, improve systems and programs to influence societal norms, and encourage and support individuals in adoption of tobacco prevention and cessation behaviors.
- Increase the adoption and sustained implementation of evidence-based strategies by clinicians designed to reduce tobacco use.
- Stimulate the creation, adoption, and implementation of evidence-based strategies and policies designed to significantly improve the effectiveness of health care or other systems in reducing tobacco use among the patients and employees of those systems.
- Implement policy changes and/or system improvements that are sustainable over time.
- Focus on underinsured and uninsured population groups by implementation of strategies and activities that may significantly reduce tobacco use and cancer-related disparities.

B. Lung Cancer Screening, Early Detection, and Cessation for individuals 55 to 77 years of age

- Develop, implement, and evaluate strategies to significantly increase use of annual LDCT screening for earlier detection of lung cancer following the USPSTF criteria and

definition of high-risk populations (history of 30 pack years of smoking, individuals between 55 and 77 years of age who currently smoke or who have quit smoking within the past 15 years), as well as meet CMS eligibility criteria for radiologists and facilities.

- Deliver evidence-based programming designed to significantly increase tobacco cessation among adults 55 to 77 years old that are being screened or considered for screening.
- Deliver education for health care providers that includes, but is not limited to, earlier detection of lung cancer, diagnosis and treatment of lung cancer, shared decision-making about eligibility, risks and benefits of lung LDCT screening, tobacco cessation programming, and comprehensive behavioral health change initiatives.
- Increase shared decision-making between the health care provider and patients about eligibility, risks, and benefits of annual lung LDCT screening.
- Stimulate the creation, adoption, and implementation of evidence-based strategies and policies designed to significantly improve the effectiveness of health systems in reducing tobacco use among the patients being screened or considered for screening.
- Implement policy changes and/or system improvements that are sustainable over time.
- Focus on underinsured and uninsured population groups by implementation of strategies and activities that may significantly reduce tobacco use and cancer-related disparities.

2.3. Award Description

The Tobacco Control and Lung Cancer Screening RFA solicits applications for eligible projects that may be up to 36 months in duration that will deliver evidence-based interventions focused on tobacco prevention (prevent tobacco use or sustained abstinence) and tobacco cessation among youth and/or adults. This RFA will also support LDCT screening for populations eligible for this intervention as defined by CMS if paired with evidence-based cessation interventions for the population to be screened.

As detailed below, **new** projects may propose comprehensive tobacco cessation programs for youth and/or adults, **(Option A)**, **or** projects may propose programs that include comprehensive tobacco cessation programs plus LDCT lung cancer screening and annual rescreening for eligible participants aged 55 to 77, **(Option B)**, **but not both**.

Expansion projects: Expansion to nonmetropolitan/medically underserved area (MUA) counties and/or offering additional clinical services is required for currently or previously funded tobacco control and lung cancer screening projects. To qualify, CPRIT requires these applicants to either expand to additional nonmetropolitan and/or MUA counties or to add the delivery of 1 or more of the following clinical services to their project.

- LDCT lung cancer screening: Expansion of project to include Option B for annual lung cancer screening if current or previously funded project included only Option A.
- Tobacco Prevention and Cessation: Expansion of project to include Option A for tobacco prevention and cessation program for any age group, in addition to the required cessation services in Option B, if current or previously funded project included only Option B.
- Screenings and rescreenings for breast, cervical, colorectal cancers, hepatitis C virus, and genetic risk factors.
- Vaccinations against HPV and hepatitis B virus.

CPRIT's priorities include a focus on underserved populations and the targeting of areas and populations where significant disparities exist. Projects should propose to develop, adopt, and implement strategies and activities that have the potential to significantly reduce tobacco use and cancer-related disparities and serve underinsured and uninsured population groups. If addressing worksites, projects should focus on worksites that are likely to have limited or no health insurance; eg, part-time or hourly workers. (See priority populations, [section 2.4](#)).

Proposals are encouraged to incorporate evidence-based interventions such as those found in Community Guide to Reducing Tobacco Use and Secondhand Smoke Exposure; CDC Policies and Practices for Cancer Prevention: Lung Cancer Screening Programs; CDC Best Practices for Comprehensive Tobacco Control Programs; and American College of Chest Physicians/American Thoracic Society Policy statement on Components Necessary for High- Quality Lung Cancer Screening. In addition, USPSTF guidelines and CMS criteria must be met if providing LDCT screening.

The following are required components of the project:

Option A. Tobacco Prevention and Cessation Services

Projects under this option for tobacco prevention and cessation services without LDCT screening must provide the following:

- Evidence-based tobacco prevention and tobacco cessation education and services for adults and/or youth that include behavioral as well as pharmacotherapy interventions (if such interventions are indicated for youth). Effective cessation interventions include individual, group, and telephone counseling as well as FDA-approved cessation medications. Programs may include prevention and cessation of any product that delivers nicotine, including combustible cigarettes, oral tobacco products, and/or electronic devices.

In addition, projects should include SOME combination of the following:

- Evidence-based strategies delivered by public health officials (eg, state or local public health agencies) designed to reduce tobacco use and increase the adoption and sustained implementation of tobacco control programs.
- Evidence-based strategies designed to mobilize communities, improve systems and programs to influence societal norms, and encourage and support individuals in adoption of prevention and cessation behaviors (eg, NCI RTIPS interventions).
- Evidence-based strategies designed to improve the knowledge, skills, and effectiveness of health care providers in providing direct tobacco cessation interventions (eg, 5 A's approach).
- Evidence-based strategies designed to improve the efficacy/effectiveness of health systems in tobacco cessation, including changes in how health systems approach tobacco cessation (eg, integration into EMRs, clinical workflows, well visit protocols).

Option B. Lung Cancer screening and early detection services plus cessation services

Projects under this option that includes lung cancer LDCT screening and relevant diagnostic interventions in addition to robust evidence-based tobacco cessation interventions must include **ALL** of the following:

- Annual LDCT lung cancer screening must be provided according to CMS and USPSTF guidelines.

- LDCT lung cancer screening facilities and radiologists must meet CMS requirements.
- Education for health care providers that includes, but is not limited to, earlier detection of lung cancer, diagnosis and treatment of lung cancer, tobacco cessation programming, and more comprehensive behavioral health change initiatives.
- Strategic educational initiatives for both the health care provider and patients focused on patient-centered health care that involves shared decision-making about eligibility, risks and benefits, and implementation of lung LDCT.
- The development, adoption, and implementation of robust evidence-based tobacco cessation interventions for individuals 55 to 77 years of age before screening as well as after LDCT screening. In cases where screening results are normal, cessation interventions begun before the results of screening are received may increase the motivation to continue with cessation treatments.
- Cessation interventions must be comprehensive and robust and integrated with the screening program. Cessation interventions must involve more than handing out educational materials or referral to either the Quitline or other cessation resources and include behavioral as well as pharmacotherapy interventions. Cessation services offered outside the clinic setting require a formal agreement/memorandum of understanding for patient follow-up and confirmation of behavioral changes for the patients referred. Patient cessation outcomes are to be reported to CPRIT.
- The development, adoption, and implementation of enhancements and improvements in health and health care systems and/or policy that can increase the effectiveness of tobacco and cancer control (ie, integration into EMRs, clinical workflow, and well visit protocols).
- The development, adoption, and implementation of procedures and protocols for frequent follow-up of patients to assess not only participation but also successful outcomes regarding accessing cessation services, sustained abstinence, and outcomes known to be related to sustained cessation.
- The development, adoption, and implementation of system policies and protocols that include but are not limited to who should be offered screening within the USPSTF guidelines, frequency of screening, who should be followed, and who should proceed to surgical resection.

- Recognizing that there are false positives and false negatives in LDCT screening, the development, adoption, and implementation of evidence-based protocols for abnormal LDCT results.
- Patient navigation into treatment when cancer is diagnosed. Applicants must describe the resources available for treatment of uninsured/underinsured patients.

CPRIT's services grants are intended to fund prevention interventions that have a demonstrated evidence base and are culturally appropriate for the priority population.

CPRIT recognizes that evidence-based services have been developed but not implemented or tested in all populations or service settings. In such cases, other forms of evidence (eg, preliminary evaluation or pilot project data) that the proposed service is appropriate for the population and has a high likelihood of success must be provided. The applicant must fully describe the base of evidence and any plans to adapt and evaluate the implementation of the program for the specific audience or situation.

CPRIT encourages traditional and nontraditional collaborative partnerships as well as leveraging of existing resources and dollars from other sources. A collaborative partnership is one in which all partners have a substantial role in the proposed project. Letters of commitment describing their role in the partnership are required from all partners.

CPRIT expects measurable outcomes of supported activities, such as a significant increase over baseline (for the proposed service area) in the provision of evidence-based services, changes in provider practice, systems changes, and cost-effectiveness. Applicants must demonstrate how these outcomes will ultimately impact incidence, mortality, morbidity, or quality of life.

Under this RFA, CPRIT **will not** consider the following:

- **Projects focusing solely on case management/patient navigation services.** Case management/patient navigation services must be paired with tobacco prevention or cessation services. Furthermore, while navigation to the point of treatment of cancer is required when cancer is discovered through a CPRIT-funded project, applications seeking funds to provide coordination of care while an individual is in treatment are not allowed under this RFA.

- **Projects focusing on tobacco prevention and cessation education without the delivery of cessation or other clinical services.**
- **Projects requesting CPRIT funding for Quitline services.** Applicants proposing the utilization of Quitline services should communicate with the Tobacco Prevention and Control program prior to submitting a CPRIT grant application to discuss the services currently offered by the Texas Department of State Health Services (DSHS).
- **Projects involving prevention/intervention research.** Applicants interested in prevention research should review CPRIT’s Academic Research RFAs (available at <http://www.cprit.texas.gov>).⁴

2.4. Priorities

Types of Cancer: Only projects proposing tobacco control interventions and lung cancer screening will be considered for funding. See [section 2.5](#) for specific areas of emphasis.

The Prevention Program’s priorities for funding include the following:

1) Populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence:

CPRIT programs must address underserved populations. Underserved populations are subgroups that are disproportionately affected by cancer. CPRIT-funded efforts must address 1 or more of these priority populations:

- Underinsured and uninsured individuals
- Medically unserved or underserved populations
- Racial, ethnic, and cultural minority populations
- Populations with low screening rates, high incidence rates, and high mortality rates, focusing on individuals never before screened or who are significantly out of compliance with nationally recommended screening guidelines.

The age of the priority population and frequency of screening for provision of clinical services described in the application must comply with established and current national guidelines (eg, USPSTF, CMS, and American Cancer Society).

2) Geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence:

While disparities and needs exist across the state, CPRIT will also prioritize applications proposing to serve geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence. In addition, projects addressing areas of emphasis (see [section 2.5](#)) will receive priority consideration.

Geographic and Population Balance in Current CPRIT Portfolio

At the programmatic level of review conducted by the Prevention Review Council (see [section 5.1](#)), priority will be given to projects that target geographic regions of the state and population subgroups that are not adequately covered by the current CPRIT Prevention project portfolio (see <https://www.cprit.state.tx.us/our-programs/prevention/portfolio-maps> and <https://www.cprit.state.tx.us/grants-funded?search=prevention>).

2.5. Specific Areas of Emphasis

CPRIT has identified the following areas of emphasis for this cycle of awards.

<u>Primary Prevention</u>
Tobacco Prevention and Control
<ul style="list-style-type: none">• Vulnerable and high-risk populations, including people with mental illness, history of substance abuse, youth, and pregnant women, that have higher tobacco usage rates than the general population.
<ul style="list-style-type: none">• Areas that have higher smoking rates per capita than other areas of the state. Public Health Regions (PHR) 2, 4, 5, 8 and 9 have significantly higher tobacco use among adults than in other regions of the state.
<u>Secondary Prevention - Screening and Early Detection Services</u>
Lung Cancer
<ul style="list-style-type: none">• Decreasing disparities in incidence and mortality rates of lung cancer in racial/ethnic populations. Blacks have higher mortality rates than Hispanics and non-Hispanic whites.
<ul style="list-style-type: none">• Increasing screening/detection rates in PHR 2, 4, and 5, where the highest rates of cancer incidence and mortality are found.

2.6. Outcome Metrics

Applicants are required to clearly describe their assessment and evaluation methodology. The applicant is required to describe final outcome measures for the project. Output measures that are

associated with the final outcome measures should be identified in the project plan and will serve as a measure of program effectiveness. Planned policy or system changes/improvements should be identified and the plan for qualitative analysis described. **Baseline data for each measure proposed are required.** In addition, applicants should describe how funds from the CPRIT grant will improve outcomes over baseline. If the applicant is not providing baseline data for a measure, the applicant must provide a well-justified explanation and describe clear plans and method(s) of measurement to collect the data necessary to establish a baseline.

Reporting Requirements

Funded projects are required to report quantitative output and outcome metrics (as appropriate for each project) through the submission of quarterly progress reports, annual reports, and a final report.

If clinical services are being paid for and provided by others, the applicant is required to report on the number of clinical services and patient outcomes (eg, cancers detected) that are delivered to the people navigated by the program.

- Quarterly progress report sections include, but are not limited to, the following:
 - Summary page, including narrative on project progress (required)
 - Services, other than clinical services, provided to the public/professionals
 - Actions taken by people/professionals as a result of education or training
 - Clinical services provided (county of residence of client is required)
 - Precursors and cancers detected
- Annual and final progress report sections include, but are not limited to, the following:
 - Key accomplishments, **including qualitative analysis of policy change and/or lasting systems change**
 - Progress toward goals and outcome objectives, including percentage increase over baseline in provision of age- and risk-appropriate education and navigation services to eligible individuals in a defined service area
 - Materials produced and publications
 - Economic impact of the project

2.7. Eligibility

- The applicant must be a Texas-based entity, such as a community-based organization, health institution, government organization, public or private company, college or university, or academic health institution.
- The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted.
- The designated Program Director (PD) will be responsible for the overall performance of the funded project. The PD must have relevant education and management experience and must reside in Texas during the project performance time.
- The evaluation of the project must be headed by a professional who has demonstrated expertise in the field and who resides in Texas during the time that the project is conducted.
- An applicant is not eligible to receive a CPRIT grant award if the applicant PD, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member.
- The applicant may submit more than 1 application, but each application must be for distinctly different services without overlap in the services provided. Applicants who do not meet this criterion will have all applications administratively withdrawn without peer review.
- If an organization has a current CPRIT grant that is the same or similar to the prevention intervention being proposed, the applicant must explain how the projects are nonduplicative or complementary.
- If the applicant or a partner is an existing Department of State Health Services (DSHS) contractor, CPRIT funds may not be used as a match, and the application must explain how this grant complements or leverages existing state and federal funds. DSHS contractors who also receive CPRIT funds must be in compliance with and fulfill all contractual obligations within CPRIT. CPRIT and DSHS reserve the right to discuss the contractual standing of any contractor receiving funds from both entities.
- Collaborations are permitted and encouraged, and collaborators may or may not reside in Texas. However, collaborators who do not reside in Texas are not eligible to receive

CPRIT funds. Subcontracting and collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.

- An applicant organization is eligible to receive a grant award only if the applicant certifies that the applicant organization, including the PD, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation created to benefit CPRIT.
- The applicant must report whether the applicant organization, the PD, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, (whether slated to receive salary or compensation under the grant award or not), are currently ineligible to receive federal grant funds because of scientific misconduct or fraud or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. CPRIT grants are funded on a reimbursement-only basis. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 6](#). All statutory provisions and relevant administrative rules can be found [on the CPRIT website](#).

2.8. Resubmission Policy

- **One resubmission** is permitted. An application is considered a resubmission if the proposed project is the same project as presented in the original submission. A change in the identity of the PD for a project or a change of title for a project that was previously submitted to CPRIT does not constitute a new application; the application would be considered a resubmission.
- Applicants who choose to resubmit should carefully consider the reasons for lack of prior success. Applications that received overall numerical scores of 5 or higher are likely to

need considerable attention. All resubmitted applications should be carefully reconstructed; a simple revision of the prior application with editorial or technical changes is not sufficient, and applicants are advised not to direct reviewers to such modest changes. A 1-page summary of the approach to the resubmission should be included. Resubmitted applications may be assigned to reviewers who did not review the original submission. Reviewers of resubmissions are asked to assess whether the resubmission adequately addresses critiques from the previous review. **Applicants should note that addressing previous critiques is advisable; however, it does not guarantee the success of the resubmission.** All resubmitted applications must conform to the structure and guidelines outlined in this RFA.

2.9. Expansion Policy

- A grant recipient that has previously been awarded grant funding from CPRIT may submit an application under this mechanism to be considered for an expansion grant if expansion of current services into additional counties and/or additional types of prevention clinical services have been included. The eligibility criteria described in [section 2.7](#) also apply to expansion applications.
- Expansion grants are intended to fund expansion of currently or previously funded projects that have demonstrated exemplary success, as evidenced by progress reports and project evaluations, and desire to further enhance their impact on priority populations. Detailed descriptions of **results, barriers, outcomes, and impact of the currently or previously funded project are required** (see outline of Most Recently Funded Project Summary, [section 4.4.12](#)).
- Proposed expansion projects should NOT be new projects but should closely follow the intent and core elements of the currently or previously funded project. Established infrastructure/processes and fully described prior project results are required. Expansion of current projects into geographic areas not well served by the CPRIT Prevention portfolio (see maps at <http://www.cprit.state.tx.us/our-programs/prevention/portfolio-maps>) will receive priority consideration.
- CPRIT expects measurable outcomes of supported activities, such as a significant increase over baseline (for the proposed service area). It is expected that baselines will have already

been established and that continued improvement over baseline is demonstrated in the current application. However, in the case of a proposed expansion where no baseline data exist for the priority population, the applicant must present clear plans and describe method(s) of measurement used to collect the data necessary to establish a baseline. Applicants must demonstrate how these outcomes will ultimately impact cancer incidence, mortality, morbidity, or quality of life.

- CPRIT also expects that applications for continuation **will not** require startup time, that applicants can demonstrate that they have overcome barriers encountered, and that applicants have identified **lasting systems changes** that improve results, efficiency, and sustainability. Leveraging of resources and plans for dissemination are expected and should be well described.

2.10. Funding Information

Applicants may request any amount of funding up to a maximum of \$1 million in total funding for new projects or up to a maximum of \$2 million in total funding for expansion projects over a maximum of 36 months. Grant funds may be used to pay for clinical services, navigation services, salary and benefits, project supplies, equipment, costs for outreach and education of populations, and travel of project personnel to project site(s). Applicants offering screening services must ensure that there is access to treatment services for patients with precancer or cancers that are detected as a result of the program and must describe access to treatment services in their application.

Requests for funds to support construction, renovation, or any other infrastructure needs or requests to support lobbying will not be approved under this mechanism. Cost sharing for equipment purchases is encouraged. Grantees may request funds for travel for 2 project staff to attend CPRIT's conference.

While this mechanism will fund diagnostic workup of abnormal LDCT results, applicants are encouraged to find additional sources to support the costlier diagnostic tests that may be needed. Proposed programs should be designed to reach and serve as many people as possible, and costly diagnostic tests could limit the reach of the program. Review of the proposals includes budget

considerations such as the average cost per service and whether the budget is appropriate and reasonable and a good investment of Texas public funds.

The budget should be proportional to the number of individuals receiving programs and services, and a significant proportion of funds is expected to be used for program delivery as opposed to program development. In addition, CPRIT seeks to fill gaps in funding rather than replace existing funding, supplant funds that would normally be expended by the applicant's organization, or make up for funding reductions from other sources.

State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the **total** award amount.

2.11. Opportunity for Applied Research

Since lung cancer screening has only recently become an approved screening tool and may occur in a variety of settings, there remain many questions and opportunities for continued study to optimize the pairing of smoking cessation services with lung cancer screening and to improve the outcomes of lung cancer screening. CPRIT encourages successful applicants to consider how they might leverage a Prevention grant award and the population being screened to address these or other research questions and apply to CPRIT's [Academic Research Program](#).

Examples of potential research questions follow:

- What are the most effective components of outreach and education strategies designed to influence underserved populations to make good decisions about their health and participate in shared decision-making and lung cancer screening?
- What are the most formidable barriers influencing the initiation of tobacco cessation counseling and lung cancer screening among underserved population groups?
- What are the most effective components of evidence-based cessation interventions delivered in conjunction with LDCT screening?
- What are effective shared decision-making interventions for LDCT?
- What is the cost-effectiveness of LDCT alone and/or in conjunction with various evidence-based interventions for tobacco cessation?
- What are the most effective evidence-based protocols for diagnostic workup of lung nodules in community settings?

- Can risk models be developed to define subgroups that might disproportionately benefit or be harmed with LDCT screening?
- What is the role of biomarkers in LDCT screening?

3. KEY DATES

RFA release	October 16, 2020
Online application opens	November 16, 2020, 7 AM central time
Application due	February 10, 2021, 4 PM central time
Application review	March-July 2021
Award notification	August 2021
Anticipated start date	August 31, 2021

Applicants will be notified of peer review panel assignment prior to the peer review meeting dates.

4. APPLICATION SUBMISSION GUIDELINES

4.1. *Instructions for Applicants* document

It is imperative that applicants read the accompanying instructions document for this RFA that will be available November 16, 2020 (<https://CPRITGrants.org>). Requirements may have changed from previous versions.

4.2. Online Application Receipt System

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The PD must create a user account in the system to start and submit an application. The Co-PD, if applicable, must also create a user account to participate in the application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (an individual who will help manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on November 16, 2020, and must be submitted by 4 PM central time on February 10, 2021. Detailed instructions for submitting an application are in the *Instructions for Applicants* document, posted on CARS.

Submission of an application is considered an acceptance of the terms and conditions of the RFA.

4.3. Submission Deadline Extension

The submission deadline may be extended for 1 or more grant applications upon a showing of good cause. All requests for extension of the submission deadline must be submitted via email to the [CPRIT Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records.

4.4. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Refer to the *Instructions for Applicants* document for details.

Submissions that are missing 1 or more components or do not meet the eligibility requirements may be administratively withdrawn without review.

4.4.1. Abstract and Significance (5,000 characters)

Clearly explain the problem(s) to be addressed, the approach(es) to the solution, and how the application is responsive to this RFA. In the event that the project is funded, the abstract will be made public; therefore, no proprietary information should be included in this statement. Initial compliance decisions are based in part upon review of this statement.

The abstract format is as follows (use headings as outlined below):

- **Need:** Include a description of need in the specific service area. Include rates of incidence, mortality, and screening in the service area compared to overall Texas rates. Describe barriers, plans to overcome these barriers, and the priority population to be served.
- **Overall Project Strategy:** Describe the project and how it will address the identified need. Clearly explain what the project is and what it will specifically do, including the services to be provided and the process/system for delivery of services and outreach to the priority population.

- **Specific Goals:** State specifically the overall goals of the proposed project; include the estimated overall numbers of people (public and/or professionals) reached, unique people (public and/or professionals) served, and the number of services.
- **Significance and Impact:** Explain how the proposed project, if successful, will have a major impact on cancer prevention and control for the population proposed to be served and for the State of Texas.

4.4.2. Goals and Objectives (700 characters each)

List only major **outcome goals** and **measurable objectives** for each year of the project. **Do not include process objectives**; these should be described in the project plan only. Include the proposed metric within both the stated Objective **and** the Measure sections (eg, Measure: 1,000 individuals will undergo LDCT and be referred for diagnostic testing as necessary). Applications may be returned for revision if the proposed metric is not included within the Measure section. Refer to the *Instructions for Applicants* document for details.

The maximum number is 3 goals with 3 objectives each. Projects will be evaluated annually on progress toward **outcome** goals and objectives. See [Appendix B](#) for instructions on writing outcome goals and objectives.

A baseline and method(s) of measurement are required for each objective. Provide both raw numbers and percent changes for the baseline and target. If a baseline has not been defined, applicants are required to explain plans to establish baseline and describe method(s) of measurement.

4.4.3. Project Timeline (2 pages)

Provide a project timeline for project activities that includes deliverables and dates. Use Years 1, 2, 3, and Months 1, 2, 3, etc, as applicable (eg, Year 1, Months 3-5) instead of specific months or years. Month 1 is the first full month of the grant award.

4.4.4. Project Plan (12 pages, fewer pages permissible)

The required project plan format follows. Applicants must use the headings outlined below.

Background: Briefly present the rationale behind the proposed service, emphasizing the critical barriers to current service delivery that will be addressed. Identify the evidence-based service to be

implemented for the priority population. Describe the race, ethnicity, age, and other defining characteristics of the population to be served.

If evidence-based strategies have not been implemented or tested for the specific population or service setting proposed, provide evidence that the proposed service is appropriate for the population and has a high likelihood of success. Baseline data for the target population and target service area are required where applicable.

Reviewers will be aware of national and state statistics, and these should be used only to compare rates for the proposed service area. Describe the geographic region of the state that the project will serve; maps are encouraged.

Goals and Objectives: Process objectives should be included in the project plan. Outcome goals and objectives will be entered in separate fields in CARS. However, if desired, outcome goals and objectives may be fully repeated or briefly summarized here. See [Appendix B](#) for instructions on writing goals and objectives.

Components of the Project: Clearly describe the need, delivery method, and evidence base (provide references) for the services as well as anticipated results. Be explicit about the base of evidence and any necessary adaptations for the proposed project. Describe why this project is nonduplicative. If an organization has a current CPRIT grant that is the same or similar to the prevention intervention being proposed, the applicant must explain how the projects are nonduplicative or complementary.

It is important to distinguish between Texas counties where the project proposes to deliver services and counties of residence of population served (see [Appendix A](#) for definitions and *Instructions for Applicants*). Only counties with service delivery should be listed in the Geographic Area to be Served section of the application. Projecting counties of residence of population served is not required but may be described in the project plan.

Clearly demonstrate the ability to provide the proposed service and describe how results will be improved over baseline and the ability to reach the priority population. If applicable, describe the method(s) that will be used to recall for appropriate rescreening those individuals who have been screened through this project.

If clinical services are being paid for and provided by others, the applicant must explain and report on the number of clinical services and patient outcomes that are delivered to the people navigated by the program. Applicants must also clearly describe plans to **ensure access to treatment services** should precancer or cancer be detected.

Evaluation Strategy: A strong commitment to evaluation of the project is required. Describe the plan for outcome and output measurements, including qualitative analysis of policy and system changes. Describe data collection and management methods, data analyses, and anticipated results. Evaluation and reporting of results should be headed by a professional who has demonstrated expertise in the field. If needed, applicants may want to consider seeking expertise at Texas-based academic cancer centers, schools/programs of public health, or the like. Applicants should budget accordingly for the evaluation activity and should involve that professional during grant application preparation to ensure, among other things, that the evaluation plan is linked to the proposed goals and objectives.

Organizational Qualifications and Capabilities: Describe the organization and its track record and success in providing health programs and services. Describe the role and qualifications of the key collaborators/partners in the project. Include information on the organization's financial stability and viability. The applicant should demonstrate how the organizational environment will contribute to a successful project. If equipment or physical resources are required to carry out the project, the applicant should describe the availability of these resources and the organizational capacity to use equipment. To ensure access to preventive services and reporting of services outcomes, applicants should demonstrate that they have provider partnerships and agreements (via memoranda of understanding) or commitments (via letters of commitment) in place.

CPRIT acknowledges that full maintenance and sustainability of projects when CPRIT funding ends may not be feasible, especially in cases involving the delivery of clinical services. However, it is important to consider sustainability early in the life cycle of a project, particularly regarding organizational characteristics and processes that are modifiable.

Washington University in St Louis has developed a useful tool ([Program Sustainability Assessment Tool](#)) to assess program capacity for sustainability. The tool assesses several factors that contribute to program sustainability. These factors include environmental support, funding stability, partnerships, organizational capacity, program evaluation, program adaptation, communication,

and strategic planning. Applicants are not required to use this tool; however, it provides practical guidance on factors that should be considered and should be included in the application to describe a program's organizational capacity for sustainability.

It is expected that steps toward building sustainability capacity for the program will be taken and plans for such be briefly described in the application. The applicant should assess and describe the factors that will contribute to the organization's capacity to facilitate sustainability.

Dissemination and Replication: Dissemination of project results and outcomes, including barriers encountered and successes achieved, is critical to building the evidence base for cancer prevention and control efforts in the state. Dissemination efforts should consider the message, source, audience, and channel (Brownson, R.C., et al. [J Pub Health Manag Pract. 24\(2\):102-111](#), March/April 2018). Dissemination methods may include, but are not limited to, presentations at workshops and seminars, one-on-one meetings, publications, news media, social media, etc.

While passive dissemination methods are common (eg, publications, presentations at professional meetings), plans should include some active dissemination methods (eg, meetings with stakeholders, blogs, social media). Applicants should describe their dissemination plans. The plans should include the kinds of audiences to be targeted and methods for reaching the targeted audiences.

Replication by others is an additional way to disseminate the project. For applicable components, describe how the project or components of the project lend themselves to application by other communities and/or organizations in the state or expansion in the same communities. Describe what components of this project can be adapted to a larger or lower resource setting. Note that some programs may have unique resources and may not lend themselves to replication by others.

4.4.5. People Reached (Indirect Contact)

Provide the estimated overall number of people (members of the public and professionals) to be reached by the funded project. The applicant is required to itemize separately the types of indirect noninteractive education and outreach activities, with estimates, that led to the calculation of the overall estimates provided. Refer to [Appendix A](#) for definitions.

4.4.6. Number of Services Delivered (Direct Contact)

Provide the estimated overall number of services directly delivered to members of the public and to professionals by the funded project. Each individual service should be counted, regardless of the number of services one person receives. The applicant is required to itemize separately the education, navigation, and clinical activities/services, with estimates, that led to the calculation of the overall estimate provided. Refer to [Appendix A](#) for definitions.

4.4.7. Number of Clinical Services Delivered

Provide the estimated overall number of clinical services directly delivered to members of the public by the funded project. Each individual clinical service should be counted, regardless of the number of services one person receives. Separately itemize the clinical services, with estimates, that led to the calculation of the overall estimate provided. Refer to [Appendix A](#) for definitions.

4.4.8. Number of Unique People Served (Direct Contact)

Provide the estimated overall number of unique members of the public and professionals served by the funded project. One person may receive multiple services but should only be counted once here. Refer to [Appendix A](#) for definitions.

4.4.9. References

Provide a concise and relevant list of references cited for the application. The successful applicant will provide referenced evidence and literature support for the proposed services.

4.4.10. Resubmission Summary

Use the template provided on the CARS (<https://CPRITGrants.org>). Describe the approach to the resubmission and how reviewers' comments were addressed. Clearly indicate to reviewers how the application has been improved in response to the critiques. Refer the reviewers to specific sections of other documents in the application where further detail on the points in question may be found. When a resubmission is evaluated, responsiveness to previous critiques is assessed.

The summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission; the applicant is not responsible for providing this document.

4.4.11. Expansion Application Documents

If the project proposed is being submitted as an expansion project, the additional document described in [section 4.4.12](#) is required.

4.4.12. Most Recently Funded Relevant Project Summary, if Applicable (3 pages)

Upload a summary that outlines the progress made with the most recently funded relevant CPRIT award. Applicants must describe results and outcomes of the most recently funded relevant award and demonstrate why further funding is warranted.

Please note that a different set of reviewers from those assigned to the previously funded application may evaluate this application. Applicants should make it easy for reviewers to compare the most recently funded relevant project with the proposed continuation/expansion project.

In the description, include the following:

- Describe the evidence-based intervention, its purpose, and how it was implemented in the priority population. Describe any adaptations made for the population served.
- List approved goals and objectives of the most recently funded grant.
- For each objective, provide the following:
 - Milestones/target dates and target metrics
 - Actual completion dates and metrics
- For the most recently funded relevant project, describe major activities; significant results, including major findings, developments or conclusions (both positive and negative); and key outcomes. If the project has not yet ended, provide projections for completion dates and final metrics. Include a discussion of objectives not fully met. Explain any barriers encountered and strategies used to overcome these.
- Describe steps taken toward building internal capacity for sustainability of the project.
- Describe systems or policy improvements and enhancements.
- Describe how project results were disseminated or plans for future dissemination of results.

4.4.13 CPRIT Grants Summary

Use the template provided on CARS (<https://CPRITGrants.org>). Provide a listing of **all** projects funded by the CPRIT Prevention program for the PD or Co-PD, regardless of their connection to this application.

4.4.14 Budget and Justification

Provide a brief outline and detailed justification of the budget for the entire proposed period of support, including salaries and benefits, travel, equipment, supplies, contractual expenses, services delivery, and other expenses. CPRIT funds will be distributed on a reimbursement basis.

Applications requesting more than the maximum allowed cost (total costs) as specified in [section 2.10](#) will be administratively withdrawn.

- **Average Cost per Person:** The average cost per person will be automatically calculated from the total cost of the project divided by the total number of unique people served (refer to [Appendix A](#)). A significant proportion of funds is expected to be used for program delivery as opposed to program development and organizational infrastructure.
- **Average Cost per Service:** The average cost per service will be automatically calculated from the total cost of the project divided by the total number of services delivered (refer to [Appendix A](#)).
- **Average Cost per Clinical Service:** The average cost per clinical service will be automatically calculated from the total cost of the project divided by the total number of clinical services delivered (refer to [Appendix A](#)).
- **Personnel:** The individual salary cap for CPRIT awards is \$200,000 per year. Describe the source of funding for all project personnel where CPRIT funds are not requested.
- **Travel:** PDs and related project staff are expected to attend CPRIT's conference. CPRIT funds may be used to send up to 2 people to the conference.
- **Equipment:** Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application. Justification must be provided for why funding for this equipment cannot be found elsewhere; CPRIT funding should not supplant existing funds. Cost sharing of equipment purchases is strongly encouraged.

- **Services Costs:**
 - CPRIT reimburses for services using Medicare reimbursement rates. Describe the source of funding for all services where CPRIT funds are not requested. If clinical services are being paid for and provided by others, the applicant is required to explain and report on the number of clinical services and patient outcomes (eg, screenings/diagnostics, vaccinations, cancer precursors, cancers detected) that are delivered to the people navigated by the program.
 - CPRIT does not allow recovery of costs related to tests that have not been recommended by the USPSTF. (See <https://www.uspreventiveservicestaskforce.org/>)
- **Other Expenses:**
 - **Incentives:** Use of incentives or positive rewards to change or elicit behavior is allowed; however, incentives may only be used based on strong evidence of their effectiveness for the purpose and in the priority population identified by the applicant. CPRIT will not fund cash incentives. The maximum dollar value allowed for an incentive per person, per activity or session, is \$25.
 - **Costs Not Related to Cancer Prevention and Control:** CPRIT does not allow recovery of any costs for services not related to cancer (eg, health physicals, HIV testing).
- **Indirect/Shared Costs:** Texas law limits the amount of grant funds that may be spent on indirect/shared expenses to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in [CPRIT's Administrative Rules](#).

4.4.15 Current and Pending Support and Sources of Funding

Use the template provided on the CARS (<https://CPRITGrants.org>). Describe the funding source and duration of **all** current and pending support for the proposed project, including a capitalization table that reflects private investors, if any.

4.4.16 Biographical Sketches

The designated PD will be responsible for the overall performance of the funded project and must have relevant education and management experience. The PD/Co-PD(s) must provide a

biographical sketch that describes his or her education and training, professional experience, awards and honors, and publications and/or involvement in programs relevant to cancer prevention and/or service delivery.

- Use the Co-PD Biographical Sketch section ONLY if a Co-PD has been identified.
- The evaluation professional must provide a biographical sketch in the Evaluation Professional Biographical Sketch section.
- Up to 3 additional biographical sketches for key personnel may be provided in the Key Personnel Biographical Sketch section.

Each biographical sketch must not exceed 2 pages and should use either the “Prevention Programs: Biographical Sketch” template provided on the CARS (<https://CPRITGrants.org>) or the NIH Biographical Sketch format. Only biographical sketches will be accepted; do not submit resumes and/or CVs. If a position is not yet filled, please upload a job description.

4.4.17 Collaborating Organizations

List all key participating organizations that will partner with the applicant organization to provide 1 or more components essential to the success of the program (eg, evaluation, clinical services, recruitment to screening). Please be sure to also include anyone listed as key personnel and/or listed under the Current & Pending Support section.

4.4.18 Letters of Commitment (10 pages)

Applicants should provide letters of commitment and/or memoranda of understanding from community organizations, key faculty, or any other component essential to the success of the program. Letters should be specific to the contribution of each organization.

5. APPLICATION REVIEW

5.1 Review Process Overview

All eligible applications will be reviewed using a 2-stage peer review process: (1) evaluation of applications by peer review panels and (2) prioritization of grant applications by the Prevention Review Council. In the first stage, applications will be evaluated by an independent review panel using the criteria listed below. In the second stage, applications judged to be meritorious by review panels will be evaluated by the Prevention Review Council and recommended for funding

based on comparisons with applications from all of the review panels and programmatic priorities. Programmatic considerations may include, but are not limited to, geographic distribution, cancer type, population served, and type of program or service. The scores are only 1 factor considered during programmatic review. At the programmatic level of review, priority will be given to proposed projects that target geographic regions of the state or population subgroups that are not well represented in the current CPRIT Prevention project portfolio.

Applications approved by Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

Each stage of application review is conducted confidentially, and all CPRIT Peer Review Panel members, Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Peer Review Panel members and Review Council members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer Review Panel members are listed by panel on CPRIT's website. **By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules, [chapter 703, section 703.9](#).**

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight

Committee member, a PIC member, a Review Panel member, or a Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention and Communications Officer, the Chief Product Development Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period when preapplications or letters of interest are accepted. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

5.2 Review Criteria

Peer review of applications will be based on primary scored criteria and secondary unscored criteria, identified below. Review panels consisting of experts in the field and advocates will evaluate and score each primary criterion and subsequently assign an overall score that reflects an overall assessment of the application. The overall evaluation score will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application and responsiveness to the RFA priorities.

5.2.1 Primary Evaluation Criteria

Impact

- Do the proposed services address an important problem or need in cancer prevention and control? Do the proposed project strategies support desired outcomes in cancer incidence, morbidity, and/or mortality? Do the proposed project strategies reach a priority population (eg, low income, minority, rural) at high risk of cancer?
- For expansion projects, does the proposed project build on its initial results (baseline)? Does it go beyond the initial project to address what the applicant has learned or explore new partnerships, new audiences, or improvements to systems?
- Will the project reach and serve/impact an appropriate number of people based on the budget allocated to providing services and the cost of providing services?
- If applicable, have partners demonstrated that the collaborative effort will provide a greater impact on cancer prevention and control than the applicant organization's effort separately?

- Does the program address adaptation, if applicable, of the evidence-based intervention to the priority population? Is the base of evidence clearly explained and referenced?

Project Strategy and Feasibility

- Does the proposed project provide services specified in the RFA?
- Are the overall program approach, strategy, and design clearly described and supported by established theory and practice? Are the proposed objectives and activities feasible within the duration of the award? Has the applicant convincingly demonstrated the short- and long-term impacts of the project?
- Has the applicant proposed policy changes and/or system improvements?
- Are possible barriers addressed and approaches for overcoming them proposed?
- Are the priority population and culturally appropriate methods to reach the priority population clearly described?
- If applicable, does the application demonstrate the availability of resources and expertise to provide case management, including followup for abnormal results and access to treatment?
- Does the program leverage partners and resources to maximize the reach of the services proposed? Does the program leverage and complement other state, federal, and nonprofit grants?

Outcomes Evaluation

- Are specific goals and measurable objectives for each year of the project provided?
- Are the proposed outcome measures appropriate for the services provided, and are the expected changes clinically significant?
- If clinical services are being paid for and provided by others, does the applicant explain the methods used to collect data and report on these clinical services and outcomes?
- Does the application provide a clear and appropriate plan for data collection and management and data analyses?
- Are clear baseline data provided for the priority population, or are clear plans included to collect baseline data?

- If an evidence-based intervention is being adapted in a population where it has not been implemented or tested, are plans for evaluation of barriers, effectiveness, and fidelity to the model described?
- Is the qualitative analysis of planned policy or system changes described?

Organizational Qualifications and Capabilities

- Do the organization and its collaborators/partners demonstrate the ability to provide the proposed preventive services?
- Does the described role of each collaborating organization make it clear that each organization adds value to the project and is committed to working together to implement the project?
- Have the appropriate personnel been recruited to design, implement, evaluate, and complete the project?
- Is the organization structurally and financially stable and viable?
- Does the applicant describe their current activities and the program's organizational capacity for sustainability?
- Does the applicant describe steps that will be taken toward building internal capacity and partnerships?
- Does the applicant describe a plan for systems changes that are sustainable over time (eg, improve results, provider practice, efficiency, cost-effectiveness)?

5.2.2 Secondary Evaluation Criteria

Budget

- Is the budget appropriate and reasonable for the scope and services of the proposed work?
- Is the cost per person served appropriate and reasonable?
- Is the proportion of the funds allocated for direct services reasonable?
- Is the project a good investment of Texas public funds?

Dissemination and Replication

- Are plans for dissemination of the project's results and outcomes, including target audiences and methods, clearly described?

- Are active dissemination strategies included and described in the plan?
- Does the applicant describe whether and/or how the project lends itself to replication of all or some components of the project by others in the state?

6. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in [CPRIT's Administrative Rules](#). Applicants are advised to review CPRIT's administrative rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires the PD of the award to submit quarterly, annual, and final progress reports. These reports summarize the progress made toward project goals and address plans for the upcoming year and performance during the previous year(s). In addition, quarterly fiscal reporting and reporting on selected metrics will be required per the instructions to award recipients. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract.

7. CONTACT INFORMATION

7.1 Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding the scope and focus of applications. Before contacting the helpdesk, please refer to the *Instructions for Applicants* document (posted on November 16, 2020), which provides a step-by-step guide to using CARS.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

7.2 Program Questions

Questions regarding the CPRIT Prevention Program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Prevention Program Office.

Tel: 512-305-8417

Email: Help@CPRITGrants.org

Website: www.cprit.texas.gov

8. RESOURCES

- The Texas Cancer Registry. <https://www.dshs.texas.gov/tcr> or contact the Texas Cancer Registry at the Department of State Health Services.
- The Community Guide. <https://www.thecommunityguide.org/>
- Cancer Control P.L.A.N.E.T. <http://cancercontrolplanet.cancer.gov>
- Guide to Clinical Preventive Services: Recommendations of the U.S. Preventive Services Task Force. <http://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/guide/>
- Brownson, R.C., Colditz, G.A., and Proctor, E.K. (Editors). *Dissemination and Implementation Research in Health: Translating Science to Practice*. Oxford University Press, March 2012
- Program Sustainability Assessment Tool, copyright 2012, Washington University, St Louis, MO, <https://www.sustaintool.org/about-us/>
- [Getting the Word Out: New Approaches for Disseminating Public Health Science](#). Ross C. Brownson, PhD; Amy A. Eyler, PhD; Jenine K. Harris, PhD; Justin B. Moore, PhD, MS; Rachel G. Tabak, PhD, RD, *Journal of Public Health Management & Practice*. 24(2):102-111, March/April 2018. https://journals.lww.com/jphmp/Fulltext/2018/03000/Getting_the_Word_Out__New_Approaches_for.4.aspx
- Centers for Disease Control and Prevention: The Program Sustainability Assessment Tool: A New Instrument for Public Health Programs. http://www.cdc.gov/pcd/issues/2014/13_0184.htm
- Centers for Disease Control and Prevention: Using the Program Sustainability Tool to Assess and Plan for Sustainability. http://www.cdc.gov/pcd/issues/2014/13_0185.htm
- Cancer Prevention and Control Research Network: Putting Public Health Evidence in Action Training Workshop. <http://cpcrn.org/pub/evidence-in-action/>
- Centers for Disease Control and Prevention. Distinguishing Public Health Research and Public Health Nonresearch. <https://www.cdc.gov/os/integrity/docs/cdc-policy-distinguishing-public-health-research-nonresearch.pdf>

9. REFERENCES

1. National Cancer Institute, <https://www.cancer.gov>
2. American Cancer Society, Cancer Facts and Figures 2016, <http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2016>
3. Texas Cancer Registry, Cancer Epidemiology and Surveillance Branch, Texas Department of State Health Services. <https://www.cancer-rates.info/tx/>
4. Centers for Disease Control and Prevention. Distinguishing Public Health Research and Public Health Nonresearch. <https://www.cdc.gov/os/integrity/docs/cdc-policy-distinguishing-public-health-research-nonresearch.pdf>

APPENDIX A: KEY TERMS

- **Activities:** A listing of the “who, what, when, where, and how” for each objective that will be accomplished.
- **Capacity Building:** Any activity (eg, training, identification of alternative resources, building internal assets) that builds durable resources and enables the grantee’s setting or community to continue the delivery of some or all components of the evidence-based intervention.
- **Clinical Services:** Number of clinical services such as screenings, diagnostic tests, vaccinations, counseling sessions, or other evidence-based preventive services delivered by a health care practitioner in an office, clinic, or health care system. Other examples include genetic testing or assessments, physical rehabilitation, tobacco cessation counseling or nicotine replacement therapy, case management, primary prevention clinical assessments, and family history screening.
- **Counties of Residence of Population Served:** Counties where the project does not plan to have a physical presence but people who live in these counties have received services. This includes counties of residence of people or places of business of professionals who participate in or receive education, navigation, or clinical services. Examples include people traveling to receive services as a result of marketing and programs accessible via the website or social media. These counties may be described in the project plan and must be reported in the quarterly progress report.
- **Counties with Service Delivery:** Counties where an activity or service will occur and the project has a physical presence for the services provided. Examples include onsite outreach and educational activities and delivery of clinical services through clinics, mobile vans, or telemedicine consults. These counties must be entered in the Geographic Area to be Served section of the application.
- **Education Services:** Number of evidence-based, culturally appropriate cancer prevention and control education and outreach services delivered to the public and to health care professionals. Examples include education or training sessions (group or individual), focus groups, and knowledge assessments. One individual may receive multiple education services.

- **Evidence-Based Program:** A program that is validated by some form of documented research or applied evidence. CPRIT’s website provides links to resources for evidence-based strategies, programs, and clinical recommendations for cancer prevention and control. To access this information, visit <https://www.cprit.state.tx.us/our-programs/prevention>.
- **Goals:** Broad statements of general purpose to guide planning. Outcome goals should be few in number and focus on aspects of highest importance to the project. ([Appendix B](#))
- **Integration:** The extent the evidence-based intervention is integrated within the culture of the grantee’s setting or community through policies and practice.
- **Navigation Services:** Number of activities/services that offer assistance to help overcome health care system barriers in a timely and informative manner and facilitate cancer screening and diagnosis to improve health care access and outcomes. Examples include patient reminders, transportation assistance, and appointment scheduling assistance. One individual may receive multiple navigation services.
- **Number of Clinical Services:** Number of [clinical services](#) delivered directly to members of the public by the funded project. One individual may receive multiple clinical services.
- **Number of Services (Direct Contact):** Number of services delivered directly to members of the public and/or professionals—direct, interactive public or professional education, outreach, training, navigation service, or clinical service, such as live educational and/or training sessions, vaccine administration, screening, diagnostics, case management/navigation services, and physician consults. One individual may receive multiple services.
- **Objectives:** Specific, **measurable**, actionable, realistic, and timely projections for outcomes; example: “Increase screening service provision in X population from Y% to Z% by 20xx.” Baseline data for the priority population must be included as part of each objective. ([Appendix B](#)) The proposed metric should be included in **both** the objective and the measure (eg, Measure: 1,000 individuals will undergo LDCT and be referred for diagnostic testing as necessary).
- **People Reached (Indirect contact):** Number of members of the public and/or professionals reached via indirect noninteractive public or professional education and outreach activities, such as mass media efforts, brochure distribution, public service

announcements, newsletters, and journals. (This category includes individuals who would be reached through activities that are directly funded by CPRIT as well as individuals who would be reached through activities that occur as a direct consequence of the CPRIT-funded project's leveraging of other resources/funding to implement the CPRIT-funded project.)

- **Unique People Served (Direct Contact):** Number of unique members of the public and/or professionals served via direct, interactive public or professional education, outreach, training, navigation service, or clinical service. This category includes individuals who would be served through activities that are directly funded by CPRIT as well as individuals who would be served through activities that occur as a direct consequence of the CPRIT-funded project's leveraging of other resources/funding to implement the CPRIT-funded project.

APPENDIX B: WRITING GOALS AND OBJECTIVES

List only major **outcome goals** and **measurable objectives** for each year of the project. **Do not include process objectives**; these should be described in the project plan only. Include the proposed metric within **both** the stated Objective and the Measure sections (eg, Measure: 1,000 individuals will undergo LDCT and be referred for diagnostic testing as necessary).

The maximum number is 3 goals with 3 objectives each. Projects will be evaluated annually on progress toward **outcome** goals and objectives.

The following guide has been adapted with permission from Appalachia Community Cancer Network, NIH Grant U54 CA 153604:

Develop well-defined outcome goals and objectives.

Goals provide a roadmap or plan for where a group wants to go. Goals can be long term (over several years) or short term (over several months). Goals should be based on needs of the community and evidence-based data.

Goals should be:

- Believable – situations or conditions that the group believes can be achieved
- Attainable – possible within a designated time
- Tangible – capable of being understood or realized
- On a timetable – with a completion date
- Win-Win – beneficial to individual members and the coalition

Objectives are measurable steps toward achieving the goal. They are clear statements of specific activities required to achieve the goal. The best objectives have several characteristics in common – S.M.A.R.T. + C:

- Specific – they tell how much (number or percent), who (participants), what (action or activity), and by when (date)
 - Example: 115 uninsured individuals age 50 and older will complete colorectal cancer screening by March 31, 2018.
- Measurable – specific measures that can be collected, detected, or obtained to determine successful attainment of the objective

- Example: How many screened at an event? How many completed pre/post assessment?
- Achievable – not only are the objectives themselves possible, it is likely that your organization will be able to accomplish them
- Relevant to the mission – your organization has a clear understanding of how these objectives fit in with the overall vision and mission of the group
- Timed – developing a timeline is important for when your task will be achieved
- Challenging – objectives should stretch the group to aim on significant improvements that are important to members of the community

Evaluate and refine your objectives

Review your developed objectives and determine the type and level of each using the following information:

There are 2 types of objectives:

- Outcome objectives – measure the “what” of a program; should be in the Goals and Objectives form ([see section 4.4.2](#))
- Process objectives – measure the “how” of a program; should be in the project plan only (see [section 4.4.4](#))

There are 3 levels of objectives:

- Community-level – objectives measure the planned community change
- Program impact – objectives measure the impact the program will have on a specific group of people
- Individual – objectives measures participant changes resulting from a specific program, using these factors:
 - Knowledge – understanding (know screening guidelines; recall the number to call for screening)
 - Attitudes – feeling about something (will consider secondhand smoke dangerous; believe eating 5 or more fruits and vegetable is important)
 - Skills – the ability to do something (complete fecal occult blood test)
 - Intentions – regarding plan for future behavior (will agree to talk to the doctor, will plan to schedule a Pap test)

- Behaviors (past or current) – to act in a particular way (will exercise 30+ minutes a day, will have a mammogram)

Well-defined outcome goals and objectives can be used to track, measure, and report progress toward achievement.

Summary Table

	Outcome – Use in Goals and Objectives	Process – Use in Project Plan only
Community-level	<p>WHAT will change in a community</p> <p><i>Example: As a result of CPRIT funding, FIT (fecal immunochemical tests) will be available to 1,500 uninsured individuals age 50 and over through 10 participating local clinics and doctors.</i></p>	<p>HOW the community change will come about</p> <p><i>Example: Contracts will be signed with participating local providers to enable uninsured individuals over age 50 have access to free colorectal cancer screening in their communities.</i></p>
Program impact	<p>WHAT will change in the target group as a result of a particular program</p> <p><i>Example: As a result of this project, 200 uninsured women between 40 and 49 will receive free breast and cervical cancer screening.</i></p>	<p>HOW the program will be implemented to affect change in a group/population</p> <p><i>Example: 2,000 female clients, between 40 and 49, will receive a letter inviting them to participate in breast and cervical cancer screening.</i></p>
Individual	<p>WHAT an individual will learn as a result of a particular program, or WHAT change an individual will make as a result of a particular program</p> <p><i>Example: As a result of one-to-one education of 500 individuals, at least 20% of participants will participate in a smoking cessation program to quit smoking.</i></p>	<p>HOW the program will be implemented to affect change in an individual’s knowledge or actions</p> <p><i>Example: As a result of one-to-one counseling, all participants will identify at least 1 smoking cessation service and 1 smoking cessation aid.</i></p>

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)

21.2 Prevention Review Panel - 1 (21.2 PRV-P1)

Observation Report

Report No. 2021-04- 21.2_PRV-P1
Program Name: Prevention
Panel Name: 21.2 Prevention Review Panel - 1 (21.2_PRV-P1)
Panel Date: April 26, 2021 and April 27, 2021
Report Date: May 6, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Prevention Review Panel - 1 (21.2_PRV-P1) meeting. The meeting was chaired by Nancy Lee and conducted via videoconference on April 26, 2021 and April 27, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Eleven (11) applications were discussed on April 26, 2021; three (3) applications were discussed, and four (4) applications were not discussed on April 27, 2021
- Panelists: One (1) panel chair, nine (9) expert reviewers and three (3) advocate reviewers were present on April 26, 2021 and one (1) panel chair, eight (8) expert reviewers and three (3) advocate reviewers on April 27, 2021
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4) were present on April 26, 2021 and three (3) on April 27, 2021
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: One (1) on both days
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. There were zero (0) COIs on applications discussed and one (1) COI on an application not discussed.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive 'M' followed by a horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

21.2 Prevention Review Council (21.2_PRC-M2)

Observation Report

Report No. 2021-06-17 21.2_PRC-M2
Program Name: Prevention
Panel Name: 21.2 Prevention Review Council (21.2_PRC-M2)
Panel Date: June 17, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Prevention Review Council (21.2_PRC-M2) meeting. The meeting was chaired by Stephen Wyatt and conducted via teleconference on June 17, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Nine (9) applications were discussed
- Panelists: One (1) panel chair, and two (2) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: One (1)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was zero (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line extending to the right.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Prevention Cycle 21.2

Awards Announced at the August 18, 2021, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Prevention Cycle 21.2 include *Evidence-Based Cancer Prevention Services*; *Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations*; *Tobacco Control and Lung Cancer Screening*; and *Dissemination of CPRIT-Funded Cancer Control Interventions*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant/Principal Investigator	Principal Investigator Institution	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
No conflicts reported.			
Applications not considered by the PIC or Oversight Committee:			
PP210023	Gail Tomlinson	The University of Texas Health Science Center at San Antonio	R. Riter

T.A.C. Section 702.19 Waiver



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS
FROM: WAYNE R. ROBERTS, CHIEF EXECUTIVE OFFICER
SUBJECT: T.A.C. § 702.19 STANDING WAIVER FOR FY 2021
DATE: AUGUST 28, 2020

Summary

This is to notify the Oversight Committee that pursuant to the authority provided to the Chief Executive Officer in T.A.C. § 702.19(e), I grant CPRIT's Chief Prevention Officer Ramona Magid a waiver from the general prohibition against communicating with grant applicants. The waiver is applicable for FY 2021. Unlike the two communication waivers I granted Ms. Magid for each FY 2020 review cycle, this standing FY 2021 waiver will be effective for both review cycles planned for FY 2021. No Oversight Committee action related to this waiver is necessary.

Background and Discussion

The Chief Prevention Officer is a statutorily mandated member of the Program Integration Committee (PIC). Texas Administrative Code § 702.19 prohibits substantive communication between the grant applicant and a member of the peer review panel, the PIC, or the Oversight Committee while the application is pending a final decision. The restriction on communication prevents even the appearance of unequal treatment during the grant review process.

Traditionally, a chief program officer leads each CPRIT program with the assistance of a program manager. The program manager fields inquiries from and provides technical help to applicants completing their CPRIT grant applications. I promoted Ms. Magid to the Chief Prevention Officer position upon Dr. Becky Garcia's retirement in June 2019. However, the prevention program manager position has remained vacant since Ms. Magid's promotion. Until CPRIT fills the program manager position, she is the sole point of contact for the prevention program. The communication waiver is necessary so that Ms. Magid can assist grant applicants who have questions during the application process.

I previously granted Ms. Magid separate waivers for the two review cycles of FY 2020. It is unlikely that CPRIT will fill the prevention program manager position in FY 2021. Accordingly, I am granting a standing waiver for Ms. Magid for FY 2021 as long as she remains the sole point of contact for the prevention program. Approving this standing waiver does not favor any grant applicant over another. Ms. Magid will provide technical assistance only and will not comment on the substance of a grant application. CPRIT will include this waiver in the grant record for the FY 2021 prevention grant applications.

De-Identified Overall Evaluation Scores

Tobacco Control and Lung Cancer Screening Prevention Cycle 21.2

Application ID	Final Overall Evaluation Score
PP210042*	2.1
PP210027*	3.1
da	3.6
db	5.6
dc	7.3

* Recommended for funding

Final Overall Evaluation Scores and Rank Order Scores

Dee Margo
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dee@deemargo.com

Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Mr. Roberts and Mr. Margo,

On behalf of the Prevention Review Council (PRC), I am pleased to provide the PRC's recommendations for the cycle 21.2 Evidence-Based Cancer Prevention Services (EBP), Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations (EPS), and Tobacco Control and Lung Cancer Screening (TCL) awards.

The PRC met on May 27, 2021 to review the applications submitted to CPRIT under the Dissemination of CPRIT-Funded Cancer Control Interventions (DI) mechanism. The PRC met again on June 17, 2021 to consider these applications and those recommended by the peer review panel following their April 26 meeting. The PRC recommends 9 projects totaling \$11,396,581.

The projects are numerically ranked in the order the PRC recommends the applications be funded. Recommended funding amounts and the overall evaluation score are stated for each grant application. The PRC made no changes to the goals, project objectives, or timelines of the applications.

Our recommendations meet the PRC's standards for grant award funding of projects that are evidence-based, deliver programs or services to underserved populations, and focus on primary, secondary, or tertiary prevention. In making these recommendations the PRC continued to consider the available funding, the composition of the current portfolio, and the programmatic priorities in the RFA which include potential for impact and return on investment, geographic distribution, cancer type and type of program. All the recommended grants address one or more of the Prevention Program priorities.

Sincerely,
Stephen W. Wyatt, DMD, MPH
Chair, CPRIT Prevention Review Council

Attachment



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Cycle 21.2 Recommended Prevention Program Awards

App. ID	Mech	Application Title	PD	Organization	Score	Rank Order	Budget
PP210045	DI	Dissemination of a Mailed Stool Testing Program for Colorectal Cancer Prevention in Underserved Communities in Texas	Pignone, Michael	The University of Texas at Austin	1.00	1	\$300,000
PP210049	EBP	Texas Southern University Breast Cancer Screening and Prevention Center	Ajewole, Veronica	Texas Southern University	1.80	2	\$1,000,000
PP210020	EPS	Vaccinating Medically Underserved Women Against HPV: Expansion of Clinical Services to Increase Access	Berenson, Abbey	The University of Texas Medical Branch at Galveston	2.00	3	\$1,999,988
PP210042	TCL	A Regional Expansion of Lung Cancer Screening and Patient Navigation (E-LSPAN)	Argenbright, Keith	The University of Texas Southwestern Medical Center	2.10	4	\$1,999,993
PP210026	DI	Taking Texas Tobacco Free: Dissemination to and Implementation Within Agencies Serving Texans Experiencing	Reitzel, Lorraine	University of Houston	2.70	5	\$299,978
PP210027	TCL	Increasing Accessibility to Smoking Cessation and Lung Cancer Screening Services for Low-Income/Uninsured Texans	McKnight, Jason	Texas A&M University System Health Science Center	3.10	6	\$999,947
PP210031	DI	Application of mHealth Technologies to Improve Latino Childhood Cancer Survivor Engagement and Use of Evidence for Personalized Follow-Up Care	Poplack, David	Baylor College of Medicine	3.30	7	\$299,982
PP210007	EPS	Strengthening Safety Net Health Systems to Improve Cervical and Colorectal Cancer Screening and Follow-up among the Medically Underserved	Montealegre, Jane R	Baylor College of Medicine	3.30	8	\$2,497,029
PP210044	TCL	Expansion of the Lung Cancer Screening and Tobacco Control (LCTC) Network to Rural and Medically Underserved Populations	Zoorob, Roger	Baylor College of Medicine	3.60	9	\$1,999,664

DI: Dissemination of CPRIT-Funded Cancer Control Interventions

EBP: Evidence-Based Cancer Prevention Services

EPS: Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations

TCL: Tobacco Control and Lung Cancer Screening



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research Recruitment
FY 2021—Cycles 10 through 12
*Recruitment of First-Time, Tenure-Track
Faculty Members***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS

RFA R-21.1-RFT

Recruitment of First-Time Tenure-Track Faculty Members

**Please also refer to the Instructions for Applicants document,
which will be posted on June 23, 2020**

Application Receipt Dates:

June 23, 2020-June 21, 2021

FY2021

Fiscal Year Award Period

September 1, 2020-August 31, 2021

TABLE OF CONTENTS

1. ABOUT CPRIT	4
1.1. ACADEMIC RESEARCH PROGRAM PRIORITIES	4
2. RATIONALE	5
3. RECRUITMENT OBJECTIVES	5
4. INSTITUTIONAL COMMITMENT	6
5. FUNDING INFORMATION	7
6. ELIGIBILITY	7
7. RESUBMISSION POLICY	10
8. RESPONDING TO THIS RFA	10
8.1. APPLICATION SUBMISSION GUIDELINES	10
8.2. APPLICATION COMPONENTS	11
8.2.1. <i>Summary of Nomination (2,000 characters)</i>	11
8.2.2. <i>Institutional Commitment (3 pages)</i>	11
8.2.3. <i>Letter of Support from Department Chair (1 page)</i>	13
8.2.4. <i>Curriculum Vitae (CV)</i>	13
8.2.5. <i>Summary of Goals and Objectives (2,000 characters)</i>	14
8.2.6. <i>Research (4 pages)</i>	14
8.2.7. <i>Research Collaboration/Synergy Plan (2 pages)</i>	14
8.2.8. <i>Publications</i>	15
8.2.9. <i>Timeline (1 page)</i>	15
8.2.10. <i>Current and Pending Support</i>	15
8.2.11. <i>Letters of Recommendation</i>	15
8.2.12. <i>Research Environment (1 page)</i>	15
8.2.13. <i>Descriptive Biography (Up to 2 pages)</i>	15
9. APPLICATION REVIEW	16
9.1. REVIEW PROCESS.....	16
9.1.1. <i>Confidentiality of Review</i>	16
9.2. REVIEW CRITERIA.....	17
10. KEY DATES	19
11. AWARD ADMINISTRATION	19
12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS	20
13. CONTACT INFORMATION	21
13.1. HELPDESK.....	21
13.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS	21

RFA VERSION HISTORY

Rev 6/23/20 RFA release

Rev 9/24/20 Section 8.2.2 – Institutional Commitment

- Added new statement that must be included in the Institutional Commitment Letter regarding the institution's financial commitment required to meet the 50% match.

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of or cures for cancer
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas
- Develop and implement the Texas Cancer Plan

1.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure

The program priorities for academic research adopted by the Oversight Committee include funding projects that address the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions
- Computational biology and analytic methods
- Childhood cancers
- Hepatocellular cancer
- Expand access to innovative clinical trials

2. RATIONALE

The aim of this award mechanism is to bolster cancer research in Texas by providing financial support to attract very promising investigators who are pursuing their first faculty appointment at the level of assistant professor (first-time, tenure-track faculty members). These individuals must have demonstrated academic excellence, innovation during predoctoral and/or postdoctoral research training, commitment to pursuing cancer research, and exceptional potential for achieving future impact in basic, translational, population-based, or clinical research. Awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research, thereby advancing cancer research efforts and promoting economic development in the State of Texas.

The recruitment of outstanding scientists will greatly enhance programs of scientific excellence in cancer research and will position Texas as a leader in the fight against cancer. Applications may address any research topic related to cancer biology, causation, prevention, detection or screening, or treatment. Candidates with research programs addressing CPRIT's priority areas for research are encouraged. These include implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions, computational biology and analytic methods, childhood cancers, hepatocellular cancer, and expansion of access to innovative clinical trials.

3. RECRUITMENT OBJECTIVES

The goal of this award mechanism is to recruit exceptional faculty to universities and/or cancer research institutions in the State of Texas. All candidates are expected to have completed their doctoral and fellowship training and to have clearly demonstrated truly superior ability as evidenced by their accomplishments during training, proposed research plan, publication record, and letters of recommendation. This CPRIT-supported initiative is designed to enhance innovative programs of excellence by providing research support for promising, early-stage investigators **seeking their first tenure-track position.**

CPRIT will provide start-up funding for newly independent investigators, with the goal of augmenting and expanding the institution's efforts in cancer research. Candidates will be expected to develop research projects within the sponsoring institution. Projects should be

appropriate for a newly independent investigator and should foster the development of preliminary data that can be used to prepare applications for future independent research project grants to further both the investigator's research career and the CPRIT mission. The institution will be expected to work with each newly recruited research faculty member to design and execute a faculty career development plan consistent with his or her research emphasis. Relevance to cancer research and to CPRIT's priority areas are important evaluation criteria for CPRIT funding.

Applications nominating individuals who are well prepared to pursue careers in patient-oriented research and who have demonstrated exceptional potential to lead innovative discovery campaigns through conduct of clinical trials are appropriate for this mechanism and encouraged.

Unless prohibited by policy, the institution is also expected to bestow on the newly recruited faculty member the prestigious title of "CPRIT Scholar in Cancer Research," and the faculty member should be strongly encouraged to use this title on letterhead, business cards, publications, and other appropriate documents. The title is to be retained as long as the individual remains in Texas.

4. INSTITUTIONAL COMMITMENT

CPRIT recruitment awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research to Texas. The funds provided by CPRIT for the recruitment of a First-Time Tenure-Track Faculty must therefore be complemented by a strong institutional commitment to the candidate's career development that includes financial commitments that are in addition to the CPRIT award. The institutional commitment should be clearly documented in the application (see [section 8.2.2](#)) and include the amount and sources of salary support and all additional financial support that will be available to the candidate's research program through the course of the CPRIT award. The financial commitments made to the candidate for his or her research program by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.

5. FUNDING INFORMATION

This award is up to 5 years and is not renewable, although individuals may apply for other future CPRIT funding as appropriate. Grant funds of up to \$2,000,000 (total costs) for the 5-year period may be requested. Funding is to be used by the candidate to support his or her research program. The award request may include indirect costs of up to 5% of the total award amount (5.263% of the direct costs). CPRIT will make every effort to be flexible in the timing for disbursement of funds; recipients will be asked at the beginning of each year for an estimate of their needs for the year. Funds may not be carried over beyond 5 years except under extraordinary circumstances with strong justification for a no-cost extension. In addition, funds for extraordinary equipment needs may be awarded in the first year of the grant if very well justified and a detailed justification is provided along with an institutional plan should the additional funds not be approved. Scholars may request funds for travel for 2 project staff to attend CPRIT's conference.

Funds from this CPRIT award may not be used for salary support of this candidate or to construct or renovate laboratory space.

No annual limit on the number of grant application submissions by Institutions has been set.

Note: Depending on the availability of funds, nominations submitted in response to this Request for Applications (RFA) during the current receipt period may be announced and awarded either in the current fiscal year (prior to August 31, 2021) or in the first quarter of the next fiscal year (starting September 1, 2021).

6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism.
- Candidates must be nominated by the president, provost, vice president for research, or appropriate dean of a Texas-based public or private institution of higher education, including academic health institutions. The application must be submitted on behalf of a specific candidate.

- A candidate may be nominated by only 1 institution. If more than 1 institution is interested in a given candidate, negotiations as to which institution will nominate him or her must be concluded before the nomination is made.
- There is no limit to the number of applications that an institution may submit during a review cycle.
- A candidate who has already accepted a position as assistant professor tenure track at the recruiting institution prior to the time that the Scientific Review Council reviews the candidate for a recruitment award is not eligible for a recruitment award, as an investment by CPRIT is obviously not necessary. No award is final until approved by the Oversight Committee at a public meeting. However, in recognition of the timeline involved with recruiting highly sought-after candidates who are often considering multiple offers, CPRIT's Academic Research program staff will notify the nominating institution of the Scientific Review Council's review decision following the Scientific Review Council meeting. If a position is offered to the candidate during the period following the Scientific Review Council's review decision but prior to the Oversight Committee's final approval, the institution does so at its own risk. There is no guarantee that the recruitment award will be approved by the Oversight Committee.
- The candidate must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, **and reside in Texas for the duration of the appointment.** The candidate must devote at least 70% time to research activities. Candidates whose major responsibilities are clinical care, teaching, or administration are not eligible.
- At the time of the application, the candidate must **not** hold an appointment at the rank of assistant professor or above (or equivalent) at an accredited academic institution, research institution, industry, government agency, or private foundation not primarily based in Texas. Candidates holding non-tenure-track appointments at the rank of assistant professor are **not** eligible for this award. Examples of such appointments include research assistant professor, adjunct research assistant professor, assistant professor (non-tenure track).
- The candidate **may or may not** reside in Texas at the time the application is submitted and may be nominated for a faculty position at the Texas institution where he or she is completing postdoctoral training.

- *Applications nominating a candidate for a faculty position at the Texas institution where he or she is completing postdoctoral training that do not clearly demonstrate a subsequent career pathway to independence for the candidate will not be looked upon with favor.*
- Successful candidates will be offered tenure-track academic positions at the rank of assistant professor.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the nominator, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant nominator, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the nominator, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, whether or not the individuals will receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.

CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 11](#) and [section 12](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

7. RESUBMISSION POLICY

Resubmissions will not be accepted for the Recruitment of First-Time, Tenure-Track Faculty Members award mechanism. Any nomination for the Recruitment of First-Time, Tenure-Track Faculty Members that was previously submitted to CPRIT and reviewed but was not recommended for funding may not be resubmitted. If a nomination was administratively rejected prior to review, it can be resubmitted in the following cycles.

8. RESPONDING TO THIS RFA

8.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application is submitted. Candidates must be nominated by the institution's president, provost, vice president for research, or appropriate dean. The individual submitting the application (Nominator) must create a user account in the system to start and submit an application. Furthermore, the Application Signing Official, who is the person authorized to sign and submit the application for the organization, and the Grants Contract/Office of Sponsored Projects Official, who is the individual who will manage the grant contract if an award is made, also must create a user account in CARS.

Dependent upon available funding, applications will be accepted on a continuous basis throughout FY21. In order to manage the timely review of nominations, it is anticipated that applications submitted by 11:59 PM central time on the 20th day of each month will be reviewed by the 15th day of the following month. For an application to be considered for review during the monthly cycle, that application must be submitted on or before 11:59 PM central time. In the event that the 20th falls on Saturday or Sunday, applications may be submitted on or before 11:59 PM central time the following Monday. CPRIT will not extend the submission deadline. During periods when CPRIT does not receive an adequate number of applications, the review may be extended into the following month. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

8.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. For details, please refer to the *Instructions for Applicants* document that will be available when the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

8.2.1. Summary of Nomination (2,000 characters)

Provide a brief summary of the nomination. Include the candidate's name, organization from which the candidate is being recruited, and also the department and/or entity within the nominator's organization where the candidate will hold the faculty position.

8.2.2. Institutional Commitment (3 pages)

CPRIT recruitment awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research to Texas. The funds provided by CPRIT for the recruitment of a First-Time Tenure-Track Faculty must therefore be complemented by a strongly documented institutional commitment to the candidate's career development that includes financial commitments that are in addition to the CPRIT award.

The following guidelines should be followed when documenting the institutional commitment to the candidate:

- The institutional commitment should be clearly documented in the form of a letter signed by the applicant institution's president, provost, or appropriate dean and include the amount and sources of salary support and all additional financial support that will be available to the candidate's research program through the course of the CPRIT award. The financial commitments made to the candidate by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.
- The Institutional Commitment letter must include the following statement regarding the institution's financial commitment required to meet the 50% match.

- This institutional financial commitment will not be offset by funds from a career transition award (K99/R00) or an investigator-initiated award received by the candidate. If an award dictates that such funds must be used for salary, the corresponding amount of institutional funds committed to pay the candidate’s salary will be re-directed to allow the candidate to use them for program support.
- Institutional Commitment as described above must be presented in a table (example below), that clearly identifies the salary amount, sources of salary, and any additional research support from institutional sources over the course of the CPRIT award. Note that a federal indirect cost rate credit cannot be used to demonstrate an institutional commitment to the candidate.
- Include a brief job description for the candidate should recruitment be successful.
- Describe the institutional environment and any professional commitments to the candidate including, but not limited to, dedicated personnel, access to students, space assignment, and access to shared equipment, and discuss all other agreements between the institution and the candidate.
- Institutions may provide additional information in support of a candidate’s research plan to demonstrate how the institutional commitment through development of strategic collaborations will foster a candidate’s cancer research. This additional information is highly encouraged when proposing a candidate with exceptional expertise and/or talent that can be directed to cancer research such as a computational biologist, chemist, etc, whose prior experience has not been directly focused on cancer research.
- Note that Texas law allows an institution of higher learning to use its federal indirect cost rate credit to comply with the requirement to demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award (see [section 12](#)). However, a federal indirect cost rate credit cannot be used to demonstrate an institutional commitment to the candidate.

Example of an acceptable Institutional Commitment table:

Candidates Name, Institutional Commitments					
	Year 1	Year 2	Year 3	Year 4	Year 5
Salary/Benefits					

Research Support					
Administrative Support					
Moving Expenses					

Total =

Note: CPRIT acknowledges that the Institutional Commitments by category may change during the course of the award; however, the total financial commitment to the candidate must remain equal to or greater than 50% of the CPRIT award.

8.2.3. Letter of Support from Department Chair (1 page)

Provide the letter of support from and signed by the chair of the department to which the candidate is being recruited. The following information should be included in the letter:

Recruitment Activities: The letter should provide a description of the recruitment activities, strategies, and priorities that have led to the nomination of this candidate.

Caliber of Candidate: The letter should include a description of the caliber of the candidate and justification of the nomination of the candidate by the institution.

Description of Candidate Duties and Certification of 70% Time Commitment to Research:

While scholars may engage in direct patient care activities and/or have some administrative or teaching duties, at least 70% of the candidate’s time must be available for research. Breach of this requirement will constitute grounds for discontinuation of funding. The certification that 70% time will be spent on research must be included.

The letter of support from the department chair must also do the following:

1. Describe how the candidate will be independent and autonomous in developing his or her research program at the institution;
2. Present a plan for mentoring that includes the design and execution of a faculty career development plan for the candidate.

8.2.4. Curriculum Vitae (CV)

Provide a complete CV and list of publications for the candidate. Only articles that have been published or that have been accepted for publication (“in press”) should be cited.

8.2.5. Summary of Goals and Objectives (2,000 characters)

List goals and objectives to be achieved during this award. **This section must be completed by the candidate.**

8.2.6. Research (4 pages)

Summarize the key elements of the candidate's research accomplishments and provide an overview of the proposed research by outlining the background and rationale, hypotheses and aims, strategies, goals, and projected impact of the focus of the research program. Highlight the innovative aspects of this effort and place it into context with regard to what pressing problem in cancer will be addressed. **This section of the application must be prepared by the candidate. References cited in this section must be included within the stated page limit. Any appropriate citation format is acceptable; official journal abbreviations should be used.**

Candidates for CPRIT Scholar Awards must include the following signed statement at the end of this section. **Applications that do not contain this signed statement will be returned without review.**

"I understand that I do not need to have made a commitment to <*nominating institution*> before this application has been submitted. However, I also understand that only 1 Texas institution may nominate me for a CPRIT Recruitment Award, and this is the nomination that I have endorsed. I understand that requests to change the recruiting institution during the recruitment process are not allowed after the application is submitted to CPRIT.

8.2.7. Research Collaboration/Synergy Plan (2 pages)

Institutions may provide additional information in support of a candidate's research plan to demonstrate how the institutional commitment through development of strategic collaborations will foster a candidate's cancer research. This additional information is highly encouraged when proposing a candidate with exceptional expertise and/or talent that can be directed to cancer research, such as a computational biologist, chemist, etc, whose prior experience has not been directly focused on cancer research. Biographical sketches of collaborators established in the research collaborative plan must be uploaded as part of the application. This will be in addition to the 2-page synergy plan (see IFA).

8.2.8. Publications

Provide the 3 most significant publications that have resulted from the candidate's research efforts. Publications should be uploaded as PDFs of full-text articles. Only articles that have been published or that have been accepted for publication ("in press") should be submitted.

8.2.9. Timeline (1 page)

Provide a general outline of anticipated major award outcomes to be tracked. Timelines will be reviewed during the evaluation of annual progress reports. If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

8.2.10. Current and Pending Support

State the funding source, duration, and title of all current and pending research support held by the candidate. If the candidate has no current or pending funding, a document stating this must be submitted. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

8.2.11. Letters of Recommendation

Provide 3 letters of recommendation from individuals who are in a position to detail the candidate's academic and scientific research accomplishments, potential for high-impact research, and ability to make a significant contribution to the field of cancer research.

8.2.12. Research Environment (1 page)

Clearly and concisely describe the research environment available to support the candidate's research program, including core facilities, training programs, and collaborative opportunities.

8.2.13. Descriptive Biography (Up to 2 pages)

Provide a brief descriptive biography of the candidate, including his or her accomplishments, education and training, professional experience, awards and honors, publications relevant to cancer research, and a brief overview of the candidate's goals if selected to receive the award.

This section of the application must be prepared by the candidate. If the application is approved for funding, this section will be made publicly available on CPRIT's website.

Candidates are advised not to include information that they consider confidential or proprietary when preparing this section.

Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or do not meet the eligibility requirements listed above will be administratively withdrawn without review.

9. APPLICATION REVIEW

9.1. Review Process

All eligible applications will be evaluated and scored by the CPRIT Scientific Review Council using the criteria listed in this RFA. Applications may be submitted continuously in response to this RFA but will generally be reviewed on a monthly basis by the CPRIT Scientific Review Council. Council members may seek additional ad hoc evaluations of candidates. Scientific Review Council members will review applications and provide an individual Overall Evaluation Score that conveys the members' recommendation related to the proposed recruitment.

Applications recommended by the Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review, prioritization, and recommendation to the CPRIT Oversight Committee for approval and funding. Approval is based on an application receiving a positive vote from at least two-thirds of the members of the Oversight Committee. The review process is described more fully in CPRIT's Administrative Rules, Texas [Administrative Code, Title 25, Chapters 701 to 703](#).

The decision of the Scientific Review Council not to recommend an application is final, and such applications may not be resubmitted for a recruitment award. Notification of review decisions is sent to the nominator.

9.1.1. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Review Council members are non-Texas residents.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed conflict of interest as set forth in CPRIT's Administrative Rules, Texas [Administrative Code, Title 25, Chapters 701 to 703](#).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention and Communications Officer, the Chief Product Development Officer, and the Commissioner of the Department of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant applicant from further consideration for a grant award.

9.2. Review Criteria

Applications will be assessed based on evaluation of the quality of the candidate and his or her potential for continued superb performance as a cancer researcher. **Also, of critical importance is the strength of the institutional commitment to the candidate. Recruitment efforts are not likely to be successful unless there is a strong commitment from both CPRIT and the host institution.** It is not necessary that a candidate agree to accept the recruitment offer at the time an application is submitted. However, applicant institutions should have reasonable expectation that the recruitment will be successful if an award is granted by CPRIT.

Review criteria will focus on the overall impression of the candidate, his or her proposed research program, and his or her long-term contribution to and impact on the field of cancer research. Questions to be considered by the reviewers are as follows:

Quality of the Candidate: Has the candidate demonstrated academic excellence? Has the candidate received excellent predoctoral and postdoctoral training? Does the candidate show exceptional potential for achieving future impact on basic, translational, clinical, or population-based cancer research in the future? Has the candidate demonstrated a commitment to cancer research? Has the candidate demonstrated independence or the potential for independence?

Scientific Merit of Proposed Research: Is the research plan comprehensive and well thought out? Does the proposed research program demonstrate innovation, creativity, and feasibility? Will it have a significant impact on the field of cancer research? Will the proposed research generate preliminary data that can be used for the preparation of applications for future independent research project grants?

Relevance of Candidate's Research: Is the proposed research likely to have a significant impact on reducing the burden of cancer in the near term? Does the research contribute to basic, translational, clinical, or population-based cancer research?

Letters of Recommendation: Do the letters of recommendation detail the candidate's academic and clinical research accomplishments, potential for high-impact research, and ability to make a significant contribution to the field of cancer research?

Research Environment: Does the institution have the necessary facilities, expertise, and resources to support the candidate's research? Is there evidence of strong institutional support? Will the candidate be free of major administrative/clinical responsibilities so that he or she can focus on growing his or her research? Has the institution identified a mentor who will design and execute a faculty career development plan for the candidate?

10. KEY DATES

RFA

RFA Release

June 23, 2020

Application Receipt and Review Timeline

Application Receipt System opens 7 AM CT	Application Receipt	Anticipated Application Review	Application Closing Date
June 23, 2020	Continuous – dependent upon available funding	Monthly by the 15 th day of the month	June 21, 2021

11. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Awards made under this RFA are not transferable to another institution. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT’s electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT’s electronic signature policy as set forth in Texas [Administrative Code, Title 25, Chapters 701 to 703](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT’s Administrative Rules, which are available at www.cprit.texas.gov.

Applicants are advised to review CPRIT’s Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in Texas [Administrative Code, Title 25, Chapters 701 to 703](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, Texas [Administrtrive Code, Title 25, Chapters 701 to 703](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. CPRIT requires funding acknowledgement on all print and visual materials, which are funded in whole or in part by CPRIT grants. Examples of print and visual materials include, but are not limited to, publications, brochures, pamphlets, project websites, videos and media materials. Unless prohibited by policy, the institution is also expected to bestow on the newly recruited faculty member the prestigious title of "CPRIT Scholar in Cancer Research," and the faculty member should be strongly encouraged to use this title on letterhead, business cards, publications, and other appropriate documents. The title is to be retained as long as the individual remains in Texas.

Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. The demonstration of available matching funds must be made at the time the award contract is executed and annually thereafter, not when the application is submitted. Grant applicants are advised to consult CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#), for specific requirements regarding the demonstration of available funding.

13. CONTACT INFORMATION

13.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff members are not in a position to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

13.2. Scientific and Programmatic Questions

Questions regarding the CPRIT Program, including questions regarding this or other funding opportunities, should be directed to the CPRIT Senior Program Manager for Academic Research.

Tel: 512-305-8491

Email: Help@CPRITGrants.org

Website: www.cprit.texas.gov

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)

21.10 Scientific Review Council Recruitment Review

(21.10 SRC-REC10) Observation Report

Report No. 2021-05-13 21.10_SRC-REC10
Program Name: Academic Research
Panel Name: 21.10 Scientific Review Council Recruitment Review (21.10_SRC-REC10)
Panel Date: May 13, 2021
Report Date: May 19, 2020

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is 21.10 Scientific Review Council Recruitment Review (21.10_SRC-REC10) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on May 13, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Nine (9) applications were discussed
- Panelists: One (1) panel chair and six (6) expert reviewers were present, and two (2) expert reviewers were not present
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

21.11 Scientific Review Council Recruitment Review

(21.11 SRC-REC11) Observation Report

Report No. 2021-06-10 21.11_SRC-REC11
Program Name: Academic Research
Panel Name: 21.11 Scientific Review Council Recruitment Review (21.11_SRC-REC11)
Panel Date: June 10, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is 21.11 Scientific Review Council Recruitment Review (21.11_SRC-REC11) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on June 10, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: thirteen (13) applications were discussed
- Panelists: One (1) panel chair and seven (7) expert reviewers and one (1) expert reviewer was not present
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were four (4) Conflicts of Interest (COIs) identified prior to and/or during the meeting. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COIs procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

21.12 Scientific Review Council Recruitment Review

(21.12 SRC-REC12) Observation Report

Report No. 2021-07-08 21.12_SRC-REC12
Program Name: Academic Research
Panel Name: 21.12 Scientific Review Council Recruitment Review (21.12_SRC-REC12)
Panel Date: July 8, 2021
Report Date: July 16, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is 21.12 Scientific Review Council Recruitment Review (21.12_SRC-REC12) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on July 8, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: five (5) applications were discussed
- Panelists: One (1) panel chair and eight (8) reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COIs procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Recruitment Cycles 21.10 – 21.12

Awards Announced at the August 18, 2021, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Recruitment Cycles 21.10 through 21.12 include *Recruitment of First-Time, Tenure-Track Faculty Members; Recruitment of Rising Stars; and Recruitment of Established Investigators*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT’s third party grant administrator, and by CPRIT.

Application ID	Applicant/Principal Investigator	Principal Investigator Organization	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
RR210070	Gulio Draetta	The University of Texas M.D. Anderson Cancer Center	R. O’Reilly
RR210083	Gulio Draetta	The University of Texas M.D. Anderson Cancer Center	M. Brown
Applications not considered by the PIC or Oversight Committee:			
RR210055	Mary Dickinson	Baylor College of Medicine	P. Jones
RR210069	Gulio Draetta	The University of Texas M.D. Anderson Cancer Center	M. Brown; M. Tempero
RR210074	Gulio Draetta	The University of Texas M.D. Anderson Cancer Center	M. Brown

De-Identified Overall Evaluation Scores

Recruitment of First-Time, Tenure-Track Faculty Members

Academic Research Recruitment Cycles 21.10 – 21.12

Application ID	Final Overall Evaluation Score
RR210056*	1.0
RR210059*	1.0
RR210082*	1.0
ea ¹	1.0
eb ²	1.0
RR210077*	1.9
RR210085*	1.9
RR210080*	2.0
RR210083*	2.0
RR210086*	2.0
RR210070*	2.3
ec	2.6
ed	2.8
ee	3.8
ef	3.9
eg	4.0
eh	4.0
ei	4.0
ej	4.0
ek	5.0

¹ This application was withdrawn by the applicant after the Scientific Review Council (SRC) meeting on May 13, 2021, but before the July 8 SRC meeting that made final recommendations to the PIC.

² This application was withdrawn by the applicant after the Scientific Review Council (SRC) meeting on May 13, 2021, but before the July 8 SRC meeting that made final recommendations to the PIC.

* Recommended for funding

Final Overall Evaluation Scores and Rank Order Scores

San Diego

**Ludwig Institute for
Cancer Research Ltd**

July 21, 2021

**Richard D. Kolodner
Ph.D.**

Mr. Dee Margo
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dee@deemargo.com

Head, Laboratory of
Cancer Genetics
San Diego Branch

Distinguished Professor of
Cellular & Molecular
Medicine, University of
California San Diego School
of Medicine

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

rkolodner@health.ucsd.edu

Dear Mr. Margo and Mr. Roberts,

San Diego Branch

UC San Diego School of
Medicine
CMM-East / Rm 3058
9500 Gilman Dr - MC 0660
La Jolla, CA 92093-0660

The Scientific Review Council (SRC) is pleased to submit this list of recruitment grant recommendations. The SRC met on May 13, 2021 (REC Cycle 21.10), on June 10, 2021 (REC Cycle 21.11) and on July 8, 2021 (REC Cycle 21.12) to review the applications submitted to CPRIT under the Recruitment of Established Investigators, Recruitment of Rising Stars and Recruitment of First-Time, Tenure Track Faculty Members.

T 858 534 7804
F 858 534 7750

The projects on the attached list are numerically ranked in the order the SRC recommends the applications be funded. Recommended funding amounts and the overall evaluation scores are stated for each grant application. There were no recommended changes to funding amounts, goals, timelines, or project objectives requested. The total amount for the applications recommended is \$27,997,698.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting candidates at all career levels that have demonstrated academic excellence, innovation, excellent training, a commitment to cancer research and exceptional potential for achieving future impact in basic, translational, population based or clinical research.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Rank	ID	Award Mechanism	Candidate	Organization	Budget	Final Overall Score
1	RR210082	RFTFM	Dr. Kyle Eagen	Baylor College of Medicine	\$2,000,000	1.0
2	RR210066	RFTFM	Dr. Chad W. Johnston	Baylor College of Medicine	\$2,000,000	1.0
3	RR210056	RFTFM	Dr. Xia Gao	Baylor College of Medicine	\$2,000,000	1.0
4	RR210059	RFTFM	Dr. Javier Garcia-Bermudez	The University of Texas Southwestern Medical Center	\$2,000,000	1.0
5	RR210067	RRS	Dr. Yong Lu	The Methodist Hospital Research Institute	\$3,998,389	1.7
6	RR210085	RFTFM	Dr. Yuan Pan	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.9
7	RR210077	RFTFM	Dr. Edward J. Grow	The University of Texas Southwestern Medical Center	\$2,000,000	1.9
8	RR210083	RFTFM	Dr. David Braun	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	2.0
9	RR210086	RFTFM	Dr. Seungwon "Sebastian" Choi	The University of Texas Southwestern Medical Center	\$2,000,000	2.0
10	RR210079	RRS	Dr. Tian Zhang	The University of Texas Southwestern Medical Center	\$4,000,000	2.0
11	RR210080	RFTFM	Dr. Jason George	Texas A&M Engineering Experiment Station	\$1,999,309	2.0
12	RR210070	RFTFM	Dr. Shih-Han Lee	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	2.3

*RRS = Recruitment of Rising Stars

RFTFM = Recruitmen of First-Time, Tenure Track Faculty Members



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research Recruitment
FY 2021—Cycles 10 through 12
*Recruitment of Rising Stars***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS

RFA R-21.1-RRS

Recruitment of Rising Stars

**Please also refer to the Instructions for Applicants document,
which will be posted on June 23, 2020**

Application Receipt Dates:

June 23, 2020-June 21, 2021

FY 2021

Fiscal Year Award Period

September 1, 2020-August 31, 2021

TABLE OF CONTENTS

1. ABOUT CPRIT	4
1.1. ACADEMIC RESEARCH PROGRAM PRIORITIES	4
2. RATIONALE	5
3. RECRUITMENT OBJECTIVES	5
4. INSTITUTIONAL COMMITMENT	6
5. FUNDING INFORMATION	7
6. ELIGIBILITY	8
7. RESUBMISSION POLICY	9
8. RESPONDING TO THIS RFA	10
8.1. APPLICATION SUBMISSION GUIDELINES	10
8.2. APPLICATION COMPONENTS	11
8.2.1. <i>Summary of Nomination (2,000 characters)</i>	11
8.2.2. <i>Institutional Commitment (3 pages)</i>	11
8.2.3. <i>Letter of Support from Department Chair (1 page)</i>	13
8.2.4. <i>Curriculum Vitae (CV)</i>	13
8.2.5. <i>Summary of Goals and Objectives (2,000 characters)</i>	13
8.2.6. <i>Research (4 pages)</i>	14
8.2.7. <i>Research Collaboration/Synergy Plan (2 pages)</i>	14
8.2.8. <i>Publications</i>	14
8.2.9. <i>Timeline (1 page)</i>	15
8.2.10. <i>Current and Pending Support</i>	15
8.2.11. <i>Research Environment (1 page)</i>	15
8.2.12. <i>Descriptive Biography (Up to 2 pages)</i>	15
9. APPLICATION REVIEW	16
9.1. REVIEW PROCESS.....	16
9.1.1. <i>Confidentiality of Review</i>	16
9.2. REVIEW CRITERIA.....	17
10. KEY DATES	18
11. AWARD ADMINISTRATION	18
12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS	19
13. CONTACT INFORMATION	20
13.1. HELPDESK.....	20
13.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS	20

RFA VERSION HISTORY

Rev 6/23/20 RFA release

Rev 10/26/20 Section 8.2.2 – Institutional Commitment

- Added new statement that must be included in the Institutional Commitment Letter regarding the institution's financial commitment required to meet the 50% match.

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of or cures for cancer
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas
- Develop and implement the Texas Cancer Plan

1.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure

The program priorities for academic research adopted by the Oversight Committee include funding projects that address the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions
- Computational biology and analytic methods
- Childhood cancers
- Hepatocellular cancer
- Expand access to innovative clinical trials

2. RATIONALE

The aim of this award mechanism is to bolster cancer research in Texas by providing financial support to attract individuals whose work has outstanding merit, who show a marked capacity for self-direction, and who demonstrate the promise for continued and enhanced contributions to the field of cancer research (“Rising Stars”). Awards are intended to provide institutions with a competitive edge in recruiting the world’s best talent in cancer research, thereby advancing cancer research efforts and promoting economic development in the State of Texas.

The recruitment of outstanding scientists will greatly enhance programs of scientific excellence in cancer research and will position Texas as a leader in the fight against cancer. Applications may address any research topic related to cancer biology, causation, prevention, detection or screening, or treatment. Candidates with research programs addressing CPRIT’s priority areas for research are encouraged. These include implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions, computational biology and analytic methods, childhood cancers, hepatocellular cancer, and expansion of access to innovative clinical trials.

3. RECRUITMENT OBJECTIVES

The goal of this award mechanism is to recruit exceptional faculty to universities and/or cancer research institutions in the State of Texas. Having already demonstrated extraordinary accomplishments during their initial years of independent research, Rising Stars represent a unique blend of scholastic aptitude, scientific rigor, and commitment to exploring transformational research through the development of creative ideas with high potential.

Candidates who have not historically worked in cancer research but are proposing creative hypotheses and research plans for this field are encouraged to apply. Similarly, candidates pursuing original and potentially high-impact basic science programs that have the potential to be translated toward clinical investigations or provide “proof of principle” are also encouraged to apply. It is expected that the candidate will contribute significantly to and have a major impact on the institution’s overall cancer research initiative. Funding will be given for exceptional candidates who will continue to develop new research methods and techniques in the life, population-based, physical, engineering, or computational sciences and apply them to solving

outstanding problems in cancer research that have been inadequately addressed or for which there may be an absence of an established paradigm or technical framework.

Ideal candidates will have specific expertise in cancer-related areas needed to address an institutional priority. Candidates are expected to be approximately at the career level of a late assistant/early associate professor or equivalent. This funding mechanism considers expertise, accomplishments, and breadth of experience vital metrics for guiding CPRIT's investment in that person's originality, insight, and potential for continued contribution. Relevance to cancer research and to CPRIT's priority areas are important evaluation criteria for CPRIT funding.

Applications nominating individuals who carry out patient-oriented research and who have demonstrated exceptional ability to lead innovative discovery campaigns through conduct of clinical trials are appropriate for this mechanism and encouraged.

Unless prohibited by policy, the institution is also expected to bestow on the newly recruited faculty member the prestigious title of "CPRIT Scholar in Cancer Research," and the faculty member should be strongly encouraged to use this title on letterhead, business cards, publications, and other appropriate documents. The title is to be retained as long as the individual remains in Texas.

4. INSTITUTIONAL COMMITMENT

CPRIT recruitment awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research to Texas. The funds provided by CPRIT for the recruitment of a Rising Star must be complemented by a strong institutional commitment to the recruitment. The institutional commitment should be clearly documented in the application (see [section 8.2.2](#)) and include the amount and sources of salary support and all additional financial support that will be available to the candidate's research program through the course of the CPRIT award. The financial commitments made to the candidate by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.

5. FUNDING INFORMATION

This is a 5-year award and is not renewable. Grant funds of up to \$4,000,000 (total costs) over a 5-year period may be requested. Exceptions to this limit will be entertained only if there is compelling written justification. Annual allocations of this award are at the discretion of the awardee as long as the total award does not exceed \$4,000,000. The award request may include indirect costs of up to 5% of the total award amount (5.263% of the direct costs). CPRIT will make every effort to be flexible in the timing for disbursement of funds; recipients will be asked at the beginning of each year for an estimate of their needs for the year. Funds may not be carried over beyond 5 years except under extraordinary circumstances with strong justification for a no-cost extension. In addition, funds for extraordinary equipment needs may be awarded in the first year of the grant if very well justified and a detailed justification is provided along with an institutional plan should the additional funds not be approved. Scholars may request funds for travel for 2 project staff to attend CPRIT's conference.

Funds from this award mechanism may be used for salary support of this candidate but may not be used to construct or renovate laboratory space.

No annual limit on the number of grant application submissions by institutions has been set.

Note that the annual salary (also referred to as direct salary or institutional base salary) that an individual may be reimbursed from a CPRIT award for FY 2021 is limited to a maximum of \$200,000. In other words, an individual may request salary proportional to the percent of effort up to a maximum of \$200,000. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities.

Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.

Note: Depending on the availability of funds, nominations submitted in response to this Request for Applications (RFA) during the current receipt period may be announced and awarded either in the current fiscal year (prior to August 31, 2021) or in the first quarter of the next fiscal year (starting September 1, 2021).

6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism.
- Candidates must be nominated by the president, provost, vice president for research, or appropriate dean of a Texas-based public or private institution of higher education, including academic health institutions. The application must be submitted on behalf of a specific candidate.
- A candidate may be nominated by only 1 institution. If more than 1 institution is interested in a given candidate, negotiations as to which institution will nominate him or her must be concluded before the nomination is made.
- There is no limit to the number of applications that an institution may submit during a review cycle.
- A candidate who has already accepted a position at the recruiting institution prior to the time that the Scientific Review Council reviews the candidate for a recruitment award is not eligible for a recruitment award, as an investment by CPRIT is obviously not necessary. No award is final until approved by the Oversight Committee at a public meeting. However, in recognition of the timeline involved with recruiting highly sought-after candidates who are often considering multiple offers, CPRIT's Academic Research program staff will notify the nominating institution of the Scientific Review Council's review decision following the Review Council meeting. If a position is offered to the candidate during the period following the Scientific Review Council's review decision but prior to the Oversight Committee's final approval, the institution does so at its own risk. There is no guarantee that the recruitment award will be approved by the Oversight Committee.
- The candidate must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, **and reside in Texas for the duration of the appointment**. The candidate must devote at least 70% time to research activities. Candidates whose major responsibilities are clinical care, teaching, or administration are not eligible.
- At the time of the application, the candidate should hold an appointment at the rank of **assistant or associate professor tenure track or tenured** (or equivalent) at an accredited

academic institution, research institution, industry, government agency, or private foundation not primarily based in Texas. The candidate must not reside in Texas at the time the application is submitted.

- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the nominator, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant nominator, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the nominator, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, whether or not the individuals will receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.

CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 11](#) and [section 12](#). All statutory provisions and relevant administrative rules can be found at www.cpriti.texas.gov.

7. RESUBMISSION POLICY

Resubmissions will not be accepted for the Recruitment of Rising Stars award mechanism. Any nomination for the Recruitment of Rising Stars that was previously submitted to CPRIT and

reviewed but was not recommended for funding may not be resubmitted. A nomination for the Recruitment of Rising Stars that was previously submitted to CPRIT for the Recruitment of First-Time, Tenure Track Faculty Member or Recruitment of Rising Stars and reviewed and recommended for funding but declined by the candidate may be submitted in response to this RFA if the candidate meets the eligibility criteria described in [section 6](#) and the application is not in the same fiscal year as the previous application. If a nomination was administratively rejected prior to review, it can be resubmitted in the following cycles. Applications being resubmitted according to the criteria permitted by this section should be submitted as a new application (refer to the IFA for more details).

8. RESPONDING TO THIS RFA

8.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application is submitted. Candidates must be nominated by the institution's president, provost, vice president for research, or appropriate dean. The individual submitting the application (Nominator) must create a user account in the system to start and submit an application. Furthermore, the Application Signing Official, who is the person authorized to sign and submit the application for the organization, and the Grants Contract/Office of Sponsored Projects Official, who is the individual who will manage the grant contract if an award is made, also must create a user account in CARS.

Dependent upon available funding, applications will be accepted on a continuous basis throughout FY21. In order to manage the timely review of nominations, it is anticipated that applications submitted by 11:59 PM central time on the 20th day of each month will be reviewed by the 15th day of the following month. For an application to be considered for review during the monthly cycle, that application must be submitted on or before 11:59 PM central time. In the event that the 20th falls on Saturday or Sunday, applications may be submitted on or before 11:59 PM central time the following Monday. CPRIT will not extend the submission deadline. During periods when CPRIT does not receive an adequate number of applications, the review

may be extended into the following month. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

8.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. For details, please refer to the *Instructions for Applicants* document that will be available when the application receipt system opens.

Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

8.2.1. Summary of Nomination (2,000 characters)

Provide a brief summary of the nomination. Include the candidate's name, organization from which the candidate is being recruited, and also the department and/or entity within the nominator's organization where the candidate will hold the faculty position.

8.2.2. Institutional Commitment (3 pages)

CPRIT recruitment awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research to Texas. The funds provided by CPRIT for the recruitment of a Rising Stars must be complemented by a strongly documented institutional commitment to the recruitment. The financial commitments made to the candidate by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.

The following guidelines should be followed when documenting the institutional commitment to the candidate:

- The institutional commitment should be clearly documented in the form of a letter signed by the applicant institution's president, provost, or appropriate dean and include the amount and sources of salary support and all additional financial support that will be available to the candidate's research program through the course of the CPRIT award. The financial commitments made to the candidate by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.

- The Institutional Commitment letter must include the following statement regarding the institution's financial commitment required to meet the 50% match.
 - This institutional financial commitment will not be offset by funds from an investigator-initiated award received by the candidate. If an award dictates that such funds must be used for salary, the corresponding amount of institutional funds committed to pay the candidate's salary will be re-directed to allow the candidate to use them for program support.
- Institutional Commitment as described above must be presented in a table (example below), that clearly identifies the salary amount, sources of salary, and any additional research support from institutional sources over the course of the CPRIT award. Note that a federal indirect cost rate credit cannot be used to demonstrate an institutional commitment to the candidate.
- Include a brief job description for the candidate should recruitment be successful.
- Describe the institutional environment and any professional commitments to the candidate including, but not limited to, dedicated personnel, access to students, space assignment, and access to shared equipment, and discuss all other agreements between the institution and the candidate.
- Institutions may provide additional information in support of a candidate's research plan to demonstrate how the institutional commitment through development of strategic collaborations will foster a candidate's cancer research. This additional information is highly encouraged when proposing a candidate with exceptional expertise and/or talent that can be directed to cancer research such as a computational biologist, chemist, etc, whose prior experience has not been directly focused on cancer research.
- Note that Texas law allows an institution of higher learning to use its federal indirect cost rate credit to comply with the requirement to demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award (see [section 12](#)). However, a federal indirect cost rate credit cannot be used to demonstrate an institutional commitment to the candidate.

Example of an acceptable Institutional Commitment table:

Candidate's Name, Institutional Commitments					
	Year 1	Year 2	Year 3	Year 4	Year 5
Salary/Benefits					
Research Support					
Administrative Support					
Moving Expenses					

Total =

Note: CPRIT acknowledges that the Institutional Commitments by category may change during the course of the award; however, the total financial commitment to the candidate must remain equal to or greater than 50% of the CPRIT award.

8.2.3. Letter of Support from Department Chair (1 page)

Provide the letter of support from and signed by the chair of the department to which the candidate is being recruited. The following information should be included in the letter:

Recruitment Activities: The letter should provide a description of the recruitment activities, strategies, and priorities that have led to the nomination of this candidate.

Caliber of Candidate: The letter should include a description of the caliber of the candidate and justification of the nomination of the candidate by the institution.

Description of Candidate Duties and Certification of 70% Time Commitment to Research:

While scholars may engage in direct patient care activities and/or have some administrative or teaching duties, at least 70% of the candidate's time must be available for research. Breach of this requirement will constitute grounds for discontinuation of funding. The certification that 70% time will be spent on research must be included.

8.2.4. Curriculum Vitae (CV)

Provide a complete CV and list of publications for the candidate.

8.2.5. Summary of Goals and Objectives (2,000 characters)

List goals and objectives to be achieved during this award. **This section must be completed by the candidate.**

8.2.6. Research (4 pages)

Summarize the key elements of the candidate’s research accomplishments and provide an overview of the proposed research by outlining the background and rationale, hypotheses and aims, strategies, goals, and projected impact of the focus of the research program. Highlight the innovative aspects of this effort and place it into context with regard to what pressing problem in cancer will be addressed. **This section of the application must be prepared by the candidate. References cited in this section must be included within the stated page limit. Any appropriate citation format is acceptable; official journal abbreviations should be used.**

Candidates for CPRIT Scholar Awards must include the following signed statement at the end of this section. **Applications that do not contain this signed statement will be returned without review.**

“I understand that I do not need to have made a commitment to *<nominating institution>* before this application has been submitted. However, I also understand that only 1 Texas institution may nominate me for a CPRIT Recruitment Award, and this is the nomination that I have endorsed. I understand that requests to change the recruiting institution during the recruitment process are not allowed after the application is submitted to CPRIT.”

8.2.7. Research Collaboration/Synergy Plan (2 pages)

Institutions may provide additional information in support of a candidate’s research plan to demonstrate how the institutional commitment through development of strategic collaborations will foster a candidate’s cancer research. This additional information is highly encouraged when proposing a candidate with exceptional expertise and/or talent that can be directed to cancer research, such as a computational biologist, chemist, etc, whose prior experience has not been directly focused on cancer research. Biographical sketches of collaborators established in the research collaborative plan must be uploaded as part of the application. This will be in addition to the 2-page synergy plan (see IFA).

8.2.8. Publications

Provide the 5 most significant publications that have resulted from the candidate’s research efforts. Publications should be uploaded as PDFs of full-text articles. Only articles that have been published or that have been accepted for publication (“in press”) should be submitted.

8.2.9. Timeline (1 page)

Provide a general outline of anticipated major award outcomes to be tracked. Timelines will be reviewed during the evaluation of annual progress reports. If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

8.2.10. Current and Pending Support

State the funding source, duration, and title of all current and pending research support held by the candidate. If the candidate has no current or pending funding, a document stating this must be submitted. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

8.2.11. Research Environment (1 page)

Briefly describe the research environment available to support the candidate's research program, including core facilities, training programs, and collaborative opportunities.

8.2.12. Descriptive Biography (Up to 2 pages)

Provide a brief descriptive biography of the candidate, including his or her accomplishments, education and training, professional experience, awards and honors, publications relevant to cancer research, and a brief overview of the candidate's goals if selected to receive the award.

This section of the application must be prepared by the candidate. If the application is approved for funding, this section will be made publicly available on CPRIT's website.

Candidates are advised not to include information that they consider confidential or proprietary when preparing this section.

Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or do not meet the eligibility requirements listed above will be administratively withdrawn without review.

9. APPLICATION REVIEW

9.1. Review Process

All eligible applications will be evaluated and scored by the CPRIT Scientific Review Council using the criteria listed in this RFA. Applications may be submitted continuously in response to this RFA but will generally be reviewed on a monthly basis by the CPRIT Scientific Review Council. Council members may seek additional ad hoc evaluations of candidates. Scientific Review Council members will review applications and provide an individual Overall Evaluation Score that conveys the members' recommendation related to the proposed recruitment.

Applications recommended by the Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review, prioritization, and recommendation to the CPRIT Oversight Committee for approval and funding. Approval is based on an application receiving a positive vote from at least two-thirds of the members of the Oversight Committee. The review process is described more fully in CPRIT's Administrative Rules, Texas [Administrative Code, Title 25, Chapters 701 to 703](#).

The decision of the Scientific Review Council not to recommend an application is final, and such applications may not be resubmitted for a recruitment award. Notification of review decisions is sent to the nominator.

9.1.1. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Review Council members are non-Texas residents.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed conflict of interest as set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention and Communications Officer, the Chief Product Development Officer, and the Commissioner of the Department of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant applicant from further consideration for a grant award.

9.2. Review Criteria

Applications will be assessed based on evaluation of the quality of the candidate and his or her potential for continued superb performance as a cancer researcher. **Also, of critical importance is the strength of the institutional commitment to the candidate. Recruitment efforts are not likely to be successful unless there is a strong commitment from CPRIT and the host institution.** It is not necessary that a candidate agree to accept the recruitment offer at the time an application is submitted. However, applicant institutions should have reasonable expectation that recruitment will be successful if an award is granted by CPRIT.

Review criteria will focus on the overall impression of the candidate, his/her proposed research program, and his/her long-term contribution to and impact on the field of cancer research.

Questions to be considered by the reviewers are as follows:

Quality of the Candidate: Has the candidate demonstrated extraordinary accomplishments during his or her initial years of independent research? Does the candidate show promise of making important contributions with significant impact to basic, translational, clinical, or population-based cancer research in the future? Has the candidate demonstrated strong self-direction, motivation, and commitment for transformative cancer research?

Scientific Merit of Proposed Research: Is the research plan comprehensive and well thought out? Does the proposed research program demonstrate innovation, creativity, and feasibility? Will it have a significant impact on the field of cancer research? Will it expand the boundaries of

cancer research beyond traditional methodology by incorporating novel and interdisciplinary techniques?

Relevance of Candidate’s Research: Is the proposed research likely to have a significant impact on reducing the burden of cancer in the near term? Does the research contribute to basic, translational, clinical, or population-based cancer research?

Research Environment: Does the institution have the necessary facilities, expertise, and resources to support the candidate’s research? Is there evidence of strong institutional support? Will the candidate be free of major administrative/clinical responsibilities so that he or she can focus on maintaining and enhancing his or her research program? Will the candidate be provided with adequate professional development opportunities to grow as a leader?

10. KEY DATES

RFA

RFA Release June 23, 2020

Application Receipt and Review Timeline

Application Receipt System opens 7 AM CT	Application Receipt	Anticipated Application Review	Application Closing Date
June 23, 2020	Continuous – dependent upon available funding	Monthly by the 15 th day of the month	June 21, 2021

11. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Awards made under this RFA are not transferable to another institution. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT’s electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT’s electronic signature policy as set forth in [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal

monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov.

Applicants are advised to review CPRIT's Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. CPRIT requires funding acknowledgement on all print and visual materials that are funded in whole or in part by CPRIT grants. Examples of print and visual materials include, but are not limited to, publications, brochures, pamphlets, project websites, videos, and media materials. Unless prohibited by policy, the institution is also expected to bestow on the newly recruited faculty member the prestigious title of "CPRIT Scholar in Cancer Research," and the faculty member should be strongly encouraged to use this title on letterhead, business cards, publications, and other appropriate documents. The title is to be retained as long as the individual remains in Texas.

Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. The demonstration of available matching funds must

be made at the time the award contract is executed and annually thereafter, not when the application is submitted. Grant applicants are advised to consult CPRIT's Administrative Rules, Texas Administrative Code, [Title 25, Chapters 701 to 703](#), for specific requirements regarding the demonstration of available funding.

13. CONTACT INFORMATION

13.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff members are not in a position to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

13.2. Scientific and Programmatic Questions

Questions regarding the CPRIT Program, including questions regarding this or other funding opportunities, should be directed to the CPRIT Senior Program Manager for Academic Research.

Tel: 512-305-8491

Email: Help@CPRITGrants.org

Website: www.cprit.texas.gov

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)

21.10 Scientific Review Council Recruitment Review

(21.10 SRC-REC10) Observation Report

Report No. 2021-05-13 21.10_SRC-REC10
Program Name: Academic Research
Panel Name: 21.10 Scientific Review Council Recruitment Review (21.10_SRC-REC10)
Panel Date: May 13, 2021
Report Date: May 19, 2020

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is 21.10 Scientific Review Council Recruitment Review (21.10_SRC-REC10) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on May 13, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Nine (9) applications were discussed
- Panelists: One (1) panel chair and six (6) expert reviewers were present, and two (2) expert reviewers were not present
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive 'M' followed by a horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

21.11 Scientific Review Council Recruitment Review

(21.11 SRC-REC11) Observation Report

Report No. 2021-06-10 21.11_SRC-REC11
Program Name: Academic Research
Panel Name: 21.11 Scientific Review Council Recruitment Review (21.11_SRC-REC11)
Panel Date: June 10, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is 21.11 Scientific Review Council Recruitment Review (21.11_SRC-REC11) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on June 10, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: thirteen (13) applications were discussed
- Panelists: One (1) panel chair and seven (7) expert reviewers and one (1) expert reviewer was not present
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were four (4) Conflicts of Interest (COIs) identified prior to and/or during the meeting. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COIs procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.12 Scientific Review Council Recruitment Review
(21.12 SRC-REC12) Observation Report

Report No. 2021-07-08 21.12_SRC-REC12
Program Name: Academic Research
Panel Name: 21.12 Scientific Review Council Recruitment Review (21.12_SRC-
REC12)
Panel Date: July 8, 2021
Report Date: July 16, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is 21.12 Scientific Review Council Recruitment Review (21.12_SRC-REC12) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on July 8, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: five (5) applications were discussed
- Panelists: One (1) panel chair and eight (8) reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COIs procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Recruitment Cycles 21.10 – 21.12

Awards Announced at the August 18, 2021, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Recruitment Cycles 21.10 through 21.12 include *Recruitment of First-Time, Tenure-Track Faculty Members; Recruitment of Rising Stars; and Recruitment of Established Investigators*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT’s third party grant administrator, and by CPRIT.

Application ID	Applicant/Principal Investigator	Principal Investigator Organization	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
RR210070	Gulio Draetta	The University of Texas M.D. Anderson Cancer Center	R. O’Reilly
RR210083	Gulio Draetta	The University of Texas M.D. Anderson Cancer Center	M. Brown
Applications not considered by the PIC or Oversight Committee:			
RR210055	Mary Dickinson	Baylor College of Medicine	P. Jones
RR210069	Gulio Draetta	The University of Texas M.D. Anderson Cancer Center	M. Brown; M. Tempero
RR210074	Gulio Draetta	The University of Texas M.D. Anderson Cancer Center	M. Brown

De-Identified Overall Evaluation Scores

Recruitment of Rising Stars

Academic Research Recruitment Cycles 21.10 – 21.12

Application ID	Final Overall Evaluation Score
RR210067*	1.7
RR210079*	2.0
fa	3.0

* Recommended for funding

Final Overall Evaluation Scores and Rank Order Scores

San Diego

Ludwig Institute for
Cancer Research Ltd

Richard D. Kolodner
Ph.D.

Head, Laboratory of
Cancer Genetics
San Diego Branch

Distinguished Professor of
Cellular & Molecular
Medicine, University of
California San Diego School
of Medicine

rkolodner@health.ucsd.edu

San Diego Branch

UC San Diego School of
Medicine
CMM-East / Rm 3058
9500 Gilman Dr - MC 0660
La Jolla, CA 92093-0660

T 858 534 7804
F 858 534 7750

July 21, 2021

Mr. Dee Margo
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dee@deemargo.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Mr. Margo and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of recruitment grant recommendations. The SRC met on May 13, 2021 (REC Cycle 21.10), on June 10, 2021 (REC Cycle 21.11) and on July 8, 2021 (REC Cycle 21.12) to review the applications submitted to CPRIT under the Recruitment of Established Investigators, Recruitment of Rising Stars and Recruitment of First-Time, Tenure Track Faculty Members.

The projects on the attached list are numerically ranked in the order the SRC recommends the applications be funded. Recommended funding amounts and the overall evaluation scores are stated for each grant application. There were no recommended changes to funding amounts, goals, timelines, or project objectives requested. The total amount for the applications recommended is \$27,997,698.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting candidates at all career levels that have demonstrated academic excellence, innovation, excellent training, a commitment to cancer research and exceptional potential for achieving future impact in basic, translational, population based or clinical research.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Rank	ID	Award Mechanism	Candidate	Organization	Budget	Final Overall Score
1	RR210082	RFTFM	Dr. Kyle Eagen	Baylor College of Medicine	\$2,000,000	1.0
2	RR210066	RFTFM	Dr. Chad W. Johnston	Baylor College of Medicine	\$2,000,000	1.0
3	RR210056	RFTFM	Dr. Xia Gao	Baylor College of Medicine	\$2,000,000	1.0
4	RR210059	RFTFM	Dr. Javier Garcia-Bermudez	The University of Texas Southwestern Medical Center	\$2,000,000	1.0
5	RR210067	RRS	Dr. Yong Lu	The Methodist Hospital Research Institute	\$3,998,389	1.7
6	RR210085	RFTFM	Dr. Yuan Pan	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.9
7	RR210077	RFTFM	Dr. Edward J. Grow	The University of Texas Southwestern Medical Center	\$2,000,000	1.9
8	RR210083	RFTFM	Dr. David Braun	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	2.0
9	RR210086	RFTFM	Dr. Seungwon "Sebastian" Choi	The University of Texas Southwestern Medical Center	\$2,000,000	2.0
10	RR210079	RRS	Dr. Tian Zhang	The University of Texas Southwestern Medical Center	\$4,000,000	2.0
11	RR210080	RFTFM	Dr. Jason George	Texas A&M Engineering Experiment Station	\$1,999,309	2.0
12	RR210070	RFTFM	Dr. Shih-Han Lee	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	2.3

*RRS = Recruitment of Rising Stars

RFTFM = Recruitmen of First-Time, Tenure Track Faculty Members



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research
FY 2021—Cycle 2
*Core Facility Support Awards***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA R-21.2-CFSA

Core Facility Support Awards

**Please also refer to the Instructions for Applicants document,
which will be posted on September 16, 2020**

Applications for this award mechanism are subject to institutional limits.
Applicants are advised to consult with their institution's
Office of Research and Sponsored Programs (or equivalent).

Application Receipt Opening Date: September 16, 2020

Application Receipt Closing Date: January 27, 2021

FY2021

Fiscal Year Award Period

September 1, 2020-August 31, 2021

TABLE OF CONTENTS

1. ABOUT CPRIT	4
1.1. ACADEMIC RESEARCH PROGRAM PRIORITIES	4
2. RATIONALE	5
3. RESEARCH OBJECTIVES	5
4. FUNDING INFORMATION	6
5. ELIGIBILITY	6
6. RESUBMISSION POLICY	9
7. RENEWAL POLICY	9
8. RESPONDING TO THIS RFA	9
8.1. APPLICATION SUBMISSION GUIDELINES	9
8.1.1. <i>Submission Deadline Extension</i>	9
8.2. APPLICATION COMPONENTS	10
8.2.1. <i>Abstract and Significance (5,000 characters)</i>	10
8.2.2. <i>Layperson’s Summary (2,000 characters)</i>	10
8.2.3. <i>Goals and Objectives</i>	11
8.2.4. <i>Timeline (1 page)</i>	11
8.2.5. <i>Institutional Support (2 pages)</i>	11
8.2.6. <i>Resubmission Summary (1 page)</i>	11
8.2.7. <i>Renewal Summary (2 pages)</i>	11
8.2.8. <i>Core Facility Plan (5 pages)</i>	12
8.2.9. <i>Documentation That the Proposed Core Facility Does Not Duplicate Existing Services (2 pages)</i> 12	
8.2.10. <i>Vertebrate Animals and/or Human Subjects (2 pages)</i>	13
8.2.11. <i>Publications/References</i>	13
8.2.12. <i>Budget and Justification</i>	13
8.2.13. <i>User Group (8 pages)</i>	14
8.2.14. <i>Biographical Sketches (5 pages each)</i>	14
8.2.15. <i>Current and Pending Support</i>	15
8.2.16. <i>Institutional/Collaborator Support and/or Other Certification (4 pages)</i>	15
8.2.17. <i>Previous Summary Statement</i>	15
8.3. FORMATTING INSTRUCTIONS	15
9. APPLICATION REVIEW	16
9.1. REVIEW PROCESS OVERVIEW	16
9.2. CONFIDENTIALITY OF REVIEW	17
9.3. REVIEW CRITERIA.....	18
9.3.1. <i>Primary Criteria</i>	18
9.3.2. <i>Secondary Criteria</i>	19
10. KEY DATES	20
11. AWARD ADMINISTRATION	20
12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS	21
13. CONTACT INFORMATION	22
13.1. HELPDESK.....	22
13.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS	22

RFA VERSION HISTORY

Rev 08/05/20 RFA release

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of or cures for cancer.
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas.
- Develop and implement the Texas Cancer Plan.

1.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure

The program priorities for academic research adopted by the Oversight Committee include funding projects that address the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions.
- Computational biology and analytic methods
- Childhood cancers
- Hepatocellular cancer
- Expansion of access to innovative clinical trials

2. RATIONALE

Core Facility Support Awards seek to facilitate the development or improvement of core facilities that will provide valuable services to support and enhance scientifically meritorious cancer research projects. A user group of Texas-based investigators must be identified, each of whom should have supported cancer research projects that will make use of the requested facility. This requirement is not intended to exclude early-career-stage investigators who have not yet secured peer-reviewed grant support. Successful applicants should be working in a research environment capable of supporting potentially high-impact cancer studies. **CPRIT is particularly interested in supporting core facilities that provide enabling services to cancer investigators from multiple Texas institutions and that address CPRIT Program Priorities.**

3. RESEARCH OBJECTIVES

CPRIT will foster cancer research in Texas by providing financial support for a wide variety of projects relevant to cancer research. This RFA solicits applications from institutions to establish or enhance core facilities (laboratory, clinical, population-based, or computer-based) that will directly support cancer research programs to advance knowledge of the causes, prevention, and/or treatment of cancer or improve quality of life for patients with and survivors of cancer.

CPRIT expects outcomes of supported activities to directly and indirectly benefit subsequent cancer research efforts, cancer public health policy, or the continuum of cancer care—from prevention to survivorship. To fulfill this vision, applications may address any topic or issue related to cancer biology, causation, prevention, detection or screening, treatment, cure, or quality of life. This award provides cancer researchers access to appropriate research infrastructure, instrumentation, and technical expertise necessary to achieve their research objectives. A wide variety of facilities can be supported, including, but not limited to, chemistry, high-throughput screening, biomedical imaging, proteomics, protein structure, molecular biology, genomics, metabolomics, animal physiology/metabolism, cell sorting, bioengineering, clinical research support, bioinformatics, and the like. Funds may be requested to develop a new facility or to enhance the capabilities of an existing facility that will directly support and impact cancer research programs at the institution and in the region. CPRIT will look with special favor on applications that demonstrate on the development of core facilities that serve multi-institutions.

4. FUNDING INFORMATION

The maximum duration for this award mechanism is 5 years. Applicants may request a maximum of \$4,000,000 in total costs. Exceptions to these limits may be granted, but only if exceptionally well justified. Allowable expenses include the cost of instruments (must be expended in the first 2 years), installation and/or necessary renovation expenses in the first year (installation/renovation expenses not to exceed 10% of the total first-year request), and maintenance/service contracts.

Installation/renovation expenses can be requested in the first year only. Equipment must be purchased within the first 2 years. In addition, applicants may request salary support and fringe benefits for the facility director, data analysts, and technical staff; travel to scientific/technical meetings or collaborating institutions is also an allowable expense for these individuals. Note all international travel must receive prior approval by CPRIT. All of these costs and expenses must be prorated for direct use in cancer research efforts. Also allowable are funds to support the use of the facility by qualified cancer research investigators for relevant projects (research supplies and services, clinical research costs, etc). Institutions must describe and justify the process to be used to disburse funds to support use of the facility by cancer investigators. Finally, some fraction of available funds may be used by the facility director for development of new or improved approaches to technical challenges. State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the total award amount.

5. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution or organization that conducts research is eligible to apply for funding under this award mechanism.
- A public or private company is not eligible for funding under this award mechanism; these entities must use the appropriate award mechanism(s) under CPRIT's Product Development Research Program.
- The Principal Investigator (PI) must be the director of the facility and must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, and must reside in Texas during the time the research that is the subject of the grant is conducted. The PI should also hold a faculty position, preferably at the level of associate or full professor or the equivalent.

- The PI must commit a minimum 10% level of effort throughout the entire award period.
- This award must be directed by the PI. Co-PIs are not permitted.
- Collaborations are permitted and encouraged, and collaborators may or may not reside in Texas. However, collaborators who do not reside in Texas are not eligible to receive CPRIT funds. Collaborators should have specific and well-defined roles. Subcontracting and collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds. In no event shall equipment purchased under this award leave the State of Texas.
- **An institution may submit only 1 application (1 new, 1 renewal, or 1 resubmission) under this RFA during this funding cycle. An exception will be made for institutions submitting applications for core facilities that support research directed toward childhood and adolescent cancer; in this case, institutions may submit 1 childhood and adolescent cancer application and 1 additional application in another aspect of cancer research (new, renewal, or resubmission).**
- For purposes of this RFA, an institution is defined as that component of a university system that has a geographically distinct campus.
- Academic institutions and health science centers that are components of the same university system and share a contiguous or near-contiguous campus are eligible to submit a single application.
- A PI may only resubmit an application that was previously not funded once (see [section 6](#)).
- Support for only 1 facility may be requested per application. Collaborative applications among institutions are permitted and encouraged. However, such collaboration must not be used as a pretext for supporting more than 1 facility at a given institution. Further, applicants must not attempt to assemble illogical technical combinations and capabilities under one roof. Examples of illogical combinations would include protein mass spectrometry with DNA sequencing or light microscopy with magnetic resonance imaging.
- The coherence of the facility and the ability of the PI/facility director to oversee all of the facility's operations will be critical components of the review process. If support is

requested for an existing facility, applicants must make it clear how CPRIT support will enhance its capabilities and improve access for cancer investigators rather than simply replace ongoing institutional support.

- An individual may serve as a PI on no more than 3 active Academic Research grants. Recruitment Grants and Research Training Awards do not count toward the 3-grant maximum; however, CPRIT considers project leaders on a MIRA award equivalent to a PI. For the purpose of calculating the number of active grants, CPRIT will consider the number of active grants at the time of the award contract effective date (for this cycle expected to be 8/31/21).
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the PI, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, whether or not those individuals are slated to receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds because of scientific misconduct or fraud or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the

CPRIT contract are listed in [section 11](#) and [section 12](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

6. RESUBMISSION POLICY

An application previously submitted to CPRIT but not funded may be resubmitted **once** and must follow all resubmission guidelines. More than 1 resubmission per application is not permitted.

7. RENEWAL POLICY

Renewal applications for existing Core Facility Support Awards that are scheduled to end in FY 2021 will be accepted in response to this RFA.

8. RESPONDING TO THIS RFA

8.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The PI must create a user account in the system to start and submit an application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant contract if an award is made) also must create a user account in CARS.

Applications will be accepted beginning at 7 AM central time on September 16, 2020 and must be submitted by 4 PM central time on January 27, 2021. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

8.1.1. Submission Deadline Extension

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grants applications will be denied. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline.

Submission deadline extensions, including the reason for the extension, will be documented as

part of the grant review process records. Please note that deadline extension requests are very rarely approved.

8.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the *IFA* document for details that will be available when the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 5](#) will be administratively rejected without review.

8.2.1. Abstract and Significance (5,000 characters)

Clearly explain the proposed program, including a summary of the facility to be developed, an outline of the goals of the research projects that will be supported, and an overview of institutional infrastructure and commitment. The specific aims of the application must be obvious from the abstract although they need not be restated verbatim from the core facility plan. Clearly address how the proposed project, if successful, will have a major impact on cancer.

Note: It is the responsibility of the applicant to capture CPRIT's attention primarily with the Abstract and Significance statement alone. Therefore, applicants are advised to prepare this section wisely. Applicants should not waste this valuable space by stating obvious facts (eg, that cancer is a significant problem, that better diagnostic and therapeutic approaches are needed urgently, or that the type of cancer of interest to the PI is important, vexing, or deadly).

8.2.2. Layperson's Summary (2,000 characters)

Provide a layperson's summary of the proposed work. Describe, in simple, nontechnical terms, the overall goals of the proposed work, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early diagnosis, prevention, or treatment. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding.

Do not include any proprietary information in the layperson's summary. The layperson's summary will also be used by advocate reviewers ([section 9.1](#)) in evaluating the significance and impact of the proposed work.

8.2.3. Goals and Objectives

List specific goals and objectives for each year of the project. These goals and objectives will also be used during the submission and evaluation of progress reports and assessment of project success if the award is made.

8.2.4. Timeline (1 page)

Provide an outline of anticipated major milestones to be tracked. Timelines will be reviewed for reasonableness, and adherence to timelines will be a criterion for continued support of successful applications. If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

8.2.5. Institutional Support (2 pages)

Each application must be accompanied by a strong letter of institutional support from the president or provost or equivalent indicating commitment to the program and certifying that this is the sole application submitted by this institution in response to this RFA. Furthermore, the letter should indicate any support of the facility for activities not related to cancer research. The letter should address the institutional oversight ensuring that the facility will be operated in a superior fashion and discussing how this will be ascertained.

8.2.6. Resubmission Summary (1 page)

An application previously submitted to CPRIT but not funded may be resubmitted **once** after careful consideration of the reasons for lack of prior success. Applicants preparing a resubmission must describe the approach to the resubmission. If a summary statement was prepared for the original application review, applicants are advised to address all noted concerns.

8.2.7. Renewal Summary (2 pages)

Applicants preparing a renewal of a CPRIT-funded core facility must describe and demonstrate that appropriate/adequate progress has been made on the current funded award to warrant further funding. Peer-reviewed grants, publications, and manuscripts in press that have resulted from work performed during the initial funded period should be listed in the renewal summary.

8.2.8. Core Facility Plan (5 pages)

Background: Present the rationale and need for the facility, emphasizing the pressing problems in cancer research that will be addressed. Address how the proposed facility does not duplicate services provided by existing facilities. Address how the proposed facility addresses CPRIT priorities.

Instrument Details: Provide details of the equipment/instruments, if any, that will be acquired.

Technical Expertise: Describe the qualifications of the facility director and other key personnel that make them suitable to oversee the establishment and operations of the facility.

Administrative Plan: Clearly describe the plan under which the operation, sharing, time allocation, and maintenance of the facility will be administered. Discuss in detail the plan for cost recovery and charge backs for core services. If a cost recovery plan is not included in the administrative plan, provide strong justification for its absence. Discuss if funds will be allocated to support the use of the facility by qualified cancer research investigators and describe the process to be used to disburse funds to support use of the facility by these cancer investigators. If some fraction of available funds is to be used by the facility director for development of new or improved approaches to technical challenges, discuss the process to identify and evaluate such development projects. Discuss whether cancer researchers from other Texas academic institutions or industry scientists have access to the facility and the terms for such access.

Training Plan: Describe the plan to train users to use the facility and to evaluate the results obtained.

Sustainability: Describe in detail the plans for continuation of the core facility service at the conclusion of the CPRIT award.

8.2.9. Documentation That the Proposed Core Facility Does Not Duplicate Existing Services (2 pages)

In this section, provide a comprehensive list of existing cores or facilities in Texas that offer researchers access to technology and services similar to that proposed in this application. Explain why the proposed core is not duplicative of these and is required to support the research of the users of the new core proposed in this application.

8.2.10. Vertebrate Animals and/or Human Subjects (2 pages)

If vertebrate animals will be used, provide an outline of the appropriate protocols that will be followed. If human subjects or human biological samples will be used, provide a plan for recruitment of subjects or acquisition of samples that will meet the time constraints of this award mechanism.

8.2.11. Publications/References

Provide a concise and relevant list of publications/references cited for the application.

8.2.12. Budget and Justification

Provide a compelling and clear justification of the budget, demonstrating need for the entire proposed period of support, including salaries and benefits, supplies, equipment, patient care costs, animal care costs, and other expenses. Applicants are advised not to interpret the maximum allowable request under this award as a suggestion that they should expand their anticipated budget to this level. However, if there is a highly specific and defensible need to request more than the maximum amount in any year(s) of the proposed budget, include a special and clearly labeled section in the budget justification that explains the request. Poorly justified requests of this type will likely have a negative impact on the overall evaluation of the application.

In preparing the requested budget, applicants should be aware of the following:

- Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit **must be specifically approved by CPRIT**. An applicant does not need to seek this approval prior to submitting the application.
- Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in CPRIT's Administrative Rules, which are available at www.cpritis.texas.gov. So-called grants management and facilities fees (eg, sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees; maintenance fees) may not be requested. Applications that include such budgetary items will be administratively withdrawn.

- The annual salary (also referred to as direct salary or institutional base salary) that an individual may be reimbursed from a CPRIT award is limited to a maximum of \$200,000. In other words, an individual may request salary proportional to the percent of effort up to a maximum of \$200,000. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization. The PI must commit a minimum 10% level of effort throughout the entire award period.
- The PI is expected to attend CPRIT's Conference. CPRIT funds may be used to send up to 2 people to the conference.

8.2.13. User Group (8 pages)

Provide concise descriptions of the research projects of major users of the facility. Provide a tabular summary of all users of the requested facility. List the names of all researchers, their academic appointment and affiliation, include user grant funded award data (project title(s)/number(s), award grant ID, award duration), a brief description of the project(s), and approximate percentage use of the facility for direct use in cancer research efforts. Discuss whether cancer researchers from other Texas academic institutions or industry scientists have access to the facility and the terms for such access. CPRIT will look with special favor on the development of core facilities that serve multi-institutions.

8.2.14. Biographical Sketches (5 pages each)

The PI should provide a biographical sketch that describes his/her education and training, professional experience, awards and honors, and publications relevant to cancer research.

A biographical sketch must be provided for the PI (as required by the online application receipt system). Up to 5 additional biographical sketches for key personnel from the user group may be provided. Each biographical sketch must not exceed 5 pages.

8.2.15. Current and Pending Support

State the funding source and duration of all current and pending support for all personnel who have included a biographical sketch with the application. For each award, provide the title, a 2-line summary of the goal of the project, and, if relevant, a statement of overlap with the current application. At a minimum, current and pending support of the PI must be provided.

8.2.16. Institutional/Collaborator Support and/or Other Certification (4 pages)

Applicants may provide letters of institutional support, collaborator support, and/or other certification documentation relevant to the proposed project. A maximum of 4 pages may be provided.

8.2.17. Previous Summary Statement

If the application is being resubmitted, the summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission. The applicant is not responsible for providing this document.

Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or that do not meet the eligibility requirements listed above will be administratively withdrawn.

8.3. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English
- **Document Format:** PDF only
- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point)
- **Line Spacing:** Single
- **Page Size:** 8.5 x 11 inches
- **Margins:** 0.75 inch, all directions
- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations must be submitted as part of the appropriate submitted document. Applicants should include text to explain illustrations that may be difficult to interpret when printed in black and white.

- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.
- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters are also acceptable as long as the journal information is stated. Include URLs of publications referenced in the application.

Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45–67.

- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants should not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see following point).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be filled out, printed, signed, scanned, and then uploaded in PDF format.

9. APPLICATION REVIEW

9.1. Review Process Overview

All eligible applications will be evaluated using a 2-stage peer review process: (1) Peer review and (2) prioritization of grant applications by the CPRIT Scientific Review Council (SRC). In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts, as well as advocate reviewers, using the criteria listed below. In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT SRC based on comparisons with applications from all of the peer review panels and programmatic priorities. Applications approved by the SRC will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across

programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, chapters 701 to 703.](#)

9.2. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, SRC members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and SRC members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website. **By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, chapters 701 to 703.](#)**

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, a Scientific Review Panel member, or an SRC member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final

decision on the grant application. The prohibition on communication does not apply to the time period prior to the opening of CARS. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

9.3. Review Criteria

Peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Review committees will evaluate and score each primary criterion and subsequently assign a global score that reflects an overall assessment of the application. **The overall assessment will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application. Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

9.3.1. Primary Criteria

Primary criteria will evaluate the scientific merit and potential impact of the proposed work contained in the application. Concerns with any of these criteria potentially indicate a major flaw in the request for the instrument/equipment. Primary criteria include the following:

Justification of Need/Value: Is the uniqueness of the facility addressed? Is the need for the facility justified? Is it necessary and appropriate for the research projects? Will the state-of-the-art facility directly support and impact cancer research programs at the institution and in the region? How will the availability of the facility offer incipient research projects by investigators at various career stages the opportunity to develop? Will the facility make the user group more competitive for external funding? Will the facility provide cancer researchers from other Texas academic institutions or industry scientists access to the facility? Does the facility address CPRIT priorities?

Quality and Significance of research projects supported: Does the facility support a significant number of different, independently funded users? Are the projects at the forefront of cancer research? Are the projects of significance in reducing cancer incidence, morbidity, or mortality?

Technical Expertise: Is there sufficient technical expertise for optimal use of the facility? How well qualified is the user group to take optimal advantage of the facility and evaluate the research

results for the proposed projects? How will the facility be maintained? Is there a satisfactory training plan for new users?

Administration: Is there assurance that the facility will be managed and operated in a superior fashion? To whom does the facility director report? Is that person committed to appropriate oversight (a letter of commitment should be submitted)? Is there an adequate plan for the management of the facility, including an appropriate system for charging for services and subsidy of user fees for specific cancer-related projects and individuals (especially early-career-stage investigators)? How will facility time be allocated among the projects? Have biosafety issues been addressed? Are there criteria and is there a mechanism for prioritization of user requests? Are there appropriate advisory committees?

Institutional Commitment: Is there clear institutional commitment for support of the facility for cancer research? Has the host institution provided an appropriate site for the facility?

9.3.2. Secondary Criteria

Secondary criteria contribute to the global score assigned to the application. Concerns with these criteria potentially question the feasibility of the proposed project.

Secondary criteria include the following:

Research Environment: Does the team have the needed expertise and resources to accomplish all aspects of the project? Are the levels of effort of the key personnel appropriate? Is there evidence of institutional support for the project?

Vertebrate Animals and/or Human Subjects: If vertebrate animals and/or human biological samples are included in the proposed research, is the vertebrate animals and/or human subjects plan adequate and sufficiently detailed? Note that certification of approval by the institutional IACUC and/or IRB, as appropriate, will be required before funding can occur.

Budget: Is the budget appropriate for the proposed work?

Duration: Is the stated duration appropriate for the proposed work?

10. KEY DATES

RFA

RFA release August 5, 2020

Application

Online application opens September 16, 2020, 7 AM central time

Application due January 27, 2021, 4 PM central time

Application review January 2021 to August 2021

Award

Award notification August 18, 2021

Anticipated start date August 31, 2021

11. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [Texas Administrative Code, Title 25, chapters 701 to 703](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. Applicants are advised to review CPRIT's Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [Texas Administrative Code, Title 25, chapters 701 to 703](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements

set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, chapters 701 to 703](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals documented in the grant award contract and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate.

CPRIT will review annual progress reports and continuation of funding is contingent upon the timely receipt of these reports and documentation of sufficient progress toward completing project goals. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of award contract. Forms and instructions will be made available at www.cprit.texas.gov.

12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. The demonstration of available matching funds must be made at the time the award contract is executed, and annually thereafter, not when the application is submitted. Grant applicants are advised to consult CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, chapters 701 to 703](#), for specific requirements regarding demonstration of available funding.

13. CONTACT INFORMATION

13.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

13.2. Scientific and Programmatic Questions

Questions regarding the CPRIT program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Senior Program Manager for Academic Research.

Tel: 512-305-8491

Email: Help@CPRITGrants.org

Website: www.cprit.texas.gov

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Cancer Biology
(21.2 AR-CB)
Observation Report

Report No. 2021-05-20 21.2_AR-CB
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Cancer Biology
(21.2_AR-CB)
Panel Date: May 20, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Cancer Biology (21.2_AR-CB) meeting. The meeting was chaired by Peter Jones and conducted via videoconference on May 20, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Eleven (11) applications were discussed and eight (8) applications were not discussed
- Panelists: One (1) panel chair, sixteen (16) expert reviewers, three (3) Ad Hoc reviewers, two (2) advocate reviewers and one (1) Ad Hoc reviewer was not present
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Six (6)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive name that appears to be 'Mara Ash'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Basic Cancer
Research – 1 (21.2 AR-BCR1)
Observation Report

Report No. 2021-05-21 21.2_AR-BCR1
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Basic Cancer Research –
1 (21.2_AR-BCR1)
Panel Date: May 21, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Basic Cancer Research – 1 (21.2_AR-BCR1) meeting. The meeting was chaired by Thomas Curran and conducted via videoconference on May 21, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: nineteen (19) applications were discussed and nineteen (19) applications were not discussed
- Panelists: One (1) panel chair, fourteen (14) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were five (5) Conflicts of Interest (COIs) identified prior to and/or during the meeting. There were three (3) COIs on applications discussed and two (2) COIs on applications not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive 'M' followed by a long horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Clinical and
Translational Cancer Research (21.2 AR-CTCR)
Observation Report

Report No. 2021-05-24 21.2_AR-CTCR
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Clinical and Translational
Cancer Research (21.2_AR-CTCR)
Panel Date: May 24, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Clinical and Translational Cancer Research (21.2_AR-CTCR) meeting. The meeting was chaired by Margaret Tempero and Richard O'Reilly and conducted via videoconference on May 24, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: twenty-one (21) applications were discussed and thirteen (13) applications were not discussed
- Panelists: Two (2) panel chairs, twenty-two (22) expert reviewers, and three (3) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were four (4) Conflicts of Interest (COIs) identified prior to and/or during the meeting. There were three (3) COIs on applications discussed and one (1) COI on an application not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed

additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Basic Cancer
Research – 2 (21.2 AR-BCR2)
Observation Report

Report No. 2021-05-25 21.2_AR-BCR2
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Basic Cancer Research –
2 (21.2_AR-BCR2)
Panel Date: May 25, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Basic Cancer Research – 2 (21.2_AR-BCR2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on May 25, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: sixteen (16) applications were discussed, and eighteen (18) applications were not discussed
- Panelists: One (1) panel chair, fifteen (15) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were five (5) Conflicts of Interest (COIs) identified prior to and/or during the meeting. There were four (4) COIs on applications discussed and one (1) COI on an application not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive 'M' followed by a long horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Imaging Technology
and Informatics (21.2 AR-ITI)
Observation Report

Report No. 2021-05-26 21.2_AR-ITI
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Imaging Technology and Informatics (21.2_AR-ITI)
Panel Date: May 26, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Imaging Technology and Informatics (21.2_AR-ITI) meeting. The meeting was chaired by Martin Pomper and conducted via teleconference on May 26, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Thirteen (13) applications were discussed, and thirteen (13) applications were not discussed
- Panelists: One (1) panel chair, nineteen (19) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were three (3) Conflicts of Interest (COIs) identified prior to and/or during the meeting. There were two (2) COIs on applications discussed and one (1) COI on an application not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive name that appears to be 'Mara Ash'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Cancer Prevention
Research (21.2 AR-CPR)
Observation Report

Report No. 2021-05-27 21.2_AR-CPR
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Cancer Prevention
Research (21.2_AR-CPR)
Panel Date: May 27, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Cancer Prevention Research (21.2_AR-CPR) meeting. The meeting was chaired by Elana Martinez and conducted via teleconference on May 27, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Five (5) applications were discussed and three (3) applications were not discussed
- Panelists: One (1) panel chair, ten (10) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to read 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

21.2 Scientific Review Council (21.2 SRC)

Observation Report

Report No. 2021-07-08 21.2_SRC
Program Name: Academic Research
Panel Name: 21.2 Scientific Review Council (21.2_SRC)
Panel Date: July 8, 2021
Report Date: July 16, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is 21.2 Scientific Review Council (21.2_SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on July 8, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: fifty-two (52) applications were discussed
- Panelists: One (1) panel chair and eight (8) reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COIs procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 21.2

Awards Announced at the August 18, 2021, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Cycle 21.2 include *Core Facility Support Awards*; *Clinical Trials Network Award*; *Early Clinical Investigator Awards*; *High-Impact/High Risk Awards*; *Texas Clinical Trials Participation Award*; and *Texas Regional Excellence in Cancer Award*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant/Principal Investigator	Principal Investigator Institution	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
RP210073	Ronald DePinho	The University of Texas M.D. Anderson Cancer Center	N. Bardeesy
RP210102	WEIXING ZHAO	The University of Texas Health Science Center at San Antonio	W. Chazin
RP210208	Stanton McHardy	The University of Texas at San Antonio	A. Tomkinson; W. Chazin; C. Rosenfeld
RP210122	Michael Overman	The University of Texas M.D. Anderson Cancer Center	H. Hochster
RP210075	Jeremy Schraw	Baylor College of Medicine	C. Li
RP210099	Anke Henning	The University of Texas Southwestern Medical Center	A. Wu; R. Berbeco

Application ID	Applicant/Principal Investigator	Principal Investigator Institution	Conflict Noted by Reviewer
RP210105	Alexei Tumanov	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP210236	Zhenpeng Qin	The University of Texas at Dallas	J. Willson
RP210140	Carlos L Arteaga	The University of Texas Southwestern Medical Center	C. Rosenfeld
Applications not considered by the PIC or Oversight Committee:			
RP210154	Charles Reynolds	Texas Tech University Health Sciences Center	Y. DeClerck
RP210215	Wei Wang	University of Houston	X. Chen
RP210113	Yinghong Wang	The University of Texas M.D. Anderson Cancer Center	R. O'Reilly
RP210172	Charles Geyer	The Methodist Hospital Research Institute	H. Hochster
RP210216	Mary Dickinson	Baylor College of Medicine	W. Kast
RP210090	Kenneth Hoyt	The University of Texas at Dallas	K. Zinn
RP210112	Peter Houghton	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP210166	Francis Yoshimoto	The University of Texas at San Antonio	J. Conejo-Garcia
RP210230	Leonidas Bleris	The University of Texas at Dallas	A. Anderson; J. Conejo-Garcia

T.A.C. Section 702.19 Waiver



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS
FROM: WAYNE R. ROBERTS, CHIEF EXECUTIVE OFFICER
SUBJECT: T.A.C. § 702.19 WAIVER
DATE: OCTOBER 28, 2020

Summary

This is to notify the Oversight Committee that pursuant to the authority provided to the Chief Executive Officer in T.A.C. § 702.19(e), I have granted Chief Scientific Officer Dr. Jim Willson a waiver from the general prohibition against communicating with a grant applicant while CPRIT is accepting and reviewing applications. The waiver is applicable to communication with Dr. Peter Houghton regarding his questions about a potential Core Facility Support Award (CFSA) application. No Oversight Committee action related to this waiver is necessary.

Discussion

The Chief Scientific Officer is a statutorily mandated member of the Program Integration Committee (PIC). Texas Administrative Code § 702.19 prohibits substantive communication between the grant applicant and a member of the peer review panel, the PIC, or the Oversight Committee while the application is pending a final decision. The communication restriction is one way that we prevent even the appearance of unequal treatment in the grant review process.

CPRIT released the cycle 21.2 CFSA Request for Applications in August and we are currently accepting applications through January 27, 2021. Dr. Peter Houghton, a professor and the director of the Greehey Children's Cancer Research Institute at The University of Texas Health Science Center at San Antonio, has substantive questions regarding childhood cancer efforts in Texas relevant to a potential CFSA application. Due to the technical nature of Dr. Houghton's questions, Dr. Willson is the only staff member with appropriate subject matter expertise to address the inquiry.

Approving this waiver ensures that a grant applicant has appropriate information necessary to submit a comprehensive application. Doing so will not favor any applicant over another in the peer review process. All CFSA applications will receive the same rigorous evaluation by independent reviewers. Dr. Willson does not discuss any substantive issues with peer reviewers related to applications under review and plays no role in the peer reviewers' decision to recommend an award to CPRIT.

The Oversight Committee does not need to take any action regarding this waiver. Dr. Willson's waiver will be part of the grant record for the FY 2021 CFSA mechanism.

De-Identified Overall Evaluation Scores

Core Facility Support Awards

Academic Research Cycle 21.2

The Scientific Review Council (SRC) did not recommend an application responsive to this RFA that has a score equal to three other applications that were recommended. As allowed by 25 T.A.C. § 703.6(d)(1), a review council's numerical rank order is substantially based on the final overall evaluation score assigned by the peer review panels, but it may also consider how well a grant application achieves program priorities set by the Oversight Committee, the overall program portfolio balance, and any other criteria described in the RFA.

Application ID	Final Overall Evaluation Score
RP210227*	1.0
RP210208*	1.1
RP210088*	1.9
RP210108*	2.0
RP210116*	2.3
RP210180*	2.5
RP210126*	2.5
RP210099*	2.8
RP210209*	2.9
RP210119*	3.1
RP210064*	3.1
RP210130*	3.1
ga	3.1
Gb	3.8
Gc	4.0
Gd	4.0
Ge	4.3
Gf	4.3
Gg	4.7
Gh	4.7
Gi	4.7
Gj	5.0
Gk	5.3
Gl	6.3
gm	6.7

* Recommended for funding

Core Facility Support Awards
Academic Research Cycle 21.2

Final Overall Evaluation Scores and Rank Order Scores

Ludwig Institute for
Cancer Research Ltd

Richard D. Kolodner
Ph.D.

Head, Laboratory of
Cancer Genetics
San Diego Branch

Distinguished Professor of
Cellular & Molecular
Medicine, University of
California San Diego School
of Medicine

rkolodner@health.ucsd.edu

San Diego Branch

UC San Diego School of
Medicine
CMM-East / Rm 3058
9500 Gilman Dr - MC 0660
La Jolla, CA 92093-0660

T 858 534 7804
F 858 534 7750

July 21, 2021

Mr. Dee Margo
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dee@deemargo.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Mr. Margo and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for Core Facility Support Awards (CFSA), Clinical Trials Network Awards (CTNA), Early Clinical Investigator Awards (ECI), High-Impact/High Risk Awards (HIHR), Texas Clinical Trials Participation Awards (TCTPA) and Texas Regional Excellence in Cancer Award (TREC).

The SRC met on July 8, 2021 to consider the applications recommended by the peer review panels following their meetings held May 20, 2021 – May 27, 2021.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the applications recommended is \$75,418,344. *Please note that the peer review panels and SRC recommended reduced budgets for applications # RP210180 and #RP210064, the reductions are reflected in the table.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Rank	ID	Mechanism	Score	Application Title	PI	Organization	Rec. Budget
1	RP210227	CFSA	1.0	Proteomics and Metabolomics Core Facility	Edwards, Dean	Baylor College of Medicine	\$3,977,681
2	RP210176	ECI	1.0	CPRIT Early Clinical Investigator Award: Moran Amit	Draetta, Gulio	The University of Texas M. D. Anderson Cancer Center	\$1,499,042
3	RP210208	CFSA	1.1	Center for Innovative Drug Discovery: Expansion of a Highly Productive Shared Cancer Drug Discovery Resource for Texas	McHardy, Stanton	The University of Texas at San Antonio	\$3,087,131
4	RP210143	TCTPA	1.5	Dan L. Duncan Comprehensive Cancer Center (DLDCCC) Harris Health Clinical Trials Financial Support Project	Mims, Martha	Baylor College of Medicine	\$1,500,000
5	RP210165	HIHRRRA	1.6	Rapid Point-of-Care Detection of Ovarian Cancer Biomarkers Using a Common Thermometer for Low-Resource Settings	Li, Xiujun (James)	The University of Texas at El Paso	\$249,999
6	RP210115	TCTPA	1.7	Enhancing Access to and Diversity in Cancer Clinical Trials Through a Financial Reimbursement and Outreach Program	Gerber, David	The University of Texas Southwestern Medical Center	\$1,499,327
7	RP210159	ECI	1.8	CPRIT Early Clinical Investigator Award: Carl Gay	Draetta, Gulio	The University of Texas M. D. Anderson Cancer Center	\$1,499,997

8	RP210088	CFSA	1.9	Targeted Therapeutic Drug Discovery and Development Program	Dalby, Kevin	The University of Texas at Austin	\$3,989,441
9	RP210205	HIHRRRA	1.9	Cytokine Factories for the Treatment of Mesothelioma	Veiseh, Omid	Rice University	\$250,000
10	RP210173	HIHRRRA	1.9	Multiplex CRISPR Genetic Modeling of Polypharmacology for Precision Medicine	Hart, Traver	The University of Texas M. D. Anderson Cancer Center	\$250,000
11	RP210108	CFSA	2.0	The GCC Microphysiological Lead Optimization and Toxicity Screening Facility	Stephan, Clifford	Texas A&M University System Health Science Center	\$3,973,083
12	RP210144	HIHRRRA	2.0	Leveraging Glioma Stem Cell Electrophysiology for Therapy	Rostomily, Robert	The Methodist Hospital Research Institute	\$248,028
13	RP210168	HIHRRRA	2.0	Overcoming Myeloma Resistance to Proteasome Inhibitors	Yi, Qing	The Methodist Hospital Research Institute	\$250,000
14	RP210062	HIHRRRA	2.0	Protein Degradation of CDK9 for Treatment of Drug-Resistant Mantle Cell Lymphoma	Zhou, Jia	The University of Texas Medical Branch at Galveston	\$250,000
15	RP210154	TREC	2.0	Texas Regional Excellence in Cancer Developmental Therapeutics Center at TTUHSC	Reynolds, Charles	Texas Tech University Health Sciences Center	\$5,999,936
16	RP210073	HIHRRRA	2.1	Identification of Collateral Lethal and Synthetic Lethal Targets in	DePinho, Ronald	The University of Texas M. D. Anderson Cancer Center	\$249,994

				Pancreatic and Colorectal Cancers			
17	RP210111	HIHRRRA	2.1	Single-Cell Proteomics to Dissect Intratumor Heterogeneity	Pan, Sheng	The University of Texas Health Science Center at Houston	\$250,000
18	RP210134	HIHRRRA	2.2	High-Throughput Discovery of Anticancer Protein Degradors	Tambar, Uttam	The University of Texas Southwestern Medical Center	\$250,000
19	RP210116	CFSA	2.3	The Genetic Design and Engineering Center (GDEC): A CPRIT Core Facility	Bao, Gang	Rice University	\$4,000,000
20	RP210158	HIHRRRA	2.3	Improving CAR T-Cell Therapy of T-ALL by Cotargeting Additional Antigens	Mamonkin, Maksim	Baylor College of Medicine	\$250,000
21	RP210206	HIHRRRA	2.4	Novel Tumor-Specific Bioactive Nanoparticles for Cancer Therapy	Nguyen, Kytai	The University of Texas at Arlington	\$249,999
22	RP210180	CFSA	2.5	Integrated Cancer Research Core (ICRC)	CHAUHAN, SUBHASH	The University of Texas Rio Grande Valley	*\$2,525,000
23	RP210126	CFSA	2.5	High-Parameter Analysis, Sorting, and Imaging Flow Cytometry Shared Resource	Berton, Michael	The University of Texas Health Science Center at San Antonio	\$3,645,500
24	RP210122	CTNA	2.5	Building a Clinical Trial Network for Texas Community Affiliates	Overman, Michael	The University of Texas M. D. Anderson Cancer Center	\$3,000,000
25	RP210164	ECI	2.5	Early Clinical Investigator Award: William Kelly	Hromas, Robert	The University of Texas Health Science Center at San Antonio	\$1,499,985
26	RP210140	ECI	2.6	Targeting Altered Metabolism in IDH-Mutant Glioma	Arteaga, Carlos	The University of Texas Southwestern Medical Center	\$1,500,000

27	RP210089	HIHRRA	2.6	Dissecting Therapeutic Immunomodulation of Gut Microbiome on Colorectal Cancer	Kim, Hyun Jung	The University of Texas at Austin	\$250,000
28	RP210079	HIHRRA	2.7	Targeting Mitochondrial NAD+ in Leukemias	Cambronne, Xiaolu	The University of Texas at Austin	\$250,000
29	RP210236	HIHRRA	2.7	Magnetomechanical Modulation of Blood-Brain Barrier Permeability	Qin, Zhenpeng	The University of Texas at Dallas	\$250,000
30	RP210234	ECI	2.7	Targeting Src Homology-2 Domain-Containing Phosphatase to Overcome Resistance to Immune Checkpoint Blockade in Pancreatic Ductal Adenocarcinoma	Johnston, Sterling	The University of Texas at Austin	\$1,443,367
31	RP210105	HIHRRA	2.8	Targeting Lymphotoxin Beta Receptor in Sensory Neurons for Control of Chemotherapy-Induced Neuropathic Pain	Tumanov, Alexei	The University of Texas Health Science Center at San Antonio	\$249,996
32	RP210068	HIHRRA	2.8	Role of Aberrant Translational Quality Control in Tumorigenesis of Glioblastoma	Wu, Zhihao	Southern Methodist University	\$249,272
33	RP210102	HIHRRA	2.8	Deciphering BRCA1-BARD1 E3 Ligase Activity in Genome Maintenance and Tumor Suppression	ZHAO, WEIXING	The University of Texas Health Science Center at San Antonio	\$250,000

34	RP210099	CFSA	2.8	North Texas Multimodal Small-Animal Imaging Core Facility	Henning, Anke	The University of Texas Southwestern Medical Center	\$3,999,929
35	RP210137	HIHRRA	2.8	Development of TCR-Based Immunotherapies Targeting Hotspot EGFR Mutations for the Treatment of Non-Small Cell Lung Cancer	Reuben, Alexandre	The University of Texas M. D. Anderson Cancer Center	\$250,000
36	RP210209	CFSA	2.9	North Texas Clinical Pharmacology Cancer Core	Putnam, William	Texas Tech University Health Sciences Center	\$2,965,226
37	RP210092	HIHRRA	3.0	Antibody-Drug Conjugate Combination Treatment for Targeting Colorectal Cancer Cell Plasticity	Carmon, Kendra	The University of Texas Health Science Center at Houston	\$250,000
38	RP210131	HIHRRA	3.0	Antibodylike Therapeutics That Target Polyclonal T Cells to CMV-Positive Glioblastomas	Maynard, Jennifer	The University of Texas at Austin	\$250,000
39	RP210075	HIHRRA	3.0	Exploring the Biological Basis of Ethnic and Social Disparities in Pediatric Acute Lymphoblastic Leukemia Outcomes	Schraw, Jeremy	Baylor College of Medicine	\$249,999
40	RP210199	HIHRRA	3.0	Treating Metastatic Cancer Using Microbubble-Assisted Ultrasound-Guided Immunotherapy of	Lux, Jacques	The University of Texas Southwestern Medical Center	\$249,011

				Cancer of Cancer (MUSIC)			
41	RP210127	HIHRRA	3.0	Engineered Enteric Nerve-Perineural Invasion Models to Improve Predictive Preclinical Screens in Early-Stage Colorectal Adenocarcinoma	Raghavan, Shreya	Texas A&M University	\$250,000
42	RP210148	HIHRRA	3.0	Novel Pharmacodynamic Assay to Predict Response to CDK4/6 Inhibitor Therapy	Trivedi, Meghana	University of Houston	\$250,000
43	RP210119	CFSA	3.1	A Preclinical Development Core for Large-Molecule Therapeutics	Liu, Qingyun	The University of Texas Health Science Center at Houston	\$3,999,999
44	RP210064	CFSA	3.1	The Adolescent and Childhood Cancer Epidemiology and Susceptibility Service (ACCESS) for Texas	Scheurer, Michael	Baylor College of Medicine	*\$4,000,000
45	RP210130	CFSA	3.1	Data Management and Analysis Core for Comparative Effectiveness Research on Cancer in Texas	Kuo, Yong-Fang	The University of Texas Medical Branch at Galveston	\$2,936,731
46	RP210070	HIHRRA	3.1	Tunable Epigenetic Remodeling to Modulate CAR T-Cell-Based Immunotherapy	Zhou, Yubin	Texas A&M University System Health Science Center	\$250,000
47	RP210132	HIHRRA	3.1	Synergy Between Epigenetic Reprogramming and Wnt Inhibition to Enhance	Frost, Jeffrey	The University of Texas Health Science Center at Houston	\$249,999

				Neuroendocrine Tumor Radionuclide Therapy			
48	RP210153	TREC	3.1	UTEP/UTMDACC Partnership for Hispanic Cancer Disparities Research	Cox, Marc	The University of Texas at El Paso	\$5,881,734
49	RP210183	HIHRRA	3.3	Virulence Modulation of <i>Helicobacter pylori</i> , the Strongest Risk Factor for Gastric Cancer	Kearney, Christopher	Baylor University	\$248,938
50	RP210213	HIHRRA	3.3	Therapeutic Inhibition of Cholangiocarcinoma Progression by Targeting Tumor- Lymphatic Cross Talk	Chakraborty, Sanjukta	Texas A&M University System Health Science Center	\$250,000

CFSA = Core Facility Support Awards

CTNA = Clinical Trials Network Award

ECI = Early Clinical Investigator Awards

HIHR = High-Impact/High Risk Awards

TCTPA = Texas Clinical Trials Participation Award

TREC = Texas Regional Excellence in Cancer Award



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research
FY 2021—Cycle 2
*Clinical Trials Network Award***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA R-21.2-CTNA

Clinical Trials Network Award

**Please also refer to the Instructions for Applicants document,
which will be posted on September 16, 2020**

Application Receipt Opening Date: September 16, 2020

Application Receipt Closing Date: January 27, 2021

FY2021

Fiscal Year Award Period

September 1, 2020-August 31, 2021

TABLE OF CONTENTS

1. OVERVIEW	4
2. ABOUT CPRIT	4
2.1. ACADEMIC RESEARCH PROGRAM PRIORITIES	5
3. RATIONALE	5
4. RESEARCH OBJECTIVES	7
5. FUNDING INFORMATION	8
6. ELIGIBILITY	9
7. RESUBMISSION POLICY	10
8. RENEWAL POLICY	11
9. RESPONDING TO THIS RFA	11
9.1. APPLICATION SUBMISSION GUIDELINES	11
9.1.1. <i>Submission Deadline Extension</i>	11
9.2. APPLICATION COMPONENTS	11
9.2.1. <i>Abstract and Significance (5,000 characters)</i>	12
9.2.2. <i>Layperson's Summary (2,000 characters)</i>	12
9.2.3. <i>Goals and Objectives</i>	12
9.2.4. <i>Timeline (1 page)</i>	12
9.2.5. <i>Network Description (10 pages)</i>	13
9.2.6. <i>Institutional Review Board agreement</i>	14
9.2.7. <i>Publications/References</i>	14
9.2.8. <i>Budget and Justification</i>	14
9.2.9. <i>Biographical Sketches (5 pages each)</i>	15
9.2.10. <i>Current and Pending Support</i>	16
9.2.11. <i>Institutional/Collaborator Support and/or Other Certification (4 pages)</i>	16
9.3. FORMATTING INSTRUCTIONS	16
10. APPLICATION REVIEW	17
10.1. APPLICATION REVIEW	17
10.2. CONFIDENTIALITY OF REVIEW	18
10.3. REVIEW CRITERIA	19
10.3.1. <i>Primary Criteria</i>	19
10.3.2. <i>Secondary Criteria</i>	20
11. KEY DATES	20
12. AWARD ADMINISTRATION	21
13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS	22
14. CONTACT INFORMATION	23
14.1. HELPDESK	23
14.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS	23

RFA Version History

Rev 08/05/20 RFA release

Rev 9/24/20 Section 9.2.5 – Network Description – B. Lead Institution

- Added the following requirement: “Lead Institution must document the mechanism(s) in place for assuring oversight of the scientific aspects and patient safety of the clinical trials available to Network Affiliates.”

1. OVERVIEW

The Cancer Prevention and Research Institute of Texas (CPRIT) aspires to develop a statewide clinical trials network that functions to speed development of new promising drugs and to increase access by cancer patients in Texas to state-of-the-art clinical trials of new treatment strategies. The Clinical Trials Network Award (CTNA) will be made to Lead Institutions (LIs) to develop and oversee a network of 2 cancer care facilities (Network Affiliates) (Stage 1). Once the initial network is satisfactorily demonstrated, the LI will be eligible to receive additional CPRIT funding to expand its network to 2 additional facilities located outside the LI current catchment (Stage 2).

LIs will provide their Network Affiliates access to phase 2 and phase 3 clinical trials appropriate for the patient population served by the affiliates. LI and Network Affiliates are required to use a common institutional review board (IRB) either provided by the lead institution or a central IRB and to share access to a Web-based clinical trials management support system (CTMS).

Ultimately, CPRIT intends to link successful LI networks into a statewide Texas Cancer Clinical Trials Network.

2. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of or cures for cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

2.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency about how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure

The program priorities for academic research adopted by the Oversight Committee include funding projects that address the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions
- Computational biology and analytic methods
- Childhood cancers
- Hepatocellular cancer
- Expansion of access to innovative clinical trials

3. RATIONALE

The past decade has spawned new strategies to treat patients with cancer. Technology has enabled scientists and clinicians to dissect individual patients' cancers down to the very genes that cause them to grow and progress, thereby opening new doors to the development of treatment specific for that patient. This *Precision Cancer Medicine*, as it has been named, requires tests or biomarkers to determine the gene/protein drivers of a given cancer and then new drugs that effectively target and block those drivers. Industry and academic centers have responded by developing new drugs that target these defective pathways, resulting in a plethora of new agents that need testing in patients. The sheer number of these new drugs and the requirement that they be tested only in the subset of patients harboring the gene/pathway alteration have made clinical testing of these new agents challenging. No longer do we test a new

drug on all patients or all patients with a specific disease like breast or colon cancer. Now these drugs must be tested on a much smaller subset of patients defined by the abnormal driver pathway in their tumor. This has resulted in the need to increase the number of patients going on clinical trials beyond the 3% to 5% of cancer patients that now participate in clinical research trials.

Another important issue is that many patients who could benefit or desire to participate in a new drug trial don't have access to those trials because (1) they are from an underserved or underinsured population without access to a cancer center, (2) they do not have close geographic access to an urban cancer center where most of these trials are offered, or (3) they can't afford to travel to another destination and stay there for the duration of the clinical trial. This problem often gives rise to a selection bias for the trial in that only insured, white, male, urban patients are studied in a clinical trial. It is recognized that different ethnic or racial groups may respond differently to a drug and need to be captured in early trials before a new drug enters the marketplace. Thus, solutions to address these issues must consider bringing the trials closer to the patients or providing support to bring the patients to the trial if it can't be done locally. These problems are particularly important in large states like Texas where patients are often hundreds of miles from an academic urban clinical research center offering state-of-the-art clinical trials of new and promising treatments.

There are other barriers to increasing access to clinical trials other than patient financial and geographic concerns, and these relate in part to the medical care available in a smaller community:

1. Oncologists don't have the necessary resources or time to establish a clinical trials program that includes an experienced research pharmacist, research nurse, study coordinator, and other staff that are critical for a busy physician to enter patients on a clinical trial.
2. Community physicians may not have the experience, knowledge, or resources to carry out clinical trial research; for example, there are many regulatory requirements that need to be followed to ensure patient safety and to address other legal issues.
3. Community physicians may not be interested in this aspect of patient care.

4. Certain trials such as sophisticated immune therapy trials with adoptive T-cell or CAR-T cell therapies, trials involving bone marrow transplantation, or those requiring repeated tumor biopsies to learn if the tumor is responding or resistant to therapy can only be done in experienced centers of excellence.

4. RESEARCH OBJECTIVES

The goal of the CTNA is to inaugurate new clinical trials networks in Texas in order to provide oncologists and their patients who currently have limited access to cancer therapeutic trials opportunities to participate in cancer trials. This mechanism will support access to phase 2 and 3 cancer therapeutic trials appropriate for a community oncology care setting. Clinical trials evaluating surgical or radiation cancer therapies or imaging are not appropriate for this mechanism. Clinical trials evaluating behavioral or prevention services are not appropriate for this mechanism.

To inaugurate this program, CPRIT plans to provide, on a competitive application basis, resources to **Lead Institutions (LIs)** to support development and operations of a clinical trials network with oncology care facilities that currently have limited access to clinical trials (**Network Affiliate**).

LIs will provide their Network Affiliates access to phase 2 and selected phase 3 trials that are appropriate for a community practice setting and meet the needs of that affiliate's patient population.

With award funds, the LI will provide their Network Affiliates access to a Web-based protocol management system; consent forms tailored to meet the language, cultural, and socioeconomic needs of the patient population served; data safety and quality control monitoring; training of research personnel, including opportunities to receive CME, CNE, and ACRP maintenance certifications; and access to LI tumor boards with capability for virtual meeting participation to assess patient eligibility for clinical trials.

Network Affiliates are required to identify a physician champion (**physician leader**) who will provide overall leadership at their site, demonstrate onsite research pharmacy capability, and identify clinical research personnel responsible for patient eligibility determination, protocol registration, data collection, and adverse event reporting.

Network Affiliates will be expected to use the LI's IRB or a central IRB to ensure timely activation of clinical trials. Agreements to use a common IRB must be in place prior to initiating the CTNA contract.

Network Affiliates will be expected to demonstrate capability for processing and storing plasma and biosamples.

Metrics of success include the following:

1. Ability to evaluate trial eligibility for all new patients and enter eligible patients on therapeutic trials.
2. Satisfactory performance on quality control and clinical protocol audit evaluations.
3. Satisfactory staff training and demonstration of continued learning.
4. Ability of Network Affiliate to enroll patients with molecularly defined subsets.
5. Referral of Network Affiliate patients suitable for more complex trials to the LI.

Once LI Networks are satisfactorily demonstrated, LI's will submit to CPRIT their plans to support expansion of the LI's Network Affiliates to up to 2 additional community-based practices that are geographically located outside the LI catchment. Note that for the purpose of this award, the LI catchment is the geographic region where greater than 80% of the LI patients reside.

5. FUNDING INFORMATION

Applicants may request a maximum of \$600,000 annually for Stage 1 and a maximum of \$900,000 annually for Stage 2. The maximum project period is 4 years.

Allowable costs include the following:

- Funds may be used for personnel salary and fringe benefits, research supplies, equipment, CTMS licensing fees, cost for central IRB review, and travel of personnel between LI and Networks sites (see [section 9.2.8](#)).
- Support up to 20% effort for the LI PI and 10% effort for the Network Affiliate physician leader are required up to a maximum full-time salary of \$200,000/year.
- Subject participation costs including diagnostic or interventional procedures associated with participation in a clinical trial and not considered routine standard of care should be

supported by other mechanisms and are not appropriate for this award, but may be counted toward the required matching funds (see [section 13](#)).

- Please see [section 9.2.8](#) and the IFA for additional information.

State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the total award amount. The 5% indirect cost expenditures may be distributed between the LI and the Network Affiliate(s); however, in no case may the actual indirect costs reported exceed 5% of grant funds expended. The LI determines whether or not a portion of the 5% indirect costs may be claimed on grant expenses submitted by a Network Affiliate to the LI.

6. ELIGIBILITY

- The LI and Network Affiliates must be Texas-based entities. The LI and Network Affiliates may be institutions, organizations, or other entities (including physician groups) that conduct clinical research; however, a public or private company operating as a clinical research organization (CRO) is not eligible for funding under this award mechanism.
- **An entity may only submit 1 application as the LI under this RFA. Network Affiliates may be listed on 1 application submitted under this RFA.**
- The Principal Investigator (PI) must have an MD or DO and must be a full-time resident of Texas at the time the application is submitted and during the entire time the grant is active.
- An individual may serve as a PI on no more than 3 active CPRIT Academic Research grants at the time of CTNA award. Recruitment and Research Training Awards do not count toward the 3-grant maximum; however, CPRIT considers MIRA Project Co-PIs equivalent to a PI. For the purpose of calculating the number of active grants, CPRIT will consider the number of active grants at the time of the award contract effective date (for this cycle expected to be August 31, 2021).
- A PI may submit both an application to this RFA and a new or renewal application to another RFA during this funding cycle.
- This award does not allow a Co-PI.

- Collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but those organizations outside Texas are not eligible to receive CPRIT grant funds.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a gift or grant to CPRIT or to any nonprofit organization specifically created to benefit CPRIT.
- Texas law prohibits a LI or Network Affiliate from receiving CPRIT grant funding if a CPRIT Oversight Committee member or the spouse of a CPRIT Oversight Committee member is employed by the LI or Network Affiliate, participates in the management of the LI or Network Affiliate, or owns or controls, directly or indirectly, an interest in the LI or Network Affiliate.
- The applicant must report whether the LI or Network Affiliate, the PI, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, whether or not those individuals are slated to receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 12](#) and [section 13](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

7. RESUBMISSION POLICY

Not applicable as this is a new CPRIT RFA.

8. RENEWAL POLICY

Not applicable as this is a new CPRIT RFA.

9. RESPONDING TO THIS RFA

9.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The PI must create a user account in the system to start and apply. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on September 16, 2020 and must be submitted by 4 PM central time on January 27, 2021. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

9.1.1. Submission Deadline Extension

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grants applications will be denied. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

9.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the *Instructions for Applicants* document for details that will be available when the application receipt system opens. Submissions that are

missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

9.2.1. Abstract and Significance (5,000 characters)

Describe the proposed clinical trials network including a description of the LI and proposed Network Affiliates for Stage 1 of the network plan. Discuss the clinical trial capabilities of the LI and the criteria for selection of Network Affiliates. Discuss opportunities for expansion of the network in Stage 2. Clearly address how the LI will oversee the proposed network and how the performance of the Network Affiliates will be monitored and evaluated.

9.2.2. Layperson's Summary (2,000 characters)

Provide a layperson's summary of the proposed clinical trials network including description of the participant sites and patient populations served. Describe, in simple, nontechnical terms, how the network will facilitate access to clinical trials, the type(s) of trials proposed for the network, and the expected impact on patient access to clinical trials. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. **Do not include any proprietary information in the layperson's summary.** The layperson's summary will also be used by advocate reviewers ([section 10.1](#)) in evaluating the significance and impact of the proposed work.

9.2.3. Goals and Objectives

List specific goals and objectives for each year of the CTNA including the plan for launching Stage 1 and for implementing Stage 2 by Year 3 of the award. These goals and objectives will also be used during the submission and evaluation of progress reports and overall assessment of project success.

9.2.4. Timeline (1 page)

Provide an outline of anticipated major milestones to be tracked in the implementation and evaluation of the network. Timelines will be reviewed for reasonableness, and adherence to timelines will be a criterion for continued support of successful applications. If the application is approved for funding, this section will be included in the award contract. Applicants are advised

not to include information that they consider confidential or proprietary when preparing this section.

9.2.5. Network Description (10 pages)

A. Principal Investigator

Discuss the qualifications and the role of the Principal Investigator.

B. Lead Institution

Describe the LI and its commitment to development of a clinical trials network. Provide an overview of the LI including a description of the LI catchment area, the LI organizational capabilities, clinical research portfolio, and the LI overall commitment to the award. **The LI is encouraged to propose telemedicine approaches to evaluate eligibility and to invite patient participation in a clinical trial at the Network Affiliate.**

Document the LI's ability to meet the goals of the CTNA including the following:

1. Access to phase 2 and selected phase 3 trials that are appropriate for a community practice setting and meet the needs of the patients served by the proposed Network Affiliates.
2. Access to a clinical trials management system that includes Web-based eligibility review and central registration and access to electronic consent forms tailored to meet the language and cultural needs of patients served by the affiliate.
3. Agreement by the LI and Network Affiliates to use a common IRB (section [9.2.6](#)).
4. Safety and quality control monitoring capability.
5. Training for Network Affiliate personnel and opportunities for network personnel to receive CME, CNE, and ACRP maintenance certification.
6. Tumor boards with capability for virtual meeting participation by Network Affiliate personnel.
7. Lead Institution must document the mechanism(s) in place for assuring oversight of the scientific aspects and patient safety of the clinical trials available to Network Affiliates.

C. Network Affiliates:

1. Identify the Network Affiliate sites and any established affiliation or agreements with the LI.
2. Identify and describe the qualifications and responsibilities of the physician leader who will oversee each Network Affiliate site.
3. Discuss the patient population and geographic region served and document the cancer patient volumes and principal cancers seen for each Network Affiliate.
4. Document that the Network Affiliate has agreed to use the LI IRB or a central IRB.
5. Document the intent and capability to establish an onsite research pharmacy capability and to recruit a clinical research coordinator responsible for eligibility determination, data collection, and to assist with IRB submissions, industry contracts, and other regulatory documentation.
6. Provide the plan for protocol access, patient registration, and drug access at each Network Affiliate (include information on the CTMS).
7. Discuss how Network Affiliate performance metrics will be monitored.
8. Discuss how the LI and Network Affiliates will ensure inclusion of women and underrepresented populations (eg, rural, elderly, low socioeconomic status individuals) in the clinical trials offered.

9.2.6. Institutional Review Board agreement

Provide documentation that the LI and Network Affiliates will use a common IRB. Certification of approval of these plans by the IRB will be required before funding can occur.

9.2.7. Publications/References

Provide a concise and relevant list of publications/references cited for the application.

9.2.8. Budget and Justification

Provide a detailed justification of the budget for the entire proposed period of support for both the LI and each Network Affiliate in Stage 1 (maximum total costs of \$600,000 for Years 1 and 2) and Stage 2 (maximum total costs of \$900,000 for Years 3 and 4), including salaries and

benefits, supplies, and equipment. All clinical trial sites supported by a CPRIT award under this RFA must be in Texas. CPRIT will not reimburse personnel expenses for employees of the LI or Network Affiliate residing outside of Texas.

Note that patient care costs associated with the conduct of a clinical trial are not appropriate for this mechanism.

In preparing the requested budget, applicants should be aware of the following:

- Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application.
- Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. So-called grants management and facilities fees (eg, sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees; maintenance fees) may not be requested. Applications that include such budgetary items will be rejected administratively and returned without review.
- The annual salary (also referred to as direct salary or institutional base salary) that an individual may receive under a CPRIT award for FY 2021 is \$200,000; CPRIT FY 2021 is from September 1, 2020, through August 31, 2021. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.

9.2.9. Biographical Sketches (5 pages each)

Applicants should provide a biographical sketch that describes their education and training, professional experience, awards and honors, and publications relevant to cancer research. A biographical sketch must be provided for the PI and each Network Affiliate Lead (as required by

the online application receipt system). Each biographical sketch must not exceed 5 pages. The NIH biosketch format is recommended.

9.2.10. Current and Pending Support

Describe the funding source and duration of all current and pending support for all personnel who have included a biographical sketch with the application. For each award, provide the title, a 2-line summary of the goal of the project, and, if relevant, a statement of overlap with the current application. At a minimum, current and pending support of the PI and, if applicable, the Co-PI must be provided. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

9.2.11. Institutional/Collaborator Support and/or Other Certification (4 pages)

Applicants may provide letters of institutional support and/or other certification documentation relevant to the proposed project. A maximum of 4 pages may be provided.

Applications that are missing 1 or more of these component; exceed the specified page, word, or budget limits; or that do not meet the eligibility requirements listed above will be administratively rejected without review.

9.3. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English
- **Document Format:** PDF only
- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point)
- **Line Spacing:** Single
- **Page Size:** 8.5 x 11 inches
- **Margins:** 0.75 inch, all directions
- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations must be submitted as part of the appropriate submitted document. Applicants should include text to explain illustrations that may be difficult to interpret when printed in black and white.

- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.
- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters are also acceptable if the journal information is stated. Include URLs of publications referenced in the application.

Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45–67.

- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants should not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see following point).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be filled out, printed, signed, scanned, and then uploaded in PDF format.

10. APPLICATION REVIEW

10.1. Application Review

Applications will undergo a 2-stage peer review process: (1) Full peer review and (2) prioritization of grant applications by the CPRIT Scientific Review Council. In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts as well as advocate reviewers using the criteria listed in [section 10.2](#). In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT Scientific Review Council based on comparisons with applications from all the peer review panels and programmatic priorities. Applications approved by Scientific Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight

Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC.

The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

10.2. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and Scientific Review Council members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in Texas Administrative Code [RULE §703.9](#)

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: An Oversight Committee Member, a PIC Member, a Scientific Review Panel member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Research Officer, and the Commissioner of State Health Services.

The prohibition on communication begins on the first day that grant applications for the grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice

regarding a final decision on the grant application. The prohibition on communication does not apply to the time period when preapplications or letters of interest are accepted. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

10.3. Review Criteria

Full peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Review committees will evaluate and score each primary criterion and subsequently assign a global score that reflects an overall assessment of the application. **The overall assessment will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application. Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

10.3.1. Primary Criteria

Primary criteria will evaluate the scientific merit and potential impact of the proposed work contained in the application. Concerns with any of these criteria potentially indicate a major flaw in the significance and/or design of the proposed study. Primary criteria include the following:

Significance and Impact: Will the proposed network expand patient access and geographic proximity to innovative clinical trials? Will the proposed network increase the diversity of the patients participating in the LI sponsored clinical trials portfolio?

Research Plan: Does the plan for the proposed network document a process for rapid and efficient access to clinical trials and does the plan incorporate best practices to ensure timely clinical treatment decisions and the output of high-quality data? Does the LI have a well-defined plan and an appropriate governance structure to coordinate activities related to the Network? Does the LI demonstrate the potential to overcome critical barriers for robust accrual to advance progress in the field? Does the LI have a history of timely activation of clinical trials? Are the LI infrastructure and policies in place to support accrual to clinical trials? Does the LI have active programs to recruit minorities and underserved patient populations to clinical trials? Do proposed Network Affiliates demonstrate a commitment to providing their patients' access to clinical trials? Is environment and setting of the proposed

Network Affiliates adequate to support a robust clinical trial program where 10% of new patients seen will be eligible to enroll on trials?

Applicant Investigator: Does the applicant investigator demonstrate the required expertise and experience to lead the network? Has the applicant devoted enough of his or her time (percent effort) to this project?

Relevance: Does the proposed research have a high degree of relevance to cancer research? This is a critical criterion for evaluation of projects for CPRIT support.

10.3.2. Secondary Criteria

Secondary criteria contribute to the global score assigned to the application. Concerns with these criteria potentially question the feasibility of the proposed research. Secondary criteria include the following:

Research Environment: Does the research team have the needed expertise, facilities, and resources to accomplish all aspects of the network? Are the levels of effort of the key personnel appropriate? Is there evidence of institutional support?

Budget: Is the budget appropriate for the proposed work?

Duration: Is the stated duration appropriate for the proposed work?

11. KEY DATES

RFA

RFA release August 5, 2020

Application

Online application opens September 16, 2020, 7 AM central time

Application due January 27, 2021, 4 PM central time

Application review January 2021 to August 2021

Award

Award notification August 18, 2021

Anticipated start date August 31, 2021

12. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. Applicants are advised to review CPRIT's Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate.

Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of award contract. Forms and instructions will be made available at www.cprit.texas.gov.

13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the grant recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. A grant recipient that is a public or private institution of higher education, as defined by §61.003, Texas Education Code, may credit toward the grant recipient's matching funds obligation the dollar amount equivalent to the difference between the indirect cost rate authorized by the federal government for research grants awarded to the grant recipient and the 5% indirect cost limit imposed by §102.203(c), Texas Health and Safety Code. Grant applicants are advised to consult CPRIT's Administrative Rules, [chapter 703, section 703.11](#), for specific requirements regarding demonstration of available funding. The demonstration of available matching funds must be made at the time the award contract is executed, and annually thereafter, not when the application is submitted.

CPRIT recognizes that an LI and/or Network Affiliate may not be considered a public or private institution of higher education or may have an FIDC rate credit that is less than 55%. If that is the case, non-CPRIT funds (eg, federal grants, industry contracts, philanthropic funds, institutional funds, etc) paid to support the clinical trials that are the subject of this award may be used to fulfill the matching funds requirement. CPRIT will also allow the grant recipient to count funds paid for the non-research related patient care costs toward the matching funds requirement. The grant recipient must submit documentation to CPRIT supporting all matching fund expenses.

14. CONTACT INFORMATION

14.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not able to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

14.2. Scientific and Programmatic Questions

Questions regarding the CPRIT program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Senior Manager for Academic Research.

Tel: 512-305-8491

Email: Help@CPRITGrants.org

Website: www.cprit.texas.gov

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Cancer Biology
(21.2 AR-CB)
Observation Report

Report No. 2021-05-20 21.2_AR-CB
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Cancer Biology
(21.2_AR-CB)
Panel Date: May 20, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Cancer Biology (21.2_AR-CB) meeting. The meeting was chaired by Peter Jones and conducted via videoconference on May 20, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Eleven (11) applications were discussed and eight (8) applications were not discussed
- Panelists: One (1) panel chair, sixteen (16) expert reviewers, three (3) Ad Hoc reviewers, two (2) advocate reviewers and one (1) Ad Hoc reviewer was not present
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Six (6)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Basic Cancer
Research – 1 (21.2 AR-BCR1)
Observation Report

Report No. 2021-05-21 21.2_AR-BCR1
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Basic Cancer Research –
1 (21.2_AR-BCR1)
Panel Date: May 21, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Basic Cancer Research – 1 (21.2_AR-BCR1) meeting. The meeting was chaired by Thomas Curran and conducted via videoconference on May 21, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: nineteen (19) applications were discussed and nineteen (19) applications were not discussed
- Panelists: One (1) panel chair, fourteen (14) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were five (5) Conflicts of Interest (COIs) identified prior to and/or during the meeting. There were three (3) COIs on applications discussed and two (2) COIs on applications not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive 'M' followed by a long horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Clinical and
Translational Cancer Research (21.2 AR-CTCR)
Observation Report

Report No. 2021-05-24 21.2_AR-CTCR
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Clinical and Translational
Cancer Research (21.2_AR-CTCR)
Panel Date: May 24, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Clinical and Translational Cancer Research (21.2_AR-CTCR) meeting. The meeting was chaired by Margaret Tempero and Richard O'Reilly and conducted via videoconference on May 24, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: twenty-one (21) applications were discussed and thirteen (13) applications were not discussed
- Panelists: Two (2) panel chairs, twenty-two (22) expert reviewers, and three (3) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were four (4) Conflicts of Interest (COIs) identified prior to and/or during the meeting. There were three (3) COIs on applications discussed and one (1) COI on an application not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed

additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Basic Cancer
Research – 2 (21.2 AR-BCR2)
Observation Report

Report No. 2021-05-25 21.2_AR-BCR2
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Basic Cancer Research –
2 (21.2_AR-BCR2)
Panel Date: May 25, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Basic Cancer Research – 2 (21.2_AR-BCR2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on May 25, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: sixteen (16) applications were discussed, and eighteen (18) applications were not discussed
- Panelists: One (1) panel chair, fifteen (15) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were five (5) Conflicts of Interest (COIs) identified prior to and/or during the meeting. There were four (4) COIs on applications discussed and one (1) COI on an application not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive name that appears to be 'Mara Ash'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Imaging Technology
and Informatics (21.2 AR-ITI)
Observation Report

Report No. 2021-05-26 21.2_AR-ITI
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Imaging Technology and Informatics (21.2_AR-ITI)
Panel Date: May 26, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Imaging Technology and Informatics (21.2_AR-ITI) meeting. The meeting was chaired by Martin Pomper and conducted via teleconference on May 26, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Thirteen (13) applications were discussed, and thirteen (13) applications were not discussed
- Panelists: One (1) panel chair, nineteen (19) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were three (3) Conflicts of Interest (COIs) identified prior to and/or during the meeting. There were two (2) COIs on applications discussed and one (1) COI on an application not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Cancer Prevention
Research (21.2 AR-CPR)
Observation Report

Report No. 2021-05-27 21.2_AR-CPR
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Cancer Prevention
Research (21.2_AR-CPR)
Panel Date: May 27, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Cancer Prevention Research (21.2_AR-CPR) meeting. The meeting was chaired by Elana Martinez and conducted via teleconference on May 27, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Five (5) applications were discussed and three (3) applications were not discussed
- Panelists: One (1) panel chair, ten (10) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

21.2 Scientific Review Council (21.2 SRC)

Observation Report

Report No. 2021-07-08 21.2_SRC
Program Name: Academic Research
Panel Name: 21.2 Scientific Review Council (21.2_SRC)
Panel Date: July 8, 2021
Report Date: July 16, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is 21.2 Scientific Review Council (21.2_SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on July 8, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: fifty-two (52) applications were discussed
- Panelists: One (1) panel chair and eight (8) reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COIs procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 21.2

Awards Announced at the August 18, 2021, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Cycle 21.2 include *Core Facility Support Awards*; *Clinical Trials Network Award*; *Early Clinical Investigator Awards*; *High-Impact/High Risk Awards*; *Texas Clinical Trials Participation Award*; and *Texas Regional Excellence in Cancer Award*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant/Principal Investigator	Principal Investigator Institution	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
RP210073	Ronald DePinho	The University of Texas M.D. Anderson Cancer Center	N. Bardeesy
RP210102	WEIXING ZHAO	The University of Texas Health Science Center at San Antonio	W. Chazin
RP210208	Stanton McHardy	The University of Texas at San Antonio	A. Tomkinson; W. Chazin; C. Rosenfeld
RP210122	Michael Overman	The University of Texas M.D. Anderson Cancer Center	H. Hochster
RP210075	Jeremy Schraw	Baylor College of Medicine	C. Li
RP210099	Anke Henning	The University of Texas Southwestern Medical Center	A. Wu; R. Berbeco

Application ID	Applicant/Principal Investigator	Principal Investigator Institution	Conflict Noted by Reviewer
RP210105	Alexei Tumanov	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP210236	Zhenpeng Qin	The University of Texas at Dallas	J. Willson
RP210140	Carlos L Arteaga	The University of Texas Southwestern Medical Center	C. Rosenfeld
Applications not considered by the PIC or Oversight Committee:			
RP210154	Charles Reynolds	Texas Tech University Health Sciences Center	Y. DeClerck
RP210215	Wei Wang	University of Houston	X. Chen
RP210113	Yinghong Wang	The University of Texas M.D. Anderson Cancer Center	R. O'Reilly
RP210172	Charles Geyer	The Methodist Hospital Research Institute	H. Hochster
RP210216	Mary Dickinson	Baylor College of Medicine	W. Kast
RP210090	Kenneth Hoyt	The University of Texas at Dallas	K. Zinn
RP210112	Peter Houghton	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP210166	Francis Yoshimoto	The University of Texas at San Antonio	J. Conejo-Garcia
RP210230	Leonidas Bleris	The University of Texas at Dallas	A. Anderson; J. Conejo-Garcia

De-Identified Overall Evaluation Scores

Clinical Trials Network Award

Academic Research Cycle 21.2

Application ID	Final Overall Evaluation Score
RP210122*	2.5
Ha	2.9
Hb	3.0
Hc	3.3
Hd	4.0

* Recommended for funding

Final Overall Evaluation Scores and Rank Order Scores

Ludwig Institute for
Cancer Research Ltd

Richard D. Kolodner
Ph.D.

Head, Laboratory of
Cancer Genetics
San Diego Branch

Distinguished Professor of
Cellular & Molecular
Medicine, University of
California San Diego School
of Medicine

rkolodner@health.ucsd.edu

San Diego Branch

UC San Diego School of
Medicine
CMM-East / Rm 3058
9500 Gilman Dr - MC 0660
La Jolla, CA 92093-0660

T 858 534 7804
F 858 534 7750

July 21, 2021

Mr. Dee Margo
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dee@deemargo.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Mr. Margo and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for Core Facility Support Awards (CFSA), Clinical Trials Network Awards (CTNA), Early Clinical Investigator Awards (ECI), High-Impact/High Risk Awards (HIHR), Texas Clinical Trials Participation Awards (TCTPA) and Texas Regional Excellence in Cancer Award (TREC).

The SRC met on July 8, 2021 to consider the applications recommended by the peer review panels following their meetings held May 20, 2021 – May 27, 2021.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the applications recommended is \$75,418,344. *Please note that the peer review panels and SRC recommended reduced budgets for applications # RP210180 and #RP210064, the reductions are reflected in the table.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Rank	ID	Mechanism	Score	Application Title	PI	Organization	Rec. Budget
1	RP210227	CFSA	1.0	Proteomics and Metabolomics Core Facility	Edwards, Dean	Baylor College of Medicine	\$3,977,681
2	RP210176	ECI	1.0	CPRIT Early Clinical Investigator Award: Moran Amit	Draetta, Gulio	The University of Texas M. D. Anderson Cancer Center	\$1,499,042
3	RP210208	CFSA	1.1	Center for Innovative Drug Discovery: Expansion of a Highly Productive Shared Cancer Drug Discovery Resource for Texas	McHardy, Stanton	The University of Texas at San Antonio	\$3,087,131
4	RP210143	TCTPA	1.5	Dan L. Duncan Comprehensive Cancer Center (DLDCCC) Harris Health Clinical Trials Financial Support Project	Mims, Martha	Baylor College of Medicine	\$1,500,000
5	RP210165	HIHRRRA	1.6	Rapid Point-of-Care Detection of Ovarian Cancer Biomarkers Using a Common Thermometer for Low-Resource Settings	Li, Xiujun (James)	The University of Texas at El Paso	\$249,999
6	RP210115	TCTPA	1.7	Enhancing Access to and Diversity in Cancer Clinical Trials Through a Financial Reimbursement and Outreach Program	Gerber, David	The University of Texas Southwestern Medical Center	\$1,499,327
7	RP210159	ECI	1.8	CPRIT Early Clinical Investigator Award: Carl Gay	Draetta, Gulio	The University of Texas M. D. Anderson Cancer Center	\$1,499,997

8	RP210088	CFSA	1.9	Targeted Therapeutic Drug Discovery and Development Program	Dalby, Kevin	The University of Texas at Austin	\$3,989,441
9	RP210205	HIHRRA	1.9	Cytokine Factories for the Treatment of Mesothelioma	Veiseh, Omid	Rice University	\$250,000
10	RP210173	HIHRRA	1.9	Multiplex CRISPR Genetic Modeling of Polypharmacology for Precision Medicine	Hart, Traver	The University of Texas M. D. Anderson Cancer Center	\$250,000
11	RP210108	CFSA	2.0	The GCC Microphysiological Lead Optimization and Toxicity Screening Facility	Stephan, Clifford	Texas A&M University System Health Science Center	\$3,973,083
12	RP210144	HIHRRA	2.0	Leveraging Glioma Stem Cell Electrophysiology for Therapy	Rostomily, Robert	The Methodist Hospital Research Institute	\$248,028
13	RP210168	HIHRRA	2.0	Overcoming Myeloma Resistance to Proteasome Inhibitors	Yi, Qing	The Methodist Hospital Research Institute	\$250,000
14	RP210062	HIHRRA	2.0	Protein Degradation of CDK9 for Treatment of Drug-Resistant Mantle Cell Lymphoma	Zhou, Jia	The University of Texas Medical Branch at Galveston	\$250,000
15	RP210154	TREC	2.0	Texas Regional Excellence in Cancer Developmental Therapeutics Center at TTUHSC	Reynolds, Charles	Texas Tech University Health Sciences Center	\$5,999,936
16	RP210073	HIHRRA	2.1	Identification of Collateral Lethal and Synthetic Lethal Targets in	DePinho, Ronald	The University of Texas M. D. Anderson Cancer Center	\$249,994

				Pancreatic and Colorectal Cancers			
17	RP210111	HIHRRRA	2.1	Single-Cell Proteomics to Dissect Intratumor Heterogeneity	Pan, Sheng	The University of Texas Health Science Center at Houston	\$250,000
18	RP210134	HIHRRRA	2.2	High-Throughput Discovery of Anticancer Protein Degradors	Tambar, Uttam	The University of Texas Southwestern Medical Center	\$250,000
19	RP210116	CFSA	2.3	The Genetic Design and Engineering Center (GDEC): A CPRIT Core Facility	Bao, Gang	Rice University	\$4,000,000
20	RP210158	HIHRRRA	2.3	Improving CAR T-Cell Therapy of T-ALL by Cotargeting Additional Antigens	Mamonkin, Maksim	Baylor College of Medicine	\$250,000
21	RP210206	HIHRRRA	2.4	Novel Tumor-Specific Bioactive Nanoparticles for Cancer Therapy	Nguyen, Kytai	The University of Texas at Arlington	\$249,999
22	RP210180	CFSA	2.5	Integrated Cancer Research Core (ICRC)	CHAUHAN, SUBHASH	The University of Texas Rio Grande Valley	*\$2,525,000
23	RP210126	CFSA	2.5	High-Parameter Analysis, Sorting, and Imaging Flow Cytometry Shared Resource	Berton, Michael	The University of Texas Health Science Center at San Antonio	\$3,645,500
24	RP210122	CTNA	2.5	Building a Clinical Trial Network for Texas Community Affiliates	Overman, Michael	The University of Texas M. D. Anderson Cancer Center	\$3,000,000
25	RP210164	ECI	2.5	Early Clinical Investigator Award: William Kelly	Hromas, Robert	The University of Texas Health Science Center at San Antonio	\$1,499,985
26	RP210140	ECI	2.6	Targeting Altered Metabolism in IDH-Mutant Glioma	Arteaga, Carlos	The University of Texas Southwestern Medical Center	\$1,500,000

27	RP210089	HIHRRA	2.6	Dissecting Therapeutic Immunomodulation of Gut Microbiome on Colorectal Cancer	Kim, Hyun Jung	The University of Texas at Austin	\$250,000
28	RP210079	HIHRRA	2.7	Targeting Mitochondrial NAD+ in Leukemias	Cambronne, Xiaolu	The University of Texas at Austin	\$250,000
29	RP210236	HIHRRA	2.7	Magnetomechanical Modulation of Blood-Brain Barrier Permeability	Qin, Zhenpeng	The University of Texas at Dallas	\$250,000
30	RP210234	ECI	2.7	Targeting Src Homology-2 Domain-Containing Phosphatase to Overcome Resistance to Immune Checkpoint Blockade in Pancreatic Ductal Adenocarcinoma	Johnston, Sterling	The University of Texas at Austin	\$1,443,367
31	RP210105	HIHRRA	2.8	Targeting Lymphotoxin Beta Receptor in Sensory Neurons for Control of Chemotherapy-Induced Neuropathic Pain	Tumanov, Alexei	The University of Texas Health Science Center at San Antonio	\$249,996
32	RP210068	HIHRRA	2.8	Role of Aberrant Translational Quality Control in Tumorigenesis of Glioblastoma	Wu, Zhihao	Southern Methodist University	\$249,272
33	RP210102	HIHRRA	2.8	Deciphering BRCA1-BARD1 E3 Ligase Activity in Genome Maintenance and Tumor Suppression	ZHAO, WEIXING	The University of Texas Health Science Center at San Antonio	\$250,000

34	RP210099	CFSA	2.8	North Texas Multimodal Small-Animal Imaging Core Facility	Henning, Anke	The University of Texas Southwestern Medical Center	\$3,999,929
35	RP210137	HIHRRA	2.8	Development of TCR-Based Immunotherapies Targeting Hotspot EGFR Mutations for the Treatment of Non-Small Cell Lung Cancer	Reuben, Alexandre	The University of Texas M. D. Anderson Cancer Center	\$250,000
36	RP210209	CFSA	2.9	North Texas Clinical Pharmacology Cancer Core	Putnam, William	Texas Tech University Health Sciences Center	\$2,965,226
37	RP210092	HIHRRA	3.0	Antibody-Drug Conjugate Combination Treatment for Targeting Colorectal Cancer Cell Plasticity	Carmon, Kendra	The University of Texas Health Science Center at Houston	\$250,000
38	RP210131	HIHRRA	3.0	Antibodylike Therapeutics That Target Polyclonal T Cells to CMV-Positive Glioblastomas	Maynard, Jennifer	The University of Texas at Austin	\$250,000
39	RP210075	HIHRRA	3.0	Exploring the Biological Basis of Ethnic and Social Disparities in Pediatric Acute Lymphoblastic Leukemia Outcomes	Schraw, Jeremy	Baylor College of Medicine	\$249,999
40	RP210199	HIHRRA	3.0	Treating Metastatic Cancer Using Microbubble-Assisted Ultrasound-Guided Immunotherapy of	Lux, Jacques	The University of Texas Southwestern Medical Center	\$249,011

				Cancer of Cancer (MUSIC)			
41	RP210127	HIHRRA	3.0	Engineered Enteric Nerve-Perineural Invasion Models to Improve Predictive Preclinical Screens in Early-Stage Colorectal Adenocarcinoma	Raghavan, Shreya	Texas A&M University	\$250,000
42	RP210148	HIHRRA	3.0	Novel Pharmacodynamic Assay to Predict Response to CDK4/6 Inhibitor Therapy	Trivedi, Meghana	University of Houston	\$250,000
43	RP210119	CFSA	3.1	A Preclinical Development Core for Large-Molecule Therapeutics	Liu, Qingyun	The University of Texas Health Science Center at Houston	\$3,999,999
44	RP210064	CFSA	3.1	The Adolescent and Childhood Cancer Epidemiology and Susceptibility Service (ACCESS) for Texas	Scheurer, Michael	Baylor College of Medicine	*\$4,000,000
45	RP210130	CFSA	3.1	Data Management and Analysis Core for Comparative Effectiveness Research on Cancer in Texas	Kuo, Yong-Fang	The University of Texas Medical Branch at Galveston	\$2,936,731
46	RP210070	HIHRRA	3.1	Tunable Epigenetic Remodeling to Modulate CAR T-Cell-Based Immunotherapy	Zhou, Yubin	Texas A&M University System Health Science Center	\$250,000
47	RP210132	HIHRRA	3.1	Synergy Between Epigenetic Reprogramming and Wnt Inhibition to Enhance	Frost, Jeffrey	The University of Texas Health Science Center at Houston	\$249,999

				Neuroendocrine Tumor Radionuclide Therapy			
48	RP210153	TREC	3.1	UTEP/UTMDACC Partnership for Hispanic Cancer Disparities Research	Cox, Marc	The University of Texas at El Paso	\$5,881,734
49	RP210183	HIHRRA	3.3	Virulence Modulation of Helicobacter pylori, the Strongest Risk Factor for Gastric Cancer	Kearney, Christopher	Baylor University	\$248,938
50	RP210213	HIHRRA	3.3	Therapeutic Inhibition of Cholangiocarcinoma Progression by Targeting Tumor-Lymphatic Cross Talk	Chakraborty, Sanjukta	Texas A&M University System Health Science Center	\$250,000

CFSA = Core Facility Support Awards

CTNA = Clinical Trials Network Award

ECI = Early Clinical Investigator Awards

HIHR = High-Impact/High Risk Awards

TCTPA = Texas Clinical Trials Participation Award

TREC = Texas Regional Excellence in Cancer Award



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research
FY 2021—Cycle 2
*Early Clinical Investigator Awards***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA R-21.2-ECI

Early Clinical Investigator Award

**Please also refer to the Instructions for Applicants document,
which will be posted on September 16, 2020**

Applications for this award mechanism are subject to institutional limits.
Applicants are advised to consult with their institution's Office of Research and
Sponsored Programs (or equivalent).

Application Receipt Opening Date: September 16, 2020

Application Receipt Closing Date: January 27, 2021

FY 2021

Fiscal Year Award Period

September 1, 2020-August 31, 2021

TABLE OF CONTENTS

1. ABOUT CPRIT	4
1.1. ACADEMIC RESEARCH PROGRAM PRIORITIES	4
2. RATIONALE	5
3. OBJECTIVES	5
4. INSTITUTIONAL COMMITMENT	7
5. FUNDING INFORMATION	7
6. ELIGIBILITY	8
7. RESUBMISSION POLICY	10
8. RESPONDING TO THIS RFA	10
8.1. APPLICATION SUBMISSION GUIDELINES	10
8.1.1. <i>Submission Deadline Extension</i>	11
8.2. APPLICATION COMPONENTS	11
8.2.1. <i>Summary of Nomination (2,000 characters)</i>	11
8.2.2. <i>Institutional Commitment (3 pages)</i>	11
8.2.3. <i>Resubmission Summary (1 page)</i>	12
8.2.4. <i>Curriculum Vitae (CV)</i>	12
8.2.5. <i>Summary of Goals and Objectives (2,000 characters)</i>	13
8.2.6. <i>Candidate Information and Career Development Plan (10 pages)</i>	13
8.2.7. <i>Mentor, Co-mentor (4-page description)</i>	14
8.2.8. <i>Mentor, Co-mentor Biographical Sketches (5 pages each)</i>	15
8.2.9. <i>Timeline (1 page)</i>	15
8.2.10. <i>Current and Pending Support</i>	15
8.2.11. <i>Letters of Recommendation</i>	16
8.2.12. <i>Research Environment (1 page)</i>	16
8.2.13. <i>Previous Summary Statement</i>	16
8.3. FORMATTING INSTRUCTIONS	16
9. APPLICATION REVIEW	17
9.1. REVIEW PROCESS.....	17
9.2. CONFIDENTIALITY OF REVIEW	18
9.3. REVIEW CRITERIA.....	19
10. KEY DATES	20
11. AWARD ADMINISTRATION	20
12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS	21
13. CONTACT INFORMATION	22
13.1. HELPDESK.....	22
13.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS	22

RFA VERSION HISTORY

Rev 08/05/20 RFA release

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of or cures for cancer.
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas.
- Develop and implement the Texas Cancer Plan.

1.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency regarding how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure

The program priorities for academic research adopted by the Oversight Committee include funding projects that address the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions
- Computational biology and analytic methods
- Childhood cancers
- Hepatocellular cancer
- Expansion of access to innovative clinical trials

2. RATIONALE

The number of highly talented individuals entering a career in clinical investigation is decreasing at a time when the excitement and challenge associated with clinical cancer research has never been greater. The reasons for the decline in cancer clinical investigators are many and include the increased demands on clinical faculty to generate clinical revenue and as a consequence, limited opportunities for clinical faculty to pursue research; the burden of medical school debt that limits a trainee's options for extending training and pursuing an academic career; and the increasingly complex nature of clinical research requiring specialized training not offered by clinical training programs. Consequently, clinical faculty often do not have the opportunity or experience required to initiate a career as a clinical investigator.

There is concern that this failure of oncology-trained clinicians to pursue careers in patient-oriented research and clinical investigation will seriously impair the ability to translate what has been discovered in the preclinical setting into advances that can benefit patients. Accordingly, there is an urgent need to develop a pipeline of cancer clinicians equipped with the skills and experience necessary to pursue careers in patient-oriented research and capable of leading innovative discovery campaigns through the conduct of clinical trials and **to provide these clinical investigators the protected time from clinical responsibilities that is required to develop and conduct investigator-initiated clinical trials.**

3. OBJECTIVES

The Early Clinical Investigator Award is designed to provide support for the career development of very promising early-career physicians with specialty training relevant to delivery of cancer care, including therapeutic intervention, early detection, and prevention. Candidates are expected to demonstrate the talent, interest, and commitment to ask questions of patients regarding their diseases and their responses to an intervention that would provide new information about the patient's malignancy and, if the intervention worked, why, or more important, if it did not, why not.

The Early Clinical Investigator Award specifically targets physicians with the following:

- **Are within the first 3 years of a faculty appointment at the assistant professor level.**
- **Have completed specialty training relevant to cancer care, detection, or prevention and are eligible to be certified by their institution to provide patient care in an oncology-related practice.**
- **Plan research that involves the conduct of clinical trials involving a therapeutic intervention, early detection, prevention, symptom control, or behavioral interventions.**

The CPRIT Early Clinical Investigator Award will do the following:

- Provide cancer physicians early in their academic career the opportunity to develop clinical research skills and to gain experience in advanced methods and experimental approaches needed to become clinical investigators.
- Provide an opportunity to establish a partnership with a laboratory-based collaborator in order to design and conduct correlative studies needed to interpret the outcome of an interventional trial.
- Provide the protected time from clinical responsibilities required to develop and conduct investigator-initiated clinical trials.
- Increase the pool of clinical investigators at Texas academic institutions who are conducting patient-oriented studies, capitalizing on basic discoveries and translating them through the conduct of innovative clinical trials involving cancer patients or individuals at risk for cancer.

To accomplish these objectives, the CPRIT Early Clinical Investigator Award will provide awards of up to \$1,500,000 for up to 5 years to physicians within the first 3 years of a faculty appointment as an assistant professor to acquire additional skills and experience in clinical research and to develop preliminary data that can be used to prepare applications for future research project grants to further both the investigator's career and the CPRIT mission. This award may be used for the following:

- To provide salary support to the candidate
- To support didactic study including enrollment in a degree-granting graduate training program to enhance theoretical and practical skills in design, implementation, and interpretation of data from clinical investigations

- To develop preclinical data and to validate correlative studies with a laboratory-based collaborator
- To support an investigator-initiated clinical trial during the award period

The host institution will be expected to work with each Early Clinical Investigator to design and execute the faculty career development plan consistent with his or her research emphasis. Relevance to cancer and to CPRIT's priority areas are important evaluation criteria for CPRIT funding. CPRIT encourages the participation of all groups underrepresented in biomedical research.

4. INSTITUTIONAL COMMITMENT

CPRIT Early Clinical Investigator Awards are intended to provide clinical faculty who are early in their first faculty position enough time for scholarly activities to develop the knowledge base, experience, and partnership(s) required of a successful clinical investigator. CPRIT recognizes that Early Clinical Investigators will need to commit time to direct patient care in order to hone their clinical expertise and that the time commitment required will vary depending on the nature of the individual's clinical practice and level of prior experience; however, **the institution must commit to limiting the clinical duties of the Early Clinical Investigator to no more than 0.5 FTE for the duration of the award.**

A critical component of the Early Clinical Investigator Award is the identification of a mentor (or co-mentors) and the design of a mentoring program that is tailored to the individual's goals and prior experience. The primary mentor should be a clinical and or translational investigator with a strong track record for conducting patient-oriented research. The mentor will be expected to provide an annual progress report that documents progress made toward the goal of independence as a clinical investigator.

5. FUNDING INFORMATION

This award is for **up to 5 years** providing applicants the opportunity to tailor the content and the duration of the award period based upon their individual program. This award is not renewable, although individuals may apply for other future CPRIT funding as appropriate.

Grant funds of up to \$1,500,000 (total costs) may be requested. Funding may be used by the Early Clinical Investigator for salary and fringe support (salary up to the CPRIT maximum of

\$200,000/FTE), for didactic study including enrollment in a degree-granting graduate program, to obtain preclinical data including correlative assay development with a laboratory collaborator, and to support the research project involving an investigator-initiated interventional clinical trial that is a required component of this award.

Applicants are encouraged to design a scholarly training and educational experience that fits the candidate's background and program plan. For example, funds to support didactic study might be emphasized in the first years of the award, and funds to develop correlative assays and to initiate an investigator-initiated clinical trial may be prorated for the later years of the award.

Requests for equipment are not appropriate for this award mechanism except in exceptional circumstances that must be very well justified. Requests for support for faculty mentors are not appropriate for this award. Funds from this award mechanism may not be used to construct or renovate laboratory space.

The award request may include indirect costs of up to 5% of the total award amount (5.263% of the direct costs). Candidates are expected to attend CPRIT's conference. CPRIT funds may be used to reimburse registration, travel, and lodging expenses.

Continuation of funding of this award is contingent upon receipt of an annual progress report that documents achievement of the approved training and project milestones (see [section 8.2.8](#)).

6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution that provides cancer care and conducts clinical cancer research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism.
- **An institution may submit only 2 applications under this RFA during this funding cycle.**
- Candidates must be nominated by the president, provost, vice president for research, or appropriate dean of a Texas-based public or private institution of higher education, including academic health institutions. The application must be submitted on behalf of a specific candidate.

- Candidates must be within 3 years of their first appointment at the assistant professor level and at the time of the application, the candidate must not have been appointed at the rank of assistant professor or equivalent at an accredited academic institution, research institution, industry, government agency, or private foundation **for more than 3 years**. Exceptions may be granted, if justified based on a career break due to family obligations or similar circumstances. The candidate must have an MD or DO degree and reside in Texas at the time an award contract is made and for the duration of the appointment.
- The candidate must have oncology subspecialty training or equivalent and be eligible to be certified by their institution to provide patient care in an oncology-related practice. Note: Pathologists and radiologists are eligible for this award.
- Candidates may not hold a Paul Calabresi Career Development Award for Clinical Oncology (K12), a Mentored Clinical Scientist Research Career Development Award (K08) program award, or similar clinical research career development award at the same time as a CPRIT Early Clinical Investigator Award.
- Individuals who have received a CPRIT First-Time Tenure-Track Faculty Award are not eligible for the Early Clinical Investigator Award.
- Candidates must have identified a mentor who is located at the applicant institution and who agrees to supervise the candidate's career development and research experience.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the nominator, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant nominator, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the nominator, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, whether or not the individuals will receive salary or

compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.

CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 11](#) and [section 12](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

7. RESUBMISSION POLICY

An application previously submitted to CPRIT but not funded may be resubmitted once, based on the eligibility criteria of the initial application, and must follow all resubmission guidelines. Note that the resubmission summary should be limited to 1 page, in which the applicant details how the revision has strengthened the application. More than 1 resubmission per application is not permitted. [See section 8.2.3.](#)

8. RESPONDING TO THIS RFA

8.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application is submitted. Candidates must be nominated by the institution's president, provost, vice president for research, or appropriate dean. The individual submitting the application (Nominator) must create a user account in the system to start and apply. Furthermore, the Application Signing Official, who is the person authorized to sign and submit the application for the organization, and the Grants Contract/Office of Sponsored Projects Official, who is the individual who will manage the grant contract if an award is made, also must create a user account in CARS. Applications will be accepted

beginning at 7 AM central time on September 16, 2020 and must be submitted by 4 PM central time on January 27, 2021. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

8.1.1. Submission Deadline Extension

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grants applications will be denied. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

8.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. For details, please refer to the *Instructions for Applicants* document that will be available when the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

8.2.1. Summary of Nomination (2,000 characters)

Provide a brief summary of the nomination. Include the candidate's name and the department and/or entity within the nominator's organization where the candidate is appointed.

8.2.2. Institutional Commitment (3 pages)

The institutional commitment should be clearly documented in the application in the form of a letter signed by the applicant institution's president, provost, or appropriate dean and the chair of the candidate's department. The following information should be included in the letter:

- Describe the candidate selection process and the organization's commitment to the candidate's career development as a clinical investigator.
- State the total award amount and duration requested.

- Document that at the time of the Early Clinical Investigator Award contract begins the candidate will be appointed at the assistant professor level (or equivalent) and will be eligible to provide patient care in a cancer-related discipline at the applicant institution.
- Document that a minimum of 50% of the candidate's effort will be available for individual career development and research during the full course of the Early Clinical Investigator Award. Breach of this requirement will constitute grounds for discontinuation of the award.
- Document how the candidate's mentoring plan and research experience was developed and how the institution will oversee the candidate's development as clinical investigator.
- Provide additional information in support of a candidate's research plan to demonstrate how the institutional commitment through development of strategic collaborations and leveraging the institution's unique strengths will foster the candidate's career trajectory.

8.2.3. Resubmission Summary (1 page)

Applicants preparing a resubmission must describe the approach to the resubmission. If a summary statement was prepared for the original application review, applicants are advised to address all noted concerns. For resubmitted applications, candidates are allowed to be within the first 5 years of a faculty appointment at the assistant professor level.

Note: An application previously submitted to CPRIT but not funded may be resubmitted **once** after careful consideration of the reasons for lack of prior success. Applications that received overall numerical scores of 5 or higher are likely to need considerable attention. Applicants may prepare a fresh research plan or modify the original research plan and mark the changes.

However, **all resubmitted applications should be carefully reconstructed**; a simple revision of the prior application with editorial or technical changes is not sufficient, and applicants are advised not to direct reviewers to such modest changes.

8.2.4. Curriculum Vitae (CV)

Provide a complete CV and list of publications for the candidate. Only articles that have been published or that have been accepted for publication (“in press”) should be cited.

8.2.5. Summary of Goals and Objectives (2,000 characters)

List very broad goals and objectives to be achieved during this award. **This section and the following section (8.2.5) must be completed by the candidate.**

8.2.6. Candidate Information and Career Development Plan (10 pages)

Candidate Background

- Describe the candidate's commitment to an academic career in patient-oriented research.
- Describe the candidate's prior training and how it relates to the goals and long-term career plans of the candidate.
- Describe all the candidate's clinical and other professional responsibilities/activities in the grantee institution beyond the commitment to career development and research and elsewhere and describe their relationship to the proposed activities on this award.
- Describe the candidate's research efforts to this point, including any publications, prior research interests, and experience.

Career Development Plan

- Describe the candidate's mentored research development plan that includes intent to implement an investigator-initiated clinical trial by Year 3 of the award. Include a timeline chart to illustrate this plan.
- Describe any didactic and research experience(s) designed to develop the necessary knowledge and research skills in scientific areas relevant to the candidate's career goals.
- Demonstrate that the candidate has received training or will participate in courses such as biostatistics, data management, epidemiology, study design, hypothesis development, and drug development including FDA regulatory policies, etc, as well as the legal and ethical issues associated with research on human subjects. **Candidates are encouraged to pursue as part of the Early Clinical Investigator Award an advanced degree-granting program to gain this knowledge.** In addition, candidates may wish to design opportunities to gain experience in clinical investigations as part of an internship or similar arrangement with a pharmaceutical organization.

Research Plan

- Describe a research plan that will lead to the design and implementation of an investigator-initiated clinical trial.
- While the focus of the Early Clinical Investigator Award is on patient-oriented research, complementary laboratory-based research directly related to the proposed patient-oriented research project may be proposed in the application and is strongly encouraged, thereby providing an opportunity to obtain preclinical data and to develop and validate any proposed correlative assays with a laboratory-based collaborator. If correlative studies are proposed, a qualified collaborator who is able and willing to participate in the design and conduct of the correlative studies needed should be identified and, if not already identified as a co-mentor, provide a letter of intent to collaborate and a biosketch.

Clinical Trial Plan

- Describe the planned investigator-initiated clinical trial protocol that the candidate will lead as the Principal Investigator, including metrics for success, and a timeline to initiation of the trial within the first 2 years of the award.
- The description should include rationale, objectives, end points, correlative studies, and statistical considerations. Trials that incorporate corresponding translational research are strongly encouraged.
- Applicants are advised to pay close attention to careful documentation of the trial's feasibility and inclusion of robust statistical considerations.

8.2.7. Mentor, Co-mentor (4-page description)

Name a primary mentor who, together with the candidate, is responsible for planning, directing, monitoring, and executing the proposed program. The primary mentor is required to be an experienced clinical investigator. Co-mentors as appropriate to the goals of the program are encouraged.

Include a statement from the mentor providing (1) information on his/her background as a clinical investigator and previous experience as a mentor, (2) a plan that describes the nature of the supervision and mentoring that will occur during the proposed award period, (3) a plan for career progression for the candidate to move from the mentored stage of his/her career to

independent research investigator status during the project period of the award, and (4) a plan for monitoring the candidate's research, publications, and progress over the course of the award.

Similar information must be provided by any co-mentor. The mentor and any co-mentor(s) should clearly describe how they will coordinate mentoring of the candidate.

The primary mentor must agree to provide annual evaluations of the candidate's progress in the annual progress report.

8.2.8. Mentor, Co-mentor Biographical Sketches (5 pages each)

Biosketches that include current and past funding for the mentor and all co-mentors must be provided. Biosketches should also include education and training, professional experience, awards and honors, and publications relevant to cancer research. Each biographical sketch must not exceed 5 pages.

8.2.9. Timeline (1 page)

Provide an outline of anticipated major award outcomes to be tracked. Timelines will be reviewed during the evaluation of annual progress reports. **Note that the progress report at the completion of Year 2 of this award must include an investigator-initiated clinical trial protocol and a detailed timeline for implementation.**

If the application is approved for funding, this section will be included in the award contract and will be used to monitor progress. Failure to demonstrate robust progress may result in early termination of the grant award. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

8.2.10. Current and Pending Support

State the funding source, duration, and title of all current and pending financial support including any research awards held by the candidate. If the candidate has no current or pending funding, a document stating this must be submitted. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

8.2.11. Letters of Recommendation

Provide 2 letters of recommendation from individuals in addition to the mentor and co-mentor who can detail the candidate's academic accomplishments, potential as a clinical investigator, and ability to make a significant contribution to the field of cancer research.

8.2.12. Research Environment (1 page)

Clearly and concisely describe the research environment available to support the candidate's research program as well as access to clinical facilities and patients, core facilities, didactic programs, and collaborative opportunities.

8.2.13. Previous Summary Statement

If the application is being resubmitted, the summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission. The applicant is not responsible for providing this document.

Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or do not meet the eligibility requirements listed above will be administratively withdrawn without review.

8.3. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English
- **Document Format:** PDF only
- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point)
- **Line Spacing:** Single
- **Page Size:** 8.5 x 11 inches
- **Margins:** 0.75 inch, all directions
- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations must be submitted as part of the appropriate submitted document. Applicants should include text to explain illustrations that may be difficult to interpret when printed in black and white.

- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.
- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters are also acceptable as long as the journal information is stated. Include URLs of publications referenced in the application.

Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45–67.
- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants should not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see following point).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be filled out, printed, signed, scanned, and then uploaded in PDF format.

9. APPLICATION REVIEW

9.1. Review Process

All applications will undergo a 2-stage peer review process: (1) Full peer review and (2) prioritization of grant applications by the CPRIT Scientific Review Council. In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts as well as advocate reviewers using the criteria listed in [section 9.3](#). Applicants will be notified of peer review panel assignments prior to the peer review meeting dates. Peer review panel membership can be found on the CPRIT website. In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT Scientific Review Council based on comparisons with applications from all the peer review panels and programmatic priorities. Applications approved by Scientific Review

Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, chapters 701 to 703](#).

9.2. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Review Council members are non-Texas residents.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed conflict of interest as set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, chapters 701 to 703](#).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: An Oversight Committee member, a PIC member, or a Scientific Review Council member.

Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention and Communications Officer, the Chief Product Development Officer, and the Commissioner of the Department of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. Intentional, serious, or frequent violations of

this rule may result in the disqualification of the grant applicant from further consideration for a grant award.

9.3. Review Criteria

Applications will be assessed based on evaluation of the quality of the candidate and his or her potential for development as a clinical investigator. **Also of critical importance is the strength of the institutional commitment to the candidate's career development and the track record of the candidate's mentor(s).**

Review criteria will focus on the overall impression of the candidate and the proposed career development plan, the institution's commitment to the candidate's career development as a clinical investigator, and his or her long-term potential to have an impact on the field of cancer research. Questions to be considered by the reviewers are as follows:

Quality of the Candidate: Has the candidate demonstrated academic excellence? Has the candidate received excellent training as a clinician in a cancer discipline? Does the candidate show exceptional potential for making an impact on cancer research in the future?

Institutional commitment and mentorship plan: Will the candidate have enough time and support to develop as a clinical investigator? Is the mentor(s) and mentorship plan well developed and tailored to guide the candidate to achieve the candidate's career goals?

Relevance of Candidate's career and clinical trials plan: Is the proposed area of focus likely to have a significant impact on reducing the burden of cancer in the near term?

Letters of Recommendation: Do the letters of recommendation detail the candidate's academic and clinical accomplishments, potential for innovation as a clinical investigator, and ability to make a significant contribution to the field of cancer research?

Research Environment: Does the institution have the necessary facilities, expertise, and resources including access to patients to support the candidate's development? Is there evidence of strong institutional support? Will the candidate's administrative/clinical responsibilities be sufficiently limited so that he or she can focus on growing his or her research? Has the institution identified a mentor who will collaborate with the candidate in the design and oversight of a faculty career development plan for the candidate? If correlative studies are proposed, is a

qualified collaborator who is able and willing to participate in the design and conduct of the correlative studies needed identified.

10. KEY DATES

RFA

RFA release August 5, 2020

Application

Online application opens September 16, 2020, 7 AM central time

Application due January 27, 2020, 4 PM central time

Application review January 2021 to August 2021

Award

Award notification August 18, 2021

Anticipated start date August 31, 2021

11. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Awards made under this RFA are not transferable to another institution. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [Texas Administrative Code, Title 25, chapters 701 to 703](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov.

Applicants are advised to review CPRIT's Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [Texas Administrative Code, Title 25, chapters 701 to 703](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, chapters 701 to 703](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals outlined in [section 8.2.4](#) and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. **CPRIT's Academic Research Program staff reviews the progress reports, and continuation of funding is contingent upon demonstration of progress and achievement of the goals set forth in [section 8.2.4](#).** Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. The demonstration of available matching funds must be made at the time the award contract is executed and annually thereafter, not when the application is submitted. Grant applicants are advised to consult CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, chapters 701 to 703](#), for specific requirements regarding the demonstration of available funding.

13. CONTACT INFORMATION

13.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff members are not in a position to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

13.2. Scientific and Programmatic Questions

Questions regarding the CPRIT Program, including questions regarding this or other funding opportunities, should be directed to the CPRIT Senior Program Manager for Academic Research.

Tel: 512-305-8491

Email: Help@CPRITGrants.org

Website: www.cprit.texas.gov

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Cancer Biology
(21.2 AR-CB)
Observation Report

Report No. 2021-05-20 21.2_AR-CB
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Cancer Biology
(21.2_AR-CB)
Panel Date: May 20, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Cancer Biology (21.2_AR-CB) meeting. The meeting was chaired by Peter Jones and conducted via videoconference on May 20, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Eleven (11) applications were discussed and eight (8) applications were not discussed
- Panelists: One (1) panel chair, sixteen (16) expert reviewers, three (3) Ad Hoc reviewers, two (2) advocate reviewers and one (1) Ad Hoc reviewer was not present
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Six (6)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive name that appears to be 'Mara Ash'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Basic Cancer
Research – 1 (21.2 AR-BCR1)
Observation Report

Report No. 2021-05-21 21.2_AR-BCR1
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Basic Cancer Research –
1 (21.2_AR-BCR1)
Panel Date: May 21, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Basic Cancer Research – 1 (21.2_AR-BCR1) meeting. The meeting was chaired by Thomas Curran and conducted via videoconference on May 21, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: nineteen (19) applications were discussed and nineteen (19) applications were not discussed
- Panelists: One (1) panel chair, fourteen (14) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were five (5) Conflicts of Interest (COIs) identified prior to and/or during the meeting. There were three (3) COIs on applications discussed and two (2) COIs on applications not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive 'M' followed by a long horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Clinical and
Translational Cancer Research (21.2 AR-CTCR)
Observation Report

Report No. 2021-05-24 21.2_AR-CTCR
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Clinical and Translational
Cancer Research (21.2_AR-CTCR)
Panel Date: May 24, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Clinical and Translational Cancer Research (21.2_AR-CTCR) meeting. The meeting was chaired by Margaret Tempero and Richard O'Reilly and conducted via videoconference on May 24, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: twenty-one (21) applications were discussed and thirteen (13) applications were not discussed
- Panelists: Two (2) panel chairs, twenty-two (22) expert reviewers, and three (3) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were four (4) Conflicts of Interest (COIs) identified prior to and/or during the meeting. There were three (3) COIs on applications discussed and one (1) COI on an application not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed

additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Basic Cancer
Research – 2 (21.2 AR-BCR2)
Observation Report

Report No. 2021-05-25 21.2_AR-BCR2
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Basic Cancer Research –
2 (21.2_AR-BCR2)
Panel Date: May 25, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Basic Cancer Research – 2 (21.2_AR-BCR2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on May 25, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: sixteen (16) applications were discussed, and eighteen (18) applications were not discussed
- Panelists: One (1) panel chair, fifteen (15) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were five (5) Conflicts of Interest (COIs) identified prior to and/or during the meeting. There were four (4) COIs on applications discussed and one (1) COI on an application not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive name that appears to be 'Mara Ash'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Imaging Technology
and Informatics (21.2 AR-ITI)
Observation Report

Report No. 2021-05-26 21.2_AR-ITI
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Imaging Technology and Informatics (21.2_AR-ITI)
Panel Date: May 26, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Imaging Technology and Informatics (21.2_AR-ITI) meeting. The meeting was chaired by Martin Pomper and conducted via teleconference on May 26, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Thirteen (13) applications were discussed, and thirteen (13) applications were not discussed
- Panelists: One (1) panel chair, nineteen (19) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were three (3) Conflicts of Interest (COIs) identified prior to and/or during the meeting. There were two (2) COIs on applications discussed and one (1) COI on an application not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Cancer Prevention
Research (21.2 AR-CPR)
Observation Report

Report No. 2021-05-27 21.2_AR-CPR
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Cancer Prevention
Research (21.2_AR-CPR)
Panel Date: May 27, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Cancer Prevention Research (21.2_AR-CPR) meeting. The meeting was chaired by Elana Martinez and conducted via teleconference on May 27, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Five (5) applications were discussed and three (3) applications were not discussed
- Panelists: One (1) panel chair, ten (10) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

21.2 Scientific Review Council (21.2 SRC)

Observation Report

Report No. 2021-07-08 21.2_SRC
Program Name: Academic Research
Panel Name: 21.2 Scientific Review Council (21.2_SRC)
Panel Date: July 8, 2021
Report Date: July 16, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is 21.2 Scientific Review Council (21.2_SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on July 8, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: fifty-two (52) applications were discussed
- Panelists: One (1) panel chair and eight (8) reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COIs procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 21.2

Awards Announced at the August 18, 2021, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Cycle 21.2 include *Core Facility Support Awards*; *Clinical Trials Network Award*; *Early Clinical Investigator Awards*; *High-Impact/High Risk Awards*; *Texas Clinical Trials Participation Award*; and *Texas Regional Excellence in Cancer Award*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant/Principal Investigator	Principal Investigator Institution	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
RP210073	Ronald DePinho	The University of Texas M.D. Anderson Cancer Center	N. Bardeesy
RP210102	WEIXING ZHAO	The University of Texas Health Science Center at San Antonio	W. Chazin
RP210208	Stanton McHardy	The University of Texas at San Antonio	A. Tomkinson; W. Chazin; C. Rosenfeld
RP210122	Michael Overman	The University of Texas M.D. Anderson Cancer Center	H. Hochster
RP210075	Jeremy Schraw	Baylor College of Medicine	C. Li
RP210099	Anke Henning	The University of Texas Southwestern Medical Center	A. Wu; R. Berbeco

Application ID	Applicant/Principal Investigator	Principal Investigator Institution	Conflict Noted by Reviewer
RP210105	Alexei Tumanov	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP210236	Zhenpeng Qin	The University of Texas at Dallas	J. Willson
RP210140	Carlos L Arteaga	The University of Texas Southwestern Medical Center	C. Rosenfeld
Applications not considered by the PIC or Oversight Committee:			
RP210154	Charles Reynolds	Texas Tech University Health Sciences Center	Y. DeClerck
RP210215	Wei Wang	University of Houston	X. Chen
RP210113	Yinghong Wang	The University of Texas M.D. Anderson Cancer Center	R. O'Reilly
RP210172	Charles Geyer	The Methodist Hospital Research Institute	H. Hochster
RP210216	Mary Dickinson	Baylor College of Medicine	W. Kast
RP210090	Kenneth Hoyt	The University of Texas at Dallas	K. Zinn
RP210112	Peter Houghton	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP210166	Francis Yoshimoto	The University of Texas at San Antonio	J. Conejo-Garcia
RP210230	Leonidas Bleris	The University of Texas at Dallas	A. Anderson; J. Conejo-Garcia

De-Identified Overall Evaluation Scores

Early Clinical Investigator Awards Academic Research Cycle 21.2

Application ID	Final Overall Evaluation Score
RP210176*	1.0
RP210159*	1.8
RP210164*	2.5
RP210140*	2.6
RP210234*	2.7
la	3.3
lb	3.9
lc	4.0
ld	4.5
le	5.0
lf	5.7

* Recommended for funding

Final Overall Evaluation Scores and Rank Order Scores

Ludwig Institute for
Cancer Research Ltd

Richard D. Kolodner
Ph.D.

Head, Laboratory of
Cancer Genetics
San Diego Branch

Distinguished Professor of
Cellular & Molecular
Medicine, University of
California San Diego School
of Medicine

rkolodner@health.ucsd.edu

San Diego Branch

UC San Diego School of
Medicine
CMM-East / Rm 3058
9500 Gilman Dr - MC 0660
La Jolla, CA 92093-0660

T 858 534 7804
F 858 534 7750

July 21, 2021

Mr. Dee Margo
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dee@deemargo.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Mr. Margo and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for Core Facility Support Awards (CFSA), Clinical Trials Network Awards (CTNA), Early Clinical Investigator Awards (ECI), High-Impact/High Risk Awards (HIHR), Texas Clinical Trials Participation Awards (TCTPA) and Texas Regional Excellence in Cancer Award (TREC).

The SRC met on July 8, 2021 to consider the applications recommended by the peer review panels following their meetings held May 20, 2021 – May 27, 2021.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the applications recommended is \$75,418,344. *Please note that the peer review panels and SRC recommended reduced budgets for applications # RP210180 and #RP210064, the reductions are reflected in the table.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Rank	ID	Mechanism	Score	Application Title	PI	Organization	Rec. Budget
1	RP210227	CFSA	1.0	Proteomics and Metabolomics Core Facility	Edwards, Dean	Baylor College of Medicine	\$3,977,681
2	RP210176	ECI	1.0	CPRIT Early Clinical Investigator Award: Moran Amit	Draetta, Gulio	The University of Texas M. D. Anderson Cancer Center	\$1,499,042
3	RP210208	CFSA	1.1	Center for Innovative Drug Discovery: Expansion of a Highly Productive Shared Cancer Drug Discovery Resource for Texas	McHardy, Stanton	The University of Texas at San Antonio	\$3,087,131
4	RP210143	TCTPA	1.5	Dan L. Duncan Comprehensive Cancer Center (DLDCCC) Harris Health Clinical Trials Financial Support Project	Mims, Martha	Baylor College of Medicine	\$1,500,000
5	RP210165	HIHRRRA	1.6	Rapid Point-of-Care Detection of Ovarian Cancer Biomarkers Using a Common Thermometer for Low-Resource Settings	Li, Xiujun (James)	The University of Texas at El Paso	\$249,999
6	RP210115	TCTPA	1.7	Enhancing Access to and Diversity in Cancer Clinical Trials Through a Financial Reimbursement and Outreach Program	Gerber, David	The University of Texas Southwestern Medical Center	\$1,499,327
7	RP210159	ECI	1.8	CPRIT Early Clinical Investigator Award: Carl Gay	Draetta, Gulio	The University of Texas M. D. Anderson Cancer Center	\$1,499,997

8	RP210088	CFSA	1.9	Targeted Therapeutic Drug Discovery and Development Program	Dalby, Kevin	The University of Texas at Austin	\$3,989,441
9	RP210205	HIHRRA	1.9	Cytokine Factories for the Treatment of Mesothelioma	Veiseh, Omid	Rice University	\$250,000
10	RP210173	HIHRRA	1.9	Multiplex CRISPR Genetic Modeling of Polypharmacology for Precision Medicine	Hart, Traver	The University of Texas M. D. Anderson Cancer Center	\$250,000
11	RP210108	CFSA	2.0	The GCC Microphysiological Lead Optimization and Toxicity Screening Facility	Stephan, Clifford	Texas A&M University System Health Science Center	\$3,973,083
12	RP210144	HIHRRA	2.0	Leveraging Glioma Stem Cell Electrophysiology for Therapy	Rostomily, Robert	The Methodist Hospital Research Institute	\$248,028
13	RP210168	HIHRRA	2.0	Overcoming Myeloma Resistance to Proteasome Inhibitors	Yi, Qing	The Methodist Hospital Research Institute	\$250,000
14	RP210062	HIHRRA	2.0	Protein Degradation of CDK9 for Treatment of Drug-Resistant Mantle Cell Lymphoma	Zhou, Jia	The University of Texas Medical Branch at Galveston	\$250,000
15	RP210154	TREC	2.0	Texas Regional Excellence in Cancer Developmental Therapeutics Center at TTUHSC	Reynolds, Charles	Texas Tech University Health Sciences Center	\$5,999,936
16	RP210073	HIHRRA	2.1	Identification of Collateral Lethal and Synthetic Lethal Targets in	DePinho, Ronald	The University of Texas M. D. Anderson Cancer Center	\$249,994

				Pancreatic and Colorectal Cancers			
17	RP210111	HIHRRRA	2.1	Single-Cell Proteomics to Dissect Intratumor Heterogeneity	Pan, Sheng	The University of Texas Health Science Center at Houston	\$250,000
18	RP210134	HIHRRRA	2.2	High-Throughput Discovery of Anticancer Protein Degradors	Tambar, Uttam	The University of Texas Southwestern Medical Center	\$250,000
19	RP210116	CFSA	2.3	The Genetic Design and Engineering Center (GDEC): A CPRIT Core Facility	Bao, Gang	Rice University	\$4,000,000
20	RP210158	HIHRRRA	2.3	Improving CAR T-Cell Therapy of T-ALL by Cotargeting Additional Antigens	Mamonkin, Maksim	Baylor College of Medicine	\$250,000
21	RP210206	HIHRRRA	2.4	Novel Tumor-Specific Bioactive Nanoparticles for Cancer Therapy	Nguyen, Kytai	The University of Texas at Arlington	\$249,999
22	RP210180	CFSA	2.5	Integrated Cancer Research Core (ICRC)	CHAUHAN, SUBHASH	The University of Texas Rio Grande Valley	*\$2,525,000
23	RP210126	CFSA	2.5	High-Parameter Analysis, Sorting, and Imaging Flow Cytometry Shared Resource	Berton, Michael	The University of Texas Health Science Center at San Antonio	\$3,645,500
24	RP210122	CTNA	2.5	Building a Clinical Trial Network for Texas Community Affiliates	Overman, Michael	The University of Texas M. D. Anderson Cancer Center	\$3,000,000
25	RP210164	ECI	2.5	Early Clinical Investigator Award: William Kelly	Hromas, Robert	The University of Texas Health Science Center at San Antonio	\$1,499,985
26	RP210140	ECI	2.6	Targeting Altered Metabolism in IDH-Mutant Glioma	Arteaga, Carlos	The University of Texas Southwestern Medical Center	\$1,500,000

27	RP210089	HIHRRA	2.6	Dissecting Therapeutic Immunomodulation of Gut Microbiome on Colorectal Cancer	Kim, Hyun Jung	The University of Texas at Austin	\$250,000
28	RP210079	HIHRRA	2.7	Targeting Mitochondrial NAD+ in Leukemias	Cambronne, Xiaolu	The University of Texas at Austin	\$250,000
29	RP210236	HIHRRA	2.7	Magnetomechanical Modulation of Blood-Brain Barrier Permeability	Qin, Zhenpeng	The University of Texas at Dallas	\$250,000
30	RP210234	ECI	2.7	Targeting Src Homology-2 Domain-Containing Phosphatase to Overcome Resistance to Immune Checkpoint Blockade in Pancreatic Ductal Adenocarcinoma	Johnston, Sterling	The University of Texas at Austin	\$1,443,367
31	RP210105	HIHRRA	2.8	Targeting Lymphotoxin Beta Receptor in Sensory Neurons for Control of Chemotherapy-Induced Neuropathic Pain	Tumanov, Alexei	The University of Texas Health Science Center at San Antonio	\$249,996
32	RP210068	HIHRRA	2.8	Role of Aberrant Translational Quality Control in Tumorigenesis of Glioblastoma	Wu, Zhihao	Southern Methodist University	\$249,272
33	RP210102	HIHRRA	2.8	Deciphering BRCA1-BARD1 E3 Ligase Activity in Genome Maintenance and Tumor Suppression	ZHAO, WEIXING	The University of Texas Health Science Center at San Antonio	\$250,000

34	RP210099	CFSA	2.8	North Texas Multimodal Small-Animal Imaging Core Facility	Henning, Anke	The University of Texas Southwestern Medical Center	\$3,999,929
35	RP210137	HIHRRA	2.8	Development of TCR-Based Immunotherapies Targeting Hotspot EGFR Mutations for the Treatment of Non-Small Cell Lung Cancer	Reuben, Alexandre	The University of Texas M. D. Anderson Cancer Center	\$250,000
36	RP210209	CFSA	2.9	North Texas Clinical Pharmacology Cancer Core	Putnam, William	Texas Tech University Health Sciences Center	\$2,965,226
37	RP210092	HIHRRA	3.0	Antibody-Drug Conjugate Combination Treatment for Targeting Colorectal Cancer Cell Plasticity	Carmon, Kendra	The University of Texas Health Science Center at Houston	\$250,000
38	RP210131	HIHRRA	3.0	Antibodylike Therapeutics That Target Polyclonal T Cells to CMV-Positive Glioblastomas	Maynard, Jennifer	The University of Texas at Austin	\$250,000
39	RP210075	HIHRRA	3.0	Exploring the Biological Basis of Ethnic and Social Disparities in Pediatric Acute Lymphoblastic Leukemia Outcomes	Schraw, Jeremy	Baylor College of Medicine	\$249,999
40	RP210199	HIHRRA	3.0	Treating Metastatic Cancer Using Microbubble-Assisted Ultrasound-Guided Immunotherapy of	Lux, Jacques	The University of Texas Southwestern Medical Center	\$249,011

				Cancer of Cancer (MUSIC)			
41	RP210127	HIHRRA	3.0	Engineered Enteric Nerve-Perineural Invasion Models to Improve Predictive Preclinical Screens in Early-Stage Colorectal Adenocarcinoma	Raghavan, Shreya	Texas A&M University	\$250,000
42	RP210148	HIHRRA	3.0	Novel Pharmacodynamic Assay to Predict Response to CDK4/6 Inhibitor Therapy	Trivedi, Meghana	University of Houston	\$250,000
43	RP210119	CFSA	3.1	A Preclinical Development Core for Large-Molecule Therapeutics	Liu, Qingyun	The University of Texas Health Science Center at Houston	\$3,999,999
44	RP210064	CFSA	3.1	The Adolescent and Childhood Cancer Epidemiology and Susceptibility Service (ACCESS) for Texas	Scheurer, Michael	Baylor College of Medicine	*\$4,000,000
45	RP210130	CFSA	3.1	Data Management and Analysis Core for Comparative Effectiveness Research on Cancer in Texas	Kuo, Yong-Fang	The University of Texas Medical Branch at Galveston	\$2,936,731
46	RP210070	HIHRRA	3.1	Tunable Epigenetic Remodeling to Modulate CAR T-Cell-Based Immunotherapy	Zhou, Yubin	Texas A&M University System Health Science Center	\$250,000
47	RP210132	HIHRRA	3.1	Synergy Between Epigenetic Reprogramming and Wnt Inhibition to Enhance	Frost, Jeffrey	The University of Texas Health Science Center at Houston	\$249,999

				Neuroendocrine Tumor Radionuclide Therapy			
48	RP210153	TREC	3.1	UTEP/UTMDACC Partnership for Hispanic Cancer Disparities Research	Cox, Marc	The University of Texas at El Paso	\$5,881,734
49	RP210183	HIHRRA	3.3	Virulence Modulation of <i>Helicobacter pylori</i> , the Strongest Risk Factor for Gastric Cancer	Kearney, Christopher	Baylor University	\$248,938
50	RP210213	HIHRRA	3.3	Therapeutic Inhibition of Cholangiocarcinoma Progression by Targeting Tumor- Lymphatic Cross Talk	Chakraborty, Sanjukta	Texas A&M University System Health Science Center	\$250,000

CFSA = Core Facility Support Awards

CTNA = Clinical Trials Network Award

ECI = Early Clinical Investigator Awards

HIHR = High-Impact/High Risk Awards

TCTPA = Texas Clinical Trials Participation Award

TREC = Texas Regional Excellence in Cancer Award



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research
FY 2021—Cycle 2
*High-Impact/High Risk Awards***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA R-21.2-HIHR

High-Impact/High-Risk Research Awards

**Please also refer to the Instructions for Applicants document,
which will be posted September 16, 2020.**

Applications for this award mechanism are subject to institutional limits.
Applicants are advised to consult with their institution's
Office of Research and Sponsored Programs (or equivalent).

Application Receipt Opening Date: September 16, 2020

Application Receipt Closing Date: January 27, 2021

FY2021

Fiscal Year Award Period

September 1, 2020-August 31, 2021

TABLE OF CONTENTS

1. ABOUT CPRIT	4
1.1. ACADEMIC RESEARCH PROGRAM PRIORITIES	4
2. RATIONALE	5
3. RESEARCH OBJECTIVES	5
4. FUNDING INFORMATION	6
5. ELIGIBILITY	6
6. RESUBMISSION POLICY	8
7. RESPONDING TO THIS RFA	8
7.1. APPLICATION SUBMISSION GUIDELINES	8
7.1.1. <i>Submission Deadline Extension</i>	8
7.2. APPLICATION COMPONENTS	9
7.2.1. <i>Abstract and Significance (5,000 characters)</i>	9
7.2.2. <i>Layperson’s Summary (2,000 characters)</i>	9
7.2.3. <i>Goals and Objectives</i>	9
7.2.4. <i>Timeline (1 page)</i>	9
7.2.5. <i>Resubmission Summary (1 page)</i>	10
7.2.6. <i>Research Plan (4 pages)</i>	10
7.2.7. <i>Vertebrate Animals and/or Human Subjects (2 pages)</i>	10
7.2.8. <i>Publications/References</i>	10
7.2.9. <i>Budget and Justification</i>	10
7.2.10. <i>Biographical Sketches (5 pages each)</i>	11
7.2.11. <i>Current and Pending Support</i>	12
7.2.12. <i>Institutional/Collaborator Support and/or Other Certification (2 pages)</i>	12
7.2.13. <i>Previous Summary Statement</i>	12
7.2.14. <i>Institutional Limits</i>	12
7.3. FORMATTING INSTRUCTIONS	13
8. APPLICATION REVIEW	14
8.1. REVIEW PROCESS OVERVIEW	14
8.2. CONFIDENTIALITY OF REVIEW	14
8.3. REVIEW CRITERIA	15
8.3.1. <i>Primary Criteria</i>	15
8.3.2. <i>Secondary Criteria</i>	16
9. KEY DATES	17
10. AWARD ADMINISTRATION	17
11. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS	18
12. CONTACT INFORMATION	19
12.1. HELPDESK.....	19
12.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS	19

RFA VERSION HISTORY

Rev 08/05/20 RFA release

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of or cures for cancer.
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas.
- Develop and implement the Texas Cancer Plan.

1.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure

The program priorities for academic research adopted by the Oversight Committee include funding projects that address the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions
- Computational biology and analytic methods
- Childhood cancers
- Hepatocellular cancer
- Expansion of access to innovative clinical trials

2. RATIONALE

CPRIT High-Impact/High-Risk (HIHR) Research Awards seek to provide short-term funding to explore the feasibility of high-risk projects that, if successful, would contribute major new insights into the etiology, diagnosis, treatment, or prevention of cancers. Because HIHR Research Awards are designed to support new ideas, preliminary data are not required. Using this mechanism, CPRIT intends to support innovative, developmental projects that focus on exceptionally promising topics that are not yet sufficiently mature to compete successfully for more conventional funding. The HIHR Research Awards are expected to provide the foundation for individual or multiple investigator awards upon completion. Applicants must explain why more conventional sources of support are not available for the proposed research and how short-term funding will lead to strong applications for additional support.

Applications that might be described as “mini-R01s” will not be competitive. **The goal of this award mechanism is to fund uncommonly great ideas that merit the opportunity to acquire preliminary data. There should be reasons for the idea to be plausible, but CPRIT acknowledges that most of the selected projects will ultimately fail to meet their primary goals. The rare proposals that succeed will be of sufficient importance to justify this program.** Applications may address any research topic related to cancer biology, causation, prevention, detection, screening, treatment, or survivorship.

3. RESEARCH OBJECTIVES

Areas of interest include laboratory research, translational studies, and population-based and/or clinical investigations. In that cancers arise from a large number of derangements of basic molecular and cellular functions, which, in turn, cause many alterations in basic biological processes, almost any aspect of biology may be relevant to cancer research, more or less directly. The *degree of relevance* to cancer research will be an important criterion for evaluation of projects for funding by CPRIT ([section 8.3.1](#)). For example, are alterations in the process in question *primarily* responsible for oncogenesis or secondary manifestations of malignant transformation? Will understanding the process or interfering with it offer selective and useful insight into prevention, diagnosis, or treatment of cancer? *Successful applicants for funding from CPRIT will have addressed these questions satisfactorily.*

4. FUNDING INFORMATION

Applicants may request a total of \$250,000 for a period of up to 24 months (2 years), inclusive of both direct and indirect costs. Because of the nature of this funding mechanism, renewal applications will not be accepted. Follow-on applications will not be funded until the time requested for the HIHR Research Award has passed. Award funds may be used to pay for salary and benefits, research supplies, equipment, and clinical costs. Requests for funds for travel to scientific meetings other than the CPRIT biennial conference are not appropriate for this funding mechanism, nor are requests for funds to support construction and/or renovation. State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the total award amount.

5. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution or organization that conducts research is eligible to apply for funding under this award mechanism. A public or private company is also eligible for funding under this award mechanism.
- The Principal Investigator (PI) must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent and reside in Texas for the period of the time that the research that is the subject of the grant application is conducted.
- A PI may submit only 1 new or resubmission application under this RFA during this funding cycle. The PI must commit a minimum 5% level of effort throughout the entire award period.
- One Co-PI may be included. An individual may serve as a Co-PI in more than 1 application but should ensure that he or she could dedicate adequate time and effort should more than 1 application be funded. The Co-PI must reside in Texas for the period of the time that the research that is the subject of the grant application is conducted.
- Collaborations are permitted and encouraged, and collaborators may or may not reside in Texas. However, collaborators who do not reside in Texas are not eligible to receive CPRIT funds. Collaborators should have specific and well-defined roles. Subcontracting and collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.

- An individual may serve as a PI on no more than 3 active Academic Research grants. Recruitment Grants and Research Training Awards do not count toward the 3-grant maximum; however, CPRIT considers project leaders on a MIRA award equivalent to a PI. For the purpose of calculating the number of active grants, CPRIT will consider the number of active grants at the time of the award contract effective date (for this cycle expected to be 8/31/21).
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the PI, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, whether or not those individuals are slated to receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 10](#) and [section 11](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

6. RESUBMISSION POLICY

An application previously submitted to CPRIT but not funded may be resubmitted once and must follow all resubmission guidelines. More than 1 resubmission is not permitted.

7. RESPONDING TO THIS RFA

7.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The PI must create a user account in the system to start and submit an application. The Co-PI, if applicable, must also create a user account to participate in the application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization), and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant contract if an award is made) also must create a user account in CARS. Please refer to the *Instructions for Applicants (IFA)* document for the instructions on adding Co-PIs to an application. The *IFA* document will be available when the application receipt system opens.

Applications will be accepted beginning at 7 AM central time on September 16, 2020 and must be submitted by 4 PM central time on January 27, 2021. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

7.1.1. Submission Deadline Extension

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grants applications will be denied. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

7.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the *Instructions for Applicants* document for details that will be available when the application receipt system opens. Submissions that are missing 1 or more components or that do not meet the eligibility requirements listed in [section 5](#) will be administratively withdrawn without review.

7.2.1. Abstract and Significance (5,000 characters)

Clearly explain the question or problem to be addressed and the approach to its answer or solution. The specific aims of the application must be obvious from the abstract, although they need not be restated verbatim from the research plan. Clearly address how the proposed project, if successful, will have a major impact on the field of cancer research or on the care of patients with cancer. Summarize how the proposed research creates new paradigms or challenges existing ones.

7.2.2. Layperson's Summary (2,000 characters)

Provide a layperson's summary of the proposed work. Describe, in simple, nontechnical terms, the overall goals of the proposed work, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer prevention research, early diagnosis, or treatment. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. Do not include any proprietary information in the layperson's summary. The layperson's summary will also be used by advocate reviewers ([section 8.1](#)) in evaluating the significance and impact of the proposed work.

7.2.3. Goals and Objectives

List specific goals and objectives for each year of the project. These goals and objectives will also be used during the submission and evaluation of progress reports and assessment of project success if the award is made.

7.2.4. Timeline (1 page)

Provide an outline of anticipated major milestones to be tracked. Timelines will be reviewed for reasonableness, and adherence to timelines will be a criterion for continued support of successful

applications. If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

7.2.5. Resubmission Summary (1 page)

An application previously submitted to CPRIT but not funded may be resubmitted **once** after careful consideration of the reasons for lack of prior success. Applicants preparing a resubmission must describe the approach to the resubmission. If a summary statement was prepared for the original application review, applicants are advised to address all noted concerns.

7.2.6. Research Plan (4 pages)

Background: Present the rationale behind the proposed project, emphasizing the pressing problem in cancer research that will be addressed. Preliminary data are not required, but strong reasoning and literature support will obviously enhance the application.

Hypothesis and Specific Aims: Concisely state the hypothesis and/or specific aims to be tested or addressed by the research described in the application.

Research Strategy: Describe the experimental design, including methods, anticipated results, potential problems or pitfalls, and alternative approaches. Preliminary data that support the proposed hypothesis are encouraged but not required.

7.2.7. Vertebrate Animals and/or Human Subjects (2 pages)

If vertebrate animals will be used, provide an outline of the appropriate protocols that will be followed. If human subjects or human biological samples will be used, provide a plan for recruitment of subjects or acquisition of samples that will meet the time constraints of this award mechanism.

7.2.8. Publications/References

Provide a concise and relevant list of publications/references cited for the application.

7.2.9. Budget and Justification

Provide a compelling justification of the budget for the entire proposed period of support, including salaries and benefits, supplies, equipment, patient care costs, animal care costs, and

other expenses. Applications requesting more than \$250,000 (total costs) over a maximum period of 24 months (2 years) will be administratively withdrawn.

In preparing the requested budget, applicants should be aware of the following:

- Major equipment purchases are discouraged for this funding mechanism. Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application.
- Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. So-called grants management and facilities fees (eg, sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees; maintenance fees) may not be requested. Applications that include such budgetary items will be rejected administratively and returned without review.
- The annual salary (also referred to as direct salary or institutional base salary) that an individual may be reimbursed from a CPRIT award is limited to a maximum of \$200,000. In other words, an individual may request salary proportional to the percent of effort up to a maximum of \$200,000. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.
- The PI must commit a minimum 5% level of effort throughout the entire award period.

7.2.10. Biographical Sketches (5 pages each)

Applicants should provide a biographical sketch that describes their education and training, professional experience, awards and honors, and publications relevant to cancer research.

A biographical sketch must be provided for the PI and, if applicable, the Co-PI (as required by the online application receipt system). Up to 2 additional biographical sketches for key personnel may be provided. Each biographical sketch must not exceed 5 pages.

7.2.11. Current and Pending Support

State the funding source and duration of all current and pending support for all personnel who have included a biographical sketch with the application. For each award, provide the title, a 2-line summary of the goal of the project and, if relevant, a statement of overlap with the current application. At a minimum, current and pending support of the PI and, if applicable, the Co-PI must be provided.

7.2.12. Institutional/Collaborator Support and/or Other Certification (2 pages)

Applicants may provide letters of institutional support, collaborator support, and/or other certification documentation relevant to the proposed project. A maximum of 2 pages may be provided.

7.2.13. Previous Summary Statement

If the application is being resubmitted, the summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission. The applicant is not responsible for providing this document.

7.2.14. Institutional Limits

In order to ensure timely and high-quality review of the most innovative and cutting-edge research with the greatest potential for advancement of cancer research, CPRIT is imposing a limit of 5 applications from an academic research institution and 1 each from public or private companies on the number of HIHR Research Award applications that may be submitted by an institution during this review cycle.

The limit on the number of applications may seem restrictive, but experience indicates that truly innovative ideas that are appropriate for this award mechanism are uncommon. CPRIT expects institutions to initiate an internal review process and only authorize submission of the appropriate number of applications that have been rigorously judged to be responsive to this RFA.

Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or that do not meet the eligibility requirements listed above will be administratively withdrawn without review.

7.3. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English
- **Document Format:** PDF only
- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point)
- **Line Spacing:** Single
- **Page Size:** 8.5 x 11 inches
- **Margins:** 0.75 inch, all directions
- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations must be submitted as part of the appropriate submitted document. Applicants should include text to explain illustrations that may be difficult to interpret when printed in black and white.
- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.
- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters are also acceptable as long as the journal information is stated. Include URLs of publications referenced in the application.

Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45–67.
- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants should not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see following point).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be filled out, printed, signed, scanned, and then uploaded in PDF format.

8. APPLICATION REVIEW

8.1. Review Process Overview

All eligible applications will be evaluated using a 2-stage peer review process: (1) Peer review and (2) prioritization of grant applications by the CPRIT Scientific Review Council (SRC). In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts, as well as advocate reviewers, using the criteria listed below. In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT SRC based on comparisons with applications from all of the peer review panels and programmatic priorities. Applications approved by the SRC will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding.

The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

8.2. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, SRC members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and SRC members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT’s Administrative Rules, Texas [Administrative Code, Title 25, chapters 701 to 703.](#)

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant’s behalf) and the following individuals: an Oversight Committee member, a PIC member, a Scientific Review Panel member, or a SRC member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Officer, and the Commissioner of State Health Services.

The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period prior to the opening of CARS. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant applicant from further consideration for a grant award.

8.3. Review Criteria

Peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Review committees will evaluate and score each primary criterion and subsequently assign a global score that reflects an overall assessment of the application. **The overall assessment will not be an average of the scores of individual criteria; rather, it will reflect the reviewers’ overall impression of the application. Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

8.3.1. Primary Criteria

Primary criteria will evaluate the scientific merit and potential impact of the proposed work contained in the application. Concerns with any of these criteria potentially indicate a major flaw in the significance and/or design of the proposed study. Primary criteria include the following:

Significance and Impact: Is the application clearly responsive to the RFA and specifically to the HIHR Research Award mechanism? What is the innovative potential of the project? Does the applicant propose new paradigms or challenge existing ones? Does the project develop state-of-

the-art technologies, methods, tools, or resources for cancer research or address important underexplored or unexplored areas? If the research project is successful, will it lead to truly substantial advances in the field rather than add modest increments of insight? Responsive applications will be highly speculative or exploratory; they need not be based on preliminary data but must have the potential for high scientific payoff because of exceptionally promising ideas.

Research Plan: Is the proposed work presented as a self-contained research project? Does the proposed research have a clearly defined hypothesis or goal that is supported by a sound scientific rationale? Are the methods appropriate, and are potential experimental obstacles and unexpected results discussed?

Applicant Investigator: Does the applicant investigator demonstrate the required creativity, expertise, experience, and accomplishments to make a significant contribution to the research? Applicants' credentials will be evaluated in a career stage-specific fashion. Have early-career-stage investigators received excellent training, and do their accomplishments to date offer great promise for a successful career? Has the applicant devoted a sufficient amount of his or her time (percent effort) to this project?

Relevance: Does the proposed research have a high degree of relevance to cancer? This will be an important criterion for evaluation of projects for CPRIT support.

8.3.2. Secondary Criteria

Secondary criteria contribute to the global score assigned to the application. Concerns with these criteria potentially question the feasibility of the proposed research. Secondary criteria include the following:

Research Environment: Does the research team have the needed expertise, facilities, and resources to accomplish all aspects of the proposed research? Are the levels of effort of the key personnel appropriate? Is there evidence of institutional support of the research team and the project?

Vertebrate Animals and/or Human Subjects: If vertebrate animals and/or human biological samples are included in the proposed research, is the vertebrate animals and/or human subjects plan adequate and sufficiently detailed? Note that certification of approval by the institutional IACUC and/or IRB, as appropriate, will be required before funding can occur.

Budget and Duration: Are the budget and the duration appropriate for the proposed work?

9. KEY DATES

RFA

RFA release August 5, 2020

Application

Online application opens September 16, 2020, 7 AM central time

Application due January 27, 2021, 4 PM central time

Application review January 2021 to August 2021

Award

Award notification August 18, 2021

Anticipated start date August 31, 2021

10. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in Texas [Administrative Code, Title 25, chapters 701 to 703](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. Applicants are advised to review CPRIT's Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in Texas [Administrative Code, Title 25, chapters 701 to 703](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements

set forth in CPRIT's Administrative Rules, Texas [Administrative Code, Title 25, chapters 701 to 703](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate.

Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of award contract. Forms and instructions will be made available at www.cprit.texas.gov.

11. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. The demonstration of available matching funds must be made at the time the award contract is executed and annually thereafter, not when the application is submitted. Grant applicants are advised to consult CPRIT's Administrative Rules, Texas [Administrative Code, Title 25, chapters 701 to 703](#) for specific requirements regarding the demonstration of available funding.

12. CONTACT INFORMATION

12.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

12.2. Scientific and Programmatic Questions

Questions regarding the CPRIT program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Senior Program Manager for Academic Research.

Tel: 512-305-8491

Email: Help@CPRITGrants.org

Website: www.cprit.texas.gov

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Cancer Biology
(21.2 AR-CB)
Observation Report

Report No. 2021-05-20 21.2_AR-CB
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Cancer Biology
(21.2_AR-CB)
Panel Date: May 20, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Cancer Biology (21.2_AR-CB) meeting. The meeting was chaired by Peter Jones and conducted via videoconference on May 20, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Eleven (11) applications were discussed and eight (8) applications were not discussed
- Panelists: One (1) panel chair, sixteen (16) expert reviewers, three (3) Ad Hoc reviewers, two (2) advocate reviewers and one (1) Ad Hoc reviewer was not present
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Six (6)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive name that appears to be 'Mara Ash'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Basic Cancer
Research – 1 (21.2 AR-BCR1)
Observation Report

Report No. 2021-05-21 21.2_AR-BCR1
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Basic Cancer Research –
1 (21.2_AR-BCR1)
Panel Date: May 21, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Basic Cancer Research – 1 (21.2_AR-BCR1) meeting. The meeting was chaired by Thomas Curran and conducted via videoconference on May 21, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: nineteen (19) applications were discussed and nineteen (19) applications were not discussed
- Panelists: One (1) panel chair, fourteen (14) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were five (5) Conflicts of Interest (COIs) identified prior to and/or during the meeting. There were three (3) COIs on applications discussed and two (2) COIs on applications not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive 'M' followed by a long horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Clinical and
Translational Cancer Research (21.2 AR-CTCR)
Observation Report

Report No. 2021-05-24 21.2_AR-CTCR
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Clinical and Translational
Cancer Research (21.2_AR-CTCR)
Panel Date: May 24, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Clinical and Translational Cancer Research (21.2_AR-CTCR) meeting. The meeting was chaired by Margaret Tempero and Richard O'Reilly and conducted via videoconference on May 24, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: twenty-one (21) applications were discussed and thirteen (13) applications were not discussed
- Panelists: Two (2) panel chairs, twenty-two (22) expert reviewers, and three (3) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were four (4) Conflicts of Interest (COIs) identified prior to and/or during the meeting. There were three (3) COIs on applications discussed and one (1) COI on an application not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed

additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive name that appears to be 'Mara Ash'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Basic Cancer
Research – 2 (21.2 AR-BCR2)
Observation Report

Report No. 2021-05-25 21.2_AR-BCR2
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Basic Cancer Research –
2 (21.2_AR-BCR2)
Panel Date: May 25, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Basic Cancer Research – 2 (21.2_AR-BCR2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on May 25, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: sixteen (16) applications were discussed, and eighteen (18) applications were not discussed
- Panelists: One (1) panel chair, fifteen (15) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were five (5) Conflicts of Interest (COIs) identified prior to and/or during the meeting. There were four (4) COIs on applications discussed and one (1) COI on an application not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive 'M' followed by a long horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Imaging Technology
and Informatics (21.2 AR-ITI)
Observation Report

Report No. 2021-05-26 21.2_AR-ITI
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Imaging Technology and Informatics (21.2_AR-ITI)
Panel Date: May 26, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Imaging Technology and Informatics (21.2_AR-ITI) meeting. The meeting was chaired by Martin Pomper and conducted via teleconference on May 26, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Thirteen (13) applications were discussed, and thirteen (13) applications were not discussed
- Panelists: One (1) panel chair, nineteen (19) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were three (3) Conflicts of Interest (COIs) identified prior to and/or during the meeting. There were two (2) COIs on applications discussed and one (1) COI on an application not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Cancer Prevention
Research (21.2 AR-CPR)
Observation Report

Report No. 2021-05-27 21.2_AR-CPR
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Cancer Prevention
Research (21.2_AR-CPR)
Panel Date: May 27, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Cancer Prevention Research (21.2_AR-CPR) meeting. The meeting was chaired by Elana Martinez and conducted via teleconference on May 27, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Five (5) applications were discussed and three (3) applications were not discussed
- Panelists: One (1) panel chair, ten (10) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

21.2 Scientific Review Council (21.2 SRC)

Observation Report

Report No. 2021-07-08 21.2_SRC
Program Name: Academic Research
Panel Name: 21.2 Scientific Review Council (21.2_SRC)
Panel Date: July 8, 2021
Report Date: July 16, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is 21.2 Scientific Review Council (21.2_SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on July 8, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: fifty-two (52) applications were discussed
- Panelists: One (1) panel chair and eight (8) reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COIs procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 21.2

Awards Announced at the August 18, 2021, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Cycle 21.2 include *Core Facility Support Awards*; *Clinical Trials Network Award*; *Early Clinical Investigator Awards*; *High-Impact/High Risk Awards*; *Texas Clinical Trials Participation Award*; and *Texas Regional Excellence in Cancer Award*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant/Principal Investigator	Principal Investigator Institution	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
RP210073	Ronald DePinho	The University of Texas M.D. Anderson Cancer Center	N. Bardeesy
RP210102	WEIXING ZHAO	The University of Texas Health Science Center at San Antonio	W. Chazin
RP210208	Stanton McHardy	The University of Texas at San Antonio	A. Tomkinson; W. Chazin; C. Rosenfeld
RP210122	Michael Overman	The University of Texas M.D. Anderson Cancer Center	H. Hochster
RP210075	Jeremy Schraw	Baylor College of Medicine	C. Li
RP210099	Anke Henning	The University of Texas Southwestern Medical Center	A. Wu; R. Berbeco

Application ID	Applicant/Principal Investigator	Principal Investigator Institution	Conflict Noted by Reviewer
RP210105	Alexei Tumanov	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP210236	Zhenpeng Qin	The University of Texas at Dallas	J. Willson
RP210140	Carlos L Arteaga	The University of Texas Southwestern Medical Center	C. Rosenfeld
Applications not considered by the PIC or Oversight Committee:			
RP210154	Charles Reynolds	Texas Tech University Health Sciences Center	Y. DeClerck
RP210215	Wei Wang	University of Houston	X. Chen
RP210113	Yinghong Wang	The University of Texas M.D. Anderson Cancer Center	R. O'Reilly
RP210172	Charles Geyer	The Methodist Hospital Research Institute	H. Hochster
RP210216	Mary Dickinson	Baylor College of Medicine	W. Kast
RP210090	Kenneth Hoyt	The University of Texas at Dallas	K. Zinn
RP210112	Peter Houghton	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP210166	Francis Yoshimoto	The University of Texas at San Antonio	J. Conejo-Garcia
RP210230	Leonidas Bleris	The University of Texas at Dallas	A. Anderson; J. Conejo-Garcia

De-Identified Overall Evaluation Scores

High-Impact/High Risk Awards

Academic Research Cycle 21.2

Application ID	Final Overall Evaluation Score
RP210165*	1.6
RP210205*	1.9
RP210173*	1.9
RP210144*	2.0
RP210168*	2.0
RP210062*	2.0
RP210073*	2.1
RP210111*	2.1
RP210134*	2.2
RP210158*	2.3
RP210206*	2.4
RP210089*	2.6
RP210079*	2.7
RP210236*	2.7
RP210105*	2.8
RP210068*	2.8
RP210102*	2.8
RP210137*	2.8
RP210092*	3.0
RP210131*	3.0
RP210148*	3.0
RP210127*	3.0
RP210075*	3.0
RP210199*	3.0
RP210070*	3.1
RP210132*	3.1
RP210213*	3.3
RP210183*	3.3
Ja	3.4
Jb	3.5
Jc	3.5
Jd	3.7
Je	3.7
Jf	3.7
Jg	3.7
Jh	3.7
Ji	3.9

* Recommended for funding

Application ID	Final Overall Evaluation Score
Jj	3.9
Jk	3.9
Jl	4.0
Jm	4.0
Jn	4.0
Jo	4.0
Jp	4.0
Jq	4.0
Jr	4.1
Js	4.3
Jt	4.3
Ju	4.3
Jv	4.3
Jw	4.3
Jx	4.3
Jy	4.3
Jz	4.3
Ka	4.3
Kb	4.3
Kc	4.3
Kd	4.4
Ke	4.6
Kf	4.7
Kg	4.7
Kh	4.7
Ki	4.7
Kj	4.7
Kk	4.7
Kl	4.7
Km	4.7
Kn	4.7
Ko	4.7
Kp	4.7
Kq	4.8
Kr	4.9
Ks	5.0
Kt	5.0
Ku	5.0
Kv	5.0
Kw	5.0

* Recommended for funding

Application ID	Final Overall Evaluation Score
Kx	5.3
Ky	5.3
Kz	5.3
La	5.3
Lb	5.7
Lc	5.7
Ld	5.7
Le	5.7
Lf	5.7
Lg	5.7
Lh	5.7
Li	5.7
Lj	5.7
Lk	6.0
Ll	6.0
Lm	6.0
Ln	6.3
Lo	6.3
Lp	6.3
Lq	6.3
Lr	6.3
Ls	6.7
Lt	6.7
Lu	7.3
Lv	7.7
Lw	8.3
Lx	8.7

* Recommended for funding

Final Overall Evaluation Scores and Rank Order Scores

Ludwig Institute for
Cancer Research Ltd

Richard D. Kolodner
Ph.D.

Head, Laboratory of
Cancer Genetics
San Diego Branch

Distinguished Professor of
Cellular & Molecular
Medicine, University of
California San Diego School
of Medicine

rkolodner@health.ucsd.edu

San Diego Branch

UC San Diego School of
Medicine
CMM-East / Rm 3058
9500 Gilman Dr - MC 0660
La Jolla, CA 92093-0660

T 858 534 7804
F 858 534 7750

July 21, 2021

Mr. Dee Margo
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dee@deemargo.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Mr. Margo and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for Core Facility Support Awards (CFSA), Clinical Trials Network Awards (CTNA), Early Clinical Investigator Awards (ECI), High-Impact/High Risk Awards (HIHR), Texas Clinical Trials Participation Awards (TCTPA) and Texas Regional Excellence in Cancer Award (TREC).

The SRC met on July 8, 2021 to consider the applications recommended by the peer review panels following their meetings held May 20, 2021 – May 27, 2021.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the applications recommended is \$75,418,344. *Please note that the peer review panels and SRC recommended reduced budgets for applications # RP210180 and #RP210064, the reductions are reflected in the table.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Rank	ID	Mechanism	Score	Application Title	PI	Organization	Rec. Budget
1	RP210227	CFSA	1.0	Proteomics and Metabolomics Core Facility	Edwards, Dean	Baylor College of Medicine	\$3,977,681
2	RP210176	ECI	1.0	CPRIT Early Clinical Investigator Award: Moran Amit	Draetta, Gulio	The University of Texas M. D. Anderson Cancer Center	\$1,499,042
3	RP210208	CFSA	1.1	Center for Innovative Drug Discovery: Expansion of a Highly Productive Shared Cancer Drug Discovery Resource for Texas	McHardy, Stanton	The University of Texas at San Antonio	\$3,087,131
4	RP210143	TCTPA	1.5	Dan L. Duncan Comprehensive Cancer Center (DLDCCC) Harris Health Clinical Trials Financial Support Project	Mims, Martha	Baylor College of Medicine	\$1,500,000
5	RP210165	HIHRRRA	1.6	Rapid Point-of-Care Detection of Ovarian Cancer Biomarkers Using a Common Thermometer for Low-Resource Settings	Li, Xiujun (James)	The University of Texas at El Paso	\$249,999
6	RP210115	TCTPA	1.7	Enhancing Access to and Diversity in Cancer Clinical Trials Through a Financial Reimbursement and Outreach Program	Gerber, David	The University of Texas Southwestern Medical Center	\$1,499,327
7	RP210159	ECI	1.8	CPRIT Early Clinical Investigator Award: Carl Gay	Draetta, Gulio	The University of Texas M. D. Anderson Cancer Center	\$1,499,997

8	RP210088	CFSA	1.9	Targeted Therapeutic Drug Discovery and Development Program	Dalby, Kevin	The University of Texas at Austin	\$3,989,441
9	RP210205	HIHRRA	1.9	Cytokine Factories for the Treatment of Mesothelioma	Veiseh, Omid	Rice University	\$250,000
10	RP210173	HIHRRA	1.9	Multiplex CRISPR Genetic Modeling of Polypharmacology for Precision Medicine	Hart, Traver	The University of Texas M. D. Anderson Cancer Center	\$250,000
11	RP210108	CFSA	2.0	The GCC Microphysiological Lead Optimization and Toxicity Screening Facility	Stephan, Clifford	Texas A&M University System Health Science Center	\$3,973,083
12	RP210144	HIHRRA	2.0	Leveraging Glioma Stem Cell Electrophysiology for Therapy	Rostomily, Robert	The Methodist Hospital Research Institute	\$248,028
13	RP210168	HIHRRA	2.0	Overcoming Myeloma Resistance to Proteasome Inhibitors	Yi, Qing	The Methodist Hospital Research Institute	\$250,000
14	RP210062	HIHRRA	2.0	Protein Degradation of CDK9 for Treatment of Drug-Resistant Mantle Cell Lymphoma	Zhou, Jia	The University of Texas Medical Branch at Galveston	\$250,000
15	RP210154	TREC	2.0	Texas Regional Excellence in Cancer Developmental Therapeutics Center at TTUHSC	Reynolds, Charles	Texas Tech University Health Sciences Center	\$5,999,936
16	RP210073	HIHRRA	2.1	Identification of Collateral Lethal and Synthetic Lethal Targets in	DePinho, Ronald	The University of Texas M. D. Anderson Cancer Center	\$249,994

				Pancreatic and Colorectal Cancers			
17	RP210111	HIHRRRA	2.1	Single-Cell Proteomics to Dissect Intratumor Heterogeneity	Pan, Sheng	The University of Texas Health Science Center at Houston	\$250,000
18	RP210134	HIHRRRA	2.2	High-Throughput Discovery of Anticancer Protein Degradors	Tambar, Uttam	The University of Texas Southwestern Medical Center	\$250,000
19	RP210116	CFSA	2.3	The Genetic Design and Engineering Center (GDEC): A CPRIT Core Facility	Bao, Gang	Rice University	\$4,000,000
20	RP210158	HIHRRRA	2.3	Improving CAR T-Cell Therapy of T-ALL by Cotargeting Additional Antigens	Mamonkin, Maksim	Baylor College of Medicine	\$250,000
21	RP210206	HIHRRRA	2.4	Novel Tumor-Specific Bioactive Nanoparticles for Cancer Therapy	Nguyen, Kytai	The University of Texas at Arlington	\$249,999
22	RP210180	CFSA	2.5	Integrated Cancer Research Core (ICRC)	CHAUHAN, SUBHASH	The University of Texas Rio Grande Valley	*\$2,525,000
23	RP210126	CFSA	2.5	High-Parameter Analysis, Sorting, and Imaging Flow Cytometry Shared Resource	Berton, Michael	The University of Texas Health Science Center at San Antonio	\$3,645,500
24	RP210122	CTNA	2.5	Building a Clinical Trial Network for Texas Community Affiliates	Overman, Michael	The University of Texas M. D. Anderson Cancer Center	\$3,000,000
25	RP210164	ECI	2.5	Early Clinical Investigator Award: William Kelly	Hromas, Robert	The University of Texas Health Science Center at San Antonio	\$1,499,985
26	RP210140	ECI	2.6	Targeting Altered Metabolism in IDH-Mutant Glioma	Arteaga, Carlos	The University of Texas Southwestern Medical Center	\$1,500,000

27	RP210089	HIHRRA	2.6	Dissecting Therapeutic Immunomodulation of Gut Microbiome on Colorectal Cancer	Kim, Hyun Jung	The University of Texas at Austin	\$250,000
28	RP210079	HIHRRA	2.7	Targeting Mitochondrial NAD+ in Leukemias	Cambronne, Xiaolu	The University of Texas at Austin	\$250,000
29	RP210236	HIHRRA	2.7	Magnetomechanical Modulation of Blood-Brain Barrier Permeability	Qin, Zhenpeng	The University of Texas at Dallas	\$250,000
30	RP210234	ECI	2.7	Targeting Src Homology-2 Domain-Containing Phosphatase to Overcome Resistance to Immune Checkpoint Blockade in Pancreatic Ductal Adenocarcinoma	Johnston, Sterling	The University of Texas at Austin	\$1,443,367
31	RP210105	HIHRRA	2.8	Targeting Lymphotoxin Beta Receptor in Sensory Neurons for Control of Chemotherapy-Induced Neuropathic Pain	Tumanov, Alexei	The University of Texas Health Science Center at San Antonio	\$249,996
32	RP210068	HIHRRA	2.8	Role of Aberrant Translational Quality Control in Tumorigenesis of Glioblastoma	Wu, Zhihao	Southern Methodist University	\$249,272
33	RP210102	HIHRRA	2.8	Deciphering BRCA1-BARD1 E3 Ligase Activity in Genome Maintenance and Tumor Suppression	ZHAO, WEIXING	The University of Texas Health Science Center at San Antonio	\$250,000

34	RP210099	CFSA	2.8	North Texas Multimodal Small-Animal Imaging Core Facility	Henning, Anke	The University of Texas Southwestern Medical Center	\$3,999,929
35	RP210137	HIHRRA	2.8	Development of TCR-Based Immunotherapies Targeting Hotspot EGFR Mutations for the Treatment of Non-Small Cell Lung Cancer	Reuben, Alexandre	The University of Texas M. D. Anderson Cancer Center	\$250,000
36	RP210209	CFSA	2.9	North Texas Clinical Pharmacology Cancer Core	Putnam, William	Texas Tech University Health Sciences Center	\$2,965,226
37	RP210092	HIHRRA	3.0	Antibody-Drug Conjugate Combination Treatment for Targeting Colorectal Cancer Cell Plasticity	Carmon, Kendra	The University of Texas Health Science Center at Houston	\$250,000
38	RP210131	HIHRRA	3.0	Antibodylike Therapeutics That Target Polyclonal T Cells to CMV-Positive Glioblastomas	Maynard, Jennifer	The University of Texas at Austin	\$250,000
39	RP210075	HIHRRA	3.0	Exploring the Biological Basis of Ethnic and Social Disparities in Pediatric Acute Lymphoblastic Leukemia Outcomes	Schraw, Jeremy	Baylor College of Medicine	\$249,999
40	RP210199	HIHRRA	3.0	Treating Metastatic Cancer Using Microbubble-Assisted Ultrasound-Guided Immunotherapy of	Lux, Jacques	The University of Texas Southwestern Medical Center	\$249,011

				Cancer of Cancer (MUSIC)			
41	RP210127	HIHRRA	3.0	Engineered Enteric Nerve-Perineural Invasion Models to Improve Predictive Preclinical Screens in Early-Stage Colorectal Adenocarcinoma	Raghavan, Shreya	Texas A&M University	\$250,000
42	RP210148	HIHRRA	3.0	Novel Pharmacodynamic Assay to Predict Response to CDK4/6 Inhibitor Therapy	Trivedi, Meghana	University of Houston	\$250,000
43	RP210119	CFSA	3.1	A Preclinical Development Core for Large-Molecule Therapeutics	Liu, Qingyun	The University of Texas Health Science Center at Houston	\$3,999,999
44	RP210064	CFSA	3.1	The Adolescent and Childhood Cancer Epidemiology and Susceptibility Service (ACCESS) for Texas	Scheurer, Michael	Baylor College of Medicine	*\$4,000,000
45	RP210130	CFSA	3.1	Data Management and Analysis Core for Comparative Effectiveness Research on Cancer in Texas	Kuo, Yong-Fang	The University of Texas Medical Branch at Galveston	\$2,936,731
46	RP210070	HIHRRA	3.1	Tunable Epigenetic Remodeling to Modulate CAR T-Cell-Based Immunotherapy	Zhou, Yubin	Texas A&M University System Health Science Center	\$250,000
47	RP210132	HIHRRA	3.1	Synergy Between Epigenetic Reprogramming and Wnt Inhibition to Enhance	Frost, Jeffrey	The University of Texas Health Science Center at Houston	\$249,999

				Neuroendocrine Tumor Radionuclide Therapy			
48	RP210153	TREC	3.1	UTEP/UTMDACC Partnership for Hispanic Cancer Disparities Research	Cox, Marc	The University of Texas at El Paso	\$5,881,734
49	RP210183	HIHRRA	3.3	Virulence Modulation of Helicobacter pylori, the Strongest Risk Factor for Gastric Cancer	Kearney, Christopher	Baylor University	\$248,938
50	RP210213	HIHRRA	3.3	Therapeutic Inhibition of Cholangiocarcinoma Progression by Targeting Tumor-Lymphatic Cross Talk	Chakraborty, Sanjukta	Texas A&M University System Health Science Center	\$250,000

CFSA = Core Facility Support Awards
 CTNA = Clinical Trials Network Award
 ECI = Early Clinical Investigator Awards
 HIHR = High-Impact/High Risk Awards
 TCTPA = Texas Clinical Trials Participation Award
 TREC = Texas Regional Excellence in Cancer Award



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research
FY 2021—Cycle 2
*Texas Clinical Trials Participation Award***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA R-21.2-TCTPA

Texas Clinical Trials Participation Program
Award

**Please also refer to the Instructions for Applicants document,
which will be posted on September 16, 2020**

Applications for this award mechanism are subject to institutional limits.
Applicants are advised to consult with their institution's
Office of Research and Sponsored Programs (or equivalent).

Application Receipt Opening Date: September 16, 2020

Application Receipt Closing Date: January 27, 2021

FY 2021

Fiscal Year Award Period

September 1, 2020-August 31, 2021

TABLE OF CONTENTS	RFA VERSION HISTORY	3
1. ABOUT CPRIT		4
1.1. ACADEMIC RESEARCH PROGRAM PRIORITIES		4
2. PURPOSE AND RATIONALE		5
3. PROGRAM COMPONENTS		6
3.1. COMPONENTS RESPONSIVE TO THIS RFA		6
3.2. METRICS OF SUCCESS		7
4. FUNDING INFORMATION		8
5. ELIGIBILITY		9
6. RESUBMISSION POLICY		10
7. RENEWAL POLICY		10
8. RESPONDING TO THIS RFA		10
8.1. APPLICATION SUBMISSION GUIDELINES		10
8.1.1. <i>Submission Deadline Extension</i>		11
8.2. APPLICATION COMPONENTS		11
8.2.1. <i>Abstract and Significance (5,000 characters)</i>		11
8.2.2. <i>Layperson’s Summary (2,000 characters)</i>		12
8.2.3. <i>Goals and Objectives</i>		12
8.2.4. <i>Timeline (1 page)</i>		12
8.2.5. <i>Project Plan (15 pages)</i>		13
8.2.6. <i>Human Subjects (2 pages)</i>		14
8.2.7. <i>Publications/References</i>		14
8.2.8. <i>Budget and Justification</i>		14
8.2.9. <i>Biographical Sketches for Key Personnel (5 pages each)</i>		15
8.2.10. <i>Current and Pending Support State</i>		15
8.2.11. <i>Institutional/Collaborator Support and/or Other Certification (10 pages)</i>		16
8.3. FORMATTING INSTRUCTIONS		16
9. APPLICATION REVIEW		17
9.1. REVIEW PROCESS OVERVIEW		17
9.2. CONFIDENTIALITY OF REVIEW		17
9.3. REVIEW CRITERIA		18
9.3.1. <i>Primary Criteria</i>		19
9.3.2. <i>Secondary Criteria</i>		20
10. KEY DATES		20
11. AWARD ADMINISTRATION		20
12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS		21
13. CONTACT INFORMATION		22
13.1. HELPDESK		22
13.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS		22

RFA VERSION HISTORY

Rev 08/05/20 RFA release

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of or cures for cancer.
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

1.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure

The program priorities for academic research adopted by the Oversight Committee include funding projects that address the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions
- Computational biology and analytic methods
- Childhood cancers
- Hepatocellular cancer
- Expansion of access to innovative clinical trials

2. PURPOSE AND RATIONALE

This RFA solicits applications targeting projects to increase the number and diversity of subjects participating in therapeutic cancer clinical trials in Texas by removing the out-of-pocket expenses related to travel to and from clinics, lodging, meals, and any extra childcare, as a barrier to participation for financially burdened subjects.

Many patients enrolled in clinical trials face a substantial travel burden and associated out-of-pocket expenses that discourage them from participating in clinical trials. While cancer centers, philanthropic organizations, and health systems provide some assistance, eg, ACS Hope Lodge, nonclinical expenses remain a significant barrier to clinical trial participation, particularly for those traveling long distances for cancer care.

To address the financial burden associated with the nonclinical out-of-pocket expenses to clinical trial participation, Massachusetts General Hospital Cancer Center developed the “Cancer Care Equity Program (CCEP).” The goal of the CCEP was to ensure that all patients with cancer have access to the best care possible, regardless of their socioeconomic status. The CCEP consisted of 3 key components: (1) community outreach and education to build awareness of available cancer options, especially clinical trials; (2) patient navigation for cancer screening and diagnosis; and (3) a financial assistance program for clinical trial participants. By assisting with travel and lodging costs, the CCEP was associated with increased trial accrual (Nipp et al, *The Oncologist*. 2016;21:467-474) and reduced financial stress experienced by patients and family (Nipp et al, *The Oncologist*. 2019;24:1048-1055). These findings suggest that nonclinical financial concerns represent a barrier to patient participation in clinical trials and underscore the importance of efforts to address these concerns.

CPRIT is undertaking a **Texas Clinical Trials Participation Program (TCTP)** to demonstrate the impact of removing the nonclinical out-of-pocket expenses related to travel to and from clinics, lodging, meals, and any extra childcare, as barriers to participation in cancer clinical trials for financially burdened subjects. The TCTP Award is conceptually based upon the successful Massachusetts General Hospital Cancer Center’s “Cancer Care Equity Program” concept (described above) and is authorized by a recent state law (HB 3147, 86th Texas Legislature) that allows sponsors of cancer clinical trials to reimburse eligible patients for nonclinical expenses associated with participating a clinical trial, including costs for travel,

lodging, parking and tolls, and other costs considered appropriate by the organization (Texas Health & Safety Code, Subtitle B, Title 2, chapter 50). See the Instructions for Applicants (IFA) for specific details regarding allowable costs.

3. PROGRAM COMPONENTS

This Request for Applications (RFA) solicits applications proposing projects to increase the number and diversity of subjects participating in therapeutic cancer clinical trials in Texas by removing nonclinical financial barriers to participation in cancer clinical trials for financially burdened subjects.

3.1. Components responsive to this RFA

Components responsive to this RFA should include the following:

1. Needs assessment that describes the patient population served by the institution and a baseline that will be used to evaluate impact on clinical trial accrual and financial stress experienced by patients and family members eligible to receive support for nonclinical out-of-pocket expenses. This assessment should include information on the number of patients seen at the institution who live outside the local catchment area (>50 miles from the clinic site).
2. Documentation of a clinical trials program that sponsors therapeutic clinical trials available to the targeted population, including baseline metrics of current accrual of the targeted population from the local catchment and from subjects living greater than 50 miles from the institution to available therapeutic clinical cancer trials and demonstration of the ability to reach the priority population.
3. Description of how the program will identify subjects eligible for reimbursement of nonclinical expenses associated with their participation in a therapeutic cancer clinical trial pursuant to V.T.C.A, Health & Safety Code, Subtitle B, Title 2, chapter 50 (<https://statutes.capitol.texas.gov/Docs/HS/htm/HS.50.v3.htm>). See IFA for specific details.
4. The program should include an overview of the process for assessing and recording the economic eligibility of potential subjects, which must meet the requirements of Texas Health & Safety Code Section 50.0003(a).

5. A plan for how the program will engage collaborating physicians and health care providers to notify prospective subjects about the program.
6. The program should include the calculation that will be utilized to determine funding available per subject and the subject's support person. This reimbursement plan may include the following:
 - (a) Reimbursement to subjects is based on financial need. See IFA for suggested guidelines.
 - (b) Reimbursement of nonclinical expenses such as travel costs, lodging, parking, tolls, and childcare costs to allow for trial participation.
 - (c) Reimbursement of expenses identified above to 1 family member, friend, or other person who attends a cancer clinical trial–related visit to support a subject.
7. A plan to evaluate the impact of the program on the participation of the targeted population in therapeutic clinical trials from both inside and outside of the local catchment area and an assessment of impact of the program on financial stress and quality-of-life measures.

3.2. Metrics of success

Metrics of success include the overall accrual of new patient volume to therapeutic clinical trials over baseline data submitted in original grant application in the following categories:

1. Ability of the program to enroll new patient volume representing economically disadvantaged patients to therapeutic trials.
2. Ability of the program to enroll new patient volume representing diverse ethnicity demographics to therapeutic trials.
3. Ability of the program to enroll new patient volume representing diverse geographic demographics to therapeutic trials.
4. Ability of the program to engage new community physicians over the baseline assessment in the overall project.

4. FUNDING INFORMATION

Applicants may request a maximum of up to \$1,500,000 in total costs for a period of 3 years.

Allowable costs include the following:

- Funds may be used for personnel salary and fringe benefits for the Project Director (PD) and additional support staff required to carry out the program functions.
- The program is **required** to use at least 66% of the total costs to reimburse subjects for nonclinical expenses such as travel costs, lodging, parking, tolls, and childcare costs associated with their participation in a therapeutic cancer clinical trial. Reimbursement for participants must be based on financial need, which may include reimbursement to participants whose income is at or below 700% of the federal poverty level (See the IFA for specific definition and reference).
- The program **may** reimburse reasonable ancillary costs as detailed in Texas Health & Safety Code Section 50.0002 to 1 family member, friend, or other person who attends a cancer clinical trial visit in order to support the subject participating in the clinical trial. See IFA for specific details.

Requests for funds to support major equipment, construction, and/or renovation will not be approved under this funding mechanism.

The program must comply with applicable federal and state laws. Participant reimbursements must be reviewed and approved by the institutional review board associated with the clinical trials for which reimbursements are provided.

State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the total award amount.

Pursuant to V.T.C.A., Health & Safety Code, Subtitle B, Title 2, chapter 50, Section 50.0005, reimbursement of eligible costs under this program do not constitute an inducement and is not considered coercion or the exertion of undue influence to participate in a cancer clinical trial. The reimbursements are meant to accomplish parity in access to cancer clinical trials for financially burdened subjects. See IFA for specific details.

5. ELIGIBILITY

- The applicant must be a Texas-based entity. Institutions, organizations, or other entities (including physician groups) that conduct cancer clinical research are eligible to apply; however, a public or private company operating as a clinical research organization (CRO) is not eligible for funding under this award mechanism.
- The PD must be a full-time resident of Texas at the time the application is submitted and during the entire time the grant is active.
- The designated PD will be responsible for the overall performance of the funded project.
- The evaluation of the project must be headed by a professional who has demonstrated expertise in clinical trials analysis and evaluation and who resides in Texas during the time that the project is conducted.
- This award does not allow a Co-PD.
- An institution or organization may submit only 1 application under this RFA.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the PD, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant PD, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member (view current Oversight Committee members here: <https://cprit.texas.gov/oversight-committee>).
- The applicant must report whether the applicant institution or organization, the PD, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, whether or not those individuals are slated to receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds because of scientific misconduct or fraud or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.

- CPRIT grants are awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. All statutory provisions and relevant administrative rules can be found at <https://cprit.texas.gov/about-us/statute-rules-and-grant-policies-guide/>.

6. RESUBMISSION POLICY

Not applicable as this is a new CPRIT RFA.

7. RENEWAL POLICY

Not applicable as this is a new CPRIT RFA.

8. RESPONDING TO THIS RFA

8.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The PD must create a user account in the system to start and submit an application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant contract if an award is made) also must create a user account in CARS. The *IFA* document will be available when the application receipt system opens. Applications will be accepted beginning at 7 AM central time on September 16, 2020 and must be submitted by 4 PM central time on January 27, 2021. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

8.1.1. Submission Deadline Extension

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grants applications will be denied. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

8.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the *IFA* document for details that will be available when the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 5](#) will be administratively withdrawn without review.

8.2.1. Abstract and Significance (5,000 characters)

Describe the proposed program including a description of the organizational structure, outcomes of a needs assessment, therapeutic clinical trial capabilities and summary of current therapeutic clinical trials available to the program, the methodology and criteria for the selection of patients to be included in the clinical trials, and the unique qualifications that will enable the applicant to meet the requirements described in [section 3](#) for the program. Discuss special assets that the proposed program will bring to the overall mission of the TCTPA Program.

The abstract format is as follows (use headings as outlined below):

- **Need:** Include a description of need in the specific service area. Describe barriers, plans to overcome these barriers, and the priority population to be served.
- **Overall Project Strategy:** Describe the project and how it will address the identified need. Clearly explain what the project is and what it will specifically do, including the services to be provided and the process/system for delivery of services and outreach to the priority population.

- **Specific Goals:** State specifically the overall goals of the proposed project; include the estimated overall numbers of subjects to be enrolled in clinical trials along with the estimated total number of subject support individuals.
- **Significance and Impact:** Explain how the proposed project, if successful, will have a major impact on increasing the number and diversity of subjects enrolled in therapeutic cancer clinical trials.

8.2.2. Layperson’s Summary (2,000 characters)

Provide a layperson’s summary of the proposed program including description of the clinical trial sites and patient population served. Describe, in simple, nontechnical terms, how the program will facilitate access to clinical trials, the type(s) of trials proposed for the program, and the expected impact on patient access to clinical trials and the expected number and diversity of patents being accrued. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. Do not include any proprietary information in the layperson’s summary. The layperson’s summary will also be used by advocate reviewers ([section 9.1](#)) in evaluating the significance and impact of the proposed work.

8.2.3. Goals and Objectives

List specific goals and objectives for each year of the award. These goals and objectives will also be used in the initial assessment of the program and in the evaluation of annual progress reports if the award is made. A baseline and method(s) of measurement are required for each objective. Provide both raw numbers and percent changes for the baseline and target. If a baseline has not been defined, applicants are required to explain plans to establish baseline and describe method(s) of measurement.

8.2.4. Timeline (1 page)

Provide an outline (chart) of anticipated major milestones to be tracked in the implementation and evaluation of the program. Timelines will be reviewed for reasonableness, and adherence to timelines will be a criterion for continued support of successful applications.

If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

8.2.5. Project Plan (15 pages)

Background: Present the rationale behind the proposed services, emphasizing the critical barriers to current service delivery that will be addressed. Identify the service to be implemented for the priority population. Describe the race, ethnicity, age, economic status, and other defining characteristics of the population to be served. Describe the needs assessment process and assessment outcomes and detail how the assessment will be utilized for benchmarking, implementation, and evaluative purposes. Demonstrate the project's access to participating cancer centers or community oncology clinical trials. Include provider(s), partnerships, and agreements (via memoranda of understanding) or commitments (via letters of commitment).

Describe the organization and its track record and success in facilitating an increase in the number and diversity of subjects enrolled in clinical trials. Describe the institution and its commitment to the program, including a description of the catchment areas, the organizational capabilities and clinical research portfolio, and the institution's overall commitment to the award. An institutional letter of support is required.

Goals and Objectives: Concisely *state* the goals and objective of the project. List specific goals and objectives for each year of the project. These goals and objectives will also be used during the submission and evaluation of progress reports and assessment of project success if the award is made. It is expected that steps toward building capacity for the program will be taken and plans for such be briefly described in the application. The applicant should describe the factors that will contribute to the organization's capacity to facilitate sustainability.

Operations Strategy: Discuss how the program will identify, enroll, and reimburse subjects.

- Based on a completed needs assessment, identify the expected number of subjects eligible to participate in the program from the institution's local catchment and the number of the subjects expected to be enrolled who live greater than 50 miles from the clinical trial point of service.

- Discuss plans for use of patient navigators in the recruitment and monitoring of subjects in the program.
- Discuss the process that will be used to validate and reimburse allowable expenses.

Evaluation Strategy: A strong commitment to evaluation of the project is required. Detail the evaluative plan for measuring the program’s impact on increasing the number and diversity of the targeted population into therapeutic clinical trials. Describe data collection and management methods, data analyses, and anticipated results.

8.2.6. Human Subjects (2 pages)

Use this section to provide any additional details that may have not been covered in the description of the program. Certification of approval of these plans by the institutional IRB will be required before funding can occur.

8.2.7. Publications/References

Provide a concise and relevant list of publications/references cited for the application.

8.2.8. Budget and Justification

Provide a compelling and clear justification of the budget, demonstrating the need for the entire proposed period of support, including salaries and benefits, projected per capita costs of enrolling patients into therapeutic clinical trials and associated costs based on the established baseline assessment, as well as costs associated with the analysis and evaluation component of the project. Applicants may request a maximum up to \$1,500,000 in total costs for a period of 3 years.

Up to one-third of the total budget may be used to support program leadership, patient navigation, administrative costs for reimbursement of subjects, and program evaluation.

Two-thirds of the total costs must be used to reimburse allowable costs. As a guide, the average out-of-pocket expenses of clinical trial participants in similar programs who live locally was \$190/visit or \$2,280 annually (assuming 1 visit/month). When a patient must travel beyond local catchment (> 50 miles) but has no travel companion, the average visit was \$400/visit or \$4,800 annually. When a patient travels beyond local catchment but requires a travel companion (32% of patients request a travel companion), the average visit was \$475/visit or \$5,100 annually.*

Note that patient care costs associated with the conduct of a clinical trial are not appropriate for this mechanism.

Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in CPRIT's Administrative Rules, which are available at www.cpriti.texas.gov. So-called grants management and facilities fees (eg, sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees; maintenance fees) may not be requested. Applications that include such budgetary items will be rejected administratively and returned without review.

The annual salary (also referred to as direct salary or institutional base salary) that an individual may be reimbursed from a CPRIT award is limited to a maximum of \$200,000. In other words, an individual may request salary proportional to the percent of effort up to a maximum of \$200,000. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, subject care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.

*Data based on Lazarex Cancer Foundation historical averages.

8.2.9. Biographical Sketches for Key Personnel (5 pages each)

Up to 5 biographical sketches including that of the Program PD and key personnel may be provided. Each individual biographical sketch must not exceed 5 pages. The NIH biosketch format is recommended.

8.2.10. Current and Pending Support State

Describe the funding source and duration of all current and pending support for the PD and all personnel who have included a biographical sketch with the application. For each award, provide the title, a 2-line summary of the goal of the project, and, if relevant, a statement of overlap with the current application. At a minimum, current and pending support of the PD and key personnel must be provided.

8.2.11. Institutional/Collaborator Support and/or Other Certification (10 pages)

As outlined in [section 8.2.5](#), applicants are required to provide letters of institutional support, collaborator support, and/or other certification documentation relevant to the proposed program. A maximum of 10 pages for all letters may be provided.

Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or that do not meet the eligibility requirements listed above will be administratively withdrawn without review.

8.3. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English
- **Document Format:** PDF only
- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point)
- **Line Spacing:** Single
- **Page Size:** 8.5 x 11 inches
- **Margins:** 0.75 inch, all directions
- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations must be submitted as part of the appropriate submitted document. Applicants should include text to explain illustrations that may be difficult to interpret when printed in black and white.
- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.
- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters are also acceptable as long as the journal information is stated. Include URLs of publications referenced in the application.

Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45–67.

- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants should not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see following point).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be filled out, printed, signed, scanned, and then uploaded in PDF format.

9. APPLICATION REVIEW

9.1. Review Process Overview

All eligible applications will be evaluated using a 2-stage peer review process: (1) Peer review and (2) prioritization of grant applications by the CPRIT Scientific Review Council (SRC). In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts, as well as advocate reviewers, using the criteria listed below. In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT SRC based on comparisons with applications from all of the peer review panels and programmatic priorities. Applications approved by the SRC will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, chapters 701 to 703.](#)

9.2. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, SRC members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign

nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and SRC members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website. **By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, chapters 701 to 703.](#)**

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, a Scientific Review Panel member, or an SRC member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period prior to the opening of CARS. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

9.3. Review Criteria

Peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Review committees will evaluate and score each primary criterion and subsequently assign a global score that reflects an overall assessment of the application. **The overall assessment will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application. Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

9.3.1. Primary Criteria

Primary criteria will evaluate the scientific merit and potential impact of the proposed work contained in the application. Concerns with any of these criteria potentially indicate a major flaw in the significance and/or design of the proposed study. Primary criteria include the following:

Significance and Impact: Will the proposed project expand patient access and geographic proximity to innovative clinical trials? Will the propose program increase the socioeconomic diversity of the patients participating in the applicant’s clinical trials portfolio?

Research Plan: Is the plan based upon a well-described need’s assessment? Does the plan for the proposed project document a process for rapid and efficient access to clinical trials, and does the plan incorporate best practices to ensure timely clinical treatment decisions and the output of high-quality data? Does the applicant have a well-defined plan and an appropriate governance structure to coordinate activities related to the project? Does the plan demonstrate the potential to overcome critical barriers for robust accrual to advance progress in the field? Does the applicant institution have a history of timely activation of clinical trials? Are infrastructure and policies in place to support accrual to clinical trials? Does the institution have active programs to recruit minorities and underserved patient populations to clinical trials? Does the plan include a robust evaluation process? Is the environment and setting of the proposed project adequate to support a robust clinical trial program where 15% of new patients seen will be eligible to enroll on trials?

Technical Expertise: Is there sufficient technical expertise to carry out the duties of the program?

Institutional Commitment: Is there demonstrated strong institutional commitment for support of the program?

Applicant Project Director: Does the applicant Project Director demonstrate the required expertise and experience to lead the project? Has the applicant devoted enough of his or her time (percent effort) to this project?

Relevance: Does the proposed research have a high degree of relevance to cancer research? This is a critical criterion for evaluation of projects for CPRIT support.

9.3.2. Secondary Criteria

Secondary criteria contribute to the global score assigned to the application. Concerns with these criteria potentially question the feasibility of the proposed research.

Secondary criteria include the following:

Research Environment: Does the research team have the needed expertise, facilities, and resources to accomplish all aspects of the project? Are the levels of effort of the key personnel appropriate? Is there evidence of institutional support?

Budget: Is the budget appropriate for the proposed work?

Duration: Is the stated duration appropriate for the proposed work?

10. KEY DATES

RFA

RFA release August 5, 2020

Application

Online application opens September 16, 2020, 7 AM central time

Application due January 27, 2021, 4 PM central time

Application review January 2021 to August 2021

Award

Award notification August 18, 2021

Anticipated start date August 31, 2021

11. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports.

Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. Applicants are advised to review CPRIT's Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals documented in the grant award contract and address plans for the upcoming year. In addition, fiscal reporting and human studies reporting will be required as appropriate.

CPRIT will review annual progress reports and continuation of funding is contingent upon the timely receipt of these reports and documentation of sufficient progress toward completing project goals. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of award contract. Forms and instructions will be made available at www.cprit.texas.gov.

12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. The demonstration of available matching funds must be made at the time the award contract is executed, and annually thereafter, not when the application is submitted. Grant applicants are advised to consult CPRIT's Administrative Rules, [chapter 703, section 703.11](#), for specific requirements regarding demonstration of available funding.

13. CONTACT INFORMATION

13.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

13.2. Scientific and Programmatic Questions

Questions regarding the CPRIT program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Senior Program Manager for Academic Research.

Tel: 512-305-8491

Email: Help@CPRITGrants.org

Website: www.cprit.texas.gov

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Cancer Biology
(21.2 AR-CB)
Observation Report

Report No. 2021-05-20 21.2_AR-CB
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Cancer Biology
(21.2_AR-CB)
Panel Date: May 20, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Cancer Biology (21.2_AR-CB) meeting. The meeting was chaired by Peter Jones and conducted via videoconference on May 20, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Eleven (11) applications were discussed and eight (8) applications were not discussed
- Panelists: One (1) panel chair, sixteen (16) expert reviewers, three (3) Ad Hoc reviewers, two (2) advocate reviewers and one (1) Ad Hoc reviewer was not present
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Six (6)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Basic Cancer
Research – 1 (21.2 AR-BCR1)
Observation Report

Report No. 2021-05-21 21.2_AR-BCR1
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Basic Cancer Research –
1 (21.2_AR-BCR1)
Panel Date: May 21, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Basic Cancer Research – 1 (21.2_AR-BCR1) meeting. The meeting was chaired by Thomas Curran and conducted via videoconference on May 21, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: nineteen (19) applications were discussed and nineteen (19) applications were not discussed
- Panelists: One (1) panel chair, fourteen (14) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were five (5) Conflicts of Interest (COIs) identified prior to and/or during the meeting. There were three (3) COIs on applications discussed and two (2) COIs on applications not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive 'M' followed by a long horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Clinical and
Translational Cancer Research (21.2 AR-CTCR)
Observation Report

Report No. 2021-05-24 21.2_AR-CTCR
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Clinical and Translational
Cancer Research (21.2_AR-CTCR)
Panel Date: May 24, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Clinical and Translational Cancer Research (21.2_AR-CTCR) meeting. The meeting was chaired by Margaret Tempero and Richard O'Reilly and conducted via videoconference on May 24, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: twenty-one (21) applications were discussed and thirteen (13) applications were not discussed
- Panelists: Two (2) panel chairs, twenty-two (22) expert reviewers, and three (3) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were four (4) Conflicts of Interest (COIs) identified prior to and/or during the meeting. There were three (3) COIs on applications discussed and one (1) COI on an application not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed

additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive name that appears to be 'Mara Ash'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Basic Cancer
Research – 2 (21.2 AR-BCR2)
Observation Report

Report No. 2021-05-25 21.2_AR-BCR2
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Basic Cancer Research –
2 (21.2_AR-BCR2)
Panel Date: May 25, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Basic Cancer Research – 2 (21.2_AR-BCR2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on May 25, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: sixteen (16) applications were discussed, and eighteen (18) applications were not discussed
- Panelists: One (1) panel chair, fifteen (15) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were five (5) Conflicts of Interest (COIs) identified prior to and/or during the meeting. There were four (4) COIs on applications discussed and one (1) COI on an application not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive name that appears to be 'Mara Ash'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Imaging Technology
and Informatics (21.2 AR-ITI)
Observation Report

Report No. 2021-05-26 21.2_AR-ITI
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Imaging Technology and Informatics (21.2_AR-ITI)
Panel Date: May 26, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Imaging Technology and Informatics (21.2_AR-ITI) meeting. The meeting was chaired by Martin Pomper and conducted via teleconference on May 26, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Thirteen (13) applications were discussed, and thirteen (13) applications were not discussed
- Panelists: One (1) panel chair, nineteen (19) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were three (3) Conflicts of Interest (COIs) identified prior to and/or during the meeting. There were two (2) COIs on applications discussed and one (1) COI on an application not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive name that appears to be 'Mara Ash'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Cancer Prevention
Research (21.2 AR-CPR)
Observation Report

Report No. 2021-05-27 21.2_AR-CPR
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Cancer Prevention
Research (21.2_AR-CPR)
Panel Date: May 27, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Cancer Prevention Research (21.2_AR-CPR) meeting. The meeting was chaired by Elana Martinez and conducted via teleconference on May 27, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Five (5) applications were discussed and three (3) applications were not discussed
- Panelists: One (1) panel chair, ten (10) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

21.2 Scientific Review Council (21.2 SRC)

Observation Report

Report No. 2021-07-08 21.2_SRC
Program Name: Academic Research
Panel Name: 21.2 Scientific Review Council (21.2_SRC)
Panel Date: July 8, 2021
Report Date: July 16, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is 21.2 Scientific Review Council (21.2_SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on July 8, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: fifty-two (52) applications were discussed
- Panelists: One (1) panel chair and eight (8) reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COIs procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 21.2

Awards Announced at the August 18, 2021, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Cycle 21.2 include *Core Facility Support Awards*; *Clinical Trials Network Award*; *Early Clinical Investigator Awards*; *High-Impact/High Risk Awards*; *Texas Clinical Trials Participation Award*; and *Texas Regional Excellence in Cancer Award*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant/Principal Investigator	Principal Investigator Institution	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
RP210073	Ronald DePinho	The University of Texas M.D. Anderson Cancer Center	N. Bardeesy
RP210102	WEIXING ZHAO	The University of Texas Health Science Center at San Antonio	W. Chazin
RP210208	Stanton McHardy	The University of Texas at San Antonio	A. Tomkinson; W. Chazin; C. Rosenfeld
RP210122	Michael Overman	The University of Texas M.D. Anderson Cancer Center	H. Hochster
RP210075	Jeremy Schraw	Baylor College of Medicine	C. Li
RP210099	Anke Henning	The University of Texas Southwestern Medical Center	A. Wu; R. Berbeco

Application ID	Applicant/Principal Investigator	Principal Investigator Institution	Conflict Noted by Reviewer
RP210105	Alexei Tumanov	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP210236	Zhenpeng Qin	The University of Texas at Dallas	J. Willson
RP210140	Carlos L Arteaga	The University of Texas Southwestern Medical Center	C. Rosenfeld
Applications not considered by the PIC or Oversight Committee:			
RP210154	Charles Reynolds	Texas Tech University Health Sciences Center	Y. DeClerck
RP210215	Wei Wang	University of Houston	X. Chen
RP210113	Yinghong Wang	The University of Texas M.D. Anderson Cancer Center	R. O'Reilly
RP210172	Charles Geyer	The Methodist Hospital Research Institute	H. Hochster
RP210216	Mary Dickinson	Baylor College of Medicine	W. Kast
RP210090	Kenneth Hoyt	The University of Texas at Dallas	K. Zinn
RP210112	Peter Houghton	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP210166	Francis Yoshimoto	The University of Texas at San Antonio	J. Conejo-Garcia
RP210230	Leonidas Bleris	The University of Texas at Dallas	A. Anderson; J. Conejo-Garcia

De-Identified Overall Evaluation Scores

Texas Clinical Trials Participation Award

Academic Research Cycle 21.2

Application ID	Final Overall Evaluation Score
RP210143*	1.5
RP210115*	1.7
Ma	4.0
Mb	5.3

* Recommended for funding

Final Overall Evaluation Scores and Rank Order Scores

Ludwig Institute for
Cancer Research Ltd

Richard D. Kolodner
Ph.D.

Head, Laboratory of
Cancer Genetics
San Diego Branch

Distinguished Professor of
Cellular & Molecular
Medicine, University of
California San Diego School
of Medicine

rkolodner@health.ucsd.edu

San Diego Branch

UC San Diego School of
Medicine
CMM-East / Rm 3058
9500 Gilman Dr - MC 0660
La Jolla, CA 92093-0660

T 858 534 7804
F 858 534 7750

July 21, 2021

Mr. Dee Margo
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dee@deemargo.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Mr. Margo and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for Core Facility Support Awards (CFSA), Clinical Trials Network Awards (CTNA), Early Clinical Investigator Awards (ECI), High-Impact/High Risk Awards (HIHR), Texas Clinical Trials Participation Awards (TCTPA) and Texas Regional Excellence in Cancer Award (TREC).

The SRC met on July 8, 2021 to consider the applications recommended by the peer review panels following their meetings held May 20, 2021 – May 27, 2021.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the applications recommended is \$75,418,344. *Please note that the peer review panels and SRC recommended reduced budgets for applications # RP210180 and #RP210064, the reductions are reflected in the table.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Rank	ID	Mechanism	Score	Application Title	PI	Organization	Rec. Budget
1	RP210227	CFSA	1.0	Proteomics and Metabolomics Core Facility	Edwards, Dean	Baylor College of Medicine	\$3,977,681
2	RP210176	ECI	1.0	CPRIT Early Clinical Investigator Award: Moran Amit	Draetta, Gulio	The University of Texas M. D. Anderson Cancer Center	\$1,499,042
3	RP210208	CFSA	1.1	Center for Innovative Drug Discovery: Expansion of a Highly Productive Shared Cancer Drug Discovery Resource for Texas	McHardy, Stanton	The University of Texas at San Antonio	\$3,087,131
4	RP210143	TCTPA	1.5	Dan L. Duncan Comprehensive Cancer Center (DLDCCC) Harris Health Clinical Trials Financial Support Project	Mims, Martha	Baylor College of Medicine	\$1,500,000
5	RP210165	HIHRRRA	1.6	Rapid Point-of-Care Detection of Ovarian Cancer Biomarkers Using a Common Thermometer for Low-Resource Settings	Li, Xiujun (James)	The University of Texas at El Paso	\$249,999
6	RP210115	TCTPA	1.7	Enhancing Access to and Diversity in Cancer Clinical Trials Through a Financial Reimbursement and Outreach Program	Gerber, David	The University of Texas Southwestern Medical Center	\$1,499,327
7	RP210159	ECI	1.8	CPRIT Early Clinical Investigator Award: Carl Gay	Draetta, Gulio	The University of Texas M. D. Anderson Cancer Center	\$1,499,997

8	RP210088	CFSA	1.9	Targeted Therapeutic Drug Discovery and Development Program	Dalby, Kevin	The University of Texas at Austin	\$3,989,441
9	RP210205	HIHRRA	1.9	Cytokine Factories for the Treatment of Mesothelioma	Veiseh, Omid	Rice University	\$250,000
10	RP210173	HIHRRA	1.9	Multiplex CRISPR Genetic Modeling of Polypharmacology for Precision Medicine	Hart, Traver	The University of Texas M. D. Anderson Cancer Center	\$250,000
11	RP210108	CFSA	2.0	The GCC Microphysiological Lead Optimization and Toxicity Screening Facility	Stephan, Clifford	Texas A&M University System Health Science Center	\$3,973,083
12	RP210144	HIHRRA	2.0	Leveraging Glioma Stem Cell Electrophysiology for Therapy	Rostomily, Robert	The Methodist Hospital Research Institute	\$248,028
13	RP210168	HIHRRA	2.0	Overcoming Myeloma Resistance to Proteasome Inhibitors	Yi, Qing	The Methodist Hospital Research Institute	\$250,000
14	RP210062	HIHRRA	2.0	Protein Degradation of CDK9 for Treatment of Drug-Resistant Mantle Cell Lymphoma	Zhou, Jia	The University of Texas Medical Branch at Galveston	\$250,000
15	RP210154	TREC	2.0	Texas Regional Excellence in Cancer Developmental Therapeutics Center at TTUHSC	Reynolds, Charles	Texas Tech University Health Sciences Center	\$5,999,936
16	RP210073	HIHRRA	2.1	Identification of Collateral Lethal and Synthetic Lethal Targets in	DePinho, Ronald	The University of Texas M. D. Anderson Cancer Center	\$249,994

				Pancreatic and Colorectal Cancers			
17	RP210111	HIHRRRA	2.1	Single-Cell Proteomics to Dissect Intratumor Heterogeneity	Pan, Sheng	The University of Texas Health Science Center at Houston	\$250,000
18	RP210134	HIHRRRA	2.2	High-Throughput Discovery of Anticancer Protein Degradors	Tambar, Uttam	The University of Texas Southwestern Medical Center	\$250,000
19	RP210116	CFSA	2.3	The Genetic Design and Engineering Center (GDEC): A CPRIT Core Facility	Bao, Gang	Rice University	\$4,000,000
20	RP210158	HIHRRRA	2.3	Improving CAR T-Cell Therapy of T-ALL by Cotargeting Additional Antigens	Mamonkin, Maksim	Baylor College of Medicine	\$250,000
21	RP210206	HIHRRRA	2.4	Novel Tumor-Specific Bioactive Nanoparticles for Cancer Therapy	Nguyen, Kytai	The University of Texas at Arlington	\$249,999
22	RP210180	CFSA	2.5	Integrated Cancer Research Core (ICRC)	CHAUHAN, SUBHASH	The University of Texas Rio Grande Valley	*\$2,525,000
23	RP210126	CFSA	2.5	High-Parameter Analysis, Sorting, and Imaging Flow Cytometry Shared Resource	Berton, Michael	The University of Texas Health Science Center at San Antonio	\$3,645,500
24	RP210122	CTNA	2.5	Building a Clinical Trial Network for Texas Community Affiliates	Overman, Michael	The University of Texas M. D. Anderson Cancer Center	\$3,000,000
25	RP210164	ECI	2.5	Early Clinical Investigator Award: William Kelly	Hromas, Robert	The University of Texas Health Science Center at San Antonio	\$1,499,985
26	RP210140	ECI	2.6	Targeting Altered Metabolism in IDH-Mutant Glioma	Arteaga, Carlos	The University of Texas Southwestern Medical Center	\$1,500,000

27	RP210089	HIHRRA	2.6	Dissecting Therapeutic Immunomodulation of Gut Microbiome on Colorectal Cancer	Kim, Hyun Jung	The University of Texas at Austin	\$250,000
28	RP210079	HIHRRA	2.7	Targeting Mitochondrial NAD+ in Leukemias	Cambronne, Xiaolu	The University of Texas at Austin	\$250,000
29	RP210236	HIHRRA	2.7	Magnetomechanical Modulation of Blood-Brain Barrier Permeability	Qin, Zhenpeng	The University of Texas at Dallas	\$250,000
30	RP210234	ECI	2.7	Targeting Src Homology-2 Domain-Containing Phosphatase to Overcome Resistance to Immune Checkpoint Blockade in Pancreatic Ductal Adenocarcinoma	Johnston, Sterling	The University of Texas at Austin	\$1,443,367
31	RP210105	HIHRRA	2.8	Targeting Lymphotoxin Beta Receptor in Sensory Neurons for Control of Chemotherapy-Induced Neuropathic Pain	Tumanov, Alexei	The University of Texas Health Science Center at San Antonio	\$249,996
32	RP210068	HIHRRA	2.8	Role of Aberrant Translational Quality Control in Tumorigenesis of Glioblastoma	Wu, Zhihao	Southern Methodist University	\$249,272
33	RP210102	HIHRRA	2.8	Deciphering BRCA1-BARD1 E3 Ligase Activity in Genome Maintenance and Tumor Suppression	ZHAO, WEIXING	The University of Texas Health Science Center at San Antonio	\$250,000

34	RP210099	CFSA	2.8	North Texas Multimodal Small-Animal Imaging Core Facility	Henning, Anke	The University of Texas Southwestern Medical Center	\$3,999,929
35	RP210137	HIHRRA	2.8	Development of TCR-Based Immunotherapies Targeting Hotspot EGFR Mutations for the Treatment of Non-Small Cell Lung Cancer	Reuben, Alexandre	The University of Texas M. D. Anderson Cancer Center	\$250,000
36	RP210209	CFSA	2.9	North Texas Clinical Pharmacology Cancer Core	Putnam, William	Texas Tech University Health Sciences Center	\$2,965,226
37	RP210092	HIHRRA	3.0	Antibody-Drug Conjugate Combination Treatment for Targeting Colorectal Cancer Cell Plasticity	Carmon, Kendra	The University of Texas Health Science Center at Houston	\$250,000
38	RP210131	HIHRRA	3.0	Antibodylike Therapeutics That Target Polyclonal T Cells to CMV-Positive Glioblastomas	Maynard, Jennifer	The University of Texas at Austin	\$250,000
39	RP210075	HIHRRA	3.0	Exploring the Biological Basis of Ethnic and Social Disparities in Pediatric Acute Lymphoblastic Leukemia Outcomes	Schraw, Jeremy	Baylor College of Medicine	\$249,999
40	RP210199	HIHRRA	3.0	Treating Metastatic Cancer Using Microbubble-Assisted Ultrasound-Guided Immunotherapy of	Lux, Jacques	The University of Texas Southwestern Medical Center	\$249,011

				Cancer of Cancer (MUSIC)			
41	RP210127	HIHRRA	3.0	Engineered Enteric Nerve-Perineural Invasion Models to Improve Predictive Preclinical Screens in Early-Stage Colorectal Adenocarcinoma	Raghavan, Shreya	Texas A&M University	\$250,000
42	RP210148	HIHRRA	3.0	Novel Pharmacodynamic Assay to Predict Response to CDK4/6 Inhibitor Therapy	Trivedi, Meghana	University of Houston	\$250,000
43	RP210119	CFSA	3.1	A Preclinical Development Core for Large-Molecule Therapeutics	Liu, Qingyun	The University of Texas Health Science Center at Houston	\$3,999,999
44	RP210064	CFSA	3.1	The Adolescent and Childhood Cancer Epidemiology and Susceptibility Service (ACCESS) for Texas	Scheurer, Michael	Baylor College of Medicine	*\$4,000,000
45	RP210130	CFSA	3.1	Data Management and Analysis Core for Comparative Effectiveness Research on Cancer in Texas	Kuo, Yong-Fang	The University of Texas Medical Branch at Galveston	\$2,936,731
46	RP210070	HIHRRA	3.1	Tunable Epigenetic Remodeling to Modulate CAR T-Cell-Based Immunotherapy	Zhou, Yubin	Texas A&M University System Health Science Center	\$250,000
47	RP210132	HIHRRA	3.1	Synergy Between Epigenetic Reprogramming and Wnt Inhibition to Enhance	Frost, Jeffrey	The University of Texas Health Science Center at Houston	\$249,999

				Neuroendocrine Tumor Radionuclide Therapy			
48	RP210153	TREC	3.1	UTEP/UTMDACC Partnership for Hispanic Cancer Disparities Research	Cox, Marc	The University of Texas at El Paso	\$5,881,734
49	RP210183	HIHRRA	3.3	Virulence Modulation of Helicobacter pylori, the Strongest Risk Factor for Gastric Cancer	Kearney, Christopher	Baylor University	\$248,938
50	RP210213	HIHRRA	3.3	Therapeutic Inhibition of Cholangiocarcinoma Progression by Targeting Tumor-Lymphatic Cross Talk	Chakraborty, Sanjukta	Texas A&M University System Health Science Center	\$250,000

CFSA = Core Facility Support Awards

CTNA = Clinical Trials Network Award

ECI = Early Clinical Investigator Awards

HIHR = High-Impact/High Risk Awards

TCTPA = Texas Clinical Trials Participation Award

TREC = Texas Regional Excellence in Cancer Award



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research
FY 2021—Cycle 2
*Texas Regional Excellence in Cancer
Award***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA R-21.2-TREC

Texas Regional Excellence in Cancer

**Please also refer to the Instructions for Applicants document,
which will be posted on September 16, 2020**

Applications for this award mechanism are subject to institutional eligibility requirements, including an invitation from CPRIT to apply based on an institutional letter of intent. Applicants are advised to consult with their institution's Office of Research and Sponsored Programs (or equivalent).

Letter of Intent due: December 4, 2020
Application Receipt Opening Date: September 16, 2020
Application Receipt Closing Date: January 27, 2021

FY 2021
Fiscal Year Award Period
September 1, 2020-August 31, 2021

TABLE OF CONTENTS

1. KEY POINTS	4
2. ABOUT CPRIT	5
2.1. ACADEMIC RESEARCH PROGRAM PRIORITIES	5
3. GOAL	6
4. BACKGROUND	6
5. PROGRAM COMPONENT DESCRIPTIONS	7
6. FUNDING INFORMATION	8
7. ELIGIBILITY	9
8. RESPONDING TO THIS RFA	10
8.1. LETTER OF INTENT	10
8.2. APPLICATION SUBMISSION GUIDELINES	10
8.3. SUBMISSION DEADLINE EXTENSION	11
8.4. APPLICATION COMPONENTS	11
8.4.1. <i>Abstract and Significance (5,000 characters)</i>	11
8.4.2. <i>Layperson’s Summary (2,000 characters)</i>	11
8.4.3. <i>Goals and Objectives</i>	12
8.4.4. <i>Timeline (Maximum of 1 page)</i>	12
8.4.5. <i>Overall Description (6 pages)</i>	12
8.4.6. <i>Administrative Core (2 pages)</i>	13
8.4.7. <i>Core Resource(s) (4 pages each)</i>	13
8.4.8. <i>Research Projects to be Funded in Year 1 (4 pages each)</i>	13
8.4.9. <i>Letters of Support (2 pages each)</i>	13
8.4.10. <i>Vertebrate Animals (1 page)</i>	14
8.4.11. <i>Human Subjects (2 pages)</i>	14
8.4.12. <i>Budget Justification</i>	14
8.4.13. <i>Biographical Sketches (5 pages each)</i>	15
8.4.14. <i>Current and Pending Support and/or Other Certifications</i>	16
8.4.15. <i>Institutional/Collaborator Support and/or Other Certification</i>	16
8.5. FORMATTING INSTRUCTIONS	16
9. APPLICATION REVIEW	17
9.1. FULL PEER REVIEW	17
9.2. CONFIDENTIALITY OF REVIEW	18
9.3. REVIEW CRITERIA	19
9.3.1. <i>Primary Criteria</i>	19
9.3.2. <i>Secondary Criteria</i>	20
10. KEY DATES	21
11. AWARD ADMINISTRATION	21
12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS	22
13. CONTACT INFORMATION	23
13.1. HELPDESK	23
13.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS	23

RFA VERSION HISTORY

Rev 08/05/20 RFA release

1. KEY POINTS

- The Texas Regional Excellence in Cancer (TREC) award is a multicomponent award designed to strengthen cancer research at institutions located in regions of Texas that have historically received low levels of peer-reviewed cancer research funding.
- Applicants may request up to \$6.0 million in CPRIT funds over 5 years to support program leadership, investigator-initiated research projects, recruitment of new junior faculty, and research infrastructure.
- The TREC award will support an established investigator with a strong record of funding to develop a center with a cohesive theme relevant to the cancer problems of the region.
- The TREC award will support investigator-initiated research projects led by faculty that stand alone as individual projects but share a common thematic cancer focus. Each research project is required to propose a timeline that includes a plan to submit an Investigator-Initiated Research Award application to CPRIT and/or the National Institutes of Health (NIH) by the end of 3 years of TREC support.
- The TREC may be used to support the recruitment of new junior faculty.
- The TREC may be used to support access to technology and core services necessary for the TREC-sponsored research projects to conduct competitive cancer research.
- Applicants are encouraged to partner with another Texas institution to address areas of technical or content expertise necessary for the TREC projects but not available in their institution. To support these partnerships, the TREC will allow subcontracts to be established with collaborating investigators, mentors, or core facilities located at another Texas institution.
- The TREC award can be renewed once to support further development of an institution's cancer research infrastructure and cancer-focused investigators.

2. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of or cures for cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

2.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure

The program priorities for academic research adopted by the Oversight Committee include funding projects that address the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions
- Computational biology and analytic methods
- Childhood cancers
- Hepatocellular cancer
- Expansion of access to innovative clinical trials

3. GOAL

The TREC award is a new CPRIT mechanism designed to strengthen the cancer research environment and to increase the number and quality of scientifically meritorious cancer research projects at institutions in geographic regions of Texas that have historically received low levels of peer reviewed cancer research funding. **A high priority is the development of cancer research programs addressing the cancer challenges affecting regions of Texas without a National Cancer Institute–Designated Cancer Center.**

4. BACKGROUND

The structure of the TREC award is modeled after the National Institutes of Health (NIH) Centers of Biomedical Research Excellence ([COBRE](#)) awards that support the establishment and development of innovative, state-of-the-art biomedical research centers at institutions in states that have historically received low levels of support from the NIH. The COBRE award provides resources to support research projects led by junior faculty and to enhance an institution's research infrastructure. In addition to improving the competitiveness of investigators and the research capacities of an institution, the COBRE program is designed to increase an institution's ability to serve its unique populations, such as rural and medically underserved communities (<https://www.nigms.nih.gov/Research/DRCB/IDeA/pages/COBRE.aspx>).

Over the past decade, CPRIT academic research awards have gone primarily to Texas institutions located along the I-35 corridor or located within the Houston metroplex with dramatic impact on accelerating the cancer research capabilities and accomplishments of those institutions. However, institutions located in other geographic regions of the state have not been as competitive for cancer research funding from [CPRIT](#) (<https://www.cprit.state.tx.us/grants-funded>) or the [National Cancer Institute \(NCI\)](#) (<https://www.nih.gov/grants-funding>). **The limited cancer research funding to these regions of Texas raises a concern that cancer-related issues affecting Texans from these geographic regions of Texas will not be adequately addressed.**

As CPRIT plans the next decade of investment in the cancer research capabilities of Texas academic research institutions, the TREC award is designed to provide an opportunity for those institutions located in geographic regions of Texas that historically have received low levels of peer

reviewed cancer research funding to develop a multidisciplinary corps of successful cancer researchers who will compete nationally for cancer research funding to address the cancer challenges facing their region.

5. PROGRAM COMPONENT DESCRIPTIONS

The TREC award will establish a multicomponent center that supports cancer research in a thematic scientific area and develops a critical mass of investigators competitive for peer-reviewed external cancer research funding. The TREC theme can be in any cancer research area: basic, translational, clinical, prevention, population research.

Principal Investigator: The institution will identify a Principal Investigator (PI) who is an established investigator with a strong record of funding to lead the program and to provide mentorship to existing and newly recruited program faculty. The PI must be willing and able to commit 20% effort to this leadership during the time the research that is the subject of the grant is conducted.

Research Projects: The TREC should support a minimum of 3 (and a maximum of 5) investigator-initiated research projects.

A majority of the research project leaders must be junior investigators appointed as assistant professor or equivalent and have not yet received an NIH R01, NSF-CAREER award, major DOD award, or CPRIT Individual Investigator Research Award. Junior faculty with a K99/R00 award or other faculty transition or development award will be eligible to lead TREC research projects. Individuals holding positions that lack independent faculty status are not eligible to lead TREC research projects.

Established independent investigators of any faculty rank who are making significant changes to their career goals by initiating new lines of research that are significantly different from their current investigative program may also serve as research project leaders. However, they cannot make up the majority of the research project leaders.

Each research project should stand alone but share a common thematic scientific focus. A TREC is required to support 3 to 5 active research projects at any given time. It is expected that a research project leader will be supported by the TREC for no more than 3 years and will move to

independent research support. Support of a project investigator by the TREC mechanism beyond a total of 3 years is not allowed.

Recruitment: A TREC supported research project award may be used to support the recruitment of new junior faculty with a cancer research focus or expertise relevant to the TREC theme.

Core resources: The TREC may support access to technology and core research services necessary to support the proposed research projects. TREC programs from Health Science Centers are encouraged to plan for core resources to support clinical trials and biospecimen access. Other investigators at the institution may also use the core facilities provided TREC participants' research needs are met first. Sharing research facilities at other Texas institutions is strongly encouraged, and subcontract awards to support such access are permitted. Renovations or construction are not appropriate for this mechanism.

Mentorship, Evaluation, and Administration: The TREC will support a formal mentoring structure for each research project, an external advisory council, and an administrative core. These components will coordinate the center's governance, mentoring, and evaluation functions.

Applicants are encouraged to partner with another Texas institution for collaboration, mentoring, and to provide access to technology or content expertise not available in their institution.

6. FUNDING INFORMATION

The maximum duration for this award mechanism is 5 years. Applicants may request a maximum of \$1,200,000 in total costs annually. Funds may be used for salary and fringe benefits, research supplies, equipment, subject participation costs including diagnostic or interventional procedures associated with participation in a clinical trial and not considered routine patient care, travel to scientific/technical meetings, and travel for external advisory council members or travel to collaborating institutions. Up to \$200,000 annually can be requested to support new faculty recruits to the institution.

Subcontracts with collaborating institutions to provide access to mentors and technical and content expertise are permitted.

State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the **total** award amount.

7. ELIGIBILITY

Eligibility to apply for a TREC award is open to a Texas institution of higher learning whose campus is located 100 miles or greater from 1 of the 4 Texas NCI-Designated Cancer Centers located in Dallas, Houston, and San Antonio.

- Applicants must complete a preapplication process (see [section 8.1](#)).
- An institution may submit only 1 application under this RFA during this funding cycle. For purposes of this RFA, an institution is defined as that component of a university system that has a President.
- A university and a health science center that are components of the same university system and share a contiguous or near-contiguous campus are strongly encouraged to submit a single application that will leverage their combined assets to build a cancer research program to serve their region.
- Academic health science centers with multiple campuses are eligible to participate in a single application under this RFA.
- The Principal Investigator (PI) must be the director of the center and must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, and must reside in Texas during the time the research that is the subject of the grant is conducted. The PI should hold a full-time faculty position, at the level of associate or full professor or the equivalent. Ideally, an institution will identify an established investigator with a record of peer-reviewed funding to lead the TREC.
- This award must be directed by the PI. Co-PIs are not permitted.
- TREC PI, research project leaders, and core resource must be located on a TREC-eligible campus located 100 miles or greater from an existing NCI-Designated Cancer Center.
- Collaborations with Texas-based institutions to provide access to technology and counsel are permitted and can be supported with TREC funds through subcontracts. Texas institutions are eligible to hold subcontracts with multiple TREC grantees.
- Collaborators may or may not reside in Texas; however, collaborators who do not reside in Texas are not eligible to receive CPRIT funds. Collaborators should have specific and

well-defined roles. Subcontracting and collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds. In no event shall equipment purchased under this award leave the State of Texas.

8. RESPONDING TO THIS RFA

8.1. Letter of Intent

A preapplication process is required to encourage interactions with the CPRIT Academic Research Program staff in the planning and development of an application. A letter of intent (LOI) must be sent electronically by 4 PM central time on December 4, 2020 to research@cprit.texas.gov. Late LOIs will not be accepted. The LOI should be addressed to the CPRIT Chief Scientific Officer and should include the biosketch (NIH format) of the proposed PI, and a summary (5-page limit) of the proposed TREC theme and planned components. The LOI must be approved prior to submission of an application in response to this RFA. If approved, CPRIT will provide a letter authorizing submission to include in the TREC application.

8.2. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The PI must create a user account in the system to start and apply. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on September 16, 2020 and must be submitted by 4 PM central time on January 27, 2021. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

8.3. Submission Deadline Extension

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grant applications will be denied. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

8.4. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the *Instructions for Applicants* document for details that will be available when the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 7](#) will be administratively withdrawn without review.

8.4.1. Abstract and Significance (5,000 characters)

Describe how the proposed TREC will build on an institutional commitment to cancer research, enhance the applicant institution's cancer research infrastructure, and provide junior faculty with the mentoring and research project funding to help them to acquire preliminary data and to successfully compete for independent peer-reviewed cancer research support. Discuss how the TREC will enhance access to technologies and content expertise not currently available to the TREC faculty. If the TREC will support collaborations and/or partnerships with other Texas institutions, discuss these plans. Discuss how the institution will monitor TREC progress.

8.4.2. Layperson's Summary (2,000 characters)

Describe, in simple, nontechnical terms, the overall goals of the proposed TREC and describe the institutional vision and commitment to building cancer research capacity and how the TREC will help to realize this vision. Discuss the specific cancer problems addressed and how the proposed projects will impact these. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. **Do not include any proprietary information in the layperson's summary.** The layperson's summary will also

be used by advocate reviewers ([section 9.1](#)) in evaluating the significance and impact of the proposed work.

8.4.3. Goals and Objectives

List specific goals and objectives for each year of the TREC. These goals and objectives will also be used during the submission and evaluation of progress reports and assessment of project success.

8.4.4. Timeline (Maximum of 1 page)

Provide an outline of anticipated major milestones to be tracked. If the application is approved for funding, this section will be included in the award contract, and adherence to timelines will be a criterion for continued support. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

8.4.5. Overall Description (6 pages)

Present a compelling rationale for the establishment of the TREC and the goals the TREC will strive to achieve; discuss the institutional commitment and existing capabilities that will be drawn upon in the implementation of these goals. In this section also do the following:

- Discuss the central theme for the TREC and how the research proposed is designed to increase an institution's ability to impact its unique populations.
- Discuss the selection, capabilities, responsibilities, and the reporting structure within the institution for the TREC PI.
- Discuss how the TREC will be organized and how the different components will interact with each other and with existing programs and resources at the institution.
- Discuss how the TREC will develop and monitor faculty development plans for each research project leader receiving TREC support. Include a discussion of how the institution intends to support TREC faculty as they transition their TREC research support to cancer research grant support through applications submitted to CPRIT and the NIH.
- If the TREC plans to support the recruitment of junior faculty, discuss how priorities for new faculty recruitment are determined and how the recruitment funds (up to \$200,000/year) will be deployed.

- Describe an evaluation plan with clear timelines and milestones to monitor and evaluate the performance of all components of the TREC and the progress of the investigators it supports. Strategies to identify and remedy deficiencies such as poor performance and lack of progress should be described. Discuss plans to form an external advisory committee (EAC) comprising scientists with expertise directly relevant to the TREC theme.
- Discuss any plans to develop formal research partnerships with other Texas institutions and how these partnerships will be governed.

8.4.6. Administrative Core (2 pages)

Describe how the PI will manage and coordinate the research projects, EAC, committees, mentors, and research cores, to implement the TREC goals. Core responsibilities include preparing program and financial reports, managing budgets, and organizing scientific and career development activities such as seminar series, workshops, and retreats.

8.4.7. Core Resource(s) (4 pages each)

Describe plans for development of any common resources or to support existing resources to accomplish the goals of the proposed research to support TREC projects. Discuss how TREC resources were selected and how they will be managed and evaluated.

8.4.8. Research Projects to be Funded in Year 1 (4 pages each)

Present the rationale, specific aims, and brief research plan for each proposed research project. Preliminary studies are not required, but they are encouraged. In the absence of preliminary results, applicants should describe prior research that serves as the key support for the proposed project. Each research project should describe its relationship to the central theme of the TREC, and the cancer relevance of the proposed research should be concisely stated. Each project must propose a timeline that includes a plan to submit an Investigator-Initiated Research Award application to CPRIT and/or the NCI by the end of 3 years of CPRIT TREC award support.

8.4.9. Letters of Support (2 pages each)

A letter of support from a senior institutional official (eg, President or Dean) must be included, outlining the institutional commitment of resources and facilities to sustain and support the

TREC throughout the period of funding and to maintain these resources beyond the period of grant support. The level of institutional commitment will differ among applicant institutions because of the variability of resources available among institutions. Additional letters from collaborators at another Texas institution and letters demonstrating regional and/or local commitment and support for the proposed center may be included in this section.

8.4.10. Vertebrate Animals (1 page for each research project or core)

If vertebrate animals will be used in any research project or core, provide a detailed plan of the protocols that will be followed and justification for the number of animals used with reference to biostatistical input for sample selection and evaluation. Certification of approval by the institutional IACUC of the proposed animal use will be required before funding can occur.

8.4.11. Human Subjects (1 page for each research project or core)

If human subjects or human biological samples will be used in any research project or core, provide a detailed plan for recruitment of subjects and/or the acquisition of samples that that will meet the time constraints of this award mechanism. Certification of approval of these plans by the institutional IRB will be required before funding can occur.

8.4.12. Budget Justification

Provide a detailed justification of the budget for each component of the TREC for the entire proposed period of support, including salaries and benefits, supplies, equipment, patient care costs, animal care costs, and other expenses.

A minimum level of effort of 20% FTE is required for the PI to devote to career guidance and administrative oversight of the TREC. The PI may not use TREC funds to supplement research activities within his/her laboratory.

Research project leaders must commit a minimum of 20% effort to their TREC research project.

Funds to compensate members of the EAC should be requested in the Administrative Core budget. EAC members can be compensated as consultants via a fee-for-service arrangement. Funds to compensate mentors should be requested in the Administrative Core budget. Each mentor may be compensated for up to 1 person-month of effort and should be listed in the

Administrative Core's budget section of the application and not in the individual research projects' budget sections.

Funds may be used to assist the institution's recruitment of junior faculty who complement the scope of the proposed program. These funds are limited to \$200,000 per year and may be used for salary, supplies, and/or equipment costs.

In preparing the requested budget, applicants should be aware of the following:

- Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application.
- Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. So-called grants management and facilities fees (eg, sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees; maintenance fees) may not be requested. Applications that include such budgetary items will be rejected administratively and returned without review.
- The annual salary (also referred to as direct salary or institutional base salary) that an individual may receive under a CPRIT award for FY 2021 is \$200,000; CPRIT FY 2021 is from September 1, 2020, through August 31, 2021. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.

8.4.13. Biographical Sketches (5 pages each)

A biographical sketch must be provided for the PI, research project leaders, any core Resource leader, and proposed EAC members. Additional biographical sketches for key collaborators or

advisors from other Texas institutions may be provided. Each biographical sketch must not exceed 5 pages. The NIH biosketch format is appropriate.

8.4.14. Current and Pending Support and/or Other Certifications

Describe the funding source and duration of all current and pending support for the PI, research project leaders, and core facility leaders. For each award, provide the title, a 2-line summary of the goal of the project, and, if relevant, a statement of overlap with the current application. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

8.4.15. Institutional/Collaborator Support and/or Other Certification

Applicants may provide letters of institutional support, collaborator support, and/or other certification documentation relevant to the proposed project. A maximum of 4 pages each may be provided.

8.5. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English
- **Document Format:** PDF only
- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point)
- **Line Spacing:** Single
- **Page Size:** 8.5 x 11 inches
- **Margins:** 0.75 inch, all directions
- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations must be submitted as part of the appropriate submitted document. Applicants should include text to explain illustrations that may be difficult to interpret when printed in black and white.
- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.

- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters are also acceptable as long as the journal information is stated. Include URLs of publications referenced in the application.

Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45–67.

- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants should not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see following point).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be filled out, printed, signed, scanned, and then uploaded in PDF format.

9. APPLICATION REVIEW

9.1. Full Peer Review

All applications submitted in response to this RFA will undergo a 2-stage peer review process: (1) Full peer review and (2) prioritization of grant applications by the CPRIT Scientific Review Council. In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts as well as advocate reviewers using the criteria listed in [section 9.3](#). In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT Scientific Review Council based on comparisons with applications from all of the peer review panels and programmatic priorities. Applications approved by Scientific Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an

open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

9.2. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and Scientific Review Council members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules (Texas Administrative Code RULE §703.9).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee Member, a PIC Member, a Scientific Review Panel member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Research Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period when preapplications or letters of interest are accepted.

Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

9.3. Review Criteria

Full peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Review committees will evaluate and score each primary criterion and subsequently assign a global score that reflects an overall assessment of the application. **The overall assessment will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application. Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

9.3.1. Primary Criteria

Primary criteria will evaluate the scientific merit and potential impact of the proposed work contained in the application. Concerns with any of these criteria potentially indicate a major flaw in the significance and/or design of the proposed study. Primary criteria include the following:

Significance and Impact:

- Do the proposed TREC theme and the proposed research projects have a high degree of relevance to cancer research?
- Will the proposed investments enhance the institution's cancer research capabilities and ability of research faculty to compete successfully for peer reviewed cancer research awards?
- Do the research projects proposed have clearly defined hypotheses or goals supported by sufficient preliminary data and/or scientific rationale?
- Will research project leaders have formal mentoring to help them acquire preliminary data and successfully compete for independent research grant support?
- Is the formation of the EAC properly described? Is the proposed scientific expertise of EAC members adequate to critique the scientific progress of the TREC and offer advice on scientific matters including the evaluation of research projects and core resources?

Applicant Investigator: Does the PI demonstrate the required experience and accomplishments to provide the necessary leadership of the TREC and to oversee mentorship of junior faculty.

Institutional Commitment: Is a strong institutional commitment demonstrated? Have internal and external evaluation processes been established to monitor progress?

Relevance: Does the proposed research have a high degree of relevance to cancer research? This is a critical criterion for evaluation of projects for CPRIT support.

9.3.2. Secondary Criteria

Secondary criteria contribute to the global score assigned to the application. Concerns with these criteria potentially question the feasibility of the proposed research. Secondary criteria include the following:

Research Environment: Does the research team have the needed expertise, facilities, and resources to accomplish all aspects of the proposed research? Are the levels of effort of the key personnel appropriate? Is there evidence of institutional support of the research team and the project?

Vertebrate Animals and/or Human Subjects: Is the vertebrate animals and/or human subjects plan adequate and sufficiently detailed?

Budget: Is the budget appropriate for the proposed work?

Duration: Is the stated duration appropriate for the proposed work?

10. KEY DATES

RFA

RFA release August 5, 2020

Application

Online application opens September 16, 2020, 7 AM central time

Application due January 27, 2021, 4 PM central time

Application review January 2021 to August 2021

Award

Award notification August 18, 2021

Anticipated start date August 31, 2021

11. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. Applicants are advised to review CPRIT's Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of award contract. Forms and instructions will be made available at www.cprit.texas.gov.

12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. A grant recipient that is a public or private institution of higher education, as defined by §61.003, Texas Education Code, may credit toward the Grant Recipient's Matching Funds obligation the dollar amount equivalent to the difference between the indirect cost rate authorized by the federal government for research grants awarded to the Grant Recipient and the 5% indirect cost limit imposed by §102.203(c), Texas Health and Safety Code. Grant applicants are advised to consult CPRIT's Administrative Rules, [chapter 703, section 703.11](#), for specific requirements regarding demonstration of available funding. The demonstration of available matching funds must be made at the time the award contract is executed, and annually thereafter, not when the application is submitted.

13. CONTACT INFORMATION

13.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

13.2. Scientific and Programmatic Questions

Questions regarding the CPRIT program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Senior Manager for Academic Research.

Tel: 512-305-8491

Email: Help@cpritgrants.org

Website: www.cprit.texas.gov

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Cancer Biology
(21.2 AR-CB)
Observation Report

Report No. 2021-05-20 21.2_AR-CB
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Cancer Biology
(21.2_AR-CB)
Panel Date: May 20, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Cancer Biology (21.2_AR-CB) meeting. The meeting was chaired by Peter Jones and conducted via videoconference on May 20, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Eleven (11) applications were discussed and eight (8) applications were not discussed
- Panelists: One (1) panel chair, sixteen (16) expert reviewers, three (3) Ad Hoc reviewers, two (2) advocate reviewers and one (1) Ad Hoc reviewer was not present
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Six (6)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Basic Cancer
Research – 1 (21.2 AR-BCR1)
Observation Report

Report No. 2021-05-21 21.2_AR-BCR1
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Basic Cancer Research –
1 (21.2_AR-BCR1)
Panel Date: May 21, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Basic Cancer Research – 1 (21.2_AR-BCR1) meeting. The meeting was chaired by Thomas Curran and conducted via videoconference on May 21, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: nineteen (19) applications were discussed and nineteen (19) applications were not discussed
- Panelists: One (1) panel chair, fourteen (14) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were five (5) Conflicts of Interest (COIs) identified prior to and/or during the meeting. There were three (3) COIs on applications discussed and two (2) COIs on applications not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive name that appears to be 'Mara Ash'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Clinical and
Translational Cancer Research (21.2 AR-CTCR)
Observation Report

Report No. 2021-05-24 21.2_AR-CTCR
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Clinical and Translational
Cancer Research (21.2_AR-CTCR)
Panel Date: May 24, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Clinical and Translational Cancer Research (21.2_AR-CTCR) meeting. The meeting was chaired by Margaret Tempero and Richard O'Reilly and conducted via videoconference on May 24, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: twenty-one (21) applications were discussed and thirteen (13) applications were not discussed
- Panelists: Two (2) panel chairs, twenty-two (22) expert reviewers, and three (3) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were four (4) Conflicts of Interest (COIs) identified prior to and/or during the meeting. There were three (3) COIs on applications discussed and one (1) COI on an application not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed

additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive name that appears to be 'Mara Ash'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Basic Cancer
Research – 2 (21.2 AR-BCR2)
Observation Report

Report No. 2021-05-25 21.2_AR-BCR2
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Basic Cancer Research –
2 (21.2_AR-BCR2)
Panel Date: May 25, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Basic Cancer Research – 2 (21.2_AR-BCR2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on May 25, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: sixteen (16) applications were discussed, and eighteen (18) applications were not discussed
- Panelists: One (1) panel chair, fifteen (15) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were five (5) Conflicts of Interest (COIs) identified prior to and/or during the meeting. There were four (4) COIs on applications discussed and one (1) COI on an application not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive 'M' followed by a long horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Imaging Technology
and Informatics (21.2 AR-ITI)
Observation Report

Report No. 2021-05-26 21.2_AR-ITI
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Imaging Technology and Informatics (21.2_AR-ITI)
Panel Date: May 26, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Imaging Technology and Informatics (21.2_AR-ITI) meeting. The meeting was chaired by Martin Pomper and conducted via teleconference on May 26, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Thirteen (13) applications were discussed, and thirteen (13) applications were not discussed
- Panelists: One (1) panel chair, nineteen (19) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were three (3) Conflicts of Interest (COIs) identified prior to and/or during the meeting. There were two (2) COIs on applications discussed and one (1) COI on an application not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive name that appears to be 'Mara Ash'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
21.2 Academic Research Review Panel - Cancer Prevention
Research (21.2 AR-CPR)
Observation Report

Report No. 2021-05-27 21.2_AR-CPR
Program Name: Academic Research
Panel Name: 21.2 Academic Research Review Panel - Cancer Prevention
Research (21.2_AR-CPR)
Panel Date: May 27, 2021
Report Date: June 21, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.2 Academic Research Review Panel - Cancer Prevention Research (21.2_AR-CPR) meeting. The meeting was chaired by Elana Martinez and conducted via teleconference on May 27, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Five (5) applications were discussed and three (3) applications were not discussed
- Panelists: One (1) panel chair, ten (10) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

21.2 Scientific Review Council (21.2 SRC)

Observation Report

Report No. 2021-07-08 21.2_SRC
Program Name: Academic Research
Panel Name: 21.2 Scientific Review Council (21.2_SRC)
Panel Date: July 8, 2021
Report Date: July 16, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is 21.2 Scientific Review Council (21.2_SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on July 8, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: fifty-two (52) applications were discussed
- Panelists: One (1) panel chair and eight (8) reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COIs procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 21.2

Awards Announced at the August 18, 2021, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Cycle 21.2 include *Core Facility Support Awards*; *Clinical Trials Network Award*; *Early Clinical Investigator Awards*; *High-Impact/High Risk Awards*; *Texas Clinical Trials Participation Award*; and *Texas Regional Excellence in Cancer Award*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant/Principal Investigator	Principal Investigator Institution	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
RP210073	Ronald DePinho	The University of Texas M.D. Anderson Cancer Center	N. Bardeesy
RP210102	WEIXING ZHAO	The University of Texas Health Science Center at San Antonio	W. Chazin
RP210208	Stanton McHardy	The University of Texas at San Antonio	A. Tomkinson; W. Chazin; C. Rosenfeld
RP210122	Michael Overman	The University of Texas M.D. Anderson Cancer Center	H. Hochster
RP210075	Jeremy Schraw	Baylor College of Medicine	C. Li
RP210099	Anke Henning	The University of Texas Southwestern Medical Center	A. Wu; R. Berbeco

Application ID	Applicant/Principal Investigator	Principal Investigator Institution	Conflict Noted by Reviewer
RP210105	Alexei Tumanov	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP210236	Zhenpeng Qin	The University of Texas at Dallas	J. Willson
RP210140	Carlos L Arteaga	The University of Texas Southwestern Medical Center	C. Rosenfeld
Applications not considered by the PIC or Oversight Committee:			
RP210154	Charles Reynolds	Texas Tech University Health Sciences Center	Y. DeClerck
RP210215	Wei Wang	University of Houston	X. Chen
RP210113	Yinghong Wang	The University of Texas M.D. Anderson Cancer Center	R. O'Reilly
RP210172	Charles Geyer	The Methodist Hospital Research Institute	H. Hochster
RP210216	Mary Dickinson	Baylor College of Medicine	W. Kast
RP210090	Kenneth Hoyt	The University of Texas at Dallas	K. Zinn
RP210112	Peter Houghton	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP210166	Francis Yoshimoto	The University of Texas at San Antonio	J. Conejo-Garcia
RP210230	Leonidas Bleris	The University of Texas at Dallas	A. Anderson; J. Conejo-Garcia

De-Identified Overall Evaluation Scores

Texas Regional Excellence in Cancer Award Academic Research Cycle 21.2

Application ID	Final Overall Evaluation Score
RP210154*	2.0
RP210153*	3.1
Na	3.8
Nb	3.9
Nc	4.2
Nd	4.3
Ne	5.3

* Recommended for funding

Texas Regional Excellence in Cancer Award
Academic Research Cycle 21.2

Final Overall Evaluation Scores and Rank Order Scores

Ludwig Institute for
Cancer Research Ltd

Richard D. Kolodner
Ph.D.

Head, Laboratory of
Cancer Genetics
San Diego Branch

Distinguished Professor of
Cellular & Molecular
Medicine, University of
California San Diego School
of Medicine

rkolodner@health.ucsd.edu

San Diego Branch

UC San Diego School of
Medicine
CMM-East / Rm 3058
9500 Gilman Dr - MC 0660
La Jolla, CA 92093-0660

T 858 534 7804
F 858 534 7750

July 21, 2021

Mr. Dee Margo
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dee@deemargo.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Mr. Margo and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for Core Facility Support Awards (CFSA), Clinical Trials Network Awards (CTNA), Early Clinical Investigator Awards (ECI), High-Impact/High Risk Awards (HIHR), Texas Clinical Trials Participation Awards (TCTPA) and Texas Regional Excellence in Cancer Award (TREC).

The SRC met on July 8, 2021 to consider the applications recommended by the peer review panels following their meetings held May 20, 2021 – May 27, 2021.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the applications recommended is \$75,418,344. *Please note that the peer review panels and SRC recommended reduced budgets for applications # RP210180 and #RP210064, the reductions are reflected in the table.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Rank	ID	Mechanism	Score	Application Title	PI	Organization	Rec. Budget
1	RP210227	CFSA	1.0	Proteomics and Metabolomics Core Facility	Edwards, Dean	Baylor College of Medicine	\$3,977,681
2	RP210176	ECI	1.0	CPRIT Early Clinical Investigator Award: Moran Amit	Draetta, Gulio	The University of Texas M. D. Anderson Cancer Center	\$1,499,042
3	RP210208	CFSA	1.1	Center for Innovative Drug Discovery: Expansion of a Highly Productive Shared Cancer Drug Discovery Resource for Texas	McHardy, Stanton	The University of Texas at San Antonio	\$3,087,131
4	RP210143	TCTPA	1.5	Dan L. Duncan Comprehensive Cancer Center (DLDCCC) Harris Health Clinical Trials Financial Support Project	Mims, Martha	Baylor College of Medicine	\$1,500,000
5	RP210165	HIHRRRA	1.6	Rapid Point-of-Care Detection of Ovarian Cancer Biomarkers Using a Common Thermometer for Low-Resource Settings	Li, Xiujun (James)	The University of Texas at El Paso	\$249,999
6	RP210115	TCTPA	1.7	Enhancing Access to and Diversity in Cancer Clinical Trials Through a Financial Reimbursement and Outreach Program	Gerber, David	The University of Texas Southwestern Medical Center	\$1,499,327
7	RP210159	ECI	1.8	CPRIT Early Clinical Investigator Award: Carl Gay	Draetta, Gulio	The University of Texas M. D. Anderson Cancer Center	\$1,499,997

8	RP210088	CFSA	1.9	Targeted Therapeutic Drug Discovery and Development Program	Dalby, Kevin	The University of Texas at Austin	\$3,989,441
9	RP210205	HIHRRA	1.9	Cytokine Factories for the Treatment of Mesothelioma	Veiseh, Omid	Rice University	\$250,000
10	RP210173	HIHRRA	1.9	Multiplex CRISPR Genetic Modeling of Polypharmacology for Precision Medicine	Hart, Traver	The University of Texas M. D. Anderson Cancer Center	\$250,000
11	RP210108	CFSA	2.0	The GCC Microphysiological Lead Optimization and Toxicity Screening Facility	Stephan, Clifford	Texas A&M University System Health Science Center	\$3,973,083
12	RP210144	HIHRRA	2.0	Leveraging Glioma Stem Cell Electrophysiology for Therapy	Rostomily, Robert	The Methodist Hospital Research Institute	\$248,028
13	RP210168	HIHRRA	2.0	Overcoming Myeloma Resistance to Proteasome Inhibitors	Yi, Qing	The Methodist Hospital Research Institute	\$250,000
14	RP210062	HIHRRA	2.0	Protein Degradation of CDK9 for Treatment of Drug-Resistant Mantle Cell Lymphoma	Zhou, Jia	The University of Texas Medical Branch at Galveston	\$250,000
15	RP210154	TREC	2.0	Texas Regional Excellence in Cancer Developmental Therapeutics Center at TTUHSC	Reynolds, Charles	Texas Tech University Health Sciences Center	\$5,999,936
16	RP210073	HIHRRA	2.1	Identification of Collateral Lethal and Synthetic Lethal Targets in	DePinho, Ronald	The University of Texas M. D. Anderson Cancer Center	\$249,994

				Pancreatic and Colorectal Cancers			
17	RP210111	HIHRRRA	2.1	Single-Cell Proteomics to Dissect Intratumor Heterogeneity	Pan, Sheng	The University of Texas Health Science Center at Houston	\$250,000
18	RP210134	HIHRRRA	2.2	High-Throughput Discovery of Anticancer Protein Degradors	Tambar, Uttam	The University of Texas Southwestern Medical Center	\$250,000
19	RP210116	CFSA	2.3	The Genetic Design and Engineering Center (GDEC): A CPRIT Core Facility	Bao, Gang	Rice University	\$4,000,000
20	RP210158	HIHRRRA	2.3	Improving CAR T-Cell Therapy of T-ALL by Cotargeting Additional Antigens	Mamonkin, Maksim	Baylor College of Medicine	\$250,000
21	RP210206	HIHRRRA	2.4	Novel Tumor-Specific Bioactive Nanoparticles for Cancer Therapy	Nguyen, Kytai	The University of Texas at Arlington	\$249,999
22	RP210180	CFSA	2.5	Integrated Cancer Research Core (ICRC)	CHAUHAN, SUBHASH	The University of Texas Rio Grande Valley	*\$2,525,000
23	RP210126	CFSA	2.5	High-Parameter Analysis, Sorting, and Imaging Flow Cytometry Shared Resource	Berton, Michael	The University of Texas Health Science Center at San Antonio	\$3,645,500
24	RP210122	CTNA	2.5	Building a Clinical Trial Network for Texas Community Affiliates	Overman, Michael	The University of Texas M. D. Anderson Cancer Center	\$3,000,000
25	RP210164	ECI	2.5	Early Clinical Investigator Award: William Kelly	Hromas, Robert	The University of Texas Health Science Center at San Antonio	\$1,499,985
26	RP210140	ECI	2.6	Targeting Altered Metabolism in IDH-Mutant Glioma	Arteaga, Carlos	The University of Texas Southwestern Medical Center	\$1,500,000

27	RP210089	HIHRRA	2.6	Dissecting Therapeutic Immunomodulation of Gut Microbiome on Colorectal Cancer	Kim, Hyun Jung	The University of Texas at Austin	\$250,000
28	RP210079	HIHRRA	2.7	Targeting Mitochondrial NAD+ in Leukemias	Cambronne, Xiaolu	The University of Texas at Austin	\$250,000
29	RP210236	HIHRRA	2.7	Magnetomechanical Modulation of Blood-Brain Barrier Permeability	Qin, Zhenpeng	The University of Texas at Dallas	\$250,000
30	RP210234	ECI	2.7	Targeting Src Homology-2 Domain-Containing Phosphatase to Overcome Resistance to Immune Checkpoint Blockade in Pancreatic Ductal Adenocarcinoma	Johnston, Sterling	The University of Texas at Austin	\$1,443,367
31	RP210105	HIHRRA	2.8	Targeting Lymphotoxin Beta Receptor in Sensory Neurons for Control of Chemotherapy-Induced Neuropathic Pain	Tumanov, Alexei	The University of Texas Health Science Center at San Antonio	\$249,996
32	RP210068	HIHRRA	2.8	Role of Aberrant Translational Quality Control in Tumorigenesis of Glioblastoma	Wu, Zhihao	Southern Methodist University	\$249,272
33	RP210102	HIHRRA	2.8	Deciphering BRCA1-BARD1 E3 Ligase Activity in Genome Maintenance and Tumor Suppression	ZHAO, WEIXING	The University of Texas Health Science Center at San Antonio	\$250,000

34	RP210099	CFSA	2.8	North Texas Multimodal Small-Animal Imaging Core Facility	Henning, Anke	The University of Texas Southwestern Medical Center	\$3,999,929
35	RP210137	HIHRRA	2.8	Development of TCR-Based Immunotherapies Targeting Hotspot EGFR Mutations for the Treatment of Non-Small Cell Lung Cancer	Reuben, Alexandre	The University of Texas M. D. Anderson Cancer Center	\$250,000
36	RP210209	CFSA	2.9	North Texas Clinical Pharmacology Cancer Core	Putnam, William	Texas Tech University Health Sciences Center	\$2,965,226
37	RP210092	HIHRRA	3.0	Antibody-Drug Conjugate Combination Treatment for Targeting Colorectal Cancer Cell Plasticity	Carmon, Kendra	The University of Texas Health Science Center at Houston	\$250,000
38	RP210131	HIHRRA	3.0	Antibodylike Therapeutics That Target Polyclonal T Cells to CMV-Positive Glioblastomas	Maynard, Jennifer	The University of Texas at Austin	\$250,000
39	RP210075	HIHRRA	3.0	Exploring the Biological Basis of Ethnic and Social Disparities in Pediatric Acute Lymphoblastic Leukemia Outcomes	Schraw, Jeremy	Baylor College of Medicine	\$249,999
40	RP210199	HIHRRA	3.0	Treating Metastatic Cancer Using Microbubble-Assisted Ultrasound-Guided Immunotherapy of	Lux, Jacques	The University of Texas Southwestern Medical Center	\$249,011

				Cancer of Cancer (MUSIC)			
41	RP210127	HIHRRA	3.0	Engineered Enteric Nerve-Perineural Invasion Models to Improve Predictive Preclinical Screens in Early-Stage Colorectal Adenocarcinoma	Raghavan, Shreya	Texas A&M University	\$250,000
42	RP210148	HIHRRA	3.0	Novel Pharmacodynamic Assay to Predict Response to CDK4/6 Inhibitor Therapy	Trivedi, Meghana	University of Houston	\$250,000
43	RP210119	CFSA	3.1	A Preclinical Development Core for Large-Molecule Therapeutics	Liu, Qingyun	The University of Texas Health Science Center at Houston	\$3,999,999
44	RP210064	CFSA	3.1	The Adolescent and Childhood Cancer Epidemiology and Susceptibility Service (ACCESS) for Texas	Scheurer, Michael	Baylor College of Medicine	*\$4,000,000
45	RP210130	CFSA	3.1	Data Management and Analysis Core for Comparative Effectiveness Research on Cancer in Texas	Kuo, Yong-Fang	The University of Texas Medical Branch at Galveston	\$2,936,731
46	RP210070	HIHRRA	3.1	Tunable Epigenetic Remodeling to Modulate CAR T-Cell-Based Immunotherapy	Zhou, Yubin	Texas A&M University System Health Science Center	\$250,000
47	RP210132	HIHRRA	3.1	Synergy Between Epigenetic Reprogramming and Wnt Inhibition to Enhance	Frost, Jeffrey	The University of Texas Health Science Center at Houston	\$249,999

				Neuroendocrine Tumor Radionuclide Therapy			
48	RP210153	TREC	3.1	UTEP/UTMDACC Partnership for Hispanic Cancer Disparities Research	Cox, Marc	The University of Texas at El Paso	\$5,881,734
49	RP210183	HIHRRA	3.3	Virulence Modulation of Helicobacter pylori, the Strongest Risk Factor for Gastric Cancer	Kearney, Christopher	Baylor University	\$248,938
50	RP210213	HIHRRA	3.3	Therapeutic Inhibition of Cholangiocarcinoma Progression by Targeting Tumor-Lymphatic Cross Talk	Chakraborty, Sanjukta	Texas A&M University System Health Science Center	\$250,000

CFSA = Core Facility Support Awards

CTNA = Clinical Trials Network Award

ECI = Early Clinical Investigator Awards

HIHR = High-Impact/High Risk Awards

TCTPA = Texas Clinical Trials Participation Award

TREC = Texas Regional Excellence in Cancer Award



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application DP210005
Texas Company Product Development Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Texas Company Product Development Awards* Request for Applications (RFA). CPRIT received eight applications in response to this RFA. This application was assigned to the product development panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

The Product Development Review Council (PDRC) recommended applications from this grant mechanism out of score order. Additionally, the PDRC did not recommend an application responsive to this RFA that has a score equal to another application that was recommended. As allowed in 25 T.A.C. § 703.6(d)(1), the PDRC’s numerical rank order is substantially based on the final overall evaluation score, but also takes into consideration how well the grant application achieves program priorities and the overall program portfolio.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 4 day of August, 2021,
 by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:28 PM

FY: 2021
CYCLE: 1
PROGRAM: Product Development
MECHANISM: Texas Company Product Development Research Awards
APPLICATION ID: DP210005
APPLICATION TITLE: Clinical Development of DT2216, a First-in-Class APTaD™ for Cancer Therapy
APPLICANT NAME: Sills, Joshua
ORGANIZATION: Dialectic Therapeutics, Inc.
PANEL NAME: Product Development Panel-2

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA approved by CPDO	11/06/2020	07/01/2021
	RFA published in Texas.gov eGrants	N/A	07/08/2021
	CPRIT Application Receipt System (CARS) opened	12/02/2020	07/01/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/01/2021
	Date application submitted	01/27/2021	07/01/2021
	Method of submission	CARS	07/01/2021
	Within receipt period	YES	07/01/2021
	Request for extension to submit application after CARS closed	N/A	07/01/2021
	Request for extension for late application submission accepted	N/A	07/01/2021
	Submission of application fee	YES	04/28/2021
Receipt, Referral, and Assignment	Administrative review notification	02/12/2021	07/01/2021
	Donation(s) made to CPRIT / foundation	NO	07/01/2021
	Assigned to primary reviewers	02/18/2021	07/01/2021
	Applicant notified of review panel assignment	02/18/2021	07/01/2021
	Primary Reviewer 1 COI signed	02/15/2021	07/01/2021
	Primary (Advocate) Reviewer 2 COI signed	02/11/2021	07/01/2021
	Primary Reviewer 3 COI signed	02/11/2021	07/01/2021
	Primary Reviewer 4 COI signed	02/12/2021	07/01/2021
Screening Teleconference Meeting	Primary Reviewer 1 critique submitted	03/16/2021	07/01/2021
	Primary (Advocate) Reviewer 2 critique submitted	03/14/2021	07/01/2021
	Primary Reviewer 3 critique submitted	03/14/2021	07/01/2021
	Primary Reviewer 4 critique submitted	03/17/2021	07/01/2021
	COI indicated by non-primary reviewer	Lee Greenberger	07/01/2021
	COI recused from participation	YES	07/01/2021
	Screening Teleconference Meeting	03/23/2021	07/01/2021
	Post-Screening Teleconference score report	03/23/2021	07/01/2021
	Post review statements signed	04/13/2021	07/01/2021
	Third Party Observer Report	04/05/2021	07/01/2021
Peer Review Meeting	Recommended for On-Site Meeting	YES	07/01/2021
	COI indicated by non-primary reviewer	Lee Greenberger	07/01/2021
	COI recused from participation	YES	07/01/2021
	Peer Review Meeting	04/21/2021	07/01/2021
	Post review statements signed	06/08/2021	07/01/2021
	Third Party Observer Report	04/30/2021	07/01/2021
	Score report delivered to CPDO	04/29/2021	07/01/2021
Due Diligence and IP Review	Recommended for due diligence and IP review	YES	07/01/2021
	Final due diligence review submitted to PDRC	06/08/2021	07/23/2021
	Intellectual Property conflict check	04/30/2021	05/13/2021
Final PDRC Recommendation	Final intellectual property review submitted	06/08/2021	07/23/2021
	COI indicated by PDRC member	NONE	07/13/2021
	COI recused from participation	N/A	07/13/2021
	Due Diligence Evaluation Meeting / PDRC Meeting	07/08/2021	07/13/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/13/2021
PIC Review	PDRC Chair Notification to PIC and OC	07/24/2021	07/26/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	N/A	
	Advance authority approved by Oversight Committee	N/A	

Comments:
 Comment

CPRIT uploaded the RFA to Texas.gov eGrants as of 11/9/2020; however, a technical/system error prevented publication.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application DP210042
Texas Company Product Development Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Texas Company Product Development Awards* Request for Applications (RFA). CPRIT received eight applications in response to this RFA. This application was assigned to the product development panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

The Product Development Review Council (PDRC) recommended applications from this grant mechanism out of score order. Additionally, the PDRC did not recommend an application responsive to this RFA that has a score equal to another application that was recommended. As allowed in 25 T.A.C. § 703.6(d)(1), the PDRC’s numerical rank order is substantially based on the final overall evaluation score, but also takes into consideration how well the grant application achieves program priorities and the overall program portfolio.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 4 day of August, 2021,
 by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:28 PM

FY: 2021
CYCLE: 1
PROGRAM: Product Development
MECHANISM: Texas Company Product Development Research Awards
APPLICATION ID: DP210042
APPLICATION TITLE: Efficacy of a Multi Tumor Associated Antigen Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant
APPLICANT NAME: Vera, Juan F
ORGANIZATION: Marker Therapeutics, Inc.
PANEL NAME: Product Development Panel-2

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA approved by CPDO	11/06/2020	07/01/2021	
	RFA published in Texas.gov eGrants	N/A	07/08/2021	
	CPRIT Application Receipt System (CARS) opened	12/02/2020	07/01/2021	
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/01/2021	
	Date application submitted	01/27/2021	07/01/2021	
	Method of submission	CARS	07/01/2021	
	Within receipt period	YES	07/01/2021	
	Request for extension to submit application after CARS closed	N/A	07/01/2021	
	Request for extension for late application submission accepted	N/A	07/01/2021	
	Submission of application fee	YES	04/28/2021	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	07/01/2021
		Donation(s) made to CPRIT / foundation	NO	07/01/2021
Assigned to primary reviewers		02/18/2021	07/01/2021	
Applicant notified of review panel assignment		02/18/2021	07/01/2021	
Primary Reviewer 1 COI signed		02/10/2021	07/01/2021	
Primary (Advocate) Reviewer 2 COI signed		02/11/2021	07/01/2021	
Primary Reviewer 3 COI signed		02/10/2021	07/01/2021	
Primary Reviewer 4 COI signed		02/10/2021	07/01/2021	
Screening Teleconference Meeting	Primary Reviewer 1 critique submitted	03/16/2021	07/01/2021	
	Primary (Advocate) Reviewer 2 critique submitted	03/14/2021	07/01/2021	
	Primary Reviewer 3 critique submitted	02/27/2021	07/01/2021	
	Primary Reviewer 4 critique submitted	03/05/2021	07/01/2021	
	COI indicated by non-primary reviewer	Rachel Humphrey	07/01/2021	
	COI recused from participation	Other: COI declared post-TC mtg	07/01/2021	
	Screening Teleconference Meeting	03/23/2021	07/01/2021	
	Post-Screening Teleconference score report	03/23/2021	07/01/2021	
	Post review statements signed	04/13/2021	07/01/2021	
	Third Party Observer Report	04/05/2021	07/01/2021	
Peer Review Meeting	Recommended for On-Site Meeting	YES	07/01/2021	
	COI indicated by non-primary reviewer	Rachel Humphrey	07/01/2021	
	COI recused from participation	YES	07/01/2021	
	Peer Review Meeting	04/21/2021	07/01/2021	
	Post review statements signed	06/08/2021	07/01/2021	
	Third Party Observer Report	04/30/2021	07/01/2021	
	Score report delivered to CPDO	04/29/2021	07/01/2021	
	Recommended for due diligence and IP review	YES	07/01/2021	
Due Diligence and IP Review	Final due diligence review submitted to PDRC	06/08/2021	07/23/2021	
	Intellectual Property conflict check	04/30/2021	05/13/2021	
	Final intellectual property review submitted	06/08/2021	07/23/2021	
Final PDRC Recommendation	COI indicated by PDRC member	NONE	07/13/2021	
	COI recused from participation	N/A	07/13/2021	
	Due Diligence Evaluation Meeting / PDRC Meeting	07/08/2021	07/13/2021	
	Third Party Observer Report	07/16/2021	07/23/2021	
	Recommended for grant award	YES	07/13/2021	
	PDRC Chair Notification to PIC and OC	07/24/2021	07/26/2021	
PIC Review	COI indicated by PIC member	None	08/03/2021	
	COI recused from participation	N/A	08/03/2021	
	PIC Review Meeting	08/03/2021	08/03/2021	
	Recommended for grant award	YES	08/03/2021	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	NO		
	Authority to advance funds requested	N/A		
Advance authority approved by Oversight Committee	N/A			

Comments:
 Comment

CPRIT uploaded the RFA to Texas.gov eGrants as of 11/9/2020; however, a technical/system error prevented publication.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP210026
Dissemination of CPRIT-Funded
Cancer Control Interventions

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Dissemination of CPRIT-Funded Cancer Control Interventions* Request for Applications (RFA). CPRIT received four applications in response to this RFA. This application was assigned to the Prevention Review Council for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

On August 28, 2020, I notified Oversight Committee members that I granted the Chief Prevention Officer, Ramona Magid, a waiver from the general prohibition against communicating, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the “CEO Affidavit-Supporting Information” packet.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:28 PM

FY: 2021
CYCLE: 2
PROGRAM: Prevention
MECHANISM: Dissemination of CPRIT-Funded Cancer Control Interventions
APPLICATION ID: PP210026
APPLICATION TITLE: Taking Texas Tobacco Free: Dissemination to and Implementation within Agencies Serving Texans Experiencing Homelessness
APPLICANT NAME: Reitzel, Lorraine R
ORGANIZATION: University of Houston
PANEL NAME: 21.2_Prevention DI

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CPO	10/09/2020	06/21/2021	
	RFA Approved by CPO (revised)	01/22/2021	06/21/2021	
	RFA published in Texas.gov eGrants	N/A	07/08/2021	
	CPRIT Application Receipt System (CARS) opened	11/16/2020	06/21/2021	
	CPRIT Application Receipt System (CARS) closed	02/10/2021	06/21/2021	
	Date application submitted	01/20/2021	06/21/2021	
	Method of submission	CARS	06/21/2021	
	Within receipt period	YES	06/21/2021	
	Request for extension to submit application after CARS closed	N/A	06/21/2021	
	Request for extension for late application submission accepted	N/A	06/21/2021	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	06/21/2021
		Donation(s) made to CPRIT / foundation	NO	06/21/2021
		Assigned to primary reviewers	04/07/2021	06/21/2021
Applicant notified of review panel assignment		N/A	06/21/2021	
Primary Reviewer 1 COI signed		03/24/2021	06/21/2021	
Primary Reviewer 2 COI signed		04/06/2021	06/21/2021	
Primary Reviewer 3 COI signed		N/A	06/21/2021	
Primary Reviewer 4 COI signed		N/A	06/21/2021	
Peer Review Meeting	Primary Reviewer 1 critique submitted	04/15/2021	06/21/2021	
	Primary Reviewer 2 critique submitted	05/16/2021	06/21/2021	
	Primary Reviewer 3 critique submitted	N/A	06/21/2021	
	Primary Reviewer 4 critique submitted	N/A	06/21/2021	
	COI indicated by non-primary reviewer	NONE	06/21/2021	
	COI recused from participation	N/A	06/21/2021	
	Discussed at Peer Review Meeting	YES	06/21/2021	
	Peer Review Meeting	05/27/2021	06/21/2021	
	Post review statements signed	05/28/2021	06/21/2021	
	Third Party Observer Report	06/21/2021	07/09/2021	
	Score report delivered to CPO	06/01/2021	06/21/2021	
	Recommended for PRC review	YES	06/21/2021	
	Final PRC Recommendation	COI indicated by PRC member	NONE	06/21/2021
COI recused from participation		N/A	06/21/2021	
PRC Meeting		06/17/2021	06/21/2021	
Third Party Observer Report		06/21/2021	07/09/2021	
Recommended for grant award		YES	06/21/2021	
PRC Chair Notification to PIC and OC		06/21/2021	06/24/2021	
PIC Review	COI indicated by PIC member	None	08/03/2021	
	COI recused from participation	N/A	08/03/2021	
	PIC Review Meeting	08/03/2021	08/03/2021	
	Recommended for grant award	YES	08/03/2021	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		

Comments:
 Comment
 CPRIT uploaded the RFA to Texas.gov eGrants as of 10/14/2020; however, a technical/system error prevented publication.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP210031
Dissemination of CPRIT-Funded
Cancer Control Interventions

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Dissemination of CPRIT-Funded Cancer Control Interventions* Request for Applications (RFA). CPRIT received four applications in response to this RFA. This application was assigned to the Prevention Review Council for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

On August 28, 2020, I notified Oversight Committee members that I granted the Chief Prevention Officer, Ramona Magid, a waiver from the general prohibition against communicating, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the “CEO Affidavit-Supporting Information” packet.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 4 day of August, 2021, by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:28 PM

FY: 2021
CYCLE: 2
PROGRAM: Prevention
MECHANISM: Dissemination of CPRIT-Funded Cancer Control Interventions
APPLICATION ID: PP210031
APPLICATION TITLE: Application of mHealth Technologies to Improve Latino Childhood Cancer Survivor Engagement and Use of Evidence for Personalized Follow-up Care and Screening
APPLICANT NAME: Poplack, David G
ORGANIZATION: Baylor College of Medicine
PANEL NAME: 21.2_Prevention DI

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CPO	10/09/2020	06/21/2021	
	RFA Approved by CPO (revised)	01/22/2021	06/21/2021	
	RFA published in Texas.gov eGrants	N/A	07/08/2021	
	CPRIT Application Receipt System (CARS) opened	11/16/2020	06/21/2021	
	CPRIT Application Receipt System (CARS) closed	02/10/2021	06/21/2021	
	Date application submitted	02/05/2021	06/21/2021	
	Method of submission	CARS	06/21/2021	
	Within receipt period	YES	06/21/2021	
	Request for extension to submit application after CARS closed	N/A	06/21/2021	
	Request for extension for late application submission accepted	N/A	06/21/2021	
	Receipt, Referral, and Assignment	Administrative review notification	02/26/2021	06/21/2021
		Donation(s) made to CPRIT / foundation	NO	06/21/2021
Assigned to primary reviewers		04/07/2021	06/21/2021	
Applicant notified of review panel assignment		N/A	06/21/2021	
Primary Reviewer 1 COI signed		03/24/2021	06/21/2021	
Primary Reviewer 2 COI signed		04/02/2021	06/21/2021	
Primary Reviewer 3 COI signed		N/A	06/21/2021	
Primary Reviewer 4 COI signed		N/A	06/21/2021	
Peer Review Meeting	Primary Reviewer 1 critique submitted	04/19/2021	06/21/2021	
	Primary Reviewer 2 critique submitted	05/17/2021	06/21/2021	
	Primary Reviewer 3 critique submitted	N/A	06/21/2021	
	Primary Reviewer 4 critique submitted	N/A	06/21/2021	
	COI indicated by non-primary reviewer	NONE	06/21/2021	
	COI recused from participation	N/A	06/21/2021	
	Discussed at Peer Review Meeting	YES	06/21/2021	
	Peer Review Meeting	05/27/2021	06/21/2021	
	Post review statements signed	05/28/2021	06/21/2021	
	Third Party Observer Report	06/21/2021	07/09/2021	
	Score report delivered to CPO	06/01/2021	06/21/2021	
	Recommended for PRC review	YES	06/21/2021	
Final PRC Recommendation	COI indicated by PRC member	NONE	06/21/2021	
	COI recused from participation	N/A	06/21/2021	
	PRC Meeting	06/17/2021	06/21/2021	
	Third Party Observer Report	06/21/2021	07/09/2021	
	Recommended for grant award	YES	06/21/2021	
PIC Review	PRC Chair Notification to PIC and OC	06/21/2021	06/24/2021	
	COI indicated by PIC member	None	08/03/2021	
	COI recused from participation	N/A	08/03/2021	
	PIC Review Meeting	08/03/2021	08/03/2021	
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021	
	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
Advance authority approved by Oversight Committee	N/A			

Comments:
Comment
 CPRIT uploaded the RFA to Texas.gov eGrants as of 10/14/2020; however, a technical/system error prevented publication.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP210045
Dissemination of CPRIT-Funded
Cancer Control Interventions

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Dissemination of CPRIT-Funded Cancer Control Interventions* Request for Applications (RFA). CPRIT received four applications in response to this RFA. This application was assigned to the Prevention Review Council for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

On August 28, 2020, I notified Oversight Committee members that I granted the Chief Prevention Officer, Ramona Magid, a waiver from the general prohibition against communicating, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the “CEO Affidavit-Supporting Information” packet.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 4 day of August, 2021,
 by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:28 PM

FY: 2021
CYCLE: 2
PROGRAM: Prevention
MECHANISM: Dissemination of CPRIT-Funded Cancer Control Interventions
APPLICATION ID: PP210045
APPLICATION TITLE: Dissemination of a mailed stool testing program for colorectal cancer prevention in underserved communities in Texas
APPLICANT NAME: Pignone, Michael
ORGANIZATION: The University of Texas at Austin
PANEL NAME: 21.2_Prevention DI

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CPO	10/09/2020	06/21/2021	
	RFA Approved by CPO (revised)	01/22/2021	06/21/2021	
	RFA published in Texas.gov eGrants	N/A	07/08/2021	
	CPRIT Application Receipt System (CARS) opened	11/16/2020	06/21/2021	
	CPRIT Application Receipt System (CARS) closed	02/10/2021	06/21/2021	
	Date application submitted	02/10/2021	06/21/2021	
	Method of submission	CARS	06/21/2021	
	Within receipt period	YES	06/21/2021	
	Request for extension to submit application after CARS closed	N/A	06/21/2021	
	Request for extension for late application submission accepted	N/A	06/21/2021	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	06/21/2021
		Donation(s) made to CPRIT / foundation	NO	06/21/2021
		Assigned to primary reviewers	04/07/2021	06/21/2021
Applicant notified of review panel assignment		N/A	06/21/2021	
Primary Reviewer 1 COI signed		04/02/2021	06/21/2021	
Primary Reviewer 2 COI signed		03/24/2021	06/21/2021	
Primary Reviewer 3 COI signed		N/A	06/21/2021	
Primary Reviewer 4 COI signed		N/A	06/21/2021	
Peer Review Meeting	Primary Reviewer 1 critique submitted	05/15/2021	06/21/2021	
	Primary Reviewer 2 critique submitted	04/21/2021	06/21/2021	
	Primary Reviewer 3 critique submitted	N/A	06/21/2021	
	Primary Reviewer 4 critique submitted	N/A	06/21/2021	
	COI indicated by non-primary reviewer	NONE	06/21/2021	
	COI recused from participation	N/A	06/21/2021	
	Discussed at Peer Review Meeting	YES	06/21/2021	
	Peer Review Meeting	05/27/2021	06/21/2021	
	Post review statements signed	05/28/2021	06/21/2021	
	Third Party Observer Report	06/21/2021	07/09/2021	
	Score report delivered to CPO	06/01/2021	06/21/2021	
	Recommended for PRC review	YES	06/21/2021	
	Final PRC Recommendation	COI indicated by PRC member	NONE	06/21/2021
COI recused from participation		N/A	06/21/2021	
PRC Meeting		06/17/2021	06/21/2021	
Third Party Observer Report		06/21/2021	07/09/2021	
Recommended for grant award		YES	06/21/2021	
PIC Review	PRC Chair Notification to PIC and OC	06/21/2021	06/24/2021	
	COI indicated by PIC member	None	08/03/2021	
	COI recused from participation	N/A	08/03/2021	
	PIC Review Meeting	08/03/2021	08/03/2021	
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021	
	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
Advance authority approved by Oversight Committee	N/A			

Comments:

Comment
 CPRIT uploaded the RFA to Texas.gov eGrants as of 10/14/2020; however, a technical/system error prevented publication.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP210049
Evidence-Based Cancer Prevention Services

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Evidence-Based Cancer Prevention Services* Request for Applications (RFA). CPRIT received 10 applications in response to this RFA. This application was assigned to the prevention panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

On August 28, 2020, I notified Oversight Committee members that I granted the Chief Prevention Officer, Ramona Magid, a waiver from the general prohibition against communicating, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the “CEO Affidavit-Supporting Information” packet.


In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 4 day of August, 2021, by WAYNE R. ROBERTS.


Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:28 PM

FY: 2021
CYCLE: 2
PROGRAM: Prevention
MECHANISM: Evidence-Based Cancer Prevention Services
APPLICATION ID: PP210049
APPLICATION TITLE: Texas Southern University Breast Cancer Screening and Prevention Center
APPLICANT NAME: Ajewole, Veronica B
ORGANIZATION: Texas Southern University
PANEL NAME: 21.2_Prevention Panel-1

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CPO	10/08/2020	06/03/2021	
	RFA Approved by CPO (revised)	01/22/2021	06/03/2021	
	RFA published in Texas.gov eGrants	N/A	07/08/2021	
	CPRIT Application Receipt System (CARS) opened	11/16/2020	06/03/2021	
	CPRIT Application Receipt System (CARS) closed	02/10/2021	06/03/2021	
	Date application submitted	02/10/2021	06/04/2021	
	Method of submission	CARS	06/04/2021	
	Within receipt period	YES	06/04/2021	
	Request for extension to submit application after CARS closed	N/A	06/04/2021	
	Request for extension for late application submission accepted	N/A	06/04/2021	
	Receipt, Referral, and Assignment	Administrative review notification	02/26/2021	06/04/2021
		Donation(s) made to CPRIT / foundation	NO	06/04/2021
		Assigned to primary reviewers	03/12/2021	06/04/2021
Applicant notified of review panel assignment		03/10/2021	06/02/2021	
Primary Reviewer 1 COI signed		03/03/2021	06/04/2021	
Primary (Advocate) Reviewer 2 COI signed		03/02/2021	06/04/2021	
Primary Reviewer 3 COI signed		03/03/2021	06/04/2021	
Primary Reviewer 4 COI signed		03/04/2021	06/04/2021	
Peer Review Meeting	Primary Reviewer 1 critique submitted	04/13/2021	06/04/2021	
	Primary (Advocate) Reviewer 2 critique submitted	04/12/2021	06/04/2021	
	Primary Reviewer 3 critique submitted	04/15/2021	06/04/2021	
	Primary Reviewer 4 critique submitted	03/18/2021	06/04/2021	
	COI indicated by non-primary reviewer	NONE	06/04/2021	
	COI recused from participation	N/A	06/04/2021	
	Discussed at Peer Review Meeting	YES	06/04/2021	
	Peer Review Meeting	04/26/2021	06/04/2021	
	Peer Review Meeting End Date	04/27/2021	06/04/2021	
	Post review statements signed	04/27/2021	06/04/2021	
	Third Party Observer Report	05/06/2021	06/04/2021	
	Score report delivered to CPO	05/07/2021	06/04/2021	
	Recommended for PRC review	YES	06/04/2021	
Final PRC Recommendation	COI indicated by PRC member	NONE	06/18/2021	
	COI recused from participation	N/A	06/18/2021	
	PRC Meeting	06/17/2021	06/18/2021	
	Third Party Observer Report	06/21/2021	07/09/2021	
	Recommended for grant award	YES	06/18/2021	
	PRC Chair Notification to PIC and OC	06/21/2021	06/24/2021	
PIC Review	COI indicated by PIC member	None	08/03/2021	
	COI recused from participation	N/A	08/03/2021	
	PIC Review Meeting	08/03/2021	08/03/2021	
	Recommended for grant award	YES	08/03/2021	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		

Comments:
 Comment
 CPRIT uploaded the RFA to Texas.gov eGrants as of 10/14/2020; however, a technical/system error prevented publication.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP210007
Expansion of Cancer Prevention Services to
Rural and Medically Underserved Populations

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the cycle 21.1 *Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations* Request for Applications (RFA). CPRIT received 12 applications in response to this RFA. This application was assigned to the prevention panel 1 for review. The Prevention Review Council (PRC) took no action on this application at its March 4, 2021, meeting and recommended it to the PIC at its June 17, 2021, meeting. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle

- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

On August 28, 2020, I notified Oversight Committee members that I granted the Chief Prevention Officer, Ramona Magid, a waiver from the general prohibition against communicating, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the “CEO Affidavit-Supporting Information” packet.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 4 day of August, 2021, by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:28 PM

FY: 2021
CYCLE: 1
PROGRAM: Prevention
MECHANISM: Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations
APPLICATION ID: PP210007
APPLICATION TITLE: Strengthening Safety Net Health Systems to Improve Cervical and Colorectal Cancer Screening and Follow-up among the Medically Underserved
APPLICANT NAME: Montealegre, Jane R
ORGANIZATION: Baylor College of Medicine
PANEL NAME: 21.1_Prevention Panel-1

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CPO	07/14/2020	02/22/2021	
	RFA published in Texas.gov eGrants	08/03/2020	02/22/2021	
	CPRIT Application Receipt System (CARS) opened	08/17/2020	02/22/2021	
	CPRIT Application Receipt System (CARS) closed	10/05/2020	02/22/2021	
	Date application submitted	10/05/2020	02/23/2021	
	Method of submission	CARS	02/23/2021	
	Within receipt period	YES	02/23/2021	
	Request for extension to submit application after CARS closed	N/A	02/23/2021	
	Request for extension for late application submission accepted	N/A	02/23/2021	
	Receipt, Referral, and Assignment	Administrative review notification	10/21/2020	02/23/2021
Donation(s) made to CPRIT / foundation		NO	02/23/2021	
Assigned to primary reviewers		11/03/2020	02/23/2021	
Applicant notified of review panel assignment		11/02/2020	02/22/2021	
Primary Reviewer 1 COI signed		10/24/2020	02/23/2021	
Primary (Advocate) Reviewer 2 COI signed		10/26/2020	02/23/2021	
Primary Reviewer 3 COI signed		10/23/2020	02/23/2021	
Primary Reviewer 4 COI signed		10/23/2020	02/23/2021	
Peer Review Meeting	Primary Reviewer 1 critique submitted	12/15/2020	02/23/2021	
	Primary (Advocate) Reviewer 2 critique submitted	12/16/2020	02/23/2021	
	Primary Reviewer 3 critique submitted	12/12/2020	02/23/2021	
	Primary Reviewer 4 critique submitted	12/11/2020	02/23/2021	
	COI indicated by non-primary reviewer	NONE	02/23/2021	
	COI recused from participation	N/A	02/23/2021	
	Discussed at Peer Review Meeting	YES	02/23/2021	
	Peer Review Meeting	01/19/2021	02/23/2021	
	Post review statements signed	01/19/2021	02/23/2021	
	Third Party Observer Report	01/25/2021	02/23/2021	
Final PRC Recommendation	Score report delivered to CPO	01/28/2021	02/23/2021	
	Recommended for PRC review	YES	02/23/2021	
	COI indicated by PRC member	NONE	03/24/2021	
	COI recused from participation	N/A	03/24/2021	
	PRC Meeting	03/04/2021	03/24/2021	
	Third Party Observer Report	03/16/2021	06/25/2021	
	Recommended for grant award	Other: No Action	03/24/2021	
	PRC Chair Notification to PIC and OC	03/09/2021	06/25/2021	
	COI indicated by PRC member (2nd Meeting)	NONE	06/24/2021	
	COI recused from participation (2nd Meeting)	N/A	06/24/2021	
PIC Review	2nd PRC Meeting	06/17/2021	06/24/2021	
	Third Party Observer Report (2nd Meeting)	06/21/2021	07/09/2021	
	Recommended for grant award	YES	06/24/2021	
	PRC Chair Notification to PIC and OC (2nd Meeting)	06/21/2021	06/24/2021	
	COI indicated by PIC member	None	08/03/2021	
	COI recused from participation	N/A	08/03/2021	
	PIC Review Meeting	08/03/2021	08/03/2021	
	Recommended for grant award	YES	08/03/2021	
	Oversight Committee Approval	CEO Notification to Oversight Committee	N/A	
		COI Indicated by Oversight Committee member	N/A	
COI Recused from participation		N/A		
Donation(s) made to CPRIT / foundation		N/A		
Presented to CPRIT Oversight Committee		N/A		
Award approved by Oversight Committee		N/A		
Authority to advance funds requested		N/A		
Advance authority approved by Oversight Committee	N/A			



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP210020
Expansion of Cancer Prevention Services to
Rural and Medically Underserved Populations

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations* Request for Applications (RFA). CPRIT received three applications in response to this RFA. This application was assigned to the prevention panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle



On August 28, 2020, I notified Oversight Committee members that I granted the Chief Prevention Officer, Ramona Magid, a waiver from the general prohibition against communicating, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the “CEO Affidavit-Supporting Information” packet.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas County of Travis
SWORN to and SUBSCRIBED before me, the undersigned authority, on the <u>4</u> day of <u>August</u> , 2021, by WAYNE R. ROBERTS.
 _____ Melanie Cleveland Notary Public, State of Texas


CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:28 PM

FY: 2021
CYCLE: 2
PROGRAM: Prevention
MECHANISM: Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations
APPLICATION ID: PP210020
APPLICATION TITLE: Vaccinating medically underserved women against HPV: Expansion of clinical services to increase access
APPLICANT NAME: Berenson, Abbey B
ORGANIZATION: The University of Texas Medical Branch at Galveston
PANEL NAME: 21.2_Prevention Panel-1

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CPO	10/08/2020	06/03/2021	
	RFA Approved by CPO (revised)	01/22/2021	06/03/2021	
	RFA published in Texas.gov eGrants	N/A	07/08/2021	
	CPRIT Application Receipt System (CARS) opened	11/16/2020	06/03/2021	
	CPRIT Application Receipt System (CARS) closed	02/10/2021	06/03/2021	
	Date application submitted	02/05/2021	06/04/2021	
	Method of submission	CARS	06/04/2021	
	Within receipt period	YES	06/04/2021	
	Request for extension to submit application after CARS closed	N/A	06/04/2021	
	Request for extension for late application submission accepted	N/A	06/04/2021	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	06/04/2021
		Donation(s) made to CPRIT / foundation	NO	06/04/2021
		Assigned to primary reviewers	03/12/2021	06/04/2021
Applicant notified of review panel assignment		03/10/2021	06/02/2021	
Primary Reviewer 1 COI signed		03/04/2021	06/04/2021	
Primary (Advocate) Reviewer 2 COI signed		03/04/2021	06/04/2021	
Primary Reviewer 3 COI signed		03/03/2021	06/04/2021	
Primary Reviewer 4 COI signed		03/08/2021	06/04/2021	
Peer Review Meeting	Primary Reviewer 1 critique submitted	03/16/2021	06/04/2021	
	Primary (Advocate) Reviewer 2 critique submitted	04/12/2021	06/04/2021	
	Primary Reviewer 3 critique submitted	04/19/2021	06/04/2021	
	Primary Reviewer 4 critique submitted	04/20/2021	06/04/2021	
	COI indicated by non-primary reviewer	NONE	06/04/2021	
	COI recused from participation	N/A	06/04/2021	
	Discussed at Peer Review Meeting	YES	06/04/2021	
	Peer Review Meeting	04/26/2021	06/04/2021	
	Peer Review Meeting End Date	04/27/2021	06/04/2021	
	Post review statements signed	04/27/2021	06/04/2021	
	Third Party Observer Report	05/06/2021	06/04/2021	
	Score report delivered to CPO	05/07/2021	06/04/2021	
	Recommended for PRC review	YES	06/18/2021	
Final PRC Recommendation	COI indicated by PRC member	NONE	06/18/2021	
	COI recused from participation	N/A	06/18/2021	
	PRC Meeting	06/17/2021	06/18/2021	
	Third Party Observer Report	06/21/2021	07/09/2021	
	Recommended for grant award	YES	06/18/2021	
	PRC Chair Notification to PIC and OC	06/21/2021	06/24/2021	
PIC Review	COI indicated by PIC member	None	08/03/2021	
	COI recused from participation	N/A	08/03/2021	
	PIC Review Meeting	08/03/2021	08/03/2021	
	Recommended for grant award	YES	08/03/2021	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		

Comments:

Comment

CPRIT uploaded the RFA to Texas.gov eGrants as of 10/14/2020; however, a technical/system error prevented publication.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP210027
Tobacco Control and Lung Cancer Screening

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Tobacco Control and Lung Cancer Screening* Request for Applications (RFA). CPRIT received five applications in response to this RFA. This application was assigned to the prevention panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

On August 28, 2020, I notified Oversight Committee members that I granted the Chief Prevention Officer, Ramona Magid, a waiver from the general prohibition against communicating, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the “CEO Affidavit-Supporting Information” packet.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:28 PM

FY: 2021
CYCLE: 2
PROGRAM: Prevention
MECHANISM: Tobacco Control and Lung Cancer Screening
APPLICATION ID: PP210027
APPLICATION TITLE: Increasing Accessibility to Smoking Cessation and Lung Cancer Screening Services for Low-income/Uninsured Texans
APPLICANT NAME: McKnight, Jason R
ORGANIZATION: Texas A&M University System Health Science Center
PANEL NAME: 21.2_Prevention Panel-1

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CPO	10/08/2020	06/03/2021	
	RFA Approved by CPO (revised)	01/22/2021	06/03/2021	
	RFA published in Texas.gov eGrants	N/A	07/08/2021	
	CPRIT Application Receipt System (CARS) opened	11/16/2020	06/03/2021	
	CPRIT Application Receipt System (CARS) closed	02/10/2021	06/03/2021	
	Date application submitted	02/10/2021	06/04/2021	
	Method of submission	CARS	06/04/2021	
	Within receipt period	YES	06/04/2021	
	Request for extension to submit application after CARS closed	N/A	06/04/2021	
	Request for extension for late application submission accepted	N/A	06/04/2021	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	06/04/2021
		Donation(s) made to CPRIT / foundation	NO	06/04/2021
		Assigned to primary reviewers	03/12/2021	06/04/2021
Applicant notified of review panel assignment		03/10/2021	06/02/2021	
Primary Reviewer 1 COI signed		03/03/2021	06/04/2021	
Primary (Advocate) Reviewer 2 COI signed		03/02/2021	06/04/2021	
Primary Reviewer 3 COI signed		03/03/2021	06/04/2021	
Primary Reviewer 4 COI signed		03/03/2021	06/04/2021	
Peer Review Meeting	Primary Reviewer 1 critique submitted	04/11/2021	06/04/2021	
	Primary (Advocate) Reviewer 2 critique submitted	04/12/2021	06/04/2021	
	Primary Reviewer 3 critique submitted	04/09/2021	06/04/2021	
	Primary Reviewer 4 critique submitted	04/18/2021	06/04/2021	
	COI indicated by non-primary reviewer	NONE	06/04/2021	
	COI recused from participation	N/A	06/04/2021	
	Discussed at Peer Review Meeting	YES	06/04/2021	
	Peer Review Meeting	04/26/2021	06/04/2021	
	Peer Review Meeting End Date	04/27/2021	06/04/2021	
	Post review statements signed	04/27/2021	06/04/2021	
	Third Party Observer Report	05/06/2021	06/04/2021	
	Score report delivered to CPO	05/07/2021	06/04/2021	
	Recommended for PRC review	YES	06/04/2021	
Final PRC Recommendation	COI indicated by PRC member	NONE	06/18/2021	
	COI recused from participation	N/A	06/18/2021	
	PRC Meeting	06/17/2021	06/18/2021	
	Third Party Observer Report	06/21/2021	07/09/2021	
	Recommended for grant award	YES	06/18/2021	
	PRC Chair Notification to PIC and OC	06/21/2021	06/24/2021	
PIC Review	COI indicated by PIC member	None	08/03/2021	
	COI recused from participation	N/A	08/03/2021	
	PIC Review Meeting	08/03/2021	08/03/2021	
	Recommended for grant award	YES	08/03/2021	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		

Comments:

Comment

CPRIT uploaded the RFA to Texas.gov eGrants as of 10/14/2020; however, a technical/system error prevented publication.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP210042
Tobacco Control and Lung Cancer Screening

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Tobacco Control and Lung Cancer Screening* Request for Applications (RFA). CPRIT received five applications in response to this RFA. This application was assigned to the prevention panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

On August 28, 2020, I notified Oversight Committee members that I granted the Chief Prevention Officer, Ramona Magid, a waiver from the general prohibition against communicating, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the “CEO Affidavit-Supporting Information” packet.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:28 PM

FY: 2021
CYCLE: 2
PROGRAM: Prevention
MECHANISM: Tobacco Control and Lung Cancer Screening
APPLICATION ID: PP210042
APPLICATION TITLE: A Regional Expansion of Lung Cancer Screening and Patient Navigation (E-LSPAN)
APPLICANT NAME: Argenbright, Keith E
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 21.2_Prevention Panel-1

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CPO	10/08/2020	06/03/2021	
	RFA Approved by CPO (revised)	01/22/2021	06/03/2021	
	RFA published in Texas.gov eGrants	N/A	07/08/2021	
	CPRIT Application Receipt System (CARS) opened	11/16/2020	06/03/2021	
	CPRIT Application Receipt System (CARS) closed	02/10/2021	06/03/2021	
	Date application submitted	02/09/2021	06/04/2021	
	Method of submission	CARS	06/04/2021	
	Within receipt period	YES	06/04/2021	
	Request for extension to submit application after CARS closed	N/A	06/04/2021	
	Request for extension for late application submission accepted	N/A	06/04/2021	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	06/04/2021
		Donation(s) made to CPRIT / foundation	NO	06/04/2021
		Assigned to primary reviewers	03/12/2021	06/04/2021
Applicant notified of review panel assignment		03/10/2021	06/02/2021	
Primary Reviewer 1 COI signed		03/03/2021	06/04/2021	
Primary (Advocate) Reviewer 2 COI signed		03/04/2021	06/04/2021	
Primary Reviewer 3 COI signed		03/08/2021	06/04/2021	
Primary Reviewer 4 COI signed		03/03/2021	06/04/2021	
Peer Review Meeting	Primary Reviewer 1 critique submitted	04/17/2021	06/04/2021	
	Primary (Advocate) Reviewer 2 critique submitted	04/15/2021	06/04/2021	
	Primary Reviewer 3 critique submitted	04/19/2021	06/04/2021	
	Primary Reviewer 4 critique submitted	03/17/2021	06/04/2021	
	COI indicated by non-primary reviewer	NONE	06/04/2021	
	COI recused from participation	N/A	06/04/2021	
	Discussed at Peer Review Meeting	YES	06/04/2021	
	Peer Review Meeting	04/26/2021	06/04/2021	
	Peer Review Meeting End Date	04/27/2021	06/04/2021	
	Post review statements signed	04/27/2021	06/04/2021	
	Third Party Observer Report	05/06/2021	06/04/2021	
	Score report delivered to CPO	05/07/2021	06/04/2021	
	Recommended for PRC review	YES	06/04/2021	
Final PRC Recommendation	COI indicated by PRC member	NONE	06/18/2021	
	COI recused from participation	N/A	06/18/2021	
	PRC Meeting	06/17/2021	06/18/2021	
	Third Party Observer Report	06/21/2021	07/09/2021	
	Recommended for grant award	YES	06/18/2021	
	PRC Chair Notification to PIC and OC	06/21/2021	06/24/2021	
PIC Review	COI indicated by PIC member	None	08/03/2021	
	COI recused from participation	N/A	08/03/2021	
	PIC Review Meeting	08/03/2021	08/03/2021	
	Recommended for grant award	YES	08/03/2021	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		

Comments:
 Comment
CPRIT uploaded the RFA to Texas.gov eGrants as of 10/14/2020; however, a technical/system error prevented publication.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP210044
Tobacco Control and Lung Cancer Screening

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Tobacco Control and Lung Cancer Screening Request for Applications (RFA)*. CPRIT received five applications in response to this RFA. This application was assigned to the prevention panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

On August 28, 2020, I notified Oversight Committee members that I granted the Chief Prevention Officer, Ramona Magid, a waiver from the general prohibition against communicating, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the “CEO Affidavit-Supporting Information” packet.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:28 PM

FY: 2021
CYCLE: 2
PROGRAM: Prevention
MECHANISM: Tobacco Control and Lung Cancer Screening
APPLICATION ID: PP210044
APPLICATION TITLE: Expansion of the Lung Cancer Screening and Tobacco Control (LCTC) Network to Rural and Medically Underserved Populations
APPLICANT NAME: Zoorob, Roger
ORGANIZATION: Baylor College of Medicine
PANEL NAME: 21.2_Prevention Panel-1

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CPO	10/08/2020	06/03/2021	
	RFA Approved by CPO (revised)	01/22/2021	06/03/2021	
	RFA published in Texas.gov eGrants	N/A	07/08/2021	
	CPRIT Application Receipt System (CARS) opened	11/16/2020	06/03/2021	
	CPRIT Application Receipt System (CARS) closed	02/10/2021	06/03/2021	
	Date application submitted	02/05/2021	06/04/2021	
	Method of submission	CARS	06/04/2021	
	Within receipt period	YES	06/04/2021	
	Request for extension to submit application after CARS closed	N/A	06/04/2021	
	Request for extension for late application submission accepted	N/A	06/04/2021	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	06/04/2021
		Donation(s) made to CPRIT / foundation	NO	06/04/2021
		Assigned to primary reviewers	03/12/2021	06/04/2021
Applicant notified of review panel assignment		03/10/2021	06/02/2021	
Primary Reviewer 1 COI signed		03/03/2021	06/04/2021	
Primary (Advocate) Reviewer 2 COI signed		03/04/2021	06/04/2021	
Primary Reviewer 3 COI signed		03/03/2021	06/04/2021	
Primary Reviewer 4 COI signed		03/03/2021	06/04/2021	
Peer Review Meeting	Primary Reviewer 1 critique submitted	03/16/2021	06/04/2021	
	Primary (Advocate) Reviewer 2 critique submitted	04/14/2021	06/04/2021	
	Primary Reviewer 3 critique submitted	04/15/2021	06/04/2021	
	Primary Reviewer 4 critique submitted	04/13/2021	06/04/2021	
	COI indicated by non-primary reviewer	NONE	06/04/2021	
	COI recused from participation	N/A	06/04/2021	
	Discussed at Peer Review Meeting	YES	06/04/2021	
	Peer Review Meeting	04/26/2021	06/04/2021	
	Peer Review Meeting End Date	04/27/2021	06/04/2021	
	Post review statements signed	04/27/2021	06/04/2021	
	Third Party Observer Report	05/06/2021	06/04/2021	
	Score report delivered to CPO	05/07/2021	06/04/2021	
	Recommended for PRC review	YES	06/04/2021	
Final PRC Recommendation	COI indicated by PRC member	NONE	06/18/2021	
	COI recused from participation	N/A	06/18/2021	
	PRC Meeting	06/17/2021	06/18/2021	
	Third Party Observer Report	06/21/2021	07/09/2021	
	Recommended for grant award	YES	06/18/2021	
	PRC Chair Notification to PIC and OC	06/21/2021	06/24/2021	
PIC Review	COI indicated by PIC member	None	08/03/2021	
	COI recused from participation	N/A	08/03/2021	
	PIC Review Meeting	08/03/2021	08/03/2021	
	Recommended for grant award	YES	08/03/2021	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		

Comments:
 Comment
 CPRIT uploaded the RFA to Texas.gov eGrants as of 10/14/2020; however, a technical/system error prevented publication.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR210056
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Dr. Xia Gao, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the cycle 21.10 through 21.12 *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received 21 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Scientific Review Council (SRC) for review. The SRC initially reviewed applications for cycles 21.10 and 21.11 on May 13 and June 10, 2021, respectively. On July 8, 2021 the SRC made its recommendations to the PIC for cycles 21.10, 21.11, and 21.12. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle

- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that two applications, each with a score of 1.0, are not included in the SRC’s recommendations to the PIC. The SRC initially reviewed these two applications on May 13, 2021. However, both applications were withdrawn by the applicant prior to the SRC’s final recommendation to the PIC on July 8, 2021.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 4 day of August, 2021,
 by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:43 PM

FY: 2021
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of First-Time, Tenure-Track Faculty Members
APPLICATION ID: RR210056
APPLICATION TITLE: First-Time, Tenure-Track: Dr. Xia Gao
APPLICANT NAME: Dickinson, Mary
ORGANIZATION: Baylor College of Medicine
PANEL NAME: Recruitment FY21_Cycle 10

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/08/2020	09/03/2020
	RFA Approved by CSO (revised)	09/24/2020	10/20/2020
	RFA published in Texas.gov eGrants	06/12/2020	09/03/2020
	CPRIT Application Receipt Cycle opened	03/23/2021	06/22/2021
	CPRIT Application Receipt Cycle closed	04/20/2021	06/22/2021
	Date application submitted	04/19/2021	06/22/2021
	Method of submission	CARS	06/22/2021
	Within receipt period	YES	06/22/2021
	Receipt, Referral, and Assignment	Administrative review notification	04/23/2021
Donation(s) made to CPRIT / foundation		NO	06/22/2021
Assigned to primary reviewers		05/03/2021	06/22/2021
Applicant notified of review panel assignment		N/A	06/22/2021
Primary Reviewer 1 COI signed		04/23/2021	06/22/2021
Primary Reviewer 2 COI signed		04/29/2021	06/22/2021
Peer Review Meeting		Primary Reviewer 1 critique submitted	05/09/2021
	Primary Reviewer 2 critique submitted	05/12/2021	06/22/2021
	COI indicated by non-primary reviewer	NONE	06/22/2021
	COI recused from participation	N/A	06/22/2021
	Discussed at Peer Review Meeting	YES	06/22/2021
	Peer Review Meeting	05/13/2021	06/22/2021
	Post review statements signed	05/14/2021	06/22/2021
	Third Party Observer Report	05/19/2021	07/23/2021
	Score report delivered to CSO	06/11/2021	06/22/2021
	Recommended for SRC review	YES	06/22/2021
	Final SRC Recommendation	COI indicated by SRC member	NONE
COI recused from participation		N/A	06/22/2021
SRC Meeting		05/13/2021	06/22/2021
Third Party Observer Report		05/19/2021	07/23/2021
Recommended for grant award		Other: No Action	06/22/2021
SRC Chair Notification to PIC and OC		N/A	07/23/2021
COI indicated by SRC member (2nd Meeting)		N/A	07/13/2021
COI recused from participation (2nd Meeting)		N/A	07/13/2021
2nd SRC Meeting		07/08/2021	07/13/2021
Third Party Observer Report (2nd Meeting)		07/16/2021	07/23/2021
Recommended for grant award		YES	07/13/2021
PIC Review	SRC Chair Notification to PIC and OC (2nd Meeting)	07/22/2021	07/23/2021
	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	08/03/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		

CPRIT maintains the identity of the attesting party.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR210059
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Javier Garcia-Bermudez, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the cycle 21.10 through 21.12 *Recruitment of First-Time, Tenure-Track Faculty Members Request for Applications (RFA)*. CPRIT received 21 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Scientific Review Council (SRC) for review. The SRC initially reviewed applications for cycles 21.10 and 21.11 on May 13 and June 10, 2021, respectively. On July 8, 2021, the SRC made its recommendations to the PIC for cycles 21.10, 21.11, and 21.12. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle

- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that two applications, each with a score of 1.0, are not included in the SRC's recommendations to the PIC. The SRC initially reviewed these two applications on May 13, 2021. However, both applications were withdrawn by the applicant prior to the SRC's final recommendation to the PIC on July 8, 2021.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 4 day of August, 2021, by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:43 PM

FY: 2021
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of First-Time, Tenure-Track Faculty Members
APPLICATION ID: RR210059
APPLICATION TITLE: Nomination of Javier Garcia-Bermudez, Ph.D. for a CPRIT Recruitment of First-Time Tenure-Track Faculty Members
APPLICANT NAME: Lee, W. P. Andrew
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: Recruitment FY21_Cycle 10

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/08/2020	09/03/2020
	RFA Approved by CSO (revised)	09/24/2020	10/20/2020
	RFA published in Texas.gov eGrants	06/12/2020	09/03/2020
	CPRIT Application Receipt Cycle opened	03/23/2021	06/22/2021
	CPRIT Application Receipt Cycle closed	04/20/2021	06/22/2021
	Date application submitted	04/19/2021	06/22/2021
	Method of submission	CARS	06/22/2021
	Within receipt period	YES	06/22/2021
	Receipt, Referral, and Assignment	Administrative review notification	04/23/2021
Donation(s) made to CPRIT / foundation		NO	06/22/2021
Assigned to primary reviewers		05/03/2021	06/22/2021
Applicant notified of review panel assignment		N/A	06/22/2021
Primary Reviewer 1 COI signed		04/23/2021	06/22/2021
Primary Reviewer 2 COI signed		04/28/2021	06/22/2021
Peer Review Meeting		Primary Reviewer 1 critique submitted	05/11/2021
	Primary Reviewer 2 critique submitted	05/11/2021	06/22/2021
	COI indicated by non-primary reviewer	NONE	06/22/2021
	COI recused from participation	N/A	06/22/2021
	Discussed at Peer Review Meeting	YES	06/22/2021
	Peer Review Meeting	05/13/2021	06/22/2021
	Post review statements signed	05/14/2021	06/22/2021
	Third Party Observer Report	05/19/2021	07/23/2021
	Score report delivered to CSO	06/11/2021	06/22/2021
	Recommended for SRC review	YES	06/22/2021
	Final SRC Recommendation	COI indicated by SRC member	NONE
COI recused from participation		N/A	06/22/2021
SRC Meeting		05/13/2021	06/22/2021
Third Party Observer Report		05/19/2021	07/23/2021
Recommended for grant award		Other: No Action	06/22/2021
SRC Chair Notification to PIC and OC		N/A	07/23/2021
COI indicated by SRC member (2nd Meeting)		N/A	07/13/2021
COI recused from participation (2nd Meeting)		N/A	07/13/2021
2nd SRC Meeting		07/08/2021	07/13/2021
Third Party Observer Report (2nd Meeting)		07/16/2021	07/23/2021
Recommended for grant award		YES	07/13/2021
PIC Review	SRC Chair Notification to PIC and OC (2nd Meeting)	07/22/2021	07/23/2021
	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	08/03/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	N/A	
	Advance authority approved by Oversight Committee	N/A	



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR210066
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Dr. Chad W. Johnston, DrPH

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the cycle 21.10 through 21.12 *Recruitment of First-Time, Tenure-Track Faculty Members Request for Applications (RFA)*. CPRIT received 21 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Scientific Review Council (SRC) for review. The SRC initially reviewed applications for cycles 21.10 and 21.11 on May 13 and June 10, 2021, respectively. On July 8, 2021, the SRC made its recommendations to the PIC for cycles 21.10, 21.11, and 21.12. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle

- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that two applications, each with a score of 1.0, are not included in the SRC’s recommendations to the PIC. The SRC initially reviewed these two applications on May 13, 2021. However, both applications were withdrawn by the applicant prior to the SRC’s final recommendation to the PIC on July 8, 2021.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 4 day of August, 2021, by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:43 PM

FY: 2021
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of First-Time, Tenure-Track Faculty Members
APPLICATION ID: RR210066
APPLICATION TITLE: First-Time, Tenure-Track: Dr. Chad W. Johnston
APPLICANT NAME: Dickinson, Mary
ORGANIZATION: Baylor College of Medicine
PANEL NAME: Recruitment FY21_Cycle 11

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/08/2020	09/03/2020
	RFA Approved by CSO (revised)	09/24/2020	10/20/2020
	RFA published in Texas.gov eGrants	06/12/2020	09/03/2020
	CPRIT Application Receipt Cycle opened	04/21/2021	06/23/2021
	CPRIT Application Receipt Cycle closed	05/20/2021	06/23/2021
	Date application submitted	05/18/2021	06/23/2021
	Method of submission	CARS	06/23/2021
	Within receipt period	YES	06/23/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	06/23/2021
Assigned to primary reviewers		05/28/2021	06/23/2021
Applicant notified of review panel assignment		N/A	06/23/2021
Primary Reviewer 1 COI signed		05/27/2021	06/23/2021
Primary Reviewer 2 COI signed		05/26/2021	06/23/2021
Peer Review Meeting		Primary Reviewer 1 critique submitted	06/07/2021
	Primary Reviewer 2 critique submitted	06/08/2021	06/23/2021
	COI indicated by non-primary reviewer	NONE	06/23/2021
	COI recused from participation	N/A	06/23/2021
	Discussed at Peer Review Meeting	YES	06/23/2021
	Peer Review Meeting	06/10/2021	06/23/2021
	Post review statements signed	06/15/2021	06/23/2021
	Third Party Observer Report	06/21/2021	07/23/2021
	Score report delivered to CSO	06/18/2021	06/23/2021
	Recommended for SRC review	YES	06/23/2021
	Final SRC Recommendation	COI indicated by SRC member	NONE
COI recused from participation		N/A	06/23/2021
SRC Meeting		06/10/2021	06/23/2021
Third Party Observer Report		06/21/2021	07/23/2021
Recommended for grant award		Other: No Action	06/23/2021
SRC Chair Notification to PIC and OC		N/A	07/23/2021
COI indicated by SRC member (2nd Meeting)		N/A	07/13/2021
COI recused from participation (2nd Meeting)		N/A	07/13/2021
2nd SRC Meeting		07/08/2021	07/13/2021
Third Party Observer Report (2nd Meeting)		07/16/2021	07/23/2021
Recommended for grant award		YES	07/13/2021
PIC Review	SRC Chair Notification to PIC and OC (2nd Meeting)	07/22/2021	07/23/2021
	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	08/03/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR210070
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Shih-Han Lee, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the cycle 21.10 through 21.12 *Recruitment of First-Time, Tenure-Track Faculty Members Request for Applications (RFA)*. CPRIT received 21 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Scientific Review Council (SRC) for review. The SRC initially reviewed applications for cycles 21.10 and 21.11 on May 13 and June 10, 2021, respectively. On July 8, 2021, the SRC made its recommendations to the PIC for cycles 21.10, 21.11, and 21.12. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle

- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that two applications, each with a score of 1.0, are not included in the SRC’s recommendations to the PIC. The SRC initially reviewed these two applications on May 13, 2021. However, both applications were withdrawn by the applicant prior to the SRC’s final recommendation to the PIC on July 8, 2021.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 4 day of August, 2021,
 by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:43 PM

FY: 2021
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of First-Time, Tenure-Track Faculty Members
APPLICATION ID: RR210070
APPLICATION TITLE: Recruitment of First-Time, Tenure-Track Faculty Members - Shih-Han Lee
APPLICANT NAME: Draetta, Gulio
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: Recruitment FY21_Cycle 11

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	06/08/2020	09/03/2020	
	RFA Approved by CSO (revised)	09/24/2020	10/20/2020	
	RFA published in Texas.gov eGrants	06/12/2020	09/03/2020	
	CPRIT Application Receipt Cycle opened	04/21/2021	06/23/2021	
	CPRIT Application Receipt Cycle closed	05/20/2021	06/23/2021	
	Date application submitted	05/20/2021	06/23/2021	
	Method of submission	CARS	06/23/2021	
	Within receipt period	YES	06/23/2021	
	Receipt, Referral, and Assignment	Administrative review notification	05/26/2021	06/23/2021
Donation(s) made to CPRIT / foundation		NO	06/23/2021	
Assigned to primary reviewers		05/28/2021	06/23/2021	
Applicant notified of review panel assignment		N/A	06/23/2021	
Primary Reviewer 1 COI signed		05/27/2021	06/23/2021	
Primary Reviewer 2 COI signed		05/25/2021	06/23/2021	
Peer Review Meeting		Primary Reviewer 1 critique submitted	06/08/2021	06/23/2021
	Primary Reviewer 2 critique submitted	06/08/2021	06/23/2021	
	COI indicated by non-primary reviewer	Richard O'Reilly	06/23/2021	
	COI recused from participation	YES	06/23/2021	
	Discussed at Peer Review Meeting	YES	06/23/2021	
	Peer Review Meeting	06/10/2021	06/23/2021	
	Post review statements signed	06/15/2021	06/23/2021	
	Third Party Observer Report	06/21/2021	07/23/2021	
	Score report delivered to CSO	06/18/2021	06/23/2021	
	Recommended for SRC review	YES	06/23/2021	
	Final SRC Recommendation	COI indicated by SRC member	Richard O'Reilly	06/23/2021
		COI recused from participation	YES	06/23/2021
		SRC Meeting	06/10/2021	06/23/2021
Third Party Observer Report		06/21/2021	07/23/2021	
Recommended for grant award		Other: No Action	06/23/2021	
SRC Chair Notification to PIC and OC		N/A	07/23/2021	
COI indicated by SRC member (2nd Meeting)		N/A	07/13/2021	
COI recused from participation (2nd Meeting)		N/A	07/13/2021	
2nd SRC Meeting		07/08/2021	07/13/2021	
Third Party Observer Report (2nd Meeting)		07/16/2021	07/23/2021	
Recommended for grant award		YES	07/13/2021	
SRC Chair Notification to PIC and OC (2nd Meeting)		07/22/2021	07/23/2021	
PIC Review	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	08/03/2021	
	COI indicated by PIC member	None	08/03/2021	
	COI recused from participation	N/A	08/03/2021	
	PIC Review Meeting	08/03/2021	08/03/2021	
	Recommended for grant award	YES	08/03/2021	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	NO		
	Authority to advance funds requested	N/A		
Advance authority approved by Oversight Committee	N/A			



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR210077
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Edward J. Grow, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the cycle 21.10 through 21.12 *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received 21 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Scientific Review Council (SRC) for review. The SRC initially reviewed applications for cycles 21.10 and 21.11 on May 13 and June 10, 2021, respectively. On July 8, 2021, the SRC made its recommendations to the PIC for cycles 21.10, 21.11, and 21.12. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle

- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle



I note that two applications, each with a score of 1.0, are not included in the SRC's recommendations to the PIC. The SRC initially reviewed these two applications on May 13, 2021. However, both applications were withdrawn by the applicant prior to the SRC's final recommendation to the PIC on July 8, 2021.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas County of Travis
SWORN to and SUBSCRIBED before me, the undersigned authority, on the <u>4</u> day of <u>August</u> , 2021, by WAYNE R. ROBERTS.
 _____ Melanie Cleveland Notary Public, State of Texas


CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:43 PM

FY: 2021
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of First-Time, Tenure-Track Faculty Members
APPLICATION ID: RR210077
APPLICATION TITLE: Nomination of Edward J. Grow, Ph.D. for a CPRIT First-Time Tenure-Track Faculty Member Award
APPLICANT NAME: Lee, W. P. Andrew
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: Recruitment FY21_Cycle 11

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/08/2020	09/03/2020
	RFA Approved by CSO (revised)	09/24/2020	10/20/2020
	RFA published in Texas.gov eGrants	06/12/2020	09/03/2020
	CPRIT Application Receipt Cycle opened	04/21/2021	06/23/2021
	CPRIT Application Receipt Cycle closed	05/20/2021	06/23/2021
	Date application submitted	05/17/2021	06/23/2021
	Method of submission	CARS	06/23/2021
	Within receipt period	YES	06/23/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	06/23/2021
Assigned to primary reviewers		05/28/2021	06/23/2021
Applicant notified of review panel assignment		N/A	06/23/2021
Primary Reviewer 1 COI signed		05/27/2021	06/23/2021
Primary Reviewer 2 COI signed		05/25/2021	06/23/2021
Peer Review Meeting		Primary Reviewer 1 critique submitted	06/08/2021
	Primary Reviewer 2 critique submitted	06/03/2021	06/23/2021
	COI indicated by non-primary reviewer	NONE	06/23/2021
	COI recused from participation	N/A	06/23/2021
	Discussed at Peer Review Meeting	YES	06/23/2021
	Peer Review Meeting	06/10/2021	06/23/2021
	Post review statements signed	06/15/2021	06/23/2021
	Third Party Observer Report	06/21/2021	07/23/2021
	Score report delivered to CSO	06/18/2021	06/23/2021
	Recommended for SRC review	YES	06/23/2021
	Final SRC Recommendation	COI indicated by SRC member	NONE
COI recused from participation		N/A	06/23/2021
SRC Meeting		06/10/2021	06/23/2021
Third Party Observer Report		06/21/2021	07/23/2021
Recommended for grant award		Other: No Action	06/23/2021
SRC Chair Notification to PIC and OC		N/A	07/23/2021
COI indicated by SRC member (2nd Meeting)		N/A	07/13/2021
COI recused from participation (2nd Meeting)		N/A	07/13/2021
2nd SRC Meeting		07/08/2021	07/13/2021
Third Party Observer Report (2nd Meeting)		07/16/2021	07/23/2021
Recommended for grant award		YES	07/13/2021
PIC Review	SRC Chair Notification to PIC and OC (2nd Meeting)	07/22/2021	07/23/2021
	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	08/03/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	N/A	
	Advance authority approved by Oversight Committee	N/A	



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR210080
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Jason George, M.D., Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the cycle 21.10 through 21.12 *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received 21 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Scientific Review Council (SRC) for review. The SRC initially reviewed applications for cycles 21.10 and 21.11 on May 13 and June 10, 2021, respectively. On July 8, 2021, the SRC made its recommendations to the PIC for cycles 21.10, 21.11, and 21.12. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle

- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that two applications, each with a score of 1.0, are not included in the SRC's recommendations to the PIC. The SRC initially reviewed these two applications on May 13, 2021. However, both applications were withdrawn by the applicant prior to the SRC's final recommendation to the PIC on July 8, 2021.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 4 day of August, 2021, by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:44 PM

FY: 2021
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of First-Time, Tenure-Track Faculty Members
APPLICATION ID: RR210080
APPLICATION TITLE: Recruitment of First Time Tenure Track Faculty Member-Jason George
APPLICANT NAME: Banks, Margaret K
ORGANIZATION: Texas A&M Engineering Experiment Station
PANEL NAME: Recruitment FY21_Cycle 11

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/08/2020	09/03/2020
	RFA Approved by CSO (revised)	09/24/2020	10/20/2020
	RFA published in Texas.gov eGrants	06/12/2020	09/03/2020
	CPRIT Application Receipt Cycle opened	04/21/2021	06/23/2021
	CPRIT Application Receipt Cycle closed	05/20/2021	06/23/2021
	Date application submitted	05/20/2021	06/23/2021
	Method of submission	CARS	06/23/2021
	Within receipt period	YES	06/23/2021
	Receipt, Referral, and Assignment	Administrative review notification	05/26/2021
Donation(s) made to CPRIT / foundation		NO	06/23/2021
Assigned to primary reviewers		05/28/2021	06/23/2021
Applicant notified of review panel assignment		N/A	06/23/2021
Primary Reviewer 1 COI signed		05/26/2021	06/23/2021
Primary Reviewer 2 COI signed		05/25/2021	06/23/2021
Peer Review Meeting		Primary Reviewer 1 critique submitted	06/08/2021
	Primary Reviewer 2 critique submitted	06/08/2021	06/23/2021
	COI indicated by non-primary reviewer	NONE	06/23/2021
	COI recused from participation	N/A	06/23/2021
	Discussed at Peer Review Meeting	YES	06/23/2021
	Peer Review Meeting	06/10/2021	06/23/2021
	Post review statements signed	06/15/2021	06/23/2021
	Third Party Observer Report	06/21/2021	07/23/2021
	Score report delivered to CSO	06/18/2021	06/23/2021
	Recommended for SRC review	YES	06/23/2021
	Final SRC Recommendation	COI indicated by SRC member	NONE
COI recused from participation		N/A	06/23/2021
SRC Meeting		06/10/2021	06/23/2021
Third Party Observer Report		06/21/2021	07/23/2021
Recommended for grant award		Other: No Action	06/23/2021
SRC Chair Notification to PIC and OC		N/A	07/23/2021
COI indicated by SRC member (2nd Meeting)		N/A	07/13/2021
COI recused from participation (2nd Meeting)		N/A	07/13/2021
2nd SRC Meeting		07/08/2021	07/13/2021
Third Party Observer Report (2nd Meeting)		07/16/2021	07/23/2021
Recommended for grant award		YES	07/13/2021
PIC Review	SRC Chair Notification to PIC and OC (2nd Meeting)	07/22/2021	07/23/2021
	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	08/03/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR210082
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Dr. Kyle Eagen, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the cycle 21.10 through 21.12 *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received 21 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Scientific Review Council (SRC) for review. The SRC initially reviewed applications for cycles 21.10 and 21.11 on May 13 and June 10, 2021, respectively. On July 8, 2021, the SRC made its recommendations to the PIC for cycles 21.10, 21.11, and 21.12. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle

- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that two applications, each with a score of 1.0, are not included in the SRC’s recommendations to the PIC. The SRC initially reviewed these two applications on May 13, 2021. However, both applications were withdrawn by the applicant prior to the SRC’s final recommendation to the PIC on July 8, 2021.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 4 day of August, 2021,
 by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:44 PM

FY: 2021
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of First-Time, Tenure-Track Faculty Members
APPLICATION ID: RR210082
APPLICATION TITLE: First-Time, Tenure-Track : Dr. Kyle Eagen
APPLICANT NAME: Dickinson, Mary
ORGANIZATION: Baylor College of Medicine
PANEL NAME: Recruitment FY21_Cycle 12

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/08/2020	09/03/2020
	RFA Approved by CSO (revised)	09/24/2020	10/20/2020
	RFA published in Texas.gov eGrants	06/12/2020	09/03/2020
	CPRIT Application Receipt Cycle opened	05/21/2021	07/13/2021
	CPRIT Application Receipt Cycle closed	06/21/2021	07/13/2021
	Date application submitted	06/21/2021	07/13/2021
	Method of submission	CARS	07/13/2021
	Within receipt period	YES	07/13/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/13/2021
Assigned to primary reviewers		06/29/2021	07/13/2021
Applicant notified of review panel assignment		N/A	07/13/2021
Primary Reviewer 1 COI signed		06/24/2021	07/13/2021
Primary Reviewer 2 COI signed		06/24/2021	07/13/2021
Peer Review Meeting		Primary Reviewer 1 critique submitted	07/04/2021
	Primary Reviewer 2 critique submitted	07/06/2021	07/13/2021
	COI indicated by non-primary reviewer	NONE	07/13/2021
	COI recused from participation	N/A	07/13/2021
	Discussed at Peer Review Meeting	YES	07/13/2021
	Peer Review Meeting	07/08/2021	07/13/2021
	Post review statements signed	07/12/2021	07/13/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Score report delivered to CSO	07/12/2021	07/13/2021
	Recommended for SRC review	YES	07/13/2021
	Final SRC Recommendation	COI indicated by SRC member	NONE
COI recused from participation		N/A	07/13/2021
SRC Meeting		07/08/2021	07/13/2021
Third Party Observer Report		07/16/2021	07/23/2021
Recommended for grant award		YES	07/13/2021
SRC Chair Notification to PIC and OC		07/22/2021	07/23/2021
PIC Review	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	08/03/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
	Recommended for grant award	YES	08/03/2021
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	N/A	
	Advance authority approved by Oversight Committee	N/A	

CPRIT maintains the identity of the attesting party.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR210083
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of David Braun, M.D., Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the cycle 21.10 through 21.12 *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received 21 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Scientific Review Council (SRC) for review. The SRC initially reviewed applications for cycles 21.10 and 21.11 on May 13 and June 10, 2021, respectively. On July 8, 2021, the SRC made its recommendations to the PIC for cycles 21.10, 21.11, and 21.12. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle

- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that two applications, each with a score of 1.0, are not included in the SRC’s recommendations to the PIC. The SRC initially reviewed these two applications on May 13, 2021. However, both applications were withdrawn by the applicant prior to the SRC’s final recommendation to the PIC on July 8, 2021.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 4 day of August, 2021,
 by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:44 PM

FY: 2021
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of First-Time, Tenure-Track Faculty Members
APPLICATION ID: RR210083
APPLICATION TITLE: Recruitment of First-Time, Tenure-Track Faculty Members - David Braun
APPLICANT NAME: Draetta, Gulio
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: Recruitment FY21_Cycle 12

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/08/2020	09/03/2020
	RFA Approved by CSO (revised)	09/24/2020	10/20/2020
	RFA published in Texas.gov eGrants	06/12/2020	09/03/2020
	CPRIT Application Receipt Cycle opened	05/21/2021	07/13/2021
	CPRIT Application Receipt Cycle closed	06/21/2021	07/13/2021
	Date application submitted	06/18/2021	07/13/2021
	Method of submission	CARS	07/13/2021
	Within receipt period	YES	07/13/2021
	Receipt, Referral, and Assignment	Administrative review notification	06/24/2021
Donation(s) made to CPRIT / foundation		NO	07/13/2021
Assigned to primary reviewers		06/29/2021	07/13/2021
Applicant notified of review panel assignment		N/A	07/13/2021
Primary Reviewer 1 COI signed		06/24/2021	07/13/2021
Primary Reviewer 2 COI signed		06/28/2021	07/13/2021
Peer Review Meeting		Primary Reviewer 1 critique submitted	07/07/2021
	Primary Reviewer 2 critique submitted	07/06/2021	07/13/2021
	COI indicated by non-primary reviewer	Myles Brown	07/13/2021
	COI recused from participation	YES	07/13/2021
	Discussed at Peer Review Meeting	YES	07/13/2021
	Peer Review Meeting	07/08/2021	07/13/2021
	Post review statements signed	07/12/2021	07/13/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Score report delivered to CSO	07/12/2021	07/13/2021
	Recommended for SRC review	YES	07/13/2021
	Final SRC Recommendation	COI indicated by SRC member	Myles Brown
COI recused from participation		YES	07/13/2021
SRC Meeting		07/08/2021	07/13/2021
Third Party Observer Report		07/16/2021	07/23/2021
Recommended for grant award		YES	07/13/2021
SRC Chair Notification to PIC and OC		07/22/2021	07/23/2021
PIC Review	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	08/03/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
	Recommended for grant award	YES	08/03/2021
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	N/A	
	Advance authority approved by Oversight Committee	N/A	

CPRIT maintains the identity of the attesting party.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR210085
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Yuan Pan, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the cycle 21.10 through 21.12 *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received 21 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Scientific Review Council (SRC) for review. The SRC initially reviewed applications for cycles 21.10 and 21.11 on May 13 and June 10, 2021, respectively. On July 8, 2021, the SRC made its recommendations to the PIC for cycles 21.10, 21.11, and 21.12. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle

- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that two applications, each with a score of 1.0, are not included in the SRC’s recommendations to the PIC. The SRC initially reviewed these two applications on May 13, 2021. However, both applications were withdrawn by the applicant prior to the SRC’s final recommendation to the PIC on July 8, 2021.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 4 day of August, 2021, by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:44 PM

FY: 2021
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of First-Time, Tenure-Track Faculty Members
APPLICATION ID: RR210085
APPLICATION TITLE: Recruitment of First-Time, Tenure-Track Faculty Members - Yuan Pan
APPLICANT NAME: Draetta, Gulio
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: Recruitment FY21_Cycle 12

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/08/2020	09/03/2020
	RFA Approved by CSO (revised)	09/24/2020	10/20/2020
	RFA published in Texas.gov eGrants	06/12/2020	09/03/2020
	CPRIT Application Receipt Cycle opened	05/21/2021	07/13/2021
	CPRIT Application Receipt Cycle closed	06/21/2021	07/13/2021
	Date application submitted	06/15/2021	07/13/2021
	Method of submission	CARS	07/13/2021
	Within receipt period	YES	07/13/2021
	Receipt, Referral, and Assignment	Administrative review notification	06/24/2021
Donation(s) made to CPRIT / foundation		NO	07/13/2021
Assigned to primary reviewers		06/29/2021	07/13/2021
Applicant notified of review panel assignment		N/A	07/13/2021
Primary Reviewer 1 COI signed		06/24/2021	07/13/2021
Primary Reviewer 2 COI signed		06/28/2021	07/13/2021
Peer Review Meeting	Primary Reviewer 1 critique submitted	07/06/2021	07/13/2021
	Primary Reviewer 2 critique submitted	07/05/2021	07/13/2021
	COI indicated by non-primary reviewer	NONE	07/13/2021
	COI recused from participation	N/A	07/13/2021
	Discussed at Peer Review Meeting	YES	07/13/2021
	Peer Review Meeting	07/08/2021	07/13/2021
	Post review statements signed	07/12/2021	07/13/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Score report delivered to CSO	07/12/2021	07/13/2021
	Recommended for SRC review	YES	07/13/2021
	Final SRC Recommendation	COI indicated by SRC member	NONE
COI recused from participation		N/A	07/13/2021
SRC Meeting		07/08/2021	07/13/2021
Third Party Observer Report		07/16/2021	07/23/2021
Recommended for grant award		YES	07/13/2021
SRC Chair Notification to PIC and OC		07/22/2021	07/23/2021
PIC Review	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	08/03/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
	Recommended for grant award	YES	08/03/2021
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	N/A	
	Advance authority approved by Oversight Committee	N/A	

CPRIT maintains the identity of the attesting party.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR210086
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Seungwon "Sebastian" Choi, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the cycle 21.10 through 21.12 *Recruitment of First-Time, Tenure-Track Faculty Members Request for Applications (RFA)*. CPRIT received 21 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Scientific Review Council (SRC) for review. The SRC initially reviewed applications for cycles 21.10 and 21.11 on May 13 and June 10, 2021, respectively. On July 8, 2021, the SRC made its recommendations to the PIC for cycles 21.10, 21.11, and 21.12. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle

- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that two applications, each with a score of 1.0, are not included in the SRC’s recommendations to the PIC. The SRC initially reviewed these two applications on May 13, 2021. However, both applications were withdrawn by the applicant prior to the SRC’s final recommendation to the PIC on July 8, 2021.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 4 day of August, 2021,
 by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:44 PM

FY: 2021
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of First-Time, Tenure-Track Faculty Members
APPLICATION ID: RR210086
APPLICATION TITLE: Recruitment of Seungwon "Sebastian" Choi, Ph.D. for a CPRIT First-Time Tenure-Track Faculty Member Award
APPLICANT NAME: Lee, W. P. Andrew
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: Recruitment FY21_Cycle 12

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/08/2020	09/03/2020
	RFA Approved by CSO (revised)	09/24/2020	10/20/2020
	RFA published in Texas.gov eGrants	06/12/2020	09/03/2020
	CPRIT Application Receipt Cycle opened	05/21/2021	07/13/2021
	CPRIT Application Receipt Cycle closed	06/21/2021	07/13/2021
	Date application submitted	06/15/2021	07/13/2021
	Method of submission	CARS	07/13/2021
	Within receipt period	YES	07/13/2021
	Receipt, Referral, and Assignment	Administrative review notification	06/24/2021
Donation(s) made to CPRIT / foundation		NO	07/13/2021
Assigned to primary reviewers		06/29/2021	07/13/2021
Applicant notified of review panel assignment		N/A	07/13/2021
Primary Reviewer 1 COI signed		06/28/2021	07/13/2021
Primary Reviewer 2 COI signed		06/24/2021	07/13/2021
Peer Review Meeting	Primary Reviewer 1 critique submitted	07/05/2021	07/13/2021
	Primary Reviewer 2 critique submitted	07/05/2021	07/13/2021
	COI indicated by non-primary reviewer	NONE	07/13/2021
	COI recused from participation	N/A	07/13/2021
	Discussed at Peer Review Meeting	YES	07/13/2021
	Peer Review Meeting	07/08/2021	07/13/2021
	Post review statements signed	07/12/2021	07/13/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Score report delivered to CSO	07/12/2021	07/13/2021
	Recommended for SRC review	YES	07/13/2021
Final SRC Recommendation	COI indicated by SRC member	NONE	07/26/2021
	COI recused from participation	N/A	07/26/2021
	SRC Meeting	07/08/2021	07/26/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/26/2021
	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
PIC Review	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	08/03/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
	Recommended for grant award	YES	08/03/2021
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	N/A	
	Advance authority approved by Oversight Committee	N/A	

CPRIT maintains the identity of the attesting party.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR210067
Recruitment of Rising Stars
Nomination of Dr. Yong Lu, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the cycle 21.10 through 21.12 *Recruitment of Rising Stars* Request for Applications (RFA). CPRIT received three applications in response to this RFA. This application was assigned to the Scientific Review Council (SRC) for review. The SRC initially reviewed applications for cycles 21.10 and 21.11 on May 13 and June 10, 2021, respectively. On July 8, 2021, the SRC made its recommendations to the PIC for cycles 21.10, 21.11, and 21.12. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle

- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:43 PM

FY: 2021
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of Rising Stars
APPLICATION ID: RR210067
APPLICATION TITLE: Overcoming Barriers to Adoptive Cell Therapy in Solid tumors
APPLICANT NAME: Sostman, Henry D
ORGANIZATION: The Methodist Hospital Research Institute
PANEL NAME: Recruitment FY21_Cycle 11

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/08/2020	12/22/2020
	RFA Approved by CSO (revised)	10/22/2020	12/22/2020
	RFA published in Texas.gov eGrants	06/12/2020	12/22/2020
	CPRIT Application Receipt Cycle opened	04/21/2021	06/23/2021
	CPRIT Application Receipt Cycle closed	05/20/2021	06/23/2021
	Date application submitted	05/13/2021	06/23/2021
	Method of submission	CARS	06/23/2021
	Within receipt period	YES	06/23/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	06/23/2021
Assigned to primary reviewers		05/28/2021	06/23/2021
Applicant notified of review panel assignment		N/A	06/23/2021
Primary Reviewer 1 COI signed		05/25/2021	06/23/2021
Primary Reviewer 2 COI signed		05/27/2021	06/23/2021
Peer Review Meeting		Primary Reviewer 1 critique submitted	06/08/2021
	Primary Reviewer 2 critique submitted	06/08/2021	06/23/2021
	COI indicated by non-primary reviewer	NONE	06/23/2021
	COI recused from participation	N/A	06/23/2021
	Discussed at Peer Review Meeting	YES	06/23/2021
	Peer Review Meeting	06/10/2021	06/23/2021
	Post review statements signed	06/15/2021	06/23/2021
	Third Party Observer Report	06/21/2021	07/23/2021
	Score report delivered to CSO	06/18/2021	06/23/2021
	Recommended for SRC review	YES	06/23/2021
	Final SRC Recommendation	COI indicated by SRC member	NONE
COI recused from participation		N/A	06/23/2021
SRC Meeting		06/10/2021	06/23/2021
Third Party Observer Report		06/21/2021	07/23/2021
Recommended for grant award		Other: No Action	06/23/2021
SRC Chair Notification to PIC and OC		N/A	07/23/2021
COI indicated by SRC member (2nd Meeting)		N/A	07/13/2021
COI recused from participation (2nd Meeting)		N/A	07/13/2021
2nd SRC Meeting		07/08/2021	07/13/2021
Third Party Observer Report (2nd Meeting)		07/16/2021	07/23/2021
Recommended for grant award		YES	07/13/2021
SRC Chair Notification to PIC and OC (2nd Meeting)	07/22/2021	07/23/2021	
PIC Review	Candidate not accepted position prior to SRC date	YES	08/03/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
	Recommended for grant award	YES	08/03/2021
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		

CPRIT maintains the identity of the attesting party.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR210079
Recruitment of Rising Stars
Nomination of Tian Zhang, M.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the cycle 21.10 through 21.12 *Recruitment of Rising Stars* Request for Applications (RFA). CPRIT received three applications in response to this RFA. This application was assigned to the Scientific Review Council (SRC) for review. The SRC initially reviewed applications for cycles 21.10 and 21.11 on May 13 and June 10, 2021, respectively. On July 8, 2021, the SRC made its recommendations to the PIC for cycles 21.10, 21.11, and 21.12. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle

- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 4 day of August, 2021,
 by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:44 PM

FY: 2021
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of Rising Stars
APPLICATION ID: RR210079
APPLICATION TITLE: Nomination of Tian Zhang, M.D. for a CPRIT Rising Stars Award
APPLICANT NAME: Lee, W. P. Andrew
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: Recruitment FY21_Cycle 11

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	06/08/2020	12/22/2020	
	RFA Approved by CSO (revised)	10/22/2020	12/22/2020	
	RFA published in Texas.gov eGrants	06/12/2020	12/22/2020	
	CPRIT Application Receipt Cycle opened	04/21/2021	06/23/2021	
	CPRIT Application Receipt Cycle closed	05/20/2021	06/23/2021	
	Date application submitted	05/17/2021	06/23/2021	
	Method of submission	CARS	06/23/2021	
	Within receipt period	YES	06/23/2021	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	06/23/2021
Donation(s) made to CPRIT / foundation		NO	06/23/2021	
Assigned to primary reviewers		05/28/2021	06/23/2021	
Applicant notified of review panel assignment		N/A	06/23/2021	
Primary Reviewer 1 COI signed		05/27/2021	06/23/2021	
Primary Reviewer 2 COI signed		05/25/2021	06/23/2021	
Peer Review Meeting		Primary Reviewer 1 critique submitted	06/08/2021	06/23/2021
	Primary Reviewer 2 critique submitted	06/08/2021	06/23/2021	
	COI indicated by non-primary reviewer	NONE	06/23/2021	
	COI recused from participation	N/A	06/23/2021	
	Discussed at Peer Review Meeting	YES	06/23/2021	
	Peer Review Meeting	06/10/2021	06/23/2021	
	Post review statements signed	06/15/2021	06/23/2021	
	Third Party Observer Report	06/21/2021	07/23/2021	
	Score report delivered to CSO	06/18/2021	06/23/2021	
	Recommended for SRC review	YES	06/23/2021	
	Final SRC Recommendation	COI indicated by SRC member	NONE	06/23/2021
		COI recused from participation	N/A	06/23/2021
		SRC Meeting	06/10/2021	06/23/2021
Third Party Observer Report		06/21/2021	07/23/2021	
Recommended for grant award		Other: No Action	06/23/2021	
SRC Chair Notification to PIC and OC		N/A	07/23/2021	
COI indicated by SRC member (2nd Meeting)		N/A	07/13/2021	
COI recused from participation (2nd Meeting)		N/A	07/13/2021	
2nd SRC Meeting		07/08/2021	07/13/2021	
Third Party Observer Report (2nd Meeting)		07/16/2021	07/23/2021	
Recommended for grant award		YES	07/13/2021	
SRC Chair Notification to PIC and OC (2nd Meeting)	07/22/2021	07/23/2021		
PIC Review	Candidate not accepted position prior to SRC date	YES	08/03/2021	
	COI indicated by PIC member	None	08/03/2021	
	COI recused from participation	N/A	08/03/2021	
	PIC Review Meeting	08/03/2021	08/03/2021	
	Recommended for grant award	YES	08/03/2021	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	NO		
	Authority to advance funds requested	N/A		
Advance authority approved by Oversight Committee	N/A			

CPRIT maintains the identity of the attesting party.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210064
Core Facility Support Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Core Facility Support Awards* Request for Applications (RFA). CPRIT received 25 applications in response to this RFA. This application was assigned to the cancer prevention research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle



I note that the Scientific Review Council (SRC) did not recommend an application responsive to this RFA that has a score equal to three other applications that were recommended. As allowed by 25 T.A.C. § 703.6(d)(1), a review council's numerical rank order is substantially based on the final overall evaluation score assigned by the peer review panels, but it may also consider how well a grant application achieves program priorities set by the Oversight Committee, the overall program portfolio balance, and any other criteria described in the RFA. I am satisfied that the SRC acted with appropriate discretion allowed to them by CPRIT's administrative rules.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas County of Travis
SWORN to and SUBSCRIBED before me, the undersigned authority, on the <u>4</u> day of <u>August</u> , 2021, by WAYNE R. ROBERTS.
 _____ Melanie Cleveland Notary Public, State of Texas


CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:28 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: Core Facilities Support Awards
APPLICATION ID: RP210064
APPLICATION TITLE: The Adolescent and Childhood Cancer Epidemiology and Susceptibility Service (ACCESS) for Texas
APPLICANT NAME: Scheurer, Michael E
ORGANIZATION: Baylor College of Medicine
PANEL NAME: 21.2 CPR

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/27/2021	07/10/2021
	Method of submission	CARS	07/10/2021
	Within receipt period	YES	07/10/2021
	Request for extension to submit application after CARS closed	N/A	07/10/2021
	Request for extension for late application submission accepted	N/A	07/10/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/10/2021
Assigned to primary reviewers		03/18/2021	07/10/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/10/2021	07/10/2021
Primary Reviewer 2 COI signed		03/04/2021	07/10/2021
Primary Reviewer 3 COI signed		03/04/2021	07/10/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/10/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/10/2021
	Primary Reviewer 2 critique submitted	N/A	07/10/2021
	Primary Reviewer 3 critique submitted	N/A	07/10/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2021
	COI indicated by non-primary reviewer	N/A	07/10/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/10/2021
	Recommended for full review	N/A	07/10/2021
	Applicant notified of outcome	N/A	07/10/2021
	Peer Review Meeting	Assigned to primary reviewers	03/18/2021
Primary Reviewer 1 COI signed		03/10/2021	07/10/2021
Primary Reviewer 2 COI signed		03/04/2021	07/10/2021
Primary Reviewer 3 COI signed		03/04/2021	07/10/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/10/2021
Primary Reviewer 1 critique submitted		05/19/2021	07/10/2021
Primary Reviewer 2 critique submitted		05/18/2021	07/10/2021
Primary Reviewer 3 critique submitted		05/21/2021	07/10/2021
Primary (Advocate) Reviewer 4 critique submitted		05/15/2021	07/10/2021
COI indicated by non-primary reviewer		NONE	07/10/2021
COI recused from participation		N/A	07/10/2021
Discussed at Peer Review Meeting		YES	07/10/2021
Peer Review Meeting		05/27/2021	07/10/2021
Post review statements signed		06/23/2021	07/10/2021
Third Party Observer Report		06/21/2021	07/10/2021
Score report delivered to CSO		06/11/2021	07/10/2021
Recommended for SRC review	YES	07/10/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210088
Core Facility Support Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Core Facility Support Awards* Request for Applications (RFA). CPRIT received 25 applications in response to this RFA. This application was assigned to the basic cancer research 1 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that the Scientific Review Council (SRC) did not recommend an application responsive to this RFA that has a score equal to three other applications that were recommended. As allowed by 25 T.A.C. § 703.6(d)(1), a review council's numerical rank order is substantially based on the final overall evaluation score assigned by the peer review panels, but it may also consider how well a grant application achieves program priorities set by the Oversight Committee, the overall program portfolio balance, and any other criteria described in the RFA. I am satisfied that the SRC acted with appropriate discretion allowed to them by CPRIT's administrative rules.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:29 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: Core Facilities Support Awards
APPLICATION ID: RP210088
APPLICATION TITLE: Targeted Therapeutic Drug Discovery & Development Program
APPLICANT NAME: Dalby, Kevin N
ORGANIZATION: The University of Texas at Austin
PANEL NAME: 21.2 BCR-1

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/27/2021	07/08/2021
	Method of submission	CARS	07/08/2021
	Within receipt period	YES	07/08/2021
	Request for extension to submit application after CARS closed	N/A	07/08/2021
	Request for extension for late application submission accepted	N/A	07/08/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/19/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/08/2021	07/12/2021
Primary Reviewer 2 COI signed		03/04/2021	07/12/2021
Primary Reviewer 3 COI signed		03/04/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
	Peer Review Meeting	Assigned to primary reviewers	03/19/2021
Primary Reviewer 1 COI signed		03/08/2021	07/12/2021
Primary Reviewer 2 COI signed		03/04/2021	07/12/2021
Primary Reviewer 3 COI signed		03/04/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/12/2021
Primary Reviewer 1 critique submitted		05/07/2021	07/12/2021
Primary Reviewer 2 critique submitted		05/13/2021	07/12/2021
Primary Reviewer 3 critique submitted		05/06/2021	07/12/2021
Primary (Advocate) Reviewer 4 critique submitted		05/03/2021	07/12/2021
COI indicated by non-primary reviewer		NONE	07/12/2021
COI recused from participation		N/A	07/12/2021
Discussed at Peer Review Meeting		YES	07/12/2021
Peer Review Meeting		05/21/2021	07/12/2021
Post review statements signed		07/09/2021	07/12/2021
Third Party Observer Report		06/21/2021	07/12/2021
Score report delivered to CSO		06/11/2021	07/12/2021
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/22/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210099
Core Facility Support Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Core Facility Support Awards* Request for Applications (RFA). CPRIT received 25 applications in response to this RFA. This application was assigned to the imaging technology and informatics panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that the Scientific Review Council (SRC) did not recommend an application responsive to this RFA that has a score equal to three other applications that were recommended. As allowed by 25 T.A.C. § 703.6(d)(1), a review council’s numerical rank order is substantially based on the final overall evaluation score assigned by the peer review panels, but it may also consider how well a grant application achieves program priorities set by the Oversight Committee, the overall program portfolio balance, and any other criteria described in the RFA. I am satisfied that the SRC acted with appropriate discretion allowed to them by CPRIT’s administrative rules.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 4 day of August, 2021,
 by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:29 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: Core Facilities Support Awards
APPLICATION ID: RP210099
APPLICATION TITLE: North Texas Multimodal Small Animal Imaging Core Facility
APPLICANT NAME: Henning, Anke
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 21.2 ITI

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/26/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/19/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/04/2021	07/12/2021
Primary Reviewer 2 COI signed		03/12/2021	07/12/2021
Primary Reviewer 3 COI signed		03/16/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/05/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/19/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/12/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/16/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/05/2021	07/12/2021
	Primary Reviewer 1 critique submitted	05/15/2021	07/12/2021
	Primary Reviewer 2 critique submitted	05/17/2021	07/12/2021
	Primary Reviewer 3 critique submitted	05/19/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	05/15/2021	07/12/2021
	COI indicated by non-primary reviewer	Anna Wu, Ross Berbeco	07/12/2021
	COI recused from participation	YES	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/26/2021	07/12/2021
	Post review statements signed	06/09/2021	07/12/2021
	Third Party Observer Report	06/21/2021	07/12/2021
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
Authority to advance funds requested	N/A		
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210108
Core Facility Support Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Core Facility Support Awards* Request for Applications (RFA). CPRIT received 25 applications in response to this RFA. This application was assigned to the basic cancer research 1 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that the Scientific Review Council (SRC) did not recommend an application responsive to this RFA that has a score equal to three other applications that were recommended. As allowed by 25 T.A.C. § 703.6(d)(1), a review council’s numerical rank order is substantially based on the final overall evaluation score assigned by the peer review panels, but it may also consider how well a grant application achieves program priorities set by the Oversight Committee, the overall program portfolio balance, and any other criteria described in the RFA. I am satisfied that the SRC acted with appropriate discretion allowed to them by CPRIT’s administrative rules.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:29 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: Core Facilities Support Awards
APPLICATION ID: RP210108
APPLICATION TITLE: The GCC Microphysiological Lead Optimization and Toxicity Screening facility
APPLICANT NAME: Stephan, Clifford C
ORGANIZATION: Texas A&M University System Health Science Center
PANEL NAME: 21.2 BCR-1

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/27/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	02/22/2021
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/19/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/13/2021	07/12/2021
Primary Reviewer 2 COI signed		03/04/2021	07/12/2021
Primary Reviewer 3 COI signed		03/08/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/19/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/13/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/08/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 1 critique submitted	05/12/2021	07/12/2021
	Primary Reviewer 2 critique submitted	05/14/2021	07/12/2021
	Primary Reviewer 3 critique submitted	05/07/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	04/27/2021	07/12/2021
	COI indicated by non-primary reviewer	NONE	07/12/2021
	COI recused from participation	N/A	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/21/2021	07/12/2021
	Post review statements signed	07/09/2021	07/12/2021
	Third Party Observer Report	06/21/2021	07/12/2021
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210116
Core Facility Support Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Core Facility Support Awards* Request for Applications (RFA). CPRIT received 25 applications in response to this RFA. This application was assigned to the basic cancer research 2 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle



I note that the Scientific Review Council (SRC) did not recommend an application responsive to this RFA that has a score equal to three other applications that were recommended. As allowed by 25 T.A.C. § 703.6(d)(1), a review council's numerical rank order is substantially based on the final overall evaluation score assigned by the peer review panels, but it may also consider how well a grant application achieves program priorities set by the Oversight Committee, the overall program portfolio balance, and any other criteria described in the RFA. I am satisfied that the SRC acted with appropriate discretion allowed to them by CPRIT's administrative rules.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas County of Travis
SWORN to and SUBSCRIBED before me, the undersigned authority, on the <u>4</u> day of <u>August</u> , 2021, by WAYNE R. ROBERTS.
 _____ Melanie Cleveland Notary Public, State of Texas


CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:35 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: Core Facilities Support Awards
APPLICATION ID: RP210116
APPLICATION TITLE: THE GENETIC DESIGN & ENGINEERING CENTER (GDEC): A CPRIT CORE FACILITY
APPLICANT NAME: Bao, Gang
ORGANIZATION: Rice University
PANEL NAME: 21.2 BCR-2

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/27/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/22/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/14/2021	07/12/2021
Primary Reviewer 2 COI signed		03/04/2021	07/12/2021
Primary Reviewer 3 COI signed		03/08/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/08/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/22/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/14/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/08/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/08/2021	07/12/2021
	Primary Reviewer 1 critique submitted	05/24/2021	07/12/2021
	Primary Reviewer 2 critique submitted	05/18/2021	07/12/2021
	Primary Reviewer 3 critique submitted	05/17/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	05/15/2021	07/12/2021
	COI indicated by non-primary reviewer	NONE	07/12/2021
	COI recused from participation	N/A	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/25/2021	07/12/2021
	Post review statements signed	06/24/2021	07/12/2021
Third Party Observer Report	06/21/2021	07/12/2021	
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210119
Core Facility Support Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Core Facility Support Awards* Request for Applications (RFA). CPRIT received 25 applications in response to this RFA. This application was assigned to the basic cancer research 1 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle



I note that the Scientific Review Council (SRC) did not recommend an application responsive to this RFA that has a score equal to three other applications that were recommended. As allowed by 25 T.A.C. § 703.6(d)(1), a review council's numerical rank order is substantially based on the final overall evaluation score assigned by the peer review panels, but it may also consider how well a grant application achieves program priorities set by the Oversight Committee, the overall program portfolio balance, and any other criteria described in the RFA. I am satisfied that the SRC acted with appropriate discretion allowed to them by CPRIT's administrative rules.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas County of Travis	
SWORN to and SUBSCRIBED before me, the undersigned authority, on the <u>4</u> day of <u>August</u> , 2021, by WAYNE R. ROBERTS.	
 _____ Melanie Cleveland Notary Public, State of Texas	

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:35 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: Core Facilities Support Awards
APPLICATION ID: RP210119
APPLICATION TITLE: A Preclinical Development Core for Large Molecule Therapeutics
APPLICANT NAME: Liu, Qingyun
ORGANIZATION: The University of Texas Health Science Center at Houston
PANEL NAME: 21.2 BCR-1

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/27/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/19/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/04/2021	07/12/2021
Primary Reviewer 2 COI signed		03/04/2021	07/12/2021
Primary Reviewer 3 COI signed		03/13/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/19/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/13/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 1 critique submitted	05/12/2021	07/12/2021
	Primary Reviewer 2 critique submitted	05/15/2021	07/12/2021
	Primary Reviewer 3 critique submitted	05/12/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	04/28/2021	07/12/2021
	COI indicated by non-primary reviewer	NONE	07/12/2021
	COI recused from participation	N/A	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/21/2021	07/12/2021
	Post review statements signed	07/09/2021	07/12/2021
Third Party Observer Report	06/21/2021	07/12/2021	
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210126
Core Facility Support Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Core Facility Support Awards* Request for Applications (RFA). CPRIT received 25 applications in response to this RFA. This application was assigned to the imaging technology and informatics panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that the Scientific Review Council (SRC) did not recommend an application responsive to this RFA that has a score equal to three other applications that were recommended. As allowed by 25 T.A.C. § 703.6(d)(1), a review council’s numerical rank order is substantially based on the final overall evaluation score assigned by the peer review panels, but it may also consider how well a grant application achieves program priorities set by the Oversight Committee, the overall program portfolio balance, and any other criteria described in the RFA. I am satisfied that the SRC acted with appropriate discretion allowed to them by CPRIT’s administrative rules.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 4 day of August, 2021,
 by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:35 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: Core Facilities Support Awards
APPLICATION ID: RP210126
APPLICATION TITLE: High Parameter Analysis, Sorting and Imaging Flow Cytometry Shared Resource
APPLICANT NAME: Berton, Michael T
ORGANIZATION: The University of Texas Health Science Center at San Antonio
PANEL NAME: 21.2 ITI

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/27/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	02/22/2021
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/19/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/04/2021	07/12/2021
Primary Reviewer 2 COI signed		03/07/2021	07/12/2021
Primary Reviewer 3 COI signed		03/05/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/05/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/19/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/07/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/05/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/05/2021	07/12/2021
	Primary Reviewer 1 critique submitted	04/26/2021	07/12/2021
	Primary Reviewer 2 critique submitted	05/11/2021	07/12/2021
	Primary Reviewer 3 critique submitted	05/19/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	05/15/2021	07/12/2021
	COI indicated by non-primary reviewer	NONE	07/12/2021
	COI recused from participation	N/A	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/26/2021	07/12/2021
	Post review statements signed	06/09/2021	07/12/2021
	Third Party Observer Report	06/21/2021	07/12/2021
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210130
Core Facility Support Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Core Facility Support Awards* Request for Applications (RFA). CPRIT received 25 applications in response to this RFA. This application was assigned to the cancer prevention research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle



I note that the Scientific Review Council (SRC) did not recommend an application responsive to this RFA that has a score equal to three other applications that were recommended. As allowed by 25 T.A.C. § 703.6(d)(1), a review council’s numerical rank order is substantially based on the final overall evaluation score assigned by the peer review panels, but it may also consider how well a grant application achieves program priorities set by the Oversight Committee, the overall program portfolio balance, and any other criteria described in the RFA. I am satisfied that the SRC acted with appropriate discretion allowed to them by CPRIT’s administrative rules.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas	
County of Travis	
SWORN to and SUBSCRIBED before me, the undersigned authority, on	
the <u>4</u> day of <u>August</u>	, 2021,
by WAYNE R. ROBERTS.	
 _____ Melanie Cleveland Notary Public, State of Texas	

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:35 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: Core Facilities Support Awards
APPLICATION ID: RP210130
APPLICATION TITLE: Data Management and Analysis Core for Comparative Effectiveness Research on Cancer in Texas
APPLICANT NAME: Kuo, Yong-Fang
ORGANIZATION: The University of Texas Medical Branch at Galveston
PANEL NAME: 21.2 CPR

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/26/2021	07/10/2021
	Method of submission	CARS	07/10/2021
	Within receipt period	YES	07/10/2021
	Request for extension to submit application after CARS closed	N/A	07/10/2021
	Request for extension for late application submission accepted	N/A	07/10/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/10/2021
Assigned to primary reviewers		03/18/2021	07/10/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/08/2021	07/10/2021
Primary Reviewer 2 COI signed		03/07/2021	07/10/2021
Primary Reviewer 3 COI signed		03/04/2021	07/10/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/10/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/10/2021
	Primary Reviewer 2 critique submitted	N/A	07/10/2021
	Primary Reviewer 3 critique submitted	N/A	07/10/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2021
	COI indicated by non-primary reviewer	N/A	07/10/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/10/2021
	Recommended for full review	N/A	07/10/2021
	Applicant notified of outcome	N/A	07/10/2021
Peer Review Meeting	Assigned to primary reviewers	03/18/2021	07/10/2021
	Primary Reviewer 1 COI signed	03/08/2021	07/10/2021
	Primary Reviewer 2 COI signed	03/07/2021	07/10/2021
	Primary Reviewer 3 COI signed	03/04/2021	07/10/2021
	Primary (Advocate) Reviewer 4 COI signed	03/04/2021	07/10/2021
	Primary Reviewer 1 critique submitted	05/17/2021	07/10/2021
	Primary Reviewer 2 critique submitted	05/20/2021	07/10/2021
	Primary Reviewer 3 critique submitted	05/21/2021	07/10/2021
	Primary (Advocate) Reviewer 4 critique submitted	05/15/2021	07/10/2021
	COI indicated by non-primary reviewer	NONE	07/10/2021
	COI recused from participation	N/A	07/10/2021
	Discussed at Peer Review Meeting	YES	07/10/2021
	Peer Review Meeting	05/27/2021	07/10/2021
	Post review statements signed	06/23/2021	07/10/2021
Third Party Observer Report	06/21/2021	07/10/2021	
Score report delivered to CSO	06/11/2021	07/10/2021	
Recommended for SRC review	YES	07/10/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210180
Core Facility Support Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Core Facility Support Awards* Request for Applications (RFA). CPRIT received 25 applications in response to this RFA. This application was assigned to the basic cancer research 2 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle



I note that the Scientific Review Council (SRC) did not recommend an application responsive to this RFA that has a score equal to three other applications that were recommended. As allowed by 25 T.A.C. § 703.6(d)(1), a review council's numerical rank order is substantially based on the final overall evaluation score assigned by the peer review panels, but it may also consider how well a grant application achieves program priorities set by the Oversight Committee, the overall program portfolio balance, and any other criteria described in the RFA. I am satisfied that the SRC acted with appropriate discretion allowed to them by CPRIT's administrative rules.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas County of Travis
SWORN to and SUBSCRIBED before me, the undersigned authority, on the <u>4</u> day of <u>August</u> , 2021, by WAYNE R. ROBERTS.
 _____ Melanie Cleveland Notary Public, State of Texas


CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:42 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: Core Facilities Support Awards
APPLICATION ID: RP210180
APPLICATION TITLE: Integrated Cancer Research Core (ICRC)
APPLICANT NAME: CHAUHAN, SUBHASH C
ORGANIZATION: The University of Texas Rio Grande Valley
PANEL NAME: 21.2 BCR-2

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/27/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/22/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/04/2021	07/12/2021
Primary Reviewer 2 COI signed		03/13/2021	07/12/2021
Primary Reviewer 3 COI signed		03/04/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/08/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/22/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/13/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/04/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/08/2021	07/12/2021
	Primary Reviewer 1 critique submitted	05/17/2021	07/12/2021
	Primary Reviewer 2 critique submitted	05/19/2021	07/12/2021
	Primary Reviewer 3 critique submitted	05/13/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	05/17/2021	07/12/2021
	COI indicated by non-primary reviewer	NONE	07/12/2021
	COI recused from participation	N/A	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/25/2021	07/12/2021
	Post review statements signed	06/24/2021	07/12/2021
	Third Party Observer Report	06/21/2021	07/12/2021
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210208
Core Facility Support Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Core Facility Support Awards* Request for Applications (RFA). CPRIT received 25 applications in response to this RFA. This application was assigned to the basic cancer research 2 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that the Scientific Review Council (SRC) did not recommend an application responsive to this RFA that has a score equal to three other applications that were recommended. As allowed by 25 T.A.C. § 703.6(d)(1), a review council's numerical rank order is substantially based on the final overall evaluation score assigned by the peer review panels, but it may also consider how well a grant application achieves program priorities set by the Oversight Committee, the overall program portfolio balance, and any other criteria described in the RFA. I am satisfied that the SRC acted with appropriate discretion allowed to them by CPRIT's administrative rules.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



MELANIE CLEVELAND
NOTARY PUBLIC
ID# 131757703
State of Texas
Comm. Exp. 10-08-2022
NOTARY WITHOUT BOND

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:43 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: Core Facilities Support Awards
APPLICATION ID: RP210208
APPLICATION TITLE: Center for Innovative Drug Discovery: Expansion of a Highly Productive Shared Cancer Drug Discovery Resource for Texas
APPLICANT NAME: McHardy, Stanton F
ORGANIZATION: The University of Texas at San Antonio
PANEL NAME: 21.2 BCR-2

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/27/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/22/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/14/2021	07/12/2021
Primary Reviewer 2 COI signed		03/14/2021	07/12/2021
Primary Reviewer 3 COI signed		03/04/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/14/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/22/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/14/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/14/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/04/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/14/2021	07/12/2021
	Primary Reviewer 1 critique submitted	05/18/2021	07/12/2021
	Primary Reviewer 2 critique submitted	05/24/2021	07/12/2021
	Primary Reviewer 3 critique submitted	05/21/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	05/02/2021	07/12/2021
	COI indicated by non-primary reviewer	Alan Tomkinson, Walter Chazin	07/12/2021
	COI recused from participation	YES	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/25/2021	07/12/2021
	Post review statements signed	06/24/2021	07/12/2021
	Third Party Observer Report	06/21/2021	07/12/2021
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
PIC Review	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
	Recommended for grant award	YES	08/03/2021
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210209
Core Facility Support Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Core Facility Support Awards* Request for Applications (RFA). CPRIT received 25 applications in response to this RFA. This application was assigned to the clinical and translational cancer research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that the Scientific Review Council (SRC) did not recommend an application responsive to this RFA that has a score equal to three other applications that were recommended. As allowed by 25 T.A.C. § 703.6(d)(1), a review council’s numerical rank order is substantially based on the final overall evaluation score assigned by the peer review panels, but it may also consider how well a grant application achieves program priorities set by the Oversight Committee, the overall program portfolio balance, and any other criteria described in the RFA. I am satisfied that the SRC acted with appropriate discretion allowed to them by CPRIT’s administrative rules.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 4 day of August, 2021,
 by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:43 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: Core Facilities Support Awards
APPLICATION ID: RP210209
APPLICATION TITLE: North Texas Clinical Pharmacology Cancer Core
APPLICANT NAME: Putnam, William C
ORGANIZATION: Texas Tech University Health Sciences Center
PANEL NAME: 21.2 C/TCR

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/27/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/22/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/13/2021	07/12/2021
Primary Reviewer 2 COI signed		03/04/2021	07/12/2021
Primary Reviewer 3 COI signed		03/04/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/22/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/13/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/04/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 1 critique submitted	05/14/2021	07/12/2021
	Primary Reviewer 2 critique submitted	05/16/2021	07/12/2021
	Primary Reviewer 3 critique submitted	05/13/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	04/11/2021	07/12/2021
	COI indicated by non-primary reviewer	NONE	07/12/2021
	COI recused from participation	N/A	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/24/2021	07/12/2021
	Post review statements signed	07/07/2021	07/12/2021
	Third Party Observer Report	06/21/2021	07/12/2021
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210227
Core Facility Support Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Core Facility Support Awards* Request for Applications (RFA). CPRIT received 25 applications in response to this RFA. This application was assigned to the basic cancer research 2 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that the Scientific Review Council (SRC) did not recommend an application responsive to this RFA that has a score equal to three other applications that were recommended. As allowed by 25 T.A.C. § 703.6(d)(1), a review council's numerical rank order is substantially based on the final overall evaluation score assigned by the peer review panels, but it may also consider how well a grant application achieves program priorities set by the Oversight Committee, the overall program portfolio balance, and any other criteria described in the RFA. I am satisfied that the SRC acted with appropriate discretion allowed to them by CPRIT's administrative rules.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas


MELANIE CLEVELAND
NOTARY PUBLIC
ID# 131757703
State of Texas
Comm. Exp. 10-08-2022
NOTARY WITHOUT BOND

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:43 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: Core Facilities Support Awards
APPLICATION ID: RP210227
APPLICATION TITLE: Proteomics and Metabolomics Core Facility
APPLICANT NAME: Edwards, Dean P
ORGANIZATION: Baylor College of Medicine
PANEL NAME: 21.2 BCR-2

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/26/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/22/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/04/2021	07/12/2021
Primary Reviewer 2 COI signed		03/04/2021	07/12/2021
Primary Reviewer 3 COI signed		03/04/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/08/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/22/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/04/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/08/2021	07/12/2021
	Primary Reviewer 1 critique submitted	05/14/2021	07/12/2021
	Primary Reviewer 2 critique submitted	05/17/2021	07/12/2021
	Primary Reviewer 3 critique submitted	05/16/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	05/16/2021	07/12/2021
	COI indicated by non-primary reviewer	NONE	07/12/2021
	COI recused from participation	N/A	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/25/2021	07/12/2021
	Post review statements signed	06/24/2021	07/12/2021
	Third Party Observer Report	06/21/2021	07/12/2021
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210122
Clinical Trials Network Award

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Clinical Trials Network Award Request for Applications (RFA)*. CPRIT received five applications in response to this RFA. This application was assigned to the clinical and translational cancer research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:35 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: Clinical Trials Network Award
APPLICATION ID: RP210122
APPLICATION TITLE: Building a Clinical Trial Network for Texas Community Affiliates
APPLICANT NAME: Overman, Michael
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 21.2 C/TCR

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	07/29/2020	07/07/2021	
	RFA Approved by CSO (revised)	09/24/2020	07/07/2021	
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021	
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021	
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021	
	Date application submitted	01/22/2021	07/12/2021	
	Method of submission	CARS	07/12/2021	
	Within receipt period	YES	07/12/2021	
	Request for extension to submit application after CARS closed	N/A	07/12/2021	
	Request for extension for late application submission accepted	N/A	07/12/2021	
	Receipt, Referral, and Assignment	Administrative review notification	02/22/2021	07/12/2021
		Donation(s) made to CPRIT / foundation	NO	07/12/2021
		Assigned to primary reviewers	03/22/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021	
Primary Reviewer 1 COI signed		03/09/2021	07/12/2021	
Primary Reviewer 2 COI signed		03/04/2021	07/12/2021	
Primary Reviewer 3 COI signed		03/17/2021	07/12/2021	
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/12/2021	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021	
	Primary Reviewer 2 critique submitted	N/A	07/12/2021	
	Primary Reviewer 3 critique submitted	N/A	07/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021	
	COI indicated by non-primary reviewer	N/A	07/12/2021	
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021	
	Recommended for full review	N/A	07/12/2021	
	Applicant notified of outcome	N/A	07/12/2021	
Peer Review Meeting	Assigned to primary reviewers	03/22/2021	07/12/2021	
	Primary Reviewer 1 COI signed	03/09/2021	07/12/2021	
	Primary Reviewer 2 COI signed	03/04/2021	07/12/2021	
	Primary Reviewer 3 COI signed	03/17/2021	07/12/2021	
	Primary (Advocate) Reviewer 4 COI signed	03/04/2021	07/12/2021	
	Primary Reviewer 1 critique submitted	05/14/2021	07/12/2021	
	Primary Reviewer 2 critique submitted	05/06/2021	07/12/2021	
	Primary Reviewer 3 critique submitted	05/16/2021	07/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	03/30/2021	07/12/2021	
	COI indicated by non-primary reviewer	Howard Hochster	07/12/2021	
	COI recused from participation	YES	07/12/2021	
	Discussed at Peer Review Meeting	YES	07/12/2021	
	Peer Review Meeting	05/24/2021	07/12/2021	
	Post review statements signed	07/07/2021	07/12/2021	
	Third Party Observer Report	06/21/2021	07/12/2021	
	Score report delivered to CSO	06/11/2021	07/12/2021	
	Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021	
	COI recused from participation	N/A	07/14/2021	
	SRC Meeting	07/08/2021	07/14/2021	
	Third Party Observer Report	07/16/2021	07/23/2021	
	Recommended for grant award	YES	07/14/2021	
	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021	
PIC Review	COI indicated by PIC member	None	08/03/2021	
	COI recused from participation	N/A	08/03/2021	
	PIC Review Meeting	08/03/2021	08/03/2021	
	Recommended for grant award	YES	08/03/2021	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210140
Early Clinical Investigator Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Early Clinical Investigator Awards* Request for Applications (RFA). CPRIT received 11 applications in response to this RFA. This application was assigned to the clinical and translational cancer research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle


In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.


Melanie Cleveland
Notary Public, State of Texas


MELANIE CLEVELAND
NOTARY PUBLIC
ID# 131757703
State of Texas
Comm. Exp. 10-08-2022
NOTARY WITHOUT BOND

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:36 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: Early Clinical Investigator Award
APPLICATION ID: RP210140
APPLICATION TITLE: Targeting Altered Metabolism in IDH Mutant Glioma
APPLICANT NAME: Arteaga, Carlos L
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 21.2 C/TCR

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021	
	RFA Approved by CSO (revised)	09/11/2020	07/07/2021	
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021	
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021	
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021	
	Date application submitted	01/27/2021	07/12/2021	
	Method of submission	CARS	07/12/2021	
	Within receipt period	YES	07/12/2021	
	Request for extension to submit application after CARS closed	N/A	07/12/2021	
	Request for extension for late application submission accepted	N/A	07/12/2021	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	07/12/2021
		Donation(s) made to CPRIT / foundation	NO	07/12/2021
		Assigned to primary reviewers	03/22/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021	
Primary Reviewer 1 COI signed		03/04/2021	07/12/2021	
Primary Reviewer 2 COI signed		03/04/2021	07/12/2021	
Primary Reviewer 3 COI signed		03/12/2021	07/12/2021	
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/12/2021	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021	
	Primary Reviewer 2 critique submitted	N/A	07/12/2021	
	Primary Reviewer 3 critique submitted	N/A	07/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021	
	COI indicated by non-primary reviewer	N/A	07/12/2021	
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021	
	Recommended for full review	N/A	07/12/2021	
	Applicant notified of outcome	N/A	07/12/2021	
Peer Review Meeting	Assigned to primary reviewers	03/22/2021	07/12/2021	
	Primary Reviewer 1 COI signed	03/04/2021	07/12/2021	
	Primary Reviewer 2 COI signed	03/04/2021	07/12/2021	
	Primary Reviewer 3 COI signed	03/12/2021	07/12/2021	
	Primary (Advocate) Reviewer 4 COI signed	03/04/2021	07/12/2021	
	Primary Reviewer 1 critique submitted	05/16/2021	07/12/2021	
	Primary Reviewer 2 critique submitted	05/17/2021	07/12/2021	
	Primary Reviewer 3 critique submitted	05/14/2021	07/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	04/09/2021	07/12/2021	
	COI indicated by non-primary reviewer	NONE	07/12/2021	
	COI recused from participation	N/A	07/12/2021	
	Discussed at Peer Review Meeting	YES	07/12/2021	
	Peer Review Meeting	05/24/2021	07/12/2021	
	Post review statements signed	07/07/2021	07/12/2021	
	Third Party Observer Report	06/21/2021	07/12/2021	
	Score report delivered to CSO	06/11/2021	07/12/2021	
	Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021	
	COI recused from participation	N/A	07/14/2021	
	SRC Meeting	07/08/2021	07/14/2021	
	Third Party Observer Report	07/16/2021	07/23/2021	
	Recommended for grant award	YES	07/14/2021	
	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021	
PIC Review	COI indicated by PIC member	None	08/03/2021	
	COI recused from participation	N/A	08/03/2021	
	PIC Review Meeting	08/03/2021	08/03/2021	
	Recommended for grant award	YES	08/03/2021	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210159
Early Clinical Investigator Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Early Clinical Investigator Awards* Request for Applications (RFA). CPRIT received 11 applications in response to this RFA. This application was assigned to the clinical and translational cancer research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:36 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: Early Clinical Investigator Award
APPLICATION ID: RP210159
APPLICATION TITLE: CPRIT Early Clinical Investigator Award-Carl Gay
APPLICANT NAME: Draetta, Gulio
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 21.2 C/TCR

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021	
	RFA Approved by CSO (revised)	09/11/2020	07/07/2021	
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021	
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021	
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021	
	Date application submitted	01/27/2021	07/12/2021	
	Method of submission	CARS	07/12/2021	
	Within receipt period	YES	07/12/2021	
	Request for extension to submit application after CARS closed	N/A	07/12/2021	
	Request for extension for late application submission accepted	N/A	07/12/2021	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	07/12/2021
		Donation(s) made to CPRIT / foundation	NO	07/12/2021
		Assigned to primary reviewers	03/22/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021	
Primary Reviewer 1 COI signed		03/11/2021	07/12/2021	
Primary Reviewer 2 COI signed		03/04/2021	07/12/2021	
Primary Reviewer 3 COI signed		03/12/2021	07/12/2021	
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/12/2021	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021	
	Primary Reviewer 2 critique submitted	N/A	07/12/2021	
	Primary Reviewer 3 critique submitted	N/A	07/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021	
	COI indicated by non-primary reviewer	N/A	07/12/2021	
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021	
	Recommended for full review	N/A	07/12/2021	
	Applicant notified of outcome	N/A	07/12/2021	
Peer Review Meeting	Assigned to primary reviewers	03/22/2021	07/12/2021	
	Primary Reviewer 1 COI signed	03/11/2021	07/12/2021	
	Primary Reviewer 2 COI signed	03/04/2021	07/12/2021	
	Primary Reviewer 3 COI signed	03/12/2021	07/12/2021	
	Primary (Advocate) Reviewer 4 COI signed	03/04/2021	07/12/2021	
	Primary Reviewer 1 critique submitted	04/21/2021	07/12/2021	
	Primary Reviewer 2 critique submitted	05/13/2021	07/12/2021	
	Primary Reviewer 3 critique submitted	05/14/2021	07/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	03/28/2021	07/12/2021	
	COI indicated by non-primary reviewer	NONE	07/12/2021	
	COI recused from participation	N/A	07/12/2021	
	Discussed at Peer Review Meeting	YES	07/12/2021	
	Peer Review Meeting	05/24/2021	07/12/2021	
	Post review statements signed	07/07/2021	07/12/2021	
	Third Party Observer Report	06/21/2021	07/12/2021	
	Score report delivered to CSO	06/11/2021	07/12/2021	
	Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021	
	COI recused from participation	N/A	07/14/2021	
	SRC Meeting	07/08/2021	07/14/2021	
	Third Party Observer Report	07/16/2021	07/23/2021	
	Recommended for grant award	YES	07/14/2021	
	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021	
PIC Review	COI indicated by PIC member	None	08/03/2021	
	COI recused from participation	N/A	08/03/2021	
	PIC Review Meeting	08/03/2021	08/03/2021	
	Recommended for grant award	YES	08/03/2021	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210164
Early Clinical Investigator Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Early Clinical Investigator Awards* Request for Applications (RFA). CPRIT received 11 applications in response to this RFA. This application was assigned to the clinical and translational cancer research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 4 day of August, 2021,
 by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:36 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: Early Clinical Investigator Award
APPLICATION ID: RP210164
APPLICATION TITLE: Early Clinical Investigator Award - William Kelly
APPLICANT NAME: Hromas, Robert
ORGANIZATION: The University of Texas Health Science Center at San Antonio
PANEL NAME: 21.2 C/TCR

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021	
	RFA Approved by CSO (revised)	09/11/2020	07/07/2021	
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021	
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021	
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021	
	Date application submitted	01/27/2021	07/12/2021	
	Method of submission	CARS	07/12/2021	
	Within receipt period	YES	07/12/2021	
	Request for extension to submit application after CARS closed	N/A	07/12/2021	
	Request for extension for late application submission accepted	N/A	07/12/2021	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	07/12/2021
		Donation(s) made to CPRIT / foundation	NO	07/12/2021
		Assigned to primary reviewers	03/22/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021	
Primary Reviewer 1 COI signed		03/06/2021	07/12/2021	
Primary Reviewer 2 COI signed		03/04/2021	07/12/2021	
Primary Reviewer 3 COI signed		03/09/2021	07/12/2021	
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/12/2021	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021	
	Primary Reviewer 2 critique submitted	N/A	07/12/2021	
	Primary Reviewer 3 critique submitted	N/A	07/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021	
	COI indicated by non-primary reviewer	N/A	07/12/2021	
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021	
	Recommended for full review	N/A	07/12/2021	
	Applicant notified of outcome	N/A	07/12/2021	
Peer Review Meeting	Assigned to primary reviewers	03/22/2021	07/12/2021	
	Primary Reviewer 1 COI signed	03/06/2021	07/12/2021	
	Primary Reviewer 2 COI signed	03/04/2021	07/12/2021	
	Primary Reviewer 3 COI signed	03/09/2021	07/12/2021	
	Primary (Advocate) Reviewer 4 COI signed	03/04/2021	07/12/2021	
	Primary Reviewer 1 critique submitted	05/15/2021	07/12/2021	
	Primary Reviewer 2 critique submitted	04/24/2021	07/12/2021	
	Primary Reviewer 3 critique submitted	05/14/2021	07/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	03/30/2021	07/12/2021	
	COI indicated by non-primary reviewer	NONE	07/12/2021	
	COI recused from participation	N/A	07/12/2021	
	Discussed at Peer Review Meeting	YES	07/12/2021	
	Peer Review Meeting	05/24/2021	07/12/2021	
	Post review statements signed	07/07/2021	07/12/2021	
	Third Party Observer Report	06/21/2021	07/12/2021	
	Score report delivered to CSO	06/11/2021	07/12/2021	
	Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021	
	COI recused from participation	N/A	07/14/2021	
	SRC Meeting	07/08/2021	07/14/2021	
	Third Party Observer Report	07/16/2021	07/23/2021	
	Recommended for grant award	YES	07/14/2021	
	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021	
PIC Review	COI indicated by PIC member	None	08/03/2021	
	COI recused from participation	N/A	08/03/2021	
	PIC Review Meeting	08/03/2021	08/03/2021	
	Recommended for grant award	YES	08/03/2021	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210176
Early Clinical Investigator Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Early Clinical Investigator Awards* Request for Applications (RFA). CPRIT received 11 applications in response to this RFA. This application was assigned to the clinical and translational cancer research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle


In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.


Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:37 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: Early Clinical Investigator Award
APPLICATION ID: RP210176
APPLICATION TITLE: CPRIT Early Clinical Investigator Award-Moran Amit
APPLICANT NAME: Draetta, Gulio
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 21.2 C/TCR

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021	
	RFA Approved by CSO (revised)	09/11/2020	07/07/2021	
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021	
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021	
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021	
	Date application submitted	01/27/2021	07/12/2021	
	Method of submission	CARS	07/12/2021	
	Within receipt period	YES	07/12/2021	
	Request for extension to submit application after CARS closed	N/A	07/12/2021	
	Request for extension for late application submission accepted	N/A	07/12/2021	
	Receipt, Referral, and Assignment	Administrative review notification	02/23/2021	07/12/2021
		Donation(s) made to CPRIT / foundation	NO	07/12/2021
		Assigned to primary reviewers	03/22/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021	
Primary Reviewer 1 COI signed		03/04/2021	07/12/2021	
Primary Reviewer 2 COI signed		03/11/2021	07/12/2021	
Primary Reviewer 3 COI signed		03/06/2021	07/12/2021	
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/12/2021	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021	
	Primary Reviewer 2 critique submitted	N/A	07/12/2021	
	Primary Reviewer 3 critique submitted	N/A	07/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021	
	COI indicated by non-primary reviewer	N/A	07/12/2021	
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021	
	Recommended for full review	N/A	07/12/2021	
	Applicant notified of outcome	N/A	07/12/2021	
Peer Review Meeting	Assigned to primary reviewers	03/22/2021	07/12/2021	
	Primary Reviewer 1 COI signed	03/04/2021	07/12/2021	
	Primary Reviewer 2 COI signed	03/11/2021	07/12/2021	
	Primary Reviewer 3 COI signed	03/06/2021	07/12/2021	
	Primary (Advocate) Reviewer 4 COI signed	03/04/2021	07/12/2021	
	Primary Reviewer 1 critique submitted	05/13/2021	07/12/2021	
	Primary Reviewer 2 critique submitted	04/21/2021	07/12/2021	
	Primary Reviewer 3 critique submitted	05/15/2021	07/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	04/01/2021	07/12/2021	
	COI indicated by non-primary reviewer	NONE	07/12/2021	
	COI recused from participation	N/A	07/12/2021	
	Discussed at Peer Review Meeting	YES	07/12/2021	
	Peer Review Meeting	05/24/2021	07/12/2021	
	Post review statements signed	07/07/2021	07/12/2021	
	Third Party Observer Report	06/21/2021	07/12/2021	
	Score report delivered to CSO	06/11/2021	07/12/2021	
	Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021	
	COI recused from participation	N/A	07/14/2021	
	SRC Meeting	07/08/2021	07/14/2021	
	Third Party Observer Report	07/16/2021	07/23/2021	
	Recommended for grant award	YES	07/14/2021	
	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021	
PIC Review	COI indicated by PIC member	None	08/03/2021	
	COI recused from participation	N/A	08/03/2021	
	PIC Review Meeting	08/03/2021	08/03/2021	
	Recommended for grant award	YES	08/03/2021	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210234
Early Clinical Investigator Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Early Clinical Investigator Awards* Request for Applications (RFA). CPRIT received 11 applications in response to this RFA. This application was assigned to the clinical and translational cancer research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:43 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: Early Clinical Investigator Award
APPLICATION ID: RP210234
APPLICATION TITLE: Targeting Src Homology-2 Domain Containing Phosphatase to Overcome Resistance to Immune Checkpoint Blockade in Pancreatic Ductal Adenocarcinoma
APPLICANT NAME: Johnston, Sterling C
ORGANIZATION: The University of Texas at Austin
PANEL NAME: 21.2 C/TCR

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021	
	RFA Approved by CSO (revised)	09/11/2020	07/07/2021	
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021	
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021	
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021	
	Date application submitted	01/27/2021	07/12/2021	
	Method of submission	CARS	07/12/2021	
	Within receipt period	YES	07/12/2021	
	Request for extension to submit application after CARS closed	N/A	07/12/2021	
	Request for extension for late application submission accepted	N/A	07/12/2021	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	07/12/2021
		Donation(s) made to CPRIT / foundation	NO	07/12/2021
		Assigned to primary reviewers	03/22/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021	
Primary Reviewer 1 COI signed		03/04/2021	07/12/2021	
Primary Reviewer 2 COI signed		03/04/2021	07/12/2021	
Primary Reviewer 3 COI signed		03/04/2021	07/12/2021	
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/12/2021	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021	
	Primary Reviewer 2 critique submitted	N/A	07/12/2021	
	Primary Reviewer 3 critique submitted	N/A	07/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021	
	COI indicated by non-primary reviewer	N/A	07/12/2021	
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021	
	Recommended for full review	N/A	07/12/2021	
	Applicant notified of outcome	N/A	07/12/2021	
Peer Review Meeting	Assigned to primary reviewers	03/22/2021	07/12/2021	
	Primary Reviewer 1 COI signed	03/04/2021	07/12/2021	
	Primary Reviewer 2 COI signed	03/04/2021	07/12/2021	
	Primary Reviewer 3 COI signed	03/04/2021	07/12/2021	
	Primary (Advocate) Reviewer 4 COI signed	03/04/2021	07/12/2021	
	Primary Reviewer 1 critique submitted	05/11/2021	07/12/2021	
	Primary Reviewer 2 critique submitted	05/17/2021	07/12/2021	
	Primary Reviewer 3 critique submitted	05/13/2021	07/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	04/17/2021	07/12/2021	
	COI indicated by non-primary reviewer	NONE	07/12/2021	
	COI recused from participation	N/A	07/12/2021	
	Discussed at Peer Review Meeting	YES	07/12/2021	
	Peer Review Meeting	05/24/2021	07/12/2021	
	Post review statements signed	07/07/2021	07/12/2021	
	Third Party Observer Report	06/21/2021	07/12/2021	
	Score report delivered to CSO	06/11/2021	07/12/2021	
	Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021	
	COI recused from participation	N/A	07/14/2021	
	SRC Meeting	07/08/2021	07/14/2021	
	Third Party Observer Report	07/16/2021	07/23/2021	
	Recommended for grant award	YES	07/14/2021	
	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021	
PIC Review	COI indicated by PIC member	None	08/03/2021	
	COI recused from participation	N/A	08/03/2021	
	PIC Review Meeting	08/03/2021	08/03/2021	
	Recommended for grant award	YES	08/03/2021	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210062
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the basic cancer research 2 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:28 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: High-Impact/High-Risk Research Awards
APPLICATION ID: RP210062
APPLICATION TITLE: Protein Degradation of CDK9 for Treatment of Drug-Resistant Mantle Cell Lymphoma
APPLICANT NAME: Zhou, Jia
ORGANIZATION: The University of Texas Medical Branch at Galveston
PANEL NAME: 21.2 BCR-2

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/21/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/22/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/13/2021	07/12/2021
Primary Reviewer 2 COI signed		03/04/2021	07/12/2021
Primary Reviewer 3 COI signed		03/14/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/08/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/22/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/13/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/14/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/08/2021	07/12/2021
	Primary Reviewer 1 critique submitted	05/16/2021	07/12/2021
	Primary Reviewer 2 critique submitted	05/13/2021	07/12/2021
	Primary Reviewer 3 critique submitted	05/17/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	05/17/2021	07/12/2021
	COI indicated by non-primary reviewer	NONE	07/12/2021
	COI recused from participation	N/A	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/25/2021	07/12/2021
	Post review statements signed	06/24/2021	07/12/2021
	Third Party Observer Report	06/21/2021	07/12/2021
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210068
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards Request for Applications (RFA)*. CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the basic cancer research 2 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melame Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:29 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: High-Impact/High-Risk Research Awards
APPLICATION ID: RP210068
APPLICATION TITLE: Role of Aberrant Translational Quality Control in Tumorigenesis of Glioblastoma
APPLICANT NAME: Wu, Zhihao
ORGANIZATION: Southern Methodist University
PANEL NAME: 21.2 BCR-2

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/22/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/22/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/04/2021	07/12/2021
Primary Reviewer 2 COI signed		03/14/2021	07/12/2021
Primary Reviewer 3 COI signed		03/04/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/14/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/22/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/14/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/04/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/14/2021	07/12/2021
	Primary Reviewer 1 critique submitted	05/13/2021	07/12/2021
	Primary Reviewer 2 critique submitted	05/17/2021	07/12/2021
	Primary Reviewer 3 critique submitted	05/15/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	05/13/2021	07/12/2021
	COI indicated by non-primary reviewer	NONE	07/12/2021
	COI recused from participation	N/A	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/25/2021	07/12/2021
	Post review statements signed	06/24/2021	07/12/2021
	Third Party Observer Report	06/21/2021	07/12/2021
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210070
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the cancer biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:29 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: High-Impact/High-Risk Research Awards
APPLICATION ID: RP210070
APPLICATION TITLE: Tunable epigenetic remodeling to modulate CAR T-cell based immunotherapy
APPLICANT NAME: Zhou, Yubin
ORGANIZATION: Texas A&M University System Health Science Center
PANEL NAME: 21.2 CB

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/07/2021	07/10/2021
	Method of submission	CARS	07/10/2021
	Within receipt period	YES	07/10/2021
	Request for extension to submit application after CARS closed	N/A	07/10/2021
	Request for extension for late application submission accepted	N/A	07/10/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/10/2021
Assigned to primary reviewers		03/23/2021	07/10/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/14/2021	07/10/2021
Primary Reviewer 2 COI signed		03/05/2021	07/10/2021
Primary Reviewer 3 COI signed		03/08/2021	07/10/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/10/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/10/2021
	Primary Reviewer 2 critique submitted	N/A	07/10/2021
	Primary Reviewer 3 critique submitted	N/A	07/10/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2021
	COI indicated by non-primary reviewer	N/A	07/10/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/10/2021
	Recommended for full review	N/A	07/10/2021
	Applicant notified of outcome	N/A	07/10/2021
Peer Review Meeting	Assigned to primary reviewers	03/23/2021	07/10/2021
	Primary Reviewer 1 COI signed	03/14/2021	07/10/2021
	Primary Reviewer 2 COI signed	03/05/2021	07/10/2021
	Primary Reviewer 3 COI signed	03/08/2021	07/10/2021
	Primary (Advocate) Reviewer 4 COI signed	03/04/2021	07/10/2021
	Primary Reviewer 1 critique submitted	05/13/2021	07/10/2021
	Primary Reviewer 2 critique submitted	05/12/2021	07/10/2021
	Primary Reviewer 3 critique submitted	05/12/2021	07/10/2021
	Primary (Advocate) Reviewer 4 critique submitted	03/24/2021	07/10/2021
	COI indicated by non-primary reviewer	NONE	07/10/2021
	COI recused from participation	N/A	07/10/2021
	Discussed at Peer Review Meeting	YES	07/10/2021
	Peer Review Meeting	05/20/2021	07/10/2021
	Post review statements signed	07/01/2021	07/10/2021
	Third Party Observer Report	06/21/2021	07/10/2021
Score report delivered to CSO	06/11/2021	07/10/2021	
Recommended for SRC review	YES	07/10/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210073
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the basic cancer research 2 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 4 day of August, 2021,
 by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:29 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: High-Impact/High-Risk Research Awards
APPLICATION ID: RP210073
APPLICATION TITLE: Identification of collateral lethal and synthetic lethal targets in pancreatic and colorectal cancers
APPLICANT NAME: DePinho, Ronald A
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 21.2 BCR-2

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/15/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/22/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/08/2021	07/12/2021
Primary Reviewer 2 COI signed		04/20/2021	07/12/2021
Primary Reviewer 3 COI signed		03/13/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/08/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/22/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/08/2021	07/12/2021
	Primary Reviewer 2 COI signed	04/20/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/13/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/08/2021	07/12/2021
	Primary Reviewer 1 critique submitted	05/18/2021	07/12/2021
	Primary Reviewer 2 critique submitted	05/23/2021	07/12/2021
	Primary Reviewer 3 critique submitted	05/16/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	05/17/2021	07/12/2021
	COI indicated by non-primary reviewer	Nabeel Bardeesy	07/12/2021
	COI recused from participation	YES	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/25/2021	07/12/2021
	Post review statements signed	06/24/2021	07/12/2021
	Third Party Observer Report	06/21/2021	07/12/2021
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210075
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the cancer prevention research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:29 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: High-Impact/High-Risk Research Awards
APPLICATION ID: RP210075
APPLICATION TITLE: EXPLORING THE BIOLOGICAL BASIS OF ETHNIC AND SOCIAL DISPARITIES IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA OUTCOMES
APPLICANT NAME: Schraw, Jeremy M
ORGANIZATION: Baylor College of Medicine
PANEL NAME: 21.2 CPR

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/26/2021	07/10/2021
	Method of submission	CARS	07/10/2021
	Within receipt period	YES	07/10/2021
	Request for extension to submit application after CARS closed	N/A	07/10/2021
	Request for extension for late application submission accepted	N/A	07/10/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/10/2021
Assigned to primary reviewers		03/18/2021	07/10/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/04/2021	07/10/2021
Primary Reviewer 2 COI signed		03/07/2021	07/10/2021
Primary Reviewer 3 COI signed		03/04/2021	07/10/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/10/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/10/2021
	Primary Reviewer 2 critique submitted	N/A	07/10/2021
	Primary Reviewer 3 critique submitted	N/A	07/10/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2021
	COI indicated by non-primary reviewer	N/A	07/10/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/10/2021
	Recommended for full review	N/A	07/10/2021
	Applicant notified of outcome	N/A	07/10/2021
Peer Review Meeting	Assigned to primary reviewers	03/18/2021	07/10/2021
	Primary Reviewer 1 COI signed	03/04/2021	07/10/2021
	Primary Reviewer 2 COI signed	03/07/2021	07/10/2021
	Primary Reviewer 3 COI signed	03/04/2021	07/10/2021
	Primary (Advocate) Reviewer 4 COI signed	03/04/2021	07/10/2021
	Primary Reviewer 1 critique submitted	05/16/2021	07/10/2021
	Primary Reviewer 2 critique submitted	05/20/2021	07/10/2021
	Primary Reviewer 3 critique submitted	05/18/2021	07/10/2021
	Primary (Advocate) Reviewer 4 critique submitted	05/15/2021	07/10/2021
	COI indicated by non-primary reviewer	Christopher Li	07/10/2021
	COI recused from participation	YES	07/10/2021
	Discussed at Peer Review Meeting	YES	07/10/2021
	Peer Review Meeting	05/27/2021	07/10/2021
	Post review statements signed	06/23/2021	07/10/2021
	Third Party Observer Report	06/21/2021	07/10/2021
Score report delivered to CSO	06/11/2021	07/10/2021	
Recommended for SRC review	YES	07/10/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210079
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the basic cancer research 2 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:29 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: High-Impact/High-Risk Research Awards
APPLICATION ID: RP210079
APPLICATION TITLE: Targeting Mitochondrial NAD+ in Leukemias
APPLICANT NAME: Cambronne, Xiaolu A
ORGANIZATION: The University of Texas at Austin
PANEL NAME: 21.2 BCR-2

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/08/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/22/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/04/2021	07/12/2021
Primary Reviewer 2 COI signed		03/04/2021	07/12/2021
Primary Reviewer 3 COI signed		03/04/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/14/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/22/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/04/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/14/2021	07/12/2021
	Primary Reviewer 1 critique submitted	05/16/2021	07/12/2021
	Primary Reviewer 2 critique submitted	05/20/2021	07/12/2021
	Primary Reviewer 3 critique submitted	05/13/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	05/13/2021	07/12/2021
	COI indicated by non-primary reviewer	NONE	07/12/2021
	COI recused from participation	N/A	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/25/2021	07/12/2021
	Post review statements signed	06/24/2021	07/12/2021
	Third Party Observer Report	06/21/2021	07/12/2021
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210089
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the clinical and translational cancer research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle


In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.


Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:29 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: High-Impact/High-Risk Research Awards
APPLICATION ID: RP210089
APPLICATION TITLE: Dissecting Therapeutic Immunomodulation of Gut Microbiome on Colorectal Cancer
APPLICANT NAME: Kim, Hyun Jung
ORGANIZATION: The University of Texas at Austin
PANEL NAME: 21.2 C/TCR

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/27/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	02/22/2021
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/22/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/04/2021	07/12/2021
Primary Reviewer 2 COI signed		03/05/2021	07/12/2021
Primary Reviewer 3 COI signed		03/04/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/22/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/05/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/04/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 1 critique submitted	05/19/2021	07/12/2021
	Primary Reviewer 2 critique submitted	04/08/2021	07/12/2021
	Primary Reviewer 3 critique submitted	04/24/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	04/06/2021	07/12/2021
	COI indicated by non-primary reviewer	NONE	07/12/2021
	COI recused from participation	N/A	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/24/2021	07/12/2021
	Post review statements signed	07/07/2021	07/12/2021
Third Party Observer Report	06/21/2021	07/12/2021	
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210092
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the basic cancer research 1 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle



- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas County of Travis
SWORN to and SUBSCRIBED before me, the undersigned authority, on the <u>4</u> day of <u>August</u> , 2021, by WAYNE R. ROBERTS.
 _____ Melanie Cleveland Notary Public, State of Texas


CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:29 PM

FY: 2021
 CYCLE: 2
 PROGRAM: Research
 MECHANISM: High-Impact/High-Risk Research Awards
 APPLICATION ID: RP210092
 APPLICATION TITLE: Antibody-Drug Conjugate Combination Treatment for Targeting Colorectal Cancer Cell Plasticity
 APPLICANT NAME: Carmon, Kendra S
 ORGANIZATION: The University of Texas Health Science Center at Houston
 PANEL NAME: 21.2 BCR-1

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/26/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/19/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/08/2021	07/12/2021
Primary Reviewer 2 COI signed		03/04/2021	07/12/2021
Primary Reviewer 3 COI signed		03/13/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/19/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/08/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/13/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 1 critique submitted	04/20/2021	07/12/2021
	Primary Reviewer 2 critique submitted	05/13/2021	07/12/2021
	Primary Reviewer 3 critique submitted	05/12/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	03/23/2021	07/12/2021
	COI indicated by non-primary reviewer	NONE	07/12/2021
	COI recused from participation	N/A	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/21/2021	07/12/2021
	Post review statements signed	07/09/2021	07/12/2021
	Third Party Observer Report	06/21/2021	07/12/2021
	Score report delivered to CSO	06/11/2021	07/12/2021
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210102
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the basic cancer research 2 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle


In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.


Melanie Cleveland
Notary Public, State of Texas



MELANIE CLEVELAND
NOTARY PUBLIC
ID# 131757703
State of Texas
Comm. Exp. 10-08-2022
NOTARY WITHOUT BOND

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:29 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: High-Impact/High-Risk Research Awards
APPLICATION ID: RP210102
APPLICATION TITLE: Deciphering BRCA1-BARD1 E3 Ligase Activity in Genome Maintenance and Tumor Suppression
APPLICANT NAME: ZHAO, WEIXING
ORGANIZATION: The University of Texas Health Science Center at San Antonio
PANEL NAME: 21.2 BCR-2

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/26/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/22/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/04/2021	07/12/2021
Primary Reviewer 2 COI signed		03/04/2021	07/12/2021
Primary Reviewer 3 COI signed		03/04/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/14/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/22/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/04/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/14/2021	07/12/2021
	Primary Reviewer 1 critique submitted	05/11/2021	07/12/2021
	Primary Reviewer 2 critique submitted	05/14/2021	07/12/2021
	Primary Reviewer 3 critique submitted	05/17/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	05/14/2021	07/12/2021
	COI indicated by non-primary reviewer	Walter Chazin	07/12/2021
	COI recused from participation	YES	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/25/2021	07/12/2021
	Post review statements signed	06/24/2021	07/12/2021
	Third Party Observer Report	06/21/2021	07/12/2021
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210105
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the basic cancer research 1 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle


In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.


Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:29 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: High-Impact/High-Risk Research Awards
APPLICATION ID: RP210105
APPLICATION TITLE: Targeting lymphotoxin beta receptor in sensory neurons for control of chemotherapy-induced neuropathic pain
APPLICANT NAME: Tumanov, Alexei V
ORGANIZATION: The University of Texas Health Science Center at San Antonio
PANEL NAME: 21.2 BCR-1

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/27/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/19/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/05/2021	07/12/2021
Primary Reviewer 2 COI signed		03/04/2021	07/12/2021
Primary Reviewer 3 COI signed		03/13/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/19/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/05/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/13/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 1 critique submitted	04/14/2021	07/12/2021
	Primary Reviewer 2 critique submitted	05/14/2021	07/12/2021
	Primary Reviewer 3 critique submitted	05/13/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	05/06/2021	07/12/2021
	COI indicated by non-primary reviewer	Jose Conejo-Garcia	07/12/2021
	COI recused from participation	YES	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/21/2021	07/12/2021
	Post review statements signed	07/09/2021	07/12/2021
	Third Party Observer Report	06/21/2021	07/12/2021
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210111
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the imaging technology and informatics panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.


Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:35 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: High-Impact/High-Risk Research Awards
APPLICATION ID: RP210111
APPLICATION TITLE: Single-cell proteomics to dissect intra-tumor heterogeneity
APPLICANT NAME: Pan, Sheng
ORGANIZATION: The University of Texas Health Science Center at Houston
PANEL NAME: 21.2 ITI

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/26/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/19/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/04/2021	07/12/2021
Primary Reviewer 2 COI signed		03/04/2021	07/12/2021
Primary Reviewer 3 COI signed		03/12/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/18/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/19/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/12/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/18/2021	07/12/2021
	Primary Reviewer 1 critique submitted	04/24/2021	07/12/2021
	Primary Reviewer 2 critique submitted	04/29/2021	07/12/2021
	Primary Reviewer 3 critique submitted	05/16/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	05/18/2021	07/12/2021
	COI indicated by non-primary reviewer	NONE	07/12/2021
	COI recused from participation	N/A	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/26/2021	07/12/2021
	Post review statements signed	06/09/2021	07/12/2021
	Third Party Observer Report	06/21/2021	07/12/2021
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210127
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the cancer biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 4 day of August, 2021,
 by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:35 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: High-Impact/High-Risk Research Awards
APPLICATION ID: RP210127
APPLICATION TITLE: Engineered enteric nerve-perineural invasion models to improve predictive preclinical screens in early stage colorectal adenocarcinoma
APPLICANT NAME: Raghavan, Shreya
ORGANIZATION: Texas A&M University
PANEL NAME: 21.2 CB

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/27/2021	07/10/2021
	Method of submission	CARS	07/10/2021
	Within receipt period	YES	07/10/2021
	Request for extension to submit application after CARS closed	N/A	07/10/2021
	Request for extension for late application submission accepted	N/A	07/10/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/10/2021
Assigned to primary reviewers		03/23/2021	07/10/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/12/2021	07/10/2021
Primary Reviewer 2 COI signed		03/04/2021	07/10/2021
Primary Reviewer 3 COI signed		03/04/2021	07/10/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/10/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/10/2021
	Primary Reviewer 2 critique submitted	N/A	07/10/2021
	Primary Reviewer 3 critique submitted	N/A	07/10/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2021
	COI indicated by non-primary reviewer	N/A	07/10/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/10/2021
	Recommended for full review	N/A	07/10/2021
	Applicant notified of outcome	N/A	07/10/2021
Peer Review Meeting	Assigned to primary reviewers	03/23/2021	07/10/2021
	Primary Reviewer 1 COI signed	03/12/2021	07/10/2021
	Primary Reviewer 2 COI signed	03/04/2021	07/10/2021
	Primary Reviewer 3 COI signed	03/04/2021	07/10/2021
	Primary (Advocate) Reviewer 4 COI signed	03/04/2021	07/10/2021
	Primary Reviewer 1 critique submitted	05/13/2021	07/10/2021
	Primary Reviewer 2 critique submitted	05/12/2021	07/10/2021
	Primary Reviewer 3 critique submitted	05/16/2021	07/10/2021
	Primary (Advocate) Reviewer 4 critique submitted	03/24/2021	07/10/2021
	COI indicated by non-primary reviewer	NONE	07/10/2021
	COI recused from participation	N/A	07/10/2021
	Discussed at Peer Review Meeting	YES	07/10/2021
	Peer Review Meeting	05/20/2021	07/10/2021
	Post review statements signed	07/01/2021	07/10/2021
	Third Party Observer Report	06/21/2021	07/10/2021
Score report delivered to CSO	06/11/2021	07/10/2021	
Recommended for SRC review	YES	07/10/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210131
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards Request for Applications (RFA)*. CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the basic cancer research 1 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 4 day of August, 2021, by WAYNE R. ROBERTS.


Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:35 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: High-Impact/High-Risk Research Awards
APPLICATION ID: RP210131
APPLICATION TITLE: Antibody-like therapeutics that target polyclonal T cells to CMV-positive glioblastomas
APPLICANT NAME: Maynard, Jennifer A
ORGANIZATION: The University of Texas at Austin
PANEL NAME: 21.2 BCR-1

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/27/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/19/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/04/2021	07/12/2021
Primary Reviewer 2 COI signed		03/08/2021	07/12/2021
Primary Reviewer 3 COI signed		03/04/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/19/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/08/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/04/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 1 critique submitted	04/28/2021	07/12/2021
	Primary Reviewer 2 critique submitted	05/12/2021	07/12/2021
	Primary Reviewer 3 critique submitted	05/17/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	05/06/2021	07/12/2021
	COI indicated by non-primary reviewer	NONE	07/12/2021
	COI recused from participation	N/A	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/21/2021	07/12/2021
	Post review statements signed	07/09/2021	07/12/2021
	Third Party Observer Report	06/21/2021	07/12/2021
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210132
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the cancer biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:36 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: High-Impact/High-Risk Research Awards
APPLICATION ID: RP210132
APPLICATION TITLE: Synergy between epigenetic reprogramming and Wnt inhibition to enhance neuroendocrine tumor radionuclide therapy
APPLICANT NAME: Frost, Jeffrey A
ORGANIZATION: The University of Texas Health Science Center at Houston
PANEL NAME: 21.2 CB

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/26/2021	07/10/2021
	Method of submission	CARS	07/10/2021
	Within receipt period	YES	07/10/2021
	Request for extension to submit application after CARS closed	N/A	07/10/2021
	Request for extension for late application submission accepted	N/A	07/10/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/10/2021
Assigned to primary reviewers		03/23/2021	07/10/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/05/2021	07/10/2021
Primary Reviewer 2 COI signed		03/14/2021	07/10/2021
Primary Reviewer 3 COI signed		03/12/2021	07/10/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/10/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/10/2021
	Primary Reviewer 2 critique submitted	N/A	07/10/2021
	Primary Reviewer 3 critique submitted	N/A	07/10/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2021
	COI indicated by non-primary reviewer	N/A	07/10/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/10/2021
	Recommended for full review	N/A	07/10/2021
	Applicant notified of outcome	N/A	07/10/2021
Peer Review Meeting	Assigned to primary reviewers	03/23/2021	07/10/2021
	Primary Reviewer 1 COI signed	03/05/2021	07/10/2021
	Primary Reviewer 2 COI signed	03/14/2021	07/10/2021
	Primary Reviewer 3 COI signed	03/12/2021	07/10/2021
	Primary (Advocate) Reviewer 4 COI signed	03/04/2021	07/10/2021
	Primary Reviewer 1 critique submitted	05/10/2021	07/10/2021
	Primary Reviewer 2 critique submitted	05/13/2021	07/10/2021
	Primary Reviewer 3 critique submitted	05/13/2021	07/10/2021
	Primary (Advocate) Reviewer 4 critique submitted	03/26/2021	07/10/2021
	COI indicated by non-primary reviewer	NONE	07/10/2021
	COI recused from participation	N/A	07/10/2021
	Discussed at Peer Review Meeting	YES	07/10/2021
	Peer Review Meeting	05/20/2021	07/10/2021
	Post review statements signed	07/01/2021	07/10/2021
	Third Party Observer Report	06/21/2021	07/10/2021
	Score report delivered to CSO	06/11/2021	07/10/2021
Recommended for SRC review	YES	07/10/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210134
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the imaging technology and informatics panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:36 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: High-Impact/High-Risk Research Awards
APPLICATION ID: RP210134
APPLICATION TITLE: High Throughput Discovery of Anti-Cancer Protein Degradators
APPLICANT NAME: Tambar, Uttam K
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 21.2 ITI

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021	
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021	
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021	
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021	
	Date application submitted	01/26/2021	07/12/2021	
	Method of submission	CARS	07/12/2021	
	Within receipt period	YES	07/12/2021	
	Request for extension to submit application after CARS closed	N/A	07/12/2021	
	Request for extension for late application submission accepted	N/A	07/12/2021	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	07/12/2021
		Donation(s) made to CPRIT / foundation	NO	07/12/2021
Assigned to primary reviewers		03/19/2021	07/12/2021	
Applicant notified of review panel assignment		03/01/2021	07/06/2021	
Primary Reviewer 1 COI signed		03/12/2021	07/12/2021	
Primary Reviewer 2 COI signed		03/13/2021	07/12/2021	
Primary Reviewer 3 COI signed		03/12/2021	07/12/2021	
Primary (Advocate) Reviewer 4 COI signed		03/05/2021	07/12/2021	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021	
	Primary Reviewer 2 critique submitted	N/A	07/12/2021	
	Primary Reviewer 3 critique submitted	N/A	07/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021	
	COI indicated by non-primary reviewer	N/A	07/12/2021	
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021	
	Recommended for full review	N/A	07/12/2021	
	Applicant notified of outcome	N/A	07/12/2021	
	Peer Review Meeting	Assigned to primary reviewers	03/19/2021	07/12/2021
Primary Reviewer 1 COI signed		03/12/2021	07/12/2021	
Primary Reviewer 2 COI signed		03/13/2021	07/12/2021	
Primary Reviewer 3 COI signed		03/12/2021	07/12/2021	
Primary (Advocate) Reviewer 4 COI signed		03/05/2021	07/12/2021	
Primary Reviewer 1 critique submitted		05/17/2021	07/12/2021	
Primary Reviewer 2 critique submitted		05/08/2021	07/12/2021	
Primary Reviewer 3 critique submitted		05/19/2021	07/12/2021	
Primary (Advocate) Reviewer 4 critique submitted		05/15/2021	07/12/2021	
COI indicated by non-primary reviewer		NONE	07/12/2021	
COI recused from participation		N/A	07/12/2021	
Discussed at Peer Review Meeting		YES	07/12/2021	
Peer Review Meeting		05/26/2021	07/12/2021	
Post review statements signed		06/09/2021	07/12/2021	
Third Party Observer Report		06/21/2021	07/12/2021	
Score report delivered to CSO	06/11/2021	07/12/2021		
Recommended for SRC review	YES	07/12/2021		
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021	
	COI recused from participation	N/A	07/14/2021	
	SRC Meeting	07/08/2021	07/14/2021	
	Third Party Observer Report	07/16/2021	07/23/2021	
	Recommended for grant award	YES	07/14/2021	
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021	
	COI indicated by PIC member	None	08/03/2021	
	COI recused from participation	N/A	08/03/2021	
	PIC Review Meeting	08/03/2021	08/03/2021	
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021	
	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
Advance authority approved by Oversight Committee	N/A			



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210137
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the clinical and translational cancer research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:36 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: High-Impact/High-Risk Research Awards
APPLICATION ID: RP210137
APPLICATION TITLE: Development of TCR-based immunotherapies targeting hotspot EGFR mutations for the treatment of non-small cell lung cancer
APPLICANT NAME: Reuben, Alexandre
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 21.2 C/TCR

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/22/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/22/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/04/2021	07/12/2021
Primary Reviewer 2 COI signed		03/04/2021	07/12/2021
Primary Reviewer 3 COI signed		03/04/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/22/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/04/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 1 critique submitted	05/11/2021	07/12/2021
	Primary Reviewer 2 critique submitted	05/19/2021	07/12/2021
	Primary Reviewer 3 critique submitted	05/14/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	04/20/2021	07/12/2021
	COI indicated by non-primary reviewer	NONE	07/12/2021
	COI recused from participation	N/A	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/24/2021	07/12/2021
	Post review statements signed	07/07/2021	07/12/2021
	Third Party Observer Report	06/21/2021	07/12/2021
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
PIC Review Meeting	PIC Review Meeting	08/03/2021	08/03/2021
	Recommended for grant award	YES	08/03/2021
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210144
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the basic cancer research 1 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 4 day of August, 2021,
 by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:36 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: High-Impact/High-Risk Research Awards
APPLICATION ID: RP210144
APPLICATION TITLE: "Leveraging glioma stem cell electrophysiology for therapy"
APPLICANT NAME: Rostomily, Robert
ORGANIZATION: The Methodist Hospital Research Institute
PANEL NAME: 21.2 BCR-1

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/27/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/19/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/04/2021	07/12/2021
Primary Reviewer 2 COI signed		03/12/2021	07/12/2021
Primary Reviewer 3 COI signed		03/13/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/19/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/12/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/13/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 1 critique submitted	05/14/2021	07/12/2021
	Primary Reviewer 2 critique submitted	05/11/2021	07/12/2021
	Primary Reviewer 3 critique submitted	05/16/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	05/07/2021	07/12/2021
	COI indicated by non-primary reviewer	NONE	07/12/2021
	COI recused from participation	N/A	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/21/2021	07/12/2021
	Post review statements signed	07/09/2021	07/12/2021
	Third Party Observer Report	06/21/2021	07/12/2021
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210148
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards Request for Applications (RFA)*. CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the clinical and translational cancer research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:36 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: High-Impact/High-Risk Research Awards
APPLICATION ID: RP210148
APPLICATION TITLE: Novel pharmacodynamic assay to predict response to CDK4/6 inhibitor therapy
APPLICANT NAME: Trivedi, Meghana V
ORGANIZATION: University of Houston
PANEL NAME: 21.2 C/TCR

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/22/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/22/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/05/2021	07/12/2021
Primary Reviewer 2 COI signed		03/17/2021	07/12/2021
Primary Reviewer 3 COI signed		03/12/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/22/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/05/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/17/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/12/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 1 critique submitted	05/16/2021	07/12/2021
	Primary Reviewer 2 critique submitted	05/19/2021	07/12/2021
	Primary Reviewer 3 critique submitted	05/14/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	04/25/2021	07/12/2021
	COI indicated by non-primary reviewer	NONE	07/12/2021
	COI recused from participation	N/A	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/24/2021	07/12/2021
	Post review statements signed	07/07/2021	07/12/2021
	Third Party Observer Report	06/21/2021	07/12/2021
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210158
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the clinical and translational cancer research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."



 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 4 day of August, 2021,
 by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:36 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: High-Impact/High-Risk Research Awards
APPLICATION ID: RP210158
APPLICATION TITLE: Improving CAR T-cell therapy of T-ALL by co-targeting additional antigens
APPLICANT NAME: Mamonkin, Maksim
ORGANIZATION: Baylor College of Medicine
PANEL NAME: 21.2 C/TCR

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/26/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/22/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/04/2021	07/12/2021
Primary Reviewer 2 COI signed		03/04/2021	07/12/2021
Primary Reviewer 3 COI signed		03/04/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
	Peer Review Meeting	Assigned to primary reviewers	03/22/2021
Primary Reviewer 1 COI signed		03/04/2021	07/12/2021
Primary Reviewer 2 COI signed		03/04/2021	07/12/2021
Primary Reviewer 3 COI signed		03/04/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/12/2021
Primary Reviewer 1 critique submitted		05/18/2021	07/12/2021
Primary Reviewer 2 critique submitted		05/14/2021	07/12/2021
Primary Reviewer 3 critique submitted		05/06/2021	07/12/2021
Primary (Advocate) Reviewer 4 critique submitted		04/28/2021	07/12/2021
COI indicated by non-primary reviewer		NONE	07/12/2021
COI recused from participation		N/A	07/12/2021
Discussed at Peer Review Meeting		YES	07/12/2021
Peer Review Meeting		05/24/2021	07/12/2021
Post review statements signed		07/07/2021	07/12/2021
Third Party Observer Report		06/21/2021	07/12/2021
Score report delivered to CSO		06/11/2021	07/12/2021
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210165
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the imaging technology and informatics panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:37 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: High-Impact/High-Risk Research Awards
APPLICATION ID: RP210165
APPLICATION TITLE: Rapid Point-of-care Detection of Ovarian Cancer Biomarkers Using a Common Thermometer for Low-Resource Settings
APPLICANT NAME: Li, Xiujun (James)
ORGANIZATION: The University of Texas at El Paso
PANEL NAME: 21.2 ITI

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021	
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021	
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021	
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021	
	Date application submitted	01/27/2021	07/12/2021	
	Method of submission	CARS	07/12/2021	
	Within receipt period	YES	07/12/2021	
	Request for extension to submit application after CARS closed	N/A	07/12/2021	
	Request for extension for late application submission accepted	N/A	07/12/2021	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	07/12/2021
		Donation(s) made to CPRIT / foundation	NO	07/12/2021
Assigned to primary reviewers		03/19/2021	07/12/2021	
Applicant notified of review panel assignment		03/01/2021	07/06/2021	
Primary Reviewer 1 COI signed		03/04/2021	07/12/2021	
Primary Reviewer 2 COI signed		03/15/2021	07/12/2021	
Primary Reviewer 3 COI signed		03/07/2021	07/12/2021	
Primary (Advocate) Reviewer 4 COI signed		03/18/2021	07/12/2021	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021	
	Primary Reviewer 2 critique submitted	N/A	07/12/2021	
	Primary Reviewer 3 critique submitted	N/A	07/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021	
	COI indicated by non-primary reviewer	N/A	07/12/2021	
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021	
	Recommended for full review	N/A	07/12/2021	
	Applicant notified of outcome	N/A	07/12/2021	
Peer Review Meeting	Assigned to primary reviewers	03/19/2021	07/12/2021	
	Primary Reviewer 1 COI signed	03/04/2021	07/12/2021	
	Primary Reviewer 2 COI signed	03/15/2021	07/12/2021	
	Primary Reviewer 3 COI signed	03/07/2021	07/12/2021	
	Primary (Advocate) Reviewer 4 COI signed	03/18/2021	07/12/2021	
	Primary Reviewer 1 critique submitted	05/12/2021	07/12/2021	
	Primary Reviewer 2 critique submitted	05/18/2021	07/12/2021	
	Primary Reviewer 3 critique submitted	05/17/2021	07/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	05/18/2021	07/12/2021	
	COI indicated by non-primary reviewer	NONE	07/12/2021	
	COI recused from participation	N/A	07/12/2021	
	Discussed at Peer Review Meeting	YES	07/12/2021	
	Peer Review Meeting	05/26/2021	07/12/2021	
	Post review statements signed	06/09/2021	07/12/2021	
	Third Party Observer Report	06/21/2021	07/12/2021	
Score report delivered to CSO	06/11/2021	07/12/2021		
Recommended for SRC review	YES	07/12/2021		
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021	
	COI recused from participation	N/A	07/14/2021	
	SRC Meeting	07/08/2021	07/14/2021	
	Third Party Observer Report	07/16/2021	07/23/2021	
	Recommended for grant award	YES	07/14/2021	
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021	
	COI indicated by PIC member	None	08/03/2021	
	COI recused from participation	N/A	08/03/2021	
	PIC Review Meeting	08/03/2021	08/03/2021	
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021	
	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
Advance authority approved by Oversight Committee	N/A			



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210168
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the basic cancer research 1 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle


In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.


Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:37 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: High-Impact/High-Risk Research Awards
APPLICATION ID: RP210168
APPLICATION TITLE: Overcoming Myeloma Resistance to Proteasome Inhibitors
APPLICANT NAME: Yi, Qing
ORGANIZATION: The Methodist Hospital Research Institute
PANEL NAME: 21.2 BCR-1

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/20/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/19/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/04/2021	07/12/2021
Primary Reviewer 2 COI signed		03/05/2021	07/12/2021
Primary Reviewer 3 COI signed		03/04/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/19/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/05/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/04/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 1 critique submitted	05/11/2021	07/12/2021
	Primary Reviewer 2 critique submitted	04/12/2021	07/12/2021
	Primary Reviewer 3 critique submitted	05/14/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	05/07/2021	07/12/2021
	COI indicated by non-primary reviewer	NONE	07/12/2021
	COI recused from participation	N/A	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/21/2021	07/12/2021
	Post review statements signed	07/09/2021	07/12/2021
	Third Party Observer Report	06/21/2021	07/12/2021
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210173
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the basic cancer research 2 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle



- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas County of Travis
SWORN to and SUBSCRIBED before me, the undersigned authority, on the <u>4</u> day of <u>August</u> , 2021, by WAYNE R. ROBERTS.
 _____ Melanie Cleveland Notary Public, State of Texas


CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:37 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: High-Impact/High-Risk Research Awards
APPLICATION ID: RP210173
APPLICATION TITLE: Multiplex CRISPR genetic modeling of polypharmacology for precision medicine
APPLICANT NAME: Hart, Traver
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 21.2 BCR-2

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/26/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/22/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/04/2021	07/12/2021
Primary Reviewer 2 COI signed		03/04/2021	07/12/2021
Primary Reviewer 3 COI signed		03/14/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/14/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/22/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/14/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/14/2021	07/12/2021
	Primary Reviewer 1 critique submitted	05/12/2021	07/12/2021
	Primary Reviewer 2 critique submitted	05/21/2021	07/12/2021
	Primary Reviewer 3 critique submitted	05/17/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	05/16/2021	07/12/2021
	COI indicated by non-primary reviewer	NONE	07/12/2021
	COI recused from participation	N/A	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/25/2021	07/12/2021
	Post review statements signed	06/24/2021	07/12/2021
Third Party Observer Report	06/21/2021	07/12/2021	
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210183
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the cancer prevention research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."

Wayne R. Roberts
 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 4 day of August, 2021,
 by WAYNE R. ROBERTS.

Melanie Cleveland
 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:42 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: High-Impact/High-Risk Research Awards
APPLICATION ID: RP210183
APPLICATION TITLE: Virulence Modulation of Helicobacter pylori, the Strongest Risk Factor for Gastric Cancer
APPLICANT NAME: Kearney, Christopher M
ORGANIZATION: Baylor University
PANEL NAME: 21.2 CPR

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/25/2021	07/10/2021
	Method of submission	CARS	07/10/2021
	Within receipt period	YES	07/10/2021
	Request for extension to submit application after CARS closed	N/A	07/10/2021
	Request for extension for late application submission accepted	N/A	07/10/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/10/2021
Assigned to primary reviewers		03/18/2021	07/10/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/08/2021	07/10/2021
Primary Reviewer 2 COI signed		03/06/2021	07/10/2021
Primary Reviewer 3 COI signed		03/04/2021	07/10/2021
Primary (Advocate) Reviewer 4 COI signed		03/07/2021	07/10/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/10/2021
	Primary Reviewer 2 critique submitted	N/A	07/10/2021
	Primary Reviewer 3 critique submitted	N/A	07/10/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2021
	COI indicated by non-primary reviewer	N/A	07/10/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/10/2021
	Recommended for full review	N/A	07/10/2021
	Applicant notified of outcome	N/A	07/10/2021
Peer Review Meeting	Assigned to primary reviewers	03/18/2021	07/10/2021
	Primary Reviewer 1 COI signed	03/08/2021	07/10/2021
	Primary Reviewer 2 COI signed	03/06/2021	07/10/2021
	Primary Reviewer 3 COI signed	03/04/2021	07/10/2021
	Primary (Advocate) Reviewer 4 COI signed	03/07/2021	07/10/2021
	Primary Reviewer 1 critique submitted	05/18/2021	07/10/2021
	Primary Reviewer 2 critique submitted	05/18/2021	07/10/2021
	Primary Reviewer 3 critique submitted	05/10/2021	07/10/2021
	Primary (Advocate) Reviewer 4 critique submitted	05/17/2021	07/10/2021
	COI indicated by non-primary reviewer	NONE	07/10/2021
	COI recused from participation	N/A	07/10/2021
	Discussed at Peer Review Meeting	YES	07/10/2021
	Peer Review Meeting	05/27/2021	07/10/2021
	Post review statements signed	06/23/2021	07/10/2021
Third Party Observer Report	06/21/2021	07/10/2021	
Score report delivered to CSO	06/11/2021	07/10/2021	
Recommended for SRC review	YES	07/10/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210199
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the imaging technology and informatics panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:42 PM

FY: 2021
 CYCLE: 2
 PROGRAM: Research
 MECHANISM: High-Impact/High-Risk Research Awards
 APPLICATION ID: RP210199
 APPLICATION TITLE: Treating Metastatic Cancer using Microbubble-assisted Ultrasound-guided Immunotherapy of Cancer of Cancer (MUSIC)
 APPLICANT NAME: Lux, Jacques
 ORGANIZATION: The University of Texas Southwestern Medical Center
 PANEL NAME: 21.2 ITI

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/27/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	02/22/2021
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/19/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/04/2021	07/12/2021
Primary Reviewer 2 COI signed		03/04/2021	07/12/2021
Primary Reviewer 3 COI signed		03/04/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/18/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/19/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/04/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/18/2021	07/12/2021
	Primary Reviewer 1 critique submitted	05/14/2021	07/12/2021
	Primary Reviewer 2 critique submitted	05/17/2021	07/12/2021
	Primary Reviewer 3 critique submitted	05/11/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	05/18/2021	07/12/2021
	COI indicated by non-primary reviewer	NONE	07/12/2021
	COI recused from participation	N/A	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/26/2021	07/12/2021
	Post review statements signed	06/09/2021	07/12/2021
Third Party Observer Report	06/21/2021	07/12/2021	
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210205
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the basic cancer research 1 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:42 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: High-Impact/High-Risk Research Awards
APPLICATION ID: RP210205
APPLICATION TITLE: Cytokine factories for the treatment of mesothelioma
APPLICANT NAME: Veisheh, Omid
ORGANIZATION: Rice University
PANEL NAME: 21.2 BCR-1

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/27/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/19/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/04/2021	07/12/2021
Primary Reviewer 2 COI signed		03/04/2021	07/12/2021
Primary Reviewer 3 COI signed		03/12/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/19/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/12/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 1 critique submitted	05/14/2021	07/12/2021
	Primary Reviewer 2 critique submitted	04/28/2021	07/12/2021
	Primary Reviewer 3 critique submitted	05/11/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	05/07/2021	07/12/2021
	COI indicated by non-primary reviewer	NONE	07/12/2021
	COI recused from participation	N/A	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/21/2021	07/12/2021
	Post review statements signed	07/09/2021	07/12/2021
	Third Party Observer Report	06/21/2021	07/12/2021
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210206
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the imaging technology and informatics panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:43 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: High-Impact/High-Risk Research Awards
APPLICATION ID: RP210206
APPLICATION TITLE: Novel tumor-specific bioactive nanoparticles for cancer therapy
APPLICANT NAME: Nguyen, Kytai T
ORGANIZATION: The University of Texas at Arlington
PANEL NAME: 21.2 ITI

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/27/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/19/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/04/2021	07/12/2021
Primary Reviewer 2 COI signed		03/07/2021	07/12/2021
Primary Reviewer 3 COI signed		03/04/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/05/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/19/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/07/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/04/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/05/2021	07/12/2021
	Primary Reviewer 1 critique submitted	05/03/2021	07/12/2021
	Primary Reviewer 2 critique submitted	05/17/2021	07/12/2021
	Primary Reviewer 3 critique submitted	04/29/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	05/15/2021	07/12/2021
	COI indicated by non-primary reviewer	NONE	07/12/2021
	COI recused from participation	N/A	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/26/2021	07/12/2021
	Post review statements signed	06/09/2021	07/12/2021
	Third Party Observer Report	06/21/2021	07/12/2021
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210213
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the cancer biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:43 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: High-Impact/High-Risk Research Awards
APPLICATION ID: RP210213
APPLICATION TITLE: Therapeutic inhibition of cholangiocarcinoma progression by targeting tumor-lymphatic crosstalk
APPLICANT NAME: Chakraborty, Sanjukta
ORGANIZATION: Texas A&M University System Health Science Center
PANEL NAME: 21.2 CB

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/27/2021	07/10/2021
	Method of submission	CARS	07/10/2021
	Within receipt period	YES	07/10/2021
	Request for extension to submit application after CARS closed	N/A	07/10/2021
	Request for extension for late application submission accepted	N/A	07/10/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/10/2021
Assigned to primary reviewers		03/23/2021	07/10/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/15/2021	07/10/2021
Primary Reviewer 2 COI signed		03/23/2021	07/10/2021
Primary Reviewer 3 COI signed		03/04/2021	07/10/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/10/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/10/2021
	Primary Reviewer 2 critique submitted	N/A	07/10/2021
	Primary Reviewer 3 critique submitted	N/A	07/10/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2021
	COI indicated by non-primary reviewer	N/A	07/10/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/10/2021
	Recommended for full review	N/A	07/10/2021
	Applicant notified of outcome	N/A	07/10/2021
Peer Review Meeting	Assigned to primary reviewers	03/23/2021	07/10/2021
	Primary Reviewer 1 COI signed	03/15/2021	07/10/2021
	Primary Reviewer 2 COI signed	03/23/2021	07/10/2021
	Primary Reviewer 3 COI signed	03/04/2021	07/10/2021
	Primary (Advocate) Reviewer 4 COI signed	03/04/2021	07/10/2021
	Primary Reviewer 1 critique submitted	05/11/2021	07/10/2021
	Primary Reviewer 2 critique submitted	05/11/2021	07/10/2021
	Primary Reviewer 3 critique submitted	05/05/2021	07/10/2021
	Primary (Advocate) Reviewer 4 critique submitted	03/24/2021	07/10/2021
	COI indicated by non-primary reviewer	NONE	07/10/2021
	COI recused from participation	N/A	07/10/2021
	Discussed at Peer Review Meeting	YES	07/10/2021
	Peer Review Meeting	05/20/2021	07/10/2021
	Post review statements signed	07/01/2021	07/10/2021
Third Party Observer Report	06/21/2021	07/10/2021	
Score report delivered to CSO	06/11/2021	07/10/2021	
Recommended for SRC review	YES	07/10/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210236
High-Impact/High-Risk Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *High-Impact/High-Risk Research Awards* Request for Applications (RFA). CPRIT received 107 applications in response to this RFA including three applications that were withdrawn. This application was assigned to the imaging technology and informatics panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:43 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: High-Impact/High-Risk Research Awards
APPLICATION ID: RP210236
APPLICATION TITLE: Magnetomechanical modulation of blood-brain barrier permeability
APPLICANT NAME: Qin, Zhenpeng
ORGANIZATION: The University of Texas at Dallas
PANEL NAME: 21.2 ITI

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/28/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/27/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/19/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/12/2021	07/12/2021
Primary Reviewer 2 COI signed		03/13/2021	07/12/2021
Primary Reviewer 3 COI signed		03/18/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/18/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
	Peer Review Meeting	Assigned to primary reviewers	03/19/2021
Primary Reviewer 1 COI signed		03/12/2021	07/12/2021
Primary Reviewer 2 COI signed		03/13/2021	07/12/2021
Primary Reviewer 3 COI signed		03/18/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/18/2021	07/12/2021
Primary Reviewer 1 critique submitted		05/17/2021	07/12/2021
Primary Reviewer 2 critique submitted		05/16/2021	07/12/2021
Primary Reviewer 3 critique submitted		05/25/2021	07/12/2021
Primary (Advocate) Reviewer 4 critique submitted		05/18/2021	07/12/2021
COI indicated by non-primary reviewer		NONE	07/12/2021
COI recused from participation		N/A	07/12/2021
Discussed at Peer Review Meeting		YES	07/12/2021
Peer Review Meeting		05/26/2021	07/12/2021
Post review statements signed		06/09/2021	07/12/2021
Third Party Observer Report		06/21/2021	07/12/2021
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	J. Willson	08/02/2021
	COI recused from participation	YES	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210115
Texas Clinical Trials Participation Award

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Texas Clinical Trials Participation Award* Request for Applications (RFA). CPRIT received four applications in response to this RFA. This application was assigned to the clinical and translational cancer research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 4 day of August, 2021,
 by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:35 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: Texas Clinical Trials Participation Program Award
APPLICATION ID: RP210115
APPLICATION TITLE: Enhancing access to and diversity in cancer clinical trials through a financial reimbursement and outreach program
APPLICANT NAME: Gerber, David E
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 21.2 C/TCR

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/30/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/26/2021	07/12/2021
	Method of submission	CARS	07/12/2021
	Within receipt period	YES	07/12/2021
	Request for extension to submit application after CARS closed	N/A	07/12/2021
	Request for extension for late application submission accepted	N/A	07/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/12/2021
Assigned to primary reviewers		03/22/2021	07/12/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/05/2021	07/12/2021
Primary Reviewer 2 COI signed		03/17/2021	07/12/2021
Primary Reviewer 3 COI signed		03/12/2021	07/12/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/12/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021
	Primary Reviewer 2 critique submitted	N/A	07/12/2021
	Primary Reviewer 3 critique submitted	N/A	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021
	COI indicated by non-primary reviewer	N/A	07/12/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021
	Recommended for full review	N/A	07/12/2021
	Applicant notified of outcome	N/A	07/12/2021
Peer Review Meeting	Assigned to primary reviewers	03/22/2021	07/12/2021
	Primary Reviewer 1 COI signed	03/05/2021	07/12/2021
	Primary Reviewer 2 COI signed	03/17/2021	07/12/2021
	Primary Reviewer 3 COI signed	03/12/2021	07/12/2021
	Primary (Advocate) Reviewer 4 COI signed	03/04/2021	07/12/2021
	Primary Reviewer 1 critique submitted	05/02/2021	07/12/2021
	Primary Reviewer 2 critique submitted	05/16/2021	07/12/2021
	Primary Reviewer 3 critique submitted	05/21/2021	07/12/2021
	Primary (Advocate) Reviewer 4 critique submitted	05/10/2021	07/12/2021
	COI indicated by non-primary reviewer	NONE	07/12/2021
	COI recused from participation	N/A	07/12/2021
	Discussed at Peer Review Meeting	YES	07/12/2021
	Peer Review Meeting	05/24/2021	07/12/2021
	Post review statements signed	07/07/2021	07/12/2021
	Third Party Observer Report	06/21/2021	07/12/2021
Score report delivered to CSO	06/11/2021	07/12/2021	
Recommended for SRC review	YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210143
Texas Clinical Trials Participation Award

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Texas Clinical Trials Participation Award* Request for Applications (RFA). CPRIT received four applications in response to this RFA. This application was assigned to the clinical and translational cancer research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 4 day of August, 2021,
 by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:36 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: Texas Clinical Trials Participation Program Award
APPLICATION ID: RP210143
APPLICATION TITLE: Dan L. Duncan Comprehensive Cancer Center (DLCCCC) Harris Health Clinical Trials Financial Support Project
APPLICANT NAME: Mims, Martha P
ORGANIZATION: Baylor College of Medicine
PANEL NAME: 21.2 C/TCR

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	07/30/2020	07/07/2021	
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021	
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021	
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021	
	Date application submitted	01/26/2021	07/12/2021	
	Method of submission	CARS	07/12/2021	
	Within receipt period	YES	07/12/2021	
	Request for extension to submit application after CARS closed	N/A	07/12/2021	
	Request for extension for late application submission accepted	N/A	07/12/2021	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	07/12/2021
		Donation(s) made to CPRIT / foundation	NO	07/12/2021
Assigned to primary reviewers		03/22/2021	07/12/2021	
Applicant notified of review panel assignment		03/01/2021	07/06/2021	
Primary Reviewer 1 COI signed		03/17/2021	07/12/2021	
Primary Reviewer 2 COI signed		03/04/2021	07/12/2021	
Primary Reviewer 3 COI signed		03/05/2021	07/12/2021	
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/12/2021	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/12/2021	
	Primary Reviewer 2 critique submitted	N/A	07/12/2021	
	Primary Reviewer 3 critique submitted	N/A	07/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/12/2021	
	COI indicated by non-primary reviewer	N/A	07/12/2021	
	Preliminary Evaluation score summary sent to Chair	N/A	07/12/2021	
	Recommended for full review	N/A	07/12/2021	
	Applicant notified of outcome	N/A	07/12/2021	
	Peer Review Meeting	Assigned to primary reviewers	03/22/2021	07/12/2021
Primary Reviewer 1 COI signed		03/17/2021	07/12/2021	
Primary Reviewer 2 COI signed		03/04/2021	07/12/2021	
Primary Reviewer 3 COI signed		03/05/2021	07/12/2021	
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/12/2021	
Primary Reviewer 1 critique submitted		05/16/2021	07/12/2021	
Primary Reviewer 2 critique submitted		05/18/2021	07/12/2021	
Primary Reviewer 3 critique submitted		05/02/2021	07/12/2021	
Primary (Advocate) Reviewer 4 critique submitted		05/10/2021	07/12/2021	
COI indicated by non-primary reviewer		NONE	07/12/2021	
COI recused from participation		N/A	07/12/2021	
Discussed at Peer Review Meeting		YES	07/12/2021	
Peer Review Meeting		05/24/2021	07/12/2021	
Post review statements signed		07/07/2021	07/12/2021	
Third Party Observer Report		06/21/2021	07/12/2021	
Score report delivered to CSO		06/11/2021	07/12/2021	
Recommended for SRC review		YES	07/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021	
	COI recused from participation	N/A	07/14/2021	
	SRC Meeting	07/08/2021	07/14/2021	
	Third Party Observer Report	07/16/2021	07/23/2021	
	Recommended for grant award	YES	07/14/2021	
	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021	
PIC Review	COI indicated by PIC member	None	08/03/2021	
	COI recused from participation	N/A	08/03/2021	
	PIC Review Meeting	08/03/2021	08/03/2021	
	Recommended for grant award	YES	08/03/2021	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210153
Texas Regional Excellence in Cancer Award

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Texas Regional Excellence in Cancer Award Request for Applications (RFA)*. CPRIT received seven applications in response to this RFA. This application was assigned to the cancer biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.


Melanie Cleveland
Notary Public, State of Texas

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:36 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: Texas Regional Excellence in Cancer Award
APPLICATION ID: RP210153
APPLICATION TITLE: UTEP/UTMDACC Partnership for Hispanic Cancer Disparities Research
APPLICANT NAME: Cox, Marc B
ORGANIZATION: The University of Texas at El Paso
PANEL NAME: 21.2 CB

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/31/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/27/2021	07/10/2021
	Method of submission	CARS	07/10/2021
	Within receipt period	YES	07/10/2021
	Request for extension to submit application after CARS closed	N/A	07/10/2021
	Request for extension for late application submission accepted	N/A	07/10/2021
	Receipt, Referral, and Assignment	Administrative review notification	02/23/2021
Donation(s) made to CPRIT / foundation		NO	07/10/2021
Assigned to primary reviewers		03/23/2021	07/10/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/10/2021	07/10/2021
Primary Reviewer 2 COI signed		03/04/2021	07/10/2021
Primary Reviewer 3 COI signed		03/08/2021	07/10/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/10/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/10/2021
	Primary Reviewer 2 critique submitted	N/A	07/10/2021
	Primary Reviewer 3 critique submitted	N/A	07/10/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2021
	COI indicated by non-primary reviewer	N/A	07/10/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/10/2021
	Recommended for full review	N/A	07/10/2021
	Applicant notified of outcome	N/A	07/10/2021
Peer Review Meeting	Assigned to primary reviewers	03/23/2021	07/10/2021
	Primary Reviewer 1 COI signed	03/10/2021	07/10/2021
	Primary Reviewer 2 COI signed	03/04/2021	07/10/2021
	Primary Reviewer 3 COI signed	03/08/2021	07/10/2021
	Primary (Advocate) Reviewer 4 COI signed	03/04/2021	07/10/2021
	Primary Reviewer 1 critique submitted	05/07/2021	07/10/2021
	Primary Reviewer 2 critique submitted	05/16/2021	07/10/2021
	Primary Reviewer 3 critique submitted	05/12/2021	07/10/2021
	Primary (Advocate) Reviewer 4 critique submitted	04/21/2021	07/10/2021
	COI indicated by non-primary reviewer	NONE	07/10/2021
	COI recused from participation	N/A	07/10/2021
	Discussed at Peer Review Meeting	YES	07/10/2021
	Peer Review Meeting	05/20/2021	07/10/2021
	Post review statements signed	07/01/2021	07/10/2021
	Third Party Observer Report	06/21/2021	07/10/2021
Score report delivered to CSO	06/11/2021	07/10/2021	
Recommended for SRC review	YES	07/10/2021	
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210154
Texas Regional Excellence in Cancer Award

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).


My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Texas Regional Excellence in Cancer Award Request for Applications (RFA)*. CPRIT received seven applications in response to this RFA. This application was assigned to the cancer biology for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 4 day of August, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 08/03/2021 17:36 PM

FY: 2021
CYCLE: 2
PROGRAM: Research
MECHANISM: Texas Regional Excellence in Cancer Award
APPLICATION ID: RP210154
APPLICATION TITLE: Texas Regional Excellence in Cancer Developmental Therapeutics Center at TTUHSC
APPLICANT NAME: Reynolds, Charles P
ORGANIZATION: Texas Tech University Health Sciences Center
PANEL NAME: 21.2 CB

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	07/31/2020	07/07/2021
	RFA published in Texas.gov eGrants	08/05/2020	07/07/2021
	CPRIT Application Receipt System (CARS) opened	09/16/2020	07/07/2021
	CPRIT Application Receipt System (CARS) closed	01/27/2021	07/07/2021
	Date application submitted	01/26/2021	07/10/2021
	Method of submission	CARS	07/10/2021
	Within receipt period	YES	07/10/2021
	Request for extension to submit application after CARS closed	N/A	07/10/2021
	Request for extension for late application submission accepted	N/A	07/10/2021
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	07/10/2021
Assigned to primary reviewers		03/23/2021	07/10/2021
Applicant notified of review panel assignment		03/01/2021	07/06/2021
Primary Reviewer 1 COI signed		03/04/2021	07/10/2021
Primary Reviewer 2 COI signed		03/04/2021	07/10/2021
Primary Reviewer 3 COI signed		03/19/2021	07/10/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/10/2021
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/10/2021
	Primary Reviewer 2 critique submitted	N/A	07/10/2021
	Primary Reviewer 3 critique submitted	N/A	07/10/2021
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/10/2021
	COI indicated by non-primary reviewer	N/A	07/10/2021
	Preliminary Evaluation score summary sent to Chair	N/A	07/10/2021
	Recommended for full review	N/A	07/10/2021
	Applicant notified of outcome	N/A	07/10/2021
	Peer Review Meeting	Assigned to primary reviewers	03/23/2021
Primary Reviewer 1 COI signed		03/04/2021	07/10/2021
Primary Reviewer 2 COI signed		03/04/2021	07/10/2021
Primary Reviewer 3 COI signed		03/19/2021	07/10/2021
Primary (Advocate) Reviewer 4 COI signed		03/04/2021	07/10/2021
Primary Reviewer 1 critique submitted		05/13/2021	07/10/2021
Primary Reviewer 2 critique submitted		05/12/2021	07/10/2021
Primary Reviewer 3 critique submitted		05/13/2021	07/10/2021
Primary (Advocate) Reviewer 4 critique submitted		05/01/2021	07/10/2021
COI indicated by non-primary reviewer		Yves DeClerck	07/10/2021
COI recused from participation		YES	07/10/2021
Discussed at Peer Review Meeting		YES	07/10/2021
Peer Review Meeting		05/20/2021	07/10/2021
Post review statements signed		07/01/2021	07/10/2021
Third Party Observer Report		06/21/2021	07/10/2021
Score report delivered to CSO		06/11/2021	07/10/2021
Recommended for SRC review		YES	07/10/2021
Final SRC Recommendation	COI indicated by SRC member	NONE	07/14/2021
	COI recused from participation	N/A	07/14/2021
	SRC Meeting	07/08/2021	07/14/2021
	Third Party Observer Report	07/16/2021	07/23/2021
	Recommended for grant award	YES	07/14/2021
PIC Review	SRC Chair Notification to PIC and OC	07/22/2021	07/23/2021
	COI indicated by PIC member	None	08/03/2021
	COI recused from participation	N/A	08/03/2021
	PIC Review Meeting	08/03/2021	08/03/2021
Oversight Committee Approval	Recommended for grant award	YES	08/03/2021
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		